Peptide and small molecule agonists of EphA and their uses

ABSTRACT

Methods and compositions for activating an EphA receptor can be used for identifying therapeutic agents for cancer.

RELATED APPLICATIONS

The present application claims priority from U.S. ProvisionalApplication No. 60/621,041, filed Oct. 23, 2004, which is hereinincorporated by reference in its entirety.

BACKGROUND

Cancer is the second leading cause of death in North American, killing557,000 people in 2002. The overall cancer risk is ½, representingtremendous burden to the all the individuals and fimilaies affected.Despite decades of intense research, a cure for most cancers is stillnot available. Recently, mechanism-based molecular therapy has emergedas increasingly attractive approach for cancer therapy.

Cancer development is underscored by two types of genetic alterations.One is the loss of function of tumor suppressor genes. The normalfunction of these genes is to keep cells in non-tumorigenic quiescentstate. Another genetic alteration is the activation of oncogenes. Whilea variety of approaches are being developed to target oncogenes,targeting tumor suppressor genes is more challenging due to their lossof function in tumor development. However, recent studies show that evenin malignant cells, tumor suppressor networks frequently remain intactbut latent. Harnessing the powerful intrinsic tumor suppressors forcancer therapy has emerged an attractive new approach in contemporarydrug discovery.

Since the discovery of the first member from an erythropoietin producinghepatoma cell line nearly two decades ago, the number of Eph receptorprotein tyrosine kinases (RPTK) has increased to 16 in vertebrate,making them the largest subfamily of RPTKs. They are divided into EphAand EphB kinases according to sequence homology and ligand bindingspecificity of the membrane-anchored ligands called ephrins. While EphAkinases bind to GPI-anchored ephrin-As, EphB kinases targettransmembrane ephrin-Bs. Earlier studies have established a regulatoryrole of Eph/ephrin interactions in neural patterning in developingnervous systems, primarily through repulsive guidance of growth conesand neurons. Genetic studies using knockout mice revealed a pivotal roleof Eph kinases in the development of cardiovascular system. The pastseveral years have seen explosive growth in investigation on Ephreceptors and their ligands, leading to the identification of diversecellular functions regulated by Eph/ephrin interactions including neuralplasticity, brain size determination, blood clotting, epithelialmorphogenesis and viral infection.

SUMMARY OF THE INVENTION

The present invention is based at least in part on the discovery thatEphA kinase (e.g., EphA1, EphA2, and EphA3) can function as a tumorsuppressor and that activation of EphA kinase (e.g., EphA1, EphA2, andEphA3) can inhibit cancer cell growth, migration and/or proliferationin, for example, prostate cancer, breast cancer, colorectal cancer, skincancer, and lung cancer.

The present invention also provides a method of identifying therapeuticagents for cancer, such as prostate cancer, breast cancer, colorectalcancer, and lung cancer. In the method, an agonist of an EphA receptorprotein (e.g., EphA1, EphA2, and EphA3) is identified. The agonist ofthe EphA receptor protein can be a therapeutic agent for cancer. Theagonist can bind to the ligand-binding domain of an EphA receptorprotein, bind to the dimerization domain of EphA receptor protein,stimulate tyrosine phosphorylation of an EphA, enhance binding of anEphA ligand to an EphA, and/or enhance dimerization and/or signaling ofan EphA.

In yet another aspect, the invention provides a method of inhibitingcell growth, migration and/or proliferation. In the method, a cell iscontacted with an agonist of EphA receptor protein (e.g., EphA1, EphA2,and EphA3). The cell can be a mammalian cell, such as a human cell. Incertain cases, the cell can be a cancer cell (e.g., a prostate cancercell, lung cancer cell, colorectal cancer cell, breast cancer cell, andskin cancer cell). The agonist can bind to the ligand-binding domain ofan EphA receptor protein, bind to the dimerization domain of EphAreceptor protein, stimulate tyrosine phosphorylation of an EphA, enhancebinding of an EphA ligand to an EphA, and/or enhance dimerization and/orsignaling of an EphA.

In certain aspects, the invention provides a method of treating theonset of cancer in an individual, such as a mammal (e.g., human),comprising administering to the individual a therapeutically effectiveamount of an agonist of EphA receptor protein (e.g., EphA1, EphA2,and/or EphA3), wherein the agonist inhibits proliferation of cancercells. The agonist can bind to the ligand-binding domain of an EphAreceptor protein, bind to the dimerization domain of EphA receptorprotein, stimulate tyrosine phosphorylation of an EphA, enhance bindingof an EphA ligand to an EphA, and/or enhance dimerization and/orsignaling of an EphA. In an aspect of the invention, the agonist of themethod can be a small molecule.

In certain aspects, the invention provides a method of activating EphAreceptor activity in a cell. The method comprises contacting the cellwith an agent that binds to the ligand-binding domain of EphA receptorprotein. The cell can be a mammalian cell, such as a human cell. Incertain cases, the cell can be a cancer cell. The agonist can bind tothe ligand-binding domain of an EphA receptor protein, bind to thedimerization domain of EphA receptor protein, stimulate tyrosinephosphorylation of an EphA, enhance binding of an EphA ligand to anEphA, and/or enhance dimerization and/or signaling of an EphA.

In certain aspects, the invention provides a method of inhibiting theRas/Raf/MEK/ERK1/2 signaling pathway. The method can compriseadministering to the individual a therapeutically effective amount of anagonist of EphA receptor protein (e.g., EphA1, EphA2, and/or EphA3),wherein the agonist inhibits proliferation of cancer cells. The agonistcan inhibit activation of the Ras/Raf/MEK/ERK1/2 signaling pathway bygrowth factor receptors, such as EGFR, PDGFR, and c-MET. The agonist canalso bind to the ligand-binding domain of an EphA receptor protein, bindto the dimerization domain of EphA receptor protein, stimulate tyrosinephosphorylation of an EphA, enhance binding of an EphA ligand to anEphA, and/or enhance dimerization and/or signaling of an EphA.

In other aspects, the invention provides a method of suppressing thePI3/AKT signaling pathway, comprising administering to the individual atherapeutically effective amount of an agonist of EphA receptor protein(e.g., EphA1, EphA2, and/or EphA3), wherein the agonist inhibitssurvival of cancer cells. The agonist can also bind to theligand-binding domain of an EphA receptor protein, bind to thedimerization domain of EphA receptor protein, stimulate tyrosinephosphorylation of an EphA, enhance binding of an EphA ligand to anEphA, and/or enhance dimerization and/or signaling of an EphA.

In other aspects, the invention provides a method of inhibitingepithelial carcinogenesis in an individual, comprising administering tothe individual a therapeutically effective amount of an agonist of EphAreceptor protein, wherein the agonist inhibits epithelialcarcinogenesis. For example, the agonist inhibits epithelialcarcinogenesis in the prostate, lung, breast, skin and colorectom. Theagonist can bind to the ligand-binding domain of an EphA receptorprotein, bind to the dimerization domain of EphA receptor protein,stimulate tyrosine phosphorylation of an EphA, enhance binding of anEphA ligand to an EphA, and/or enhance dimerization and/or signaling ofan EphA. In an aspect of the invention, the agonist of the method can bea small molecule.

In other aspects, the invention provides a method of treating diseaseswhere EphA is overexpressed. These diseases can include, for example,restenosis, inflammation, asthma, chronic obstructive lung diseases andabnormal angiogenesis in eyes. The method can comprise administering tothe individual a therapeutically effective amount of an agonist of EphAreceptor protein. The agonist can bind to the ligand-binding domain ofan EphA receptor protein, bind to the dimerization domain of EphAreceptor protein, stimulate tyrosine phosphorylation of an EphA, enhancebinding of an EphA ligand to an EphA, and/or enhance dimerization and/orsignaling of an EphA.

In further aspects, the invention provides a method of stimulating atleast one of neural synaptogenesis, axon pathfinding, long termpotentiation of neural cells. The method can comprise administering tothe individual a therapeutically effective amount of an agonist of EphAreceptor protein. The agonist can bind to the ligand-binding domain ofan EphA receptor protein, bind to the dimerization domain of EphAreceptor protein, stimulate tyrosine phosphorylation of an EphA, enhancebinding of an EphA ligand to an EphA, and/or enhance dimerization and/orsignaling of an EphA.

In other aspects, the EphA agonist can comprise an exogenous ornon-native peptide or small molecule have a molecular weight of about 50daltons to about 2500 daltons. The EphA small molecule agonist inaccordance with an aspect of the invention comprises an EphA smallmolecule agonist having the general formula: A-L-B (II), wherein A and Bare independently selected from aryl and heteroaryl; and L is selectedfrom C1-12alkyl and —C1-6alkyl-amino-C1-6alkyl. Exemplary smallmolecules include, but are not limited to, doxazosin, labetalol,dobutamine, and(di-meo-isoquinolin-1-ylmethyl)-et-di-meo-pyrido(2,1-a)isoquinolin,hydrobromide S120103. The small molecule agonist can bind to theligand-binding domain of an EphA receptor protein, bind to thedimerization domain of EphA receptor protein, stimulate tyrosinephosphorylation of an EphA, enhance binding of an EphA ligand to anEphA, and/or enhance dimerization and/or signaling of an EphA.

In certain aspects, the invention provides an EphA peptide agonist(e.g., EphA1, EphA2, or EphA3 peptide agonist) comprising about 4 toabout 20 amino acids. The peptide can be selected from the groupconsisting of: (a) a peptide having at least 40% sequence identify toany of SEQ ID NOs: 1-3; and (b) a peptide of SEQ ID NOs: 1-3. Or it canbe a peptide with discernable structural similarities to the peptides.The EphA peptide can bind to the ligand-binding domain of an EphAreceptor protein, bind to the dimerization domain of EphA receptorprotein, stimulate tyrosine phosphorylation of an EphA, enhance bindingof an EphA ligand to an EphA, and/or enhance dimerization and/orsignaling of an EphA.

Optionally, the agonist binds to the ligand-binding domain of an EphA2receptor protein, binds to the dimerization domain of EphA2 receptorprotein, stimulates tyrosine phosphorylation of an EphA2, enhancesbinding of an EphA2 ligand to an EphA2, and/or enhances dimerizationand/or signaling of an EphA2.

In yet another aspect, the invention provides a method of treating orpreventing the onset of cancer (e.g., prostate cancer, breast cancer,colorectal cancer, skin cancer, and lung cancer) in an individualcomprising administering to the individual a therapeutically effectiveamount of a small molecule agonist as described above.

In certain aspects, the invention provides a method of treating orpreventing the onset of cancer in an individual, comprisingadministering to the individual a therapeutically effective amount of apeptide agonist as described above.

In certain aspects, the invention provides a transgenic knockout mousehaving germline and somatic cells in which at least one allele of thegenomic EphA gene (e.g., EphA1, EphA2, or EphA3 gene) is disrupted andat least one allele of a tumor suppressor gene is disrupted. Preferably,the transgenic mouse exhibits increased susceptibility to the formationof prostate tumors as compared to a transgenic mouse having germline andsomatic cells in which at least one allele of the tumor suppressor genealone is disrupted. Exemplary tumor suppressor genes include p53, p63,p73, p16, PTEN, APC, Rb and Nkx 3.1.

In certain aspects, the invention provides a transgenic knockout mousehaving germline and somatic cells in which at least one allele of thegenomic EphA gene (e.g., EphA1, EphA2, or EphA3 gene) is disrupted and atransgene encoding an oncogene is expressed. Preferably, the transgenicknockout mouse exhibits increased susceptibility to the formation ofprostate tumors as compared to a transgenic knockout mouse havingexpressing the transgene alone (i.e., the TRAMP (transgenicadenocarcinoma mouse prostate) mouse). For example, the oncogene encodesT, Myc, and Ras antigen oncoprotein.

In certain aspects, the invention provides a method of identifying atherapeutic agent for cancer cancer (e.g., prostate cancer, breastcancer, colorectal cancer, skin cancer, and lung cancer), comprisingadministering a test agent to the transgenic knockout mouse as describedabove.

In certain aspects, the invention provides a method of identifying atherapeutic agent for cancer cancer (e.g., prostate cancer, breastcancer, colorectal cancer, skin cancer, and lung cancer), comprisingadministering a test agent to a cell isolated from the transgenicknockout mouse as described above.

In certain aspects, the invention provides a method of assaying for anagonist of EphA kinase (e.g., EphA1, EphA2, or EphA3), comprising: a)contacting an EphA polypeptide with a test agent; and b) determiningwhether the agent binds to EphA. Optionally, binding of the agent toEphA is determined by a method selected from the group consisting ofyeast two-hybrid assay, fluorescence polarization assay, fluorescenceresonance energy transfer (FRET) assay, solid phase binding assay, andELISA.

In certain aspects, the invention provides a method of assaying for anagonist of EphA kinase (e.g., EphA1, EphA2, or EphA3), comprising: a)contacting an EphA polypeptide with a test agent; and b) determiningwhether the agent stimulates EphA activity. For example, the agentactivates EphA tyrosine phosphorylation. Optionally, EphA tyrosinephosphorylation is determined by an immunoassay.

In certain aspects, the invention provides a method of identifying atherapeutic agent for cancer, comprising identifying an agent selectedfrom the group consisting of: 1) an agent which binds to an EphAreceptor protein kinase (e.g., EphA1, EphA2, or EphA3); 2) an agentwhich stimulates phosphorylation of an EphA receptor protein; 3) anagent which enhances dimerization and/or signaling of an EphA receptorprotein; and 4) an agent which enhances binding of an EphA ligand to anEphA receptor protein. Optionally, the agent binds to the ligand-bindingdomain of EphA receptor protein.

In certain aspects, the present invention provides a crystallinemolecule comprising an EphA2 ligand binding domain (LBD). In oneembodiment, the molecule is an EphA2 protein. In another embodiment, themolecule is an EphA2 LBD. In certain embodiments, the invention providescrystal compositions comprising an EphA2 protein or an EphA2 LBD in thepresence or absence of a chemical entity. The invention also provides amethod of crystallizing an EphA2 protein or an EphA2 LBD.

The invention further provides a computer comprising a data storagemedium which comprises the structure coordinates of a moleculecomprising all or part of the EphA2 ligand binding domain (LBD). Suchstorage medium, when read and utilized by a computer programmed withappropriate software, displays on a computer screen or similar viewingdevice, a three-dimensional graphical representation of a molecule ormolecular complex comprising such ligand binding structure.

The invention provides methods for screening, designing, optimizing,evaluating, and identifying compounds which bind to an EphA2 molecule orits LBD. Such compounds can be potential inhibitors (antagonists) oractivators (agonists) of EphA2 proteins.

The invention also provides a method for determining at least a portionof the three-dimensional structure of molecules which contain at leastsome structurally similar features to an EphA2 protein (e.g., EphA2LBD). This is achieved by using at least some of the structurecoordinates obtained from the EphA2 protein as described herein.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1. (A) EphA2 is the primary EphA kinase expressed on human prostatecancer cells. Cell surface proteins were labeled with membraneimpermeable biotin (Method). Top panel: Saturating amount ofephrin-A1-Fc (EA1-Fc) was used to precipitate most EphA kinases. Lowerpanel: EphA2 was first immunodepleted from cell lysates with anEphA2-specific antibody. Saturating amount of ephrin-A1-Fc was thenadded to the EphA2-depleted cell lysates to precipitate other members ofEphA kinases. The precipitates were subject immunoblot with HRP-labeledavidin. (B) Expression of EphA2, but not other EphA kinases andephrin-As, is elevated in cell lines derived from more malignantprostate cancer. Total cellular proteins were immunoblotted with theindicated antibodies. (C) Immunofluorescence staining of EphA2. Humanprostate cancer cells grown on cover slip were stained with anti-EphA2antibody. Texas-Red labeled secondary was used to visualize the boundprimary antibody (D) DU-145 and MatLyLu cells were stimulated withephrin-A1-Fc for indicated times and lysed. EphA2 immunoprecipitationwas carried out to determine the activation status of EphA2 usinganti-phosphotyrosine antibody. The same membranes were stripped andre-blotted for total EphA2. To determine the ERK activation status,total cell lysates were analyzed by immunoblot using anti-phospho ERK(p-ERK) antibody. Same membranes were stripped and blotted with totalERK.

FIG. 2. EphA activation inhibited DU-145 cell migration. (A) Expressionof c-Met is elevated in cell lines derived from more malignant prostatecancer. Total cellular proteins were immunoblotted with anti-humanc-Met. An anti-tubulin blot was used as a control for protein loading.(B) In a modified Boyden chamber assay, DU-145 cells were placed in theupper chamber and allowed to migrate to the lower chamber containingindicated reagents. After 8 hours, cells were stained with crystalviolet and cells remaining in the upper chamber were removed. Top panel:Cells migrated to the undersides of membrane were counted; six highpower fields were counted. Results represent means±S.D. Representativefields were shown in the lower panel. (C) Ephrin-A1-Fc inhibits DU-145cell migration when HGF/SF was uniformly presented in both sides ofmembranes. The experiment was carried out as described in A. (D)Inhibition of cell scattering by immobilized ephrin-A1 in a SOIL assay(Method). Ephrin-A1-Fc or control Fc was immobilized on 6-well culturedishes. Freshly confluent DU-145 cells on cover slips were transferredto the coated surfaces. Cells were stimulated with HGF/SF to inducemigration off the cover slips to immobilized Fc or ephrin-A1-Fc. After48 hours, cells were fixed and stained with crystal violet. The cellsthat had migrated to the coated surface were photographed after removingcover slips. (E) DU-145 cells were grown to confluency and a wound wasgenerated by scratching monolayer with a 200 μl pipette tip. The woundhealing was recorded prior to and 12 hours after the addition of Fc,ephrin-A1-Fc (1 μg/ml) and/or HGF/SF (20 ng/ml). Representative resultsfrom 3 independent experiments are shown.

FIG. 3. EphA activation inhibited DU-145 cell invasion. DU-145 cellswere placed in the upper chamber of MatriGel-coated Transwell. Fc,ephrin-A1-Fc, HGF/SF/Fc or HGF/SF/ephrin-A1-Fc, were added in the lowerchamber. After 24 hours, cells invading through MatriGel and migrated tothe undersides of membrane were counted. Representative results(mean±S.D.) from three independent experiments are shown.

FIG. 4. EphA activation attenuated cell scattering induced by HGF/SF.DU-145 cells were cultured in the presence of indicated reagents. Cellmorphology was recorded 24 and 48 hours after the initiation oftreatments (A). Numbers of total cells and cells without contact withother cells were counted in 6-8 randomly chosen fields (B). * HGF/SF/Fcvs. HGF/SF/ephrinA1-Fc: p<10⁻⁵.

FIG. 5. (A) Ephrin-A1 co-stimulation inhibited the loss of E-cadherininduced by HGF/SF. DU-145 cells were treated as indicated for 24 or 48hours. Cell lysates were subject to anti-E-cadherin immunoblot. Samemembrane was stripped and blotted with anti-ERK1 as loading control.Relative intensity of E-cadherin=intensities of E-cadherinband/intensity of ERK band. (B) Immunofluorescent staining of E-cadherinafter 24 hours of the indicated treatment. Note almost exclusivecytoplasmic staining pattern in HGF/SF treated cells, while cotreatmentwith ephrin-A1 restored significant levels of E-cadherin at cell-celljunction. (C) Ephrin-A1-Fc pre-treatment preserved E-cadherin expressionin HGF/SF treated cells. DU-145 cells were pre-treated with Fc orephrin-A1-Fc for 24 hours. HGF/SF was then added. The cells werecultured for another 24 hours and lysed for anti-E-cadherin immunoblot.Anti-ERK1 was used as loading control. (D) Cells grown on cover slipsreceived same treatment as in C were subject to anti-E-cadherinimmunofluorescence analysis. Note the significant preservation ofE-cadherin localization at cell-cell adhesion site by ephrin-A1-Fccompared with Fc control. (E) Numbers of total cells and cells withoutcontact with other cells were counted in 6-8 randomly chosen fields. *Fc/HGF/SF vs. ephrin-A1-Fc/HGF/SF: p=4.6×10⁻⁷.

FIG. 6. Schematic illustration of phage display technique that was usedto isolate the EphA2-binding peptides.

FIG. 7, Kinetics of EP1-Fc Binding to EphA2 Receptor on Cell Surface.96-well Removawell were coated with 1 mg/mL EphA2-Fc. ¹²⁵I-labeled14-3-3 proteins were allowed to bind to the wells in the presence ofserially diluted unlabeled EP1-Fc starting with a 500-fold molar excess.Bound material was counted (left). Data were subject to Scatchardanalysis (right). Each data point represents the mean from duplicatewells with variation of less than 10%.

FIG. 8. Specific Binding of EP1-Fc to EphA2 Receptor. A: ¹²⁵I labelingof PC3 cells. PC3 cells (10×10⁶) were labeled with 125I (0.5 mCi). Then,cell lysates were incubated with EP1-Fc fusion peptide, ephrin-A1-Fc(EA1-Fc), or human Fc as indicated. Equal amount of cell lysate was usedin each experimental group. EP1-Fc only bound to EphA2. B: WesternBlotting Analysis. PC3 cell lysates were incubated with EP1-Fc fusionprotein, ephrin-A1 protein, or human Fc. The immune complexes wereblotted with anti-EphA2. EP1 specifically precipitated EphA2.

FIG. 9. EP1 is an EphA2 Kinase Agonist. PC3 cells (1×10⁶ cells/ml) werestimulated with different concentrations of EP1-Fc, GST-EP1, orephrin-A1-Fc for 10 min. EphA2 was precipitated with anti-EphA2. Theimmune complex was blotted for PY to detect EphA2 activation (toppanel), or for EphA2 to show equal loading (lower panel). Datarepresents one of three similar experimental results.

FIG. 10. Time Course Induction of Tyrosine Phosphorylation of EphA2Receptor by EphrinA1-Fc Fusion Protein. PC3 cells were stimulated with 1mg/ml ephrinA1-Fc for different periods of time as indicated. Afterstimulation, cell lysates were made and were incubated with ephrinA1-Fcfusion protein (2 mg EphrinA1/100 mg cell lysate) for 1 hr at 4° C.EphA2 receptor-ligand complex was precipitated with g-bind beads andsubjected to Western blotting analysis. Upper panel protein bands weredetected by a monoclonal antibody against phosphorylated tyrosineresidue and represented the protein tyrosine phosphorylation of EphA2receptor. Lower panel protein bands were detected by a polyclonalantibody against Eph-A2 receptor and demonstrated a equal amount ofprotein was loaded on SDS gel. Data represents one of three similarexperimental results.

FIG. 11. Activation of EphA2 downstream signaling by EP1-Fc. PC3 cellswere stimulated with the indicated concentrations of ephrinA1-Fc orEP1-Fc fusion proteins and lysed in RIPA buffer. EphA2 activation statuswas examined by immunoprecipitating EphA2 and blotting forphosphotyrosine or EphA2 itself (top panel). Inhibition of ERK1/2, adownstream signaling event of EphA2 characterized in our lab, wasexamined by blotting total cell lysates with anti-p-ERK1/2.

FIG. 12. Inhibition of cell growth by EP1-Fc. About 80 pRNS-1 prostateepithelial cells were seeded into each well on 12-well dishes in thepresence of indicated concentrations of ephrin-A1-Fc. Cells werecultured for 10 days. Clonal growth was visualized by crystal violetstaining.

FIG. 13. Inhibition of cell proliferation by EP 1-Fc. Subconfluent PC3or pRNS-1 cells were stimulated with the indicated reagents overnight.Next day cells were labeled with ³H-thymidine for 2 hours. ³H-thymidineincorporation into isolated DNA synthesis was determined byscintillation counting.

FIG. 14. EP1 and EP2 peptides have sequence similarities to ephrins.Letters underlined in ephrin-A1 and ephrin-B2 indicate major receptorbinding residues. Letters underlined in EP1 represent residues that weresystemically mutated into alanines to determine the effects on EphA2binding and activation (see FIG. 15).

FIG. 15. Identification of EP1 residues critical for EphA2 activation.Four out of five EP1 residues that align with receptor-binding regionsof ephrins are critical for EphA2 activation. Mutation to alanine wasperformed at the indicated positions (see letters in FIG. 15 forreference), and the resultant EP 1-Fc mutants were used to stimulate PC3cells for 10 min at 10 mg/ml for ability to activate EphA2.

FIG. 16. Predicted binding of EP1 to EphA2 kinase ligand binding domain.

FIG. 17. An agonistic peptide for EphA2 selected from phage displaylibraries.

FIG. 18. Time course of EphA2 activation by EP 1-Fc in PC3 cells.

FIG. 19. EP1-Fc induced PC3 cell rounding. PC3 cells cultured oncoverslips were stimulated with the indicated concentrations ofephrinA1-Fc, EP1-Fc of Fc for 10 min. Cells were then fixed andphotographed.

FIG. 20. EP1-Fc has moderate inhibitory effects on PC3 xenograft growthin nude mice. A) Systemic (i.p.) administration of ephrin-A1-Fc (5 mg/g)or EP1-Fc (10 mg/g) inhibited s.c. tumor growth of GFP-PC-3 cellscompared with human IgG control (10 mg/g). The lack of effects afterthree weeks of treatment likely reflects production of anti-ephrin-A-Fcand anti-EP1-Fc antibodies in the recipient animals. B) BothEphrin-A1-Fc and EP1-Fc, but not human IgG, target to GFP-PC-3 tumors.Frozen sections were stained with biotinylated rabbit anti-human Fc, andHRP-conjugated streptavidin.

FIG. 21. The overall computer-aided drug design targeting EphA2 kinase.

FIG. 22. Structure-based and computer-aided drug design targeting EphA2kinase.

FIG. 23. The steps of DOCK algorithm. The docking calculations wereperformed on the Linux cluster of the Ohio Supercomputer Center.

FIG. 24. Step 1 of DOCK: molecular modeling of EphA2 ligand bindingdomain.

FIG. 25. Step 2 of DOCK: establishing pharmacophore.

FIG. 26. Step 3 of DOCK: generating spheres fitting into the activesite.

FIG. 27. Structure and function of dobutamine as an EphA2 agonisticcompound. PC-3 cells were stimulated with the indicated concentration ofdobutamine, EphA2 was immunoprecipitated and tested for activationstatus by blotting with anti-phosphotyrosine (PY99).

FIG. 28. Structure and function of labetalol as an EphA2 agonisticcompound. A) EphA2 activation by labetalol. B) BIAcore binding curvesfor interaction of labetalol with EphA2 kinase. The increasingconcentrations of labetalol (0, 20 mM, 40 mM, 80 mM, 160 mM, 320 mM, 640nM, 1.25 mM and 2.5 mM) were injected over EphA2 kinase ligand-bindingdomain immobilized on the sensor chip.

FIG. 29. Structure and function of doxazosin as an EphA2 agonisticcompound. A) Doxazosin activates EphA2. Although prominent activationwas observed at 200 mM, weaker activation can be seen at 40 mM. B)BIAcore binding curves shows direct binding of Doxazosin to EphA2.

FIG. 30. The EphA2 agonists demonstrate shared structural features.

FIG. 31. Structure and function of another EphA2 agonistic compound:(di-meo-isoquinolin-1-ylmethyl)-et-di-meo-pyrido(2,1-a)isoquinolin,hydrobromide S120103. This compound was found by search chemicaldatabase with the shared common structure deduced from known binders.The data confirmed the validity of common backbone structures.

FIG. 32. Crystal structure of EphA2 ligand binding domain. A). Ribbondiagram. B). Molecular surface representation.

FIG. 33. Dimerization of EphA2 ligand-binding domain through hydrophobicinteractions.

FIG. 34, Arrangement of EphA2-LBD in the crystal indicates ahexamerization interface.

FIG. 35. Hexamerization interface involves electrostatic interactions.

FIG. 36. EphA2 kinase is present on cell surface as a dimer. Cellsurface proteins were cross-linked with a membrane impermeable DSP andlysed. EphA2 was immunoprecipitated with anti-EphA2 antibody. Theprecipitate materials were separated on SDS-PAGE under reducing ornon-reducing conditions, and blotted for EphA2.

FIG. 37. Activation of EphB2, but not EphA2 on PC-3 cells requiressuper-clustering of ligands. Ephrin-A1-Fc (EA1-Fc) or ephrin-B1-Fc(EB1-Fc) at indicated final concentrations were either used directly tostimulate PC-3 cells, or pre-clustered with anti-Fc antibody before cellstimulation. EphA2 or EphB2 were immunoprecipitated and blotted foractivation status with PY99 antibody.

FIG. 38. Clustering of ephrin-A1-Fc did not increase the inhibitoryeffects of EphA2 activation on integrin-mediated cell adhesion tofibronectin.

FIG. 39. Characterization of EphA2 expression in mouse skin and role ofEphA2 in tumor development. Characterization of EphA2 expression inmouse skin and role of EphA2 in tumor development. A) Expression ofEphA2 in skin extracts from wild-type and EphA2 KO mice. Wild-type andEphA2 mutant mice at P8 were sacrificed. Skin tissues were removed fromsimilar regions and snap-frozen in liquid nitrogen. The frozen tissueswere grinded, lysed in RIPA buffer, and subjected to immunoblot withrabbit polyclonal anti-EphA2 antibodies. The same membrane was re-probedfor GAPDH as loading control. B) Expression of β-gal in EphA2 KO mouseskin. Frozen sections were fixed and stained with X-gal and followed bycounterstaining with nuclear Fast-Red. C) Expression of EphA2 in theskin from wild-type and EphA2 KO mice. Skin frozen sections (7 μm) werestained with goat polyclonal antibodies that recognize the ectodomain ofEphA2 followed by detection with donkey anti-goat IgG conjugated withFITC. Images were taken on a Leica microscope equipped with SPOT-RTdigital camera. Note the cytoplasmic staining pattern of the trappedEphA2-β-geo fusion protein in EphA2-knockout mouse skin D) EphA2 KO miceare more susceptible to DMBA/TPA two-stage chemical carcinogenesiscompared to wild-type mice, while heterozygous mice showed anintermediate phenotype. Pictures were taken 13 weeks after DMBAinitiation.

FIG. 40. Skin carcinogenesis of wild-type and EphA2 mutant mice. A)Average number of papillomas per mouse following DMBA/TPA two-stagechemical carcinogenesis. Mice were euthanized at week 16 due to largetumor burden in the knockout group of mice. B) Tumor incidence. C)Growth rate of tumors measured by average number of tumors reaching 4 mmin diameter or larger. D) Immunoblot to show EphA2 expression in tumorsfrom wild type and EphA2 mutant mice.

FIG. 41. EphA2 was up-regulated during skin tumorigenesis. Mice weresacrificed 16 weeks after DMBA initiation. Skin tumors were dissectedand frozen sections with normal skin attached were cut. They werestained with X-gal (A, B) or a goat polyclonal antibody that recognizesthe ectodomain of EphA2 (C, D). A) A tumor from an EphA2^(+/−) mice. B)Normal skin next to tumor shown in A. C) A tumor from an EphA2^(−/−)mouse. Arrow, normal skin; arrow head, papilloma. D) A tumor from anEphA2^(−/−) mouse. Note the substantial upregulation of EphA2 inwild-type tumor with typical membrane-staining pattern; mutantEphA2-β-geo fusion protein was also overexpressed, but was trapped incytoplasm.

FIG. 42. Compartmentalized expression of EphA2 and ephrin-A1 in mouseskin. A) Frozen sections were obtained from tumor-free areas onDMBA/TPA-treated mice and were co-stained with a goat polyclonalantibody that recognizes EphA2 ectodomain and a rabbit polyclonalanti-ephrin-A1 antibody. Note the thickened epidermal layer due torepeated TPA treatment compared with control untreated skin (panel Cbelow). S, Suprebasal; B, Basal; arrows, outer root shaft; arrow heads,precortex. B) Insets from A showing basal-suprabasal gradient expressionof EphA2 and basal expression of ephrin-A1 in epidermis. C) EphA2 andephrin-A1 expression in untreated normal skin from wild type andknockout mice. D) Representative papillomas from wild type and knockoutmice stained for EphA2 and ephrin-A1.

FIG. 43. EphA2 kinase is required for ephrin-A1-induced inhibition ofERK1/2 MAP kinase and growth suppression in primary keratinocytes. A)EphA kinase activation by ephrin-A1 in EphA2⁺⁺ and EphA2⁻⁻ but notEphA2⁻⁻ keratinocytes. Keratinocytes were isolated from newborn (P1)mice and cultured on matrigel-coated culture plates. They werestimulated with 1.0 μg/ml of ephrin-A 1-Fc for 10 min. The unstimulatedcells were used as control. EphA receptors including EphA2 wereprecipitated from the cell lysates using ephrin-A1-Fc, and weresubjected to immunoblot analysis with rabbit polyclonalanti-phospho-EphA/B antibody. Membrane was stripped and blotted againfor total EphA2. B) Ephrin-A1 stimulation leads to inactivation ofERK1/2 MAPK in EphA2⁻⁺ and EphA2^(−/−) but not EphA2^(−/−)keratinocytes. Total cell lysates were analyzed by immunoblot with theindicated antibodies. The band densities from p-ERK blot were normalizedto the corresponding total ERK1 blot. The ratios of p-ERK betweenephrin-A1-treated and untreated were shown in the lower panel. C).Ephrin-A1 stimulation inhibits clonal growth of EphA2⁻⁻ and EphA2^(−/−)but not EphA2^(−/−) keratinocytes. Primary keratinocytes were plated on6-well plates coated with matrigel at 5,000 cells/well, and allowed togrow for 12 days in the presence of Fc (0.5 μg/ml) or ephrin-A1-Fc (1.0μg/ml).

FIG. 44. Deletion of EphA2 leads to accelerated cell proliferation ratein skin tumors. A) Tumors were harvested from mice sacrificed 16 weekspost DMBA initiation, Paraffin-embedded sections were stained with anantibody against Ki67 proliferation marker. B) Quantitative analysis ofproliferation index. Randomly selected tumor sections from threedifferent animals of each genotype were stained for Ki67 (EphA2^(−/+),n=9; EphA2^(−/−), n=12; EphA2^(−/−), n=11). Total numbers ofKi67-positive cells were counted on digital images that cover the entiretumor sections. They were divided by total tumor areas measured usingMetaMorph 6.2r4 imaging software (Universal Imaging) and normalized towild type control. The differences between EphA2^(+/−) and EphA2^(−/−)or EphA2^(−/−) were statistically significant (P<0.001, one way ANOVA).C) Quantitative analyses of apoptosis by TUNEL staining. No significantdifferences were detected among different genotypes.

FIG. 45. Malignant progression of DMBA/TPA-induced tumors in wild typeand EphA2 mutant mice. A) TPA treatment was stopped at 16 weekspost-DMBA initiation. Tumors were collected 10 weeks later and processedfor staining with hematoxylin and eosin (a-e), anti-keratin 14 (f-g) orX-gal (i). a, A benign lesion from a wild type (+/+) mouse. b, Aninvasive carcinoma from a wild type mouse. c-d, An invasive squamouscell carcinoma from a knockout mice (−/−). e, A knockout spindle cellcarcinoma. f, Keratin 14 staining a wild type papilloma. g-h, Keratin 14staining of an invasive EphA2^(−/−) carcinoma showing spindle cellsinfiltrating into tumor stroma. i, X-gal staining of a frozen sectioncut from the same tumor as in (h) showing EphA2-β-geo fusion proteinexpression. B) Tumors arising in EphA2 knockout exhibited higherincidence of malignant conversion. Histopathological examinations wereperformed on the indicated numbers of tumors from each genotype. Tumorswith clear evidence of invasive growth were quantitated.

FIG. 46. A) EphA2 is overexpressed in osseous but not lymph nodemetastases of human prostate cancer specimens obtained from rapidautopsy. B) Inhibition of Akt activities in PC-3 cells upon stimulationof EphA2 with its cognitive ligand ephrin-A1 (EA1-Fe). C) Dominantnegative EphA2 abolished the inhibitory effects of ephrin-A1 treatmenton Akt and ERK activities. DU145 cells were infected with a retroviralvector expressing wild type (WT) or a dominant negative mutant EphA2where the entire cytoplasmic tail was replaced with GFP. An antibodyagainst the ectodomain of EphA2 was used to determine the expression ofendogenous (vector control). WT- and DN-EphA2. D) Upregulation of EphA2by Ras but not Myc oncogene in NRP152 normal rat prostate epithelialcells.

FIG. 47. A) Expression of β-gal in EphA2 KO mouse lung. Frozen sectionswere fixed and stained with X-gal and followed by counterstaining withnuclear Fast-Red. B) Expression of EphA2 in the lung from wild-typemice. Lung frozen sections were stained with goat polyclonal antibodiesthat recognize the ectodomain of EphA2 followed by detection with donkeyanti-goat IgG conjugated with FITC. C) EphA kinase activation byephrin-A1 in H125, H1975 and SKMES human non-small cell lung cancercells. Cells were stimulated with 2 ig/ml of ephrin-A1-Fc for 10 and 30minutes. Ephrin-A1 stimulation inhibits ERK and AKT phosphorylation.These data suggest that agonists for EphA kinases can also be used totarget human lung cancers.

FIG. 48. A illustrates expression of EphA1 and EphA2 in human breastcancer cell lines. Note that EphA1 are more broadly distributed thanEphA2. FIG. 48B illustrates that EphA1 and EphA2 are upregulated inmouse breast tumors induced by HER2/Neu, but not in tumors induced byluteinizinghormone (LH). Upregulation of EphA2 is present in 30% humanbreast cancer.

FIG. 49A illustrates expression of EphA1 in DU145 cells infected withvector control (control) and EphA1 expression retrovirus. FIG. 49Billustrates that about 2,000 cells were plated on 12-well plates in theregular culture medium (10% serum) and low serum medium (0.5%). Cellwere cultured for 7 days (10% serum) or 18 days (0.5%). FIG. 49Billustrates that proliferation of prostatic epithelial cells expressingEphA1 and activated with Ephrin-A1 is inhibited.

FIG. 50A illustrates that the mutation (EphA3DN) in VACO 451 cellscaused loss of EphA3 kinase activities (Note that there is no pEphA/Bsignal). FIG. 50B illustrates that VACO-451 cells were infected withretroviral vectors that express wild type (WT) EphA3. Clones thatexpress high (EphA3-H) and medium (EphA3-M) levels of EphA3 as well asvector control cells were subject to growth in soft agar assay shown inFIG. 50C.

DETAILED DESCRIPTION

The present invention relates to methods and compositions that providefor the treatment, inhibition, and management of diseases and disordersassociated with the expression or overexpression of EphA kinases (e.g.,EphA1, EphA2, and EphA3) and/or cell hyperproliferative diseases anddisorders. The present invention is based at least in part on thediscovery that EphA kinases (e.g., EphA1, EphA2, and EphA3) can functionas a tumor suppressor and that activation of EphA kinase (e.g., EphA1,EphA2, and EphA3) can inhibit cancer cell growth, migration and/orproliferation in, for example, prostate cancer, breast cancer,colorectal cancer, skin cancer, and lung cancer.

A particular aspect of the invention relates to methods and therapeuticagents or compositions containing compounds that inhibit cancer cellproliferation, invasion, and survival, particularly those cancer cellsthat overexpress EphA kinase or cancer cells that have a hyperactiveRas/Raf/MEK/ERK1/2 and/or PI3/AKT signaling pathway. The therapeuticagents or compounds can comprise agonists of EphA (e.g., EphA1, EphA2,and EphA3). Exemplary agonists of EphA kinase (e.g., EphA1, EphA2, andEphA3) can include peptide and small molecule EphA kinase agonists.

The present invention further relates to methods and therapeutic agentsfor the treatment, inhibition, or management of metastases of cancers ofepithelial cell origin, especially human cancers of the breast, lung,skin, prostate, bladder, and pancreas, and renal cell carcinomas andmelanomas. Other aspects of the present invention relate to methods ofinhibiting proliferation of cancer cells by suppressing theRas/Raf/MEK/ERK1/2 signaling pathway with a therapeutic agent inaccordance with the present invention. Still other aspects of thepresent invention relate to methods of inhibiting cancer cell survivalby suppressing PI3/AKT signaling pathway with a therapeutic agent inaccordance with the present invention.

Further compositions and methods of the invention include other types ofactive ingredients in combination with the therapeutic agents of theinvention. In other embodiments, the methods of the invention are usedto treat, prevent or manage other diseases or disorders associated withcell hyperproliferation, for example but not limited to restenosis,inflammation, asthma, chronic obstructive lung diseases, abnormalangiogenesis (particularly in the eyes), psoriasis, etc. The presentinvention also relates to methods for the treatment, inhibition, andmanagement of cancer or other hyperproliferative cell disorder ordisease that has become partially or completely refractory to current orstandard cancer treatment, such as chemotherapy, radiation therapy,hormonal therapy, and biological therapy.

In an additional aspect, the invention provides methods of screening foranti-cancer agents, particularly anti-metastatic cancer agents byadministering a test agent to the EphA knockout mouse or to a cellisolated from the knockout mouse. The knockout mouse can have germlineand somatic cells in which at least one allele of the genomic EphA gene(e.g., EphA1, EphA2, or EphA3 gene) is disrupted. The mouse can becrossed with other knockout mouse where at least one allele of anothertumor suppressor gene is disrupted. An exemplary, knockout mouseexhibits increased susceptibility to the formation of tumors as comparedto a knockout mouse having germline and somatic cells in which at leastone allele of the tumor suppressor gene alone is disrupted. Exemplarytumor suppressor genes include p53, p63, p73, p16, PTEN, Rb, Apc, andNkx 3.1. In certain aspects, the knockout mouse can have a germline andsomatic cells in which at least one allele of the genomic EphA gene(e.g., EphA1, EphA2, or EphA3 gene) is disrupted and a transgeneencoding an oncogene is expressed. The transgenic mouse exhibitsincreased susceptibility to the formation of tumors as compared to atransgenic mouse having expressing the transgene alone. For example, theoncogene encodes T antigen. Myc, and Ras oncoprotein.

In certain aspects, the invention provides a method of assaying for anagonist of EphA kinase (e.g., EphA 1, EphA2, or EphA3), comprising: a)contacting an EphA polypeptide with a test agent; and b) determiningwhether the agent binds to EphA. Optionally, binding of the agent toEphA kinase is determined by a method selected from the group consistingof yeast two-hybrid assay, solid phase binding assay, fluorescencepolarization assay, fluorescence resonance energy transfer (FRET) assay,and ELISA.

In certain aspects, the invention provides a method of assaying for anagonist of EphA kinase (e.g., EphA1, EphA2, or EphA3), comprising: a)contacting an EphA polypeptide with a test agent; and b) determiningwhether the agent stimulates EphA activity. For example, the agentactivates EphA tyrosine phosphorylation. Optionally, EphA tyrosinephosphorylation is determined by an immunoassay.

In certain aspects, the invention provides a method of identifying atherapeutic agent for cancer, comprising identifying an agent selectedfrom the group consisting of: 1) an agent which binds to an EphAreceptor protein kinase (e.g., EphA1, EphA2, or EphA3); 2) an agentwhich stimulates phosphorylation of an EphA receptor protein; 3) anagent which enhances dimerization of an EphA receptor protein; and 4) anagent which enhances binding of an EphA ligand to an EphA receptorprotein. Optionally, the agent binds to the ligand-binding domain ofEphA receptor protein.

In certain aspects, the present invention provides a crystallinemolecule (crystal structure?) comprising an EphA2 ligand binding domain(LBD). In one embodiment, the molecule is an EphA2 protein. In anotherembodiment, the molecule is an EphA2 LBD. In certain embodiments, theinvention provides crystal compositions comprising an EphA2 protein oran EphA2 LBD in the presence or absence of a chemical entity. Theinvention also provides a method of crystallizing an EphA2 protein or anEphA2 LBD.

The invention further provides a computer comprising a data storagemedium which comprises the structure coordinates of a moleculecomprising all or part of the EphA2 ligand binding domain (LBD). Suchstorage medium, when read and utilized by a computer programmed withappropriate software, displays on a computer screen or similar viewingdevice, a three-dimensional graphical representation of a molecule ormolecular complex comprising such ligand binding structure.

The invention provides methods for screening, designing, optimizing,evaluating, and identifying compounds which bind to an EphA2 molecule orits LBD based on the crystal structure. Such compounds can be potentialinhibitors (antagonists) or activators (agonists) of EphA2 proteins.

The invention also provides a method for determining at least a portionof the three-dimensional structure of molecules which contain at leastsome structurally similar features to an EphA2 protein (e.g., EphA2LBD). This is achieved by using at least some of the structurecoordinates obtained from the EphA2 protein as described herein.

I. EphA Polypeptides and Nucleic Acids

In certain aspects, wildtype or variant EphA polypeptides are used as atarget for screening or selecting agonists of EphA. Exemplary EphApolypeptides can comprise EphA1, EphA2, or EphA3. EphA1, EphA2, or EphA3in accordance with the present invention can have amino sequencessubstantially similar to native mammalian or wild type EphA1, EphA2, orEphA3. For example, EphA1, EphA2, or EphA3 can have amino sequencessubstantially similar to, respectively, SEQ ID NO: 4, SEQ ID NO: 5, SEQID NO: 6.

The EphA1, EphA2, or EphA3 polypeptides of the present invention canalso be a variant of native mammalian or wildtype EphA1, EphA2, orEphA3, such as a fragment, analog and derivative of mammalian EphA1,EphA2, or EphA3. Such variants can include, for example, a polypeptideencoded by a naturally occurring allelic variant of a native EphA1,EphA2, or EphA3 gene (i.e., a naturally occurring nucleic acid thatencodes a naturally occurring mammalian EphA1, EphA2, or EphA3), apolypeptide encoded by an alternative splice form of a native EphA1,EphA2, or EphA3 gene, a polypeptide encoded by a homolog or ortholog ofa native Eph-A1, EphA2, or EphA3 gene, and a polypeptide encoded by anon-naturally occurring variant of a native EphA1, EphA2, or EphA3 gene.

EphA1, EphA2, or EphA3 variants can have a peptide (or amino acid)sequence that differs from native EphA1, EphA2, or EphA3 in one or moreamino acids. The peptide sequence of such variants can feature adeletion, addition, or substitution of one or more amino acids of EphA1,EphA2, or EphA3 protein. Amino acid insertions are preferably of about 1to 4 contiguous amino acids, and deletions are preferably of about 1 to10 contiguous amino acids. Variant EphA1, EphA2, or EphA3 proteinssubstantially maintain a native EphA1, EphA2, or EphA3 proteinfunctional activity. Exemplary, EphA1, EphA2, or EphA3 variants can bemade by expressing nucleic acid molecules within the invention thatfeature silent or conservative changes.

In accordance with an aspect of the invention, variant polypeptides havean amino acid sequence that is at least 75% identical to an amino acidsequence as set forth in SEQ ID NO: 4, SEQ ID NO: 5, or SEQ ID NO: 6. Inother aspects, the variant polypeptide has an amino acid sequence atleast 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% identical to an aminoacid sequence as set forth in SEQ ID NO: 4, SEQ ID NO: 5, or SEQ ID NO:6.

EphA1, EphA2, or EphA3 fragments corresponding to one or more particularmotifs and/or domains or to arbitrary sizes, are within the scope of thepresent invention. Isolated peptidyl portions of EphA1, EphA2, or EphA3proteins can be obtained by screening peptides recombinantly producedfrom the corresponding fragment of the nucleic acid encoding suchpeptides. In addition, fragments can be chemically synthesized usingtechniques known in the art such as conventional Merrifield solid phasef-Moc or t-Boc chemistry. For example, a EphA1, EphA2, or EphA3polypeptide of the present invention may be arbitrarily divided intofragments of desired length with no overlap of the fragments, orpreferably divided into overlapping fragments of a desired length. Thefragments can be produced recombinantly and tested to identify thosepeptidyl fragments which can function as agonists of a native EphA1,EphA2, or EphA3.

Variants of EphA1, EphA2, or EphA3 polypeptide can also includerecombinant forms of the proteins. Recombinant polypeptides of thepresent invention, in addition to a EphA1, EphA2, or EphA3, are encodedby a nucleic acid that can have at least 85% sequence identity with thenucleic acid sequence of a gene encoding a mammalian protein. EphA1,EphA2, or EphA3 polypeptides variants can include agonistic forms of thepolypeptide that constitutively express the functional activities of anative EphA1, EphA2, or EphA3. Other variants can include those that areresistant to proteolytic cleavage, as for example, due to mutations,which alter protease target sequences. Whether a change in the aminoacid sequence of a peptide results in a variant having one or morefunctional activities of a native EphA1, EphA2, or EphA3 can be readilydetermined by testing the variant for a native EphA1, EphA2, or EphA3protein functional activity.

In certain aspects, the application provides various domains orfragments of the EphA2 polypeptide, such as a ligand-binding domain(LBD) of an EphA2 polypeptide. In one embodiment, the applicationrelates to an EphA2 LBD (SEQ ID NO: 7), and variant polypeptidesthereof. In certain embodiments, variant polypeptides have an amino acidsequence that is at least 75% identical to an amino acid sequence as setforth in SEQ ID NO: 7. In other embodiments, the variant polypeptide hasan amino acid sequence at least 80%, 85%, 90%, 95%, 97%, 98%, 99% or100% identical to an amino acid sequence as set forth in SEQ ID NO: 7.

In certain aspects, the application provides fusion polypeptidescomprising an EphA polypeptide (e.g., EphA1, EphA2, or EphA3) or adomain thereof and a second domain. The second domain may comprise oneor more fusion domains. In another aspect, the fusion protein cancomprise an EphA polypeptide or a domain thereof and a second domainselected from the group consisting of a dimerizing polypeptide, apurification polypeptide, a stabilizing polypeptide, and a targetingpolypeptide. Well known examples of such fusion domains include, forexample, polyhistidine, Glu-Glu, glutathione S transferase (GST),thioredoxin, protein A, protein G, and an immunoglobulin heavy chainconstant region (Fc), maltose binding protein (MBP), which areparticularly useful for isolation of the fusion polypeptide by affinitychromatography. For the purpose of affinity purification, relevantmatrices for affinity chromatography, such as glutathione-, amylase-,and nickel- or cobalt-conjugated resins are used. Many of such matricesare available in “kit” form, such as the Pharmacia GST purificationsystem and the QIAexpress™ system (Qiagen) useful with (HIS₆) fusionpartners. Another fusion domain well known in the art is greenfluorescent protein (GFP). This fusion partner serves as a fluorescent“tag” which allows the fusion polypeptide of the invention to beidentified by fluorescence microscopy or by flow cytometry. Fusiondomains also include “epitope tags,” which are usually short peptidesequences for which a specific antibody is available. Well known epitopetags for which specific monoclonal antibodies are readily availableinclude FLAG, influenza virus hemagglutinin (HA), and c-myc tags. Insome cases, the fusion domains have a protease cleavage site, such asfor Factor Xa or Thrombin, which allow the relevant protease topartially digest the fusion EphA polypeptide (e.g., EphA1, EphA2, orEphA3) and thereby liberate the recombinant polypeptide therefrom. Theliberated polypeptide can then be isolated from the fusion partner bysubsequent chromatographic separation.

In certain aspects, this application relates to a fusion proteincomprising an EphA polypeptide or a domain thereof and an immunoglobulinelement. In certain embodiments, the an EphA polypeptide or a domainthereof comprises extracellular portions of the EphA polypeptide.

In certain aspects, the application relates to a fusion proteincomprising an EphA2 polypeptide or a domain thereof and animmunoglobulin element, wherein the immunoglobulin element comprises animmunoglobulin heavy chain. In certain embodiments, the immunoglobulinelement comprises an Fc domain. In certain instances, the immunoglobulinheavy chain is selected from the group consisting of an IgM, IgD, IgE,and IgA heavy chains. In further aspects, the immunoglobulin heavy chainis selected from the group consisting of an IgG1, IgG2β, IgG2α, and IgG3heavy chains. The immunoglobulin element may comprise the CH1 and Fcdomains in certain embodiments. In certain instances, the immunoglobulinelement comprises a CH1 domain of a first immunoglobulin class and a CH1domain of a second immunoglobulin class, wherein the first and secondimmunoglobulin classes are not the same.

In additional embodiments, the present application relates to a fusionprotein comprising a EphA polypeptide (e.g., EphA1, EphA2, or EphA3) ora domain thereof and an immunoglobulin element, further comprising adimerizing polypeptide.

In certain embodiments, the application also relates to a compositioncomprising a fusion protein of the invention and a pharmaceuticallyacceptable carrier.

In certain embodiments, the dimerizing polypeptide comprises anamphiphilic polypeptide. The amphiphilic polypeptide may comprise up to50 amino acids, up to 30 amino acids, up to 20 amino acids, or up to 10amino acids. In certain embodiments, the dimerizing polypeptidecomprises a peptide helix bundle. In certain embodiments, the dimerizingpolypeptide comprises a leucine zipper. The leucine zipper may be a junzipper or a fos zipper. In certain embodiments, the dimerizingpolypeptide comprises a polypeptide having positively or negativelycharged residues wherein said polypeptide binds to another peptidebearing opposite charges.

In further embodiments, the application relates to a fusion proteincomprising an amino acid sequence that is at least 90% identical to theamino acid sequence of SEQ ID NO:7. In certain aspects, the applicationrelates to a nucleic acid sequence encoding a polypeptide fusioncomprising an EphA polypeptide or a domain thereof and an immunoglobulinelement. In certain embodiments, the application relates to a nucleicacid sequence encoding a polypeptide at least 90% identical to the aminoacid sequence set forth in SEQ ID NO:7. In additional embodiments, theapplication relates to a nucleic acid sequence encoding an EphApolypeptide or a domain thereof polypeptide comprising one or more pointmutations wherein said point mutations increase the binding affinity ofsaid an EphA polypeptide or a domain thereof.

In other aspects, the invention relates to a nucleic acids encoding EphApolypeptides or variants thereof, such as nucleic acids encoding EphA1,EphA2, EphA3, or EphA2 LBD (e.g., SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO:6, and SEQ ID NO: 7). Nucleic acids that encode EphA1, EphA2, EphA3, orEphA2 can be a native or non-native nucleic acid and be in the form ofRNA or in the form of DNA (e.g. cDNA, genomic DNA, and synthetic DNA).The DNA can be double-stranded or single-stranded, and ifsingle-stranded may be the coding (sense) strand or non-coding(anti-sense) strand. For example, nucleic acid molecules that encode theEphA1, EphA2, EphA3, or EphA2 LBD can have sequences substantiallysimilar to, respectively, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, andSEQ ID NO: 11.

Other nucleic acid molecules that encode EphA1, EphA2, EphA3, or EphA2LBD within the invention can be variants of a native EphA1, EphA2,EphA3, or EphA2 LBD gene, such as those that encode fragments, analogsand derivatives of a native EphA1, EphA2, EphA3, or EphA2 LBDpolypeptides. Such variants may be, for example, a naturally occurringallelic variant of a native EphA1, EphA2, EphA3, or EphA2 LBD gene, ahomolog of a native EphA1, EphA2. EphA3, or EphA2 LBD gene, or anon-naturally occurring variant of a native EphA1, EphA2, EphA3, orEphA2 LBD gene. These variants have a nucleotide sequence that differsfrom a native EphA1, EphA2, EphA3, or EphA2 LBD gene in one or morebases. For example, the nucleotide sequence of such variants can featurea deletion, addition, or substitution of one or more nucleotides of anative EphA1, EphA2, EphA3, or EphA2 LBD gene. Nucleic acid insertionsare preferably of about 1 to 10 contiguous nucleotides, and deletionsare preferably of about 1 to 10 contiguous nucleotides.

In other aspects, EphA nucleotide sequences also include nucleotidesequences that will hybridize under highly stringent conditions to thenucleotide sequences designated in SEQ ID NO: 8, SEQ ID NO: 9, SEQ IDNO: 10, and SEQ ID NO: 11, or fragments thereof. One of ordinary skillin the art will understand readily that appropriate stringencyconditions which promote DNA hybridization can be varied. One ofordinary skill in the art will understand readily that appropriatestringency conditions which promote DNA hybridization can be varied. Forexample, one could perform the hybridization at 6.0× sodiumchloride/sodium citrate (SSC) at about 45° C., followed by a wash of2.0×SSC at 50° C. For example, the salt concentration in the wash stepcan be selected from a low stringency of about 2.0×SSC at 50° C. to ahigh stringency of about 0.2×SSC at 50° C. In addition, the temperaturein the wash step can be increased from low stringency conditions at roomtemperature, about 22° C., to high stringency conditions at about 65° C.Both temperature and salt may be varied, or temperature or saltconcentration may be held constant while the other variable is changed.In one embodiment, the invention provides nucleic acids which hybridizeunder low stringency conditions of 6×SSC at room temperature followed bya wash at 2×SSC at room temperature.

In further embodiments, the EphA nucleotide sequences of the inventioncan be isolated, recombinant, and/or fused with a heterologousnucleotide sequence, or in a DNA library.

In yet other embodiments, the application provides dimers and/ormultimeric forms of the EphA polypeptide and domains thereof. Multimericforms of the EphA2 include: dimers, trimers, tetramers, pentamers andhexamers.

II. Crystallizable Compositions and Crystals of EphA2 Polypeptides

According to one aspect, the invention provides a crystallizablecomposition or crystal comprising an EphA2 polypeptide, such as an EphA2ligand binding domain (LBD) in the presence or absence of a chemicalentity. The ligand binding domain may be complexed or uncomplexed with aligand or a compound. The EphA2 protein may be produced by anywell-known method, including synthetic methods, such as solid phase,liquid phase and combination solid phase/liquid phase syntheses;recombinant DNA methods, including cDNA cloning, optionally combinedwith site directed mutagenesis; and/or purification of the naturalproducts. In a preferred embodiment, the protein is overexpressed in anE. coli system or a baculovirus system.

The invention also provides a method of making crystals of EphA2 protein(e.g., an EphA2 LBD) in the presence or absence of a chemical entity.Such methods comprise the steps of: a) producing and purifying EphA2protein: b) combining said EphA2 protein, or a homologue thereof in thepresence or absence of a chemical entity with a crystallization solutionto produce a crystallizable composition; and c) subjecting saidcrystallizable composition to conditions which promote crystallization.The crystallization solution may include, but is not limited to,polyethylene glycol (PEG) at between about 10% to 30% v/v, 100-300 mMammonium sulphate and a buffer that maintains pH at between about 4.0and 8. In one embodiment, the crystallization solution comprises 25% PEG3350, 50 mM 2-(N-morpholino) ethanesulfonic acid (MES) at pH 6.0 and 200mM ammonium sulphate.

By way of example, the crystallizable composition comprisesunphosphorylated Aurora-2 protein kinase domain, 25% PEG 3350, 50 mM2-(Nmorpholino)ethanesulfonic acid (MES) at pH 6.0, and 200 mM ammoniumsulphate. In a more preferred embodiment, the crystallizable compositioncomprises unphosphorylated Aurora-2 protein kinase domain, 25% PEG 3350,50 mM 2-(Nmorpholino)ethanesulfonic acid (MES) at pH 6 or 200 mMammonium sulphate and a chemical entity selected from the groupconsisting of an inhibitor and substrate analogue.

Devices for promoting crystallization can include but are not limited tothe hanging-drop, sitting-drop, sandwich-drop, dialysis, microbatch ormicrotube batch devices (see. e.g., U.S. Pat. Nos. 4,886,646, 5,096,676,5,130,105, 5,221,410, and 5,400,741 herein incorporated by reference intheir entirety). The hanging-drop, sitting-drop and some adaptations ofthe microbatch methods produce crystals by vapor diffusion. The hangingdrop and sitting drop containing the crystallizable composition isequilibrated against a reservoir containing a higher or lowerconcentration of precipitant. As the drop approaches equilibrium withthe reservoir, the saturation of protein in the solution leads to theformation of crystals. Other methods of making crystals of proteins canbe found in, for example, U.S. Pat. No. 6,090,609, PCT publication Nos.WO 04/060310, WO 03/092607, and WO 03/022877 (incorporated herein byreference, in their entirety).

It would be appreciated that one can vary the crystallization conditionsto identify other crystallization conditions that would produce crystalsof EphA2 proteins in the presence or absence of a chemical entity. Suchvariations include, but are not limited to, adjusting pH, proteinconcentration and/or crystallization temperature, changing the identityor concentration of salt and/or precipitant used, using a differentmethod for crystallization, or introducing additives such as detergents(e.g., TWEEN 20 (monolaurate), LDOA, Brji 30 (4 lauryl ether)), sugars(e.g., glucose, maltose), organic compounds (e.g., dioxane,dimethylformamide), lanthanide ions, or polyionic compounds that aid incrystallizations. High throughput crystallization assays may also beused to assist in finding or optimizing the crystallization condition.

It will also be appreciated that a set of structure coordinates for amolecule or a or a portion thereof, is a relative set of points thatdefine a shape in three dimensions. Thus, it is possible that anentirely different set of coordinates could define a similar oridentical shape. Moreover, slight variations in the individualcoordinates will have little effect on overall shape. The variations incoordinates may be generated as a result of mathematical manipulationsof the EphA2 structure coordinates. For example, the structurecoordinates set forth in Table 1 could be manipulated bycrystallographic permutations of the structure coordinates,fractionalization of the structure coordinates, integer additions orsubtractions to sets of the structure coordinates, inversion of thestructure coordinates or any combination of the above.

Alternatively, modifications in the crystal structure due to mutations,additions, substitutions, and/or deletions of amino acids, or otherchanges in any of the components that make up the crystal could alsoaccount for variations in structure coordinates. If such variations arewithin a certain root mean square deviation as compared to the originalcoordinates, the resulting three-dimensional shape is consideredencompassed by this invention.

According to another embodiment, this invention provided amachine-readable data storage medium, comprising a data storage materialencoded with machine-readable data, Wherein said data defines theabove-mentioned EphA2 molecules. In one embodiment, the data defines theabove-mentioned EphA2 LBD by comprising the structure coordinates ofsaid amino acid residues according to any one of Table 1.

In order to use the structural coordinates generated for a crystallinesubstance of this invention, e.g., the structural coordinates shown inTable 1 of the EphA2 LBD (SEQ ID NO: 7), it is often necessary ordesirable to display them as, or convert them to, graphicalrepresentation, such as a three-dimensional shape, or to otherwisemanipulate them. This is typically accomplished by the use ofcommercially available software such as a program which is capable ofgenerating three-dimensional graphical representations of molecules orportions thereof from a set of structural coordinates.

By way of illustration, a non-exclusive list of computer programs forviewing or otherwise manipulating protein structures include thefollowing: Midas (University of California, San Francisco); MidasPlus(University of California, San Francisco); MOIL (University ofIllinois); Yummie (Yale University); Sybyl (Tripos, Inc.);Insight/Discover (Biosym Technologies); MacroModel (ColumbiaUniversity); Quanta (Molecular Simulations, Inc.); Cerius (MolucularSimulations, Inc.); Alchemy (Tripos, Inc.); LabVision (Tripos, Inc.);Rasmol (Glaxo Research and Development); Ribbon (University of Alabama);NAOMI (Oxford University); Explorer Eyechem (Silicon Graphics, Inc.);Univision (Cray Research); Molscript (Uppsala University); Chem-3D(Cambridge Scientific); Chain (Baylor College of Medicine); 0 (UppsalaUniversity); GRASP (Columbia University); X-Plor (Molecular Simulations,Inc.; Yale University); Spartan (Wavefunction, Inc.); Catalyst(Molecular Simulations, Inc.); Molcadd (Tripos. Inc.); VMD (Universityof Illinois/Beckman Institute); Sculpt (Interactive Simulations, Inc.):Procheck (Brookhaven National Laboratory): DGEOM (QCPE); RE VIEW (BrunelUniversity); Modeller (Birbeck College, University of London); Xmol(Minnesota Supercomputing Center); Protein Expert (CambridgeScientific); HyperChem (Hypercube); MD Display (University ofWashington); PKB (National Center for Biotechnology Information, NIH);ChemX (Chemical Design, Ltd.); Cameleon (Oxford Molecular, Inc.); Iditis(Oxford Molecular, Inc.).

Therefore, according to another embodiment, this invention provides amachine-readable data storage medium comprising a data storage materialencoded with machine readable data. In one embodiment, a machineprogrammed with instructions for using said data, is capable ofgenerating a three-dimensional structure of the EphA2 molecules that aredescribed herein.

This invention also provides a computer comprising: (a) amachine-readable data storage medium comprising a data storage materialencoded with machine-readable data, wherein said data defines an EphA2molecule; (b) a working memory for storing instructions for processingsaid machine-readable data; (c) a central processing unit (CPU) coupledto said working memory and to said machine-readable data storage mediumfor processing said machine readable data and means for generatingthree-dimensional structural information of said molecule; and (d)output hardware coupled to said central processing unit for outputtingthree-dimensional structural information of said molecule, orinformation produced using said three-dimensional structural informationof said molecule.

The availability of the three-dimensional structure of EphA2 makesstructure-based drug discovery approaches possible. Structure-basedapproaches include de Novo molecular design, computer-aided optimizationof lead molecules, and computer-based selection of candidate drugstructures based on structural criteria. New peptidomimetic modules maybe developed directly from the structure of a peptide ligand by designor database searches for conformationally-restricted peptidereplacements. Alternatively, structure-based lead discovery may beaccomplished using the target protein structure stripped of its ligand.Multiple uncomplexed states of EphA2 can be generated by several methodsto provide additional target conformations. The experimental coordinatesand the resulting uncomplexed models can be subjected to techniques,such as receptor site mapping to identify sites of favorable interactionenergies between the structure of the target protein and potentialligands or chemical moieties (“fragments” or “seeds”). Such evaluationmay be followed by procedures such as fragment seed linking and growth.Fragment seed linking refers to methods for designing structures thatcontain “linked” “seeds”, i.e. chemical structures comprising two ormore of the mapped moieties appropriately spaced to reach the respectivesites of favorable interactions. Growth refers to the design ofstructures which extend, based on receptor site mapping or to fillavailable space, a given molecule or moiety. Based on the receptor sitemapping data, one may also select potential ligands from databases ofchemical structures. Potential ligands, or suboptimal ligands, ofwhatever source, can be refined by using the receptor site maps tofilter multiple ligand conformations and orientations according toenergetic preferences.

Receptor site mapping encompasses a variety of computational proceduresthat identify energetically favorable binding sites on macromolecules.The most straightforward procedures involve “painting” asolvent-accessible surface (or an otherwise generated cast) of themacromolecular target according to empirically determined physicalproperties, such as electrostatic or lipophilic potential, degree ofcurvature, and hydrogen-bonding character. Such methods for thuscharacterizing the surface of a macromolecule are incorporated inprograms such as Grasp (Columbia University), DelPhi (BiosymTechnologies), MOLCAD (Tripos, Inc.), and Hint (Virginia CommonwealthUniversity). Subsequent molecule design involves identification ordesign of ligands that possess features complimentarity to theidentified surface characteristics. More advanced algorithms involve theactual calculation of interaction enthalpies between the target andpotential ligands or fragments. In practice, the coordinates of theprotein or protein fragment of interest (which may be rotated orotherwise transformed) are stripped of any undesired ligand (or portionthereof) and/or of any undesired solvent molecules. The coordinates arethen processed to attach molecular mechanics parameters to the atomicpositions to provide a processed target for mapping. The target may bepartitioned into discrete binding sites. The target or partitioned sitesthereof are flooded with given functional group fragments that aresubsequently allowed to relax into desired locations, as in the programMCSS (Molecular Simulations, Inc.), or are encased within a regularlattice of site points on which single fragment probes are positionedsequentially; examples of programs that exploit the site-latticealgorithm include Grin/Grid (Molecular Discovery, Ltd.), Ludi (BiosymTechnologies), Leapfrog (Tripos, Inc.), and Legend (University ofTokyo). In both techniques, the enthalpic contribution to bindingaffinity is estimated with a molecular mechanics force-field, andappropriate positions of selected functional groups are determinedsystematically.

In the site-lattice approach, a box is defined enclosing a desiredportion of the target within a defined lattice. The lattice resolution,i.e., the distance between lattice points, may be defined by thepractitioner or may be set by the computer program. Likewise, otherparameters of points within the lattice, such as hydrophobicity or othercharacteristics, may be similarly defined. Probes (i.e. computer models)of one or more selected moieties, functional groups, molecules ormolecular fragments are positioned at lattice points and the interactionenergy of the probe-target pair is determined for each such latticepoint. The data for each selected moiety, functional group, etc. iscollected and may be recovered as a data set, visualized on a computermonitor or printed out in various text or graphic formats

As an alternative to positioning a moiety at each of a set of latticepoints, one may, as previously mentioned, flood the target (defined bythe coordinates as described above) with multiple copies of a selectedfragment, moiety, molecule, etc. by superimposing the multiple copiesinto the vicinity of the protein target. The model is then subjected togroup minimization (i.e., molecular mechanics minimization) calculationsto identify points or areas of favorable interaction. Data may behandled as in the lattice approach.

Receptor site maps provide the seeds for ligand evolution via Databasesearches and for Grow/link methods for de Novo design of new chemicalentities. Programs for ligand growth first access extensible fragmentdictionaries in order to place appropriate functional groups at sitepoints. A genetic algorithm or a subgraph isomorphism protocol is theninvoked to connect the fragments with small aliphatic chains or rings.Stochastic enhancements may be introduced by modification of internaldegrees of freedom as well as translation and rotation of the candidatemodel within the binding cavity. The resulting sets of molecules arescored and filtered by functions that consider the steric constraints ofthe binding site, the complimentarity of electrostatic and hydrophobicinteractions, and a solvation estimate. Programs of this type that couldbe applied for the design of new ligands for ZAP-NC (SEQ ID NO: 38)include Ludi (Biosym Technologies), Leapfrog (Tripos, Inc.), Legend(University of Tokyo), Grow (Upjohn), Builder/Delegate (University ofCalifornia, San Francisco), and Sprout (University of Leeds). Cliquedetection methods provide an alternative strategy to site mapping andligand growth. DOCK (University of California, San Francisco) andsimilar programs fill a given binding site with the smallest set ofatom-sized spheres possible; a database search then attempts to orientligands such that the atoms superimpose onto the centers (or “nuclei”)of the site-tilling spheres. The shape complimentarity is augmented byscoring functions that include the steric requirements of the cavity anda potential energy function.

Optimization of ligands (from any source) may be enhanced using thethree dimensional structural of EphA2. Use of receptor site maps ofEphA2 may be used to identify preferred positions for functional groupcomponents of ligands, and can be used to filter or constrainconformational searches of ligand structures which would otherwisetypically be controlled by minimal steric considerations of the ligandstructures themselves. The availability of an explicit binding site alsopermits one to determine the mode of ligand binding to the targetprotein via methods that utilize force-fields directly in simulatedannealing, distance geometry, Metropolis Monte Carlo, or stochasticsearches for binding modes. Examples of programs that can be applied torationalize ligand binding to EphA2 include Autodock (Scripps Clinic),DGEOM (QCPE #590), Sculpt (interactive Simulations, Inc.), or any of themolecular dynamics programs described above. Once a tractable set ofpossible binding orientations is obtained, one can readily identify theappropriate mode of binding through modifications in test ligandsdesigned to alter in a predictable fashion the binding affinity of eachmodel under consideration. For instance, a ligand may be modified tocontain a functional group at a position which is inconsistent with onebinding model, yet consistent with another model. Binding data can thenbe used to weed out “disproven” models. Once iterative weeding ofunlikely binding modes generates an appropriate model, possibilities forimprovement of the lead become readily apparent from the local proteinenvironment.

An alternative protocol for ligand optimization involves 3D databasesearching in conjunction with knowledge of the binding site. Modelingcan reveal multiple candidates for the bioactive conformation of a givenligand. A probe for the correct conformation can include a 3D search toidentify several constrained mimics of each possible conformer.Structure-activity relationships of the unconstrained ligand wouldsuggest which functional groups should be retained in the constrainedmimics. Finally, the steric and electrostatic requirements of thebinding site could constitute a filter for prioritizing the resultantpossibilities.

III. EphA Therapeutic Agents

As used herein, the term “Eph-A therapeutic agent” is a generic termwhich include any compound (agent) which regulates signaling through theEphA pathway. This compound can also suppress or inhibit signaling ofthe PI3/AKT pathway and/or MAPK/ERK1/2 pathway. Exemplary, EphAtherapeutic agents can be used for treating cancer (tumor). In certainembodiments, EphA therapeutic agent can activate function of EphA (e.g.,EphA1, EphA2, or EphA3), enhance the interaction of an EphA ligand(e.g., ephrin A1 and ephrin A5) and EphA (e.g., EphA1, EphA2, or EphA3),activate the phosphorylation of EphA (e.g., EphA1, EphA2, or EphA3),enhance dimerization of EphA (e.g., EphA1, EphA2, or EphA3), or activateany of the downstream signaling events upon binding of an EphA ligand(e.g., ephrin A1 and ephrin A5) to EphA (e.g., EphA1, EphA2, or EphA3).For example, the EphA therapeutic agents can be capable of binding to anEphA2 polypeptide (e.g., the ligand-binding domain of an EphA2polypeptide) and function as EphA2 ligands.

Generally, the EphA therapeutic agents include any substances that actas agonists of EphA. Such EphA therapeutic agents include, but are notlimited to, a protein, a peptide, a small organic molecule, apeptidomimetic, an antibody, and a nucleic acid. In an aspect of theinvention, these substances can comprise exogenous or non-nativepeptides or small molecules that have a molecular weight of about 50daltons to about 2,500 daltons.

In certain specific aspects, the EphA therapeutic agents of the presentinvention include a peptide, such as those which activate EphA kinasefunction. These peptides are also referred to herein as EphA agonisticor binding peptides. These agonistic peptides can specifically targetthe ligand-binding domain of EphA kinase. Optionally, these peptides canactivate EphA kinases (EphA1, EphA2 and EphA3) and suppress AKT kinaseand/or MAPK/ERK1/2 kinase.

In one aspect, EphA1-, EphA2-, or EphA3-agonistic peptides in accordancewith the present invention can have amino sequences or structuressubstantially similar to native mammalian or wild type ephrins. Forexample, ephrin-A1 and ephrin-B2 can have amino sequences substantiallysimilar to, respectively, SEQ ID NO: 12 and SEQ ID NO: 13.

The agonistic peptides of EphA1, EphA2, or EphA3 of the presentinvention can also be a variant of native mammalian or wildtype ephrins,such as a fragment, analog and derivative of mammalian ephrin-As andephrin-Bs. Such variants can include, for example, a polypeptide encodedby a naturally occurring allelic variant of a native ephrin gene (i.e.,a naturally occurring nucleic acid that encodes a naturally occurringmammalian ephrins), a polypeptide encoded by an alternative splice formof a native ephrins gene, a polypeptide encoded by a homolog or orthologof a native ephrin gene, and a polypeptide encoded by a non-naturallyoccurring variant of a native ephrin gene.

EphA1-, EphA2-, or EphA3-agonistic peptides can have a peptide (or aminoacid) sequence that differs from native ephrins in one or more aminoacids. The peptide sequence of such variants can feature a deletion,addition, or substitution of one or more amino acids of ephrin protein.Amino acid insertions are preferably of about 1 to 4 contiguous aminoacids, and deletions are preferably of about 1 to 10 contiguous aminoacids. Variant EphA1-, EphA2-, or EphA3-binding peptides substantiallymaintain a native ephrin protein functional activity. Exemplary, EphA1-,EphA2-, or EphA3-binding peptides can be made by expressing nucleic acidmolecules within the invention that feature silent or conservativechanges.

In accordance with an aspect of the invention, variant EphA1-, EphA2-,or EphA3-agonistic peptides can have an amino acid sequence that is atleast 40% identical to an amino acid sequence as set forth in SEQ ID NO:12 and SEQ ID NO: 13. In other aspects, the variant EphA1-, EphA2-, orEphA3-agonistic peptides has an amino acid sequence at least 40%, 50%,60%, 70/0/, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% identical to anamino acid sequence as set forth in SEQ ID NO: 12 and 13.

Ephrin fragments corresponding to one or more particular motifs and/ordomains or to arbitrary sizes, are within the scope of the presentinvention. Isolated peptidyl portions of ephrin proteins can be obtainedby screening peptides recombinantly produced from the correspondingfragment of the nucleic acid encoding such peptides. In addition,fragments can be chemically synthesized using techniques known in theart such as conventional Merrifield solid phase f-Moc or t-Bocchemistry. For example, a EphA1, EphA2, or EphA3 agonistic peptide ofthe present invention may be arbitrarily divided into fragments ofdesired length with no overlap of the fragments, or preferably dividedinto overlapping fragments of a desired length. The fragments can beproduced recombinantly and tested to identify those peptidyl fragmentswhich can function as agonists of a native EphA1, EphA2, or EphA3receptors.

Variants of ephrin polypeptide can also include recombinant forms of theproteins. Recombinant polypeptides of the present invention, in additionto ephrin-A1, and ephrin-B2, are encoded by a nucleic acid that can haveat least 85% sequence identity with the nucleic acid sequence of a geneencoding a mammalian protein. Ephrin polypeptide variants can includeagonistic forms of the polypeptide that constitutively express thefunctional activities of a native ephrins. Other variants can includethose that are resistant to proteolytic cleavage, as for example, due tomutations, which alter protease target sequences. Whether a change inthe amino acid sequence of a peptide results in a variant having one ormore functional activities of a native ephrin can be readily determinedby testing the variant for a native ephrin protein functional activity.

In certain aspects, the EphA1-, EphA2-, or EphA3-agonistic peptides cancomprise fusion polypeptides including an EphA binding peptide or adomain thereof and a second domain. The second domain may comprise oneor more fusion domains. In another aspect, the fusion protein cancomprise an EphA binding polypeptide or a domain thereof and a seconddomain selected from the group consisting of a dimerizing polypeptide, apurification polypeptide, a stabilizing polypeptide, and a targetingpolypeptide.

In certain aspects, the EphA1-, EphA2-, or EphA3-agonistic peptides caninclude a fusion protein comprising an EphA-binding polypeptide or adomain thereof and an immunoglobulin element. In certain embodiments,the an EphA-binding polypeptide or a domain thereof comprisesextracellular portions of the ephrin-A polypeptide.

In certain aspects, the EphA1-, EphA2-, or EphA3-agonistic peptides caninclude a fusion protein comprising an EphA-agonistic peptide or adomain thereof and an immunoglobulin element wherein the immunoglobulinelement comprises an immunoglobulin heavy chain. In certain embodiments,the immunoglobulin element comprises an Fc domain. In certain instances,the immunoglobulin heavy chain is selected from the group consisting ofan IgM, IgD, IgE, and IgA heavy chains. In further aspects, theimmunoglobulin heavy chain is selected from the group consisting of anIgG1, IgG2β, IgG2α, and IgG3 hearty chains. The immunoglobulin elementmay comprise the CH1 and Fc domains in certain embodiments. In certaininstances, the immunoglobulin element comprises a CH1 domain of a firstimmunoglobulin class and a CH1 domain of a second immunoglobulin class,wherein the first and second immunoglobulin classes are not the same.

In additional embodiments, the present application relates to a fusionprotein comprising a polypeptide that binds to EphA kinases (e.g.,EphA1, EphA2, or EphA3) or a domain thereof and an immunoglobulinelement, further comprising a dimerizing polypeptide.

In certain embodiments, the application also relates to a compositioncomprising a fusion protein of the invention and a pharmaceuticallyacceptable carrier.

In certain embodiments, the dimerizing polypeptide comprises anamphiphilic polypeptide. The amphiphilic polypeptide may comprise up to50 amino acids, up to 30 amino acids, up to 20 amino acids, or up to 10amino acids. In certain embodiments, the dimerizing polypeptidecomprises a peptide helix bundle. In certain embodiments, the dimerizingpolypeptide comprises a leucine zipper. The leucine zipper may be a junzipper or a fos zipper. In certain embodiments, the dimerizingpolypeptide comprises a polypeptide having positively or negativelycharged residues wherein said polypeptide binds to another peptidebearing opposite charges.

In further embodiments, the application relates to a fusion proteincomprising an amino acid sequence that is at least 90% identical to theamino acid sequence of SEQ ID NO: 12 and SEQ ID NO: 13. In certainaspects, the application relates to a nucleic acid sequence encoding apolypeptide fusion comprising an EphA binding peptide or a domainthereof and an immunoglobulin element. In certain embodiments, theapplication relates to a nucleic acid sequence encoding a polypeptide atleast 90% identical to the amino acid sequence set forth in SEQ ID NO:12 or SEQ ID NO: 2. In additional embodiments, the application relatesto a nucleic acid sequence encoding an EphA polypeptide or a domainthereof polypeptide comprising one or more point mutations wherein saidpoint mutations increase the binding affinity of said an EphApolypeptide or a domain thereof.

In another aspect, the EphA agonistic peptides can comprise about 4 toabout 20 amino acids and have a molecular weight of about 600 daltons toabout 2,500 daltons. The EphA agonistic peptides include, but are notlimited to, EP1 (SEQ ID NO: 1), EP2 (SEQ ID NO: 2), and EP3 (SEQ ID NO:3). In certain embodiments, an EphA agonistic peptide has an amino acidsequence that is at least 80% identical to an amino acid sequence as setforth in SEQ ID NO: 1, 2 or 3. In certain cases, the functional varianthas an amino acid sequence at least 40%, 50%, 60%, 70%, 85%, 90%, 95%,97%, 98%, 99% or 100% identical to an amino acid sequence as set forthin SEQ ID NO: 1, 2 or 3.

In certain embodiments, the present invention contemplates makingfunctional variants by modifying the structure of an EphA agonisticpeptide for such purposes as enhancing therapeutic efficacy, orstability (e.g., ex vivo shelf life and resistance to proteolyticdegradation in vivo). Modified EphA agonistic peptides can be produced,for instance, by amino acid substitution, deletion, or addition. Forinstance, it is reasonable to expect that an isolated replacement of aleucine with an isoleucine or valine, an aspartate with a glutamate, athreonine with a serine, or a similar replacement of an amino acid witha structurally related amino acid (e.g., conservative mutations) willnot have a major effect on the biological activity of the resultingmolecule. Conservative replacements are those that take place within afamily of amino acids that are related in their side chains. Whether achange in the amino acid sequence of an EphA agonistic peptide resultsin a functional homolog can be readily determined by assessing theability of the variant EphA agonistic peptide to produce a response incells in a fashion similar to the wild-type EphA agonistic peptide.

The present invention further contemplates a method of generatingmutants, particularly sets of combinatorial mutants of the EphAagonistic peptides, as well as truncation mutants; pools ofcombinatorial mutants are especially useful for identifying functionalvariant sequences. The purpose of screening such combinatorial librariesmay be to generate, for example, peptide variants which can act aseither agonists or antagonist of EphA, or alternatively, which possessnovel activities all together. A variety of screening assays areprovided below, and such assays may be used to evaluate variants. Forexample, an EphA2 agonistic peptide variant may be screened for itsability to bind to an EphA2 polypeptide (full-length EphA2 or the LBD ofEphA2) or for its ability to enhance binding of an EphA2 ligand to acell expressing an EphA2 receptor. Optionally, an EphA agonistic peptidevariant may be screened for its binding to EphA (full-length EphA or theLBD of EphA) with high affinity and specificity.

In other aspects, the EphA therapeutic agents of the present inventioninclude a small molecule compound, such as those which activate EphAkinase function as well as those that suppress AKT kinase function andMAPK/ERK1/2 function. These small molecule compounds are also referredto herein as EphA agonistic compounds. Optionally, these agonisticcompounds specifically target the ligand-binding domain of EphA kinase.

Exemplary, the EphA agonistic compounds include, but are not limited tocompounds, such as dobutamine, labetalol, doxazosin, and(di-meo-isoquinolin-1-ylmethyl)-et-di-meo-pyrido(2,1-a)isoquinolin,hydrobromide S120103 shown in FIGS. 28-32.

One aspect of the invention relates to a small molecule compound ofFormula (I)

wherein

R¹ is selected from H, C₁₋₆alkyl, C₁₋₆aralkyl, C₁₋₆alkanoyl, aryl,heterocyclyl, C₁₋₆heterocyclylalkyl, C₁₋₆carbocyclylalkyl, andcarbocyclyl, or two occurrences of R¹ together are C₁₋₆alkyl, therebyforming a ring;

R², R³, and R⁴ are independently selected from H, C₁₋₆alkyl,C₁₋₆aralkyl, C₁₋₆heterocyclylalkyl, and C₁₋₆carbocyclylalkyl, preferablyR², R³, and R⁴ are independently selected from H and C₁₋₆alkyl;

R⁵ is selected from C₁₋₆alkyl, C₁₋₆alkoxy, halogen, C₁₋₆alkanoyl,C₁₋₆alkoxycarbonyl, C(O)N(R⁶)(R⁷), and SO₂N(R⁶)(R⁷);

R⁶ and R⁷ are independently selected from H and C₁₋₆alkyl;

X is selected from CH₂, NH, and O;

each Y is independently selected from CH and N;

m is an integer from 1 to 2;

n is an integer from 1 to 3; and

p is an integer from 0 to 3.

In certain embodiments, R¹ is selected from H and C₁₋₆alkyl, X is O, andn is an integer from 1 to 3. In preferred embodiments, n is 2, X is O,and R¹ is C₁₋₆alkyl. In other embodiments, n is 2, X is O, R¹ is methyl,and the substituents are located at the 3- and 4-positions of thearomatic ring.

In certain embodiments, R², R³, and R⁴ are independently selected H andC₁₋₆ lower alkyl. In still other embodiments, R², R³, and R⁴ are all H.

In certain embodiments, m is 1 and each Y is independently selected fromCH and N. In preferred embodiments, m is 1 and each occurrence of Y isN.

Another aspect of the invention relates to a compound comprising atleast one aryl or heteroaryl ring. In other such embodiments, candidatecompounds comprise two aryl or heteroaryl rings connected by a linkerthat is 5-10 atoms in length. In still other embodiments, candidatecompounds have a structure of Formula (II)A-L-B  (II)

wherein

A and B are independently selected from aryl and heteroaryl; and

L is selected from C₁₋₁₂alkyl and —C₁₋₆alkyl-amino-C₁₋₆alkyl-.

In certain embodiments, candidate compounds have a structure of Formula(III)

wherein

R⁸ is selected from H, C₁₋₆alkyl, C₁₋₆aralkyl, C₁₋₆alkanoyl, aryl,heterocyclyl, C₁₋₆heterocyclylalkyl, C₁₋₆carbocyclylalkyl, andcarbocyclyl, or two occurrences of R¹ together are C₁₋₆alkyl, therebyforming a ring;

R⁹ and R¹⁰ are independently selected from H, C₁₋₆alkyl, C₁₋₆aralkyl,C₁₋₆heterocyclylalkyl, and C₁₋₆carbocyclylalkyl;

R¹¹ is selected from H, OH, C₁₋₆alkoxy, and C₁₋₆alkanoyl, preferably OH;

X₁ is selected from NH and O;

m₁ is an integer from 1 to 2; and

n₁ is an integer from 1 to 3.

In certain embodiments, R⁸ is selected from H and C₁₋₆alkyl, X is NH,and n is an integer from 1 to 3. In other embodiments, n is 2, X is NH,and R⁸ is H. In still other embodiments, n is 2, X is NH, R⁸ is H, andthe substituents are located at the 3- and 4-positions of the aromaticring.

In certain embodiments, R⁹ and R¹⁰ are independently selected from H andC₁₋₆alkyl. In other embodiments, R⁹ is H and R³ is C₁₋₆alkyl. In morepreferred embodiments, R² is H and R³ is methyl.

In certain embodiments, m₁ is 1 and R¹¹ is selected from H, OH,C₁₋₆alkoxy, and C₁₋₆alkanoyl. In other embodiments, m₁ is 1 and R¹¹ isOH. In still other preferred embodiments, m₁ is 1, R¹¹ is OH, and theR¹¹ substituent is located at the 4-position of the aromatic ring.

As used herein, the term “C₁₋₆alkanoyl,” can be represented by thegeneral formula:—C(O)—C₁₋₆alkyl.

The term “C_(x-y)alkyl” refers to substituted or unsubstituted saturatedhydrocarbon groups, including straight-chain alkyl and branched-chainalkyl groups that contain from x to y carbons in the chain, includinghaloalkyl groups, such as trifluoromethyl and 2,2,2-trifluoroethyl, etc.C0 alkyl indicates a hydrogen where the group is in a terminal position,a bond if internal.

The term “alkoxy” refers to an alkyl group having an oxygen attachedthereto. Representative alkoxy groups include methoxy, ethoxy, propoxy,tert-butoxy and the like. An “ether” is two hydrocarbons covalentlylinked by an oxygen. Accordingly, the substituent of an alkyl thatrenders that alkyl an ether is or resembles an alkoxy.

The term “C₁₋₆alkoxycarbonyl”, as used herein can be represented by thegeneral formula—C(O)OC₁₋₆alkyl.

The term “C₁₋₆aralkyl”, as used herein, refers to a C₁₋₆alkyl groupsubstituted with an aryl group.

The term “aryl” as used herein includes 5-, 6-, and 7-memberedsubstituted or unsubstituted single-ring aromatic groups in which eachatom of the ring is carbon. The term “aryl” also includes polycyclicring systems having two or more cyclic rings in which two or morecarbons are common to two adjoining rings wherein at least one of therings is aromatic, e.g., the other cyclic rings can be cycloalkyls,cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and/or heterocyclyls.Aryl groups include benzene, naphthalene, phenanthrene, phenol, aniline,and the like.

The terms “carbocycle” and “carbocyclyl”, as used herein, refer to anon-aromatic substituted or unsubstituted ring in which each atom of thering is carbon. The terms “carbocycle” and “carbocyclyl” also includepolycyclic ring systems having two or more cyclic rings in which two ormore carbons are common to two adjoining rings wherein at least one ofthe rings is carbocyclic, e.g., the other cyclic rings can becycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and/orheterocyclyls.

The term “C₁₋₆carbocyclylalkyl”, as used herein, refers to a C₁₋₆alkylgroup substituted with a carbocycle.

The term “carbonyl” is art-recognized and includes such moieties as canbe represented by the general formula:

wherein X₂ is a bond or represents an oxygen or a sulfur, and R²represents a hydrogen, an alkyl, an alkenyl, —(CH₂)_(m)—R⁸ or apharmaceutically acceptable salt, R^(12′) represents a hydrogen, analkyl, an alkenyl or —(CH₂)_(m)—R⁸, where m and R⁸ are as defined above.Where X₂ is an oxygen and R¹² or R^(12′) is not hydrogen, the formularepresents an “ester”. Where X₂ is an oxygen, and R¹² is a hydrogen, theformula represents a “carboxylic acid”.

The term “heteroatom” as used herein means an atom of any element otherthan carbon or hydrogen. Preferred heteroatoms are nitrogen, oxygen,phosphorus, and sulfur.

The terms “heterocyclyl” or “heterocyclic group” refer to substituted orunsubstituted non-aromatic 3- to 10-membered ring structures, morepreferably 3- to 7-membered rings, whose ring structures include one tofour heteroatoms. The term terms “heterocyclyl” or “heterocyclic group”also include polycyclic ring systems having two or more cyclic rings inwhich two or more carbons are common to two adjoining rings wherein atleast one of the rings is heterocyclic, e.g., the other cyclic rings canbe cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and/orheterocyclyls. Heterocyclyl groups include, for example, piperidine,piperazine, pyrrolidine, morpholine, lactones, lactams, and the like.

The term “C₁₋₆heterocycloalkyl” refers to a C₁₋₆alkyl group substitutedwith a heterocyclic group.

The terms “polycyclyl” or “polycyclic” refer to two or more rings (e.g.,cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and/orheterocyclyls) in which two or more carbons are common to two adjoiningrings, e.g., the rings are “fused rings”. Each of the rings of thepolycycle can be substituted or unsubstituted.

In certain aspects, the EphA therapeutic agents of the present inventioninclude a peptidomimetic, for example, peptide-like molecules. As usedherein, the term “peptidomimetic” includes chemically modified peptidesand peptide-like molecules that contain non-naturally occurring aminoacids, peptoids, and the like. Peptidomimetics provide variousadvantages over a peptide, including enhanced stability whenadministered to a subject. Methods for identifying a peptidomimetic arewell known in the art and include the screening of databases thatcontain libraries of potential peptidomimetics. For example, theCambridge Structural Database contains a collection of greater than300,000 compounds that have known crystal structures (Allen et al., ActaCrystallogr. Section B, 35:2331 (1979)). Where no crystal structure of atarget molecule is available, a structure can be generated using, forexample, the program CONCORD (Rusinko et al., J. Chem. Inf. Comput. Sci.29:251 (1989)). Another database, the Available Chemicals Directory(Molecular Design Limited, Informations Systems: San Leandro Calif.),contains about 100,000 compounds that are commercially available andalso can be searched to identify potential peptidomimetics of an EphApolypeptide (e.g., an EphA2 LBD).

As described herein, small molecule compounds may encompass numerouschemical classes, though typically they are organic molecules,preferably small organic compounds having a molecular weight of morethan about 50 and less than about 2,500 daltons. Candidate agentscomprise functional groups necessary for structural interaction withproteins, particularly hydrogen bonding, and typically include at leastan amine, carbonyl, hydroxyl, sulfhydryl or carboxyl group Candidatesmall molecule compounds can be obtained from a wide variety of sourcesincluding libraries of synthetic or natural compounds. For example,numerous means are available for random and directed synthesis of a widevariety of organic compounds and biomolecules, including expression ofrandomized oligonucleotides. Alternatively, libraries of naturalcompounds in the form of bacterial, fungal, plant, and animal extractsare available or readily produced. Additionally, natural orsynthetically produced libraries and compounds can be modified throughconventional chemical, physical, and biochemical means. Knownpharmacological agents may be subjected to directed or random chemicalmodifications, such as acylation, alkylation, esterification, andamidification, to produce structural analogs.

In certain aspects, the EphA2 therapeutic agents include antibodies, forexample, antibodies that are specifically reactive with an EphA2.Antibodies may be polyclonal or monoclonal: intact or truncated, e.g.,F(ab′)2, Fab, Fv; xenogeneic, allogeneic, syngeneic, or modified formsthereof, e.g., humanized, chimeric, etc.

For example, by using immunogens derived from an EphA2 polypeptide,anti-protein/anti-peptide antisera or monoclonal antibodies can be madeby standard protocols (see, for example, Antibodies: A Laboratory Manualed. by Harlow and Lane (Cold Spring Harbor Press: 1988)). A mammal, suchas a mouse, a hamster or rabbit can be immunized with an immunogenicform of the peptide. (e.g. a polypeptide or an antigenic fragment whichis capable of eliciting an antibody response, or a fusion protein).Techniques for conferring immunogenicity on a protein or peptide includeconjugation to carriers or other techniques well known in the art. Animmunogenic portion of an EphA2 polypeptide can be administered in thepresence of adjuvant. The progress of immunization can be monitored bydetection of antibody titers in plasma or serum. Standard ELISA or otherimmunoassays can be used with the immunogen as antigen to assess thelevels of antibodies. In one embodiment, antibodies of the invention arespecific for the extracellular portion (e.g., the LBD) of the EphAprotein (e.g., EphA1, EphA1, or EphA3). In another embodiment,antibodies of the invention are specific for the intracellular portionor the transmembrane portion of the EphA protein (e.g., EphA1, EphA1, orEphA3). In a further embodiment, antibodies of the invention arespecific for the extracellular portion of the EphA2 protein (e.g.,EphA1, EphA1, or EphA3).

Following immunization of an animal with an antigenic preparation of anEphA polypeptide (e.g., EphA1, EphA1, or EphA3), antisera can beobtained and, if desired, polyclonal antibodies can be isolated from theserum. To produce monoclonal antibodies, antibody-producing cells(lymphocytes) can be harvested from an immunized animal and fused bystandard somatic cell fusion procedures with immortalizing cells such asmyeloma cells to yield hybridoma cells. Such techniques are well knownin the art, and include, for example, the hybridoma technique(originally developed by Kohler and Milstein, (1975) Nature, 256:495-497), the human B cell hybridoma technique (Kozbar et al., (1983)Immunology Today, 4: 72), and the EBV-hybridoma technique to producehuman monoclonal antibodies (Cole et al., (1985) Monoclonal Antibodiesand Cancer Therapy, Alan R. Liss, Inc. pp. 77-96). Hybridoma cells canbe screened immunochemically for production of antibodies specificallyreactive with an EphA2 polypeptide and monoclonal antibodies isolatedfrom a culture comprising such hybridoma cells.

The term antibody as used herein is intended to include fragmentsthereof which are also specifically reactive with an EphA polypeptides.Antibodies can be fragmented using conventional techniques and thefragments screened for utility in the same manner as described above forwhole antibodies. For example, F(ab)2 fragments can be generated bytreating antibody with pepsin. The resulting F(ab)2 fragment can betreated to reduce disulfide bridges to produce Fab fragments. Theantibody of the present invention is further intended to includebispecific, single-chain, and chimeric and humanized molecules havingaffinity for an EphA polypeptide conferred by at least one CDR region ofthe antibody. Techniques for the production of single chain antibodies(U.S. Pat. No. 4,946,778) can also be adapted to produce single chainantibodies. Also, transgenic mice or other organisms including othermammals, may be used to express humanized antibodies. In preferredembodiments, the antibodies further comprises a label attached theretoand able to be detected (e.g., the label can be a radioisotope,fluorescent compound, enzyme or enzyme co-factor).

In certain preferred embodiments, an antibody of the invention is amonoclonal antibody, and in certain embodiments the invention makesavailable methods for generating novel antibodies. For example, a methodfor generating a monoclonal antibody that binds specifically to an EphApolypeptide (e.g., EphA1, EphA1, or EphA3) may comprise administering toa mouse an amount of an immunogenic composition comprising the EphApolypeptide (e.g., EphA1, EphA1, or EphA3) effective to stimulate adetectable immune response, obtaining antibody-producing cells (e.g.,cells from the spleen) from the mouse and fusing the antibody-producingcells with myeloma cells to obtain antibody-producing hybridomas, andtesting the antibody-producing hybridomas to identify a hybridoma thatproduces a monoclonal antibody that binds specifically to the EphApolypeptide. Once obtained, a hybridoma can be propagated in a cellculture, optionally in culture conditions where the hybridoma-derivedcells produce the monoclonal antibody that binds specifically to theEphA polypeptide. The monoclonal antibody may be purified from the cellculture.

In addition, the techniques used to screen antibodies in order toidentify a desirable antibody may influence the properties of theantibody obtained. For example, an antibody to be used for certaintherapeutic purposes will preferably be able to target a particular celltype. Accordingly, to obtain antibodies of this type, it may bedesirable to screen for antibodies that bind to cells that express theantigen of interest (e.g., by fluorescence activated cell sorting).Likewise, if an antibody is to be used for binding an antigen insolution, it may be desirable to test solution binding. A variety ofdifferent techniques are available for testing antibody:antigeninteractions to identify particularly desirable antibodies. Suchtechniques include ELISAs, surface plasmon resonance binding assays(e.g. the Biacore binding assay, Bia-core AB, Uppsala, Sweden), sandwichassays (e.g. the paramagnetic bead system of IGEN International, Inc.,Gaithersburg, Md.), western blots, immunoprecipitation assays andimmunohistochemistry.

The present invention also contemplates anti-tumor therapeutic agentsobtainable from the screening methods described as below under “Methodsof Screening.”

IV. Knockout Animals

Another aspect of the invention relates to knockout non-human animalshaving at least one allele of the genomic EphA gene disrupted (e.g.,EphA1 and EphA2 knockout animals). Exemplary, EphA2 knockout mice aredescribed in Iwakura et al., Mechanisms of Development, 102 (2001)95-1005; and Skames et al., Nature Genetics, vol. 28, July 2001.

In one specific embodiment, the above-mentioned EphA knockout animalsfurther can have at least one allele of another tumor suppressor genedisrupted. For example, the tumor suppressor gene is selected from thegroup consisting of p53, p63, p73, p16, Mxi1, PTEN, Rb, Apc and Nkx 3.1.Preferably, the double knockout animals exhibits increasedsusceptibility to the formation of tumors (e.g., prostate, lung, breast,skin and colorectal cancer) as compared to a transgenic mouse having thetumor suppressor gene alone disrupted.

It has been suggested that p53, p63, p73, p16, Mxi1, PTEN, Rb, Apc andNkx 3.1 play an important role in various human cancers, and decreasedexpression of one of these tumor suppressor genes may lead to cancerdevelopment. See, e.g., US20040132120, WO 04/00010, WO 99/13068, Eagleet al., (1995) Nat Genet 9: 249-55, which are all incorporated herein byreference.

In another specific embodiment, the above-mentioned EphA knockoutanimals can be bred to other transgenic mouse that express an oncogene.For example, the oncogene encodes T antigen, Myc, Akt, or Rasoncoprotein. Preferably, the knockout animals exhibit increasedsusceptibility to the formation of tumors (e.g., prostate cancer) ascompared to a transgenic mouse having expressing the transgene alone(i.e., the TRAMP (transgenic adenocarcinoma mouse prostate) and MPAKTmouse).

Further, a number of transgenic models of prostate cancer have beenreported in the literature (see, e.g. U.S. Pat. Nos. 5,907,078,5,917,124, 6,323,390, and Zhang et al., Prostate 43: 278-285 (2000),Buttyan et al., Cancer Metatasis Review 12: 11-19 (1993), Shibata etal., Toxicol Pathol 26: 177-183 (1998), and Greenberg et al., MolEndocrinol 8: 230-239 (1994), which are incorporated herein byreference). Prostate cancer transgenic mice known in the art include theTRAMP model expressing the vital oncogenes large and small T antigen,probasin driving large T antigen, C3 driving c-Myc, probasin drivingandrogen receptor, probasin driving IGF-1, probasin driving NAT1 andNAT2, ptobasin driving Ras, C3 driving the SV40 large T antigen, C3driving the SV40 T early region, C3 driving the polyoma virus middle Tgene, C3 driving Bcl-2, MMTV LTR driving the SV40 T antigen, MMTV LTRdriving int2/fgf3 and wap, CR2 driving the SV40 T antigen, fetal G-yglobin driving the SV40 large T antigen, ARR2PB driving the CAT reportergene, probasin driving Bcl-2, and gp91-phox driving the SV40 earlyregion. Thus, the present invention contemplates use of the abovetransgenic animal models to cross with the above-mentioned EphA knockoutanimals.

Another aspect of the invention relates to methods of identifying atherapeutic agent for cancer, comprising administering a test agent tothe subject transgenic animals.

In one embodiment, the transgenic non-human animals is a mammal, such asa mouse, rat, rabbit, goat, sheep, dog, cat, cow or non-human primate.Without being bound to theory, it is proposed that such an animal maydisplay a phenomenon associated with reduced or increased chance ofcancer development. Accordingly, such a transgenic animal may serve as auseful animal model to study the progression of cancer diseases.

Transgenic animals comprise an exogenous nucleic acid sequence presentas an extrachromosomal element or stably integrated in all or a portionof its cells, especially in germ cells. Unless otherwise indicated, itwill be assumed that a transgenic animal comprises stable changes to thegermline sequence. During the initial construction of the animal,“chimeras” or “chimeric animals” are generated, in which only a subsetof cells have the altered genome. Chimeras are primarily used forbreeding purposes in order to generate the desired transgenic animal.Animals having a heterozygous alteration are generated by breeding ofchimeras. Male and female heterozygotes are typically bred to generatehomozygous animals.

The exogenous gene is usually either from a different species than theanimal host, or is otherwise altered in its coding or non-codingsequence. The introduced gene may be a wild-type gene, naturallyoccurring polymorphism, or a genetically manipulated sequence, forexample having deletions, substitutions or insertions in the coding ornon-coding regions. Where the introduced gene is a coding sequence, itis usually operably linked to a promoter, which may be constitutive orinducible, and other regulatory sequences required for expression in thehost animal.

The successful expression of the transgene can be detected by any ofseveral means well known to those skilled in the art. Non-limitingexamples include Northern blot, in situ hybridization of mRNA analysis,Western blot analysis, immunohistochemistry, and FACS analysis ofprotein expression.

In a further aspect, the invention features non-human animal cellsderived from the above-mentioned transgenic animals. For example, theanimal cell (e.g., somatic cell or germ cell) can be obtained from thetransgenic animal. Transgenic somatic cells or cell lines can be used,for example, in drug screening assays. Transgenic germ cells, on theother hand, can be used in generating transgenic progeny.

DNA constructs for random integration need not include regions ofhomology to mediate recombination. Where homologous recombination isdesired, the DNA constructs will comprise at least a portion of thetarget gene with the desired genetic modification, and will includeregions of homology to the target locus. Conveniently, markers forpositive and negative selection are included. Methods for generatingcells having targeted gene modifications through homologousrecombination are known in the art. For various techniques fortransfecting mammalian cells, see Keown et al. (1990) Methods inEnzymology 185:527-537.

The chimeric animals are screened for the presence of the modified geneand males and females having the modification are mated to producehomozygous progeny. If the gene alterations cause lethality at somepoint in development, tissues or organs can be maintained as allogeneicor congenic grafts or transplants, or in in vitro culture.

To illustrate, the transgenic animals and cell lines are particularlyuseful in screening compounds that have potential as prophylactic ortherapeutic treatments of diseases, such as cancer. Screening for auseful drug would involve administering the candidate drug over a rangeof doses to the transgenic animal, and assaying at various time pointsfor the effect(s) of the drug on the disease or disorder beingevaluated.

For example, EphA2 knock out mice can be used to test new EphA2agonists. A skin carcinogenesis model using EphA2−/− and EphA+/+ micecan serve as a valuable tool to investigate the specificity and potencyof future drugs that target EphA2. Because the skin is readilyaccessible to topical drug application, the compounds can easily andquantitatively tested. For example, if a compound inhibits tumor growthon wild type (EphA2+/+) mice but not knockout (EphA2−/−) mice, it willsupport the possibility that the compounds has anti-tumor effects byspecifically targeting EphA2.

Similarly, the knockout mice can be used to test EphA targeted drugs inother types of cancers induced in other organs, or induced by differentmechanisms. For example, by crossing EphA2−/− mice with othertumor-susceptible mice such as TRAMP mice that spontaneously developprostate cancer, we can see how EphA2 deletion will affect TRAMP tumordevelopment. If EphA2 is found to play a role, new EphA2-targeted drugscan be tested by comparing the effects on EphA+/− and EphA2−/− hostanimals.

Additionally, the knockout mice can be useful in testing EphA-targetingcompounds in other diseases in addition to cancer. Examples includeneurodegeneration, blood clotting, inflammation, and cardiovasculardiseases.

Alternatively, or additionally, the therapeutic agents or compoundscould be administered prior to or simultaneously with exposure toinduction of the disease, if applicable.

V. Drug Screening Assays

The present invention provides methods and compositions that enhanceexpression and/or activity of an EphA receptor. This present applicationfurther describes methods and compositions that inhibit cellproliferation and cancer growth. In particular, methods and compositionsfor inhibiting carcinogenesis are described herein. Exemplary agentshave one or more of the following activities: bind to an EphA receptorprotein (e.g., a ligand binding domain or a dimerization domain of anEphA1 protein, EphA2 protein, or EphA3 protein), stimulate tyrosinephosphorylation of an EphA, enhance binding of an EphA ligand to anEphA, enhance dimerization of an EphA, enhance expression of an EphA(mRNA or protein), inhibit cancer cell proliferation, inhibit cancercell adhesion, proliferation, spreading and/or migration, and/orsuppress or inhibit signaling of the PI3/AKT pathway and/or MAPK/ERK1/2pathway. The present invention further contemplates methods ofidentifying additional agents which possess one or more of thesefunctions. These above-mentioned activities that characterize the agentsof the present invention will also be referred to herein as “desiredantitumor activity.” Without being bound by theory, an agent identifiedby the subject methods as having one or more of the desired activitiesmay work via any one of a number of mechanisms.

Agent screened (e.g., a single agent, a combination of two or moreagents, a library of agents) include nucleic acids, peptides, proteins,antibodies, antisense RNAs, RNAi constructs (including siRNAs), DNAenzymes, ribozymes, morpholino constructs, chemical compounds, and smallorganic molecules. Agents may be screened individually, in combination,or as a library of agents.

In many drug screening programs that test libraries of nucleic acids,polypeptides, chemical compounds and natural extracts, high throughputassays are desirable to increase the number of agents surveyed in agiven period of time. Assays that are performed in cell-free systems,such as may be derived with purified or semi-purified proteins, areoften preferred as “primary” screens in that they can be generated topermit rapid development and relatively easy detection of an alterationin a molecular target which is mediated by a test agent. Cell freesystems include in vitro systems (preparations of proteins and agentscombined in a test tube, Petri dish, etc.), as well as cell free systemssuch as those prepared from egg extracts or reticulocyte lysates.Moreover, the effects of cellular toxicity and/or bioavailability of thetest agents can be generally ignored in such a system, the assay insteadbeing focused primarily on the effect of the agent.

A primary screen can be used to narrow down agents that are more likelyto have an effect on cancer progression, in vitro and/or in vivo. Such acell free system for use in the present invention may include abiochemical assay measuring activity of an EphA protein. To furtherillustrate, an EphA polypeptide may be contacted with one or more agents(e.g., individual candidate agents, combinations of two or more agents,a library of nucleic acids, polypeptides, small organic molecules,chemical compounds, etc.) and the ability of the agent to enhance theactivity of the EphA polypeptide can be measured. The activity of theEphA polypeptide can be assessed by comparing the tyrosinephosphorylation level of the EphA polypeptide. One or more agents whichincrease the tyrosine phosphorylation level, in comparison to thetyrosine phosphorylation level of the EphA polypeptide in the absence ofthe one or more agents, is a candidate agent for use in the subjectmethods. Similarly, an EphA polypeptide may be contacted with one ormore agents (e.g., individual candidate agents, combinations of two ormore agents, a library of nucleic acids, polypeptides, small organicmolecules, chemical compounds, etc.) and the ability of the agent todecrease the tyrosine phosphorylation level of an EphA can be measured.

The efficacy of the agent can be assessed by generating dose responsecurves from data obtained using various concentrations of the testagent. Moreover, a control assay can also be performed to provide abaseline for comparison. Such candidates can be further tested forefficacy in inhibiting proliferation of cancer cells in vitro, forefficacy in inhibiting adhesion, spreading or migration of cancer cellsin vitro, for efficacy in increasing the activity and/or expression ofthe EphA in other assays, for efficacy in tumor growth or spreading(e.g., prostate cancer) in vitro or in vivo. For example, the efficacyof the agent can be tested in vivo in any of the prostate cancer animalmodels, as described above.

In addition to cell-free assays, such as described above, the inventionfurther contemplates the generation of cell-based assays for identifyingagents having one or more of the desired anti-tumor activities.Cell-based assays may be performed as either a primary screen, or as asecondary screen to confirm the activity of agents identified in a cellfree screen, as outlined in detail above. Such cell based assays canemploy any cell-type. Exemplary cell types include cancer cell lines,primary tumor xenoplant cultures, and prostate cells. Cells in cultureare contacted with one or more agents, and the ability of the one ormore agents to inhibit cell proliferation or migration/adhesion ismeasured. Agents which inhibit cell proliferation or migration/adhesionare candidate agents for use in the subject methods of inhibiting cancerdevelopment.

One class of agents that may enhance the activity and/or expression ofan EphA are agents which bind directly to an EphA protein, for example,antibodies, small organic molecules, agonistic variants of the wildtypeprotein, and agonistic fragments of the wildtype protein. Accordingly,the present invention contemplates screening for agents which bind to,either directly or indirectly an EphA protein.

There are numerous approaches to screening for EphA therapeutic agentsin tumor therapy. For example, high-throughput screening of compounds ormolecules can be carried out to identify agents or drugs which inhibittumor growth. Test agents to be assessed for their anti-tumor effectscan be any chemical (element, molecule, compound, drug), madesynthetically, made by recombinant techniques or isolated from a naturalsource. For example, test agents can be peptides, polypeptides,peptoids, sugars, hormones, or nucleic acid molecules (such as antisenseor RNAi nucleic acid molecules). In addition, test agents can be smallmolecules or molecules of greater complexity made by combinatorialchemistry, for example, and compiled into libraries. These libraries cancomprise, for example, alcohols, alkyl halides, amines, amides, esters,aldehydes, ethers and other classes of organic compounds. Test agentscan also be natural or genetically engineered products isolated fromlysates or growth media of cells—bacterial, animal or plant—or can bethe cell lysates or growth media themselves. Presentation of testcompounds to the test system can be in either an isolated form or asmixtures of compounds, especially in initial screening steps.

For example, an assay can be carried out to screen for compounds thatspecifically enhance binding of an EphA ligand to an EphA receptor(e.g., EphA2 ligand to and EphA2 receptor), such as, by enhancingbinding of labeled ligand- or receptor-Fc fusion proteins toimmortalized cells. As used herein, the term EphA includes a full-lengthand a portion of an EphA polypeptide such as a ligand-binding domain.Compounds identified through this screening can then be tested in animalmodels of cancer (e.g., tumor xenografts implanted in nude mice) toassess their anti-tumor activity in vivo. For example, the identifiedcompounds can be tested in prostate cancer models such as the TRAMP(transgenic adenocarcinoma mouse prostate) mouse, the Nkx 3.1 geneknockout mouse, or any other knockout animals as described above, under“Knockout Animals”.

In one embodiment of an assay to identify a substance that enhanceinteraction of two cell surface molecules (e.g., an ephrin A1 andEphA2), samples of cells expressing one type of cell surface molecule(e.g., EphA2, a soluble portion thereof, or a EphA2 fusion protein suchas a fusion of the ligand-binding domain and the Fc domain of IgG) arecontacted with either labeled ligand (e.g., ephrin A1) plus a testcompound (or group of test compounds). The amount of labeled ligandwhich has bound to the cells is determined. A higher amount of label(where the label can be, for example, a radioactive isotope, afluorescent or colormetric label) in the sample contacted with the testcompound(s) is an indication that the test compound(s) enhance or inducebinding. The reciprocal assay using cells expressing an EphA2 ligand(e.g., ephrin A1 or a soluble form thereof) can be used to test for asubstance that enhances or induces the binding of an EphA2 receptor orsoluble portion thereof.

An assay to identify a substance which enhances interaction between anEphA receptor and an ephrin ligand can be performed with the component(e.g., cells, purified protein, including fusion proteins and portionshaving binding activity) which is not to be in competition with a testcompound, linked to a solid support. The solid support can be anysuitable solid phase or matrix, such as a bead, the wall of a plate orother suitable surface (e.g., a well of a microtiter plate), column poreglass (CPG) or a pin that can be submerged into a solution, such as in awell. Linkage of cells or purified protein to the solid support can beeither direct or through one or more linker molecules.

In one embodiment, an isolated or purified protein (e.g., anEphA2\receptor or an ephrin ligand) can be immobilized on a suitableaffinity matrix by standard techniques, such as chemical cross-linking,or via an antibody raised against the isolated or purified protein, andbound to a solid support. The matrix can be packed in a column or othersuitable container and is contacted with one or more compounds (e.g., amixture) to be tested under conditions suitable for binding of thecompound to the protein. For example, a solution containing compoundscan be made to flow through the matrix. The matrix can be washed with asuitable wash buffer to remove unbound compounds and non-specificallybound compounds. Compounds which remain bound can be released by asuitable elution buffer. For example, a change in the ionic strength orpH of the elution buffer can lead to a release of compounds.Alternatively, the elution buffer can comprise a release component orcomponents designed to disrupt binding of compounds (e.g., one or moreligands or receptors, as appropriate, or analogs thereof which candisrupt binding or competitively inhibit binding of test compound to theprotein).

Fusion proteins comprising all of, or a portion of, a protein (e.g., anEphA receptor or an ephrin ligand) linked to a second moiety notoccurring in that protein as found in nature can be prepared for use inanother embodiment of the method. Suitable fusion proteins for thispurpose include those in which the second moiety comprises an affinityligand (e.g., an enzyme, antigen, epitope). The fusion proteins can beproduced by inserting the protein (e.g., an EphA receptor or an ephrinligand) or a portion thereof into a suitable expression vector whichencodes an affinity ligand. The expression vector can be introduced intoa suitable host cell for expression. Host cells are disrupted and thecell material, containing fusion protein, can be bound to a suitableaffinity matrix by contacting the cell material with an affinity matrixunder conditions sufficient for binding of the affinity ligand portionof the fusion protein to the affinity matrix.

In other embodiments, other assays can be used for screening forcompounds that stimulates functions (e.g., phosphorylation ordimerization) of EphA (e.g., EphA1, EphA2, or EphA3). Methods ofdetecting protein phosphorylation and dimerization can be achieved bytechniques such as immunoprecipitations, Western blots, andcross-linking assays. In these cases, antibodies may be used in avariety of detection techniques. Detailed methods have been described inthe working examples.

In certain embodiments, the invention relates to methods for selectingor screening for a compound capable of binding to an EphA receptor. Thecompound may be a naturally occurring biomolecule synthesized in vivo orin vitro. The compound may be optionally derivatized with anothercompound. One advantage of this modification is that the derivatizingcompound may be used to facilitate the EphA compound complex collection,e.g., after separation of compound and an EphA receptor. Non-limitingexamples of derivatizing groups include biotin, fluorescein,digoxygenin, green fluorescent protein, isotopes, polyhistidine,magnetic beads, glutathione S transferase, photoactivatible crosslinkersor any combinations thereof.

The interaction between the compound and an EphA receptor may becovalent or non-covalent. Optionally, the compound may or may notdisplay affinity for other Eph receptors. For example, binding betweenEphA2 and a compound can be identified at the protein level using invitro biochemical methods, including photo-crosslinking, radiolabeledligand binding, and affinity chromatography (Jakoby W B et al., 1974,Methods in Enzymology 46: 1). Alternatively, small molecules can beimmobilized on an agarose matrix and used to screen extracts of avariety of cell types and organisms.

Another useful technique to closely associate binding of a compound withDNA encoding an EphA2 is phage display. In phage display, which has beenpredominantly used in the monoclonal antibody field, peptide or proteinlibraries are created on the viral surface and screened for activity(Smith G P, 1985, Science 228:1315). Phages are panned for a targetprotein which is connected to a solid phase (Parmley S F et al., 1988,Gene 73:305). One of the advantages of phage display is that the cDNA isin the phage and thus no separate cloning step is required.

In a specific embodiment, the invention relate to methods of identifyingor selecting a compound capable of binding to an EphA, comprising: (a)providing coordinates defining the three dimensional structure of theEphA ligand-binding domain: (b) characterizing points associated withthat three dimensional structure with respect to the favorability ofinteractions with one or more selected functional groups; (c) providinga database of one or more candidate compounds; and (d) identifying fromthe database those compounds having structures which best fit the pointsof favorable interaction with the three dimensional structure.

VI. Methods of Treatment

The present invention provides methods of treating an individualsuffering from cancer through administering to the individual atherapeutically effective amount of an EphA therapeutic agent asdescribed above. The present invention provides methods of preventing orreducing the onset of cancer in an individual through administering tothe individual an effective amount of an EphA therapeutic agent. Thesemethods are particularly aimed at therapeutic and prophylactictreatments of animals, and more particularly, humans.

The term “preventing” is art-recognized, and when used in relation to acondition, such as a local recurrence (e.g., pain), a disease such ascancer, a syndrome complex such as heart failure or any other medicalcondition, is well understood in the art, and includes administration ofa composition which reduces the frequency of, or delays the onset of,symptoms of a medical condition in a subject relative to a subject whichdoes not receive the composition. Thus, prevention of cancer includes,for example, reducing the number of detectable cancerous growths in apopulation of patients receiving a prophylactic treatment relative to anuntreated control population, and/or delaying the appearance ofdetectable cancerous growths in a treated population versus an untreatedcontrol population, e.g., by a statistically and/or clinicallysignificant amount. Prevention of an infection includes, for example,reducing the number of diagnoses of the infection in a treatedpopulation versus an untreated control population, and/or delaying theonset of symptoms of the infection in a treated population versus anuntreated control population. Prevention of pain includes, for example,reducing the magnitude of, or alternatively delaying, pain sensationsexperienced by subjects in a treated population versus an untreatedcontrol population.

Cancers and related disorders that can be treated, prevented, or managedby methods, EphA therapeutic agents and compositions of the presentinvention include but are not limited to cancers include the following:leukemias, such as but not limited to, acute leukemia, acute lymphocyticleukemia, acute myelocytic leukemias, such as, myeloblastic,promyelocytic, myelomonocytic, monocytic, and erythroleukemia leukemiasand myelodysplastic syndrome; chronic leukemias, such as but not limitedto, chronic myelocytic (granulocytic) leukemia, chronic lymphocyticleukemia, hairy cell leukemia; polycythemia vera; lymphomas such as butnot limited to Hodgkin's disease, non-Hodgkin's disease; multiplemyelomas such as but not limited to smoldering multiple myeloma,nonsecretory myeloma, osteosclerotic myeloma, plasma cell leukemia,solitary plasmacytoma and extramedullary plasmacytoma; Waldenstrom'smacroglobulinemia; monoclonal gammopathy of undetermined significance;benign monoclonal gammopathy; heavy chain disease; bone and connectivetissue sarcomas such as but not limited to bone sarcoma, osteosarcoma,chondrosarcoma, Ewing's sarcoma, malignant giant cell tumor,fibrosarcoma of bone, chordoma, periosteal sarcoma, soft-tissuesarcomas, angiosarcoma (hemangiosarcoma), fibrosarcoma, Kaposi'ssarcoma, leiomyosarcoma, liposarcoma, lymphangiosarcoma, neurilemmoma,rhabdomyosarcoma, synovial sarcoma; brain tumors such as but not limitedto, glioma, astrocytoma, brain stem glioma, ependymoma,oligodendroglioma, nonglial tumor, acoustic neurinoma,craniopharyngioma, medulloblastoma, meningioma, pineocytoma,pineoblastoma, primary brain lymphoma; breast cancer including but notlimited to ductal carcinoma, adenocarcinoma, lobular (small cell)carcinoma, intraductal carcinoma, medullary breast cancer, mucinousbreast cancer, tubular breast cancer, papillary breast cancer, Paget'sdisease, and inflammatory breast cancer; adrenal cancer such as but notlimited to pheochromocytom and adrenocortical carcinoma; thyroid cancersuch as but not limited to papillary or follicular thyroid cancer,medullary thyroid cancer and anaplastic thyroid cancer; pancreaticcancer such as but not limited to, insulinoma, gastrinoma, glucagonoma,vipoma, somatostatin-secreting tumor, and carcinoid or islet cell tumor;pituitary cancers such as but limited to Cushing's disease,prolactin-secreting tumor, acromegaly, and diabetes insipius; eyecancers such as but not limited to ocular melanoma such as irismelanoma, choroidal melanoma, and cilliary body melanoma, andretinoblastoma; vaginal cancers such as squamous cell carcinoma,adenocarcinoma, and melanoma; vulvar cancer such as squamous cellcarcinoma, melanoma, adenocarcinoma, basal cell carcinoma, sarcoma, andPaget's disease; cervical cancers such as but not limited to, squamouscell carcinoma, and adenocarcinoma; uterine cancers such as but notlimited to endometrial carcinoma and uterine sarcoma; ovarian cancerssuch as but not limited to, ovarian epithelial carcinoma, borderlinetumor, germ cell tumor, and stromal tumor; esophageal cancers such asbut not limited to, squamous cancer, adenocarcinoma, adenoid cysticcarcinoma, mucoepidermoid carcinoma, adenosquamous carcinoma, sarcoma,melanoma, plasmacytoma, verrucous carcinoma, and oat cell (small cell)carcinoma; stomach cancers such as but not limited to, adenocarcinoma,fungating (polypoid), ulcerating, superficial spreading, diffuselyspreading, malignant lymphoma, liposarcoma, fibrosarcoma, andcarcinosarcoma; colon cancers; rectal cancers; liver cancers such as butnot limited to hepatocellular carcinoma and hepatoblastoma; gallbladdercancers such as adenocarcinoma; cholangiocarcinomas such as but notlimited to papillary, nodular, and diffuse; lung cancers such asnon-small cell lung cancer, squamous cell carcinoma (epidermoidcarcinoma), adenocarcinoma, large-cell carcinoma and small-cell lungcancer; testicular cancers such as but not limited to germinal tumor,seminoma, anaplastic, classic (typical), spermatocytic, nonseminoma,embryonal carcinoma, teratoma carcinoma, choriocarcinoma (yolk-sactumor), prostate cancers such as but not limited to, prostaticintraepithelial neoplasia, adenocarcinoma, leiomyosarcoma, andrhabdomyosarcoma; penal cancers; oral cancers such as but not limited tosquamous cell carcinoma; basal cancers; salivary gland cancers such asbut not limited to adenocarcinoma, mucoepidermoid carcinoma, andadenoidcystic carcinoma; pharynx cancers such as but not limited tosquamous cell cancer, and verrucous; skin cancers such as but notlimited to, basal cell carcinoma, squamous cell carcinoma and melanoma,superficial spreading melanoma, nodular melanoma, lentigo malignantmelanoma, acral lentiginous melanoma; kidney cancers such as but notlimited to renal cell carcinoma, adenocarcinoma, hypemephroma,fibrosarcoma, transitional cell cancer (renal pelvis and/or uterer);Wilms' tumor; bladder cancers such as but not limited to transitionalcell carcinoma, squamous cell cancer, adenocarcinoma, carcinosarcoma. Inaddition, cancers include myxosarcoma, osteogenic sarcoma,endotheliosarcoma, lymphangioendotheliosarcoma, mesothelioma, synovioma,hemangioblastoma, epithelial carcinoma, cystadenocarcinoma, bronchogeniccarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillarycarcinoma and papillary adenocarcinomas (for a review of such disorders,see Fishman et al., 1985, Medicine, 2d Ed., J. B. Lippincott Co.,Philadelphia and Murphy et al., 1997, Informed Decisions: The CompleteBook of Cancer Diagnosis, Treatment, and Recovery, Viking Penguin,Penguin Books U.S.A., Inc., United States of America)

Accordingly, the methods and EphA therapeutic agents of the inventionare also useful in the treatment or prevention of a variety of cancersor other abnormal proliferative diseases, including (but not limited to)the following: carcinoma, including that of the bladder, breast,prostate, rectal, colon, kidney, liver, lung, ovary, pancreas, stomach,cervix, thyroid and skin; including squamous cell carcinoma;hematopoietic tumors of lymphoid lineage, including leukemia, acutelymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma,T-cell lymphoma, Burkitt's lymphoma; hematopoietic tumors of myeloidlineage, including acute and chronic myelogenous leukemias andpromyclocytic leukemia; tumors of mesenchymal origin, includingfibrosarcoma and rhabdomyoscarcoma; other tumors, including melanoma,seminoma, tetratocarcinoma, neuroblastoma and glioma; tumors of thecentral and peripheral nervous system, including astrocytoma,neuroblastoma, glioma, and schwannomas; tumors of mesenchymal origin,including fibrosarcoma, rhabdomyoscarama, and osteosarcoma; and othertumors, including melanoma, xeroderma pigmentosum, keratoactanthoma,seminoma, thyroid follicular cancer and teratocarcinoma. It is alsocontemplated that cancers caused by aberrations in apoptosis would alsobe treated by the methods and compositions of the invention. Suchcancers may include but not be limited to follicular lymphomas,carcinomas with p53 mutations, hormone dependent tumors of the breast,prostate and ovary, and precancerous lesions such as familialadenomatous polyposis, and myelodysplastic syndromes. In specificembodiments, malignancy or dysproliferative changes (such as metaplasiasand dysplasias), or hyperproliferative disorders, are treated orprevented in the skin, lung, colon, rectum, breast, prostate, bladder,kidney, pancreas, ovary, or uterus. In other specific embodiments,sarcoma, melanoma, or leukemia is treated or prevented.

In some embodiments, the cancer is malignant and overexpresses EphA. Inother embodiments, the disorder to be treated is a pre-cancerouscondition associated with cells that overexpress EphA. In a specificembodiments, the pre-cancerous condition is high-grade prostaticintraepithelial neoplasia (PIN), fibroadenoma of the breast, fibrocysticdisease, or compound nevi.

In certain embodiments, EphA therapeutic agents of the invention can bedelivered to cancer cells by site-specific means. Cell-type-specificdelivery can be provided by conjugating a therapeutic agent to atargeting molecule, for example, one that selectively binds to theaffected cells. Methods for targeting include conjugates, such as thosedescribed in U.S. Pat. No. 5,391,723. Targeting vehicles, such asliposomes, can be used to deliver a compound, for example, byencapsulating the compound in a liposome containing a cell-specifictargeting molecule. Methods for targeted delivery of compounds toparticular cell types are well-known to those skilled in the art.

In certain embodiments, one or more EphA therapeutic agents can beadministered, together (simultaneously) or at different times(sequentially). In addition, therapy by administration of one or moreEphA therapeutic agents is combined with the administration of one ormore therapies such as, but not limited to, chemotherapies, radiationtherapies, hormonal therapies, and/or biologicaltherapies/immunotherapie-s. Prophylactic/therapeutic agents include, butare not limited to, proteinaceous molecules, including, but not limitedto, peptides, polypeptides, proteins, including post-translationallymodified proteins, antibodies etc.; or small molecules (less than 1000daltons), inorganic or organic compounds; or nucleic acid moleculesincluding, but not limited to, double-stranded or single-stranded DNA,or double-stranded or single-stranded RNA, as well as triple helixnucleic acid molecules. Prophylavtic/therapeutic agents can be derivedfrom any known organism (including, but not limited to, animals, plants,bacteria, fungi, and protista, or viruses) or from a library ofsynthetic molecules.

In a specific embodiment, the methods of the invention encompassadministration of an EphA the respective agent in combination with theadministration of one or more prophylactic/therapeutic agents that areinhibitors of kinases such as, but not limited to, ABL, ACK, AFK, AKT(e.g., AKT-1, AKT-2, and AKT-3), ALK, AMP-PK, ATM, Aurora1, Aurora2,bARKI, bArk2, BLK, BMX, BTK, CAK, CaM kinase, CDC2, CDK, CK, COT, CTD,DNA-PK, EGF-R, ErbB-1, ErbB-2, ErbB-3, ErbB-4, ERK (e.g., ERK1, ERK2,ERK3, ERK4, ERK5, ERK6, ERK7), ERT-PK, FAK, FGR (e.g., FGF1R, FGF2R),FLT (e.g., FLT-1, FLT-2, FLT-3, FLT-4), FRK, FYN, GSK (e.g., GSK1, GSK2,GSK3-alpha, GSK3-beta, GSK4, GSK5), G-protein coupled receptor kinases(GRKs), HCK, HER2, HKII, JAK (e.g., JAK1, JAK2, JAK3, JAK4), JNK (e.g.,JNK1, JNK2, JNK3), KDR, KIT, IGF-1 receptor, IKK-1, IKK-2, INSR (insulinreceptor), IRAK1 IRAK2, IRK, ITK, LCK, LOK, LYN, MAPK, MAPKAPK-1,MAPKAPK-2, MEK, MET, MFPK, MHCK, MLCK, MLK3, NEU, NIK, PDGF receptoralpha, PDGF receptor beta, PHK, PI-3 kinase, PKA, PKB, PKC, PKG, PRK1,PYK2, p38 kinases, p135tyk2, p34cdc2, p42cdc2, p42mapk, p44 mpk, RAF,RET, RIP, RIP-2, RK, RON, RS kinase, SRC, SYK, S6K, TAK1, TEC, TIE1,TIE2, TRKA, TXK, TYK2, UL13, VEGFR1, VEGFR2, YES, YRK, ZAP-70, and allsubtypes of these kinases (see e.g., Hardie and Hanks (1995) The ProteinKinase Facts Book, I and II, Academic Press, San Diego, Calif.). Inother embodiments, an EphA therapeutic agent is administered incombination with the administration of one or moreprophylactic/therapeutic agents that are inhibitors of Eph receptorkinases (e.g., EphA2, EphA4). In still another embodiment, an EphAtherapeutic agent is administered in combination with the administrationof one or more prophylactic/therapeutic agents that are inhibitors ofEphA.

In another specific embodiment, the methods of the invention encompassadministration of EphA therapeutic agents in combination with theadministration of one or more prophylactic/therapeutic agents that areangiogenesis inhibitors such as, but not limited to: Angiostatin(plasminogen fragment); antiangiogenic antithrombin III; Angiozyme;ABT-627; Bay 12-9566; Benefin; Bevacizumab; BMS-275291:cartilage-derived inhibitor (CDI): CAI; CD59 complement fragment;CEP-7055; Col 3; Combretastatin A-4; Endostatin (collagen XVIIIfragment); fibronectin fragment. Gro-beta; Halofuginone; Heparinases;Heparin hexasaccharide fragment; HMV833; Human chorionic gonadotropin(hCG); IM-862; Interferon alpha/beta/gamma; Interferon inducible protein(IP-10); Interleukin-12; Kringle 5 (plasminogen fragment); Marimastat;Metalloproteinase inhibitors (TIMPs); 2-Methoxyestradiol; MMI 270 (CGS27023A); MoAb IMC-1C11; Neovastat; NM-3; Panzem; PI-88; Placentalribonuclease inhibitor; Plasminogen activator inhibitor; Plateletfactor-4 (PF4); Prinomastat; Prolactin 16 kD fragment;Proliferin-related protein (PRP); PTK 787/ZK 222594; Retinoids;Solimastat; Squalamine; SS 3304; SU 5416; SU6668; SU11248;Tetrahydrocortisol-S; tetrathiomolybdate; thalidomide. Thrombospondin-1(TSP-1); TNP-470; Transforming growth factor-beta (TGF-.beta.);Vasculostatin; Vasostatin (calreticulin fragment); ZD6126; ZD6474;farnesyl transferase inhibitors (FTI); and bisphosphonates.

In another specific embodiment, the methods of the invention encompassadministration of EphA therapeutic agents in combination with theadministration of one or more prophylactic/therapeutic agents that areanti-cancer agents such as, but not limited to: acivicin, aclarubicin,acodazole hydrochloride, acronine, adozelesin, aldesleukin, altretamine,ambomycin, ametantrone acetate, aminoglutethimide, amsacrine,anastrozole, anthramycin, asparaginase, asperlin, azacitidine, azetepa,azotomycin, batimastat, benzodepa, bicalutamide, bisantrenehydrochloride, bisnafide dimesylate, bizelesin, bleomycin sulfate,brequinar sodium, bropirimine, busulfan, cactinomycin, calusterone,caracemide, carbetimer, carboplatin, carmustine, carubicinhydrochloride, carzelesin, cedefingol, chlorambucil, cirolemycin,cisplatin, cladribine, crisnatol mesylate, cyclophosphamide, cytarabine,dacarbazine, dactinomycin, daunorubicin hydrochloride, decarbazine,decitabine, dexormaplatin, dezaguanine, dezaguanine mesylate,diaziquone, docetaxel, doxorubicin, doxorubicin hydrochloride,droloxifene, droloxifene citrate, dromostanolone propionate, duazomycin,edatrexate, eflornithine hydrochloride, elsamitrucin, enloplatin,enpromate, epipropidine, epirubicin hydrochloride, erbulozole,esorubicin hydrochloride, estramustine, estramustine phosphate sodium,etanidazole, etoposide, etoposide phosphate, etoprine, fadrozolehydrochloride, fazarabine, fenretinide, floxuridine, fludarabinephosphate, fluorouracil, flurocitabine, fosquidone, fostriecin sodium,gemcitabine, gemcitabine hydrochloride, hydroxyurea, idarubicinhydrochloride, ifosfamide, ilmofosine, interleukin 2 (includingrecombinant interleukin 2, or rIL2), interferon alpha-2a, interferonalpha-2b, interferon alpha-n1, interferon alpha-n3, interferon beta-I a,interferon gamma-I b, iproplatin, irinotecan hydrochloride, lanreotideacetate, letrozole, leuprolide acetate, liarozole hydrochloride,lometrexol sodium, lomustine, losoxantrone hydrochloride, masoprocol,maytansine, mechlorethamine hydrochloride, megestrol acetate,melengestrol acetate, melphalan, menogaril, mercaptopurine,methotrexate, methotrexate sodium, metoprine, meturedepa, mitindomide,mitocarcin, mitocromin, mitogillin, mitomalcin, mitomycin, mitosper,mitotane, mitoxantrone hydrochloride, mycophenolic acid, nitrosoureas,nocodazole, nogalamycin, onaplatin, oxisuran, paclitaxel, pegaspargase,peliomycin, pentamustine, peplomycin sulfate, perfosfamide, pipobroman,piposulfan, piroxantrone hydrochloride, plicamycin, plomestane, porfimersodium, porfiromycin, prednimustine, procarbazine hydrochloride,puromycin, puromycin hydrochloride, pyrazofurin, riboprine, rogletimide,safingol, safingol hydrochloride, semustine, simtrazene, sparfosatesodium, sparsomycin, spirogermanium hydrochloride, spiromustine,spiroplatin, streptonigrin, streptozocin, sulofenur, talisomycin,tecogalan sodium, tegafur, teloxantrone hydrochloride, temoporfin,teniposide, teroxirone, testolactone, thiamiprine, thioguanine,thiotepa, tiazofurin, tirapazamine, toremifene citrate, trestoloneacetate, triciribine phosphate, trimetrexate, trimetrexate glucuronate,triptorelin, tubulozole hydrochloride, uracil mustard, uredepa,vapreotide, verteporfin, vinblastine sulfate, vincristine sulfate,vindesine, vindesine sulfate, vinepidine sulfate, vinglycinate sulfate,vinleurosine sulfate, vinorelbine tartrate, vinrosidine sulfate,vinzolidine sulfate, vorozole, zeniplatin, zinostatin, zorubicinhydrochloride. Other anti-cancer drugs include, but are not limited to:20-epi-1,25 dihydroxyvitamin D3,5-ethynyluracil, abiraterone,aclarubicin, acylfulvene, adecypenol, adozelesin, aldesleukin, ALL-TKantagonists, altretamine, ambamustine, amidox, amifostine,aminolevulinic acid, amrubicin, amsacrine, anagrelide, anastrozole,andrographolide, angiogenesis inhibitors, antagonist D, antagonist G,antarelix, anti-dorsalizing morphogenetic protein-1, antiandrogens,antiestrogens, antineoplaston, aphidicolin glycinate, apoptosis genemodulators, apoptosis regulators, apurinic acid, ara-CDP-DL-PTBA,arginine deaminase, asulacrine, atamestane, atrimustine, axinastatin 1,axinastatin 2, axinastatin 3, azasetron, azatoxin, azatyrosine, baccatinIII derivatives, balanol, batimastat, BCR/ABL antagonists,benzochlorins, benzoylstaurosporine, beta lactam derivatives,beta-alethine, betaclamycin B, betulinic acid, bFGF inhibitor,bicalutamide, bisantrene, bisaziridinylspermine, bisnafide, bistrateneA, bizelesin, breflate, bropirimine, budotitane, buthionine sulfoximine,calcipotriol, calphostin C, camptothecin derivatives, canarypox IL-2,capecitabine, carboxamide-amino-triazole, carboxyamidotriazole, CaRestM3, CARN 700, cartilage derived inhibitor, carzelesin, casein kinaseinhibitors (ICOS), castanospermine, cecropin B, cetrorelix,chloroquinoxaline sulfonamide, cicaprost, cis-porphyrin, cladribine,clomifene analogues, clotrimazole, collismycin A, collismycin B,combretastatin A4, combretastatin analogue, conagenin, crambescidin 816,crisnatol, cryptophycin 8, cryptophycin A derivatives, curacin A,cyclopentanthraquinones, cycloplatam, cypemycin, cytarabine ocfosfate,cytolytic factor, cytostatin, dacliximab, decitabine, dehydrodidemnin B,deslorelin, dexamethasone, dexifosfamide, dexrazoxane, dexverapamil,diaziquone, didemnin B, didox, diethylnorspermine,dihydro-5-azacytidine, dihydrotaxol, dioxamycin, diphenyl spiromustine,docetaxel, docosanol, dolasetron, doxifluridine, droloxifene,dronabinol, duocarmycin SA, ebselen, ecomustine, edelfosine,edrecolomab, eflomithine, elemene, emitefur, epirubicin, epristeride,estramustine analogue, estrogen agonists, estrogen antagonists,etanidazole, etoposide phosphate, exemestane, fadrozole, fazarabine,fenretinide, filgrastim, finasteride, flavopiridol, flezelastine,fluasterone, fludarabine, fluorodaunorunicin hydrochloride, forfenimex,formestane, fostriecin, fotemustine, gadolinium texaphyrin, galliumnitrate, galocitabine, ganirelix, gelatinase inhibitors, gemcitabine,glutathione inhibitors, hepsulfam, heregulin, hexamethylenebisacetamide, hypericin, ibandronic acid, idarubicin, idoxifene,idramrantone, ilmofosine, ilomastat, imidazoacridones, imiquimod,immunostimulant peptides, insulin-like growth factor-1 receptorinhibitor, interferon agonists, interferons, interleukins, iobenguane,iododoxorubicin, ipomeanol, iroplact, irsogladine, isobengazole,isohomohalicondrin B, itasetron, jasplakinolide, kahalalide F,lamellarin-N triacetate, lanreotide, leinamycin, lenograstim, lentinansulfate, leptolstatin, letrozole, leukemia inhibiting factor, leukocytealpha interferon, leuprolide+estrogen+progesterone, leuprorelin,levamisole, liarozole, linear polyamine analogue, lipophilicdisaccharide peptide, lipophilic platinum compounds, lissoclinamide 7,lobaplatin, lombricine, lometrexol, lonidamine, losoxantrone,lovastatin, loxoribine, lurtotecan, lutetium texaphyrin, lysofylline,lytic peptides, maitansine, mannostatin A, marimastat, masoprocol,maspin, matrilysin inhibitors, matrix metalloproteinase inhibitors,menogaril, merbarone, meterelin, methioninase, metoclopramide, MIFinhibitor, mifepristone, miltefosine, mirimostim, mismatched doublestranded RNA, mitoguazone, mitolactol, mitomycin analogues, mitonafide,mitotoxin fibroblast growth factor-saporin, mitoxantrone, mofarotene,molgramostim, monoclonal antibody, human chorionic gonadotrophin,monophosphoryl lipid A+myobacterium cell wall sk, mopidamol, multipledrug resistance gene inhibitor, multiple tumor suppressor 1 basedtherapy, mustard anticancer agent mycaperoxide B, mycobacterial cellwall extract, myriaporone, N-acetyldinaline, N-substituted benzamides,nafarelin, nagrestip, naloxone+pentazocine, napavin, naphterpin,nartograstim, nedaplatin, nemorubicin, neridronic acid, neutralendopeptidase, nilutamide, nisamycin, nitric oxide modulators, nitroxideantioxidant, nitrullyn, O6-benzylguanine, octreotide, okicenone,oligonucleotides, onapristone, ondansetron, ondansetron, oracin, oralcytokine inducer, ormaplatin, osaterone, oxaliplatin, oxaunomycin,paclitaxel, paclitaxel analogues, paclitaxel derivatives, palauamine,palmitoylrhizoxin, pamidronic acid, panaxytriol, panomifene, parabactin,pazelliptine, pegaspargase, peldesine, pentosan polysulfate sodium,pentostatin, pentrozole, perflubron, perfosfamide, perillyl alcohol,phenazinomycin, phenylacetate, phosphatase inhibitors, picibanil,pilocarpine hydrochloride, pirarubicin, piritrexim, placetin A, placetinB, plasminogen activator inhibitor, platinum complex, platinumcompounds, platinum-triamine complex, porfimer sodium, porfiromycin,prednisone, propyl bis-acridone, prostaglandin J2, proteasomeinhibitors, protein A-based immune modulator, protein kinase Cinhibitor, protein kinase C inhibitors, microalgal, protein tyrosinephosphatase inhibitors, purine nucleoside phosphorylase inhibitors,purpurins, pyrazoloacridine, pyridoxylated hemoglobin polyoxyethyleneconjugate, raf antagonists, raltitrexed, ramosetron, ras farnesylprotein transferase inhibitors, ras inhibitors, ras-GAP inhibitor,retelliptine demethylated, rhenium Re 186 etidronate, rhizoxin,ribozymes, R11 retinamide, rogletimide, rohitukine, romurtide,roquinimex, rubiginone B1, ruboxyl, safingol, saintopin, SarCNU,carcophytol A, sargramostim, Sdi 1 mimetics, semustine, senescencederived inhibitor 1, sense oligonucleotides, signal transductioninhibitors, signal transduction modulators, single chain antigen bindingprotein, sizofuran, sobuzoxane, sodium borocaptate, sodiumphenylacetate, solverol, somatomedin binding protein, sonermin,sparfosic acid, spicamycin D, spiromustine, splenopentin, spongistatin1, squalamine, stem cell inhibitor, stem-cell division inhibitors,stipiamide, stromelysin inhibitors, sulfinosine, superactive vasoactiveintestinal peptide antagonist, suradista, suramin, swainsonine,synthetic glycosaminoglycans, tallimustine, tamoxifen methiodide,tauromustine, taxol, tazarotene, tecogalan sodium, tegafur,tellurapyrylium, telomerase inhibitors, temoporfin, temozolomide,teniposide, tetrachlorodecaoxide, tetrazomine, thaliblastine,thalidomide, thiocoraline, thioguanine, thrombopoietin, thrombopoietinmimetic, thymalfasin, thymopoietin receptor agonist, thymotrinan,thyroid stimulating hormone, tin ethyl etiopurpurin, tirapazamine,titanocene bichloride, topsentin, toremifene, totipotent stem cellfactor, translation inhibitors, tretinoin, triacetyluridine,triciribine, trimetrexate, triptorelin, tropisetron, turosteride,tyrosine kinase inhibitors, tyrphostins, UBC inhibitors, ubenimex,urogenital sinus-derived growth inhibitory factor, urokinase receptorantagonists, vapreotide, variolin B, vector system, erythrocyte genetherapy, velaresol, veramine, verdins, verteporfin, vinorelbine,vinxaltine, vitaxin, vorozole, zanoterone, zeniplatin, zilascorb, andzinostatin stimalamer. Preferred additional anti-cancer drugs are5-fluorouracil and leucovorin.

In more particular embodiments, the present invention also comprises theadministration of one or more EphA therapeutic agents in combinationwith the administration of one or more therapies such as, but notlimited to anti-cancer agents such as those disclosed.

The invention also encompasses administration of the EphA therapeuticagents in combination with radiation therapy comprising the use ofx-rays, gamma rays and other sources of radiation to destroy the cancercells. In preferred embodiments, the radiation treatment is administeredas external beam radiation or teletherapy wherein the radiation isdirected from a remote source. In other preferred embodiments, theradiation treatment is administered as internal therapy or brachytherapywherein a radioactive source is placed inside the body close to cancercells or a tumor mass.

Cancer therapies and their dosages, routes of administration andrecommended usage are known in the art and have been described in suchliterature as the Physician's Desk Reference (56th ed., 2002).

In one specific embodiment, patients with breast cancer can beadministered an effective amount of EphA therapeutic agent. In anotherembodiment, the EphA therapeutic agent of the invention can beadministered in combination with an effective amount of one or moreother agents useful for breast cancer therapy including but not limitedto: doxorubicin, epirubicin, the combination of doxorubicin andcyclophosphamide (AC), the combination of cyclophosphamide, doxorubicinand 5-fluorouracil (CAF), the combination of cyclophosphamide,epirubicin and 5-fluorouracil (CEF), herceptin, tamoxifen, thecombination of tamoxifen and cytotoxic chemotherapy, taxanes (such asdocetaxel and paclitaxel). In a further embodiment, EphA therapeuticagents can be administered with taxanes plus standard doxorubicin andcyclophosphamide for adjuvant treatment of node-positive, localizedbreast cancer.

In another specific embodiment, patients with pre-cancerous fibroadenomaof the breast or fibrocystic disease can be administered EphAtherapeutic agents to treat the disorder and decrease the likelihoodthat it will progress to malignant breast cancer. Additionally, patientsrefractory to treatment, particularly hormonal therapy, moreparticularly tamoxifen therapy, can be administered EphA therapeuticagents to treat the cancer and/or render the patient non-refractory orresponsive.

In another embodiment, patients with colon cancer can be administered aneffective amount of one or more EphA therapeutic agents. In yet anotherembodiment, EphA therapeutic agents can be administered in combinationwith an effective amount of one or more other agents useful for coloncancer therapy including but not limited to: the combination of 5-FU andleucovorin, the combination of 5-FU and levamisole, irinotecan (CPT-11)or the combination of irinotecan, 5-FU and leucovorin (IFL).

In other embodiments, patients with prostate cancer can be administeredan effective amount of one or more EphA therapeutic agents. In anotherembodiment, the EphA therapeutic agents can be administered incombination with an effective amount of one or more other agents usefulfor prostate cancer therapy including but not limited to: external-beamradiation therapy, interstitial implantation of radioisotopes (i.e.,I.sup.125, palladium, iridium), leuprolide or other LHRH agonists,non-steroidal antiandrogens (flutamide, nilutamide, bicalutamide),steroidal antiandrogens (cyproterone acetate), the combination ofleuprolide and flutamide, estrogens such as DES, chlorotrianisene,ethinyl estradiol, conjugated estrogens U.S.P., DES-diphosphate,radioisotopes, such as strontium-89, the combination of external-beamradiation therapy and strontium-89, second-line hormonal therapies suchas aminoglutethimide, hydrocortisone, flutamide withdrawal,progesterone, and ketoconazole, low-dose prednisone, or otherchemotherapy regimens reported to produce subjective improvement insymptoms and reduction in PSA level including docetaxel, paclitaxel,estramustine/docetaxel, estramustine/etoposide,estramustine/vinblastine, and estramustine/paclitaxel.

In a specific embodiment, patients with pre-cancerous high-gradeprostatic intraepithelial neoplasia (PIN) are administered an EphA2therapeutic agents of the invention to treat the disorder and decreasethe likelihood that it will progress to malignant prostate cancer.

In specific embodiments, patients with melanoma are administered aneffective amount of EphA therapeutic agents of the invention. In anotherembodiment, the EphA therapeutic agents can be administered incombination with an effective amount of one or more other agents usefulfor melanoma cancer therapy including but not limited to: dacarbazine(DTIC), nitrosoureas such as carmustine (BCNU) and lomustine (CCNU),agents with modest single agent activity including vinca alkaloids,platinum compounds, and taxanes, the Dartmouth regimen (cisplatin, BCNU,and DTIC), interferon alpha (IFN-A), and interleukin-2 (IL-2). In aspecific embodiment, an effective amount of one or more EphA therapeuticagents can be administered in combination with isolated hyperthermiclimb perfusion (ILP) with melphalan (L-PAM), with or without tumornecrosis factor-alpha (TNF-alpha) to patients with multiple brainmetastases, bone metastases, and spinal cord compression to achievesymptom relief and some shrinkage of the tumor with radiation therapy.

In a specific embodiment, patients with pre-cancerous compound nevi areadministered EphA therapeutic agents to treat the disorder and decreasethe likelihood that it will progress to malignant melanoma.

In specific embodiments, patients with ovarian cancer are administeredan effective amount of one or more EphA therapeutic agents of theinvention. In another embodiment, the EphA therapeutic agents can beadministered in combination with an effective amount of one or moreother agents useful for ovarian cancer therapy including but not limitedto: intraperitoneal radiation therapy, such as P³² therapy, totalabdominal and pelvic radiation therapy, cisplatin, the combination ofpaclitaxel (Taxol) or docetaxel (Taxotere) and cisplatin or carboplatin,the combination of cyclophosphamide and cisplatin, the combination ofcyclophosphamide and carboplatin, the combination of 5-FU andleucovorin, etoposide, liposomal doxorubicin, gemcitabine or topotecan.It is contemplated that an effective amount of one or more EphAtherapeutic agents can be administered in combination with theadministration Taxol for patients with platinum-refractory disease.Included is the treatment of patients with refractory ovarian cancerincluding administration of: ifosfamide in patients with disease that isplatinum-refractory, hexamethylmelamine (HMM) as salvage chemotherapyafter failure of cisplatin-based combination regimens, and tamoxifen inpatients with detectable levels of cytoplasmic estrogen receptor ontheir tumors.

In specific embodiments, patients with small lung cell cancer areadministered an effective amount of one or more EphA therapeutic agents.In another embodiment, the antibodies of the invention can beadministered in combination with an effective amount of one or moreother agents useful for lung cancer therapy including but not limitedto: thoracic radiation therapy, cisplatin, vincristine, doxorubicin, andetoposide, alone or in combination, the combination of cyclophosphamide,doxorubicin, vincristine/etoposide, and cisplatin (CAV/EP), localpalliation with endobronchial laser therapy, endobronchial stents,and/or brachytherapy.

In other specific embodiments, patients with non-small lung cell cancerare administered an effective amount of one or more EphA therapeuticagents in combination with an effective amount of one or more otheragents useful for lung cancer therapy including but not limited to:palliative radiation therapy, the combination of cisplatin, vinblastineand mitomycin, the combination of cisplatin and vinorelbine, paclitaxel,docetaxel or gemcitabine, the combination of carboplatin and paclitaxel,interstitial radiation therapy for endobronchial lesions or stereotacticradiosurgery.

VII. Administration and Pharmaceutical Compositions

EphA therapeutic agents as described herein can be administered invarious forms, depending on the disorder to be treated and the age,condition, and body weight of the patient, as is well known in the art.For example, where the compounds are to be administered orally, they maybe formulated as tablets, capsules, granules, powders, or syrups; or forparenteral administration, they may be formulated as injections(intravenous, intramuscular, or subcutaneous), drop infusionpreparations, or suppositories. For application by the ophthalmic mucousmembrane route, they may be formulated as eye drops or eye ointments.These formulations can be prepared by conventional means, and, ifdesired, the active ingredient may be mixed with any conventionaladditive, such as an excipient, a binder, a disintegrating agent, alubricant, a corrigent, a solubilizing agent, a suspension aid, anemulsifying agent or a coating agent. Although the dosage will varydepending on the symptoms, age and body weight of the patient, thenature and severity of the disorder to be treated or prevented, theroute of administration and the form of the drug, in general, a dailydosage of from 0.01 to 2000 mg of the compound is recommended for anadult human patient, and this may be administered in a single dose or individed doses.

The precise time of administration and/or amount of the agent that willyield the most effective results in terms of efficacy of treatment in agiven patient will depend upon the activity, pharmacokinetics, andbioavailability of a particular compound, physiological condition of thepatient (including age, sex, disease type and stage, general physicalcondition, responsiveness to a given dosage, and type of medication),route of administration, etc. However, the above guidelines can be usedas the basis for fine-tuning the treatment, e.g., determining theoptimum time and/or amount of administration, which will require no morethan routine experimentation consisting of monitoring the subject andadjusting the dosage and/or timing.

The phrase “pharmaceutically acceptable” is employed herein to refer tothose ligands, materials, compositions, and/or dosage forms which are,within the scope of sound medical judgment, suitable for use in contactwith the tissues of human beings and animals without excessive toxicity,irritation, allergic response, or other problem or complication,commensurate with a reasonable benefit/risk ratio. The phrase“pharmaceutically acceptable carrier” as used herein means apharmaceutically acceptable material, composition or vehicle, such as aliquid or solid filler, diluent, excipient, solvent or encapsulatingmaterial, involved in carrying or transporting the subject chemical fromone organ or portion of the body, to another organ or portion of thebody. Each carrier must be “acceptable” in the sense of being compatiblewith the other ingredients of the formulation and not injurious to thepatient.

Wetting agents, emulsifiers, and lubricants, such as sodium laurylsulfate and magnesium stearate, as well as coloring agents, releaseagents, coating agents, sweetening, flavoring, and perfuming agents,preservatives and antioxidants can also be present in the compositions.

Examples of pharmaceutically acceptable antioxidants include: (1) watersoluble antioxidants, such as ascorbic acid, cysteine hydrochloride,sodium bisulfate, sodium metabisulfite, sodium sulfite, and the like;(2) oil-soluble antioxidants, such as ascorbyl palmitate, butylatedhydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propylgallate, alpha-tocopherol, and the like; and (3) metal chelating agents,such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol,tartaric acid, phosphoric acid, and the like.

Formulations useful in the methods of the present invention includethose suitable for oral, nasal, topical (including buccal andsublingual), rectal, vaginal, aerosol, and/or parenteral administration.The formulations may conveniently be presented in unit dosage form andmay be prepared by any methods well known in the art of pharmacy. Theamount of active ingredient which can be combined with a carriermaterial to produce a single dosage form will vary depending upon thehost being treated and the particular mode of administration. The amountof active ingredient which can be combined with a carrier material toproduce a single dosage form will generally be that amount of thecompound which produces a therapeutic effect. Generally, out of onehundred percent, this amount will range from about 1 percent to aboutninety-nine percent of active ingredient, preferably from about 5percent to about 70 percent, most preferably from about 10 percent toabout 30 percent.

Formulations suitable for oral administration may be in the form ofcapsules, cachets, pills, tablets, lozenges (using a flavored basis,usually sucrose and acacia or tragacanth), powders, granules, or as asolution or a suspension in an aqueous or non-aqueous liquid, or as anoil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup,or as pastilles (using an inert base, such as gelatin and glycerin, orsucrose and acacia) and/or as mouthwashes, and the like, each containinga predetermined amount of a therapeutic agent as an active ingredient. Acompound may also be administered as a bolus, electuary or paste.

Liquid dosage forms for oral administration include pharmaceuticallyacceptable emulsions, microemulsions, solutions, suspensions, syrups,and elixirs. In addition to the active ingredient, the liquid dosageforms may contain inert diluents commonly used in the art, such as, forexample, water or other solvents, solubilizing agents, and emulsifierssuch as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethylacetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyleneglycol, oils (in particular, cottonseed, groundnut, corn, germ, olive,castor, and sesame oils), glycerol, tetrahydrofuryl alcohol,polyethylene glycols, and fatty acid esters of sorbitan, and mixturesthereof.

Formulations which are suitable for vaginal administration also includepessaries, tampons, creams, gels, pastes, foams, or spray formulationscontaining such carriers as are known in the art to be appropriate.Dosage forms for the topical or transdermal administration of atherapeutic agent include powders, sprays, ointments, pastes, creams,lotions, gels, solutions, patches, and inhalants. The active componentmay be mixed under sterile conditions with a pharmaceutically acceptablecarrier, and with any preservatives, buffers, or propellants which maybe required.

The therapeutic agent can be alternatively administered by aerosol. Thisis accomplished by preparing an aqueous aerosol, liposomal preparation,or solid particles containing the compound. A nonaqueous (e.g.,fluorocarbon propellant) suspension could be used. Sonic nebulizers arepreferred because they minimize exposing the agent to shear, which canresult in degradation of the compound. Ordinarily, an aqueous aerosol ismade by formulating an aqueous solution or suspension of the agenttogether with conventional pharmaceutically acceptable carriers andstabilizers. The carriers and stabilizers vary with the requirements ofthe particular compound, but typically include nonionic surfactants(Tweens, Pluronics, or polyethylene glycol), innocuous proteins likeserum albumin, sorbitan esters, oleic acid, lecithin, amino acids suchas glycine, buffers, salts, sugars, or sugar alcohols. Aerosolsgenerally are prepared from isotonic solutions.

Transdermal patches have the added advantage of providing controlleddelivery of an therapeutic agent to the body. Such dosage forms can bemade by dissolving or dispersing the agent in the proper medium.Absorption enhancers can also be used to increase the flux of thetherapeutic agent across the skin. The rate of such flux can becontrolled by either providing a rate controlling membrane or dispersingthe peptidomimetic in a polymer matrix or gel.

Pharmaceutical compositions of this invention suitable for parenteraladministration comprise one or more EphA2 therapeutic agent(s) incombination with one or more pharmaceutically acceptable sterileisotonic aqueous or nonaqueous solutions, dispersions, suspensions oremulsions, or sterile powders which may be reconstituted into sterileinjectable solutions or dispersions just prior to use, which may containantioxidants, buffers, bacteriostats, solutes which render theformulation isotonic with the blood of the intended recipient orsuspending or thickening agents.

Examples of suitable aqueous and nonaqueous carriers which may beemployed in the pharmaceutical compositions of the invention includewater, ethanol, polyols (such as glycerol, propylene glycol,polyethylene glycol, and the like), and suitable mixtures thereof,vegetable oils, such as olive oil, and injectable organic esters, suchas ethyl oleate. Proper fluidity can be maintained, for example, by theuse of coating materials, such as lecithin, by the maintenance of therequired particle size in the case of dispersions, and by the use ofsurfactants.

In some cases, in order to prolong the effect of a drug, it is desirableto slow the absorption of the drug from subcutaneous or intramuscularinjection. This may be accomplished by the use of a liquid suspension ofcrystalline or amorphous material having poor water solubility. The rateof absorption of the drug then depends upon its rate of dissolutionwhich, in turn, may depend upon crystal size and crystalline form.Alternatively, delayed absorption of a parenterally administered drugform is accomplished by dissolving or suspending the drug in an oilvehicle.

Injectable depot forms are made by forming microencapsule matrices ofsubject therapeutic agent in biodegradable polymers such aspolylactide-polyglycolide. Depending on the ratio of drug to polymer,and the nature of the particular polymer employed, the rate of drugrelease can be controlled Examples of other biodegradable polymersinclude poly(orthoesters) and poly(anhydrides). Depot injectableformulations are also prepared by entrapping the drug in liposomes ormicroemulsions which are compatible with body tissue.

When the EphA therapeutic agent(s) of the present invention areadministered as pharmaceuticals to humans and animals, they can be givenper se or as a pharmaceutical composition containing, for example, 0.1to 99.5% (more preferably, 0.5 to 90%) of active ingredient incombination with a pharmaceutically acceptable carrier.

The preparations of agents may be given orally, parenterally, topically,or rectally. They are of course given by forms suitable for eachadministration route. For example, they are administered in tablets orcapsule form, by injection, inhalation, eye lotion, ointment,suppository, infusion; topically by lotion or ointment; and rectally bysuppositories. Oral administration is preferred.

These EphA therapeutic agent(s) may be administered to humans and otheranimals for therapy by any suitable route of administration, includingorally, nasally, as by, for example, a spray, rectally, intravaginally,parenterally, intracistemally, and topically, as by powders, ointmentsor drops, including buccally and sublingually.

Actual dosage levels of the active ingredients in the pharmaceuticalcompositions of this invention may be varied so as to obtain an amountof the active ingredient which is effective to achieve the desiredtherapeutic response for a particular patient, composition, and mode ofadministration, without being toxic to the patient.

EXAMPLES

The invention now being generally described, it will be more readilyunderstood by reference to the following examples which are includedmerely for purposes of illustration of certain aspects and embodimentsof the present invention, and are not intended to limit the invention.

Example 1 Stimulation of EphA Kinases on Prostate Adenocarcinoma CellsAntagonizes c-Met-Mediated Chemotaxis and Invasion

1. EphA2, but not its Ephrin-A Ligands, is Highly Expressed inMetastatic Prostate Cancer Cells of Human or Rat Origin.

We have previously identified EphA2 as the primary EphA kinase expressedin PC-3 cells. Immunodepletion experiment (Methods) revealed that EphA2is also the major EphA kinase in other human prostate cancer cell lines(FIG. 1A). Interestingly, cells derived from distal metastasis includingPC-3 and DU-145 expressed much higher levels of EphA2 than cells derivedfrom primary tumor (CWR22R) or local metastasis (LNCaP) (FIGS. 1B andC). However, because these cells were derived from differentindividuals, a correlative relationship between EphA2 expression andtumor progression cannot be established. Thus, we examined theexpression of EphA2 in a series of rat prostate cancer cell linesderived from the same original tumor, Dunning rat tumor R-3327. WhileR-3327-G (G) is a slow growing and androgen responsive subline with lowmetastatic ability, AT-1 is independent of androgen but remains poorlymetastatic. MatLu and MatLyLu arose from AT-1, but are highly metastaticto lung (MatLu and MatLyLu) and lymph node (MatLyLu). We found thatEphA2 expression was low in G line, moderately increased in AT-1, andgreatly elevated in MatLu and MatLyLu variants (FIG. 1B), suggesting apossible correlation between EphA2 expression and tumor progression. Incontrast to EphA2, other EphA kinases, including EphA1, EphA3 and EphA4,showed no consistent changes during tumor progression in human or ratcell lines (FIG. 1B). Like other Eph kinases, EphA2 is promiscuous inligand recognition and can bind to multiple ephrinA ligands. Immunoblotwith a panel of antibodies against several ephrin-As showed that theligands were expressed in low levels, and did not exhibit significantdifferences among the cell lines examined (FIG. 1B). In summary, whileEphA2 expression is elevated in cell lines derived more metastaticcancers, ephrin-A expression remains low and relatively constant.

Next, we examined ligand responsiveness and downstream signaling ofEphA2 kinase in cells that overexpress it. DU-145 and MatLyLu werestimulated with ephrin-A1 dimerized by fusion to the heavy chain ofhuman IgG1 (ephrin-A1-Fc). Similar to what we reported in PC-3 cells, inboth DU-145 and MatLyLu EphA2 activation readily occurred in two minutesafter the addition of ephrin-A 1-Fc and persisted for the duration ofthe experiment (FIG. 1D). ERK1/2 activity was reduced as EphA2 becameactivated, consistent with our previous report in a number of celllines, including PC-3 cells. Therefore, EphA2, but not other EphAkinases or its cognitive ligands, was highly expressed in metastaticprostate cancer cells; ligation of unoccupied EphA2 receptor readilytransduced signals into cell interior.

2. EphA2 Activation Antagonized Stimulatory Effects of HGF/SFon CellMigration and Wound Healing

In prostate cancer, there is a direct correlation between cell motilityin vitro and metastasis in vivo. Cell motility in turn is stimulated bythe acquisition of paracrine/autocrine loops which frequently developduring prostate cancer progression. HGF/SF is one such cytokine that issuspected to play a critical role in both prostate cancer cell spreadingfrom original tumor site and prostate cancer cell homing to the bones.Interestingly, we found that EphA2 expression paralleled that of c-Met(FIG. 2A); low in LNCaP and CWR22R and high in DU-145 and PC-3, asreported previously. Because HGF/SF-c-Met axis has been implicated inmalignant progression of prostate cancer, we next investigated howactivation of EphA2 overexpressed on metastatic prostate cancer cellsmay impact HGF/SF-stimulated cell migration and invasion. DU-145 cellswere chosen for these studies because they have been frequently used asa model to assess the role of HGF/SF-c-Met axis in prostate cancerprogression.

First we performed a chemotactic cell migration assay using modifiedBoyden chamber system (Methods). DU-145 cells were placed in the upperchamber while Fc, ephrin-A1-Fc, HGF/Fc, or HGF/ephrin-A1-Fc was addedinto the lower chamber (FIG. 2B). In comparison with Fc control, thepresence of ephrin-A1-Fc in the lower chamber reduced the basal level ofcell migration (columns 1 vs. 2; p=4×10⁻⁴). HGF/SF stimulated cellmigration (columns 1 vs. 3; p=1.5×10⁻⁶), which was also potentlyinhibited by ephrin-A1-Fc (columns 3 vs. 4; p=1.9×10⁻⁵). Therefore,ephrin-A1 inhibited both basal and HGF/SF-induced cell migration.

The Boyden chamber assay measures the cellular response to a gradient ofHGF/SF and may simulate tumor cell homing to target organs secretingchemotactic factors. On the other hand, tumor cells in original tumorsite may be constantly exposed to growth factors produced by tumor cellsthemselves (autocrine), or surrounding stromal cells, or infiltratingleukocytes (paracrine). We tested if exogenously added ephrin-A1 ligandexhibited inhibitory effect on cell migration in a growth factor-filledenvironment. To this end, HGF/SF was added to both sides of chamberswhile Fc or ephrin-A1-Fc was added to the lower chambers only (FIG. 2C).The presence of 1HGF/SF elevated cell motility (columns 1 vs. 2:p=2.0×10⁻⁵). When ephrin-A1-Fc was added to the lower chamber, EphA2activation significantly reduced the number of cells migrated to theunderside of membrane (columns 2 vs. 3; p=5.1×10⁻⁴).

Because both Eph receptors and ephrin ligands are membrane-bound,Eph/ephrin interactions in vivo take place upon cell-cell contact. Tosimulate this condition, a recently described SOIL assay was carried outto test whether the immobilized ephrin-A1 ligand was able to inhibitchemokinetic cell migration. DU-145 cells grown to near confluence oncover slips were transferred to plates pre-coated with either Fc orephrin-A1-Fc. HGF/SF or equal volumes of PBS control was added to theculture medium to induce chemokinetic cell migration. FIG. 2D shows thatimmobilized ephrin-A1-Fc reduced basal levels of cell migration offcover slips. When HGF/SF was applied, cell migration was increased.However, the increase in cell migration induced by HGF/SF wassignificantly reduced on the ephrin-A1-Fc coated surface.

When tumors metastasize, they may disseminate as individual cells or asa group of cells (chain migration). In the latter case, thecharacteristics of cell-cell adhesion are still present. To test ifEphA2 activation inhibited chain migration, a wound-healing assay wascarried out (FIG. 2E). A wound was generated on confluent DU-145 cellsusing a micropipette tip. In comparison with Fc, ephrin-A1-Fc treatmentslowed down the speed of wound closing. When ephrin-A1-Fc was usedtogether with HGF/SF, the wound closing was also delayed compared withcells treated HGF/SF and Fc. This again demonstrated in the inhibitoryeffect of EphA2 activation on cell motility. In sum, EphA2 activationpotently antagonizes the stimulatory effects of HGF/SF on four differentmodes of cell motility.

3. EphA2 Activation Suppressed HGF/SF-Induced Invasion Through MatriGel

In addition to increased cell motility, the ability to invade throughextracellular matrix is another characteristic of metastatic tumorcells. Therefore, we next examined the consequence of EphA activation oninvasive ability of DU-145 cells induced by HGF/SF. The assay system issimilar to Boyden chamber used in the cell migration assay, but themembranes were coated with growth factor-reduced MatriGel. Twenty-fourhours after plating, cells invading through MatriGel and migrating tothe underside of the membranes were counted (FIG. 3). The presence ofephrin-A1-Fc in the lower chamber marginally reduced the basal cellinvasion (columns 1 vs. 2; p=0.06). Addition of HGF/SF to the lowerchamber significantly increased chemotactic cell invasion (columns 1 vs.3; p=0.001). When ephrin-A1-Fc was added together with HGF/SF in thelower chamber, the number of cells invading through MatriGel wassignificantly reduced (columns 3 vs. 4; p=2×10⁻⁴). Therefore, activationof EphA receptor has negative effects on malignant prostate cancer cellinvasion.

4. EphA2 Activation Inhibited DU-145 Cell Scattering Induced by HGF/SFand Preserved E-Cadherin Mediated Cell-Cell Adhesion

Tumor cells scattering/detaching from primary tumors is considered asthe first step in tumor metastasis. In addition to promoting cellmigration and invasion, HGF/SF is known to disrupt cell-cell adhesionmediated by E-cadherin, induce epithelial-mesenchymal transition (EMT)and cause cell scattering. Therefore, we examined the effects of EphA2activation on EMT and scattering induced by HGF/SF. DU-145 cells weretreated with Fc (control) or ephrin-A1-Fc in the presence or absence ofHGF/SF. Cell morphology was recorded 24 and 48 hours after the additionof stimuli (FIGS. 4A and B). In control Fc-treated cells, only about 5%of cells were found as individual cells with no direct contact withneighboring cells, while remaining cells aggregate to form colonies withtypical epithelial morphology. Ephrin-A1-Fc treatment consistentlyinduced more compact cobblestone morphology (FIG. 4A). Following 24 hourHGF treatment, most of cells underwent EMT characterized by detachmentfrom each other and transformation into spindle-shaped fibroblasticmorphology. However, in the presence of ephrin-A1-Fc cell-cell contactwas significantly retained; the fraction of scattered cells was reducedfrom 95% to 15% accompanied by a more rounded morphology compared withcells treated HGF and Fc. This change of morphology persisted for 48hours (FIG. 4A right panel and FIG. 4B lower panel). Thus ephrin-A1-Fcsignificantly suppressed HGF-induced EMT in DU-145 cells.

It has been reported that HGF/SF induces E-cadherin degradation inprostate cancer cells, which in turn contributes to its cell scatteringeffect. We next examined the changes in E-cadherin expression in cellsstimulated with HGF/SF, ephrin-A1-Fc or both. Ephrin-A1-Fc treatmentmoderately increased E-cadherin expression (FIG. 5A, lanes 1 vs. 2 and 5vs. 6). In agreement with previous reports, HGF/SF treated cells lostmost E-cadherin (lanes 3 and 7). When HGF/SF and ephrin-A1-Fc were addedtogether, E-cadherin was significantly preserved when compared withHGF/SF treated cells (lanes 3 vs. 4 and 7 vs. 8). To further verify thisresult, an immunofluorescence staining was carried out. As shown in FIG.5B, E-cadherin resided at cell-cell junction in Fc and ephrin-A1-Fctreated cells as expected. In HGF/SF treated cells, E-cadherin stainingshowed largely cytosolic pattern at 24 hours, which persisted to 48hours Note that in some HGF/SF-treated cells, E-cadherin disappearedfrom the cell-cell junctions even in those cells that remainedjuxtaposed to each other. When ephrin-A1-Fc was added together withHGF/SF, E-cadherin expression at cell-cell junctions was dramaticallyretained in comparison with HGF/SF/Fc treated cells. This contrasts withimmunoblot results (FIG. 5A), where only a moderate increase inE-cadherin level was detected. Therefore, while HGF/SF/ephrin-A1-Fccotreatment moderately prevents the loss of total cellular E-cadherin,it dramatically preserves the localization of E-cadherin at cell-celladhesion sites.

To test if ephrin-A1 can serve as a preventative measure to reduce cellscattering and EMT induced by HGF/SF, we pretreated DU-145 cells with Fcor ephrin-A1-Fc for 24 hours before HGF/SF was added for additional 24hours. At the end of treatment, immunoblot (FIG. 5C) was carried out todetect E-cadherin expression. Ephrin-A1-Fc treatment increasedE-cadherin expression at 48 hours in comparison with Fc treatment (lanes2 vs. 3), whereas HGF/SF decreased E-cadherin expression (lanes 2 vs.5). More importantly, pretreatment with ephrin-A1-Fc significantlyprevented HGF/SF-induced down-regulation of total cellular E-cadherin(FIG. 5C, lanes 5 vs. 6), to a greater extent than cells exposed to bothephrin-A1 and HGF/SF at the same time (FIG. 5A, lanes 3 and 4, or 7 and8). Similar to cells co-treated with HGF and ephrin-A1-Fc (FIG. 5B),immunofluorescence staining revealed that significant fraction ofE-cadherin was retained at cell-cell junction (FIG. 5D). Our resultsindicate that EphA2 activation can be used as a preventive measure toreduce metastasis by preserving E-cadherin expression and inhibitingEMT.

5. Materials and Methods

A. Cells and Reagents

CWR22R, PC-3, and LNCaP cells were cultured in RPMI medium (GIBCO)supplemented with 0.29 mg/ml glutamine, 100 μg/ml streptomycin, 100units/ml penicillin (GIBCO), and 10% fetal bovine serum (HyClone).DU-145 cells and rat prostate cancer cells (G, AT-1, MatLu, and MatLyLu)were maintained in DMEM medium containing same supplements as in RPMImedium. HGF/SF, and goat anti-EphA1, EphA4, ephrin-A1, ephrin-A2, andephrin-A4 were purchased from R&D Systems. Fc and Ephrin-A1-Fc wereprepared as previously described. Rabbit anti-EphA2, rabbit anti-humanc-Met, mouse anti-phosphotyrosine (PY99), mouse anti-phospho ERK(p-ERK), rabbit anti-ERK and horse radish peroxidase (HRP)-conjugatedgoat anti-mouse IgG were purchased from Santa Cruz. Mouseanti-E-cadherin was purchased from Transduction Laboratory Rabbitanti-EphA3 was a gift from Dr. E. Pasquale. HRP-conjugated Protein A,Texas Red-conjugated goat anti-rabbit IgG and FITC-conjugated rabbitanti-mouse IgG were from Jackson ImmunoResearch.

B. Immunofluorescence

Cells were cultured on cover slips in 24-well dishes for 24 hours, fixedin 4% formaldehyde for 20 minutes and permeabilized with 0.5% NP-40 for10 minutes. Blocking was performed using blocking solution containing 2%BSA and 2% goat serum in PBS. Subsequently, cells were incubated with 1μg/ml anti-EphA2 or anti-E-cadherin antibody. A Texas Red-conjugatedgoat anti-rabbit IgG or FITC-conjugated rabbit anti-mouse IgG was usedto visualize the primary antibodies. Vector-Shield mounting solutioncontaining DPI (Vector Laboratories) was used to mount the cover slipsonto slides.

C. Cell Stimulation, Immunoprecipitation, and Immunoblotting

Cells cultured in 6 well plates at 70-80% confluence were stimulatedwith 0.5 μg/ml Fc, 1 μg/ml ephrinA1-Fc or 20 ng/ml HGF/SF or theircombinations as indicated. After stimulation, cells were lysed in RIPAbuffer (20 mM Tris, pH7.4, 125 mM NaCl, 20 mM NaF, 0.1% SDS, 10%glycerol, 0.5% sodium deoxycholate, and 1% TX-100, 0.5 mM Na₃VO₄)containing protease inhibitors (1 mM phenylmethylsulphonyl fluoride, and2 μg/ml each of aprotinin and leupeptin). Cell lysates were clarified bycentrifugation at 13,000 rpm for 5 min. Immunoprecipitation was carriedout by adding anti-EphA2 antibody to clarified cell lysates andincubated for 1 hour at 4° C. The immunocomplex was captured usingγ-bind beads (Pharmacia). Cell lysates or precipitated proteins wereseparated on 4-20% Tris-glycine gels (Invitrogen) and transferred toImmobilon-P PVDF membranes (Millipore). Membranes were blotted accordingto manufacturer's suggestion. For quantitative analysis, band densitieswere measured using KODAK ID imagine analysis software (Eastman KodakCompany).

D. Immunodepletion

Cell surface proteins were labeled with biotin using ImmunoPureNHS-LC-Biotin (Pierce) according to manufacturer's suggestion. Cellswere lysed in RIPA buffer and an EphA2-specific antibody was used toremove EphA2 molecules from cell lysates by repeatedimmunoprecipitation. The specificity of the antibody was verified usingEphA2 knockout mice, where EphA2 but not other EphA kinases was absentfrom homozygous embryonic tissues (not shown). EphrinA1, whichrecognized all members of EphA kinases, was then used to precipitate theremaining EphA kinases. Avidin immunoblot was carried out to detect thepresence of ephrinA1-precipitated EphA kinases in the cell lysates withor without prior EphA2 depletion.

E. Cell Migration and Invasion Assay

Modified Boyden chambers of 8 μm pore size (Costar) were used formigration assay. Both sides of the membranes were coated with 10 μg/mlcollagen at 4° C. overnight. Serum free medium containing 20 ng/mlHGF/SF and/or 1 μg/ml ephrin-A1-Fc was added to the lower chamber, while10⁵ cells in 100 μl RPMI containing 0.5% BSA were placed in the upperchamber. After incubating at 37° C. for 8 hours, cells were fixed in 4%paraformaldehyde and stained with crystal violet. The cells remaining inthe upper chamber were removed using cotton swabs. Cells migrated to theunderside of the membrane were counted under 200× magnification.

For invasion assay, the upper chamber was coated with 50 μg of growthfactor-reduced MatriGel (BD) according to manufacturer's instructions.The same procedure as in migration assay was followed, except that thecells were allowed 24 hours to migrate to the underside of themembranes.

F. Wound Healing Assay

A wound was generated by scratching the monolayer of confluent DU-145cells using a micropipette tip. The cells were then washed twice withculture medium and imagines of the wounds were taken immediately atmarked area using Leica DMIRE2 microscope. Fc or ephrin-A1-Fc in thepresence or absence of HGF/SF were then added to the culture medium andcells were cultured for 12 hours. Imagines of the same areas were takenagain at the end of incubation.

G. Scattering onto Immobilized Ligand (SOIL) Assay

The SOIL assay was performed essentially as described. Briefly,ephrin-A1-Fc (4 μg/ml) or Fc (2 μg/ml) was coated on 6-well culturedishes overnight at 4° C. and the wells were washed with PBS. DU-145cells were grown on cover slips in 24-well dishes to near confluence.Cover slips were transferred cell-side-up onto the coated 6-well dishescontaining 1.5 ml culture medium with or without HGF/SF. Cover slipswere gently pressed down with pipette tips. After 48 hours, cells werefixed with 4% paraformaldehyde for 20 min and stained with crystalviolet. Cover slips were removed, and the rings of cells that havescattered and migrated onto the immobilized Fc or ephrin-A1-Fc werephotographed.

Example 2 Identification and Characterization of Peptide Agonists ofEphA2 Kinase

1. Phage Peptide Display Library Technology

The overall strategy for isolating peptides that bind to target proteinsusing phage display libraries (Scott and Smith, 1990; Koivunen et al.,1994) is illustrated in FIG. 6. In this powerful technology, randompeptide sequences are fused to amino-terminus of pIII coat proteins ofM13-derived filamentous bacterial phage by inserting randomoligonucleotides into the 5′ end of pIII DNA. Libraries containing over109 peptide motifs can be generated. They are amplified in bacteria andconcentrated to 1012-14 phage particles/ml, so that each motif will berepresented hundreds of times in a small volume of library for eachapplication. Each phage particle has a copy of single stranded DNAencoding one peptide sequence, and can be readily amplified andsequenced. To isolate peptides that bind to target proteins, phagedisplay libraries are incubated with proteins immobilized on plates.Unbound phage are washed away; bound phage are amplified and used foranother round of selection on target proteins. Following such repeatedselections, individual clones of phage capable of specific binding totarget proteins will be amplified, and insert DNA can be readilysequenced to decipher the displayed peptides.

2. Production of Recombinant Ectodomains of EphA2 and EphB3 Kinases

To produce recombinant EphA2, the entire coding sequences of EphA2kinase extracellular domain was fused to the heavy chain of human IgG1.The resultant plasmid, pcDNA3-CD5-EphA2-Fc, was transfected into humanembryonic kidney cells (293). The attachment of CD5 signal peptideenables secretion of EphA2-Fc chimera into cell culture media, while thedisulfide bond formed between the two Fc chains bridges the EphA2-Fctogether to form dimers. The recombinant protein was purified from cellculture medium on Protein-A affinity matrix that binds to Fc. EphB3-Fcwas produced in the same manner.

3. Affinity Selection

Recombinant EphA2-Fc or EphB3-Fc was coated on 96-well plates at 100μg/ml overnight at 4° C. Fc fragment alone was used as negative control.Non-specific binding sites were blocked by 1% BSA. In the initialscreening, X2CX14CX2 and X2CX18 phage display libraries were used, whereC is cysteine and X represents any amino acids. The displayed peptidesfrom X2CX14CX2 library are presumably cyclic due to disulfide bondformed between the two cysteines. Our previous experiences show thatbiopanning using libraries containing one constant cysteine (such as CX9or X2CX18 libraries) frequently result in selection of another cysteine,enabling disulfide bond formation within the selected peptides (Wang etal., 1995; Wang et al., 1999). This may reflect better bindingaffinities of cyclic peptides. For biopanning, about 10¹¹ transducingunits of the phage library were incubated for 4 hr at 25° C. in coatedmicrotiter wells phage biopanning buffer (Tris-buffered saline buffercontaining 200 μl of 1% (w/v) BSA). A fixed protein coatingconcentration (100 μg/ml) was used in the first two biopannings, but inthe subsequent biopannings, the recombinant protein was coated at 100-to 10,000-fold lower concentrations to select for high affinitysequences. Phage that remain bound after extensive washing with TBS-0.5%(v/v) Tween 20 were eluted with a low pH buffer (0.1 M glycine buffer,pH 2.2). The eluted phage particles were amplified by infecting Fpilus-positive bacteria K91kan. Phage that were secreted into mediumwere collected from cleared overnight cultures by polyethylene glycolprecipitation, and used for subsequent rounds of biopanning.

4. Identification and Characterization of EphA2-Binding Peptides

TABLE 2 EphA2- and EphB3-binding peptides isolated from phage displaylibraries Library of Target Kinase Name Peptides Sequence origin EphA2EP1 RRCVWSTNVYSMEPALFCAA X2CX14CX2 EP2 YSCCLNLYTPWPLCDCVEEWA X2CX18 EP3HSCKALSSTHGMAWPESAL Mutant* EphB3 HP1 PLCDNARVVRSYTRPRQCSS X2CX14CX2 HP2QWWCCDYPNACRLHTTPCDS Mutant *Mutant: We have found over the years thatrepeated selection for high binders frequently leads to the emergence ofmutant phage clones that deviate from the predicted sequences of thelibraries used.

We have isolated three EphA2-binding and two-EphB3 binding peptides (seeTable 2). One of the peptides, EP1, binds to EphA2 with high affinityand specificity. In fact, EphA2 was the only cell surface protein thatwas targeted by EP1. Several lines of evidence demonstrate that EP1 is afunctional agonist of EphA2 (see FIGS. 7-20 for details).

For example, M13 phage displaying EP1 peptide, or recombinant EP1 fusedto Fc or GST can specifically bind to EphA2 with high affinity (Kd=8.2nM). This affinity is much higher than the recently reportedEphA2-binding peptides from others. Those peptides have over 10 foldlower affinities. The affinity is remarkable in light of the fact thatEP1 peptide only mimics part of the receptor-ligand interactioninterface.

Like the native ligand, ephrin-A1, dimeric EP1-Fc or GST-EP1, but notmonomeric EP1 induces dose-dependent EphA2 tyrosine phosphorylation inseveral different cell lines, including those derived from cancer.Because monomeric form of EP1 peptide binds to EphA2 without activatingit, monomeric EP1 peptide or its derivatives can act as antagonists ofEphA2 kinase. Therefore, EP: peptide can be either agonist orantagonist, depending on aggregation status.

As shown in FIGS. 7-20, cells treated with EP1-Fc adapt a roundmorphology. EphA2 activation by EP1 suppressed integrin function andcauses reduced cell adhesion. EP1 inhibited mitogen-activated proteinkinase or MPK. In keeping with the growth promotion activity of MAPK,EP1 inhibited cancer cell growth. Preliminary studies showed thatsystemic administration of Ep1-Fc could have suppressive effect on thegrowth of prostate cancer xenograft in nude mice.

Our results suggest that EP1 peptide is a specific EphA2 agonist.Because of its ability to inhibit cell motility and growth, EP1represents a novel agent in the management of both physiological andpathological processes where cell growth and motility play a role.Examples include, but not limit to, neural regeneration, dementia, woundhealing, inflammation, blood clotting, treatment or prevention of tumorgrowth and metastasis. In addition, since Eph kinases are highlyexpressed in brain, and play an important role in the learning in adultsand development of nervous system in the embryo, EP1 can also be used inenhancing memory, and correcting developmental defects in nervoussystem. EP1 and related peptides as well as other therapeutics derivedfrom it can serve as lead molecules for development of new therapeuticsfor these diseases.

Example 3 Identification and Characterization of Small Molecule Agonistsof EphA2 Kinase

1. Materials and Methods

The overall scheme of computer-aided drug design targeting EphA2 kinaseis illustrated in FIG. 21. See FIGS. 22-26 for details.

DOCK 5.0 was used to screen the Available Chemical Directory (ACD)(Molecular Design Limited Information Systems, San Leandro, Calif.),containing CONCORD generated 3D-coordinates of the ˜350,000 commerciallyavailable compounds, for potential EphA2 agonists. Prior to screening,ACD was filtered with program FILTER (OpenEye Scientific Software) toremove non-drug like compounds that comply with Lipinski rule of five.According to this rule, the drug-like compounds in general should have≦700 molecular weight, logP (lipophylic coefficient—an estimate ofhydrophobicity based on a calculated logarithm of the octanol-waterpartitioning)≦5, number of hydrogen bond donors≦5, number of hydrogenacceptors≦10 and no reactive functional groups. This reduced the size ofACD from 350,000 compounds to 30,000 compounds. Of these, the highestscoring 500-1000 compound-bound orientations were output by DOCK and thecompounds used for experiments. The Gasteiger-Marsili atomic chargeswere then assigned to the molecules in the databases using BABELfreeware utility. The rigid conformations for each compound weregenerated by OMEGA (OpenEye Scientific Software), and docked in turn toEphA2 kinase binding site. EphA2 kinase structure was obtained viahomology modeling of EphB2 kinase bound to ephrin-B2 crystal structureusing program MODELLER. Program DOCK5.1 implements geometry-basedapproach for the docking of the small ligands. The computer programSPHGEN was used to create clusters of overlapping spheres within EphA2kinase solvent accessible surface of the binding site. The spherepositions in the dock sites were selected using interactive graphicaldisplay of the surface curvature. The sphere cluster represents anegative image of the docking site. Program DOCK matched atoms of eachcompound from the database to the centers of the spheres to search forfavorable binding orientations. DOCK scored each orientation based onthe ligand's complementarity to the protein surface using an AMBERinteraction force field that included van der Waals and electrostaticterms. The docking was performed on Beowulf Linux Cluster of the OhioSupercomputer Center consisting of 128 computing nodes with 1.4 GHzprocessor and 2 Gb of RAM. Compounds that activated EphA2 kinase in theassays were used in substructure search for additional compounds fromthe ACD, and these groups of similar compounds were also testedexperimentally. All chemicals used in the screening were purchased fromSigma Chemical, Aldrich, the Sigma-Aldrich Library of Rare Chemicals(SALOR), Maybridge (Ryan Scientific, SC), or Acros Organics.

2. Identification and Characterization of Small Molecule Agonists ofEphA2 Kinase

In these studies, we specifically targeted the ligand-binding domain ofEphA2 receptor tyrosine kinase (RTK). We previously found that thepredicted major ligand-binding site on EphA2 kinase is unexpectedlysmall involving only two to three amino acids from the ligand, thoughthe prevailing belief in the field is that large surface areas areinvolved in RTK-ligand interactions, and as a result, RTK-ligandinteraction is very hard, if not impossible, to target with smallcompounds.

We identified three compounds from these studies: Dobutamine, Doxazosin,and Labetalol. The structures of these compounds and their functions asEphA2 agonists are shown in FIGS. 27-29. Examination of these identifiedcompounds demonstrates shared chemical features (FIG. 30), suggestingthat a family of compounds may target Eph kinases. Such features providea structural framework for derivatization of the compounds.

Thus, we used this minimal structure to search the chemical database forrelated compounds. Multiple compounds were identified. Among the twocompounds that we could order from Sigma, one of them activated EphA2(see, e.g., FIG. 31). This result confirms our understanding that thisstructure is suitable for use in finding and testing more compounds, andcan lead to the discovery of preferred side chains for higher affinityand better selectivity binding.

All the compounds that we have identified are currently used as clinicaldrugs. 1) Doxazosin, a long-acting alpha (1)-blocker, is used as acomponent of combination therapy for patients with stage 1 and stage 2hypertension and for patients with concomitant hypertension andhyperlipidemia or glucose intolerance. 2) Labetalol, a compound thatblocks both alpha- and beta-adrenergic receptors, is the only drug ofits class currently available in the United States, and is currentlyused in managing hypertension that is difficult to control with pure β-or α-blockers. 3) Dobutamine on the other hand is widely used in stressechocardiography, that is considered as a relatively well-tolerateddiagnostic modality. The potential future usage of the compounds andtheir derivatives in treating cancer (e.g., prostate cancer) areunexpected.

Example 4 Crystal Structure of EphA2 Kinase Ligand-Binding Domain:Insight on Cellular Functions and Strategies for Targeted Drug Discovery

We have solved the crystal structure of EphA2 ligand-binding domain(LBD) (see FIG. 32). The crystal structure of EphA2 LBD shows overallstructural similarities with EphB2 LBD. The coordinates of the crystalstructure of EphA2 LBD are listed in Table 1.

However, unlike EphB2 LBD which is a monomer, EphA2 LBD form dimers inthe crystal through hydrophobic interactions (FIG. 33). The arrangementin the crystal also suggests further assembly of the dimers intohexamers through electrostatic interactions (FIGS. 34-35).

Consistent with structural data, EphA2, but not EphB2, can be detectedin dimeric form on cell surface (FIG. 36). Cell surface proteins werecross-linked with a membrane impermeable DSP and lysed. EphA2 wasimmunoprecipitated with anti-EphA2 antibody, The precipitate materialswere separated on SDS-PAGE under reducing or non-reducing conditions,and blotted for EphA2. Further, the dimeric EphA2 has distinct kineticsof ligand induced activation and requires different aggregation statusof ligands for receptor activation.

FIG. 37 shows that activation of EphB2, but not EphA2 on PC-3 cellsrequires super-clustering of ligands. Ephrin-A1-Fc (EA1-Fc) orephrin-B1-Fc (EB1-Fc) at indicated final concentrations were either useddirectly to stimulate PC-3 cells, or pre-clustered with anti-Fc antibodybefore cell stimulation. EphA2 or EphB2 were immunoprecipitated andblotted for activation status with PY99 antibody. FIG. 38 shows thatclustering of ephrin-A 1-Fc did not increase the inhibitory effects ofEphA2 activation on integrin-mediated cell adhesion to fibronectin.

In sum, the structure of EphA2 LBD will facilitate the design andoptimization of novel therapeutics targeted at EphA2.

Example 5 Disruption of EphA2 Causes Gene Dosage-DependentSusceptibility to Carcinogenesis in Mouse Skin

We sought to directly test the role of EphA2 in malignant transformationof epithelial cells in vivo using EphA2 knockout mice. In a classicalDMBA/TPA two stage skin carcinogenesis model, homozygous deletion ofEphA2 resulted in dramatically elevated susceptibility to skin tumordevelopment and progression. Not only were there increased tumormultiplicity and shortened latency, EphA2-null tumors also showed asignificantly accelerated malignant progression toward a more invasivephenotype. Interestingly, similar to what has been reported in manytypes of human cancer, EphA2 was overexpressed in tumor cells comparedadjacent normal tissue. Loss of EphA2 did not appear to affectapoptosis, but was associated with increased tumor cell proliferation.Treatment of primary keratinocytes from wild type mice with ephrin-A1inhibited ERK1/2 activities and suppressed cell growth; both effectswere abolished in EphA2-null keratinocytes. Collectively, these resultssuggest that EphA2 is a tumor suppressor gene in mammalian skin.Overexpression of EphA2 frequently observed in human cancer mayrepresent a compensatory defensive feedback mechanism to control tumorgrowth and progression.

Results

Homozygous Deletion or Haploinsufficiency of EphA2 Caused IncreasedSusceptibility to Skin Carcinogenesis

To investigate the role of EphA2 kinase in the development of mammalianskin tumors, we used the previously described EphA2 knockout micegenerated by secretory trapping strategy. The secretory trapping vectorwas inserted at the boundary between exon 4 and intron 5, leading to thetruncation of EphA2 from the second fibronectin type III repeat in theectodomain to the carboxyl terminal end. Similar to other lines of EphA2knockout mice, the secretory trapping EphA2-null mice are fertile,develop and grow normally. Immunoblot of postnatal day two (P2) skinextract detected EphA2 expression in wild type mice but not inhomozygous mutant, while heterozygous mice showed intermediateexpression (FIG. 39A). X-gal staining for β-geo under the control ofEphA2 promoter revealed that EphA2 was expressed in interfollicularepidermis, hair follicles and sebaceous glands (FIG. 39B).

A classical two stage carcinogenesis protocol was carried out to induceskin tumors, which entails tumor initiation by topical application of7,12-dimethylbenz[a]anthrocene (DMBA) followed by tumor promotion bytwice a week applications of 12-O-tetradecanoylphorbol-13-acetate (TPA).It has been well-established that most skin tumors induced using thisprotocol harbor activating mutation of Ha-Ras. We found that disruptionof EphA2 notably increased susceptibility to skin tumorigenesis (FIG.39D and FIG. 40). In wild type mice, benign tumors (mostly papillomas)started to appear around 8 weeks post DMBA treatment. By 10 weeks, about50% mice had developed tumors. In contrast, EphA2-null mice developedfirst tumors at 6 weeks, affecting 50% mice between week 7 and 8,reflecting a 2 to 3 weeks shortening in median tumor latency relative towild type mice (FIG. 40B). By 10 weeks, the average number of tumors permouse had reached 13.4, a 7-fold increase over wild type mice (FIG.40A).

In addition to the increased tumor multiplicity and shortened latency,tumors arising in EphA2 homozygous knockout mice also displayedsignificantly accelerated growth rate (FIG. 40C). Tumors in knockoutmice rapidly grew to 4 mm or larger which contrasted with slow-growingtumors on wild type mice. The large tumor burden in the knockout micenecessitated the termination of the experiment at 16 weeks after DMBAinitiation. To monitor tumor progression, a subgroup of mice from eachgenotype was kept for additional 10 weeks in the absence of further TPAtreatment (below).

Interestingly, mice heterozygous for EphA2 knockout exhibitedintermediate susceptibility to skin carcinogenesis in terms of tumornumbers, incidence as well as growth rate. This did not appear to be dueto the loss of heterozygosity, as immunoblot of tumor protein extractsrevealed that EphA2 was expressed at the levels consistent withheterozygous deletion (FIG. 40D). Thus the tumor suppressor function ofEphA2 is gene dosage-dependent, and EphA2 haploinsufficiency causesincreased susceptibility to skin carcinogenesis.

EphA2 was Overexpressed in Chemically-Induced Skin Tumors

Overexpression of EphA2 has been frequently observed in many differenttypes of human cancers compared with normal tissues, which has led tothe suggestion that EphA2 may be an oncoprotein. We next examinedexpression of EphA2 in chemically induced skin tumors. X-gal staining ofpapillomas from heterozygous mice showed that EphA2 expression wassignificantly elevated in tumor cells compared with the surroundingunaffected normal skin (FIG. 41A, B). Similarly, immunofluorescenceanalysis revealed overexpression of endogenous EphA2 in tumors from wildtype with the typical membrane staining pattern (FIG. 41C). Because theantibody was raised against the entire ectodomain of EphA2, it shouldalso recognize the EphA2 (exon 1-4 in the extodomain)-□-geo fusionprotein trapped inside the cells. We found that the fusion protein wasalso upregulated in tumor parenchyma with the expected intracellularexpression pattern (FIG. 41D). These results suggest that EphA2 isupregulated during skin epithelial tumorigenesis.

EphA2 and Ephrin-A1 Showed Complimentary Expression Pattern in Epidermis

Eph kinases and their membrane-anchored ligands mediate cell-cellcontact signaling. To understand how EphA2 may exert its tumorsuppressor function in mammalian skin, we sought to determine theexpression pattern of ephrin-A1, a cognitive ligand for EphA2. For thispurpose we performed double immunofluorescence staining with a goatanti-EphA2 and a rabbit anti-ephrin-A1 antibody. We found that EphA2 andephrin-A1 were expressed in complementary pattern in mouse skin. In thenormal epidermis adjacent to tumors (FIG. 42A, B), EphA2 was expressedin a basal to suprabasal gradient with lower expression in the basallayer and high expression in spinous layer. In contrast, ephrin-A1expression was primarily restricted to the basal layer of cells (FIG.42B). Such compartmentalized expression patterns were also noted in hairfollicles (FIG. 42A). For example, EphA2 and ephrin-A1 were expressed incomplementary gradients in precortex (arrow heads, note the opposinggradients between EphA2 and ephrin-A1) as well as in outer root sheath(arrows). However the exact identities of cell types that expressephrin-A1 or EphA2 remain to be determined. The complementaryEphA2/ephrin-A1 expression was also evident in adult mouse skin notexposed to DMBA/TPA (FIG. 42C). The basal-restricted expression ofephrin-A1 suggests that EphA2/ephrin-A1 interactions are largelyconfined to the basal cells and immediate neighboring suprabasal cells.

Next we examined EphA2/ephrin-A1 expression in tumor tissues. Similar tonormal epidermis, ephrin-A1 was detected at a thin layer of cellsabutting the basement membrane. On the other hand, EphA2 was highlyexpressed in tumor parenchyma with lower expression near the basementmembrane. In keeping with secretory trapping of the knockout allele,tumor from wild type mice showed predominantly membrane EphA2 stainingin contrast with the mostly cytoplasmic pattern for the homozygousmutant (FIG. 42D). In contrast to EphA2, we did not observe anyoverexpression of ephrin-A1 in tumors from all three genotypes byimmunoblot or immunofluorescence analyses compared with adjacent normaltissues (not shown). In sum, EphA2 and ephrin-A1 were expressed incomplementary pattern in normal epidermis. Expression of EphA2 but notephrin-A1 was upregulated in tumors.

EphA2 Activation Inhibited ERK1/2 Activities and Reduced Clonal Growthin Wild Type but not EphA2-Null Keratinocytes In Vitro

To determine cellular mechanisms underlying the increased susceptibilityto skin tumorigenesis, primary keratinocytes were isolated and culturedfrom epidermis of neonatal (P1) mice. They were stimulated withephrin-A1 fused to the heavy chain of human IgG1 (ephrin-A1-Fc). EphAkinases including EphA2 were precipitated with excess ephrin-A1-Fc, andblotted with antibody raised against phosphorylated dityrosine peptidethat is highly conserved in the juxtamembrane region of all Eph kinases.Phosphorylation of this region has been correlated with Eph receptoractivation. We found that EphA2 could be readily activated by ephrin-A1in wild type and heterozygous keratinocytes (FIG. 44A). Interestingly,p-EphA/B signal were undetectable in EphA2-null keratinocytes despitethe fact that ephrin-A1-Fc precipitation should have brought down mostEphA kinases, suggesting that EphA2 was the predominant EphA kinaseexpressed in primary keratinocytes.

We reported previously EphA2 activation suppressed ERK1/2 activities andreduced cell growth in several different cell types. Similarly, weobserved that ERK1/2 activities were significantly attenuated in wildtype keratinocytes upon ligand stimulation of EphA2 (FIG. 43B).Homozygous deletion of EphA2 completely abolished the inhibitoryeffects, while heterozygous keratinocytes showed an intermediateresponse. In a clonal growth assay, treatment with ephrin-A1-Fcsuppressed the growth of wild type and heterozygous keratinocytes (FIG.43C). In contrast, EphA2 knockout keratinocytes were resistant toephrin-A1-induced growth inhibition. Thus EphA2 in keratinocytes exertsnegative growth regulatory function possibly through inhibition ofERK1/2 MAP kinase.

Deletion of EphA2 Caused Increased Skin Tumor Cell Proliferation.

Increased tumor growth in knockout mice (FIG. 39D and FIG. 40) couldresult from either increased cell proliferation or decreased apoptosisor both. Staining for Ki67 cell proliferation marker showed EphA2homozygous deletion led to significantly increased cell proliferationindex compared wild type control (FIGS. 44A and B). Cells inheterozygous tumors also exhibited accelerated growth rateindistinguishable from homozygous tumors, which may reflect theincreased heterozygous tumor growth rate between 13 to 16 weeks postDMBA treatment (FIG. 40C). Apoptosis did not appear to be a majorcontributing factor, as TUNEL staining of tumor sections did not detectnoticeable differences among different genotypes (FIG. 44C). In bothnormal epidermis and skin tumors ephrin-A1 expression is localized tobasal layer of cells abutting basement membrane (FIG. 42), where therewas active cell proliferation. Our data suggest that EphA2 signalingupon contact with ephrin-A1 may exert negative growth in this region;deletion of EphA2 may diminish such inhibitory effects leading toincreased cell proliferation.

Accelerated Malignant Tumor Progression in EphA2 Homozygous KnockoutMice

A well-established function of Eph kinases is the regulation of growthcone and cell motility, primarily through repulsive mechanisms (Gale andYancopoulos, 1997, Flanagan and Vanderhaeghen, 1998). Cell motility isrelated to tumor progression toward a more invasive and metastaticphenotype. However, because skin tumors rarely metastasize, we focusedon invasive progression instead. For this purpose, TPA treatment wasstopped at 16 weeks, and subgroups of mice were observed for additional10 weeks. During this time, most tumors either started to regress orgrew slowly, while some tumors showed signs of malignant progressiongrossly as evidenced by inward growth and bloody appearance in tumorcenters. Histolopathological analyses revealed that while most tumorscomprised of benign papillomas with varying degrees of differentiation(FIG. 45A), a significant fraction of tumors had progressed to squamouscell carcinoma with clear evidence of local invasion by 26 weeks (FIG.45). Several tumors from EphA2-null mice had developed spindle cellmorphology (FIG. 45A). Staining for keratin 14, a keratinocyte marker,confirmed the epithelial origin of invasive spindle cells (FIG. 45A).These invasive cells also express EphA2-β-geo fusion protein revealed byX-gal staining (FIG. 45A). Quantitative analyses show that EphA2-nulltumors were twice as likely to develop fully invasive phenotype comparedwith tumors from wild type mice (FIG. 45B). Interestingly, tumors fromheterozygous mice shared similar rate of malignant conversion as wildtype tumors. This is in contrast with the intermediate phenotype intumor number, incidence and growth rate (FIGS. 39D and 40). Thus whilehaploinsufficiency of EphA2 can predispose cells to tumor development,EphA2 plays a dominant role in suppressing invasive tumor progression.

Discussion

In this report, we provide experimental evidence to demonstrate thatEphA2 is expressed in epidermal and follicular keratinocytes andfunctions as a tumor suppressor gene during mammalian skincarcinogenesis. EphA2 deletion resulted in susceptibility tochemically-induced skin tumorigenesis with significantly increased tumornumber, shortened latency, accelerated growth rate, as well as higherrate of malignant conversion. In vitro, ephrin-A1 stimulation of wildtype but EphA2-null keratinocytes attenuated ERK1/2 activities andsuppressed cell proliferation. EphA2 and ephrin-A1 are expressed in acomplementary pattern in epidermis, largely limiting their interactionsto the basal layer of epidermal cells where active cell proliferationnormally takes place. Consistent with these in vitro and in vivoobservations, loss of EphA2 resulted in higher proliferation rate inbasal layers of tumor cells, which may be a contributing mechanism oftumor susceptibility.

EphA2 was originally called epithelial cell kinase (Eck) because of itswide distribution in epithelial cells in vitro and in vivo. Since thennumerous studies have reported overexpression of EphA2 in a diversearray of human cancer including breast, lung, prostate and gastriccancer. However the role of EphA2 kinase in epithelial tumorigenesisremains unclear. While some in vitro studies support EphA2 as anoncogene, others are more consistent with anti-tumorigenic functions.The EphA2 knockout mice allowed us to directly address the role of EphA2in tumor etiology and progression in mammalian skin using awell-established two-stage carcinogenesis model. The dramaticallyincreased susceptibility of EphA2 knockout mice supports a tumorsuppressor role of EphA2 in mammalian epithelial cells. Interestingly,we found that EphA2 was overexpressed in chemically-induced skin tumorsrelative to neighboring normal skin, similar to what have been observedin many human cancers. Moreover, treatment of several breast cancer celllines with U1026, an inhibitor of MEK, reduced EphA2 expression. It hasbeen well-established that most DMBA/TPA-induced mouse skin tumorsharbor activating mutation in H-Ras, which may contribute to EphA2upregulation in these tumors. Since deletion of EphA2 resulted insubstantially increased tumor susceptibility, we propose that theupregulated EphA2 suppresses tumor initiation and progression, and mayrepresent a compensatory feedback defensive mechanism against malignanttransformation.

Activating point mutations of Ras occur in 15% of all humanmalignancies, most prominently in pancreatic and colorectal cancers.Moreover, Ras/ERK signaling cascade can be activated by acquisition ofparacrine and autocrine loops in different human tumors. Although therelationship between Ras/ERK activation status and EphA2 expressionremains to be determined in human cancer, it is possible that abnormalincreases in ERK1/2 MAPK activities may be one of the underlying causesfor EphA2 overexpression in human cancer. Because activation of MAPK hasbeen linked to malignant, the transcriptional upregulation of EphA2 bythe activated MAPK may also explain the reported correlations betweenEphA2 overexpression and poor prognosis in different types of humancancers. In this context, EphA2 overexpression may be more likely to bea marker of tumor progression rather than an etiological event.

Our results also predict that loss or reduced EphA2 expression maypredispose cells to malignant transformation. Supporting this notion,EphA2 is mapped to human chromosome 1p36.13, a region frequently lost inneuroblastoma, melanoma, prostate cancer and other tumors. Cytogeneticand molecular analyses have linked the loss of 1p36 to chordoma, a raretumor arising from notochordal remnants in axial skeleton Candidate genescreening identified EphA2 as a possible oncosuppressor gene. In keepingwith the latter studies, kinked tail has been observed in one line ofEphA2 knockout mice associated with abnormal notochord development,although no chordoma has been reported in these mice.

Our data show that haploinsufficiency can predispose mouse skin tochemical carcinogenesis. Further investigation is needed to characterizeLOH of EphA2 locus or other mechanisms that may lead to reduced EphA2expression in human tumors. Indeed, in some existing reports on EphA2expression in human cancers, down regulation or total lack of EphA2expression is present in significant fractions of the cases. Forexample, about 50% human esophageal squamous cell carcinoma are negativefor EphA2 expression.

EphA2 homozygous knockout appears to promote invasive progression ofmammalian skin tumors. Early studies on Eph kinases have linked Ephkinase activation to repulsive guidance of growth cones and neurons.Recent genetic studies using knockout mice show that negative regulationof cell motility as a predominant outcome upon Eph/ephrin interactionsin vivo, not only in the nervous system but also in epithelial tissues.This is mainly achieved through complementary expression of Eph kinasesand ephrin ligand. For example, EphB3 is expressed at the bottom ofmouse intestinal crypts while its cognitive ligands (ephrin-B1 and -B2)are expressed in the top to bottom gradient along the wall of crypts.Paneth cells expressing EphB3 at the bottom of the crypt becomesmislocalized when EphB3 is deleted suggesting EphB3/ephrin-B interactioninhibit Paneth cell migration in vivo. We found EphA2 and ephrin-A1expression was compartmentalized in mouse interfollicular epidermis andhair follicles. In epidermis, ephrin-A1 is expressed at the basal layer,while EphA2 is expressed in a basal-suprabasal gradient. Conceivably,invading tumors overexpressing EphA2 may be repulsed or stopped in trackupon contact with ephrin-A1-presenting basal layer cells; loss of EphA2may render invading cells less responsive to the repulsive effects andfacilitates tumor invasion.

In sum we have found that EphA2 is a tumor suppressor gene in mammalianskin. Caution may need to be exercised in therapeutic strategiesdesigned to systemically down-regulate EphA2 from cell surfaces.

Materials and Methods

EphA2 Knockout Mice and Multistage Skin Carcinogenesis

EphA2 knockout mice on C57B1/6/129 genetic background were generatedthrough secretory gene trapping. They were backcrossed for 4 generationsto FVB/N mice which were then bred with each other to generate cohortsof female Eph-A2^(−/−), EphA2^(−/−) and EphA2^(−/−) mice that were usedin subsequent studies. For two-stage chemical carcinogenesis, the backsof 8-week-old mice were shaved and treated with a single application ofDMBA (25 μg in 200 μl acetone; Sigma) followed by twice a weekapplications of TPA (200 μl of 100 μM solution in acetone; Sigma). Micewere visually inspected weekly and tumor number and sizes werequantitated. Sixteen weeks post DMBA initiation, mice were divided intotwo subgroups; one group were sacrificed while another group were keptfor observation of malignant conversion in the absence of further TPAtreatment for additional 10 weeks. Mice were sacrificed if moribund, ifany individual tumor reached a diameter of 1.5 cm, or at the terminationof the experiments. Tumors were processed for biochemical analyses bysnap-frozen in liquid nitrogen, embedded in OCT and submerged in liquidnitrogen for frozen section, or fixed in 4% paraformaldehyde for laterparaffin embedment and staining with hematoxylin and eosin.

Detection of β-Galactosidase Activity

Skin and tumors were processed for frozen sections (skin 7 μm, and tumor12 μm). Staining of skin and tumor was performed after fixation in 4%paraformaldehyde for 10 minutes and stained in X-gal solution (1 mg/ml)at 37° C. for 24 hours. Sections were counterstained with nuclear fastred (Vector) for 15 min at room temperature, washed with distilledwater, dehydrated by increasing concentrations of ethanol and mountedwith Permount (Fisher Scientific).

Tissue Extraction

Tumors were snap-frozen in liquid nitrogen at stored at −80° C. Sampleswere homogenized in ice-cold lysis buffer containing 20 mM Tris (pH7.4), 125 mM NaCl, 10%, glycerol, 1% Triton X-100, 0.5% DCA, 0.1% SDS,20 mM NaF, 1 mM PMSF, 4 μg/ml aprotiniin, 4 μg/ml leupeptina and 1 mMNa₃VO₄. Then samples were centrifuged at 20,800 g for 10 minutes at 4°C. Protein concentrations in supernatant were measured using the BCAprotein assay kit (Bio-Rad, Hercules. Calif.). Equal amounts of proteinextracts were resolved by SDS-PAGE and electrotransferred ontopolyvinylidene difluoride membranes (Millipore), which were then blottedwith the indicated antibodies.

Proliferation and Apoptotic Assays.

Skin tumors were fixed in 4% paraformaldehyde overnight and embedded inparaffin. To detect the proliferative cells in tumors,immunohistochemical studies were performed using a polyclonal NCL-Ki67-prabbit antibody (Castra). Paraffin embedded sections (5 μm thick) weredeparaffinized in xylene, hydrated in series of alcohols, immersed incitrate buffer (10 mM sodium citrate, 0.05% Tween 20, pH 6.0) for 10minutes at 95° C. After cooling down to RT, sections were blocked with5% normal goat serum in Tris-buffered saline for 1 h at RT to reducenonspecific staining and then incubated with primary antibodies (1:1000)overnight at 4° C. Biotinylated secondary antibody (1:500) andavidin-biotin-peroxidase system (Vector) were used. Color immunostainingwas revealed using diaminobenzidine with metal enhancer (Vector). Theapoptotic tumor cells on paraffin sections were detected using a TUNELkit without antigen retrieval following the manufacturer's instructions(Roche). Sections were mounted with DAPI-containing mounting medium(Vector).

The number of positive tumor cells was enumerated independently by tworesearchers. Quotients were converted to density (positive cells/unitarbitrary tumor area). The ANOVA for unpaired samples was used for allstatistical analyses. The post-hoc analysis is Bonferroni Test.

Immunofluorescence

Frozen sections of skin or tumors were fixed with 4% Paraformaldehyde.After washing with PBS, the sections were blocked with 50 mM NH₄Cl andpermeabilized with 0.3% NP-40 for 10 minutes. The sections were thenincubated with goat polyclonal antibodies that recognize the ectodomainof mouse Eph-A2 (R&D) and rabbit polyclonal anti-ephrin-A1 (Santa Cruz)at RT for 1 hour followed by detection with donkey anti-goat IgG-FITCand donkey anti-rabbit IgG-Red X (Jackson ImmunoResearch) at RT for 30min. Images were taken using Leica microscope.

Primary Keratinocyte Isolation, Stimulation, Immunoprecipitation, andImmunoblotting

Primary keratinocytes were isolated from neonatal mouse skin asdescribed previously (Caldelari et al., 2000). Briefly, the entire P1mouse skin was dissected and incubated with 5 U/ml dispase II(Boehringer Mannheim) overnight at 4° C. Epidermal layer was separatedfrom decimal layer using forceps, minced and digested with 0.25%trypsin/0.05 mM EDTA. After neutralizing trypsin by washing withserum-containing medium, cells were filtered through sterile gauze pads,spun down and resuspended in serum-free keratinocytes culture medium(Gibco) containing pituitary extract, 5 ng/ml EGF, 100 U/ml penicillin,0.1 mg/ml streptomycin, and 0.25 μg/ml amphotericin, and plated on6-well plates precoated with 50 μg/ml matrigel. Cell stimulation withephrin-A1-Fc, immunoprecipitation, and immunoblot were carried asdescribed preciously (Miao et al., 2003; Miao et al., 2005).

Example 6 EphA2 Activation Inhibited Akt Activities

We have found that EphA2 activation inhibits Akt kinase activities. Weobserved that EphA2 is overexpressed in osseous but not lymph nodemetastases of human prostate cancer specimens obtained from rapidautopsy (FIG. 46A). We further observed inhibition of Akt activities inPC-3 cells upon stimulation of EphA2 with its cognitive ligand ephrin-A1(EA1-Fc) (FIG. 46B). Additionally, dominant negative EphA2 abolished theinhibitory effects of ephrin-A1 treatment on Akt and ERK activities.DU145 cells were infected with a retroviral vector expressing wild type(WT) or a dominant negative mutant EphA2 where the entire cytoplasmictail was replaced with GFP. An antibody against the ectodomain of EphA2was used to determine the expression of endogenous (vector control), WT-and DN-EphA2 (FIG. 46C). We further observed upregulation of EphA2 byRas but not Myc oncogene in NRP152 normal rat prostate epithelial cells(FIG. 46D).

Example 7 EphA2 Agonists can be Targeted for Treatment of Lung Cancer

We have found that EphA2 is highly overexpressed in mouse lungepithelial cells in vivo, and human lung cancer cells in vitro.Moreover, activation of EphA2 on human lung cancer cells, can inhibittheir malignant behaviors including suppression of ERK1/2 MAPK kinaseand Akt kinase activities.

FIG. 47A illustrates the expression of β-gal in EphA2 knockout mouselung. Frozen sections were fixed and stained with X-gal and followed bycounterstaining with nuclear Fast-Red. FIG. 47B illustrates expressionof EphA2 in the lung from wild-type mice. Lung frozen sections werestained with goat polyclonal antibodies that recognize the ectodomain ofEphA2 followed by detection with donkey anti-goat IgG conjugated withFITC. FIG. 47C illustrates EphA kinase activation by ephrin-A1 in H125,H1975 and SKMES human non-small cell lung cancer cells. Cells werestimulated width 2 ig/ml of ephrin-A1-Fc for 10 and 30 minutes.Ephrin-A1 stimulation inhibits ERK and AKT phosphorylation. These datasuggest that agonists for EphA kinases can also be used to target humanlung cancers.

Example 8 EphA1 and EphA2 Agonists can be Targeted for Treatment ofBreast Cancer

We have found that EphA1 and EphA2 are highly overexpressed in a subsetof human breast cancer cells in vitro. Moreover, activation of EphA1EphA2 on human lung cancer cells, can inhibit their malignant behaviorsincluding suppression of ERK1/2 MAPK kinase and Akt kinase activities.

FIG. 49A illustrates expression of EphA1 and EphA2 in human breastcancer cell lines. Note that EphA1 are more broadly distributed thanEphA2. FIG. 48B illustrates that EphA1 and EphA2 are upregulated inmouse breast tumors induced by HER2/Neu, but not in tumors induced byluteinizinghormone (LH). Upregulation of EphA2 is present in 30% humanbreast cancer. These data suggest that EphA1 and EphA2 agonists can beused together with HER2/Neu inhibitor such as Herceptin for breastcancer treatment.

Example 9 Expression of EphA1 in Prostatic Epithelial Cells SuppressedCell Proliferation

We have found that EphA1 is expressed in prostatic epithelial cells.Moreover, activation of EphA1 on prostatic epithelial cells can inhibittheir malignant behaviors.

DU145 human prostatic epithelial cells were infected with retrovirusexpressing EphA1. FIG. 49A illustrates expression of EphA1 in DU145cells infected with vector control (control) and EphA1 expressionretrovirus. FIG. 49B illustrates that about 2,000 cells were plated on12-well plates in the regular culture medium (10% serum) and low serummedium (0.5%). Cell were cultured for 7 days (10% serum) or 18 days(0.5%). FIG. 49B illustrates that proliferation of prostatic epithelialcells expressing EphA1 and activated with Ephrin-A1 is inhibited.

Example 10 Expression of Wild Type EphA3 in VACO 451 Human ColorectalCancer Cells Inhibited Cell Growth in Soft Afar

FIG. 50 shows that either EphA3 overexpression or activation by itsagonists (ephrin-A5) can suppress human colorectal cancer growth. Pleasenote EphA3 receptor prefers ephrin-A5 as its ligand. Both EphA1 receptoronly uses ephrin-A1 as ligand. EphA2 uses both ephrin-A1 and ephrin-A5as ligands. Kinch's patent only claims ephrin-A1 on EphA2.

VACO-451 human colorectal cancer cells harbor Aspartate to Asparaginemutation at position 806 (D806N) in EphA3 that was first reported twoyear ago (Science 300:949). However the role of this mutation is notknown. FIG. 50A illustrates that the mutation (EphA3DN) in VACO 451cells caused loss of EphA3 kinase activities (Note that there is nopEphA/B signal). FIG. 50B illustrates that VACO-451 cells were infectedwith retroviral vectors that express wild type (WT) EphA3. Clones thatexpress high (EphA3-H) and medium (EphA3-M) levels of EphA3 as well asvector control cells were subject to growth in soft agar assay shown inFIG. 50C. Ephrin-A5-Fc, the preferred ligand for EphA3 were used tostimulate EphA3.Fc was used as controls. Note that high level ofexpression of WT-EphA3 inhibited basal proliferation of VACO-451 cells(EphA3-H, untreated). Cells expressing medium levels of EphA3 cangrowth-inhibited by ephrin-A5-Fc treatment (EphA3-M, Ephrin-A5-Fc).Therefore, overexpression or agonist activation of WT-EphA3 can overcomethe effects of mutant EphA3 and mediate suppression of human colorectalcancer cell growth. These data strongly suggest that EphA3 is a tumorsuppressor gene in human colorectal cancer. Because colorectal tumorsfrequently express wild type EphA3 agonists such as its native ephrin-A5ligand, peptides or small molecules for EphA3 can have therapeuticefficacy against this disease.

Those skilled in the art will recognize, or be able to ascertain usingno more than routine experimentation, numerous equivalents to thecompounds and methods of use thereof described herein. Such equivalentsare considered to be within the scope of this invention and are coveredby the following claims.

All of the above-cited references and publications are herebyincorporated by reference.

TABLE 1 REMARK coordinates from minimization and B-factor refinementREMARK refinement resolution: 20-2.5 A REMARK starting r = 0.3042 free_r= 0.3245 REMARK final r = 0.2761 free_r = 0.3129 REMARK rmsd bonds =0.041983 rmsd angles = 3.03383 REMARK B rmsd for bonded mainchain atoms= 1.066 target = 1.5 REMARK B rmsd for bonded sidechain atoms = 1.696target = 2.0 REMARK B rmsd for angle mainchain atoms = 1.623 target =2.0 REMARK B rmsd for angle sidechain atoms = 2.369 target = 2.5 REMARKtarget = mlf final wa = 45 REMARK final rweight = 0.9016 (with wa = 45)REMARK md-method = torsion annealing schedule = slowcool REMARK startingtemperature = 6000 total md steps = 60 * 6 .786 REMARK cycles = 1coordinate steps = 20 B-factor steps = 10) REMARK sg = P1 a = 41.271 b =91.187 c = 91.132 alpha = 117.144 beta = 97.270 gamma = 10♭ REMARKtopology file 1: CNS_TOPPAR:protein.top REMARK topology file 2:CNS_TOPPAR:dna-rna.top REMARK topology file 3: CNS_TOPPAR:water.topREMARK topology file 4: CNS_TOPPAR:ion.top REMARK parameter file 1:CNS_TOPPAR:protein_rep.param REMARK parameter file 2:CNS_TOPPAR:dna-rna_rep.param REMARK parameter file 3:CNS_TOPPAR:water_rep.param REMARK parameter file 4: CNS_TOPPAR:ion.paramREMARK molecular structure file: generate_A2E_m1.mtf REMARK inputcoordinates: generate_A2E_m1.pdb REMARK anomalous f′ f″ library:CNS_XRAYLIB:anom_cu.lib REMARK reflection file = A2E1_P1.rfree.xhklREMARK ncs = restrain ncs file = ncs_restrain.def REMARK B-correctionresolution: 6.0-2.5 REMARK initial B-factor correction applied to fobs:REMARK B11 = 3.647 B22 = −4.919 B33 = 1.272 REMARK B12 = −3.796 B13 =−4.111 B23 = −4.116 REMARK B-factor correction applied to coordinatearray B: −6.062 REMARK bulk solvent: density level = 0.391263e/A{circumflex over ( )}3, B-factor = 26.9639 A{circumflex over ( )}2REMARK reflections with |Fobs|/sigma_F < 0.0 rejected REMARK reflectionswith |Fobs| > 10000 * rms(Fobs) rejected REMARK theoretical total numberof refl. in resol. range:  38923 (100.0%) REMARK number of unobservedreflections (no entry or |F| = 0): 3427 (8.8%) REMARK number ofreflections rejected:    0 (0.0%) REMARK total number of reflectionsused:    35496 (91.2%) REMARK number of reflections in workingset:    33700 (86.6%) REMARK number of reflections in test set:    1796(4.6%) CRYST1 41.271 91.187 91.132 117.14 97.27 100.79 P 1 REMARKFILENAME = “refine_A2E_m1.pdb” REMARK DATE: 10-Jun-2004 17:00:27 createdby user: raj REMARK VERSION: 1.1 ATOM 1 CB GLU C 1 −15.004 4.724 13.0781.00 17.75 C ATOM 2 CG GLU C 1 −14.257 3.538 13.626 1.00 18.82 C ATOM 3CD GLU C 1 −12.754 3.914 14.007 1.00 21.05 C ATOM 4 OE1 GLU C 1 −12.4474.771 14.930 1.00 19.92 C ATOM 5 OE2 GLU C 1 −11.900 3.321 13.327 1.0020.67 C ATOM 6 C GLU C 1 −17.072 3.828 11.802 1.00 16.40 C ATOM 7 O GLUC 1 −17.439 2.690 11.967 1.00 15.52 C ATOM 8 N GLU C 1 −17.074 4.26214.301 1.00 18.29 C ATOM 9 CA GLU C 1 −16.556 4.692 13.003 1.00 16.80 CATOM 10 N VAL C 2 −17.090 4.405 10.609 1.00 15.76 C ATOM 11 CA VAL C 2−17.528 3.693 9.441 1.00 15.70 C ATOM 12 CB VAL C 2 −18.411 4.621 8.6341.00 16.83 C ATOM 13 CG1 VAL C 2 −18.683 4.079 7.316 1.00 16.18 C ATOM14 CG2 VAL C 2 −19.650 4.887 9.413 1.00 15.55 C ATOM 15 C VAL C 2−16.237 3.303 8.704 1.00 16.27 C ATOM 16 O VAL C 2 −15.370 4.117 8.5471.00 15.66 C ATOM 17 N VAL C 3 −16.122 2.055 8.293 1.00 16.15 C ATOM 18CA VAL C 3 −14.958 1.529 7.694 1.00 14.85 C ATOM 19 CB VAL C 3 −14.5410.179 8.340 1.00 15.10 C ATOM 20 CG1 VAL C 3 −13.210 −0.257 7.763 1.0014.66 C ATOM 21 CG2 VAL C 3 −14.378 0.292 9.857 1.00 14.16 C ATOM 22 CVAL C 3 −15.110 1.253 6.301 1.00 17.23 C ATOM 23 O VAL C 3 −15.962 0.4235.917 1.00 18.22 C ATOM 24 N LEU C 4 −14.254 1.871 5.498 1.00 17.37 CATOM 25 CA LEU C 4 −14.228 1.647 4.005 1.00 17.09 C ATOM 26 CB LEU C 4−14.170 2.991 3.292 1.00 16.69 C ATOM 27 CG LEU C 4 −14.961 4.115 3.9491.00 17.30 C ATOM 28 CD1 LEU C 4 −14.708 5.451 3.203 1.00 17.74 C ATOM29 CD2 LEU C 4 −16.522 3.787 3.929 1.00 16.42 C ATOM 30 C LEU C 4−12.942 0.942 3.667 1.00 16.85 C ATOM 31 O LEU C 4 −11.981 1.557 3.4511.00 19.17 C ATOM 32 N LEU C 5 −12.848 −0.306 3.497 1.00 15.95 C ATOM 33CA LEU C 5 −11.504 −0.831 3.312 1.00 14.42 C ATOM 34 CB LEU C 5 −10.5930.084 2.487 1.00 13.73 C ATOM 35 CG LEU C 5 −9.240 −0.637 2.321 1.0014.68 C ATOM 36 CD1 LEU C 5 −9.471 −2.088 2.129 1.00 16.89 C ATOM 37 CD2LEU C 5 −8.536 −0.165 1.088 1.00 14.75 C ATOM 38 C LEU C 5 −10.785−1.223 4.638 1.00 14.88 C ATOM 39 O LEU C 5 −10.450 −0.383 5.511 1.0015.75 C ATOM 40 N ASP C 6 −10.505 −2.511 4.743 1.00 14.34 C ATOM 41 CAASP C 6 −9.847 −3.120 5.846 1.00 13.16 C ATOM 42 CB ASP C 6 −10.857−3.464 6.861 1.00 14.82 C ATOM 43 CG ASP C 6 −10.255 −3.927 8.078 1.0015.96 C ATOM 44 OD1 ASP C 6 −10.949 −4.555 8.907 1.00 17.35 C ATOM 45OD2 ASP C 6 −9.057 −3.659 8.215 1.00 18.85 C ATOM 46 C ASP C 6 −9.149−4.394 5.412 1.00 14.48 C ATOM 47 O ASP C 6 −9.701 −5.537 5.423 1.0013.67 C ATOM 48 N PHE C 7 −7.918 −4.200 5.020 1.00 14.40 C ATOM 49 CAPHE C 7 −7.061 −5.258 4.587 1.00 14.40 C ATOM 50 CB PHE C 7 −5.647−4.712 4.395 1.00 16.49 C ATOM 51 CG PHE C 7 −4.669 −5.762 3.989 1.0017.58 C ATOM 52 CD1 PHE C 7 −4.660 −6.242 2.672 1.00 18.30 C ATOM 53 CD2PHE C 7 −3.790 −6.322 4.937 1.00 16.90 C ATOM 54 CE1 PHE C 7 −3.755−7.320 2.311 1.00 19.82 C ATOM 55 CE2 PHE C 7 −2.895 −7.355 4.591 1.0016.72 C ATOM 56 CZ PHE C 7 −2.864 −7.867 3.293 1.00 18.15 C ATOM 57 CPHE C 7 −7.010 −6.520 5.464 1.00 15.38 C ATOM 58 O PHE C 7 −7.197 −7.5904.939 1.00 14.26 C ATOM 59 N ALA C 8 −6.710 −6.395 6.772 1.00 15.28 CATOM 60 CA ALA C 8 −6.653 −7.605 7.612 1.00 15.33 C ATOM 61 CB ALA C 8−6.164 −7.255 8.976 1.00 14.79 C ATOM 62 C ALA C 8 −7.965 −8.476 7.7111.00 16.23 C ATOM 63 O ALA C 8 −7.902 −9.588 8.236 1.00 16.77 C ATOM 64N ALA C 9 −9.132 −8.011 7.223 1.00 15.41 C ATOM 65 CA ALA C 9 −10.345−8.793 7.318 1.00 15.60 C ATOM 66 CB ALA C 9 −11.474 −7.940 7.596 1.008.58 C ATOM 67 C ALA C 9 −10.642 −9.596 6.037 1.00 17.90 C ATOM 68 O ALAC 9 −11.451 −10.514 6.066 1.00 20.08 C ATOM 69 N ALA C 10 −10.026 −9.2644.894 1.00 19.38 C ATOM 70 CA ALA C 10 −10.354 −9.904 3.567 1.00 19.92 CATOM 71 CB ALA C 10 −10.108 −8.914 2.437 1.00 18.74 C ATOM 72 C ALA C 10−9.653 −11.226 3.288 1.00 20.97 C ATOM 73 O ALA C 10 −8.472 −11.2732.793 1.00 20.38 C ATOM 74 N GLY C 11 −10.416 −12.278 3.696 1.00 22.55 CATOM 75 CA GLY C 11 −10.074 −13.755 3.669 1.00 23.79 C ATOM 76 C GLY C11 −9.661 −14.443 2.317 1.00 23.88 C ATOM 77 O GLY C 11 −10.210 −15.4341.778 1.00 23.75 C ATOM 78 N GLY C 12 −8.572 −13.847 1.823 1.00 23.88 CATOM 79 CA GLY C 12 −7.889 −14.175 0.581 1.00 23.28 C ATOM 80 C GLY C 12−7.055 −12.921 0.206 1.00 22.26 C ATOM 81 O GLY C 12 −6.915 −12.601−1.016 1.00 21.82 C ATOM 82 N GLU C 13 −6.552 −12.211 1.220 1.00 21.36 CATOM 83 CA GLU C 13 −5.712 −11.060 0.981 1.00 21.86 C ATOM 84 CB GLU C13 −4.552 −11.514 0.072 1.00 23.26 C ATOM 85 CG GLU C 13 −4.451 −13.134−0.427 1.00 25.86 C ATOM 86 CD GLU C 13 −2.946 −13.608 −0.960 1.00 27.90C ATOM 87 OE1 GLU C 13 −1.897 −12.904 −0.354 1.00 29.27 C ATOM 88 OE2GLU C 13 −2.788 −14.655 −1.925 1.00 22.76 C ATOM 89 C GLU C 13 −6.374−9.709 0.378 1.00 22.11 C ATOM 90 O GLU C 13 −6.506 −8.669 1.111 1.0021.05 C ATOM 91 N LEU C 14 −6.730 −9.765 −0.930 1.00 21.29 C ATOM 92 CALEU C 14 −7.419 −8.725 −1.566 1.00 22.15 C ATOM 93 CB LEU C 14 −7.119−7.407 −0.816 1.00 21.79 C ATOM 94 CG LEU C 14 −8.419 −6.952 −0.086 1.0022.91 C ATOM 95 CD1 LEU C 14 −7.996 −6.434 1.317 1.00 19.58 C ATOM 96CD2 LEU C 14 −9.350 −5.790 −0.951 1.00 21.91 C ATOM 97 C LEU C 14 −7.183−8.491 −3.081 1.00 23.19 C ATOM 98 O LEU C 14 −6.079 −8.868 −3.720 1.0023.58 C ATOM 99 N GLY C 15 −8.157 −7.723 −3.622 1.00 22.34 C ATOM 100 CAGLY C 15 −8.075 −7.305 −5.012 1.00 21.66 C ATOM 101 C GLY C 15 −7.140−6.091 −5.126 1.00 20.91 C ATOM 102 O GLY C 15 −7.722 −4.974 −5.262 1.0021.83 C ATOM 103 N TRP C 16 −5.774 −6.251 −5.067 1.00 19.98 C ATOM 104CA TRP C 16 −4.838 −5.052 −5.159 1.00 19.24 C ATOM 105 CB TRP C 16−3.974 −4.830 −3.829 1.00 18.05 C ATOM 106 CG TRP C 16 −4.839 −4.377−2.597 1.00 17.76 C ATOM 107 CD2 TRP C 16 −4.487 −3.566 −1.452 1.0017.05 C ATOM 108 CE2 TRP C 16 −5.617 −3.602 −0.595 1.00 17.12 C ATOM 109CE3 TRP C 16 −3.394 −2.845 −1.085 1.00 16.14 C ATOM 110 CD1 TRP C 16−6.069 −4.805 −2.361 1.00 18.77 C ATOM 111 NE1 TRP C 16 −6.546 −4.369−1.191 1.00 18.83 C ATOM 112 CZ2 TRP C 16 −5.637 −2.957 0.633 1.00 15.62C ATOM 113 CZ3 TRP C 16 −3.455 −2.192 0.155 1.00 16.51 C ATOM 114 CH2TRP C 16 −4.565 −2.258 0.976 1.00 15.46 C ATOM 115 C TRP C 16 −3.919−5.094 −6.340 1.00 16.61 C ATOM 116 O TRP C 16 −3.550 −6.108 −6.732 1.0017.35 C ATOM 117 N LEU C 17 −3.557 −3.944 −6.830 1.00 15.80 C ATOM 118CA LEU C 17 −2.646 −3.690 −7.928 1.00 15.71 C ATOM 119 CB LEU C 17−3.107 −2.437 −8.695 1.00 14.73 C ATOM 120 CG LEU C 17 −2.314 −2.286−9.962 1.00 16.81 C ATOM 121 CD1 LEU C 17 −2.216 −3.708 −10.549 1.0019.36 C ATOM 122 CD2 LEU C 17 −2.891 −1.396 −10.997 1.00 17.17 C ATOM123 C LEU C 17 −1.144 −3.500 −7.447 1.00 14.20 C ATOM 124 O LEU C 17−0.831 −2.796 −6.485 1.00 14.02 C ATOM 125 N THR C 18 −0.248 −4.124−8.185 1.00 14.48 C ATOM 126 CA THR C 18 1.161 −4.110 −7.834 1.00 16.26C ATOM 127 CB THR C 18 1.536 −5.471 −7.327 1.00 15.53 C ATOM 128 OG1 THRC 18 1.520 −5.436 −5.903 1.00 13.54 C ATOM 129 CG2 THR C 18 2.802 −5.879−7.832 1.00 17.28 C ATOM 130 C THR C 18 1.912 −3.711 −9.016 1.00 15.70 CATOM 131 O THR C 18 1.863 −4.409 −9.953 1.00 14.52 C ATOM 132 N HIS C 192.597 −2.575 −8.971 1.00 17.08 C ATOM 133 CA HIS C 19 3.222 −2.102−10.143 1.00 18.52 C ATOM 134 CB HIS C 19 3.354 −0.643 −10.159 1.0019.18 C ATOM 135 CG HIS C 19 3.559 −0.056 −11.547 1.00 20.82 C ATOM 136CD2 HIS C 19 4.234 1.063 −11.963 1.00 20.60 C ATOM 137 ND1 HIS C 193.237 −0.752 −12.694 1.00 20.78 C ATOM 138 CE1 HIS C 19 3.718 −0.105−13.747 1.00 21.27 C ATOM 139 NE2 HIS C 19 4.335 0.995 −13.335 1.0022.21 C ATOM 140 C HIS C 19 4.513 −2.888 −10.472 1.00 21.18 C ATOM 141 OHIS C 19 4.679 −4.038 −9.970 1.00 21.99 C ATOM 142 N PRO C 20 5.561−2.267 −10.972 1.00 20.76 C ATOM 143 CD PRO C 20 6.051 −1.414 −9.8441.00 19.53 C ATOM 144 CA PRO C 20 6.552 −3.327 −11.309 1.00 19.69 C ATOM145 CB PRO C 20 7.556 −3.246 −10.174 1.00 21.06 C ATOM 146 CG PRO C 207.623 −1.692 −9.891 1.00 20.36 C ATOM 147 C PRO C 20 5.803 −4.767−11.576 1.00 20.95 C ATOM 148 O PRO C 20 5.440 −5.196 −12.756 1.00 22.36C ATOM 149 N TYR C 21 5.466 −5.478 −10.519 1.00 19.20 C ATOM 150 CA TYRC 21 4.794 −6.805 −10.535 1.00 16.82 C ATOM 151 CB TYR C 21 3.674 −6.944−11.528 1.00 17.06 C ATOM 152 CG TYR C 21 3.072 −8.321 −11.379 1.0018.30 C ATOM 153 CD1 TYR C 21 2.327 −8.642 −10.217 1.00 17.87 C ATOM 154CE1 TYR C 21 2.016 −9.968 −9.857 1.00 16.08 C ATOM 155 CD2 TYR C 213.484 −9.422 −12.211 1.00 19.33 C ATOM 156 CE2 TYR C 21 3.197 −10.764−11.803 1.00 16.95 C ATOM 157 CZ TYR C 21 2.470 −10.996 −10.626 1.0016.92 C ATOM 158 OH TYR C 21 2.211 −12.271 −10.119 1.00 17.61 C ATOM 159C TYR C 21 5.837 −7.871 −10.844 1.00 15.77 C ATOM 160 O TYR C 21 6.248−7.947 −11.960 1.00 15.52 C ATOM 161 N GLY C 22 6.184 −8.688 −9.860 1.0014.91 C ATOM 162 CA GLY C 22 7.204 −9.676 −10.023 1.00 15.48 C ATOM 163C GLY C 22 8.279 −9.684 −8.926 1.00 15.80 C ATOM 164 O GLY C 22 8.519−10.714 −8.292 1.00 16.63 C ATOM 165 N LYS C 23 8.832 −8.505 −8.673 1.0015.76 C ATOM 166 CA LYS C 23 9.93 1 −8.225 −7.798 1.00 15.49 C ATOM 167CB LYS C 23 11.128 −7.757 −8.643 1.00 15.81 C ATOM 168 CG LYS C 2311.847 −8.749 −9.451 1.00 17.47 C ATOM 169 CD LYS C 23 11.530 −8.488−11.028 1.00 21.34 C ATOM 170 CE LYS C 23 11.892 −9.694 −11.940 1.0020.67 C ATOM 171 NZ LYS C 23 13.372 −9.866 −12.235 1.00 23.93 C ATOM 172C LYS C 23 9.632 −7.144 −6.744 1.00 14.48 C ATOM 173 O LYS C 23 10.412−7.000 −5.832 1.00 14.66 C ATOM 174 N GLY C 24 8.575 −6.363 −6.928 1.0013.83 C ATOM 175 CA GLY C 24 8.160 −5.378 −5.942 1.00 12.38 C ATOM 176 CGLY C 24 7.396 −5.995 −4.739 1.00 12.13 C ATOM 177 O GLY C 24 7.775−7.006 −4.128 1.00 8.63 C ATOM 178 N TRP C 25 6.299 −5.307 −4.430 1.0013.10 C ATOM 179 CA TRP C 25 5.349 −5.704 −3.396 1.00 13.94 C ATOM 180CB TRP C 25 4.292 −4.620 −3.317 1.00 15.51 C ATOM 181 CG TRP C 25 4.648−3.271 −2.788 1.00 15.71 C ATOM 182 CD2 TRP C 25 4.765 −2.912 −1.3851.00 15.60 C ATOM 183 CE2 TRP C 25 4.966 −1.528 −1.318 1.00 15.15 C ATOM184 CE3 TRP C 25 4.697 −3.639 −0.197 1.00 14.68 C ATOM 185 CD1 TRP C 254.799 −2.112 −3.480 1.00 15.32 C ATOM 186 NE1 TRP C 25 4.986 −1.055−2.595 1.00 15.46 C ATOM 187 CZ2 TRP C 25 5.106 −0.888 −0.158 1.00 15.58C ATOM 188 CZ3 TRP C 25 4.839 −2.974 0.958 1.00 15.80 C ATOM 189 CH2 TRPC 25 5.030 −1.622 0.985 1.00 14.18 C ATOM 190 C TRP C 25 4.667 −7.133−3.766 1.00 14.77 C ATOM 191 O TRP C 25 4.160 −7.407 −4.894 1.00 12.76 CATOM 192 N ASP C 26 4.723 −8.048 −2.798 1.00 15.85 C ATOM 193 CA ASP C26 4.147 −9.363 −2.916 1.00 16.48 C ATOM 194 CB ASP C 26 5.184 −10.536−2.917 1.00 19.04 C ATOM 195 CG ASP C 26 6.058 −10.686 −4.199 1.00 23.71C ATOM 196 OD1 ASP C 26 6.109 −9.866 −5.305 1.00 24.73 C ATOM 197 OD2ASP C 26 6.797 −11.759 −4.110 1.00 26.80 C ATOM 198 C ASP C 26 3.222−9.661 −1.707 1.00 16.33 C ATOM 199 O ASP C 26 3.560 −9.438 −0.555 1.0015.68 C ATOM 200 N LEU C 27 2.062 −10.208 −2.012 1.00 16.44 C ATOM 201CA LEU C 27 1.114 −10.649 −1.028 1.00 16.23 C ATOM 202 CB LEU C 27−0.190 −10.854 −1.703 1.00 16.58 C ATOM 203 CG LEU C 27 −1.307 −10.911−0.729 1.00 16.90 C ATOM 204 CD1 LEU C 27 −1.354 −9.795 0.274 1.00 17.08C ATOM 205 CD2 LEU C 27 −2.461 −10.910 −1.619 1.00 16.77 C ATOM 206 CLEU C 27 1.680 −11.942 −0.532 1.00 15.66 C ATOM 207 O LEU C 27 2.128−12.754 −1.314 1.00 15.50 C ATOM 208 N MET C 28 1.701 −12.132 0.778 1.0015.44 C ATOM 209 CA MET C 28 2.231 −13.346 1.360 1.00 13.78 C ATOM 210CB MET C 28 3.659 −13.158 1.946 1.00 17.79 C ATOM 211 CG MET C 28 4.536−12.246 1.142 1.00 21.18 C ATOM 212 SD MET C 28 6.291 −12.114 1.400 1.0026.24 C ATOM 213 CE MET C 28 6.825 −13.986 2.081 1.00 25.34 C ATOM 214 CMET C 28 1.296 −13.634 2.472 1.00 14.21 C ATOM 215 O MET C 28 0.660−12.708 3.089 1.00 11.21 C ATOM 216 N GLN C 29 1.293 −14.947 2.791 1.0015.27 C ATOM 217 CA GLN C 29 0.444 −15.481 3.801 1.00 16.73 C ATOM 218CB GLN C 29 −0.528 −16.484 3.213 1.00 17.54 C ATOM 219 CG GLN C 29−1.726 −16.589 4.051 1.00 20.17 C ATOM 220 CD GLN C 29 −2.438 −17.9273.960 1.00 21.49 C ATOM 221 OE1 GLN C 29 −3.619 −17.942 3.647 1.00 23.22C ATOM 222 NE2 GLN C 29 −1.743 −19.041 4.297 1.00 21.22 C ATOM 223 C GLNC 29 1.073 −16.101 5.006 1.00 19.00 C ATOM 224 O GLN C 29 1.692 −17.1174.905 1.00 21.71 C ATOM 225 N ASN C 30 0.950 −15.560 6.213 1.00 18.32 CATOM 226 CA ASN C 30 1.531 −16.333 7.291 1.00 14.58 C ATOM 227 CB ASN C30 2.282 −15.440 8.252 1.00 14.70 C ATOM 228 CG ASN C 30 3.616 −15.0537.762 1.00 13.44 C ATOM 229 OD1 ASN C 30 4.054 −14.021 8.005 1.00 13.88C ATOM 230 ND2 ASN C 30 4.263 −15.913 7.092 1.00 14.82 C ATOM 231 C ASNC 30 0.388 −16.975 8.024 1.00 15.16 C ATOM 232 O ASN C 30 −0.820 −16.6837.869 1.00 13.52 C ATOM 233 N ILE C 31 0.741 −17.880 8.876 1.00 14.87 CATOM 234 CA ILE C 31 −0.281 −18.455 9.605 1.00 15.34 C ATOM 235 CB ILE C31 −0.701 −19.681 8.903 1.00 17.37 C ATOM 236 CG2 ILE C 31 0.482 −20.6078.844 1.00 21.11 C ATOM 237 CG1 ILE C 31 −1.895 −20.337 9.612 1.00 17.91C ATOM 238 CD1 ILE C 31 −2.177 −21.603 8.969 1.00 16.50 C ATOM 239 C ILEC 31 0.039 −18.649 11.048 1.00 14.95 C ATOM 240 O ILE C 31 1.109 −19.04111.459 1.00 14.93 C ATOM 241 N MET C 32 −0.933 −18.329 11.871 1.00 15.04C ATOM 242 CA MET C 32 −0.785 −18.430 13.374 1.00 14.55 C ATOM 243 CBMET C 32 −0.646 −17.071 14.045 1.00 15.86 C ATOM 244 CG MET C 32 0.721−16.489 14.179 1.00 17.67 C ATOM 245 SD MET C 32 1.919 −17.682 14.9691.00 20.19 C ATOM 246 CE MET C 32 0.684 −18.349 16.331 1.00 18.20 C ATOM247 C MET C 32 −2.014 −18.991 13.960 1.00 14.04 C ATOM 248 O MET C 32−3.046 −18.352 13.907 1.00 12.26 C ATOM 249 N ASN C 33 −1.844 −20.11714.623 1.00 14.69 C ATOM 250 CA ASN C 33 −2.924 −20.884 15.208 1.0015.93 C ATOM 251 CB ASN C 33 −3.487 −20.236 16.473 1.00 17.27 C ATOM 252CG ASN C 33 −2.456 −19.929 17.473 1.00 18.35 C ATOM 253 OD1 ASN C 33−1.800 −20.819 18.107 1.00 19.28 C ATOM 254 ND2 ASN C 33 −2.243 −18.64217.621 1.00 18.73 C ATOM 255 C ASN C 33 −4.052 −21.034 14.183 1.00 16.26C ATOM 256 O ASN C 33 −5.197 −20.714 14.458 1.00 16.56 C ATOM 257 N ASPC 34 −3.683 −21.518 13.010 1.00 16.32 C ATOM 258 CA ASP C 34 −4.558−21.752 11.958 1.00 15.92 C ATOM 259 CB ASP C 34 −5.588 −22.822 12.3301.00 16.38 C ATOM 260 CG ASP C 34 −5.016 −24.191 12.395 1.00 18.08 CATOM 261 OD1 ASP C 34 −3.808 −24.400 12.539 1.00 19.11 C ATOM 262 OD2ASP C 34 −5.828 −25.108 12.322 1.00 22.27 C ATOM 263 C ASP C 34 −5.199−20.511 11.478 1.00 16.91 C ATOM 264 O ASP C 34 −6.165 −20.558 10.7201.00 18.46 C ATOM 265 N MET C 35 −4.772 −19.358 11.906 1.00 17.43 C ATOM266 CA MET C 35 −5.403 −18.173 11.285 1.00 17.50 C ATOM 267 CB MET C 35−5.652 −17.116 12.349 1.00 18.01 C ATOM 268 CG MET C 35 −6.768 −17.48713.254 1.00 18.47 C ATOM 269 SD MET C 35 −8.470 −17.564 12.502 1.0021.76 C ATOM 270 CE MET C 35 −8.399 −19.587 12.396 1.00 20.90 C ATOM 271C MET C 35 −4.510 −17.612 10.121 1.00 16.67 C ATOM 272 O MET C 35 −3.314−17.504 10.265 1.00 17.59 C ATOM 273 N PRO C 36 −5.059 −17.428 8.9221.00 17.02 C ATOM 274 CD PRO C 36 −6.270 −18.030 8.307 1.00 16.90 C ATOM275 CA PRO C 36 −4.186 −16.879 7.879 1.00 16.22 C ATOM 276 CB PRO C 36−4.980 −17.086 6.549 1.00 15.98 C ATOM 277 CG PRO C 36 −6.418 −17.1936.988 1.00 16.13 C ATOM 278 C PRO C 36 −4.020 −15.385 8.152 1.00 16.23 CATOM 279 O PRO C 36 −4.984 −14.690 8.340 1.00 15.04 C ATOM 280 N ILE C37 −2.776 −14.916 8.115 1.00 16.96 C ATOM 281 CA ILE C 37 −2.394 −13.5228.352 1.00 16.12 C ATOM 282 CB ILE C 37 −1.285 −13.510 9.477 1.00 17.38C ATOM 283 CG2 ILE C 37 −1.025 −12.155 9.920 1.00 17.18 C ATOM 284 CG1ILE C 37 −1.741 −14.364 10.732 1.00 17.97 C ATOM 285 CD1 ILE C 37 −3.072−14.095 11.112 1.00 15.01 C ATOM 286 C ILE C 37 −1.805 −13.003 7.0181.00 17.59 C ATOM 287 O ILE C 37 −0.650 −13.322 6.625 1.00 17.01 C ATOM288 N TYR C 38 −2.566 −12.270 6.242 1.00 17.42 C ATOM 289 CA TYR C 38−1.982 −11.777 5.040 1.00 17.51 C ATOM 290 CB TYR C 38 −3.058 −11.4704.047 1.00 17.90 C ATOM 291 CG TYR C 38 −3.703 −12.732 3.537 1.00 17.43C ATOM 292 CD1 TYR C 38 −4.640 −13.412 4.296 1.00 17.04 C ATOM 293 CE1TYR C 38 −5.101 −14.601 3.832 1.00 15.48 C ATOM 294 CD2 TYR C 38 −3.280−13.315 2.311 1.00 16.75 C ATOM 295 CE2 TYR C 38 −3.734 −14.468 1.8931.00 13.66 C ATOM 296 CZ TYR C 38 −4.629 −15.103 2.634 1.00 14.25 C ATOM297 OH TYR C 38 −5.073 −16.260 2.262 1.00 11.37 C ATOM 298 C TYR C 38−1.159 −10.513 5.174 1.00 18.42 C ATOM 299 O TYR C 38 −1.462 −9.6926.049 1.00 18.62 C ATOM 300 N MET C 39 −0.158 −10.319 4.297 1.00 16.82 CATOM 301 CA MET C 39 0.585 −9.093 4.340 1.00 15.74 C ATOM 302 CB MET C39 1.756 −9.186 5.312 1.00 14.27 C ATOM 303 CG MET C 39 3.034 −9.7054.787 1.00 14.04 C ATOM 304 SD MET C 39 3.712 −10.557 6.122 1.00 16.96 CATOM 305 CE MET C 39 5.352 −11.469 5.422 1.00 18.70 C ATOM 306 C MET C39 1.081 −8.690 2.979 1.00 16.55 C ATOM 307 O MET C 39 1.146 −9.5302.125 1.00 16.81 C ATOM 308 N TYR C 40 1.385 −7.406 2.742 1.00 15.57 CATOM 309 CA TYR C 40 2.041 −7.029 1.501 1.00 15.44 C ATOM 310 CB TYR C40 1.297 −5.830 0.900 1.00 16.44 C ATOM 311 CG TYR C 40 0.354 −6.227−0.199 1.00 17.62 C ATOM 312 CD1 TYR C 40 −1.026 −6.230 −0.003 1.0016.88 C ATOM 313 CE1 TYR C 40 −1.882 −6.700 −0.954 1.00 17.13 C ATOM 314CD2 TYR C 40 0.855 −6.709 −1.430 1.00 18.88 C ATOM 315 CE2 TYR C 40−0.031 −7.191 −2.426 1.00 18.98 C ATOM 316 CZ TYR C 40 −1.391 −7.189−2.159 1.00 18.47 C ATOM 317 OH TYR C 40 −2.170 −7.766 −3.074 1.00 19.23C ATOM 318 C TYR C 40 3.538 −6.664 1.852 1.00 14.48 C ATOM 319 O TYR C40 3.810 −5.892 2.726 1.00 14.77 C ATOM 320 N SER C 41 4.516 −7.2861.261 1.00 14.82 C ATOM 321 CA SER C 41 5.897 −6.869 1.588 1.00 16.01 CATOM 322 CB SER C 41 6.528 −7.731 2.638 1.00 15.65 C ATOM 323 OG SER C41 6.051 −8.986 2.515 1.00 16.99 C ATOM 324 C SER C 41 6.889 −6.7240.429 1.00 14.68 C ATOM 325 O SER C 41 6.610 −7.158 −0.666 1.00 15.09 CATOM 326 N VAL C 42 8.020 −6.087 0.704 1.00 15.16 C ATOM 327 CA VAL C 429.050 −5.903 −0.300 1.00 15.80 C ATOM 328 CB VAL C 42 9.231 −4.507−0.958 1.00 15.47 C ATOM 329 CG1 VAL C 42 9.416 −4.680 −2.420 1.00 13.89C ATOM 330 CG2 VAL C 42 8.216 −3.501 −0.493 1.00 14.31 C ATOM 331 C VALC 42 10.235 −5.830 0.478 1.00 15.19 C ATOM 332 O VAL C 42 10.162 −5.3031.552 1.00 15.32 C ATOM 333 N CYS C 43 11.336 −6.249 −0.130 1.00 15.63 CATOM 334 CA CYS C 43 12.641 −6.162 0.479 1.00 17.26 C ATOM 335 C CYS C43 13.772 −6.010 −0.627 1.00 16.60 C ATOM 336 O CYS C 43 14.716 −6.729−0.709 1.00 17.93 C ATOM 337 CB CYS C 43 12.847 −7.395 1.425 1.00 15.56C ATOM 338 SG CYS C 43 14.172 −7.176 2.674 1.00 14.73 C ATOM 339 N ASN C44 13.692 −5.060 −1.490 1.00 16.41 C ATOM 340 CA ASN C 44 14.773 −4.953−2.454 1.00 15.99 C ATOM 341 CB ASN C 44 14.231 −4.585 −3.855 1.00 15.86C ATOM 342 CG ASN C 44 13.285 −5.595 −4.346 1.00 15.89 C ATOM 343 OD1ASN C 44 12.363 −5.255 −5.084 1.00 18.30 C ATOM 344 ND2 ASN C 44 13.477−6.857 −3.947 1.00 13.28 C ATOM 345 C ASN C 44 15.729 −3.909 −2.008 1.0014.64 C ATOM 346 O ASN C 44 15.881 −2.903 −2.664 1.00 13.26 C ATOM 347 NVAL C 45 16.389 −4.218 −0.898 1.00 14.55 C ATOM 348 CA VAL C 45 17.314−3.314 −0.205 1.00 15.57 C ATOM 349 CB VAL C 45 17.383 −3.552 1.358 1.0015.52 C ATOM 350 CG1 VAL C 45 16.058 −3.285 1.982 1.00 15.10 C ATOM 351CG2 VAL C 45 17.936 −4.986 1.712 1.00 13.86 C ATOM 352 C VAL C 45 18.684−3.439 −0.726 1.00 15.57 C ATOM 353 O VAL C 45 19.619 −2.683 −0.349 1.0015.67 C ATOM 354 N MET C 46 18.832 −4.373 −1.612 1.00 15.75 C ATOM 355CA MET C 46 20.145 −4.545 −2.131 1.00 17.08 C ATOM 356 CB MET C 4620.405 −6.040 −2.040 1.00 19.61 C ATOM 357 CG MET C 46 21.723 −6.486−1.469 1.00 23.59 C ATOM 358 SD MET C 46 22.190 −6.004 0.240 1.00 26.46C ATOM 359 CE MET C 46 21.505 −7.450 1.233 1.00 24.33 C ATOM 360 C MET C46 20.274 −3.973 −3.592 1.00 16.44 C ATOM 361 O MET C 46 21.226 −4.237−4.265 1.00 15.50 C ATOM 362 N SER C 47 19.332 −3.208 −4.077 1.00 16.14C ATOM 363 CA SER C 47 19.446 −2.718 −5.427 1.00 17.24 C ATOM 364 CB SERC 47 18.596 −3.580 −6.390 1.00 18.07 C ATOM 365 OG SER C 47 18.238−4.856 −5.729 1.00 24.24 C ATOM 366 C SER C 47 18.893 −1.324 −5.372 1.0017.18 C ATOM 367 O SER C 47 17.985 −1.043 −4.602 1.00 17.58 C ATOM 368 NGLY C 48 19.370 −0.411 −6.210 1.00 17.77 C ATOM 369 CA GLY C 48 18.9200.959 −6.056 1.00 18.52 C ATOM 370 C GLY C 48 17.716 1.340 −6.865 1.0019.80 C ATOM 371 O GLY C 48 17.057 0.459 −7.555 1.00 19.82 C ATOM 372 NASP C 49 17.349 2.614 −6.739 1.00 20.17 C ATOM 373 CA ASP C 49 16.3003.056 −7.601 1.00 19.90 C ATOM 374 CB ASP C 49 16.766 2.841 −9.017 1.0021.41 C ATOM 375 CG ASP C 49 18.121 3.539 −9.341 1.00 23.59 C ATOM 376OD1 ASP C 49 19.021 2.845 −9.946 1.00 23.24 C ATOM 377 OD2 ASP C 4918.264 4.772 −9.019 1.00 23.68 C ATOM 378 C ASP C 49 15.025 2.220 −7.4541.00 20.73 C ATOM 379 O ASP C 49 14.442 1.820 −8.493 1.00 21.44 C ATOM380 N GLN C 50 14.599 1.843 −6.244 1.00 19.56 C ATOM 381 CA GLN C 5013.324 1.117 −6.237 1.00 16.81 C ATOM 382 CB GLN C 50 13.150 0.309−4.951 1.00 17.39 C ATOM 383 CG GLN C 50 14.168 −0.710 −4.702 1.00 16.10C ATOM 384 CD GLN C 50 14.195 −1.686 −5.816 1.00 16.66 C ATOM 385 OE1GLN C 50 13.257 −2.387 −6.034 1.00 14.47 C ATOM 386 NE2 GLN C 50 15.302−1.705 −6.579 1.00 19.03 C ATOM 387 C GLN C 50 12.204 2.168 −6.365 1.0016.44 C ATOM 388 O GLN C 50 12.304 3.328 −5.896 1.00 15.48 C ATOM 389 NASP C 51 11.144 1.755 −7.043 1.00 14.63 C ATOM 390 CA ASP C 51 9.9652.597 −7.183 1.00 13.54 C ATOM 391 CB ASP C 51 10.067 3.519 −8.405 1.0012.26 C ATOM 392 CG ASP C 51 8.926 4.540 −8.462 1.00 13.54 C ATOM 393OD1 ASP C 51 8.742 5.212 −9.546 1.00 15.68 C ATOM 394 OD2 ASP C 51 8.2064.699 −7.482 1.00 6.49 C ATOM 395 C ASP C 51 8.791 1.618 −7.306 1.0012.72 C ATOM 396 O ASP C 51 8.164 1.463 −8.318 1.00 10.92 C ATOM 397 NASN C 52 8.555 0.906 −6.266 1.00 13.08 C ATOM 398 CA ASN C 52 7.467−0.069 −6.259 1.00 14.86 C ATOM 399 CB ASN C 52 7.918 −1.310 −5.516 1.0016.00 C ATOM 400 CG ASN C 52 9.214 −1.764 −5.968 1.00 15.83 C ATOM 401OD1 ASN C 52 9.315 −2.289 −7.045 1.00 17.59 C ATOM 402 ND2 ASN C 5210.230 −1.531 −5.185 1.00 15.66 C ATOM 403 C ASN C 52 6.144 0.443 −5.6441.00 14.59 C ATOM 404 O ASN C 52 6.109 1.050 −4.553 1.00 13.67 C ATOM405 N TRP C 53 5.072 0.185 −6.381 1.00 14.67 C ATOM 406 CA TRP C 533.770 0.663 −6.031 1.00 14.81 C ATOM 407 CB TRP C 53 3.267 1.605 −7.1101.00 15.06 C ATOM 408 CG TRP C 53 4.022 2.883 −7.095 1.00 14.87 C ATOM409 CD2 TRP C 53 3.603 4.155 −6.565 1.00 14.90 C ATOM 410 CE2 TRP C 534.603 5.070 −6.845 1.00 15.37 C ATOM 411 CE3 TRP C 53 2.479 4.605 −5.9021.00 15.09 C ATOM 412 CD1 TRP C 53 5.191 3.074 −7.621 1.00 14.18 C ATOM413 NE1 TRP C 53 5.581 4.377 −7.500 1.00 15.13 C ATOM 414 CZ2 TRP C 534.517 6.412 −6.486 1.00 14.96 C ATOM 415 CZ3 TRP C 53 2.401 5.952 −5.5541.00 14.48 C ATOM 416 CH2 TRP C 53 3.403 6.819 −5.844 1.00 14.84 C ATOM417 C TRP C 53 2.733 −0.345 −5.746 1.00 14.12 C ATOM 418 O TRP C 532.596 −1.322 −6.437 1.00 12.93 C ATOM 419 N LEU C 54 2.007 −0.064 −4.6571.00 14.58 C ATOM 420 CA LEU C 54 0.872 −0.916 −4.177 1.00 14.59 C ATOM421 CB LEU C 54 1.127 −1.493 −2.785 1.00 15.39 C ATOM 422 CG LEU C 54−0.081 −2.242 −2.262 1.00 15.10 C ATOM 423 CD1 LEU C 54 −0.309 −3.415−3.129 1.00 12.99 C ATOM 424 CD2 LEU C 54 0.151 −2.671 −0.822 1.00 13.24C ATOM 425 C LEU C 54 −0.354 −0.032 −4.138 1.00 13.10 C ATOM 426 O LEU C54 −0.381 0.940 −3.481 1.00 10.78 C ATOM 427 N ARG C 55 −1.374 −0.390−4.914 1.00 13.50 C ATOM 428 CA ARG C 55 −2.561 0.427 −4.939 1.00 13.73C ATOM 429 CB ARG C 55 −2.831 1.053 −6.301 1.00 14.24 C ATOM 430 CG ARGC 55 −4.088 1.876 −6.283 1.00 15.23 C ATOM 431 CD ARG C 55 −4.432 2.595−7.462 1.00 14.95 C ATOM 432 NE ARG C 55 −5.417 2.000 −8.419 1.00 17.98C ATOM 433 CZ ARG C 55 −5.486 0.714 −8.754 1.00 18.51 C ATOM 434 NH1 ARGC 55 −4.646 −0.173 −8.164 1.00 21.52 C ATOM 435 NH2 ARG C 55 −6.2780.308 −9.738 1.00 17.10 C ATOM 436 C ARG C 55 −3.721 −0.391 −4.498 1.0013.75 C ATOM 437 O ARG C 55 −3.844 −1.526 −4.839 1.00 14.16 C ATOM 438 NTHR C 56 −4.538 0.196 −3.646 1.00 12.99 C ATOM 439 CA THR C 56 −5.664−0.466 −3.167 1.00 12.35 C ATOM 440 CB THR C 56 −6.325 0.308 −2.077 1.0013.02 C ATOM 441 OG1 THR C 56 −6.880 1.499 −2.639 1.00 10.81 C ATOM 442CG2 THR C 56 −5.376 0.614 −0.981 1.00 13.51 C ATOM 443 C THR C 56 −6.700−0.443 −4.352 1.00 13.32 C ATOM 444 O THR C 56 −6.524 0.196 −5.431 1.009.12 C ATOM 445 N ASN C 57 −7.836 −1.123 −4.096 1.00 14.07 C ATOM 446 CAASN C 57 −8.901 −0.987 −5.065 1.00 16.18 C ATOM 447 CB ASN C 57 −9.829−2.129 −5.020 1.00 19.82 C ATOM 448 CG ASN C 57 −9.642 −3.056 −6.2671.00 23.43 C ATOM 449 OD1 ASN C 57 −8.589 −3.777 −6.397 1.00 23.30 CATOM 450 ND2 ASN C 57 −10.652 −3.013 −7.218 1.00 23.69 C ATOM 451 C ASNC 57 −9.722 0.264 −4.911 1.00 16.38 C ATOM 452 O ASN C 57 −9.671 1.016−3.904 1.00 16.53 C ATOM 453 N TRP C 58 −10.468 0.525 −5.941 1.00 15.57C ATOM 454 CA TRP C 58 −11.404 1.665 −6.002 1.00 15.61 C ATOM 455 CB TRPC 58 −12.307 1.442 −7.223 1.00 16.24 C ATOM 456 CG TRP C 58 −13.4232.350 −7.437 1.00 18.26 C ATOM 457 CD2 TRP C 58 −13.344 3.709 −7.5781.00 18.32 C ATOM 458 CE2 TRP C 58 −14.634 4.178 −7.989 1.00 19.74 CATOM 459 CE3 TRP C 58 −12.343 4.575 −7.412 1.00 18.59 C ATOM 460 CD1 TRPC 58 −14.753 2.018 −7.730 1.00 21.57 C ATOM 461 NE1 TRP C 58 −15.4683.122 −8.069 1.00 21.88 C ATOM 462 CZ2 TRP C 58 −14.896 5.491 −8.2511.00 19.42 C ATOM 463 CZ3 TRP C 58 −12.588 5.879 −7.678 1.00 19.66 CATOM 464 CH2 TRP C 58 −13.852 6.334 −8.095 1.00 21.01 C ATOM 465 C TRP C58 −12.242 1.670 −4.694 1.00 15.46 C ATOM 466 O TRP C 58 −12.898 0.688−4.349 1.00 15.54 C ATOM 467 N VAL C 59 −12.257 2.776 −3.993 1.00 15.25C ATOM 468 CA VAL C 59 −12.992 2.860 −2.740 1.00 15.38 C ATOM 469 CB VALC 59 −12.025 3.110 −1.498 1.00 15.71 C ATOM 470 CG1 VAL C 59 −12.8263.253 −0.214 1.00 14.97 C ATOM 471 CG2 VAL C 59 −11.023 1.981 −1.3631.00 14.53 C ATOM 472 C VAL C 59 −13.941 4.009 −2.838 1.00 14.14 C ATOM473 O VAL C 59 −13.521 5.128 −3.071 1.00 15.05 C ATOM 474 N TYR C 60−15.221 3.709 −2.689 1.00 12.50 C ATOM 475 CA TYR C 60 −16.288 4.697−2.752 1.00 12.76 C ATOM 476 CB TYR C 60 −17.682 4.023 −2.667 1.00 12.55C ATOM 477 CG TYR C 60 −18.168 3.379 −3.889 1.00 14.86 C ATOM 478 CD1TYR C 60 −18.129 1.970 −4.013 1.00 16.43 C ATOM 479 CE1 TYR C 60 −18.4531.332 −5.208 1.00 16.67 C ATOM 480 CD2 TYR C 60 −18.557 4.126 −5.0321.00 16.15 C ATOM 481 CE2 TYR C 60 −18.870 3.448 −6.246 1.00 16.37 CATOM 482 CZ TYR C 60 −18.805 2.073 −6.270 1.00 16.74 C ATOM 483 OH TYR C60 −19.081 1.399 −7.394 1.00 19.79 C ATOM 484 C TYR C 60 −16.148 5.645−1.547 1.00 12.01 C ATOM 485 O TYR C 60 −15.858 5.238 −0.405 1.00 10.57C ATOM 486 N ARG C 61 −16.389 6.889 −1.793 1.00 13.41 C ATOM 487 CA ARGC 61 −16.303 7.873 −0.756 1.00 16.13 C ATOM 488 CB ARG C 61 −16.0359.289 −1.344 1.00 16.34 C ATOM 489 CG ARG C 61 −16.213 10.472 −0.3261.00 15.50 C ATOM 490 CD ARG C 61 −15.825 11.817 −0.899 1.00 14.99 CATOM 491 NE ARG C 61 −16.858 12.376 −1.756 1.00 14.84 C ATOM 492 CZ ARGC 61 −17.972 12.953 −1.348 1.00 14.09 C ATOM 493 NH1 ARG C 61 −18.23513.093 −0.068 1.00 14.64 C ATOM 494 NH2 ARG C 61 −18.882 13.340 −2.2301.00 17.65 C ATOM 495 C ARG C 61 −17.566 7.928 0.054 1.00 17.40 C ATOM496 O ARG C 61 −17.563 8.099 1.269 1.00 18.04 C ATOM 497 N GLY C 62−18.689 7.764 −0.628 1.00 18.83 C ATOM 498 CA GLY C 62 −19.999 7.8990.052 1.00 19.72 C ATOM 499 C GLY C 62 −20.215 9.296 0.663 1.00 20.09 CATOM 500 O GLY C 62 −20.187 10.334 0.028 1.00 20.22 C ATOM 501 N GLU C63 −20.451 9.334 1.956 1.00 20.61 C ATOM 502 CA GLU C 63 −20.643 10.6082.642 1.00 20.87 C ATOM 503 CB GLU C 63 −21.786 10.393 3.630 1.00 21.19C ATOM 504 CG GLU C 63 −22.081 11.555 4.452 1.00 22.23 C ATOM 505 CD GLUC 63 −22.822 12.702 3.645 1.00 25.26 C ATOM 506 OE1 GLU C 63 −22.97913.940 4.218 1.00 25.31 C ATOM 507 OE2 GLU C 63 −23.257 12.359 2.4311.00 25.18 C ATOM 508 C GLU C 63 −19.326 11.140 3.356 1.00 20.95 C ATOM509 O GLU C 63 −19.345 12.210 3.906 1.00 21.09 C ATOM 510 N ALA C 64−18.196 10.419 3.307 1.00 19.93 C ATOM 511 CA ALA C 64 −16.973 10.8963.907 1.00 19.42 C ATOM 512 CB ALA C 64 −15.910 9.827 3.700 1.00 16.08 CATOM 513 C ALA C 64 −16.434 12.279 3.369 1.00 20.27 C ATOM 514 O ALA C64 −16.559 12.584 2.153 1.00 21.09 C ATOM 515 N GLU C 65 −15.890 13.1334.266 1.00 19.73 C ATOM 516 CA GLU C 65 −15.164 14.401 3.832 1.00 19.14C ATOM 517 CB GLU C 65 −15.596 15.667 4.553 1.00 19.64 C ATOM 518 CG GLUC 65 −17.104 15.883 4.640 1.00 23.17 C ATOM 519 CD GLU C 65 −17.70716.641 3.433 1.00 24.28 C ATOM 520 OE1 GLU C 65 −17.312 17.860 3.3481.00 22.82 C ATOM 521 OE2 GLU C 65 −18.550 16.004 2.579 1.00 25.96 CATOM 522 C GLU C 65 −13.643 14.162 4.217 1.00 17.69 C ATOM 523 O GLU C65 −12.725 14.429 3.475 1.00 17.49 C ATOM 524 N ARG C 66 −13.411 13.6585.410 1.00 17.03 C ATOM 525 CA ARG C 66 −12.061 13.352 5.893 1.00 17.12C ATOM 526 CB ARG C 66 −11.764 14.133 7.218 1.00 16.91 C ATOM 527 CG ARGC 66 −10.306 14.046 7.605 1.00 18.27 C ATOM 528 CD ARG C 66 −9.68315.458 7.790 1.00 20.62 C ATOM 529 NE ARG C 66 −8.180 15.454 7.909 1.0021.59 C ATOM 530 CZ ARG C 66 −7.304 16.080 7.082 1.00 21.79 C ATOM 531NH1 ARG C 66 −7.670 16.817 6.030 1.00 18.07 C ATOM 532 NH2 ARG C 66−6.010 15.959 7.354 1.00 23.80 C ATOM 533 C ARG C 66 −12.048 11.8336.151 1.00 15.75 C ATOM 534 O ARG C 66 −13.047 11.278 6.541 1.00 15.91 CATOM 535 N ASN C 67 −10.961 11.138 5.918 1.00 15.81 C ATOM 536 CA ASN C67 −10.997 9.696 6.222 1.00 16.61 C ATOM 537 CB ASN C 67 −10.965 8.8124.970 1.00 17.01 C ATOM 538 CG ASN C 67 −10.022 9.370 3.954 1.00 20.16 CATOM 539 OD1 ASN C 67 −10.002 10.651 3.847 1.00 23.04 C ATOM 540 ND2 ASNC 67 −9.281 8.533 3.158 1.00 15.55 C ATOM 541 C ASN C 67 −9.750 9.5446.958 1.00 16.39 C ATOM 542 O ASN C 67 −8.885 10.271 6.791 1.00 16.08 CATOM 543 N ASN C 68 −9.668 8.591 7.819 1.00 16.80 C ATOM 544 CA ASN C 68−8.494 8.368 8.564 1.00 17.27 C ATOM 545 CB ASN C 68 −9.009 8.233 9.9591.00 17.76 C ATOM 546 CG ASN C 68 −9.423 9.586 10.567 1.00 18.95 C ATOM547 OD1 ASN C 68 −8.538 10.273 11.035 1.00 16.81 C ATOM 548 ND2 ASN C 68−10.765 9.985 10.527 1.00 18.00 C ATOM 549 C ASN C 68 −7.922 7.041 8.0671.00 18.61 C ATOM 550 O ASN C 68 −8.704 6.106 7.574 1.00 19.02 C ATOM551 N PHE C 69 −6.620 6.883 8.099 1.00 17.64 C ATOM 552 CA PHE C 69−6.165 5.541 7.749 1.00 17.28 C ATOM 553 CB PHE C 69 −5.688 5.298 6.3211.00 17.92 C ATOM 554 CG PHE C 69 −5.419 6.452 5.626 1.00 19.58 C ATOM555 CD1 PHE C 69 −4.551 7.381 6.168 1.00 21.45 C ATOM 556 CD2 PHE C 69−6.019 6.652 4.415 1.00 19.61 C ATOM 557 CE1 PHE C 69 −4.254 8.573 5.5121.00 24.20 C ATOM 558 CE2 PHE C 69 −5.774 7.790 3.673 1.00 21.19 C ATOM559 CZ PHE C 69 −4.874 8.815 4.209 1.00 24.38 C ATOM 560 C PHE C 69−5.081 5.088 8.623 1.00 18.10 C ATOM 561 O PHE C 69 −4.054 5.805 8.8271.00 18.03 C ATOM 562 N GLU C 70 −5.340 3.895 9.143 1.00 16.63 C ATOM563 CA GLU C 70 −4.470 3.266 10.031 1.00 15.02 C ATOM 564 CB GLU C 70−5.324 2.700 11.168 1.00 17.52 C ATOM 565 CG GLU C 70 −4.617 2.44212.509 1.00 18.57 C ATOM 566 CD GLU C 70 −5.382 1.493 13.346 1.00 19.86C ATOM 567 OE1 GLU C 70 −5.453 1.687 14.626 1.00 21.08 C ATOM 568 OE2GLU C 70 −5.899 0.509 12.706 1.00 19.56 C ATOM 569 C GLU C 70 −3.6772.159 9.292 1.00 14.57 C ATOM 570 O GLU C 70 −4.285 1.242 8.678 1.0010.89 C ATOM 571 N LEU C 71 −2.327 2.330 9.409 1.00 14.10 C ATOM 572 CALEU C 71 −1.222 1.478 8.894 1.00 14.43 C ATOM 573 CB LEU C 71 −0.2092.317 8.044 1.00 14.85 C ATOM 574 CG LEU C 71 −0.854 2.930 6.831 1.0015.51 C ATOM 575 CD1 LEU C 71 0.030 3.890 6.192 1.00 15.35 C ATOM 576CD2 LEU C 71 −1.217 1.812 5.786 1.00 16.96 C ATOM 577 C LEU C 71 −0.4160.749 10.032 1.00 15.05 C ATOM 578 O LEU C 71 0.033 1.357 10.966 1.0014.64 C ATOM 579 N ASN C 72 −0.281 −0.568 9.911 1.00 15.72 C ATOM 580 CAASN C 72 0.437 −1.440 10.812 1.00 16.49 C ATOM 581 CB ASN C 72 −0.504−2.530 11.469 1.00 17.41 C ATOM 582 CG ASN C 72 −1.252 −2.016 12.6551.00 19.02 C ATOM 583 OD1 ASN C 72 −2.275 −2.582 13.142 1.00 17.92 CATOM 584 ND2 ASN C 72 −0.757 −0.872 13.150 1.00 23.18 C ATOM 585 C ASN C72 1.476 −2.108 9.854 1.00 16.50 C ATOM 586 O ASN C 72 1.129 −2.7478.861 1.00 16.04 C ATOM 587 N PHE C 73 2.767 −1.970 10.208 1.00 17.42 CATOM 588 CA PHE C 73 3.860 −2.495 9.376 1.00 17.24 C ATOM 589 CB PHE C73 4.191 −1.486 8.275 1.00 17.53 C ATOM 590 CG PHE C 73 4.538 −0.0718.835 1.00 17.80 C ATOM 591 CD1 PHE C 73 5.837 0.321 9.039 1.00 17.98 CATOM 592 CD2 PHE C 73 3.566 0.835 9.224 1.00 16.76 C ATOM 593 CE1 PHE C73 6.150 1.586 9.622 1.00 17.28 C ATOM 594 CE2 PHE C 73 3.938 2.0429.783 1.00 17.58 C ATOM 595 CZ PHE C 73 5.236 2.391 9.968 1.00 15.99 CATOM 596 C PHE C 73 5.079 −2.690 10.222 1.00 16.69 C ATOM 597 O PHE C 735.099 −2.240 11.356 1.00 16.65 C ATOM 598 N THR C 74 6.070 −3.389 9.6481.00 16.30 C ATOM 599 CA THR C 74 7.323 −3.602 10.344 1.00 15.99 C ATOM600 CB THR C 74 7.637 −5.030 10.708 1.00 16.29 C ATOM 601 OG1 THR C 748.102 −5.725 9.559 1.00 16.84 C ATOM 602 CG2 THR C 74 6.462 −5.68711.238 1.00 16.04 C ATOM 603 C THR C 74 8.296 −3.207 9.354 1.00 16.08 CATOM 604 O THR C 74 7.978 −3.263 8.164 1.00 15.79 C ATOM 605 N VAL C 759.486 −2.846 9.859 1.00 15.67 C ATOM 606 CA VAL C 75 10.588 −2.430 9.0411.00 15.14 C ATOM 607 CB VAL C 75 10.631 −0.968 9.038 1.00 14.70 C ATOM608 CG1 VAL C 75 11.718 −0.486 8.153 1.00 14.81 C ATOM 609 CG2 VAL C 759.328 −0.459 8.619 1.00 11.48 C ATOM 610 C VAL C 75 11.910 −3.082 9.4581.00 16.55 C ATOM 611 O VAL C 75 12.390 −2.865 10.562 1.00 17.70 C ATOM612 N ARG C 76 12.478 −3.900 8.572 1.00 16.81 C ATOM 613 CA ARG C 7613.674 −4.587 8.899 1.00 17.67 C ATOM 614 CB ARG C 76 14.010 −5.6447.878 1.00 15.23 C ATOM 615 CG ARG C 76 15.251 −6.412 8.301 1.00 13.87 CATOM 616 CD ARG C 76 15.321 −7.760 7.806 1.00 11.63 C ATOM 617 NE ARG C76 16.684 −8.167 7.765 1.00 13.29 C ATOM 618 CZ ARG C 76 17.177 −9.1687.054 1.00 14.89 C ATOM 619 NH1 ARG C 76 16.407 −9.953 6.262 1.00 16.10C ATOM 620 NH2 ARG C 76 18.447 −9.352 7.078 1.00 12.90 C ATOM 621 C ARGC 76 14.741 −3.563 8.944 1.00 18.32 C ATOM 622 O ARG C 76 14.731 −2.7188.072 1.00 20.70 C ATOM 623 N ASP C 77 15.584 −3.590 9.975 1.00 17.83 CATOM 624 CA ASP C 77 16.687 −2.651 10.177 1.00 17.11 C ATOM 625 CB ASP C77 17.387 −3.056 11.471 1.00 16.72 C ATOM 626 CG ASP C 77 18.739 −2.40511.641 1.00 16.50 C ATOM 627 OD1 ASP C 77 19.051 −1.441 10.921 1.0015.73 C ATOM 628 OD2 ASP C 77 19.517 −2.876 12.498 1.00 18.00 C ATOM 629C ASP C 77 17.654 −2.688 9.020 1.00 16.72 C ATOM 630 O ASP C 77 18.189−3.743 8.681 1.00 15.85 C ATOM 631 N CYS C 78 17.895 −1.566 8.376 1.0016.47 C ATOM 632 CA CYS C 78 18.850 −1.606 7.297 1.00 15.68 C ATOM 633 CCYS C 78 20.228 −2.120 7.616 1.00 15.97 C ATOM 634 O CYS C 78 20.903−2.609 6.688 1.00 17.02 C ATOM 635 CB CYS C 78 18.954 −0.269 6.649 1.0015.33 C ATOM 636 SG CYS C 78 17.666 0.104 5.300 1.00 16.43 C ATOM 637 NASN C 79 20.655 −2.064 8.880 1.00 15.32 C ATOM 638 CA ASN C 79 21.992−2.583 9.271 1.00 14.36 C ATOM 639 CB ASN C 79 22.566 −1.877 10.504 1.0014.39 C ATOM 640 CG ASN C 79 22.841 −0.470 10.251 1.00 14.59 C ATOM 641OD1 ASN C 79 22.765 0.327 11.117 1.00 14.40 C ATOM 642 ND2 ASN C 7923.162 −0.151 9.035 1.00 17.51 C ATOM 643 C ASN C 79 22.072 −4.065 9.5231.00 13.32 C ATOM 644 O ASN C 79 23.139 −4.570 9.862 1.00 13.38 C ATOM645 N SER C 80 20.953 −4.746 9.367 1.00 13.54 C ATOM 646 CA SER C 8020.858 −6.200 9.522 1.00 13.57 C ATOM 647 CB SER C 80 19.492 −6.6429.998 1.00 14.15 C ATOM 648 OG SER C 80 18.456 −6.293 9.068 1.00 17.60 CATOM 649 C SER C 80 21.145 −6.916 8.229 1.00 13.26 C ATOM 650 O SER C 8020.878 −8.057 8.149 1.00 12.58 C ATOM 651 N PHE C 81 21.623 −6.255 7.2071.00 14.32 C ATOM 652 CA PHE C 81 21.992 −6.997 6.031 1.00 15.91 C ATOM653 CB PHE C 81 21.382 −6.284 4.788 1.00 16.99 C ATOM 654 CG PHE C 8119.855 −6.248 4.760 1.00 17.54 C ATOM 655 CD1 PHE C 81 19.136 −5.1355.252 1.00 17.59 C ATOM 656 CD2 PHE C 81 19.163 −7.330 4.321 1.00 16.61C ATOM 657 CE1 PHE C 81 17.740 −5.163 5.273 1.00 18.11 C ATOM 658 CE2PHE C 81 17.751 −7.356 4.348 1.00 16.61 C ATOM 659 CZ PHE C 81 17.032−6.288 4.814 1.00 15.81 C ATOM 660 C PHE C 81 23.522 −6.900 6.020 1.0015.87 C ATOM 661 O PHE C 81 24.029 −5.885 5.664 1.00 16.90 C ATOM 662 NPRO C 82 24.261 −7.946 6.369 1.00 16.15 C ATOM 663 CD PRO C 82 23.706−9.294 6.221 1.00 16.60 C ATOM 664 CA PRO C 82 25.757 −8.016 6.437 1.0016.00 C ATOM 665 CB PRO C 82 26.070 −9.513 6.476 1.00 15.93 C ATOM 666CG PRO C 82 24.801 −10.158 6.915 1.00 15.66 C ATOM 667 C PRO C 82 26.565−7.315 5.358 1.00 15.67 C ATOM 668 O PRO C 82 26.282 −7.451 4.175 1.0015.19 C ATOM 669 N GLY C 83 27.600 −6.569 5.762 1.00 15.91 C ATOM 670 CAGLY C 83 28.419 −5.840 4.808 1.00 16.39 C ATOM 671 C GLY C 83 27.499−4.683 4.619 1.00 16.93 C ATOM 672 O GLY C 83 26.349 −4.746 5.007 1.0017.54 C ATOM 673 N GLY C 84 27.838 −3.590 4.009 1.00 17.51 C ATOM 674 CAGLY C 84 26.750 −2.546 4.081 1.00 17.82 C ATOM 675 C GLY C 84 25.539−2.647 3.197 1.00 17.97 C ATOM 676 O GLY C 84 25.512 −3.587 2.394 1.0018.51 C ATOM 677 N ALA C 85 24.495 −1.798 3.321 1.00 17.97 C ATOM 678 CAALA C 85 23.365 −1.883 2.304 1.00 17.60 C ATOM 679 CB ALA C 85 22.093−2.662 2.830 1.00 18.25 C ATOM 680 C ALA C 85 23.024 −0.503 1.916 1.0016.46 C ATOM 681 O ALA C 85 21.941 −0.129 2.099 1.00 16.70 C ATOM 682 NSER C 86 23.986 0.235 1.388 1.00 15.18 C ATOM 683 CA SER C 86 23.8201.616 0.977 1.00 13.85 C ATOM 684 CB SER C 86 24.953 2.013 0.043 1.0014.60 C ATOM 685 OG SER C 86 24.943 1.373 −1.209 1.00 16.68 C ATOM 686 CSER C 86 22.544 2.083 0.454 1.00 11.83 C ATOM 687 O SER C 86 22.1703.104 0.821 1.00 10.67 C ATOM 688 N SER C 87 21.856 1.342 −0.416 1.0011.52 C ATOM 689 CA SER C 87 20.506 1.837 −0.939 1.00 12.31 C ATOM 690CB SER C 87 20.287 1.403 −2.407 1.00 12.25 C ATOM 691 OG SER C 87 20.0270.025 −2.444 1.00 9.42 C ATOM 692 C SER C 87 19.245 1.433 −0.086 1.0010.33 C ATOM 693 O SER C 87 18.131 1.854 −0.342 1.00 9.89 C ATOM 694 NCYS C 88 19.470 0.661 0.938 1.00 9.34 C ATOM 695 CA CYS C 88 18.4220.293 1.794 1.00 11.87 C ATOM 696 C CYS C 88 17.806 1.521 2.488 1.0011.37 C ATOM 697 O CYS C 88 18.447 2.435 2.759 1.00 10.75 C ATOM 698 CBCYS C 88 18.948 −0.718 2.807 1.00 10.90 C ATOM 699 SG CYS C 88 17.825−1.457 4.014 1.00 12.35 C ATOM 700 N LYS C 89 16.535 1.508 2.757 1.0012.48 C ATOM 701 CA LYS C 89 15.884 2.668 3.303 1.00 15.53 C ATOM 702 CBLYS C 89 14.892 3.302 2.251 1.00 15.24 C ATOM 703 CG LYS C 89 15.5823.906 0.991 1.00 16.83 C ATOM 704 CD LYS C 89 16.380 5.159 1.363 1.0016.74 C ATOM 705 CE LYS C 89 17.025 5.752 0.096 1.00 19.87 C ATOM 706 NZLYS C 89 17.564 7.165 0.144 1.00 23.75 C ATOM 707 C LYS C 89 15.0722.273 4.503 1.00 16.48 C ATOM 708 O LYS C 89 14.856 1.065 4.661 1.0017.34 C ATOM 709 N GLU C 90 14.628 3.229 5.366 1.00 16.18 C ATOM 710 CAGLU C 90 13.717 2.795 6.445 1.00 17.21 C ATOM 711 CB GLU C 90 14.4172.642 7.793 1.00 15.58 C ATOM 712 CG GLU C 90 15.566 1.626 7.714 1.0016.97 C ATOM 713 CD GLU C 90 16.467 1.605 8.878 1.00 17.68 C ATOM 714OE1 GLU C 90 16.867 2.716 9.343 1.00 19.21 C ATOM 715 OE2 GLU C 9016.753 0.460 9.305 1.00 16.91 C ATOM 716 C GLU C 90 12.429 3.575 6.5431.00 17.15 C ATOM 717 O GLU C 90 11.935 3.874 7.628 1.00 18.73 C ATOM718 N THR C 91 11.880 3.920 5.389 1.00 16.29 C ATOM 719 CA THR C 9110.604 4.591 5.386 1.00 14.86 C ATOM 720 CB THR C 91 10.731 6.096 5.3771.00 13.50 C ATOM 721 OG1 THR C 91 11.535 6.442 4.278 1.00 12.68 C ATOM722 CG2 THR C 91 11.417 6.649 6.720 1.00 12.90 C ATOM 723 C THR C 919.959 4.125 4.075 1.00 15.38 C ATOM 724 O THR C 91 10.607 3.461 3.2541.00 14.39 C ATOM 725 N PHE C 92 8.663 4.463 3.930 1.00 16.22 C ATOM 726CA PHE C 92 7.884 4.306 2.690 1.00 16.61 C ATOM 727 CB PHE C 92 7.1412.997 2.620 1.00 17.58 C ATOM 728 CG PHE C 92 6.152 2.805 3.684 1.0017.54 C ATOM 729 CD1 PHE C 92 4.831 2.974 3.433 1.00 16.76 C ATOM 730CD2 PHE C 92 6.530 2.290 4.898 1.00 16.83 C ATOM 731 CE1 PHE C 92 3.9082.584 4.386 1.00 18.27 C ATOM 732 CE2 PHE C 92 5.621 1.911 5.828 1.0016.18 C ATOM 733 CZ PHE C 92 4.322 2.044 5.587 1.00 15.78 C ATOM 734 CPHE C 92 6.920 5.407 2.539 1.00 17.38 C ATOM 735 O PHE C 92 6.611 6.0183.513 1.00 17.53 C ATOM 736 N ASN C 93 6.379 5.618 1.345 1.00 16.65 CATOM 737 CA ASN C 93 5.453 6.697 1.087 1.00 15.55 C ATOM 738 CB ASN C 935.905 7.407 −0.084 1.00 15.47 C ATOM 739 CG ASN C 93 7.140 8.053 0.1801.00 15.77 C ATOM 740 OD1 ASN C 93 7.264 8.675 1.220 1.00 16.38 C ATOM741 ND2 ASN C 93 8.079 7.941 −0.716 1.00 12.39 C ATOM 742 C ASN C 934.005 6.423 0.918 1.00 15.95 C ATOM 743 O ASN C 93 3.643 5.387 0.4551.00 15.02 C ATOM 744 N LEU C 94 3.167 7.356 1.356 1.00 15.08 C ATOM 745CA LEU C 94 1.795 7.138 1.246 1.00 15.41 C ATOM 746 CB LEU C 94 1.1307.217 2.622 1.00 14.54 C ATOM 747 CG LEU C 94 −0.407 7.139 2.781 1.0013.57 C ATOM 748 CD1 LEU C 94 −0.896 5.742 2.229 1.00 12.30 C ATOM 749CD2 LEU C 94 −0.738 7.387 4.237 1.00 11.51 C ATOM 750 C LEU C 94 1.1018.099 0.276 1.00 16.76 C ATOM 751 O LEU C 94 1.243 9.318 0.447 1.0017.39 C ATOM 752 N TYR C 95 0.309 7.596 −0.706 1.00 16.13 C ATOM 753 CATYR C 95 −0.403 8.472 −1.645 1.00 14.79 C ATOM 754 CB TYR C 95 0.2028.401 −3.007 1.00 15.35 C ATOM 755 CG TYR C 95 1.595 8.955 −3.207 1.0016.40 C ATOM 756 CD1 TYR C 95 2.737 8.392 −2.598 1.00 14.72 C ATOM 757CE1 TYR C 95 3.984 8.880 −2.864 1.00 15.06 C ATOM 758 CD2 TYR C 95 1.77910.015 −4.096 1.00 17.38 C ATOM 759 CE2 TYR C 95 3.040 10.478 −4.3771.00 17.62 C ATOM 760 CZ TYR C 95 4.119 9.923 −3.761 1.00 16.43 C ATOM761 OH TYR C 95 5.237 10.596 −4.075 1.00 17.48 C ATOM 762 C TYR C 95−1.828 8.080 −1.826 1.00 14.51 C ATOM 763 O TYR C 95 −2.292 6.995 −1.4361.00 13.37 C ATOM 764 N TYR C 96 −2.548 8.952 −2.496 1.00 14.66 C ATOM765 CA TYR C 96 −3.976 8.672 −2.809 1.00 14.95 C ATOM 766 CB TYR C 96−4.914 9.099 −1.663 1.00 14.56 C ATOM 767 CG TYR C 96 −5.192 10.566−1.638 1.00 14.19 C ATOM 768 CD1 TYR C 96 −6.346 11.081 −2.172 1.0014.77 C ATOM 769 CE1 TYR C 96 −6.609 12.447 −2.162 1.00 15.77 C ATOM 770CD2 TYR C 96 −4.293 11.420 −1.102 1.00 14.17 C ATOM 771 CE2 TYR C 96−4.529 12.798 −1.072 1.00 15.90 C ATOM 772 CZ TYR C 96 −5.677 13.313−1.589 1.00 15.84 C ATOM 773 OH TYR C 96 −5.829 14.661 −1.515 1.00 15.15C ATOM 774 C TYR C 96 −4.327 9.444 −4.048 1.00 14.09 C ATOM 775 O TYR C96 −3.531 10.213 −4.529 1.00 13.38 C ATOM 776 N ALA C 97 −5.528 9.218−4.564 1.00 14.37 C ATOM 777 CA ALA C 97 −6.007 9.991 −5.760 1.00 15.65C ATOM 778 CB ALA C 97 −5.420 9.446 −7.170 1.00 13.99 C ATOM 779 C ALA C97 −7.462 9.811 −5.658 1.00 14.46 C ATOM 780 O ALA C 97 −7.922 8.853−5.023 1.00 14.24 C ATOM 781 N GLU C 98 −8.156 10.799 −6.163 1.00 14.58C ATOM 782 CA GLU C 98 −9.643 10.833 −6.175 1.00 16.26 C ATOM 783 CB GLUC 98 −10.158 12.151 −5.655 1.00 14.43 C ATOM 784 CG GLU C 98 −10.20512.254 −4.171 1.00 14.61 C ATOM 785 CD GLU C 98 −10.760 13.660 −3.7011.00 15.33 C ATOM 786 OE1 GLU C 98 −10.001 14.686 −3.589 1.00 16.29 CATOM 787 OE2 GLU C 98 −11.972 13.747 −3.465 1.00 13.77 C ATOM 788 C GLUC 98 −10.162 10.751 −7.609 1.00 15.27 C ATOM 789 O GLU C 98 −9.56811.304 −8.524 1.00 16.65 C ATOM 790 N SER C 99 −11.210 10.021 −7.8541.00 14.95 C ATOM 791 CA SER C 99 −11.792 10.038 −9.217 1.00 15.27 CATOM 792 CB SER C 99 −11.070 9.251 −10.343 1.00 12.89 C ATOM 793 OG SERC 99 −10.998 7.950 −10.079 1.00 11.54 C ATOM 794 C SER C 99 −13.2489.702 −9.256 1.00 15.17 C ATOM 795 O SER C 99 −13.785 9.114 −8.380 1.0015.16 C ATOM 796 N ASP C 100 −13.916 10.193 −10.290 1.00 16.26 C ATOM797 CA ASP C 100 −15.279 9.862 −10.348 1.00 17.25 C ATOM 798 CB ASP C100 −16.049 10.981 −11.001 1.00 17.20 C ATOM 799 CG ASP C 100 −16.10212.299 −10.116 1.00 18.84 C ATOM 800 OD1 ASP C 100 −16.354 12.201 −8.8731.00 15.96 C ATOM 801 OD2 ASP C 100 −15.880 13.436 −10.736 1.00 18.65 CATOM 802 C ASP C 100 −15.517 8.541 −11.023 1.00 16.98 C ATOM 803 O ASP C100 −16.594 8.067 −10.928 1.00 17.07 C ATOM 804 N LEU C 101 −14.5027.981 −11.662 1.00 16.55 C ATOM 805 CA LEU C 101 −14.579 6.782 −12.3841.00 17.40 C ATOM 806 CB LEU C 101 −14.164 6.934 −13.872 1.00 17.11 CATOM 807 CG LEU C 101 −14.332 8.115 −14.768 1.00 18.53 C ATOM 808 CD1LEU C 101 −13.833 9.320 −14.105 1.00 17.20 C ATOM 809 CD2 LEU C 101−13.515 7.888 −16.055 1.00 17.86 C ATOM 810 C LEU C 101 −13.548 5.813−11.772 1.00 17.42 C ATOM 811 O LEU C 101 −12.594 6.199 −11.165 1.0016.28 C ATOM 812 N ASP C 102 −13.785 4.539 −12.022 1.00 17.92 C ATOM 813CA ASP C 102 −12.969 3.443 −11.584 1.00 20.65 C ATOM 814 CB ASP C 102−13.814 2.165 −11.557 1.00 18.60 C ATOM 815 CG ASP C 102 −13.106 1.028−10.918 1.00 18.96 C ATOM 816 OD1 ASP C 102 −11.808 0.985 −10.963 1.0020.16 C ATOM 817 OD2 ASP C 102 −13.806 0.129 −10.332 1.00 16.85 C ATOM818 C ASP C 102 −11.846 3.270 −12.661 1.00 21.62 C ATOM 819 O ASP C 102−12.116 2.808 −13.800 1.00 23.44 C ATOM 820 N TYR C 103 −10.586 3.518−12.294 1.00 21.22 C ATOM 821 CA TYR C 103 −9.476 3.377 −13.288 1.0020.10 C ATOM 822 CB TYR C 103 −8.109 3.910 −12.681 1.00 20.71 C ATOM 823CG TYR C 103 −8.002 5.399 −12.673 1.00 21.26 C ATOM 824 CD1 TYR C 103−8.209 6.137 −13.820 1.00 22.06 C ATOM 825 CE1 TYR C 103 −8.104 7.532−13.810 1.00 23.09 C ATOM 826 CD2 TYR C 103 −7.695 6.054 −11.514 1.0021.47 C ATOM 827 CE2 TYR C 103 −7.580 7.464 −11.458 1.00 22.82 C ATOM828 CZ TYR C 103 −7.773 8.218 −12.584 1.00 23.49 C ATOM 829 OH TYR C 103−7.629 9.620 −12.491 1.00 23.07 C ATOM 830 C TYR C 103 −9.200 1.978−13.748 1.00 18.60 C ATOM 831 O TYR C 103 −8.315 1.768 −14.617 1.0016.86 C ATOM 832 N GLY C 104 −9.909 1.016 −13.152 1.00 17.81 C ATOM 833CA GLY C 104 −9.606 −0.366 −13.501 1.00 18.05 C ATOM 834 C GLY C 104−8.088 −0.603 −13.234 1.00 18.59 C ATOM 835 O GLY C 104 −7.583 −0.280−12.170 1.00 18.80 C ATOM 836 N THR C 105 −7.352 −1.083 −14.218 1.0018.58 C ATOM 837 CA THR C 105 −5.963 −1.423 −14.061 1.00 17.73 C ATOM838 CB THR C 105 −5.781 −2.686 −14.867 1.00 19.00 C ATOM 839 OG1 THR C105 −6.033 −3.777 −14.001 1.00 19.76 C ATOM 840 CG2 THR C 105 −4.489−2.848 −15.430 1.00 19.62 C ATOM 841 C THR C 105 −4.940 −0.279 −14.3861.00 18.86 C ATOM 842 O THR C 105 −3.725 −0.382 −14.108 1.00 17.71 CATOM 843 N ASN C 106 −5.450 0.825 −14.934 1.00 18.05 C ATOM 844 CA ASN C106 −4.671 2.012 −15.206 1.00 17.77 C ATOM 845 CB ASN C 106 −5.514 3.140−15.781 1.00 20.51 C ATOM 846 CG ASN C 106 −5.817 2.948 −17.216 1.0022.54 C ATOM 847 OD1 ASN C 106 −6.661 3.690 −17.843 1.00 23.63 C ATOM848 ND2 ASN C 106 −5.146 1.938 −17.791 1.00 23.46 C ATOM 849 C ASN C 106−4.090 2.649 −14.013 1.00 17.25 C ATOM 850 O ASN C 106 −4.651 3.511−13.468 1.00 14.62 C ATOM 851 N PHE C 107 −2.906 2.288 −13.659 1.0018.46 C ATOM 852 CA PHE C 107 −2.346 2.998 −12.509 1.00 19.89 C ATOM 853CB PHE C 107 −1.622 2.055 −11.575 1.00 19.98 C ATOM 854 CG PHE C 107−0.824 2.782 −10.557 1.00 19.62 C ATOM 855 CD1 PHE C 107 −1.475 3.471−9.536 1.00 19.36 C ATOM 856 CD2 PHE C 107 0.534 2.782 −10.608 1.0019.04 C ATOM 857 CE1 PHE C 107 −0.818 4.136 −8.601 1.00 19.11 C ATOM 858CE2 PHE C 107 1.265 3.448 −9.656 1.00 20.27 C ATOM 859 CZ PHE C 1070.566 4.130 −8.643 1.00 21.42 C ATOM 860 C PHE C 107 −1.348 4.084−12.989 1.00 20.78 C ATOM 861 O PHE C 107 −0.392 3.825 −13.772 1.0022.06 C ATOM 862 N GLN C 108 −1.529 5.298 −12.519 1.00 21.35 C ATOM 863CA GLN C 108 −0.649 6.398 −13.022 1.00 21.28 C ATOM 864 CB GLN C 108−1.498 7.442 −13.724 1.00 23.32 C ATOM 865 CG GLN C 108 −2.486 6.903−14.807 1.00 25.78 C ATOM 866 CD GLN C 108 −1.785 6.786 −16.145 1.0025.85 C ATOM 867 OE1 GLN C 108 −2.447 6.308 −17.091 1.00 29.58 C ATOM868 NE2 GLN C 108 −0.484 7.219 −16.254 1.00 21.35 C ATOM 869 C GLN C 108−0.031 7.128 −11.872 1.00 19.53 C ATOM 870 O GLN C 108 −0.701 8.041−11.329 1.00 19.54 C ATOM 871 N LYS C 109 1.191 6.790 −11.493 1.00 17.60C ATOM 872 CA LYS C 109 1.754 7.445 −10.256 1.00 17.03 C ATOM 873 CB LYSC 109 3.206 7.047 −10.021 1.00 16.95 C ATOM 874 CG LYS C 109 4.126 8.186−10.323 1.00 17.11 C ATOM 875 CD LYS C 109 5.549 7.735 −10.579 1.0018.36 C ATOM 876 CE LYS C 109 6.183 7.039 −9.391 1.00 18.42 C ATOM 877NZ LYS C 109 7.700 7.235 −9.639 1.00 19.07 C ATOM 878 C LYS C 109 1.6529.004 −10.297 1.00 16.60 C ATOM 879 O LYS C 109 1.364 9.638 −9.328 1.0016.33 C ATOM 880 N ARG C 110 1.815 9.587 −11.457 1.00 16.33 C ATOM 881CA ARG C 110 1.753 10.955 −11.531 1.00 15.92 C ATOM 882 CB ARG C 1102.175 11.355 −12.894 1.00 17.89 C ATOM 883 CG ARG C 110 3.663 11.535−12.862 1.00 20.69 C ATOM 884 CD ARG C 110 4.493 10.195 −12.977 1.0021.88 C ATOM 885 NE ARG C 110 5.921 10.471 −12.658 1.00 22.87 C ATOM 886CZ ARG C 110 6.421 10.787 −11.425 1.00 23.51 C ATOM 887 NH1 ARG C 1105.583 10.904 −10.319 1.00 22.39 C ATOM 888 NH2 ARG C 110 7.764 10.880−11.300 1.00 20.43 C ATOM 889 C ARG C 110 0.463 11.557 −11.156 1.0016.16 C ATOM 890 O ARG C 110 0.442 12.768 −10.913 1.00 14.92 C ATOM 891N LEU C 111 −0.583 10.706 −11.057 1.00 16.99 C ATOM 892 CA LEU C 111−1.977 11.126 −10.747 1.00 18.63 C ATOM 893 CB LEU C 111 −3.002 10.210−11.444 1.00 17.82 C ATOM 894 CG LEU C 111 −2.912 10.475 −12.965 1.0018.40 C ATOM 895 CD1 LEU C 111 −4.070 9.592 −13.642 1.00 19.34 C ATOM896 CD2 LEU C 111 −2.955 11.920 −13.409 1.00 12.31 C ATOM 897 C LEU C111 −2.195 11.189 −9.279 1.00 17.61 C ATOM 898 O LEU C 111 −3.019 11.916−8.816 1.00 20.04 C ATOM 899 N PHE C 112 −1.396 10.449 −8.561 1.00 17.22C ATOM 900 CA PHE C 112 −1.425 10.432 −7.097 1.00 16.36 C ATOM 901 CBPHE C 112 −0.866 9.103 −6.616 1.00 15.03 C ATOM 902 CG PHE C 112 −1.8258.007 −6.798 1.00 15.70 C ATOM 903 CD1 PHE C 112 −2.258 7.635 −8.0871.00 17.36 C ATOM 904 CD2 PHE C 112 −2.350 7.332 −5.667 1.00 16.44 CATOM 905 CE1 PHE C 112 −3.238 6.575 −8.265 1.00 16.99 C ATOM 906 CE2 PHEC 112 −3.300 6.296 −5.760 1.00 16.53 C ATOM 907 CZ PHE C 112 −3.7715.901 −7.081 1.00 17.72 C ATOM 908 C PHE C 112 −0.700 11.584 −6.387 1.0014.41 C ATOM 909 O PHE C 112 0.262 12.140 −6.855 1.00 14.04 C ATOM 910 NTHR C 113 −1.189 11.929 −5.225 1.00 14.82 C ATOM 911 CA THR C 113 −0.64012.974 −4.398 1.00 16.04 C ATOM 912 CB THR C 113 −1.725 13.885 −3.9321.00 15.19 C ATOM 913 OG1 THR C 113 −2.138 14.659 −5.045 1.00 15.56 CATOM 914 CG2 THR C 113 −1.266 14.802 −2.853 1.00 13.51 C ATOM 915 C THRC 113 −0.048 12.317 −3.209 1.00 16.12 C ATOM 916 O THR C 113 −0.62111.386 −2.657 1.00 17.22 C ATOM 917 N LYS C 114 1.115 12.785 −2.820 1.0015.60 C ATOM 918 CA LYS C 114 1.720 12.212 −1.619 1.00 16.33 C ATOM 919CB LYS C 114 3.220 12.571 −1.473 1.00 16.05 C ATOM 920 CG LYS C 1143.926 11.969 −0.260 1.00 15.39 C ATOM 921 CD LYS C 114 5.473 12.137−0.269 1.00 17.26 C ATOM 922 CE LYS C 114 6.073 11.587 1.093 1.00 18.39C ATOM 923 NZ LYS C 114 7.534 11.693 1.303 1.00 17.84 C ATOM 924 C LYS C114 0.939 12.700 −0.368 1.00 15.30 C ATOM 925 O LYS C 114 0.565 13.882−0.276 1.00 13.95 C ATOM 926 N ILE C 115 0.672 11.766 0.556 1.00 14.93 CATOM 927 CA ILE C 115 0.070 12.181 1.813 1.00 16.71 C ATOM 928 CB ILE C115 −0.872 11.184 2.381 1.00 16.08 C ATOM 929 CG2 ILE C 115 −1.16111.504 3.777 1.00 14.42 C ATOM 930 CG1 ILE C 115 −2.147 11.197 1.4851.00 17.47 C ATOM 931 CD1 ILE C 115 −3.112 10.001 1.568 1.00 14.68 CATOM 932 C ILE C 115 1.198 12.469 2.815 1.00 16.70 C ATOM 933 O ILE C115 1.193 13.590 3.402 1.00 17.46 C ATOM 934 N ASP C 116 2.160 11.5342.962 1.00 15.34 C ATOM 935 CA ASP C 116 3.214 11.688 3.922 1.00 15.16 CATOM 936 CB ASP C 116 2.565 11.631 5.337 1.00 16.72 C ATOM 937 CG ASP C116 3.507 11.967 6.518 1.00 18.35 C ATOM 938 OD1 ASP C 116 3.039 11.6857.657 1.00 20.63 C ATOM 939 OD2 ASP C 116 4.629 12.546 6.399 1.00 19.13C ATOM 940 C ASP C 116 4.165 10.546 3.824 1.00 14.13 C ATOM 941 O ASP C116 3.829 9.530 3.269 1.00 12.38 C ATOM 942 N THR C 117 5.352 10.7364.423 1.00 13.35 C ATOM 943 CA THR C 117 6.382 9.720 4.576 1.00 14.15 CATOM 944 CB THR C 117 7.749 10.346 4.842 1.00 14.06 C ATOM 945 OG1 THR C117 8.146 11.164 3.742 1.00 15.03 C ATOM 946 CG2 THR C 117 8.766 9.2955.153 1.00 10.20 C ATOM 947 C THR C 117 5.984 8.862 5.851 1.00 14.73 CATOM 948 O THR C 117 5.722 9.431 6.877 1.00 14.43 C ATOM 949 N ILE C 1185.897 7.528 5.744 1.00 14.43 C ATOM 950 CA ILE C 118 5.584 6.689 6.8561.00 14.79 C ATOM 951 CB ILE C 118 4.711 5.525 6.393 1.00 13.52 C ATOM952 CG2 ILE C 118 4.368 4.585 7.553 1.00 10.20 C ATOM 953 CG1 ILE C 1183.485 6.138 5.677 1.00 13.33 C ATOM 954 CD1 ILE C 118 2.715 7.304 6.3261.00 10.59 C ATOM 955 C ILE C 118 6.905 6.192 7.507 1.00 16.12 C ATOM956 O ILE C 118 7.762 5.635 6.851 1.00 16.34 C ATOM 957 N ALA C 1197.087 6.400 8.798 1.00 15.22 C ATOM 958 CA ALA C 119 8.319 5.994 9.3841.00 15.08 C ATOM 959 CB ALA C 119 9.107 7.202 9.723 1.00 14.05 C ATOM960 C ALA C 119 8.078 5.127 10.607 1.00 15.05 C ATOM 961 O ALA C 1197.129 5.318 11.314 1.00 14.96 C ATOM 962 N PRO C 120 8.904 4.098 10.8271.00 13.67 C ATOM 963 CD PRO C 120 9.971 3.513 9.999 1.00 13.16 C ATOM964 CA PRO C 120 8.667 3.279 12.001 1.00 13.68 C ATOM 965 CB PRO C 1209.373 1.965 11.653 1.00 13.97 C ATOM 966 CG PRO C 120 10.542 2.44510.918 1.00 12.91 C ATOM 967 C PRO C 120 9.261 3.881 13.313 1.00 14.60 CATOM 968 O PRO C 120 10.363 4.385 13.363 1.00 13.32 C ATOM 969 N ASP C121 8.485 3.769 14.377 1.00 16.21 C ATOM 970 CA ASP C 121 8.896 4.20615.656 1.00 17.91 C ATOM 971 CB ASP C 121 7.738 4.225 16.561 1.00 20.47C ATOM 972 CG ASP C 121 6.647 4.925 15.961 1.00 23.77 C ATOM 973 OD1 ASPC 121 6.090 4.302 14.857 1.00 27.96 C ATOM 974 OD2 ASP C 121 6.331 6.07816.524 1.00 22.54 C ATOM 975 C ASP C 121 9.867 3.212 16.163 1.00 17.96 CATOM 976 O ASP C 121 10.600 3.535 17.059 1.00 18.85 C ATOM 977 N GLU C122 9.864 2.037 15.562 1.00 17.75 C ATOM 978 CA GLU C 122 10.676 0.95115.999 1.00 17.87 C ATOM 979 CB GLU C 122 9.970 0.156 17.070 1.00 18.40C ATOM 980 CG GLU C 122 9.711 0.846 18.383 1.00 21.02 C ATOM 981 CD GLUC 122 9.368 −0.224 19.512 1.00 24.88 C ATOM 982 OE1 GLU C 122 8.172−0.711 19.571 1.00 23.80 C ATOM 983 OE2 GLU C 122 10.336 −0.622 20.3341.00 27.42 C ATOM 984 C GLU C 122 11.075 −0.022 14.900 1.00 17.91 C ATOM985 O GLU C 122 10.316 −0.863 14.417 1.00 17.57 C ATOM 986 N ILE C 12312.335 0.064 14.571 1.00 17.91 C ATOM 987 CA ILE C 123 12.863 −0.68313.527 1.00 18.35 C ATOM 988 CB ILE C 123 14.144 0.005 13.151 1.00 20.03C ATOM 989 CG2 ILE C 123 15.060 0.171 14.414 1.00 20.64 C ATOM 990 CG1ILE C 123 14.926 −0.887 12.194 1.00 21.95 C ATOM 991 CD1 ILE C 12316.340 −0.245 11.974 1.00 24.39 C ATOM 992 C ILE C 123 13.060 −2.05814.054 1.00 18.60 C ATOM 993 O ILE C 123 13.309 −2.157 15.203 1.00 18.92C ATOM 994 N THR C 124 12.955 −3.137 13.277 1.00 17.58 C ATOM 995 CA THRC 124 13.211 −4.456 13.911 1.00 16.37 C ATOM 996 CB THR C 124 12.405−5.571 13.220 1.00 15.20 C ATOM 997 OG1 THR C 124 11.032 −5.459 13.5451.00 16.03 C ATOM 998 CG2 THR C 124 12.806 −6.901 13.661 1.00 12.84 CATOM 999 C THR C 124 14.675 −4.809 13.759 1.00 15.64 C ATOM 1000 O THR C124 15.173 −4.844 12.638 1.00 17.40 C ATOM 1001 N VAL C 125 15.397−5.103 14.804 1.00 14.78 C ATOM 1002 CA VAL C 125 16.851 −5.376 14.5441.00 14.89 C ATOM 1003 CB VAL C 125 17.901 −4.802 15.665 1.00 12.90 CATOM 1004 CG1 VAL C 125 17.999 −3.280 15.513 1.00 12.50 C ATOM 1005 CG2VAL C 125 17.526 −5.280 17.071 1.00 7.31 C ATOM 1006 C VAL C 125 17.140−6.828 14.433 1.00 12.40 C ATOM 1007 O VAL C 125 16.341 −7.608 14.8141.00 11.55 C ATOM 1008 N SER C 126 18.310 −7.125 13.922 1.00 12.82 CATOM 1009 CA SER C 126 18.729 −8.470 13.729 1.00 15.48 C ATOM 1010 CBSER C 126 20.166 −8.530 13.330 1.00 15.12 C ATOM 1011 OG SER C 12620.670 −9.724 13.803 1.00 16.64 C ATOM 1012 C SER C 126 18.513 −9.41814.888 1.00 15.96 C ATOM 1013 O SER C 126 18.022 −10.554 14.699 1.0016.98 C ATOM 1014 N SER C 127 18.804 −9.021 16.089 1.00 16.15 C ATOM1015 CA SER C 127 18.607 −9.977 17.114 1.00 16.97 C ATOM 1016 CB SER C127 19.433 −9.596 18.302 1.00 18.26 C ATOM 1017 OG SER C 127 18.923−8.342 18.847 1.00 18.77 C ATOM 1018 C SER C 127 17.186 −10.086 17.5491.00 16.94 C ATOM 1019 O SER C 127 16.907 −10.972 18.348 1.00 16.88 CATOM 1020 N ASP C 128 16.326 −9.150 17.089 1.00 17.11 C ATOM 1021 CA ASPC 128 14.866 −9.095 17.322 1.00 16.94 C ATOM 1022 CB ASP C 128 14.252−7.854 16.657 1.00 19.22 C ATOM 1023 CG ASP C 128 14.345 −6.675 17.4981.00 20.29 C ATOM 1024 OD1 ASP C 128 14.171 −5.536 16.992 1.00 18.82 CATOM 1025 OD2 ASP C 128 14.613 −6.956 18.691 1.00 22.88 C ATOM 1026 CASP C 128 14.153 −10.289 16.795 1.00 15.76 C ATOM 1027 O ASP C 12813.204 −10.757 17.424 1.00 14.59 C ATOM 1028 N PHE C 129 14.576 −10.75615.634 1.00 16.85 C ATOM 1029 CA PHE C 129 13.981 −12.047 15.098 1.0019.44 C ATOM 1030 CB PHE C 129 14.496 −12.320 13.657 1.00 17.91 C ATOM1031 CG PHE C 129 14.135 −11.171 12.704 1.00 17.50 C ATOM 1032 CD1 PHE C129 15.042 −10.156 12.423 1.00 16.43 C ATOM 1033 CD2 PHE C 129 12.825−11.092 12.164 1.00 17.70 C ATOM 1034 CE1 PHE C 129 14.644 −9.106 11.6221.00 16.15 C ATOM 1035 CE2 PHE C 129 12.427 −10.034 11.353 1.00 17.36 CATOM 1036 CZ PHE C 129 13.318 −9.055 11.081 1.00 16.61 C ATOM 1037 C PHEC 129 14.608 −12.883 16.094 1.00 18.93 C ATOM 1038 O PHE C 129 15.124−12.347 17.055 1.00 22.39 C ATOM 1039 N GLU C 130 14.576 −14.168 16.0311.00 19.21 C ATOM 1040 CA GLU C 130 15.421 −14.921 17.095 1.00 19.34 CATOM 1041 CB GLU C 130 16.878 −14.462 17.117 1.00 17.61 C ATOM 1042 CGGLU C 130 17.850 −15.455 16.393 1.00 20.72 C ATOM 1043 CD GLU C 13019.365 −15.257 16.801 1.00 22.99 C ATOM 1044 OE1 GLU C 130 20.086−16.272 16.743 1.00 27.11 C ATOM 1045 OE2 GLU C 130 19.872 −14.14817.203 1.00 23.98 C ATOM 1046 C GLU C 130 14.833 −14.733 18.468 1.0017.85 C ATOM 1047 O GLU C 130 14.485 −15.667 19.111 1.00 17.80 C ATOM1048 N ALA C 131 14.796 −13.513 18.914 1.00 18.18 C ATOM 1049 CA ALA C131 14.100 −13.221 20.100 1.00 20.17 C ATOM 1050 CB ALA C 131 14.516−11.897 20.555 1.00 18.74 C ATOM 1051 C ALA C 131 12.714 −13.133 19.3831.00 21.44 C ATOM 1052 O ALA C 131 12.678 −13.020 18.111 1.00 23.59 CATOM 1053 N ARG C 132 11.565 −13.167 20.037 1.00 20.71 C ATOM 1054 CAARG C 132 10.445 −13.093 19.110 1.00 20.05 C ATOM 1055 CB ARG C 1329.402 −14.170 19.390 1.00 20.95 C ATOM 1056 CG ARG C 132 9.466 −15.39118.338 1.00 22.36 C ATOM 1057 CD ARG C 132 10.856 −16.007 17.969 1.0019.04 C ATOM 1058 NE ARG C 132 10.696 −17.249 17.181 1.00 17.98 C ATOM1059 CZ ARG C 132 11.404 −17.553 16.094 1.00 16.18 C ATOM 1060 NH1 ARG C132 12.284 −16.709 15.670 1.00 17.02 C ATOM 1061 NH2 ARG C 132 11.289−18.685 15.444 1.00 15.79 C ATOM 1062 C ARG C 132 9.871 −11.741 19.2331.00 20.40 C ATOM 1063 O ARG C 132 8.662 −11.561 19.379 1.00 19.61 CATOM 1064 N HIS C 133 10.727 −10.760 19.089 1.00 19.25 C ATOM 1065 CAHIS C 133 10.248 −9.438 19.340 1.00 18.99 C ATOM 1066 CB HIS C 13311.194 −8.721 20.346 1.00 20.52 C ATOM 1067 CG HIS C 133 11.339 −9.40621.674 1.00 22.22 C ATOM 1068 CD2 HIS C 133 10.805 −10.568 22.162 1.0022.76 C ATOM 1069 ND1 HIS C 133 12.011 −8.804 22.722 1.00 23.05 C ATOM1070 CE1 HIS C 133 11.869 −9.558 23.811 1.00 23.50 C ATOM 1071 NE2 HIS C133 11.142 −10.634 23.500 1.00 23.71 C ATOM 1072 C HIS C 133 10.190−8.639 18.117 1.00 19.04 C ATOM 1073 O HIS C 133 10.863 −7.604 18.0291.00 18.89 C ATOM 1074 N VAL C 134 9.405 −9.059 17.139 1.00 18.94 C ATOM1075 CA VAL C 134 9.383 −8.243 15.938 1.00 19.11 C ATOM 1076 CB VAL C134 8.788 −8.993 14.801 1.00 19.31 C ATOM 1077 CG1 VAL C 134 8.843−8.135 13.548 1.00 18.74 C ATOM 1078 CG2 VAL C 134 9.645 −10.165 14.5801.00 20.64 C ATOM 1079 C VAL C 134 8.617 −6.982 16.219 1.00 18.47 C ATOM1080 O VAL C 134 7.635 −7.045 16.885 1.00 18.73 C ATOM 1081 N LYS C 1359.027 −5.844 15.712 1.00 18.50 C ATOM 1082 CA LYS C 135 8.337 −4.59916.068 1.00 18.59 C ATOM 1083 CB LYS C 135 9.391 −3.507 16.323 1.0018.68 C ATOM 1084 CG LYS C 135 10.630 −4.004 17.112 1.00 18.29 C ATOM1085 CD LYS C 135 10.223 −4.466 18.519 1.00 18.52 C ATOM 1086 CE LYS C135 11.394 −4.339 19.441 1.00 19.17 C ATOM 1087 NZ LYS C 135 11.049−5.140 20.613 1.00 21.80 C ATOM 1088 C LYS C 135 7.320 −4.076 15.0751.00 18.01 C ATOM 1089 O LYS C 135 7.628 −3.674 13.918 1.00 17.93 C ATOM1090 N LEU C 136 6.111 −4.086 15.575 1.00 16.80 C ATOM 1091 CA LEU C 1364.893 −3.714 14.896 1.00 16.57 C ATOM 1092 CB LEU C 136 3.835 −4.72515.373 1.00 15.74 C ATOM 1093 CG LEU C 136 2.580 −4.743 14.585 1.0016.98 C ATOM 1094 CD1 LEU C 136 1.866 −3.552 15.056 1.00 20.09 C ATOM1095 CD2 LEU C 136 2.757 −4.722 13.063 1.00 15.42 C ATOM 1096 C LEU C136 4.564 −2.205 15.184 1.00 16.88 C ATOM 1097 O LEU C 136 4.283 −1.78516.293 1.00 16.37 C ATOM 1098 N ASN C 137 4.659 −1.405 14.162 1.00 16.58C ATOM 1099 CA ASN C 137 4.368 −0.023 14.256 1.00 16.46 C ATOM 1100 CBASN C 137 5.291 0.701 13.355 1.00 17.29 C ATOM 1101 CG ASN C 137 6.6990.633 13.813 1.00 18.26 C ATOM 1102 OD1 ASN C 137 7.166 1.395 14.7101.00 14.12 C ATOM 1103 ND2 ASN C 137 7.439 −0.268 13.143 1.00 18.71 CATOM 1104 C ASN C 137 2.935 0.338 13.791 1.00 17.10 C ATOM 1105 O ASN C137 2.379 −0.300 12.838 1.00 16.99 C ATOM 1106 N VAL C 138 2.331 1.36814.417 1.00 15.92 C ATOM 1107 CA VAL C 138 0.990 1.780 13.998 1.00 14.40C ATOM 1108 CB VAL C 138 −0.019 1.695 15.096 1.00 14.26 C ATOM 1109 CG1VAL C 138 −1.307 2.137 14.586 1.00 12.91 C ATOM 1110 CG2 VAL C 138−0.079 0.298 15.652 1.00 14.68 C ATOM 1111 C VAL C 138 1.096 3.18613.550 1.00 15.51 C ATOM 1112 O VAL C 138 1.618 3.990 14.285 1.00 15.05C ATOM 1113 N GLU C 139 0.665 3.480 12.329 1.00 15.47 C ATOM 1114 CA GLUC 139 0.758 4.842 11.868 1.00 17.22 C ATOM 1115 CB GLU C 139 1.892 5.03110.866 1.00 16.43 C ATOM 1116 CG GLU C 139 3.328 5.152 11.459 1.00 14.63C ATOM 1117 CD GLU C 139 3.525 6.271 12.462 1.00 11.48 C ATOM 1118 OE1GLU C 139 2.812 7.222 12.366 1.00 10.36 C ATOM 1119 OE2 GLU C 139 4.4046.176 13.285 1.00 10.49 C ATOM 1120 C GLU C 139 −0.532 5.294 11.222 1.0018.19 C ATOM 1121 O GLU C 139 −1.016 4.633 10.284 1.00 19.36 C ATOM 1122N GLU C 140 −1.116 6.385 11.694 1.00 16.67 C ATOM 1123 CA GLU C 140−2.371 6.832 11.124 1.00 15.97 C ATOM 1124 CB GLU C 140 −3.475 6.89012.162 1.00 18.08 C ATOM 1125 CG GLU C 140 −4.802 7.308 11.564 1.0020.03 C ATOM 1126 CD GLU C 140 −6.042 6.829 12.412 1.00 22.88 C ATOM1127 OE1 GLU C 140 −6.496 7.661 13.297 1.00 23.16 C ATOM 1128 OE2 GLU C140 −6.544 5.636 12.199 1.00 21.79 C ATOM 1129 C GLU C 140 −2.265 8.15310.507 1.00 14.69 C ATOM 1130 O GLU C 140 −1.588 9.011 11.022 1.00 14.14C ATOM 1131 N ARG C 141 −2.898 8.346 9.371 1.00 12.49 C ATOM 1132 CA ARGC 141 −2.788 9.666 8.798 1.00 12.49 C ATOM 1133 CB ARG C 141 −1.8309.778 7.625 1.00 12.74 C ATOM 1134 CG ARG C 141 −0.396 9.431 7.802 1.0013.13 C ATOM 1135 CD ARG C 141 0.582 10.531 8.077 1.00 10.46 C ATOM 1136NE ARG C 141 1.150 10.038 9.254 1.00 11.34 C ATOM 1137 CZ ARG C 1412.300 9.443 9.419 1.00 10.91 C ATOM 1138 NH1 ARG C 141 3.143 9.272 8.5101.00 13.01 C ATOM 1139 NH2 ARG C 141 2.474 8.757 10.497 1.00 11.47 CATOM 1140 C ARG C 141 −4.129 9.957 8.338 1.00 11.65 C ATOM 1141 O ARG C141 −4.958 9.159 8.529 1.00 9.33 C ATOM 1142 N SER C 142 −4.315 11.0837.683 1.00 13.04 C ATOM 1143 CA SER C 142 −5.632 11.479 7.265 1.00 15.38C ATOM 1144 CB SER C 142 −6.442 11.975 8.456 1.00 17.13 C ATOM 1145 OGSER C 142 −6.341 13.383 8.533 1.00 23.20 C ATOM 1146 C SER C 142 −5.61812.507 6.177 1.00 15.69 C ATOM 1147 O SER C 142 −4.673 13.275 5.988 1.0015.02 C ATOM 1148 N VAL C 143 −6.688 12.495 5.400 1.00 16.53 C ATOM 1149CA VAL C 143 −6.673 13.388 4.286 1.00 16.86 C ATOM 1150 CB VAL C 143−5.827 12.708 3.084 1.00 19.58 C ATOM 1151 CG1 VAL C 143 −6.419 11.3872.573 1.00 20.57 C ATOM 1152 CG2 VAL C 143 −5.766 13.671 1.939 1.0022.25 C ATOM 1153 C VAL C 143 −8.058 13.846 3.911 1.00 15.79 C ATOM 1154O VAL C 143 −9.055 13.274 4.341 1.00 15.61 C ATOM 1155 N GLY C 144−8.117 14.952 3.189 1.00 14.79 C ATOM 1156 CA GLY C 144 −9.395 15.4822.830 1.00 13.21 C ATOM 1157 C GLY C 144 −9.428 16.973 2.789 1.00 13.26C ATOM 1158 O GLY C 144 −8.384 17.552 2.995 1.00 11.03 C ATOM 1159 N PROC 145 −10.609 17.604 2.496 1.00 15.31 C ATOM 1160 CD PRO C 145 −10.93719.046 2.512 1.00 13.87 C ATOM 1161 CA PRO C 145 −11.818 16.816 2.2231.00 15.80 C ATOM 1162 CB PRO C 145 −12.915 17.833 2.328 1.00 15.43 CATOM 1163 CG PRO C 145 −12.274 19.082 1.952 1.00 13.64 C ATOM 1164 C PROC 145 −11.867 16.130 0.873 1.00 18.60 C ATOM 1165 O PRO C 145 −11.42716.680 −0.187 1.00 21.50 C ATOM 1166 N LEU C 146 −12.381 14.908 0.8931.00 19.39 C ATOM 1167 CA LEU C 146 −12.606 14.111 −0.351 1.00 18.25 CATOM 1168 CB LEU C 146 −12.741 12.651 0.040 1.00 16.86 C ATOM 1169 CGLEU C 146 −11.410 11.862 −0.009 1.00 16.11 C ATOM 1170 CD1 LEU C 146−10.321 12.665 0.401 1.00 16.87 C ATOM 1171 CD2 LEU C 146 −11.499 10.5970.774 1.00 13.50 C ATOM 1172 C LEU C 146 −13.882 14.682 −0.942 1.0017.64 C ATOM 1173 O LEU C 146 −14.709 15.223 −0.201 1.00 18.04 C ATOM1174 N THR C 147 −14.009 14.633 −2.250 1.00 17.08 C ATOM 1175 CA THR C147 −15.231 15.109 −2.921 1.00 16.67 C ATOM 1176 CB THR C 147 −15.07016.528 −3.516 1.00 15.26 C ATOM 1177 OG1 THR C 147 −14.069 16.495 −4.5681.00 15.39 C ATOM 1178 CG2 THR C 147 −14.761 17.514 −2.467 1.00 12.84 CATOM 1179 C THR C 147 −15.738 14.229 −4.112 1.00 16.65 C ATOM 1180 O THRC 147 −16.826 14.425 −4.492 1.00 17.31 C ATOM 1181 N ARG C 148 −14.93213.316 −4.683 1.00 16.30 C ATOM 1182 CA ARG C 148 −15.300 12.522 −5.8341.00 15.65 C ATOM 1183 CB ARG C 148 −14.081 12.114 −6.654 1.00 16.33 CATOM 1184 CG ARG C 148 −13.103 13.229 −6.804 1.00 16.53 C ATOM 1185 CDARG C 148 −13.467 14.244 −7.845 1.00 16.51 C ATOM 1186 NE ARG C 148−14.265 15.300 −7.266 1.00 18.28 C ATOM 1187 CZ ARG C 148 −15.378 15.770−7.830 1.00 19.65 C ATOM 1188 NH1 ARG C 148 −15.815 15.261 −8.959 1.0018.97 C ATOM 1189 NH2 ARG C 148 −16.053 16.762 −7.280 1.00 18.92 C ATOM1190 C ARG C 148 −16.070 11.289 −5.440 1.00 14.87 C ATOM 1191 O ARG C148 −16.195 10.981 −4.276 1.00 13.89 C ATOM 1192 N LYS C 149 −16.52910.551 −6.425 1.00 14.82 C ATOM 1193 CA LYS C 149 −17.332 9.391 −6.1611.00 15.19 C ATOM 1194 CB LYS C 149 −17.806 8.838 −7.486 1.00 16.32 CATOM 1195 CG LYS C 149 −19.073 7.962 −7.516 1.00 17.87 C ATOM 1196 CDLYS C 149 −19.334 7.378 −8.986 1.00 20.75 C ATOM 1197 CE LYS C 149−20.288 6.173 −8.961 1.00 22.45 C ATOM 1198 NZ LYS C 149 −19.765 4.816−9.600 1.00 24.66 C ATOM 1199 C LYS C 149 −16.466 8.422 −5.437 1.0014.88 C ATOM 1200 O LYS C 149 −16.930 7.686 −4.620 1.00 15.41 C ATOM1201 N GLY C 150 −15.181 8.433 −5.759 1.00 14.10 C ATOM 1202 CA GLY C150 −14.273 7.544 −5.095 1.00 12.16 C ATOM 1203 C GLY C 150 −12.7897.935 −4.982 1.00 10.99 C ATOM 1204 O GLY C 150 −12.402 9.020 −5.3491.00 9.42 C ATOM 1205 N PHE C 151 −12.015 6.996 −4.452 1.00 10.22 C ATOM1206 CA PHE C 151 −10.655 7.183 −4.256 1.00 11.34 C ATOM 1207 CB PHE C151 −10.497 8.108 −3.042 1.00 12.39 C ATOM 1208 CG PHE C 151 −10.7577.434 −1.742 1.00 13.49 C ATOM 1209 CD1 PHE C 151 −9.726 6.677 −1.0851.00 14.82 C ATOM 1210 CD2 PHE C 151 −12.004 7.409 −1.200 1.00 12.88 CATOM 1211 CE1 PHE C 151 −10.024 5.945 0.049 1.00 13.30 C ATOM 1212 CE2PHE C 151 −12.240 6.690 −0.097 1.00 11.97 C ATOM 1213 CZ PHE C 151−11.270 5.962 0.524 1.00 12.66 C ATOM 1214 C PHE C 151 −9.788 5.903−4.104 1.00 10.68 C ATOM 1215 O PHE C 151 −10.229 4.792 −3.808 1.00 8.97C ATOM 1216 N TYR C 152 −8.504 6.135 −4.277 1.00 12.40 C ATOM 1217 CATYR C 152 −7.502 5.081 −4.170 1.00 15.55 C ATOM 1218 CB TYR C 152 −6.7694.789 −5.515 1.00 16.45 C ATOM 1219 CG TYR C 152 −7.561 4.258 −6.6481.00 16.56 C ATOM 1220 CD1 TYR C 152 −8.128 5.100 −7.554 1.00 16.73 CATOM 1221 CE1 TYR C 152 −8.953 4.650 −8.608 1.00 17.90 C ATOM 1222 CD2TYR C 152 −7.782 2.917 −6.772 1.00 17.59 C ATOM 1223 CE2 TYR C 152−8.587 2.422 −7.800 1.00 17.82 C ATOM 1224 CZ TYR C 152 −9.185 3.321−8.752 1.00 18.54 C ATOM 1225 OH TYR C 152 −9.925 2.916 −9.917 1.0018.81 C ATOM 1226 C TYR C 152 −6.446 5.535 −3.156 1.00 14.75 C ATOM 1227O TYR C 152 −6.138 6.720 −2.949 1.00 13.40 C ATOM 1228 N LEU C 153−5.901 4.506 −2.570 1.00 15.80 C ATOM 1229 CA LEU C 153 −4.775 4.630−1.711 1.00 17.48 C ATOM 1230 CB LEU C 153 −5.082 4.004 −0.379 1.0016.77 C ATOM 1231 CG LEU C 153 −5.108 5.033 0.767 1.00 16.27 C ATOM 1232CD1 LEU C 153 −5.999 6.219 0.533 1.00 13.82 C ATOM 1233 CD2 LEU C 153−5.514 4.235 1.942 1.00 15.52 C ATOM 1234 C LEU C 153 −3.619 3.839−2.415 1.00 17.30 C ATOM 1235 O LEU C 153 −3.865 2.841 −3.127 1.00 18.68C ATOM 1236 N ALA C 154 −2.376 4.319 −2.247 1.00 16.79 C ATOM 1237 CAALA C 154 −1.224 3.671 −2.828 1.00 15.00 C ATOM 1238 CB ALA C 154 −0.9754.254 −4.284 1.00 13.77 C ATOM 1239 C ALA C 154 0.020 3.821 −1.901 1.0013.98 C ATOM 1240 O ALA C 154 0.172 4.734 −1.146 1.00 12.97 C ATOM 1241N PHE C 155 0.896 2.870 −2.042 1.00 15.24 C ATOM 1242 CA PHE C 155 2.0962.767 −1.330 1.00 16.11 C ATOM 1243 CB PHE C 155 1.993 1.624 −0.308 1.0016.37 C ATOM 1244 CG PHE C 155 0.732 1.641 0.473 1.00 15.83 C ATOM 1245CD1 PHE C 155 −0.372 1.068 −0.020 1.00 16.52 C ATOM 1246 CD2 PHE C 1550.700 2.187 1.762 1.00 14.95 C ATOM 1247 CE1 PHE C 155 −1.498 1.0080.768 1.00 17.05 C ATOM 1248 CE2 PHE C 155 −0.405 2.162 2.585 1.00 14.86C ATOM 1249 CZ PHE C 155 −1.487 1.587 2.126 1.00 17.75 C ATOM 1250 C PHEC 155 3.332 2.595 −2.190 1.00 14.69 C ATOM 1251 O PHE C 155 3.474 1.658−3.008 1.00 15.30 C ATOM 1252 N GLN C 156 4.237 3.540 −1.979 1.00 14.37C ATOM 1253 CA GLN C 156 5.478 3.558 −2.698 1.00 13.82 C ATOM 1254 CBGLN C 156 5.686 4.928 −3.276 1.00 14.37 C ATOM 1255 CG GLN C 156 6.8034.896 −4.183 1.00 16.30 C ATOM 1256 CD GLN C 156 7.477 6.270 −4.211 1.0019.36 C ATOM 1257 OE1 GLN C 156 7.073 7.159 −3.449 1.00 22.97 C ATOM1258 NE2 GLN C 156 8.469 6.480 −5.085 1.00 18.07 C ATOM 1259 C GLN C 1566.662 3.066 −1.849 1.00 12.04 C ATOM 1260 O GLN C 156 6.924 3.583 −0.8131.00 9.77 C ATOM 1261 N ASP C 157 7.284 1.960 −2.285 1.00 12.99 C ATOM1262 CA ASP C 157 8.439 1.437 −1.628 1.00 13.12 C ATOM 1263 CB ASP C 1578.463 0.004 −1.606 1.00 13.69 C ATOM 1264 CG ASP C 157 9.772 −0.507−1.371 1.00 14.74 C ATOM 1265 OD1 ASP C 157 10.255 −1.142 −2.309 1.0019.26 C ATOM 1266 OD2 ASP C 157 10.373 −0.346 −0.321 1.00 12.98 C ATOM1267 C ASP C 157 9.593 1.996 −2.398 1.00 15.54 C ATOM 1268 O ASP C 1579.641 2.043 −3.617 1.00 15.20 C ATOM 1269 N ILE C 158 10.523 2.510−1.619 1.00 17.08 C ATOM 1270 CA ILE C 158 11.632 3.195 −2.112 1.0016.04 C ATOM 1271 CB ILE C 158 11.574 4.599 −1.477 1.00 18.55 C ATOM1272 CG2 ILE C 158 12.598 4.831 −0.309 1.00 18.76 C ATOM 1273 CG1 ILE C158 11.654 5.595 −2.595 1.00 19.12 C ATOM 1274 CD1 ILE C 158 10.3765.838 −3.161 1.00 19.37 C ATOM 1275 C ILE C 158 12.868 2.424 −1.873 1.0016.72 C ATOM 1276 O ILE C 158 13.964 2.894 −2.158 1.00 16.75 C ATOM 1277N GLY C 159 12.734 1.163 −1.500 1.00 15.75 C ATOM 1278 CA GLY C 15913.979 0.451 −1.213 1.00 14.22 C ATOM 1279 C GLY C 159 14.170 −0.0050.257 1.00 13.55 C ATOM 1280 O GLY C 159 15.274 −0.298 0.691 1.00 13.37C ATOM 1281 N ALA C 160 13.076 −0.063 0.995 1.00 12.98 C ATOM 1282 CAALA C 160 13.070 −0.478 2.372 1.00 14.02 C ATOM 1283 CB ALA C 160 12.1300.324 3.137 1.00 11.02 C ATOM 1284 C ALA C 160 12.610 −1.902 2.386 1.0015.55 C ATOM 1285 O ALA C 160 12.159 −2.414 1.376 1.00 17.74 C ATOM 1286N CYS C 161 12.764 −2.572 3.519 1.00 15.31 C ATOM 1287 CA CYS C 16112.301 −3.928 3.713 1.00 13.33 C ATOM 1288 C CYS C 161 11.128 −3.7574.711 1.00 14.35 C ATOM 1289 O CYS C 161 11.271 −3.767 5.942 1.00 12.41C ATOM 1290 CB CYS C 161 13.370 −4.707 4.360 1.00 13.85 C ATOM 1291 SGCYS C 161 13.204 −6.501 4.441 1.00 15.17 C ATOM 1292 N VAL C 162 9.953−3.588 4.126 1.00 14.84 C ATOM 1293 CA VAL C 162 8.730 −3.386 4.852 1.0015.10 C ATOM 1294 CB VAL C 162 7.900 −2.192 4.301 1.00 16.83 C ATOM 1295CG1 VAL C 162 6.952 −1.666 5.347 1.00 17.71 C ATOM 1296 CG2 VAL C 1628.767 −1.142 3.768 1.00 16.83 C ATOM 1297 C VAL C 162 7.752 −4.542 4.7431.00 15.20 C ATOM 1298 O VAL C 162 7.612 −5.183 3.701 1.00 14.43 C ATOM1299 N ALA C 163 6.998 −4.715 5.823 1.00 15.44 C ATOM 1300 CA ALA C 1635.911 −5.708 5.815 1.00 16.00 C ATOM 1301 CB ALA C 163 6.240 −6.8656.768 1.00 15.45 C ATOM 1302 C ALA C 163 4.602 −4.989 6.189 1.00 15.74 CATOM 1303 O ALA C 163 4.355 −4.657 7.347 1.00 17.21 C ATOM 1304 N LEU C164 3.771 −4.702 5.224 1.00 14.86 C ATOM 1305 CA LEU C 164 2.589 −4.0295.601 1.00 14.15 C ATOM 1306 CB LEU C 164 2.167 −3.143 4.446 1.00 14.73C ATOM 1307 CG LEU C 164 1.013 −2.152 4.751 1.00 16.19 C ATOM 1308 CD1LEU C 164 1.303 −1.263 5.898 1.00 15.73 C ATOM 1309 CD2 LEU C 164 0.687−1.305 3.493 1.00 16.58 C ATOM 1310 C LEU C 164 1.530 −5.024 6.017 1.0014.06 C ATOM 1311 O LEU C 164 0.945 −5.713 5.233 1.00 13.78 C ATOM 1312N LEU C 165 1.249 −5.141 7.287 1.00 14.72 C ATOM 1313 CA LEU C 165 0.241−6.098 7.685 1.00 14.71 C ATOM 1314 CB LEU C 165 0.676 −6.678 8.983 1.0017.36 C ATOM 1315 CG LEU C 165 2.191 −6.783 9.134 1.00 19.08 C ATOM 1316CD1 LEU C 165 2.505 −7.270 10.574 1.00 20.83 C ATOM 1317 CD2 LEU C 1652.650 −7.759 8.125 1.00 18.59 C ATOM 1318 C LEU C 165 −1.185 −5.5987.868 1.00 13.83 C ATOM 1319 O LEU C 165 −2.099 −6.348 8.204 1.00 13.10C ATOM 1320 N SER C 166 −1.413 −4.324 7.714 1.00 13.38 C ATOM 1321 CASER C 166 −2.770 −3.861 7.984 1.00 14.28 C ATOM 1322 CB SER C 166 −3.070−3.821 9.530 1.00 14.83 C ATOM 1323 OG SER C 166 −4.363 −3.423 9.7941.00 15.81 C ATOM 1324 C SER C 166 −3.000 −2.514 7.391 1.00 12.48 C ATOM1325 O SER C 166 −2.093 −1.658 7.421 1.00 11.92 C ATOM 1326 N VAL C 167−4.177 −2.350 6.802 1.00 11.32 C ATOM 1327 CA VAL C 167 −4.498 −1.0886.223 1.00 11.82 C ATOM 1328 CB VAL C 167 −4.408 −1.133 4.735 1.00 12.98C ATOM 1329 CG1 VAL C 167 −4.779 0.255 4.082 1.00 14.70 C ATOM 1330 CG2VAL C 167 −3.137 −1.590 4.360 1.00 13.51 C ATOM 1331 C VAL C 167 −5.916−0.831 6.557 1.00 12.08 C ATOM 1332 O VAL C 167 −6.744 −1.523 5.981 1.008.67 C ATOM 1333 N ARG C 168 −6.212 0.099 7.520 1.00 13.23 C ATOM 1334CA ARG C 168 −7.628 0.397 7.800 1.00 15.58 C ATOM 1335 CB ARG C 168−8.096 0.278 9.225 1.00 17.24 C ATOM 1336 CG ARG C 168 −8.951 −0.9409.407 1.00 18.34 C ATOM 1337 CD ARG C 168 −9.865 −0.944 10.642 1.0019.27 C ATOM 1338 NE ARG C 168 −9.636 0.244 11.473 1.00 20.09 C ATOM1339 CZ ARG C 168 −10.609 0.799 12.205 1.00 20.67 C ATOM 1340 NH1 ARG C168 −11.875 0.266 12.193 1.00 17.38 C ATOM 1341 NH2 ARG C 168 −10.2871.842 12.963 1.00 20.84 C ATOM 1342 C ARG C 168 −7.879 1.754 7.351 1.0016.98 C ATOM 1343 O ARG C 168 −6.957 2.579 7.503 1.00 17.76 C ATOM 1344N VAL C 169 −9.088 1.951 6.730 1.00 16.72 C ATOM 1345 CA VAL C 169−9.591 3.252 6.205 1.00 15.30 C ATOM 1346 CB VAL C 169 −9.706 3.3264.683 1.00 14.52 C ATOM 1347 CG1 VAL C 169 −10.179 4.738 4.252 1.0013.37 C ATOM 1348 CG2 VAL C 169 −8.448 3.022 4.085 1.00 14.06 C ATOM1349 C VAL C 169 −10.995 3.479 6.728 1.00 15.01 C ATOM 1350 O VAL C 169−11.877 2.693 6.470 1.00 13.61 C ATOM 1351 N TYR C 170 −11.194 4.6037.425 1.00 15.47 C ATOM 1352 CA TYR C 170 −12.479 4.879 8.024 1.00 15.46C ATOM 1353 CB TYR C 170 −12.586 4.167 9.375 1.00 16.79 C ATOM 1354 CGTYR C 170 −11.674 4.763 10.386 1.00 18.16 C ATOM 1355 CD1 TYR C 170−12.113 5.844 11.175 1.00 18.90 C ATOM 1356 CE1 TYR C 170 −11.268 6.47312.116 1.00 18.78 C ATOM 1357 CD2 TYR C 170 −10.353 4.298 10.536 1.0018.22 C ATOM 1358 CE2 TYR C 170 −9.474 4.917 11.448 1.00 17.98 C ATOM1359 CZ TYR C 170 −9.944 6.008 12.254 1.00 18.15 C ATOM 1360 OH TYR C170 −9.151 6.594 13.188 1.00 14.60 C ATOM 1361 C TYR C 170 −12.720 6.3288.209 1.00 14.88 C ATOM 1362 O TYR C 170 −11.794 7.107 8.180 1.00 14.31C ATOM 1363 N TYR C 171 −13.992 6.671 8.346 1.00 14.84 C ATOM 1364 CATYR C 171 −14.302 8.010 8.612 1.00 15.86 C ATOM 1365 CB TYR C 171−14.795 8.701 7.341 1.00 16.35 C ATOM 1366 CG TYR C 171 −16.154 8.3626.931 1.00 17.45 C ATOM 1367 CD1 TYR C 171 −17.192 9.144 7.252 1.0017.20 C ATOM 1368 CE1 TYR C 171 −18.475 8.797 6.918 1.00 19.15 C ATOM1369 CD2 TYR C 171 −16.387 7.219 6.260 1.00 18.50 C ATOM 1370 CE2 TYR C171 −17.643 6.852 5.920 1.00 20.16 C ATOM 1371 CZ TYR C 171 −18.7217.637 6.244 1.00 20.05 C ATOM 1372 OH TYR C 171 −20.038 7.319 5.875 1.0020.35 C ATOM 1373 C TYR C 171 −15.274 8.142 9.845 1.00 16.95 C ATOM 1374O TYR C 171 −15.907 7.151 10.271 1.00 16.33 C ATOM 1375 N LYS C 172−15.321 9.332 10.446 1.00 17.75 C ATOM 1376 CA LYS C 172 −16.183 9.48911.571 1.00 18.48 C ATOM 1377 CB LYS C 172 −15.823 10.704 12.373 1.0018.50 C ATOM 1378 CG LYS C 172 −14.937 10.407 13.521 1.00 18.95 C ATOM1379 CD LYS C 172 −13.741 9.624 13.129 1.00 20.66 C ATOM 1380 CE LYS C172 −12.885 9.228 14.397 1.00 23.41 C ATOM 1381 NZ LYS C 172 −11.66010.288 14.683 1.00 27.40 C ATOM 1382 C LYS C 172 −17.669 9.502 11.2661.00 20.58 C ATOM 1383 O LYS C 172 −18.188 10.327 10.490 1.00 20.57 CATOM 1384 N LYS C 173 −18.343 8.562 11.975 1.00 22.28 C ATOM 1385 CA LYSC 173 −19.779 8.239 11.944 1.00 21.82 C ATOM 1386 CB LYS C 173 −20.1907.802 13.285 1.00 23.19 C ATOM 1387 CG LYS C 173 −19.122 6.895 13.8881.00 22.78 C ATOM 1388 CD LYS C 173 −18.318 7.810 14.944 1.00 24.22 CATOM 1389 CE LYS C 173 −16.888 7.193 15.257 1.00 23.12 C ATOM 1390 NZLYS C 173 −16.244 7.299 13.885 1.00 23.30 C ATOM 1391 C LYS C 173−20.622 9.374 11.531 1.00 22.79 C ATOM 1392 O LYS C 173 −20.873 9.53410.316 1.00 22.95 C ATOM 1393 N CYS C 174 −21.092 10.134 12.506 1.0022.56 C ATOM 1394 CA CYS C 174 −21.914 11.370 12.247 1.00 22.70 C ATOM1395 CB CYS C 174 −21.552 12.124 10.948 1.00 20.84 C ATOM 1396 SG CYS C174 −23.020 13.047 9.898 1.00 21.57 C ATOM 1397 C CYS C 174 −23.39011.086 12.239 1.00 23.42 C ATOM 1398 O CYS C 174 −23.982 10.802 13.3971.00 25.84 C ATOM 1399 OXT CYS C 174 −23.889 11.074 11.082 1.00 23.67 CATOM 1400 CB GLU A 1 −30.144 22.219 47.292 1.00 20.61 A ATOM 1401 CG GLUA 1 −29.420 22.176 45.924 1.00 18.39 A ATOM 1402 CD GLU A 1 −27.86921.751 46.036 1.00 19.19 A ATOM 1403 OE1 GLU A 1 −27.491 20.565 46.3561.00 16.42 A ATOM 1404 OE2 GLU A 1 −27.012 22.625 45.773 1.00 17.29 AATOM 1405 C GLU A 1 −32.206 23.708 47.128 1.00 20.09 A ATOM 1406 O GLU A1 −32.651 24.092 46.009 1.00 19.59 A ATOM 1407 N GLU A 1 −32.193 21.39546.144 1.00 21.48 A ATOM 1408 CA GLU A 1 −31.708 22.273 47.272 1.0020.31 A ATOM 1409 N VAL A 2 −32.131 24.493 48.221 1.00 19.76 A ATOM 1410CA VAL A 2 −32.599 25.889 48.166 1.00 18.22 A ATOM 1411 CB VAL A 2−33.555 26.198 49.402 1.00 20.00 A ATOM 1412 CG1 VAL A 2 −33.860 27.73449.566 1.00 19.89 A ATOM 1413 CG2 VAL A 2 −34.874 25.500 49.229 1.0019.78 A ATOM 1414 C VAL A 2 −31.372 26.753 48.169 1.00 16.63 A ATOM 1415O VAL A 2 −30.481 26.600 48.973 1.00 15.44 A ATOM 1416 N VAL A 3 −31.33627.680 47.254 1.00 16.56 A ATOM 1417 CA VAL A 3 −30.182 28.551 47.1191.00 16.56 A ATOM 1418 CB VAL A 3 −29.752 28.620 45.607 1.00 15.55 AATOM 1419 CG1 VAL A 3 −28.557 29.469 45.397 1.00 13.95 A ATOM 1420 CG2VAL A 3 −29.534 27.184 45.105 1.00 13.72 A ATOM 1421 C VAL A 3 −30.32829.914 47.627 1.00 15.87 A ATOM 1422 O VAL A 3 −31.111 30.679 47.1641.00 16.59 A ATOM 1423 N LEU A 4 −29.469 30.255 48.559 1.00 17.69 A ATOM1424 CA LEU A 4 −29.444 31.625 49.161 1.00 18.80 A ATOM 1425 CB LEU A 4−29.254 31.412 50.675 1.00 17.97 A ATOM 1426 CG LEU A 4 −30.023 30.28551.345 1.00 17.71 A ATOM 1427 CD1 LEU A 4 −29.841 30.209 52.865 1.0015.89 A ATOM 1428 CD2 LEU A 4 −31.496 30.638 51.029 1.00 18.91 A ATOM1429 C LEU A 4 −28.154 32.144 48.532 1.00 18.69 A ATOM 1430 O LEU A 4−27.149 31.528 48.663 1.00 21.16 A ATOM 1431 N LEU A 5 −28.042 33.21847.858 1.00 18.50 A ATOM 1432 CA LEU A 5 −26.641 33.388 47.352 1.0017.67 A ATOM 1433 CB LEU A 5 −25.640 33.680 48.491 1.00 16.77 A ATOM1434 CG LEU A 5 −24.339 34.238 47.916 1.00 16.76 A ATOM 1435 CD1 LEU A 5−24.725 35.287 46.951 1.00 17.28 A ATOM 1436 CD2 LEU A 5 −23.563 34.92548.972 1.00 17.78 A ATOM 1437 C LEU A 5 −25.946 32.395 46.403 1.00 16.46A ATOM 1438 O LEU A 5 −25.640 31.213 46.694 1.00 16.11 A ATOM 1439 N ASPA 6 −25.637 32.974 45.259 1.00 17.45 A ATOM 1440 CA ASP A 6 −24.99432.322 44.135 1.00 17.21 A ATOM 1441 CB ASP A 6 −26.048 31.652 43.2971.00 17.99 A ATOM 1442 CG ASP A 6 −25.436 30.781 42.271 1.00 18.73 AATOM 1443 OD1 ASP A 6 −26.150 30.375 41.329 1.00 19.01 A ATOM 1444 OD2ASP A 6 −24.220 30.478 42.415 1.00 19.10 A ATOM 1445 C ASP A 6 −24.27133.349 43.269 1.00 16.89 A ATOM 1446 O ASP A 6 −24.848 33.954 42.3181.00 17.73 A ATOM 1447 N PHE A 7 −22.998 33.521 43.582 1.00 15.87 A ATOM1448 CA PHE A 7 −22.177 34.483 42.899 1.00 14.20 A ATOM 1449 CB PHE A 7−20.747 34.339 43.461 1.00 14.14 A ATOM 1450 CG PHE A 7 −19.773 35.20742.762 1.00 14.00 A ATOM 1451 CD1 PHE A 7 −19.815 36.546 42.946 1.0012.77 A ATOM 1452 CD2 PHE A 7 −18.867 34.650 41.843 1.00 13.64 A ATOM1453 CE1 PHE A 7 −18.979 37.324 42.246 1.00 16.65 A ATOM 1454 CE2 PHE A7 −18.020 35.449 41.119 1.00 15.75 A ATOM 1455 CZ PHE A 7 −18.058 36.79241.307 1.00 16.19 A ATOM 1456 C PHE A 7 −22.175 34.424 41.352 1.00 12.61A ATOM 1457 O PHE A 7 −22.361 35.381 40.674 1.00 10.68 A ATOM 1458 N ALAA 8 −21.845 33.261 40.841 1.00 13.83 A ATOM 1459 CA ALA A 8 −21.81333.043 39.385 1.00 16.56 A ATOM 1460 CB ALA A 8 −21.367 31.569 39.0491.00 14.94 A ATOM 1461 C ALA A 8 −23.102 33.403 38.581 1.00 17.05 A ATOM1462 O ALA A 8 −23.007 33.517 37.414 1.00 18.55 A ATOM 1463 N ALA A 9−24.280 33.623 39.186 1.00 18.47 A ATOM 1464 CA ALA A 9 −25.461 34.04138.397 1.00 19.00 A ATOM 1465 CB ALA A 9 −26.632 33.335 38.873 1.0017.92 A ATOM 1466 C ALA A 9 −25.770 35.522 38.426 1.00 19.68 A ATOM 1467O ALA A 9 −26.648 36.004 37.628 1.00 20.64 A ATOM 1468 N ALA A 10−25.150 36.283 39.348 1.00 19.73 A ATOM 1469 CA ALA A 10 −25.415 37.75639.476 1.00 20.11 A ATOM 1470 CB ALA A 10 −25.066 38.145 40.845 1.0017.25 A ATOM 1471 C ALA A 10 −24.755 38.691 38.395 1.00 21.21 A ATOM1472 O ALA A 10 −23.530 39.184 38.455 1.00 21.50 A ATOM 1473 N GLY A 11−25.572 38.868 37.348 1.00 23.06 A ATOM 1474 CA GLY A 11 −25.287 39.66836.087 1.00 24.47 A ATOM 1475 C GLY A 11 −24.812 41.144 36.120 1.0024.88 A ATOM 1476 O GLY A 11 −25.264 42.074 35.393 1.00 24.62 A ATOM1477 N GLY A 12 −23.799 41.296 36.979 1.00 25.59 A ATOM 1478 CA GLY A 12−23.119 42.559 37.330 1.00 25.75 A ATOM 1479 C GLY A 12 −22.229 42.20338.540 1.00 24.97 A ATOM 1480 O GLY A 12 −22.008 43.073 39.415 1.0025.38 A ATOM 1481 N GLU A 13 −21.742 40.939 38.610 1.00 25.09 A ATOM1482 CA GLU A 13 −20.785 40.492 39.719 1.00 25.73 A ATOM 1483 CB GLU A13 −19.589 41.534 39.826 1.00 25.00 A ATOM 1484 CG GLU A 13 −19.56042.881 38.834 1.00 25.50 A ATOM 1485 CD GLU A 13 −18.014 43.635 38.5521.00 26.00 A ATOM 1486 OE1 GLU A 13 −16.929 42.909 38.672 1.00 25.65 AATOM 1487 OE2 GLU A 13 −17.946 44.908 38.178 1.00 22.20 A ATOM 1488 CGLU A 13 −21.596 40.403 41.145 1.00 25.32 A ATOM 1489 O GLU A 13 −22.09939.304 41.567 1.00 26.20 A ATOM 1490 N LEU A 14 −21.815 41.575 41.7731.00 25.22 A ATOM 1491 CA LEU A 14 −22.562 41.641 43.023 1.00 24.81 AATOM 1492 CB LEU A 14 −22.315 40.353 43.781 1.00 24.37 A ATOM 1493 CGLEU A 14 −23.588 39.413 43.704 1.00 24.64 A ATOM 1494 CD1 LEU A 14−23.058 37.951 43.554 1.00 21.79 A ATOM 1495 CD2 LEU A 14 −24.607 39.55545.108 1.00 22.80 A ATOM 1496 C LEU A 14 −22.278 42.821 43.976 1.0023.76 A ATOM 1497 O LEU A 14 −21.183 43.607 43.888 1.00 24.51 A ATOM1498 N GLY A 15 −23.202 42.903 44.930 1.00 21.61 A ATOM 1499 CA GLY A 15−23.082 43.933 45.937 1.00 20.41 A ATOM 1500 C GLY A 15 −22.153 43.37147.043 1.00 20.40 A ATOM 1501 O GLY A 15 −22.760 42.961 48.035 1.0021.06 A ATOM 1502 N TRP A 16 −20.779 43.315 46.923 1.00 19.56 A ATOM1503 CA TRP A 16 −19.930 42.783 48.039 1.00 18.45 A ATOM 1504 CB TRP A16 −19.130 41.488 47.648 1.00 17.83 A ATOM 1505 CG TRP A 16 −19.97840.253 47.290 1.00 16.30 A ATOM 1506 CD2 TRP A 16 −19.631 38.866 47.3651.00 15.31 A ATOM 1507 CE2 TRP A 16 −20.715 38.147 46.873 1.00 14.76 AATOM 1508 CE3 TRP A 16 −18.522 38.162 47.787 1.00 15.63 A ATOM 1509 CD1TRP A 16 −21.230 40.283 46.746 1.00 16.24 A ATOM 1510 NE1 TRP A 16−21.667 39.050 46.500 1.00 14.81 A ATOM 1511 CZ2 TRP A 16 −20.729 36.74746.792 1.00 14.10 A ATOM 1512 CZ3 TRP A 16 −18.531 36.761 47.703 1.0016.22 A ATOM 1513 CH2 TRP A 16 −19.645 36.067 47.204 1.00 15.07 A ATOM1514 C TRP A 16 −18.907 43.835 48.553 1.00 17.68 A ATOM 1515 O TRP A 16−18.430 44.712 47.844 1.00 17.87 A ATOM 1516 N LEU A 17 −18.552 43.66349.791 1.00 16.41 A ATOM 1517 CA LEU A 17 −17.614 44.533 50.513 1.0014.62 A ATOM 1518 CB LEU A 17 −18.088 44.664 51.981 1.00 16.20 A ATOM1519 CG LEU A 17 −17.258 45.615 52.729 1.00 17.18 A ATOM 1520 CD1 LEU A17 −17.153 46.831 51.840 1.00 19.80 A ATOM 1521 CD2 LEU A 17 −17.85846.013 54.027 1.00 18.98 A ATOM 1522 C LEU A 17 −16.169 43.956 50.4311.00 13.85 A ATOM 1523 O LEU A 17 −15.885 42.704 50.539 1.00 11.11 AATOM 1524 N THR A 18 −15.275 44.924 50.271 1.00 14.24 A ATOM 1525 CA THRA 18 −13.866 44.675 50.074 1.00 15.95 A ATOM 1526 CB THR A 18 −13.52645.037 48.650 1.00 16.79 A ATOM 1527 OG1 THR A 18 −13.611 43.849 47.8921.00 19.07 A ATOM 1528 CG2 THR A 18 −12.264 45.588 48.512 1.00 17.50 AATOM 1529 C THR A 18 −13.071 45.458 51.044 1.00 17.17 A ATOM 1530 O THRA 18 −12.979 46.664 50.920 1.00 15.32 A ATOM 1531 N HIS A 19 −12.47444.757 52.004 1.00 19.08 A ATOM 1532 CA HIS A 19 −11.805 45.523 52.9941.00 19.72 A ATOM 1533 CB HIS A 19 −11.563 44.847 54.296 1.00 21.56 AATOM 1534 CG HIS A 19 −11.382 45.815 55.457 1.00 22.29 A ATOM 1535 CD2HIS A 19 −10.804 45.623 56.693 1.00 22.19 A ATOM 1536 ND1 HIS A 19−11.707 47.164 55.377 1.00 21.42 A ATOM 1537 CE1 HIS A 19 −11.325 47.75456.502 1.00 21.73 A ATOM 1538 NE2 HIS A 19 −10.776 46.848 57.321 1.0022.58 A ATOM 1539 C HIS A 19 −10.609 46.227 52.451 1.00 21.35 A ATOM1540 O HIS A 19 −10.626 46.446 51.228 1.00 22.86 A ATOM 1541 N PRO A 20−9.478 46.362 53.204 1.00 21.93 A ATOM 1542 CD PRO A 20 −8.929 45.00053.370 1.00 18.35 A ATOM 1543 CA PRO A 20 −8.451 47.209 52.594 1.0017.85 A ATOM 1544 CB PRO A 20 −7.416 46.245 52.216 1.00 18.59 A ATOM1545 CG PRO A 20 −7.437 45.347 53.310 1.00 17.43 A ATOM 1546 C PRO A 20−9.157 48.120 51.495 1.00 19.39 A ATOM 1547 O PRO A 20 −9.565 49.28351.775 1.00 21.39 A ATOM 1548 N TYR A 21 −9.393 47.642 50.289 1.00 19.03A ATOM 1549 CA TYR A 21 −10.068 48.381 49.176 1.00 16.97 A ATOM 1550 CBTYR A 21 −11.165 49.409 49.519 1.00 16.41 A ATOM 1551 CG TYR A 21−11.722 49.888 48.213 1.00 16.93 A ATOM 1552 CD1 TYR A 21 −12.522 48.98747.357 1.00 16.85 A ATOM 1553 CE1 TYR A 21 −12.909 49.349 46.040 1.0014.93 A ATOM 1554 CD2 TYR A 21 −11.346 51.131 47.675 1.00 16.75 A ATOM1555 CE2 TYR A 21 −11.708 51.461 46.362 1.00 16.00 A ATOM 1556 CZ TYR A21 −12.497 50.571 45.559 1.00 15.78 A ATOM 1557 OH TYR A 21 −12.83050.913 44.277 1.00 14.59 A ATOM 1558 C TYR A 21 −9.055 49.148 48.4081.00 17.07 A ATOM 1559 O TYR A 21 −8.600 50.185 48.833 1.00 17.64 A ATOM1560 N GLY A 22 −8.690 48.649 47.239 1.00 17.38 A ATOM 1561 CA GLY A 22−7.721 49.344 46.441 1.00 17.28 A ATOM 1562 C GLY A 22 −6.691 48.41945.891 1.00 17.91 A ATOM 1563 O GLY A 22 −6.416 48.489 44.691 1.00 18.44A ATOM 1564 N LYS A 23 −6.188 47.541 46.763 1.00 18.11 A ATOM 1565 CALYS A 23 −5.157 46.626 46.504 1.00 16.98 A ATOM 1566 CB LYS A 23 −3.91747.067 47.264 1.00 17.85 A ATOM 1567 CG LYS A 23 −3.263 48.363 46.8481.00 19.43 A ATOM 1568 CD LYS A 23 −3.598 49.529 47.804 1.00 21.52 AATOM 1569 CE LYS A 23 −3.140 50.942 47.303 1.00 22.17 A ATOM 1570 NZ LYSA 23 −1.619 51.220 47.303 1.00 24.09 A ATOM 1571 C LYS A 23 −5.47545.237 46.912 1.00 17.24 A ATOM 1572 O LYS A 23 −4.685 44.329 46.6421.00 17.00 A ATOM 1573 N GLY A 24 −6.558 45.018 47.663 1.00 17.20 A ATOM1574 CA GLY A 24 −6.872 43.601 48.035 1.00 15.98 A ATOM 1575 C GLY A 24−7.693 42.939 46.863 1.00 15.70 A ATOM 1576 O GLY A 24 −7.356 43.00745.674 1.00 13.53 A ATOM 1577 N TRP A 25 −8.783 42.319 47.289 1.00 15.85A ATOM 1578 CA TRP A 25 −9.720 41.663 46.493 1.00 16.43 A ATOM 1579 CBTRP A 25 −10.776 41.080 47.418 1.00 15.35 A ATOM 1580 CG TRP A 25−10.373 39.929 48.289 1.00 13.73 A ATOM 1581 CD2 TRP A 25 −10.297 38.54147.903 1.00 14.01 A ATOM 1582 CE2 TRP A 25 −10.114 37.799 49.085 1.0013.88 A ATOM 1583 CE3 TRP A 25 −10.379 37.877 46.691 1.00 14.00 A ATOM1584 CD1 TRP A 25 −10.211 39.955 49.584 1.00 12.03 A ATOM 1585 NE1 TRP A25 −10.052 38.719 50.080 1.00 11.95 A ATOM 1586 CZ2 TRP A 25 −10.03036.379 49.113 1.00 15.46 A ATOM 1587 CZ3 TRP A 25 −10.292 36.517 46.6761.00 16.23 A ATOM 1588 CH2 TRP A 25 −10.123 35.748 47.877 1.00 15.71 AATOM 1589 C TRP A 25 −10.370 42.613 45.446 1.00 16.61 A ATOM 1590 O TRPA 25 −10.837 43.641 45.808 1.00 16.49 A ATOM 1591 N ASP A 26 −10.28742.293 44.137 1.00 17.06 A ATOM 1592 CA ASP A 26 −10.963 43.081 43.0751.00 17.84 A ATOM 1593 CB ASP A 26 −10.090 43.807 41.968 1.00 21.07 AATOM 1594 CG ASP A 26 −9.046 44.799 42.484 1.00 26.72 A ATOM 1595 OD1ASP A 26 −9.001 45.248 43.817 1.00 29.43 A ATOM 1596 OD2 ASP A 26 −8.22845.212 41.472 1.00 28.76 A ATOM 1597 C ASP A 26 −11.911 42.086 42.2591.00 15.88 A ATOM 1598 O ASP A 26 −11.624 40.876 41.982 1.00 13.97 AATOM 1599 N LEU A 27 −13.028 42.692 41.866 1.00 15.66 A ATOM 1600 CA LEUA 27 −14.071 42.091 41.046 1.00 15.83 A ATOM 1601 CB LEU A 27 −15.30242.866 41.255 1.00 16.02 A ATOM 1602 CG LEU A 27 −16.475 42.089 40.7161.00 17.41 A ATOM 1603 CD1 LEU A 27 −16.681 40.580 41.010 1.00 16.07 AATOM 1604 CD2 LEU A 27 −17.498 43.010 41.266 1.00 17.28 A ATOM 1605 CLEU A 27 −13.519 42.248 39.648 1.00 15.27 A ATOM 1606 O LEU A 27 −13.02943.278 39.298 1.00 15.19 A ATOM 1607 N MET A 28 −13.508 41.173 38.9041.00 16.05 A ATOM 1608 CA MET A 28 −12.929 41.211 37.584 1.00 17.04 AATOM 1609 CB MET A 28 −11.574 40.513 37.532 1.00 18.58 A ATOM 1610 CGMET A 28 −10.629 40.936 38.604 1.00 21.13 A ATOM 1611 SD MET A 28 −8.86540.466 38.338 1.00 24.21 A ATOM 1612 CE MET A 28 −8.470 41.463 36.6711.00 18.54 A ATOM 1613 C MET A 28 −13.889 40.476 36.710 1.00 16.61 AATOM 1614 O MET A 28 −14.555 39.478 37.139 1.00 16.17 A ATOM 1615 N GLNA 29 −14.005 41.021 35.502 1.00 17.51 A ATOM 1616 CA GLN A 29 −14.85240.427 34.484 1.00 18.12 A ATOM 1617 CB GLN A 29 −15.790 41.437 33.9621.00 17.95 A ATOM 1618 CG GLN A 29 −16.883 40.666 33.235 1.00 20.50 AATOM 1619 CD GLN A 29 −17.684 41.533 32.242 1.00 21.15 A ATOM 1620 OE1GLN A 29 −18.832 41.870 32.517 1.00 21.69 A ATOM 1621 NE2 GLN A 29−17.069 41.904 31.087 1.00 20.45 A ATOM 1622 C GLN A 29 −14.196 39.75933.272 1.00 18.32 A ATOM 1623 O GLN A 29 −13.741 40.443 32.397 1.0019.74 A ATOM 1624 N ASN A 30 −14.146 38.431 33.201 1.00 17.77 A ATOM1625 CA ASN A 30 −13.623 37.797 32.005 1.00 15.07 A ATOM 1626 CB ASN A30 −12.947 36.529 32.369 1.00 12.46 A ATOM 1627 CG ASN A 30 −11.63936.736 32.903 1.00 9.35 A ATOM 1628 OD1 ASN A 30 −11.214 35.902 33.5931.00 10.48 A ATOM 1629 ND2 ASN A 30 −10.978 37.793 32.588 1.00 5.89 AATOM 1630 C ASN A 30 −14.783 37.487 31.060 1.00 15.49 A ATOM 1631 O ASNA 30 −16.006 37.487 31.399 1.00 15.16 A ATOM 1632 N ILE A 31 −14.41937.163 29.854 1.00 16.09 A ATOM 1633 CA ILE A 31 −15.465 36.835 28.9461.00 16.13 A ATOM 1634 CB ILE A 31 −15.857 38.058 28.227 1.00 16.78 AATOM 1635 CG2 ILE A 31 −14.699 38.552 27.514 1.00 19.70 A ATOM 1636 CG1ILE A 31 −16.945 37.757 27.285 1.00 16.56 A ATOM 1637 CD1 ILE A 31−17.497 38.969 26.625 1.00 17.54 A ATOM 1638 C ILE A 31 −15.140 35.70328.050 1.00 14.66 A ATOM 1639 O ILE A 31 −14.112 35.550 27.493 1.0014.57 A ATOM 1640 N MET A 32 −16.096 34.853 27.960 1.00 15.06 A ATOM1641 CA MET A 32 −16.026 33.641 27.173 1.00 15.91 A ATOM 1642 CB MET A32 −16.014 32.389 28.107 1.00 17.12 A ATOM 1643 CG MET A 32 −14.60831.880 28.320 1.00 22.20 A ATOM 1644 SD MET A 32 −13.604 31.795 26.5551.00 25.10 A ATOM 1645 CE MET A 32 −14.699 30.970 25.767 1.00 19.44 AATOM 1646 C MET A 32 −17.218 33.520 26.327 1.00 13.81 A ATOM 1647 O META 32 −18.282 33.427 26.872 1.00 13.32 A ATOM 1648 N ASN A 33 −17.03333.424 25.019 1.00 14.24 A ATOM 1649 CA ASN A 33 −18.193 33.255 24.0741.00 15.59 A ATOM 1650 CB ASN A 33 −18.776 31.866 24.145 1.00 14.39 AATOM 1651 CG ASN A 33 −17.777 30.830 23.791 1.00 15.26 A ATOM 1652 OD1ASN A 33 −17.188 30.799 22.648 1.00 15.93 A ATOM 1653 ND2 ASN A 33−17.543 29.959 24.742 1.00 13.46 A ATOM 1654 C ASN A 33 −19.291 34.26124.323 1.00 14.63 A ATOM 1655 O ASN A 33 −20.483 33.922 24.375 1.0014.99 A ATOM 1656 N ASP A 34 −18.846 35.500 24.473 1.00 14.29 A ATOM1657 CA ASP A 34 −19.742 36.544 24.841 1.00 14.93 A ATOM 1658 CB ASP A34 −20.758 36.667 23.709 1.00 13.79 A ATOM 1659 CG ASP A 34 −20.24637.466 22.589 1.00 13.87 A ATOM 1660 OD1 ASP A 34 −19.035 37.382 22.3031.00 14.27 A ATOM 1661 OD2 ASP A 34 −21.079 38.165 22.002 1.00 15.44 AATOM 1662 C ASP A 34 −20.409 36.389 26.250 1.00 14.80 A ATOM 1663 O ASPA 34 −21.340 37.112 26.585 1.00 15.37 A ATOM 1664 N MET A 35 −20.00835.437 27.060 1.00 15.26 A ATOM 1665 CA MET A 35 −20.638 35.359 28.3941.00 15.61 A ATOM 1666 CB MET A 35 −20.894 33.916 28.864 1.00 17.23 AATOM 1667 CG MET A 35 −21.928 33.152 28.026 1.00 18.09 A ATOM 1668 SDMET A 35 −23.650 33.777 28.179 1.00 21.57 A ATOM 1669 CE MET A 35−23.615 35.064 26.686 1.00 17.94 A ATOM 1670 C MET A 35 −19.689 36.05729.421 1.00 15.02 A ATOM 1671 O MET A 35 −18.525 35.808 29.416 1.0014.05 A ATOM 1672 N PRO A 36 −20.174 37.078 30.159 1.00 15.31 A ATOM1673 CD PRO A 36 −21.473 37.772 30.084 1.00 15.65 A ATOM 1674 CA PRO A36 −19.303 37.690 31.168 1.00 14.10 A ATOM 1675 CB PRO A 36 −20.09238.930 31.608 1.00 14.62 A ATOM 1676 CG PRO A 36 −21.477 38.545 31.3671.00 16.28 A ATOM 1677 C PRO A 36 −19.137 36.635 32.331 1.00 13.66 AATOM 1678 O PRO A 36 −20.069 36.042 32.787 1.00 13.00 A ATOM 1679 N ILEA 37 −17.903 36.383 32.734 1.00 15.08 A ATOM 1680 CA ILE A 37 −17.55435.429 33.825 1.00 14.63 A ATOM 1681 CB ILE A 37 −16.448 34.505 33.3201.00 14.48 A ATOM 1682 CG2 ILE A 37 −16.130 33.423 34.286 1.00 12.08 AATOM 1683 CG1 ILE A 37 −16.903 33.865 31.967 1.00 14.43 A ATOM 1684 CD1ILE A 37 −18.267 33.310 31.998 1.00 13.79 A ATOM 1685 C ILE A 37 −17.01336.299 34.925 1.00 16.18 A ATOM 1686 O ILE A 37 −15.926 36.868 34.8031.00 16.90 A ATOM 1687 N TYR A 38 −17.719 36.486 36.020 1.00 17.36 AATOM 1688 CA TYR A 38 −17.136 37.378 37.053 1.00 16.88 A ATOM 1689 CBTYR A 38 −18.207 38.141 37.793 1.00 16.17 A ATOM 1690 CG TYR A 38−18.755 39.244 36.962 1.00 15.71 A ATOM 1691 CD1 TYR A 38 −19.825 39.04036.162 1.00 15.39 A ATOM 1692 CE1 TYR A 38 −20.344 40.048 35.404 1.0015.51 A ATOM 1693 CD2 TYR A 38 −18.168 40.515 36.987 1.00 15.78 A ATOM1694 CE2 TYR A 38 −18.653 41.547 36.261 1.00 15.96 A ATOM 1695 CZ TYR A38 −19.784 41.338 35.447 1.00 16.85 A ATOM 1696 OH TYR A 38 −20.31142.442 34.756 1.00 14.56 A ATOM 1697 C TYR A 38 −16.359 36.580 38.0571.00 17.33 A ATOM 1698 O TYR A 38 −16.652 35.385 38.239 1.00 17.90 AATOM 1699 N MET A 39 −15.328 37.195 38.647 1.00 16.65 A ATOM 1700 CA META 39 −14.554 36.520 39.695 1.00 15.61 A ATOM 1701 CB MET A 39 −13.44435.654 39.106 1.00 15.80 A ATOM 1702 CG MET A 39 −12.125 36.399 38.9021.00 17.77 A ATOM 1703 SD MET A 39 −11.333 35.681 37.416 1.00 18.25 AATOM 1704 CE MET A 39 −9.922 36.945 37.071 1.00 19.47 A ATOM 1705 C META 39 −13.930 37.578 40.677 1.00 14.10 A ATOM 1706 O MET A 39 −13.76238.720 40.330 1.00 12.66 A ATOM 1707 N TYR A 40 −13.695 37.164 41.9031.00 13.25 A ATOM 1708 CA TYR A 40 −13.048 38.004 42.885 1.00 14.58 AATOM 1709 CB TYR A 40 −13.850 37.931 44.183 1.00 15.11 A ATOM 1710 CGTYR A 40 −14.791 39.088 44.370 1.00 16.47 A ATOM 1711 CD1 TYR A 40−16.107 38.943 44.230 1.00 16.78 A ATOM 1712 CE1 TYR A 40 −16.985 40.02844.308 1.00 16.22 A ATOM 1713 CD2 TYR A 40 −14.335 40.371 44.633 1.0018.19 A ATOM 1714 CE2 TYR A 40 −15.213 41.444 44.740 1.00 17.31 A ATOM1715 CZ TYR A 40 −16.547 41.239 44.556 1.00 16.46 A ATOM 1716 OH TYR A40 −17.443 42.240 44.593 1.00 17.01 A ATOM 1717 C TYR A 40 −11.52137.546 43.091 1.00 13.43 A ATOM 1718 O TYR A 40 −11.202 36.380 43.5101.00 13.34 A ATOM 1719 N SER A 41 −10.566 38.388 42.740 1.00 12.81 AATOM 1720 CA SER A 41 −9.165 37.920 42.931 1.00 14.33 A ATOM 1721 CB SERA 41 −8.522 37.466 41.601 1.00 14.23 A ATOM 1722 OG SER A 41 −8.78138.351 40.593 1.00 13.54 A ATOM 1723 C SER A 41 −8.181 38.874 43.6681.00 14.20 A ATOM 1724 O SER A 41 −8.498 40.070 43.870 1.00 13.80 A ATOM1725 N VAL A 42 −7.026 38.330 44.063 1.00 14.03 A ATOM 1726 CA VAL A 42−5.999 39.088 44.766 1.00 13.16 A ATOM 1727 CB VAL A 42 −5.810 38.89446.320 1.00 14.01 A ATOM 1728 CG1 VAL A 42 −5.471 40.231 46.977 1.0012.12 A ATOM 1729 CG2 VAL A 42 −6.907 38.054 46.969 1.00 10.35 A ATOM1730 C VAL A 42 −4.858 38.309 44.506 1.00 14.94 A ATOM 1731 O VAL A 42−4.897 37.109 44.575 1.00 14.80 A ATOM 1732 N CYS A 43 −3.766 38.99944.414 1.00 16.23 A ATOM 1733 CA CYS A 43 −2.470 38.369 44.163 1.0016.19 A ATOM 1734 C CYS A 43 −1.376 39.298 44.775 1.00 16.34 A ATOM 1735O CYS A 43 −0.508 39.783 44.100 1.00 17.73 A ATOM 1736 CB CYS A 43−2.304 38.170 42.625 1.00 15.20 A ATOM 1737 SG CYS A 43 −1.074 36.92142.058 1.00 14.30 A ATOM 1738 N ASN A 44 −1.432 39.585 46.053 1.00 16.39A ATOM 1739 CA ASN A 44 −0.340 40.409 46.677 1.00 15.98 A ATOM 1740 CBASN A 44 −0.923 41.328 47.714 1.00 14.91 A ATOM 1741 CG ASN A 44 −1.73142.344 47.126 1.00 14.66 A ATOM 1742 OD1 ASN A 44 −2.623 42.872 47.7551.00 12.27 A ATOM 1743 ND2 ASN A 44 −1.408 42.694 45.863 1.00 16.87 AATOM 1744 C ASN A 44 0.643 39.429 47.361 1.00 14.72 A ATOM 1745 O ASN A44 0.780 39.410 48.596 1.00 14.08 A ATOM 1746 N VAL A 45 1.244 38.58146.531 1.00 14.47 A ATOM 1747 CA VAL A 45 2.163 37.528 46.960 1.00 16.62A ATOM 1748 CB VAL A 45 2.358 36.337 45.873 1.00 16.01 A ATOM 1749 CG1VAL A 45 1.098 35.682 45.677 1.00 19.11 A ATOM 1750 CG2 VAL A 45 2.89436.838 44.474 1.00 13.44 A ATOM 1751 C VAL A 45 3.551 37.996 47.258 1.0015.11 A ATOM 1752 O VAL A 45 4.309 37.271 47.917 1.00 15.44 A ATOM 1753N MET A 46 3.839 39.176 46.773 1.00 15.58 A ATOM 1754 CA MET A 46 5.14839.827 46.864 1.00 17.80 A ATOM 1755 CB MET A 46 5.353 40.558 45.5231.00 17.71 A ATOM 1756 CG MET A 46 6.582 40.245 44.799 1.00 18.80 A ATOM1757 SD MET A 46 7.128 38.569 44.461 1.00 20.77 A ATOM 1758 CE MET A 466.495 38.470 42.581 1.00 19.70 A ATOM 1759 C MET A 46 5.241 40.84848.064 1.00 17.95 A ATOM 1760 O MET A 46 6.213 41.588 48.188 1.00 17.74A ATOM 1761 N SER A 47 4.232 40.910 48.925 1.00 18.15 A ATOM 1762 CA SERA 47 4.355 41.829 50.065 1.00 18.92 A ATOM 1763 CB SER A 47 3.519 43.01849.819 1.00 17.61 A ATOM 1764 OG SER A 47 3.317 43.020 48.362 1.00 21.61A ATOM 1765 C SER A 47 3.840 40.989 51.212 1.00 19.31 A ATOM 1766 O SERA 47 2.977 40.071 50.970 1.00 20.83 A ATOM 1767 N GLY A 48 4.367 41.19252.425 1.00 18.04 A ATOM 1768 CA GLY A 48 3.916 40.397 53.543 1.00 16.84A ATOM 1769 C GLY A 48 2.708 40.926 54.324 1.00 16.90 A ATOM 1770 O GLYA 48 2.107 41.981 54.005 1.00 16.51 A ATOM 1771 N ASP A 49 2.301 40.15555.320 1.00 16.64 A ATOM 1772 CA ASP A 49 1.248 40.677 56.137 1.00 17.21A ATOM 1773 CB ASP A 49 1.724 42.035 56.746 1.00 18.61 A ATOM 1774 CGASP A 49 3.197 41.983 57.403 1.00 20.95 A ATOM 1775 OD1 ASP A 49 4.02042.820 56.969 1.00 18.22 A ATOM 1776 OD2 ASP A 49 3.486 41.115 58.3261.00 20.34 A ATOM 1777 C ASP A 49 −0.037 40.942 55.395 1.00 16.54 A ATOM1778 O ASP A 49 −0.665 41.916 55.629 1.00 16.58 A ATOM 1779 N GLN A 50−0.472 40.112 54.477 1.00 16.90 A ATOM 1780 CA GLN A 50 −1.706 40.49253.814 1.00 16.35 A ATOM 1781 CB GLN A 50 −1.830 39.819 52.486 1.0017.36 A ATOM 1782 CG GLN A 50 −0.809 40.260 51.433 1.00 15.30 A ATOM1783 CD GLN A 50 −0.855 41.683 51.124 1.00 14.08 A ATOM 1784 OE1 GLN A50 −1.806 42.190 50.601 1.00 10.11 A ATOM 1785 NE2 GLN A 50 0.205 42.36551.478 1.00 15.68 A ATOM 1786 C GLN A 50 −2.810 40.052 54.680 1.00 15.01A ATOM 1787 O GLN A 50 −2.688 38.994 55.291 1.00 13.81 A ATOM 1788 N ASPA 51 −3.851 40.893 54.753 1.00 14.67 A ATOM 1789 CA ASP A 51 −5.06240.582 55.508 1.00 14.53 A ATOM 1790 CB ASP A 51 −4.920 41.146 56.9571.00 15.70 A ATOM 1791 CG ASP A 51 −6.074 40.697 57.895 1.00 17.32 AATOM 1792 OD1 ASP A 51 −6.348 41.439 58.855 1.00 17.12 A ATOM 1793 OD2ASP A 51 −6.719 39.628 57.630 1.00 15.67 A ATOM 1794 C ASP A 51 −6.20541.241 54.743 1.00 12.91 A ATOM 1795 O ASP A 51 −6.825 42.199 55.1581.00 10.60 A ATOM 1796 N ASN A 52 −6.473 40.726 53.590 1.00 13.33 A ATOM1797 CA ASN A 52 −7.579 41.301 52.776 1.00 13.33 A ATOM 1798 CB ASN A 52−7.145 41.345 51.350 1.00 13.76 A ATOM 1799 CG ASN A 52 −5.788 41.89451.220 1.00 13.29 A ATOM 1800 OD1 ASN A 52 −5.626 43.066 51.416 1.0011.04 A ATOM 1801 ND2 ASN A 52 −4.795 41.030 50.960 1.00 10.02 A ATOM1802 C ASN A 52 −8.872 40.505 52.926 1.00 12.57 A ATOM 1803 O ASN A 52−8.830 39.325 52.989 1.00 11.99 A ATOM 1804 N TRP A 53 −9.993 41.21153.021 1.00 12.58 A ATOM 1805 CA TRP A 53 −11.264 40.663 53.276 1.0012.59 A ATOM 1806 CB TRP A 53 −11.724 41.102 54.640 1.00 12.71 A ATOM1807 CG TRP A 53 −10.998 40.454 55.727 1.00 13.17 A ATOM 1808 CD2 TRP A53 −11.422 39.380 56.544 1.00 13.99 A ATOM 1809 CE2 TRP A 53 −10.41939.203 57.524 1.00 14.37 A ATOM 1810 CE3 TRP A 53 −12.526 38.557 56.5611.00 14.91 A ATOM 1811 CD1 TRP A 53 −9.815 40.833 56.199 1.00 12.85 AATOM 1812 NE1 TRP A 53 −9.438 40.108 57.254 1.00 13.28 A ATOM 1813 CZ2TRP A 53 −10.514 38.220 58.533 1.00 14.42 A ATOM 1814 CZ3 TRP A 53−12.598 37.606 57.534 1.00 15.27 A ATOM 1815 CH2 TRP A 53 −11.602 37.43958.516 1.00 15.14 A ATOM 1816 C TRP A 53 −12.315 40.986 52.286 1.0013.00 A ATOM 1817 O TRP A 53 −12.464 42.103 51.820 1.00 12.18 A ATOM1818 N LEU A 54 −13.102 39.965 52.035 1.00 13.32 A ATOM 1819 CA LEU A 54−14.171 40.016 51.098 1.00 13.42 A ATOM 1820 CB LEU A 54 −13.930 39.04349.882 1.00 13.96 A ATOM 1821 CG LEU A 54 −15.117 38.905 48.870 1.0013.44 A ATOM 1822 CD1 LEU A 54 −15.399 40.219 48.098 1.00 9.17 A ATOM1823 CD2 LEU A 54 −14.860 37.786 47.872 1.00 13.81 A ATOM 1824 C LEU A54 −15.363 39.529 51.873 1.00 14.07 A ATOM 1825 O LEU A 54 −15.40038.376 52.408 1.00 13.77 A ATOM 1826 N ARG A 55 −16.370 40.389 51.9051.00 12.79 A ATOM 1827 CA ARG A 55 −17.565 40.038 52.552 1.00 12.60 AATOM 1828 CB ARG A 55 −17.892 41.012 53.702 1.00 13.35 A ATOM 1829 CGARG A 55 −19.114 40.510 54.434 1.00 15.65 A ATOM 1830 CD ARG A 55−19.448 41.114 55.684 1.00 16.71 A ATOM 1831 NE ARG A 55 −20.442 42.24555.672 1.00 17.61 A ATOM 1832 CZ ARG A 55 −20.532 43.173 54.720 1.0016.94 A ATOM 1833 NH1 ARG A 55 −19.732 43.093 53.678 1.00 20.71 A ATOM1834 NH2 ARG A 55 −21.252 44.252 54.859 1.00 13.85 A ATOM 1835 C ARG A55 −18.727 39.991 51.599 1.00 12.37 A ATOM 1836 O ARG A 55 −18.90440.856 50.765 1.00 11.74 A ATOM 1837 N THR A 56 −19.566 39.001 51.7951.00 12.35 A ATOM 1838 CA THR A 56 −20.722 38.858 50.974 1.00 13.39 AATOM 1839 CB THR A 56 −21.391 37.522 51.123 1.00 13.61 A ATOM 1840 OG1THR A 56 −21.942 37.436 52.436 1.00 11.92 A ATOM 1841 CG2 THR A 56−20.465 36.436 50.847 1.00 11.93 A ATOM 1842 C THR A 56 −21.695 39.82451.579 1.00 14.05 A ATOM 1843 O THR A 56 −21.446 40.457 52.634 1.0013.41 A ATOM 1844 N ASN A 57 −22.853 39.910 50.906 1.00 15.23 A ATOM1845 CA ASN A 57 −23.887 40.768 51.416 1.00 16.42 A ATOM 1846 CB ASN A57 −24.714 41.330 50.324 1.00 19.08 A ATOM 1847 CG ASN A 57 −24.62542.843 50.266 1.00 22.41 A ATOM 1848 OD1 ASN A 57 −23.609 43.375 49.8101.00 21.78 A ATOM 1849 ND2 ASN A 57 −25.690 43.585 50.788 1.00 24.12 AATOM 1850 C ASN A 57 −24.712 40.016 52.363 1.00 15.24 A ATOM 1851 O ASNA 57 −24.608 38.813 52.440 1.00 15.05 A ATOM 1852 N TRP A 58 −25.47240.775 53.131 1.00 15.35 A ATOM 1853 CA TRP A 58 −26.412 40.268 54.1571.00 16.65 A ATOM 1854 CB TRP A 58 −27.316 41.436 54.605 1.00 17.35 AATOM 1855 CG TRP A 58 −28.455 41.168 55.513 1.00 20.52 A ATOM 1856 CD2TRP A 58 −28.365 40.564 56.777 1.00 21.19 A ATOM 1857 CE2 TRP A 58−29.626 40.717 57.428 1.00 22.55 A ATOM 1858 CE3 TRP A 58 −27.343 39.91057.432 1.00 20.49 A ATOM 1859 CD1 TRP A 58 −29.748 41.647 55.405 1.0023.58 A ATOM 1860 NE1 TRP A 58 −30.476 41.366 56.582 1.00 24.89 A ATOM1861 CZ2 TRP A 58 −29.846 40.243 58.723 1.00 22.52 A ATOM 1862 CZ3 TRP A58 −27.569 39.432 58.719 1.00 21.09 A ATOM 1863 CH2 TRP A 58 −28.81539.607 59.353 1.00 22.11 A ATOM 1864 C TRP A 58 −27.266 39.134 53.5511.00 15.75 A ATOM 1865 O TRP A 58 −27.919 39.330 52.584 1.00 15.79 AATOM 1866 N VAL A 59 −27.263 37.973 54.153 1.00 16.08 A ATOM 1867 CA VALA 59 −28.047 36.917 53.641 1.00 16.01 A ATOM 1868 CB VAL A 59 −27.13035.760 53.208 1.00 17.38 A ATOM 1869 CG1 VAL A 59 −27.979 34.549 52.6601.00 17.74 A ATOM 1870 CG2 VAL A 59 −26.071 36.278 52.228 1.00 14.35 AATOM 1871 C VAL A 59 −29.034 36.412 54.693 1.00 16.20 A ATOM 1872 O VALA 59 −28.583 35.952 55.791 1.00 17.04 A ATOM 1873 N TYR A 60 −30.36036.456 54.354 1.00 13.74 A ATOM 1874 CA TYR A 60 −31.427 35.933 55.1931.00 11.31 A ATOM 1875 CB TYR A 60 −32.778 36.150 54.573 1.00 12.23 AATOM 1876 CG TYR A 60 −33.201 37.576 54.599 1.00 14.43 A ATOM 1877 CD1TYR A 60 −33.333 38.302 53.427 1.00 14.20 A ATOM 1878 CE1 TYR A 60−33.702 39.665 53.491 1.00 15.83 A ATOM 1879 CD2 TYR A 60 −33.435 38.26755.848 1.00 15.03 A ATOM 1880 CE2 TYR A 60 −33.799 39.653 55.876 1.0014.90 A ATOM 1881 CZ TYR A 60 −33.939 40.335 54.738 1.00 14.54 A ATOM1882 OH TYR A 60 −34.369 41.678 54.756 1.00 14.78 A ATOM 1883 C TYR A 60−31.265 34.448 55.413 1.00 11.30 A ATOM 1884 O TYR A 60 −30.940 33.74954.517 1.00 8.53 A ATOM 1885 N ARG A 61 −31.507 33.990 56.621 1.00 11.48A ATOM 1886 CA ARG A 61 −31.355 32.641 56.961 1.00 13.28 A ATOM 1887 CBARG A 61 −31.174 32.500 58.440 1.00 14.14 A ATOM 1888 CG ARG A 61−31.306 31.023 58.935 1.00 16.63 A ATOM 1889 CD ARG A 61 −30.924 30.79060.460 1.00 18.13 A ATOM 1890 NE ARG A 61 −31.953 31.360 61.361 1.0017.67 A ATOM 1891 CZ ARG A 61 −33.131 30.791 61.627 1.00 15.86 A ATOM1892 NH1 ARG A 61 −33.415 29.602 61.088 1.00 15.52 A ATOM 1893 NH2 ARG A61 −34.031 31.470 62.317 1.00 14.08 A ATOM 1894 C ARG A 61 −32.60631.904 56.583 1.00 16.13 A ATOM 1895 O ARG A 61 −32.528 30.770 56.1181.00 16.81 A ATOM 1896 N GLY A 62 −33.759 32.579 56.717 1.00 17.25 AATOM 1897 CA GLY A 62 −35.087 31.993 56.526 1.00 18.15 A ATOM 1898 C GLYA 62 −35.272 30.769 57.438 1.00 19.05 A ATOM 1899 O GLY A 62 −35.10630.832 58.619 1.00 19.19 A ATOM 1900 N GLU A 63 −35.557 29.617 56.8611.00 19.16 A ATOM 1901 CA GLU A 63 −35.739 28.421 57.619 1.00 19.78 AATOM 1902 CB GLU A 63 −36.917 27.663 56.954 1.00 19.93 A ATOM 1903 CGGLU A 63 −37.178 26.276 57.537 1.00 21.72 A ATOM 1904 CD GLU A 63−37.919 26.346 58.911 1.00 25.80 A ATOM 1905 OE1 GLU A 63 −38.009 25.27359.724 1.00 26.27 A ATOM 1906 OE2 GLU A 63 −38.406 27.531 59.188 1.0027.57 A ATOM 1907 C GLU A 63 −34.448 27.534 57.719 1.00 19.89 A ATOM1908 O GLU A 63 −34.496 26.467 58.286 1.00 21.37 A ATOM 1909 N ALA A 64−33.292 27.937 57.196 1.00 19.68 A ATOM 1910 CA ALA A 64 −32.076 27.09457.281 1.00 18.50 A ATOM 1911 CB ALA A 64 −31.053 27.699 56.386 1.0018.35 A ATOM 1912 C ALA A 64 −31.446 26.879 58.658 1.00 17.72 A ATOM1913 O ALA A 64 −31.413 27.790 59.422 1.00 17.67 A ATOM 1914 N GLU A 65−31.001 25.671 58.987 1.00 17.83 A ATOM 1915 CA GLU A 65 −30.284 25.39460.262 1.00 17.38 A ATOM 1916 CB GLU A 65 −30.760 24.136 60.961 1.0018.13 A ATOM 1917 CG GLU A 65 −32.285 23.982 61.075 1.00 23.15 A ATOM1918 CD GLU A 65 −32.922 24.513 62.373 1.00 24.29 A ATOM 1919 OE1 GLU A65 −32.455 23.863 63.379 1.00 25.84 A ATOM 1920 OE2 GLU A 65 −33.80525.493 62.345 1.00 23.65 A ATOM 1921 C GLU A 65 −28.797 25.158 59.8761.00 16.53 A ATOM 1922 O GLU A 65 −27.901 25.623 60.511 1.00 16.58 AATOM 1923 N ARG A 66 −28.551 24.329 58.869 1.00 16.58 A ATOM 1924 CA ARGA 66 −27.187 24.072 58.290 1.00 17.43 A ATOM 1925 CB ARG A 66 −26.80722.598 58.288 1.00 17.81 A ATOM 1926 CG ARG A 66 −25.342 22.405 58.0471.00 18.30 A ATOM 1927 CD ARG A 66 −24.815 21.331 59.039 1.00 20.74 AATOM 1928 NE ARG A 66 −23.350 21.159 59.040 1.00 22.55 A ATOM 1929 CZARG A 66 −22.547 21.542 60.049 1.00 23.63 A ATOM 1930 NH1 ARG A 66−23.043 22.123 61.173 1.00 24.37 A ATOM 1931 NH2 ARG A 66 −21.244 21.33359.940 1.00 24.53 A ATOM 1932 C ARG A 66 −27.203 24.544 56.787 1.0017.07 A ATOM 1933 O ARG A 66 −28.201 24.307 56.078 1.00 17.08 A ATOM1934 N ASN A 67 −26.187 25.253 56.340 1.00 17.17 A ATOM 1935 CA ASN A 67−26.167 25.698 54.981 1.00 18.28 A ATOM 1936 CB ASN A 67 −26.093 27.21654.818 1.00 18.83 A ATOM 1937 CG ASN A 67 −25.183 27.796 55.806 1.0021.35 A ATOM 1938 OD1 ASN A 67 −25.104 27.249 56.949 1.00 25.96 A ATOM1939 ND2 ASN A 67 −24.519 28.897 55.499 1.00 19.58 A ATOM 1940 C ASN A67 −24.916 25.107 54.524 1.00 18.09 A ATOM 1941 O ASN A 67 −24.00224.869 55.308 1.00 18.74 A ATOM 1942 N ASN A 68 −24.889 24.801 53.2371.00 17.86 A ATOM 1943 CA ASN A 68 −23.691 24.262 52.616 1.00 18.28 AATOM 1944 CB ASN A 68 −24.179 23.077 51.817 1.00 19.82 A ATOM 1945 CGASN A 68 −24.515 22.017 52.687 1.00 22.30 A ATOM 1946 OD1 ASN A 68−23.561 21.328 53.208 1.00 23.10 A ATOM 1947 ND2 ASN A 68 −25.861 21.84452.994 1.00 23.44 A ATOM 1948 C ASN A 68 −23.092 25.400 51.728 1.0016.96 A ATOM 1949 O ASN A 68 −23.860 26.277 51.200 1.00 16.56 A ATOM1950 N PHE A 69 −21.766 25.451 51.593 1.00 16.86 A ATOM 1951 CA PHE A 69−21.235 26.425 50.592 1.00 17.91 A ATOM 1952 CB PHE A 69 −20.743 27.69151.112 1.00 17.80 A ATOM 1953 CG PHE A 69 −20.526 27.630 52.477 1.0019.28 A ATOM 1954 CD1 PHE A 69 −19.633 26.693 52.977 1.00 21.07 A ATOM1955 CD2 PHE A 69 −21.127 28.572 53.320 1.00 18.31 A ATOM 1956 CE1 PHE A69 −19.335 26.745 54.384 1.00 24.18 A ATOM 1957 CE2 PHE A 69 −20.86128.653 54.682 1.00 19.30 A ATOM 1958 CZ PHE A 69 −19.975 27.766 55.2551.00 20.98 A ATOM 1959 C PHE A 69 −20.152 25.883 49.800 1.00 17.93 AATOM 1960 O PHE A 69 −19.184 25.230 50.300 1.00 18.87 A ATOM 1961 N GLUA 70 −20.402 26.084 48.518 1.00 17.62 A ATOM 1962 CA GLU A 70 −19.56325.578 47.497 1.00 16.65 A ATOM 1963 CB GLU A 70 −20.476 24.911 46.4521.00 17.59 A ATOM 1964 CG GLU A 70 −19.766 23.887 45.635 1.00 18.37 AATOM 1965 CD GLU A 70 −20.473 23.617 44.312 1.00 18.22 A ATOM 1966 OE1GLU A 70 −20.606 22.406 43.938 1.00 18.80 A ATOM 1967 OE2 GLU A 70−20.861 24.637 43.689 1.00 17.15 A ATOM 1968 C GLU A 70 −18.765 26.73446.979 1.00 14.76 A ATOM 1969 O GLU A 70 −19.298 27.804 46.583 1.0013.26 A ATOM 1970 N LEU A 71 −17.461 26.480 47.021 1.00 14.00 A ATOM1971 CA LEU A 71 −16.424 27.400 46.513 1.00 14.48 A ATOM 1972 CB LEU A71 −15.410 27.708 47.638 1.00 15.21 A ATOM 1973 CG LEU A 71 −16.08928.303 48.784 1.00 15.78 A ATOM 1974 CD1 LEU A 71 −15.260 28.207 49.9191.00 17.13 A ATOM 1975 CD2 LEU A 71 −16.514 29.700 48.423 1.00 16.10 AATOM 1976 C LEU A 71 −15.628 26.782 45.360 1.00 12.93 A ATOM 1977 O LEUA 71 −15.178 25.663 45.525 1.00 12.07 A ATOM 1978 N ASN A 72 −15.43527.555 44.297 1.00 12.98 A ATOM 1979 CA ASN A 72 −14.714 27.243 43.0751.00 14.94 A ATOM 1980 CB ASN A 72 −15.681 27.159 41.788 1.00 17.39 AATOM 1981 CG ASN A 72 −16.447 25.804 41.709 1.00 21.16 A ATOM 1982 OD1ASN A 72 −17.411 25.553 40.931 1.00 21.52 A ATOM 1983 ND2 ASN A 72−15.948 24.861 42.529 1.00 25.39 A ATOM 1984 C ASN A 72 −13.699 28.36242.884 1.00 13.68 A ATOM 1985 O ASN A 72 −14.047 29.525 42.778 1.0013.31 A ATOM 1986 N PHE A 73 −12.417 27.993 42.800 1.00 14.73 A ATOM1987 CA PHE A 73 −11.311 28.959 42.717 1.00 15.21 A ATOM 1988 CB PHE A73 −10.975 29.403 44.151 1.00 14.12 A ATOM 1989 CG PHE A 73 −10.62228.191 45.061 1.00 13.08 A ATOM 1990 CD1 PHE A 73 −9.314 27.783 45.2261.00 10.42 A ATOM 1991 CD2 PHE A 73 −11.611 27.463 45.682 1.00 12.01 AATOM 1992 CE1 PHE A 73 −8.983 26.657 46.033 1.00 12.55 A ATOM 1993 CE2PHE A 73 −11.262 26.353 46.465 1.00 15.26 A ATOM 1994 CZ PHE A 73 −9.91825.953 46.652 1.00 11.88 A ATOM 1995 C PHE A 73 −10.079 28.276 42.1571.00 14.55 A ATOM 1996 O PHE A 73 −10.007 27.077 42.023 1.00 15.70 AATOM 1997 N THR A 74 −9.072 29.088 41.952 1.00 15.15 A ATOM 1998 CA THRA 74 −7.798 28.661 41.436 1.00 16.00 A ATOM 1999 CB THR A 74 −7.53129.062 40.002 1.00 15.00 A ATOM 2000 OG1 THR A 74 −7.152 30.433 39.9081.00 16.70 A ATOM 2001 CG2 THR A 74 −8.677 28.961 39.307 1.00 15.46 AATOM 2002 C THR A 74 −6.787 29.331 42.249 1.00 14.55 A ATOM 2003 O THR A74 −7.052 30.365 42.830 1.00 14.86 A ATOM 2004 N VAL A 75 −5.629 28.72642.272 1.00 14.53 A ATOM 2005 CA VAL A 75 −4.531 29.201 43.070 1.0014.75 A ATOM 2006 CB VAL A 75 −4.524 28.379 44.355 1.00 14.30 A ATOM2007 CG1 VAL A 75 −3.366 28.682 45.211 1.00 14.75 A ATOM 2008 CG2 VAL A75 −5.783 28.611 45.052 1.00 10.73 A ATOM 2009 C VAL A 75 −3.225 29.12742.281 1.00 14.09 A ATOM 2010 O VAL A 75 −2.837 28.073 41.847 1.00 13.03A ATOM 2011 N ARG A 76 −2.621 30.299 42.020 1.00 14.12 A ATOM 2012 CAARG A 76 −1.370 30.335 41.284 1.00 14.41 A ATOM 2013 CB ARG A 76 −1.06231.712 40.814 1.00 13.21 A ATOM 2014 CG ARG A 76 0.125 31.760 40.0421.00 10.77 A ATOM 2015 CD ARG A 76 0.073 32.882 39.018 1.00 9.49 A ATOM2016 NE ARG A 76 1.431 33.136 38.674 1.00 10.33 A ATOM 2017 CZ ARG A 761.934 34.262 38.198 1.00 12.71 A ATOM 2018 NH1 ARG A 76 1.147 35.28637.949 1.00 11.89 A ATOM 2019 NH2 ARG A 76 3.282 34.425 38.136 1.0012.56 A ATOM 2020 C ARG A 76 −0.285 29.777 42.231 1.00 16.34 A ATOM 2021O ARG A 76 −0.220 30.041 43.464 1.00 17.36 A ATOM 2022 N ASP A 77 0.44828.844 41.677 1.00 17.02 A ATOM 2023 CA ASP A 77 1.543 28.184 42.3371.00 17.11 A ATOM 2024 CB ASP A 77 2.197 27.213 41.330 1.00 18.78 A ATOM2025 CG ASP A 77 3.650 26.713 41.783 1.00 20.06 A ATOM 2026 OD1 ASP A 774.021 26.820 42.955 1.00 19.73 A ATOM 2027 OD2 ASP A 77 4.385 26.18940.954 1.00 20.07 A ATOM 2028 C ASP A 77 2.541 29.233 42.802 1.00 16.81A ATOM 2029 O ASP A 77 2.923 30.156 42.018 1.00 16.50 A ATOM 2030 N CYSA 78 2.914 29.153 44.078 1.00 16.36 A ATOM 2031 CA CYS A 78 3.871 30.14344.662 1.00 16.72 A ATOM 2032 C CYS A 78 5.236 30.207 44.007 1.00 15.14A ATOM 2033 O CYS A 78 5.811 31.270 43.850 1.00 14.09 A ATOM 2034 CB CYSA 78 4.027 29.991 46.187 1.00 17.53 A ATOM 2035 SG CYS A 78 2.644 30.93447.082 1.00 19.32 A ATOM 2036 N ASN A 79 5.707 29.051 43.551 1.00 14.59A ATOM 2037 CA ASN A 79 6.938 29.011 42.826 1.00 13.80 A ATOM 2038 CBASN A 79 7.395 27.615 42.834 1.00 14.81 A ATOM 2039 CG ASN A 79 7.70927.132 44.175 1.00 15.52 A ATOM 2040 OD1 ASN A 79 7.873 25.956 44.4151.00 14.64 A ATOM 2041 ND2 ASN A 79 7.833 28.061 45.100 1.00 21.08 AATOM 2042 C ASN A 79 6.893 29.589 41.352 1.00 13.29 A ATOM 2043 O ASN A79 7.881 29.519 40.666 1.00 12.02 A ATOM 2044 N SER A 80 5.771 30.16840.922 1.00 12.90 A ATOM 2045 CA SER A 80 5.672 30.682 39.587 1.00 14.97A ATOM 2046 CB SER A 80 4.310 30.444 38.931 1.00 15.80 A ATOM 2047 OGSER A 80 3.335 31.267 39.612 1.00 24.05 A ATOM 2048 C SER A 80 5.96132.138 39.622 1.00 14.22 A ATOM 2049 O SER A 80 5.705 32.842 38.711 1.0013.44 A ATOM 2050 N PHE A 81 6.425 32.641 40.723 1.00 14.95 A ATOM 2051CA PHE A 81 6.838 34.018 40.661 1.00 16.50 A ATOM 2052 CB PHE A 81 6.22834.685 41.855 1.00 17.07 A ATOM 2053 CG PHE A 81 4.705 34.708 41.8341.00 16.77 A ATOM 2054 CD1 PHE A 81 3.942 33.742 42.498 1.00 15.78 AATOM 2055 CD2 PHE A 81 4.008 35.702 41.117 1.00 15.43 A ATOM 2056 CE1PHE A 81 2.544 33.764 42.440 1.00 13.87 A ATOM 2057 CE2 PHE A 81 2.61935.686 41.097 1.00 13.42 A ATOM 2058 CZ PHE A 81 1.887 34.707 41.7621.00 11.30 A ATOM 2059 C PHE A 81 8.425 33.937 40.665 1.00 17.18 A ATOM2060 O PHE A 81 9.011 33.579 41.632 1.00 18.01 A ATOM 2061 N PRO A 829.106 34.283 39.580 1.00 17.28 A ATOM 2062 CD PRO A 82 8.540 35.23138.632 1.00 17.29 A ATOM 2063 CA PRO A 82 10.601 34.233 39.436 1.0018.20 A ATOM 2064 CB PRO A 82 10.888 35.012 38.154 1.00 17.89 A ATOM2065 CG PRO A 82 9.613 35.169 37.510 1.00 17.42 A ATOM 2066 C PRO A 8211.399 34.834 40.584 1.00 18.30 A ATOM 2067 O PRO A 82 11.098 35.96240.991 1.00 17.90 A ATOM 2068 N GLY A 83 12.447 34.103 41.011 1.00 19.38A ATOM 2069 CA GLY A 83 13.305 34.445 42.159 1.00 20.29 A ATOM 2070 CGLY A 83 12.408 33.965 43.261 1.00 20.44 A ATOM 2071 O GLY A 83 11.25133.524 42.944 1.00 21.15 A ATOM 2072 N GLY A 84 12.785 33.977 44.5491.00 20.09 A ATOM 2073 CA GLY A 84 11.711 33.434 45.472 1.00 19.03 AATOM 2074 C GLY A 84 10.452 34.298 45.792 1.00 18.38 A ATOM 2075 O GLY A84 10.394 35.471 45.386 1.00 16.33 A ATOM 2076 N ALA A 85 9.400 33.76046.447 1.00 19.08 A ATOM 2077 CA ALA A 85 8.262 34.697 46.823 1.00 20.80A ATOM 2078 CB ALA A 85 6.942 34.524 45.898 1.00 19.17 A ATOM 2079 C ALAA 85 7.932 34.332 48.220 1.00 20.07 A ATOM 2080 O ALA A 85 6.869 33.82448.490 1.00 22.94 A ATOM 2081 N SER A 86 8.854 34.538 49.103 1.00 18.77A ATOM 2082 CA SER A 86 8.737 34.167 50.529 1.00 16.77 A ATOM 2083 CBSER A 86 9.883 34.851 51.283 1.00 14.82 A ATOM 2084 OG SER A 86 9.86936.252 51.035 1.00 10.04 A ATOM 2085 C SER A 86 7.414 34.362 51.253 1.0014.87 A ATOM 2086 O SER A 86 7.045 33.465 51.954 1.00 14.56 A ATOM 2087N SER A 87 6.676 35.449 51.067 1.00 12.96 A ATOM 2088 CA SER A 87 5.38835.598 51.774 1.00 12.45 A ATOM 2089 CB SER A 87 5.128 37.031 52.1181.00 9.17 A ATOM 2090 OG SER A 87 4.876 37.737 50.961 1.00 7.17 A ATOM2091 C SER A 87 4.136 35.046 51.040 1.00 13.90 A ATOM 2092 O SER A 873.020 35.088 51.565 1.00 14.54 A ATOM 2093 N CYS A 88 4.331 34.51149.832 1.00 14.94 A ATOM 2094 CA CYS A 88 3.258 33.989 49.047 1.00 15.17A ATOM 2095 C CYS A 88 2.773 32.796 49.736 1.00 14.84 A ATOM 2096 O CYSA 88 3.511 32.087 50.299 1.00 13.64 A ATOM 2097 CB CYS A 88 3.733 33.65447.657 1.00 17.44 A ATOM 2098 SG CYS A 88 2.587 32.896 46.469 1.00 17.56A ATOM 2099 N LYS A 89 1.458 32.671 49.744 1.00 16.19 A ATOM 2100 CA LYSA 89 0.734 31.552 50.369 1.00 16.99 A ATOM 2101 CB LYS A 89 −0.23232.151 51.413 1.00 18.17 A ATOM 2102 CG LYS A 89 0.525 32.873 52.4781.00 20.10 A ATOM 2103 CD LYS A 89 1.413 31.897 53.399 1.00 19.59 A ATOM2104 CE LYS A 89 1.967 32.736 54.645 1.00 21.69 A ATOM 2105 NZ LYS A 892.642 31.850 55.706 1.00 24.41 A ATOM 2106 C LYS A 89 −0.092 30.79549.369 1.00 15.95 A ATOM 2107 O LYS A 89 −0.358 31.297 48.351 1.00 15.66A ATOM 2108 N GLU A 90 −0.574 29.623 49.713 1.00 18.02 A ATOM 2109 CAGLU A 90 −1.418 28.853 48.782 1.00 18.81 A ATOM 2110 CB GLU A 90 −0.68327.705 48.112 1.00 17.83 A ATOM 2111 CG GLU A 90 0.571 28.238 47.3391.00 18.11 A ATOM 2112 CD GLU A 90 1.358 27.195 46.672 1.00 17.99 A ATOM2113 OE1 GLU A 90 1.537 26.122 47.269 1.00 17.80 A ATOM 2114 OE2 GLU A90 1.778 27.466 45.540 1.00 19.48 A ATOM 2115 C GLU A 90 −2.640 28.34349.430 1.00 19.05 A ATOM 2116 O GLU A 90 −3.068 27.227 49.160 1.00 21.56A ATOM 2117 N THR A 91 −3.216 29.165 50.307 1.00 18.83 A ATOM 2118 CATHR A 91 −4.505 28.775 50.906 1.00 17.39 A ATOM 2119 CB THR A 91 −4.36527.932 52.214 1.00 16.31 A ATOM 2120 OG1 THR A 91 −3.676 28.712 53.1631.00 16.46 A ATOM 2121 CG2 THR A 91 −3.650 26.654 51.997 1.00 11.93 AATOM 2122 C THR A 91 −5.142 30.143 51.235 1.00 15.93 A ATOM 2123 O THR A91 −4.452 31.225 51.074 1.00 14.38 A ATOM 2124 N PHE A 92 −6.430 30.04451.621 1.00 14.99 A ATOM 2125 CA PHE A 92 −7.213 31.203 52.064 1.0015.58 A ATOM 2126 CB PHE A 92 −7.876 31.983 50.900 1.00 15.72 A ATOM2127 CG PHE A 92 −8.920 31.221 50.168 1.00 16.39 A ATOM 2128 CD1 PHE A92 −10.264 31.409 50.449 1.00 15.99 A ATOM 2129 CD2 PHE A 92 −8.54030.377 49.124 1.00 16.52 A ATOM 2130 CE1 PHE A 92 −11.263 30.773 49.6901.00 18.53 A ATOM 2131 CE2 PHE A 92 −9.476 29.707 48.322 1.00 17.39 AATOM 2132 CZ PHE A 92 −10.886 29.882 48.578 1.00 18.44 A ATOM 2133 C PHEA 92 −8.242 30.805 53.055 1.00 14.35 A ATOM 2134 O PHE A 92 −8.58129.657 53.092 1.00 14.78 A ATOM 2135 N ASN A 93 −8.766 31.755 53.8131.00 13.07 A ATOM 2136 CA ASN A 93 −9.714 31.493 54.878 1.00 11.84 AATOM 2137 CB ASN A 93 −9.257 32.211 56.077 1.00 12.12 A ATOM 2138 CG ASNA 93 −8.055 31.647 56.603 1.00 12.16 A ATOM 2139 OD1 ASN A 93 −7.88930.458 56.699 1.00 11.78 A ATOM 2140 ND2 ASN A 93 −7.169 32.508 56.9461.00 13.65 A ATOM 2141 C ASN A 93 −11.107 31.792 54.732 1.00 10.74 AATOM 2142 O ASN A 93 −11.444 32.821 54.158 1.00 10.01 A ATOM 2143 N LEUA 94 −11.939 30.915 55.262 1.00 10.68 A ATOM 2144 CA LEU A 94 −13.36231.142 55.202 1.00 11.85 A ATOM 2145 CB LEU A 94 −14.033 29.936 54.5961.00 11.21 A ATOM 2146 CG LEU A 94 −15.566 29.808 54.593 1.00 12.23 AATOM 2147 CD1 LEU A 94 −16.166 30.993 53.718 1.00 13.28 A ATOM 2148 CD2LEU A 94 −15.934 28.439 54.106 1.00 11.46 A ATOM 2149 C LEU A 94 −13.97531.416 56.578 1.00 12.45 A ATOM 2150 O LEU A 94 −13.774 30.654 57.5101.00 12.43 A ATOM 2151 N TYR A 95 −14.800 32.453 56.665 1.00 14.58 AATOM 2152 CA TYR A 95 −15.509 32.934 57.901 1.00 16.11 A ATOM 2153 CBTYR A 95 −14.860 34.250 58.457 1.00 17.37 A ATOM 2154 CG TYR A 95−13.433 34.175 58.995 1.00 17.38 A ATOM 2155 CD1 TYR A 95 −12.323 33.88058.157 1.00 16.12 A ATOM 2156 CE1 TYR A 95 −11.035 33.773 58.685 1.0016.68 A ATOM 2157 CD2 TYR A 95 −13.217 34.367 60.358 1.00 17.38 A ATOM2158 CE2 TYR A 95 −11.975 34.265 60.902 1.00 17.10 A ATOM 2159 CZ TYR A95 −10.881 33.972 60.086 1.00 16.95 A ATOM 2160 OH TYR A 95 −9.72633.813 60.723 1.00 17.24 A ATOM 2161 C TYR A 95 −16.945 33.360 57.6491.00 15.17 A ATOM 2162 O TYR A 95 −17.387 33.689 56.528 1.00 14.25 AATOM 2163 N TYR A 96 −17.651 33.481 58.764 1.00 15.31 A ATOM 2164 CA TYRA 96 −19.049 33.954 58.691 1.00 14.79 A ATOM 2165 CB TYR A 96 −20.05132.801 58.489 1.00 14.57 A ATOM 2166 CG TYR A 96 −20.276 31.976 59.6961.00 13.64 A ATOM 2167 CD1 TYR A 96 −21.503 31.994 60.301 1.00 14.40 AATOM 2168 CE1 TYR A 96 −21.750 31.254 61.431 1.00 15.60 A ATOM 2169 CD2TYR A 96 −19.274 31.206 60.232 1.00 13.00 A ATOM 2170 CE2 TYR A 96−19.482 30.446 61.362 1.00 13.72 A ATOM 2171 CZ TYR A 96 −20.713 30.44461.979 1.00 14.85 A ATOM 2172 OH TYR A 96 −20.885 29.572 63.041 1.0013.43 A ATOM 2173 C TYR A 96 −19.321 34.638 60.007 1.00 13.97 A ATOM2174 O TYR A 96 −18.519 34.591 60.855 1.00 12.95 A ATOM 2175 N ALA A 97−20.441 35.324 60.093 1.00 14.90 A ATOM 2176 CA ALA A 97 −20.986 35.93561.308 1.00 16.05 A ATOM 2177 CB ALA A 97 −20.441 37.367 61.529 1.0016.09 A ATOM 2178 C ALA A 97 −22.516 35.933 61.106 1.00 16.05 A ATOM2179 O ALA A 97 −23.006 36.047 60.005 1.00 16.49 A ATOM 2180 N GLU A 98−23.257 35.713 62.177 1.00 16.04 A ATOM 2181 CA GLU A 98 −24.710 35.68562.149 1.00 16.83 A ATOM 2182 CB GLU A 98 −25.173 34.568 63.003 1.0016.04 A ATOM 2183 CG GLU A 98 −25.241 33.303 62.337 1.00 15.83 A ATOM2184 CD GLU A 98 −25.813 32.170 63.298 1.00 17.91 A ATOM 2185 OE1 GLU A98 −25.029 31.501 64.068 1.00 19.30 A ATOM 2186 OE2 GLU A 98 −27.05731.949 63.289 1.00 16.71 A ATOM 2187 C GLU A 98 −25.202 36.987 62.7861.00 16.82 A ATOM 2188 O GLU A 98 −24.498 37.476 63.700 1.00 18.03 AATOM 2189 N SER A 99 −26.305 37.574 62.320 1.00 14.68 A ATOM 2190 CA SERA 99 −26.799 38.703 63.003 1.00 14.15 A ATOM 2191 CB SER A 99 −26.00240.050 62.908 1.00 13.68 A ATOM 2192 OG SER A 99 −26.041 40.773 61.7291.00 13.53 A ATOM 2193 C SER A 99 −28.229 38.919 62.707 1.00 14.72 AATOM 2194 O SER A 99 −28.675 38.491 61.714 1.00 13.40 A ATOM 2195 N ASPA 100 −28.966 39.559 63.636 1.00 14.50 A ATOM 2196 CA ASP A 100 −30.33039.791 63.401 1.00 15.71 A ATOM 2197 CB ASP A 100 −31.152 39.835 64.7021.00 16.92 A ATOM 2198 CG ASP A 100 −31.199 38.523 65.407 1.00 19.17 AATOM 2199 OD1 ASP A 100 −31.517 37.513 64.703 1.00 19.49 A ATOM 2200 OD2ASP A 100 −30.913 38.454 66.703 1.00 19.99 A ATOM 2201 C ASP A 100−30.541 41.046 62.605 1.00 16.56 A ATOM 2202 O ASP A 100 −31.627 41.20962.081 1.00 17.24 A ATOM 2203 N LEU A 101 −29.527 41.886 62.490 1.0016.21 A ATOM 2204 CA LEU A 101 −29.594 43.192 61.824 1.00 15.59 A ATOM2205 CB LEU A 101 −29.110 44.365 62.731 1.00 17.35 A ATOM 2206 CG LEU A101 −29.383 44.587 64.202 1.00 20.31 A ATOM 2207 CD1 LEU A 101 −28.90943.361 64.925 1.00 20.38 A ATOM 2208 CD2 LEU A 101 −28.596 45.820 64.8151.00 21.78 A ATOM 2209 C LEU A 101 −28.541 43.160 60.727 1.00 15.15 AATOM 2210 O LEU A 101 −27.517 42.494 60.897 1.00 13.01 A ATOM 2211 N ASPA 102 −28.799 43.984 59.693 1.00 15.38 A ATOM 2212 CA ASP A 102 −27.98444.195 58.530 1.00 16.74 A ATOM 2213 CB ASP A 102 −28.825 44.867 57.5321.00 17.87 A ATOM 2214 CG ASP A 102 −28.172 44.991 56.198 1.00 20.24 AATOM 2215 OD1 ASP A 102 −26.981 45.278 56.061 1.00 20.82 A ATOM 2216 OD2ASP A 102 −28.893 44.772 55.214 1.00 22.85 A ATOM 2217 C ASP A 102−26.866 45.151 58.833 1.00 17.55 A ATOM 2218 O ASP A 102 −27.129 46.36158.955 1.00 18.18 A ATOM 2219 N TYR A 103 −25.612 44.674 58.892 1.0017.54 A ATOM 2220 CA TYR A 103 −24.469 45.564 59.255 1.00 17.18 A ATOM2221 CB TYR A 103 −23.133 44.807 59.425 1.00 18.78 A ATOM 2222 CG TYR A103 −22.965 44.114 60.690 1.00 21.08 A ATOM 2223 CD1 TYR A 103 −23.21544.710 61.948 1.00 22.54 A ATOM 2224 CE1 TYR A 103 −23.067 43.921 63.1961.00 22.15 A ATOM 2225 CD2 TYR A 103 −22.584 42.823 60.681 1.00 22.23 AATOM 2226 CE2 TYR A 103 −22.445 42.069 61.899 1.00 22.86 A ATOM 2227 CZTYR A 103 −22.688 42.594 63.100 1.00 23.05 A ATOM 2228 OH TYR A 103−22.587 41.581 64.091 1.00 23.96 A ATOM 2229 C TYR A 103 −24.163 46.71558.302 1.00 16.77 A ATOM 2230 O TYR A 103 −23.333 47.635 58.606 1.0015.36 A ATOM 2231 N GLY A 104 −24.805 46.687 57.165 1.00 16.27 A ATOM2232 CA GLY A 104 −24.529 47.699 56.198 1.00 16.52 A ATOM 2233 C GLY A104 −23.022 47.628 55.844 1.00 17.80 A ATOM 2234 O GLY A 104 −22.39646.560 55.526 1.00 18.17 A ATOM 2235 N THR A 105 −22.360 48.781 55.8671.00 18.37 A ATOM 2236 CA THR A 105 −20.946 48.817 55.539 1.00 18.03 AATOM 2237 CB THR A 105 −20.694 50.173 54.925 1.00 19.27 A ATOM 2238 OG1THR A 105 −20.974 50.101 53.542 1.00 20.04 A ATOM 2239 CG2 THR A 105−19.335 50.536 54.991 1.00 20.09 A ATOM 2240 C THR A 105 −19.939 48.44856.693 1.00 17.66 A ATOM 2241 O THR A 105 −18.730 48.251 56.517 1.0016.55 A ATOM 2242 N ASN A 106 −20.479 48.249 57.872 1.00 18.01 A ATOM2243 CA ASN A 106 −19.667 47.899 59.036 1.00 18.91 A ATOM 2244 CB ASN A106 −20.483 47.870 60.327 1.00 20.77 A ATOM 2245 CG ASN A 106 −20.83749.209 60.828 1.00 22.33 A ATOM 2246 OD1 ASN A 106 −21.671 49.336 61.7941.00 24.28 A ATOM 2247 ND2 ASN A 106 −20.228 50.243 60.224 1.00 24.12 AATOM 2248 C ASN A 106 −19.019 46.577 59.027 1.00 17.88 A ATOM 2249 O ASNA 106 −19.488 45.635 59.616 1.00 17.47 A ATOM 2250 N PHE A 107 −17.89646.479 58.436 1.00 17.57 A ATOM 2251 CA PHE A 107 −17.321 45.192 58.6091.00 18.13 A ATOM 2252 CB PHE A 107 −16.576 44.850 57.350 1.00 17.71 AATOM 2253 CG PHE A 107 −15.874 43.556 57.451 1.00 17.42 A ATOM 2254 CD1PHE A 107 −16.591 42.369 57.509 1.00 17.57 A ATOM 2255 CD2 PHE A 107−14.503 43.519 57.556 1.00 15.83 A ATOM 2256 CE1 PHE A 107 −15.90041.212 57.679 1.00 18.23 A ATOM 2257 CE2 PHE A 107 −13.788 42.355 57.7261.00 15.10 A ATOM 2258 CZ PHE A 107 −14.428 41.220 57.789 1.00 17.88 AATOM 2259 C PHE A 107 −16.379 45.074 59.874 1.00 19.33 A ATOM 2260 O PHEA 107 −15.532 45.942 60.155 1.00 18.82 A ATOM 2261 N GLN A 108 −16.48744.019 60.620 1.00 19.60 A ATOM 2262 CA GLN A 108 −15.640 43.896 61.7981.00 20.41 A ATOM 2263 CB GLN A 108 −16.473 43.904 63.082 1.00 22.43 AATOM 2264 CG GLN A 108 −17.496 45.134 63.280 1.00 25.28 A ATOM 2265 CDGLN A 108 −16.718 46.364 63.879 1.00 25.17 A ATOM 2266 OE1 GLN A 108−17.315 47.423 64.137 1.00 27.70 A ATOM 2267 NE2 GLN A 108 −15.39046.206 64.069 1.00 23.26 A ATOM 2268 C GLN A 108 −15.028 42.520 61.7931.00 21.53 A ATOM 2269 O GLN A 108 −15.685 41.530 62.285 1.00 22.45 AATOM 2270 N LYS A 109 −13.820 42.366 61.284 1.00 19.79 A ATOM 2271 CALYS A 109 −13.287 41.012 61.256 1.00 18.63 A ATOM 2272 CB LYS A 109−11.809 41.058 60.830 1.00 18.31 A ATOM 2273 CG LYS A 109 −10.908 40.52561.919 1.00 18.87 A ATOM 2274 CD LYS A 109 −9.470 40.939 61.728 1.0021.42 A ATOM 2275 CE LYS A 109 −8.809 40.206 60.651 1.00 21.73 A ATOM2276 NZ LYS A 109 −7.380 40.488 61.013 1.00 22.81 A ATOM 2277 C LYS A109 −13.423 40.262 62.608 1.00 18.13 A ATOM 2278 O LYS A 109 −13.62439.060 62.694 1.00 18.78 A ATOM 2279 N ARG A 110 −13.329 40.977 63.6821.00 17.45 A ATOM 2280 CA ARG A 110 −13.368 40.287 64.955 1.00 17.69 AATOM 2281 CB ARG A 110 −12.862 41.250 66.045 1.00 17.73 A ATOM 2282 CGARG A 110 −11.322 41.059 66.094 1.00 18.44 A ATOM 2283 CD ARG A 110−10.555 41.810 64.919 1.00 20.47 A ATOM 2284 NE ARG A 110 −9.106 41.41764.948 1.00 22.91 A ATOM 2285 CZ ARG A 110 −8.628 40.151 64.662 1.0024.85 A ATOM 2286 NH1 ARG A 110 −9.486 39.118 64.318 1.00 25.48 A ATOM2287 NH2 ARG A 110 −7.324 39.871 64.717 1.00 22.96 A ATOM 2288 C ARG A110 −14.622 39.661 65.314 1.00 16.37 A ATOM 2289 O ARG A 110 −14.60138.845 66.205 1.00 16.01 A ATOM 2290 N LEU A 111 −15.663 40.011 64.5551.00 16.52 A ATOM 2291 CA LEU A 111 −16.978 39.529 64.754 1.00 17.54 AATOM 2292 CB LEU A 111 −17.959 40.574 64.341 1.00 17.09 A ATOM 2293 CGLEU A 111 −17.843 41.842 65.276 1.00 17.28 A ATOM 2294 CD1 LEU A 111−19.065 42.772 64.863 1.00 17.11 A ATOM 2295 CD2 LEU A 111 −17.88041.439 66.775 1.00 15.51 A ATOM 2296 C LEU A 111 −17.203 38.303 64.0321.00 16.72 A ATOM 2297 O LEU A 111 −18.138 37.612 64.295 1.00 17.85 AATOM 2298 N PHE A 112 −16.322 37.995 63.125 1.00 16.34 A ATOM 2299 CAPHE A 112 −16.450 36.737 62.307 1.00 16.65 A ATOM 2300 CB PHE A 112−15.868 36.980 60.883 1.00 15.82 A ATOM 2301 CG PHE A 112 −16.806 37.67859.985 1.00 16.56 A ATOM 2302 CD1 PHE A 112 −17.158 38.994 60.218 1.0017.89 A ATOM 2303 CD2 PHE A 112 −17.365 37.004 58.878 1.00 17.94 A ATOM2304 CE1 PHE A 112 −18.050 39.659 59.383 1.00 17.24 A ATOM 2305 CE2 PHEA 112 −18.237 37.610 58.032 1.00 17.18 A ATOM 2306 CZ PHE A 112 −18.59038.952 58.282 1.00 19.79 A ATOM 2307 C PHE A 112 −15.774 35.500 62.9321.00 15.53 A ATOM 2308 O PHE A 112 −14.821 35.597 63.700 1.00 15.65 AATOM 2309 N THR A 113 −16.325 34.351 62.638 1.00 15.63 A ATOM 2310 CATHR A 113 −15.764 33.079 63.055 1.00 16.35 A ATOM 2311 CB THR A 113−16.855 32.285 63.666 1.00 16.84 A ATOM 2312 OG1 THR A 113 −17.32233.061 64.785 1.00 18.03 A ATOM 2313 CG2 THR A 113 −16.409 30.809 63.9991.00 14.82 A ATOM 2314 C THR A 113 −15.198 32.327 61.822 1.00 15.72 AATOM 2315 O THR A 113 −15.704 32.373 60.706 1.00 14.96 A ATOM 2316 N LYSA 114 −14.104 31.676 62.044 1.00 15.64 A ATOM 2317 CA LYS A 114 −13.44331.008 61.014 1.00 15.90 A ATOM 2318 CB LYS A 114 −11.912 30.819 61.3101.00 16.29 A ATOM 2319 CG LYS A 114 −11.099 29.965 60.180 1.00 16.29 AATOM 2320 CD LYS A 114 −9.570 30.011 60.191 1.00 15.56 A ATOM 2321 CELYS A 114 −8.940 28.971 59.236 1.00 17.03 A ATOM 2322 NZ LYS A 114−7.415 28.710 59.138 1.00 13.54 A ATOM 2323 C LYS A 114 −14.157 29.67960.876 1.00 16.82 A ATOM 2324 O LYS A 114 −14.449 29.032 61.875 1.0016.00 A ATOM 2325 N ILE A 115 −14.470 29.301 59.616 1.00 16.38 A ATOM2326 CA ILE A 115 −15.053 28.039 59.382 1.00 15.89 A ATOM 2327 CB ILE A115 −15.992 28.100 58.230 1.00 15.93 A ATOM 2328 CG2 ILE A 115 −16.31426.715 57.782 1.00 13.30 A ATOM 2329 CG1 ILE A 115 −17.195 28.951 58.6681.00 16.64 A ATOM 2330 CD1 ILE A 115 −18.272 29.496 57.610 1.00 10.99 AATOM 2331 C ILE A 115 −13.897 27.041 59.092 1.00 16.73 A ATOM 2332 O ILEA 115 −13.840 25.960 59.635 1.00 15.74 A ATOM 2333 N ASP A 116 −12.96127.442 58.242 1.00 17.50 A ATOM 2334 CA ASP A 116 −11.915 26.546 57.8681.00 17.61 A ATOM 2335 CB ASP A 116 −12.548 25.412 57.023 1.00 18.39 AATOM 2336 CG ASP A 116 −11.629 24.148 56.836 1.00 17.79 A ATOM 2337 OD1ASP A 116 −12.094 23.193 56.151 1.00 17.14 A ATOM 2338 OD2 ASP A 116−10.537 24.091 57.402 1.00 18.20 A ATOM 2339 C ASP A 116 −10.957 27.34356.973 1.00 17.39 A ATOM 2340 O ASP A 116 −11.214 28.461 56.561 1.0016.71 A ATOM 2341 N THR A 117 −9.831 26.684 56.722 1.00 18.12 A ATOM2342 CA THR A 117 −8.768 27.065 55.771 1.00 18.26 A ATOM 2343 CB THR A117 −7.455 26.400 56.193 1.00 18.79 A ATOM 2344 OG1 THR A 117 −7.11026.908 57.494 1.00 21.00 A ATOM 2345 CG2 THR A 117 −6.377 26.619 55.0961.00 15.58 A ATOM 2346 C THR A 117 −9.215 26.347 54.433 1.00 16.73 AATOM 2347 O THR A 117 −9.551 25.151 54.450 1.00 16.01 A ATOM 2348 N ILEA 118 −9.213 27.077 53.347 1.00 15.95 A ATOM 2349 CA ILE A 118 −9.54526.536 52.040 1.00 15.82 A ATOM 2350 CB ILE A 118 −10.449 27.571 51.2701.00 14.60 A ATOM 2351 CG2 ILE A 118 −10.742 27.117 49.805 1.00 13.61 AATOM 2352 CG1 ILE A 118 −11.725 27.826 52.133 1.00 13.78 A ATOM 2353 CD1ILE A 118 −12.492 26.658 52.696 1.00 7.19 A ATOM 2354 C ILE A 118 −8.22026.300 51.271 1.00 15.52 A ATOM 2355 O ILE A 118 −7.455 27.219 51.0071.00 14.88 A ATOM 2356 N ALA A 119 −7.948 25.052 50.942 1.00 15.84 AATOM 2357 CA ALA A 119 −6.751 24.637 50.253 1.00 16.43 A ATOM 2358 CBALA A 119 −6.074 23.626 51.071 1.00 14.00 A ATOM 2359 C ALA A 119 −7.05024.003 48.918 1.00 16.98 A ATOM 2360 O ALA A 119 −7.880 23.140 48.9011.00 18.64 A ATOM 2361 N PRO A 120 −6.328 24.350 47.820 1.00 17.80 AATOM 2362 CD PRO A 120 −5.112 25.193 47.718 1.00 16.98 A ATOM 2363 CAPRO A 120 −6.586 23.729 46.504 1.00 17.40 A ATOM 2364 CB PRO A 120−5.861 24.631 45.502 1.00 17.55 A ATOM 2365 CG PRO A 120 −4.633 24.81746.167 1.00 17.39 A ATOM 2366 C PRO A 120 −5.985 22.369 46.399 1.0017.81 A ATOM 2367 O PRO A 120 −4.844 22.132 46.795 1.00 18.69 A ATOM2368 N ASP A 121 −6.762 21.451 45.824 1.00 18.67 A ATOM 2369 CA ASP A121 −6.275 20.076 45.509 1.00 18.28 A ATOM 2370 CB ASP A 121 −7.40219.252 45.051 1.00 21.03 A ATOM 2371 CG ASP A 121 −8.617 19.451 45.9221.00 24.83 A ATOM 2372 OD1 ASP A 121 −9.329 20.691 45.822 1.00 28.44 AATOM 2373 OD2 ASP A 121 −8.844 18.394 46.670 1.00 20.99 A ATOM 2374 CASP A 121 −5.311 20.228 44.338 1.00 17.03 A ATOM 2375 O ASP A 121 −4.45119.395 44.165 1.00 16.57 A ATOM 2376 N GLU A 122 −5.447 21.319 43.5991.00 15.97 A ATOM 2377 CA GLU A 122 −4.618 21.542 42.494 1.00 17.00 AATOM 2378 CB GLU A 122 −5.276 20.994 41.213 1.00 16.86 A ATOM 2379 CGGLU A 122 −5.559 19.473 41.144 1.00 20.41 A ATOM 2380 CD GLU A 122−5.887 18.941 39.688 1.00 23.62 A ATOM 2381 OE1 GLU A 122 −7.048 19.09339.185 1.00 24.17 A ATOM 2382 OE2 GLU A 122 −4.946 18.385 39.027 1.0026.00 A ATOM 2383 C GLU A 122 −4.167 22.995 42.268 1.00 16.38 A ATOM2384 O GLU A 122 −4.887 23.946 41.860 1.00 16.97 A ATOM 2385 N ILE A 123−2.900 23.149 42.463 1.00 15.91 A ATOM 2386 CA ILE A 123 −2.316 24.44342.305 1.00 17.38 A ATOM 2387 CB ILE A 123 −0.971 24.367 43.115 1.0017.70 A ATOM 2388 CG2 ILE A 123 −0.093 23.163 42.540 1.00 17.69 A ATOM2389 CG1 ILE A 123 −0.204 25.587 42.953 1.00 19.25 A ATOM 2390 CD1 ILE A123 1.230 25.355 43.544 1.00 22.89 A ATOM 2391 C ILE A 123 −2.128 24.62640.799 1.00 15.56 A ATOM 2392 O ILE A 123 −1.918 23.689 40.163 1.0015.45 A ATOM 2393 N THR A 124 −2.165 25.814 40.244 1.00 15.05 A ATOM2394 CA THR A 124 −1.959 25.968 38.794 1.00 15.55 A ATOM 2395 CB THR A124 −2.804 27.068 38.247 1.00 13.97 A ATOM 2396 OG1 THR A 124 −4.11526.619 38.208 1.00 13.46 A ATOM 2397 CG2 THR A 124 −2.447 27.405 36.9321.00 15.40 A ATOM 2398 C THR A 124 −0.538 26.337 38.519 1.00 16.06 AATOM 2399 O THR A 124 −0.164 27.475 38.851 1.00 18.24 A ATOM 2400 N VALA 125 0.289 25.479 37.951 1.00 15.30 A ATOM 2401 CA VAL A 125 1.68525.902 37.739 1.00 14.15 A ATOM 2402 CB VAL A 125 2.688 24.716 37.6431.00 14.84 A ATOM 2403 CG1 VAL A 125 2.705 23.977 38.955 1.00 14.73 AATOM 2404 CG2 VAL A 125 2.295 23.725 36.483 1.00 15.11 A ATOM 2405 C VALA 125 1.943 26.795 36.561 1.00 13.94 A ATOM 2406 O VAL A 125 1.10927.042 35.750 1.00 12.19 A ATOM 2407 N SER A 126 3.142 27.321 36.5441.00 14.58 A ATOM 2408 CA SER A 126 3.562 28.174 35.503 1.00 16.85 AATOM 2409 CB SER A 126 5.043 28.365 35.607 1.00 19.38 A ATOM 2410 OG SERA 126 5.598 28.622 34.297 1.00 25.35 A ATOM 2411 C SER A 126 3.23027.677 34.076 1.00 16.00 A ATOM 2412 O SER A 126 2.605 28.417 33.2581.00 16.05 A ATOM 2413 N SER A 127 3.647 26.463 33.777 1.00 15.26 A ATOM2414 CA SER A 127 3.371 26.007 32.446 1.00 15.44 A ATOM 2415 CB SER A127 4.203 24.792 32.130 1.00 14.37 A ATOM 2416 OG SER A 127 3.762 23.76732.959 1.00 15.90 A ATOM 2417 C SER A 127 1.896 25.754 32.173 1.00 14.54A ATOM 2418 O SER A 127 1.561 25.669 31.056 1.00 15.91 A ATOM 2419 N ASPA 128 1.045 25.670 33.211 1.00 14.80 A ATOM 2420 CA ASP A 128 −0.43825.478 33.134 1.00 15.58 A ATOM 2421 CB ASP A 128 −1.097 25.349 34.5431.00 17.66 A ATOM 2422 CG ASP A 128 −0.975 23.978 35.125 1.00 21.33 AATOM 2423 OD1 ASP A 128 −1.170 23.805 36.394 1.00 22.26 A ATOM 2424 OD2ASP A 128 −0.693 22.975 34.354 1.00 25.25 A ATOM 2425 C ASP A 128 −1.15326.617 32.331 1.00 13.45 A ATOM 2426 O ASP A 128 −2.083 26.406 31.5661.00 12.49 A ATOM 2427 N PHE A 129 −0.752 27.818 32.520 1.00 13.93 AATOM 2428 CA PHE A 129 −1.312 28.837 31.679 1.00 17.22 A ATOM 2429 CBPHE A 129 −0.793 30.191 32.184 1.00 17.05 A ATOM 2430 CG PHE A 129−1.139 30.441 33.600 1.00 17.73 A ATOM 2431 CD1 PHE A 129 −0.262 30.09734.628 1.00 17.88 A ATOM 2432 CD2 PHE A 129 −2.400 30.922 33.934 1.0018.02 A ATOM 2433 CE1 PHE A 129 −0.646 30.222 35.962 1.00 16.12 A ATOM2434 CE2 PHE A 129 −2.790 31.053 35.268 1.00 16.75 A ATOM 2435 CZ PHE A129 −1.886 30.689 36.286 1.00 16.66 A ATOM 2436 C PHE A 129 −0.64928.463 30.449 1.00 16.93 A ATOM 2437 O PHE A 129 −0.090 27.443 30.4801.00 19.64 A ATOM 2438 N GLU A 130 −0.589 29.214 29.382 1.00 16.76 AATOM 2439 CA GLU A 130 0.227 28.725 28.118 1.00 16.09 A ATOM 2440 CB GLUA 130 1.679 28.449 28.424 1.00 15.22 A ATOM 2441 CG GLU A 130 2.64529.502 27.986 1.00 16.93 A ATOM 2442 CD GLU A 130 4.074 28.955 27.9131.00 20.23 A ATOM 2443 OE1 GLU A 130 4.901 29.664 27.260 1.00 23.39 AATOM 2444 OE2 GLU A 130 4.418 27.834 28.492 1.00 21.59 A ATOM 2445 C GLUA 130 −0.378 27.435 27.626 1.00 16.79 A ATOM 2446 O GLU A 130 −0.77827.445 26.535 1.00 17.11 A ATOM 2447 N ALA A 131 −0.340 26.341 28.4191.00 17.32 A ATOM 2448 CA ALA A 131 −1.079 25.165 28.170 1.00 18.32 AATOM 2449 CB ALA A 131 −0.715 24.257 29.167 1.00 18.08 A ATOM 2450 C ALAA 131 −2.477 25.730 28.478 1.00 19.42 A ATOM 2451 O ALA A 131 −2.59226.880 28.989 1.00 22.36 A ATOM 2452 N ARG A 132 −3.599 25.095 28.2441.00 18.69 A ATOM 2453 CA ARG A 132 −4.726 25.950 28.725 1.00 16.77 AATOM 2454 CB ARG A 132 −5.636 26.248 27.562 1.00 18.47 A ATOM 2455 CGARG A 132 −5.750 27.745 27.137 1.00 20.86 A ATOM 2456 CD ARG A 132−4.500 28.474 26.757 1.00 19.10 A ATOM 2457 NE ARG A 132 −4.750 29.79026.148 1.00 16.56 A ATOM 2458 CZ ARG A 132 −3.988 30.886 26.383 1.0016.52 A ATOM 2459 NH1 ARG A 132 −2.990 30.828 27.232 1.00 16.01 A ATOM2460 NH2 ARG A 132 −4.095 32.020 25.669 1.00 13.84 A ATOM 2461 C ARG A132 −5.327 25.029 29.756 1.00 15.97 A ATOM 2462 O ARG A 132 −6.44124.569 29.688 1.00 14.52 A ATOM 2463 N HIS A 133 −4.517 24.746 30.7261.00 16.18 A ATOM 2464 CA HIS A 133 −4.893 23.823 31.725 1.00 17.38 AATOM 2465 CB HIS A 133 −3.889 22.645 31.801 1.00 19.77 A ATOM 2466 CGHIS A 133 −3.820 21.795 30.569 1.00 22.45 A ATOM 2467 CD2 HIS A 133−4.362 21.935 29.313 1.00 23.99 A ATOM 2468 ND1 HIS A 133 −3.130 20.58830.556 1.00 24.20 A ATOM 2469 CE1 HIS A 133 −3.253 20.023 29.349 1.0023.96 A ATOM 2470 NE2 HIS A 133 −3.995 20.816 28.578 1.00 23.21 A ATOM2471 C HIS A 133 −4.963 24.478 33.092 1.00 17.44 A ATOM 2472 O HIS A 133−4.365 23.961 34.088 1.00 16.09 A ATOM 2473 N VAL A 134 −5.690 25.59933.180 1.00 18.14 A ATOM 2474 CA VAL A 134 −5.757 26.229 34.528 1.0019.36 A ATOM 2475 CB VAL A 134 −6.376 27.591 34.454 1.00 18.62 A ATOM2476 CG1 VAL A 134 −6.472 28.157 35.826 1.00 18.67 A ATOM 2477 CG2 VAL A134 −5.473 28.462 33.654 1.00 16.73 A ATOM 2478 C VAL A 134 −6.53625.279 35.490 1.00 19.78 A ATOM 2479 O VAL A 134 −7.496 24.600 35.0751.00 21.16 A ATOM 2480 N LYS A 135 −6.095 25.152 36.730 1.00 18.73 AATOM 2481 CA LYS A 135 −6.819 24.228 37.616 1.00 17.83 A ATOM 2482 CBLYS A 135 −5.807 23.424 38.448 1.00 17.21 A ATOM 2483 CG LYS A 135−4.605 22.951 37.727 1.00 15.58 A ATOM 2484 CD LYS A 135 −5.036 22.08736.574 1.00 18.48 A ATOM 2485 CE LYS A 135 −3.866 21.168 36.147 1.0020.04 A ATOM 2486 NZ LYS A 135 −4.299 20.273 34.987 1.00 20.60 A ATOM2487 C LYS A 135 −7.886 24.883 38.550 1.00 16.46 A ATOM 2488 O LYS A 135−7.627 25.714 39.417 1.00 15.08 A ATOM 2489 N LEU A 136 −9.111 24.43938.292 1.00 16.27 A ATOM 2490 CA LEU A 136 −10.317 24.834 38.985 1.0016.45 A ATOM 2491 CB LEU A 136 −11.383 24.858 37.946 1.00 16.50 A ATOM2492 CG LEU A 136 −12.595 25.597 38.350 1.00 16.78 A ATOM 2493 CD1 LEU A136 −13.241 24.627 39.277 1.00 18.17 A ATOM 2494 CD2 LEU A 136 −12.31526.942 38.982 1.00 14.56 A ATOM 2495 C LEU A 136 −10.600 23.835 40.1391.00 16.32 A ATOM 2496 O LEU A 136 −10.750 22.644 39.951 1.00 16.33 AATOM 2497 N ASN A 137 −10.596 24.353 41.363 1.00 16.39 A ATOM 2498 CAASN A 137 −10.850 23.524 42.566 1.00 16.74 A ATOM 2499 CB ASN A 137−9.871 23.892 43.685 1.00 15.25 A ATOM 2500 CG ASN A 137 −8.452 23.53043.300 1.00 15.41 A ATOM 2501 OD1 ASN A 137 −8.028 22.366 43.427 1.0010.58 A ATOM 2502 ND2 ASN A 137 −7.711 24.535 42.810 1.00 14.69 A ATOM2503 C ASN A 137 −12.244 23.662 43.082 1.00 15.08 A ATOM 2504 O ASN A137 −12.844 24.683 42.934 1.00 15.46 A ATOM 2505 N VAL A 138 −12.80022.630 43.670 1.00 15.12 A ATOM 2506 CA VAL A 138 −14.144 22.834 44.2091.00 15.70 A ATOM 2507 CB VAL A 138 −15.233 21.997 43.540 1.00 14.13 AATOM 2508 CG1 VAL A 138 −16.480 22.304 44.141 1.00 13.82 A ATOM 2509 CG2VAL A 138 −15.315 22.291 42.116 1.00 12.43 A ATOM 2510 C VAL A 138−14.035 22.453 45.633 1.00 13.50 A ATOM 2511 O VAL A 138 −13.567 21.40345.950 1.00 13.10 A ATOM 2512 N GLU A 139 −14.425 23.363 46.511 1.0014.73 A ATOM 2513 CA GLU A 139 −14.335 23.033 47.932 1.00 16.50 A ATOM2514 CB GLU A 139 −13.186 23.796 48.575 1.00 14.98 A ATOM 2515 CG GLU A139 −11.803 23.266 48.364 1.00 12.51 A ATOM 2516 CD GLU A 139 −11.61921.920 48.901 1.00 13.08 A ATOM 2517 OE1 GLU A 139 −12.391 21.506 49.7691.00 14.13 A ATOM 2518 OE2 GLU A 139 −10.670 21.195 48.490 1.00 14.62 AATOM 2519 C GLU A 139 −15.657 23.366 48.552 1.00 17.15 A ATOM 2520 O GLUA 139 −16.223 24.406 48.245 1.00 18.65 A ATOM 2521 N GLU A 140 −16.17122.495 49.398 1.00 18.43 A ATOM 2522 CA GLU A 140 −17.467 22.780 50.0141.00 19.20 A ATOM 2523 CB GLU A 140 −18.593 21.819 49.576 1.00 21.05 AATOM 2524 CG GLU A 140 −19.955 22.098 50.298 1.00 21.51 A ATOM 2525 CDGLU A 140 −21.206 21.645 49.532 1.00 22.50 A ATOM 2526 OE1 GLU A 140−21.587 20.401 49.716 1.00 20.99 A ATOM 2527 OE2 GLU A 140 −21.73822.561 48.760 1.00 21.17 A ATOM 2528 C GLU A 140 −17.318 22.578 51.4551.00 18.30 A ATOM 2529 O GLU A 140 −16.613 21.694 51.824 1.00 17.70 AATOM 2530 N ARG A 141 −18.003 23.406 52.265 1.00 17.54 A ATOM 2531 CAARG A 141 −17.920 23.317 53.722 1.00 16.16 A ATOM 2532 CB ARG A 141−16.975 24.387 54.362 1.00 16.13 A ATOM 2533 CG ARG A 141 −15.468 24.39653.924 1.00 14.95 A ATOM 2534 CD ARG A 141 −14.572 23.598 54.787 1.0014.90 A ATOM 2535 NE ARG A 141 −13.905 22.646 53.936 1.00 19.63 A ATOM2536 CZ ARG A 141 −12.788 22.875 53.246 1.00 21.12 A ATOM 2537 NH1 ARG A141 −12.142 24.007 53.321 1.00 24.71 A ATOM 2538 NH2 ARG A 141 −12.44522.078 52.269 1.00 23.25 A ATOM 2539 C ARG A 141 −19.297 23.623 54.1651.00 16.33 A ATOM 2540 O ARG A 141 −20.133 24.040 53.389 1.00 15.48 AATOM 2541 N SER A 142 −19.512 23.475 55.449 1.00 16.69 A ATOM 2542 CASER A 142 −20.811 23.737 55.958 1.00 17.43 A ATOM 2543 CB SER A 142−21.663 22.497 55.758 1.00 17.22 A ATOM 2544 OG SER A 142 −21.450 21.56956.777 1.00 20.06 A ATOM 2545 C SER A 142 −20.824 24.223 57.404 1.0017.75 A ATOM 2546 O SER A 142 −19.934 23.958 58.201 1.00 18.77 A ATOM2547 N VAL A 143 −21.838 24.954 57.759 1.00 17.53 A ATOM 2548 CA VAL A143 −21.859 25.452 59.080 1.00 17.98 A ATOM 2549 CB VAL A 143 −21.03326.804 59.185 1.00 18.53 A ATOM 2550 CG1 VAL A 143 −21.717 27.949 58.3771.00 18.87 A ATOM 2551 CG2 VAL A 143 −20.898 27.170 60.620 1.00 18.81 AATOM 2552 C VAL A 143 −23.277 25.544 59.679 1.00 17.11 A ATOM 2553 O VALA 143 −24.269 25.588 58.970 1.00 15.63 A ATOM 2554 N GLY A 144 −23.35625.461 61.012 1.00 16.75 A ATOM 2555 CA GLY A 144 −24.663 25.493 61.6421.00 17.48 A ATOM 2556 C GLY A 144 −24.702 24.825 63.010 1.00 17.29 AATOM 2557 O GLY A 144 −23.745 24.257 63.448 1.00 18.36 A ATOM 2558 N PROA 145 −25.831 24.877 63.699 1.00 16.61 A ATOM 2559 CD PRO A 145 −26.12524.003 64.832 1.00 15.62 A ATOM 2560 CA PRO A 145 −27.075 25.554 63.2121.00 17.28 A ATOM 2561 CB PRO A 145 −28.182 24.952 64.050 1.00 15.36 AATOM 2562 CG PRO A 145 −27.514 24.511 65.251 1.00 14.52 A ATOM 2563 CPRO A 145 −27.129 27.051 63.260 1.00 17.91 A ATOM 2564 O PRO A 145−26.682 27.663 64.197 1.00 19.36 A ATOM 2565 N LEU A 146 −27.664 27.66162.230 1.00 18.61 A ATOM 2566 CA LEU A 146 −27.728 29.101 62.174 1.0018.08 A ATOM 2567 CB LEU A 146 −27.793 29.511 60.733 1.00 17.61 A ATOM2568 CG LEU A 146 −26.448 29.981 60.097 1.00 17.71 A ATOM 2569 CD1 LEU A146 −25.325 29.104 60.545 1.00 15.07 A ATOM 2570 CD2 LEU A 146 −26.61430.067 58.576 1.00 14.26 A ATOM 2571 C LEU A 146 −29.034 29.353 62.8721.00 19.06 A ATOM 2572 O LEU A 146 −29.975 28.513 62.791 1.00 19.16 AATOM 2573 N THR A 147 −29.136 30.515 63.526 1.00 18.42 A ATOM 2574 CATHR A 147 −30.362 30.863 64.269 1.00 17.55 A ATOM 2575 CB THR A 147−30.202 30.609 65.815 1.00 17.02 A ATOM 2576 OG1 THR A 147 −29.21631.528 66.365 1.00 16.67 A ATOM 2577 CG2 THR A 147 −29.862 29.225 66.0611.00 14.10 A ATOM 2578 C THR A 147 −30.839 32.298 64.123 1.00 16.88 AATOM 2579 O THR A 147 −32.005 32.545 64.449 1.00 17.08 A ATOM 2580 N ARGA 148 −29.967 33.200 63.659 1.00 16.22 A ATOM 2581 CA ARG A 148 −30.31634.639 63.503 1.00 15.89 A ATOM 2582 CB ARG A 148 −29.062 35.541 63.4971.00 16.69 A ATOM 2583 CG ARG A 148 −28.038 35.232 64.583 1.00 17.98 AATOM 2584 CD ARG A 148 −28.543 35.611 65.942 1.00 17.51 A ATOM 2585 NEARG A 148 −29.354 34.517 66.526 1.00 19.64 A ATOM 2586 CZ ARG A 148−30.469 34.723 67.227 1.00 20.42 A ATOM 2587 NH1 ARG A 148 −30.91735.982 67.398 1.00 21.38 A ATOM 2588 NH2 ARG A 148 −31.089 33.711 67.8171.00 18.15 A ATOM 2589 C ARG A 148 −31.129 34.947 62.287 1.00 14.37 AATOM 2590 O ARG A 148 −31.299 34.104 61.468 1.00 13.36 A ATOM 2591 N LYSA 149 −31.579 36.168 62.154 1.00 13.83 A ATOM 2592 CA LYS A 149 −32.41636.489 61.083 1.00 14.61 A ATOM 2593 CB LYS A 149 −32.897 37.930 61.2371.00 15.01 A ATOM 2594 CG LYS A 149 −34.057 38.412 60.378 1.00 15.29 AATOM 2595 CD LYS A 149 −34.424 39.801 60.648 1.00 17.79 A ATOM 2596 CELYS A 149 −35.340 40.284 59.560 1.00 19.23 A ATOM 2597 NZ LYS A 149−34.937 41.563 58.825 1.00 21.75 A ATOM 2598 C LYS A 149 −31.590 36.31059.859 1.00 15.86 A ATOM 2599 O LYS A 149 −32.102 35.907 58.851 1.0015.91 A ATOM 2600 N GLY A 150 −30.280 36.558 59.982 1.00 16.26 A ATOM2601 CA GLY A 150 −29.339 36.463 58.862 1.00 15.32 A ATOM 2602 C GLY A150 −27.814 36.239 59.124 1.00 14.43 A ATOM 2603 O GLY A 150 −27.37935.958 60.227 1.00 13.14 A ATOM 2604 N PHE A 151 −27.041 36.352 58.0391.00 13.31 A ATOM 2605 CA PHE A 151 −25.682 36.028 58.018 1.00 12.33 AATOM 2606 CB PHE A 151 −25.526 34.554 58.108 1.00 13.58 A ATOM 2607 CGPHE A 151 −25.881 33.854 56.916 1.00 14.77 A ATOM 2608 CD1 PHE A 151−24.930 33.577 55.924 1.00 14.61 A ATOM 2609 CD2 PHE A 151 −27.12033.350 56.724 1.00 16.07 A ATOM 2610 CE1 PHE A 151 −25.221 32.818 54.8221.00 12.57 A ATOM 2611 CE2 PHE A 151 −27.356 32.567 55.536 1.00 14.88 AATOM 2612 CZ PHE A 151 −26.381 32.330 54.638 1.00 13.09 A ATOM 2613 CPHE A 151 −24.843 36.538 56.852 1.00 12.81 A ATOM 2614 O PHE A 151−25.378 36.968 55.805 1.00 11.71 A ATOM 2615 N TYR A 152 −23.510 36.52257.094 1.00 11.83 A ATOM 2616 CA TYR A 152 −22.502 36.957 56.211 1.0011.41 A ATOM 2617 CB TYR A 152 −21.777 38.187 56.695 1.00 12.88 A ATOM2618 CG TYR A 152 −22.576 39.456 56.766 1.00 13.73 A ATOM 2619 CD1 TYR A152 −23.156 39.827 57.909 1.00 12.41 A ATOM 2620 CE1 TYR A 152 −23.88540.918 57.962 1.00 14.83 A ATOM 2621 CD2 TYR A 152 −22.747 40.231 55.6921.00 13.12 A ATOM 2622 CE2 TYR A 152 −23.474 41.332 55.762 1.00 14.32 AATOM 2623 CZ TYR A 152 −24.075 41.709 56.881 1.00 14.37 A ATOM 2624 OHTYR A 152 −24.912 42.884 56.879 1.00 14.66 A ATOM 2625 C TYR A 152−21.472 35.918 56.115 1.00 12.73 A ATOM 2626 O TYR A 152 −21.174 35.17457.015 1.00 12.39 A ATOM 2627 N LEU A 153 −20.900 35.885 54.949 1.0012.34 A ATOM 2628 CA LEU A 153 −19.824 35.042 54.690 1.00 12.32 A ATOM2629 CB LEU A 153 −20.205 34.227 53.512 1.00 13.52 A ATOM 2630 CG LEU A153 −20.286 32.792 53.658 1.00 15.11 A ATOM 2631 CD1 LEU A 153 −21.08932.379 54.833 1.00 16.91 A ATOM 2632 CD2 LEU A 153 −20.802 32.266 52.3681.00 15.24 A ATOM 2633 C LEU A 153 −18.668 36.011 54.366 1.00 12.63 AATOM 2634 O LEU A 153 −18.897 37.135 53.812 1.00 12.38 A ATOM 2635 N ALAA 154 −17.433 35.610 54.681 1.00 12.02 A ATOM 2636 CA ALA A 154 −16.30436.449 54.324 1.00 12.50 A ATOM 2637 CB ALA A 154 −16.011 37.539 55.4471.00 12.18 A ATOM 2638 C ALA A 154 −15.051 35.624 54.016 1.00 13.66 AATOM 2639 O ALA A 154 −14.813 34.528 54.494 1.00 12.69 A ATOM 2640 N PHEA 155 −14.241 36.199 53.184 1.00 13.96 A ATOM 2641 CA PHE A 155 −13.03635.558 52.824 1.00 14.10 A ATOM 2642 CB PHE A 155 −13.071 35.266 51.3351.00 16.08 A ATOM 2643 CG PHE A 155 −14.345 34.561 50.850 1.00 16.01 AATOM 2644 CD1 PHE A 155 −15.470 35.248 50.639 1.00 16.10 A ATOM 2645 CD2PHE A 155 −14.376 33.241 50.665 1.00 15.30 A ATOM 2646 CE1 PHE A 155−16.487 34.639 50.302 1.00 16.20 A ATOM 2647 CE2 PHE A 155 −15.46132.617 50.300 1.00 16.47 A ATOM 2648 CZ PHE A 155 −16.478 33.288 50.1231.00 16.92 A ATOM 2649 C PHE A 155 −11.697 36.397 53.166 1.00 14.58 AATOM 2650 O PHE A 155 −11.445 37.591 52.803 1.00 13.24 A ATOM 2651 N GLNA 156 −10.807 35.700 53.823 1.00 13.93 A ATOM 2652 CA GLN A 156 −9.62536.323 54.112 1.00 13.71 A ATOM 2653 CB GLN A 156 −9.379 36.203 55.6021.00 13.83 A ATOM 2654 CG GLN A 156 −8.257 36.950 56.057 1.00 13.02 AATOM 2655 CD GLN A 156 −7.571 36.311 57.281 1.00 14.74 A ATOM 2656 OE1GLN A 156 −7.728 35.132 57.614 1.00 15.14 A ATOM 2657 NE2 GLN A 156−6.783 37.120 57.961 1.00 14.94 A ATOM 2658 C GLN A 156 −8.477 35.76453.289 1.00 13.37 A ATOM 2659 O GLN A 156 −8.144 34.588 53.340 1.0012.61 A ATOM 2660 N ASP A 157 −7.925 36.641 52.486 1.00 13.45 A ATOM2661 CA ASP A 157 −6.735 36.333 51.769 1.00 13.90 A ATOM 2662 CB ASP A157 −6.657 37.129 50.447 1.00 12.65 A ATOM 2663 CG ASP A 157 −5.21837.263 49.918 1.00 10.99 A ATOM 2664 OD1 ASP A 157 −4.764 38.356 49.6701.00 10.97 A ATOM 2665 OD2 ASP A 157 −4.556 36.263 49.760 1.00 9.35 AATOM 2666 C ASP A 157 −5.518 36.691 52.692 1.00 14.12 A ATOM 2667 O ASPA 157 −5.392 37.778 53.263 1.00 12.79 A ATOM 2668 N ILE A 158 −4.57935.759 52.672 1.00 14.90 A ATOM 2669 CA ILE A 158 −3.407 35.849 53.5051.00 15.25 A ATOM 2670 CB ILE A 158 −3.426 34.544 54.397 1.00 17.06 AATOM 2671 CG2 ILE A 158 −2.443 33.544 54.027 1.00 17.78 A ATOM 2672 CG1ILE A 158 −3.447 34.949 55.787 1.00 17.51 A ATOM 2673 CD1 ILE A 158−4.757 35.545 56.100 1.00 19.43 A ATOM 2674 C ILE A 158 −2.138 36.05952.749 1.00 15.38 A ATOM 2675 O ILE A 158 −1.064 35.821 53.283 1.0013.62 A ATOM 2676 N GLY A 159 −2.254 36.599 51.542 1.00 15.77 A ATOM2677 CA GLY A 159 −1.097 36.712 50.680 1.00 17.22 A ATOM 2678 C GLY A159 −0.931 35.557 49.594 1.00 18.21 A ATOM 2679 O GLY A 159 0.196 35.15449.117 1.00 19.55 A ATOM 2680 N ALA A 160 −2.063 34.965 49.212 1.0017.80 A ATOM 2681 CA ALA A 160 −2.121 33.947 48.142 1.00 16.39 A ATOM2682 CB ALA A 160 −3.070 32.938 48.487 1.00 13.65 A ATOM 2683 C ALA A160 −2.564 34.706 46.851 1.00 16.03 A ATOM 2684 O ALA A 160 −2.94335.866 46.905 1.00 16.85 A ATOM 2685 N CYS A 161 −2.415 34.033 45.7091.00 16.56 A ATOM 2686 CA CYS A 161 −2.797 34.457 44.381 1.00 15.69 AATOM 2687 C CYS A 161 −3.995 33.557 44.102 1.00 16.70 A ATOM 2688 O CYSA 161 −3.909 32.436 43.476 1.00 19.03 A ATOM 2689 CB CYS A 161 −1.73134.174 43.315 1.00 12.72 A ATOM 2690 SG CYS A 161 −1.995 35.055 41.7281.00 12.05 A ATOM 2691 N VAL A 162 −5.146 34.032 44.558 1.00 17.69 AATOM 2692 CA VAL A 162 −6.410 33.301 44.360 1.00 18.16 A ATOM 2693 CBVAL A 162 −7.206 33.192 45.632 1.00 18.04 A ATOM 2694 CG1 VAL A 162−8.109 31.968 45.524 1.00 19.49 A ATOM 2695 CG2 VAL A 162 −6.374 33.16546.788 1.00 16.56 A ATOM 2696 C VAL A 162 −7.398 33.957 43.382 1.0016.54 A ATOM 2697 O VAL A 162 −7.427 35.164 43.252 1.00 15.67 A ATOM2698 N ALA A 163 −8.162 33.146 42.705 1.00 16.38 A ATOM 2699 CA ALA A163 −9.198 33.665 41.862 1.00 17.65 A ATOM 2700 CB ALA A 163 −8.90433.381 40.454 1.00 17.99 A ATOM 2701 C ALA A 163 −10.499 32.981 42.3041.00 17.25 A ATOM 2702 O ALA A 163 −10.755 31.756 42.021 1.00 17.62 AATOM 2703 N LEU A 164 −11.313 33.710 43.077 1.00 15.86 A ATOM 2704 CALEU A 164 −12.560 33.053 43.531 1.00 16.46 A ATOM 2705 CB LEU A 164−12.935 33.638 44.856 1.00 15.91 A ATOM 2706 CG LEU A 164 −14.132 32.86345.309 1.00 16.76 A ATOM 2707 CD1 LEU A 164 −13.934 31.386 45.420 1.0016.22 A ATOM 2708 CD2 LEU A 164 −14.483 33.431 46.679 1.00 17.86 A ATOM2709 C LEU A 164 −13.672 33.198 42.456 1.00 16.32 A ATOM 2710 O LEU A164 −14.228 34.303 42.214 1.00 15.35 A ATOM 2711 N LEU A 165 −13.96532.086 41.786 1.00 15.90 A ATOM 2712 CA LEU A 165 −14.893 32.173 40.6831.00 15.98 A ATOM 2713 CB LEU A 165 −14.371 31.338 39.523 1.00 18.46 AATOM 2714 CG LEU A 165 −12.904 31.401 39.149 1.00 19.16 A ATOM 2715 CD1LEU A 165 −12.786 30.532 37.975 1.00 18.88 A ATOM 2716 CD2 LEU A 165−12.455 32.781 38.875 1.00 19.34 A ATOM 2717 C LEU A 165 −16.314 31.79240.942 1.00 15.01 A ATOM 2718 O LEU A 165 −17.169 32.033 40.143 1.0012.87 A ATOM 2719 N SER A 166 −16.588 31.206 42.093 1.00 15.03 A ATOM2720 CA SER A 166 −17.973 30.832 42.330 1.00 15.35 A ATOM 2721 CB SER A166 −18.337 29.517 41.645 1.00 16.26 A ATOM 2722 OG SER A 166 −19.61629.064 42.030 1.00 15.63 A ATOM 2723 C SER A 166 −18.183 30.642 43.7631.00 15.44 A ATOM 2724 O SER A 166 −17.285 30.080 44.426 1.00 15.59 AATOM 2725 N VAL A 167 −19.376 31.038 44.222 1.00 14.76 A ATOM 2726 CAVAL A 167 −19.661 30.929 45.617 1.00 14.49 A ATOM 2727 CB VAL A 167−19.475 32.274 46.342 1.00 14.49 A ATOM 2728 CG1 VAL A 167 −19.87132.137 47.811 1.00 16.55 A ATOM 2729 CG2 VAL A 167 −18.106 32.722 46.2481.00 13.26 A ATOM 2730 C VAL A 167 −21.094 30.635 45.679 1.00 15.69 AATOM 2731 O VAL A 167 −21.910 31.490 45.391 1.00 15.32 A ATOM 2732 N ARGA 168 −21.435 29.443 46.080 1.00 16.34 A ATOM 2733 CA ARG A 168 −22.81529.103 46.159 1.00 17.42 A ATOM 2734 CB ARG A 168 −23.190 27.884 45.2571.00 19.57 A ATOM 2735 CG ARG A 168 −24.058 28.268 44.101 1.00 20.89 AATOM 2736 CD ARG A 168 −25.063 27.120 43.548 1.00 22.42 A ATOM 2737 NEARG A 168 −24.827 25.805 44.163 1.00 22.02 A ATOM 2738 CZ ARG A 168−25.783 24.866 44.333 1.00 22.04 A ATOM 2739 NH1 ARG A 168 −27.04425.067 43.943 1.00 18.96 A ATOM 2740 NH2 ARG A 168 −25.430 23.702 44.8511.00 20.64 A ATOM 2741 C ARG A 168 −23.019 28.677 47.601 1.00 18.43 AATOM 2742 O ARG A 168 −22.142 27.961 48.194 1.00 17.76 A ATOM 2743 N VALA 169 −24.201 29.103 48.121 1.00 17.97 A ATOM 2744 CA VAL A 169 −24.64928.809 49.473 1.00 17.47 A ATOM 2745 CB VAL A 169 −24.753 30.115 50.3031.00 18.56 A ATOM 2746 CG1 VAL A 169 −25.135 29.776 51.832 1.00 17.98 AATOM 2747 CG2 VAL A 169 −23.485 30.866 50.198 1.00 18.50 A ATOM 2748 CVAL A 169 −26.021 28.233 49.421 1.00 17.60 A ATOM 2749 O VAL A 169−26.930 28.852 48.855 1.00 17.71 A ATOM 2750 N TYR A 170 −26.245 27.09250.050 1.00 16.67 A ATOM 2751 CA TYR A 170 −27.574 26.517 49.910 1.0015.97 A ATOM 2752 CB TYR A 170 −27.659 25.729 48.589 1.00 15.88 A ATOM2753 CG TYR A 170 −26.793 24.476 48.632 1.00 15.42 A ATOM 2754 CD1 TYR A170 −27.283 23.263 49.097 1.00 16.32 A ATOM 2755 CE1 TYR A 170 −26.47322.165 49.189 1.00 15.91 A ATOM 2756 CD2 TYR A 170 −25.464 24.536 48.2651.00 15.99 A ATOM 2757 CE2 TYR A 170 −24.646 23.465 48.330 1.00 13.92 AATOM 2758 CZ TYR A 170 −25.141 22.300 48.772 1.00 15.55 A ATOM 2759 OHTYR A 170 −24.377 21.157 48.786 1.00 15.77 A ATOM 2760 C TYR A 170−27.814 25.600 50.996 1.00 14.37 A ATOM 2761 O TYR A 170 −26.855 25.17051.584 1.00 13.51 A ATOM 2762 N TYR A 171 −29.093 25.270 51.230 1.0014.25 A ATOM 2763 CA TYR A 171 −29.415 24.314 52.282 1.00 17.08 A ATOM2764 CB TYR A 171 −29.960 25.061 53.513 1.00 16.40 A ATOM 2765 CG TYR A171 −31.336 25.620 53.395 1.00 17.35 A ATOM 2766 CD1 TYR A 171 −32.40024.964 53.943 1.00 17.57 A ATOM 2767 CE1 TYR A 171 −33.714 25.492 53.8741.00 19.28 A ATOM 2768 CD2 TYR A 171 −31.546 26.821 52.751 1.00 18.36 AATOM 2769 CE2 TYR A 171 −32.814 27.372 52.661 1.00 20.15 A ATOM 2770 CZTYR A 171 −33.923 26.694 53.243 1.00 19.74 A ATOM 2771 OH TYR A 171−35.161 27.253 53.227 1.00 19.54 A ATOM 2772 C TYR A 171 −30.379 23.24851.797 1.00 17.02 A ATOM 2773 O TYR A 171 −31.028 23.427 50.735 1.0017.21 A ATOM 2774 N LYS A 172 −30.503 22.202 52.574 1.00 17.77 A ATOM2775 CA LYS A 172 −31.377 21.122 52.162 1.00 20.62 A ATOM 2776 CB LYS A172 −31.026 19.829 52.787 1.00 18.75 A ATOM 2777 CG LYS A 172 −30.21219.065 51.840 1.00 20.24 A ATOM 2778 CD LYS A 172 −28.875 19.676 51.6251.00 19.52 A ATOM 2779 CE LYS A 172 −28.109 18.749 50.724 1.00 21.99 AATOM 2780 NZ LYS A 172 −26.875 18.114 51.301 1.00 22.59 A ATOM 2781 CLYS A 172 −32.843 21.247 52.307 1.00 22.07 A ATOM 2782 O LYS A 172−33.402 21.254 53.447 1.00 23.49 A ATOM 2783 N LYS A 173 −33.462 21.18751.134 1.00 22.88 A ATOM 2784 CA LYS A 173 −34.906 21.408 50.891 1.0023.62 A ATOM 2785 CB LYS A 173 −35.420 20.479 49.769 1.00 23.63 A ATOM2786 CG LYS A 173 −34.377 20.336 48.611 1.00 23.88 A ATOM 2787 CD LYS A173 −33.517 19.081 48.962 1.00 24.16 A ATOM 2788 CE LYS A 173 −32.10119.153 48.374 1.00 24.59 A ATOM 2789 NZ LYS A 173 −31.326 20.209 49.1301.00 23.73 A ATOM 2790 C LYS A 173 −35.722 21.191 52.081 1.00 23.37 AATOM 2791 O LYS A 173 −36.163 22.164 52.782 1.00 22.35 A ATOM 2792 N CYSA 174 −35.822 19.868 52.308 1.00 23.68 A ATOM 2793 CA CYS A 174 −36.65319.339 53.420 1.00 25.47 A ATOM 2794 CB CYS A 174 −36.310 20.061 54.8201.00 28.65 A ATOM 2795 SG CYS A 174 −37.928 20.841 55.663 1.00 38.26 AATOM 2796 C CYS A 174 −38.188 19.492 53.081 1.00 23.26 A ATOM 2797 O CYSA 174 −38.793 18.418 53.021 1.00 21.44 A ATOM 2798 OXT CYS A 174 −38.73820.665 52.935 1.00 22.35 A ATOM 2799 CB GLU D 1 23.133 −17.287 30.6371.00 18.26 D ATOM 2800 CG GLU D 1 22.443 −16.571 29.605 1.00 19.88 DATOM 2801 CD GLU D 1 20.960 −16.165 30.052 1.00 22.33 D ATOM 2802 OE1GLU D 1 20.840 −15.311 30.988 1.00 22.04 D ATOM 2803 OE2 GLU D 1 19.926−16.683 29.498 1.00 22.42 D ATOM 2804 C GLU D 1 25.184 −18.446 29.4501.00 16.10 D ATOM 2805 O GLU D 1 25.611 −18.051 28.387 1.00 14.62 D ATOM2806 N GLU D 1 25.238 −16.052 30.537 1.00 18.38 D ATOM 2807 CA GLU D 124.686 −17.410 30.546 1.00 17.26 D ATOM 2808 N VAL D 2 25.185 −19.74529.779 1.00 16.37 D ATOM 2809 CA VAL D 2 25.660 −20.782 28.836 1.0019.16 D ATOM 2810 CB VAL D 2 26.600 −21.854 29.528 1.00 18.63 D ATOM2811 CG1 VAL D 2 26.955 −22.952 28.556 1.00 18.71 D ATOM 2812 CG2 VAL D2 27.841 −21.167 30.040 1.00 16.94 D ATOM 2813 C VAL D 2 24.472 −21.44928.137 1.00 17.16 D ATOM 2814 O VAL D 2 23.555 −21.985 28.745 1.00 17.83D ATOM 2815 N VAL D 3 24.476 −21.370 26.830 1.00 16.85 D ATOM 2816 CAVAL D 3 23.296 −21.845 26.149 1.00 18.25 D ATOM 2817 CB VAL D 3 22.838−20.797 25.025 1.00 16.66 D ATOM 2818 CG1 VAL D 3 21.493 −21.162 24.4141.00 16.08 D ATOM 2819 CG2 VAL D 3 22.691 −19.506 25.598 1.00 15.53 DATOM 2820 C VAL D 3 23.381 −23.195 25.496 1.00 17.54 D ATOM 2821 O VAL D3 24.037 −23.312 24.475 1.00 16.88 D ATOM 2822 N LEU D 4 22.688 −24.17226.059 1.00 17.89 D ATOM 2823 CA LEU D 4 22.573 −25.518 25.455 1.0019.77 D ATOM 2824 CB LEU D 4 22.442 −26.529 26.591 1.00 17.98 D ATOM2825 CG LEU D 4 23.225 −26.130 27.835 1.00 17.46 D ATOM 2826 CD1 LEU D 423.113 −27.153 28.967 1.00 14.15 D ATOM 2827 CD2 LEU D 4 24.727 −26.06427.318 1.00 18.38 D ATOM 2828 C LEU D 4 21.245 −25.597 24.635 1.00 21.14D ATOM 2829 O LEU D 4 20.160 −25.821 25.193 1.00 24.43 D ATOM 2830 N LEUD 5 21.186 −25.543 23.344 1.00 20.80 D ATOM 2831 CA LEU D 5 19.799−25.575 22.762 1.00 18.34 D ATOM 2832 CB LEU D 5 18.890 −26.609 23.3981.00 17.64 D ATOM 2833 CG LEU D 5 17.600 −26.612 22.627 1.00 16.76 DATOM 2834 CD1 LEU D 5 17.963 −26.672 21.241 1.00 17.33 D ATOM 2835 CD2LEU D 5 16.804 −27.816 22.972 1.00 15.84 D ATOM 2836 C LEU D 5 19.042−24.240 22.767 1.00 17.42 D ATOM 2837 O LEU D 5 18.670 −23.668 23.7991.00 17.75 D ATOM 2838 N ASP D 6 18.799 −23.828 21.519 1.00 16.76 D ATOM2839 CA ASP D 6 18.157 −22.591 21.152 1.00 16.04 D ATOM 2840 CB ASP D 619.177 −21.459 21.171 1.00 16.52 D ATOM 2841 CG ASP D 6 18.504 −20.11821.147 1.00 17.49 D ATOM 2842 OD1 ASP D 6 19.212 −19.065 20.882 1.0019.98 D ATOM 2843 OD2 ASP D 6 17.267 −20.104 21.385 1.00 16.83 D ATOM2844 C ASP D 6 17.469 −22.664 19.767 1.00 14.86 D ATOM 2845 O ASP D 617.998 −22.319 18.694 1.00 12.99 D ATOM 2846 N PHE D 7 16.238 −23.06819.870 1.00 15.80 D ATOM 2847 CA PHE D 7 15.355 −23.291 18.760 1.0016.74 D ATOM 2848 CB PHE D 7 13.941 −23.531 19.271 1.00 16.84 D ATOM2849 CG PHE D 7 12.942 −23.677 18.172 1.00 16.20 D ATOM 2850 CD1 PHE D 712.855 −24.868 17.476 1.00 15.83 D ATOM 2851 CD2 PHE D 7 12.118 −22.59217.797 1.00 14.38 D ATOM 2852 CE1 PHE D 7 11.958 −24.963 16.432 1.0016.41 D ATOM 2853 CE2 PHE D 7 11.209 −22.679 16.744 1.00 13.94 D ATOM2854 CZ PHE D 7 11.109 −23.827 16.061 1.00 14.35 D ATOM 2855 C PHE D 715.327 −22.180 17.745 1.00 17.65 D ATOM 2856 O PHE D 7 15.493 −22.45916.600 1.00 17.38 D ATOM 2857 N ALA D 8 15.055 −20.956 18.192 1.00 18.28D ATOM 2858 CA ALA D 8 14.986 −19.825 17.324 1.00 19.21 D ATOM 2859 CBALA D 8 14.433 −18.497 18.097 1.00 19.34 D ATOM 2860 C ALA D 8 16.303−19.488 16.619 1.00 19.50 D ATOM 2861 O ALA D 8 16.334 −18.546 15.8551.00 20.94 D ATOM 2862 N ALA D 9 17.411 −20.184 16.841 1.00 19.75 D ATOM2863 CA ALA D 9 18.618 −19.795 16.150 1.00 19.50 D ATOM 2864 CB ALA D 919.717 −19.700 17.137 1.00 15.15 D ATOM 2865 C ALA D 9 18.915 −20.77815.040 1.00 19.76 D ATOM 2866 O ALA D 9 19.682 −20.474 14.089 1.00 22.02D ATOM 2867 N ALA D 10 18.296 −21.952 15.089 1.00 20.29 D ATOM 2868 CAALA D 10 18.629 −23.092 14.085 1.00 20.80 D ATOM 2869 CB ALA D 10 18.375−24.470 14.796 1.00 17.31 D ATOM 2870 C ALA D 10 17.925 −23.004 12.6471.00 21.69 D ATOM 2871 O ALA D 10 16.721 −23.525 12.352 1.00 21.42 DATOM 2872 N GLY D 11 18.661 −22.275 11.806 1.00 22.77 D ATOM 2873 CA GLYD 11 18.307 −21.909 10.406 1.00 25.02 D ATOM 2874 C GLY D 11 17.979−23.070 9.436 1.00 26.27 D ATOM 2875 O GLY D 11 18.668 −23.388 8.3851.00 26.22 D ATOM 2876 N GLY D 12 16.891 −23.743 9.891 1.00 26.12 D ATOM2877 CA GLY D 12 16.326 −24.985 9.285 1.00 25.36 D ATOM 2878 C GLY D 1215.558 −25.673 10.462 1.00 24.70 D ATOM 2879 O GLY D 12 15.608 −26.92910.617 1.00 23.78 D ATOM 2880 N GLU D 13 14.946 −24.821 11.345 1.0023.90 D ATOM 2881 CA GLU D 13 14.056 −25.309 12.439 1.00 22.69 D ATOM2882 CB GLU D 13 12.902 −26.124 11.776 1.00 24.76 D ATOM 2883 CG GLU D13 12.838 −26.281 10.219 1.00 25.93 D ATOM 2884 CD GLU D 13 11.367−26.658 9.554 1.00 26.31 D ATOM 2885 OE1 GLU D 13 10.399 −26.138 10.2371.00 26.05 D ATOM 2886 OE2 GLU D 13 11.270 −27.359 8.391 1.00 22.11 DATOM 2887 C GLU D 13 14.787 −26.239 13.539 1.00 23.02 D ATOM 2888 O GLUD 13 15.117 −25.784 14.666 1.00 20.63 D ATOM 2889 N LEU D 14 15.056−27.503 13.110 1.00 22.70 D ATOM 2890 CA LEU D 14 15.817 −28.380 13.8961.00 22.97 D ATOM 2891 CB LEU D 14 15.569 −28.037 15.344 1.00 23.47 DATOM 2892 CG LEU D 14 16.874 −27.502 15.990 1.00 23.92 D ATOM 2893 CD1LEU D 14 16.440 −26.161 16.869 1.00 23.60 D ATOM 2894 CD2 LEU D 1417.689 −28.653 16.806 1.00 17.35 D ATOM 2895 C LEU D 14 15.561 −29.87813.709 1.00 23.92 D ATOM 2896 O LEU D 14 14.460 −30.327 13.128 1.0025.25 D ATOM 2897 N GLY D 15 16.497 −30.637 14.338 1.00 22.05 D ATOM2898 CA GLY D 15 16.379 −32.077 14.402 1.00 19.66 D ATOM 2899 C GLY D 1515.522 −32.510 15.643 1.00 19.22 D ATOM 2900 O GLY D 15 16.127 −32.95916.667 1.00 18.12 D ATOM 2901 N TRP D 16 14.156 −32.404 15.598 1.0019.56 D ATOM 2902 CA TRP D 16 13.287 −32.805 16.791 1.00 20.14 D ATOM2903 CB TRP D 16 12.362 −31.660 17.402 1.00 19.90 D ATOM 2904 CG TRP D16 13.115 −30.500 17.892 1.00 19.90 D ATOM 2905 CD2 TRP D 16 12.767−29.561 18.937 1.00 19.40 D ATOM 2906 CE2 TRP D 16 13.840 −28.667 19.0571.00 19.94 D ATOM 2907 CE3 TRP D 16 11.710 −29.404 19.752 1.00 17.02 DATOM 2908 CD1 TRP D 16 14.343 −30.116 17.436 1.00 21.03 D ATOM 2909 NE1TRP D 16 14.784 −29.018 18.135 1.00 22.34 D ATOM 2910 CZ2 TRP D 1613.842 −27.617 20.011 1.00 19.77 D ATOM 2911 CZ3 TRP D 16 11.736 −28.33520.709 1.00 17.86 D ATOM 2912 CH2 TRP D 16 12.774 −27.482 20.822 1.0017.65 D ATOM 2913 C TRP D 16 12.383 −33.924 16.352 1.00 20.53 D ATOM2914 O TRP D 16 12.136 −34.037 15.173 1.00 22.33 D ATOM 2915 N LEU D 1711.885 −34.672 17.327 1.00 19.02 D ATOM 2916 CA LEU D 17 11.024 −35.80617.144 1.00 16.88 D ATOM 2917 CB LEU D 17 11.525 −36.960 18.027 1.0017.70 D ATOM 2918 CG LEU D 17 10.641 −38.166 17.961 1.00 18.58 D ATOM2919 CD1 LEU D 17 10.424 −38.386 16.363 1.00 20.41 D ATOM 2920 CD2 LEU D17 11.290 −39.343 18.676 1.00 19.12 D ATOM 2921 C LEU D 17 9.580 −35.43417.507 1.00 15.78 D ATOM 2922 O LEU D 17 9.302 −34.696 18.477 1.00 13.95D ATOM 2923 N THR D 18 8.680 −36.029 16.746 1.00 14.57 D ATOM 2924 CATHR D 18 7.267 −35.707 16.829 1.00 14.95 D ATOM 2925 CB THR D 18 6.839−34.956 15.609 1.00 13.77 D ATOM 2926 OG1 THR D 18 6.822 −33.608 15.9551.00 13.59 D ATOM 2927 CG2 THR D 18 5.595 −35.378 15.076 1.00 13.63 DATOM 2928 C THR D 18 6.592 −36.998 16.902 1.00 18.64 D ATOM 2929 O THR D18 6.605 −37.745 15.888 1.00 18.69 D ATOM 2930 N HIS D 19 5.945 −37.26018.043 1.00 19.91 D ATOM 2931 CA HIS D 19 5.336 −38.526 18.184 1.0022.13 D ATOM 2932 CB HIS D 19 5.056 −38.890 19.620 1.00 22.27 D ATOM2933 CG HIS D 19 4.712 −40.342 19.805 1.00 22.49 D ATOM 2934 CD2 HIS D19 4.108 −41.012 20.822 1.00 21.23 D ATOM 2935 ND1 HIS D 19 5.057−41.303 18.870 1.00 23.27 D ATOM 2936 CE1 HIS D 19 4.691 −42.494 19.3111.00 21.94 D ATOM 2937 NE2 HIS D 19 4.125 −42.347 20.495 1.00 21.24 DATOM 2938 C HIS D 19 4.126 −38.724 17.288 1.00 25.10 D ATOM 2939 O HIS D19 4.246 −38.321 16.073 1.00 26.98 D ATOM 2940 N PRO D 20 2.923 −39.22317.801 1.00 24.54 D ATOM 2941 CD PRO D 20 2.337 −38.414 18.904 1.0023.36 D ATOM 2942 CA PRO D 20 1.943 −39.360 16.673 1.00 22.95 D ATOM2943 CB PRO D 20 0.908 −38.311 16.988 1.00 23.40 D ATOM 2944 CG PRO D 200.757 −38.621 18.588 1.00 23.20 D ATOM 2945 C PRO D 20 2.669 −39.17815.291 1.00 23.63 D ATOM 2946 O PRO D 20 3.179 −40.170 14.725 1.00 24.25D ATOM 2947 N TYR D 21 2.837 −37.936 14.792 1.00 22.75 D ATOM 2948 CATYR D 21 3.567 −37.676 13.486 1.00 22.40 D ATOM 2949 CB TYR D 21 4.702−38.650 13.092 1.00 21.58 D ATOM 2950 CG TYR D 21 5.308 −38.068 11.8111.00 22.38 D ATOM 2951 CD1 TYR D 21 5.951 −36.809 11.851 1.00 22.41 DATOM 2952 CE1 TYR D 21 6.306 −36.090 10.613 1.00 23.51 D ATOM 2953 CD2TYR D 21 5.024 −38.655 10.522 1.00 23.15 D ATOM 2954 CE2 TYR D 21 5.360−37.975 9.271 1.00 23.29 D ATOM 2955 CZ TYR D 21 5.987 −36.701 9.3541.00 23.84 D ATOM 2956 OH TYR D 21 6.207 −35.964 8.260 1.00 25.73 D ATOM2957 C TYR D 21 2.588 −37.757 12.349 1.00 21.78 D ATOM 2958 O TYR D 212.263 −38.865 11.900 1.00 22.23 D ATOM 2959 N GLY D 22 2.150 −36.60511.903 1.00 22.04 D ATOM 2960 CA GLY D 22 1.171 −36.620 10.882 1.0023.00 D ATOM 2961 C GLY D 22 0.169 −35.551 11.242 1.00 23.84 D ATOM 2962O GLY D 22 0.012 −34.530 10.475 1.00 24.54 D ATOM 2963 N LYS D 23 −0.448−35.735 12.429 1.00 23.43 D ATOM 2964 CA LYS D 23 −1.508 −34.778 12.8571.00 23.57 D ATOM 2965 CB LYS D 23 −2.860 −35.530 13.037 1.00 22.92 DATOM 2966 CG LYS D 23 −3.463 −36.240 11.737 1.00 22.29 D ATOM 2967 CDLYS D 23 −2.928 −37.785 11.512 1.00 21.61 D ATOM 2968 CE LYS D 23 −3.277−38.354 10.084 1.00 21.28 D ATOM 2969 NZ LYS D 23 −4.818 −38.278 9.6221.00 20.96 D ATOM 2970 C LYS D 23 −1.158 −33.990 14.144 1.00 22.88 DATOM 2971 O LYS D 23 −1.876 −33.023 14.539 1.00 23.25 D ATOM 2972 N GLYD 24 −0.036 −34.368 14.774 1.00 21.47 D ATOM 2973 CA GLY D 24 0.314−33.642 15.964 1.00 18.97 D ATOM 2974 C GLY D 24 1.055 −32.353 15.6101.00 17.81 D ATOM 2975 O GLY D 24 0.657 −31.609 14.751 1.00 15.25 D ATOM2976 N TRP D 25 2.155 −32.160 16.324 1.00 18.12 D ATOM 2977 CA TRP D 253.026 −31.027 16.240 1.00 18.49 D ATOM 2978 CB TRP D 25 4.076 −31.18417.355 1.00 18.84 D ATOM 2979 CG TRP D 25 3.671 −31.032 18.815 1.0017.23 D ATOM 2980 CD2 TRP D 25 3.561 −29.789 19.500 1.00 16.26 D ATOM2981 CE2 TRP D 25 3.342 −30.094 20.871 1.00 15.33 D ATOM 2982 CE3 TRP D25 3.620 −28.453 19.087 1.00 14.96 D ATOM 2983 CD1 TRP D 25 3.509−32.038 19.781 1.00 16.74 D ATOM 2984 NE1 TRP D 25 3.326 −31.455 21.0161.00 15.48 D ATOM 2985 CZ2 TRP D 25 3.190 −29.105 21.793 1.00 14.61 DATOM 2986 CZ3 TRP D 25 3.471 −27.484 20.016 1.00 15.02 D ATOM 2987 CH2TRP D 25 3.258 −27.812 21.361 1.00 13.66 D ATOM 2988 C TRP D 25 3.718−30.935 14.847 1.00 19.46 D ATOM 2989 O TRP D 25 4.318 −31.960 14.3581.00 18.97 D ATOM 2990 N ASP D 26 3.630 −29.749 14.188 1.00 18.86 D ATOM2991 CA ASP D 26 4.270 −29.557 12.867 1.00 18.98 D ATOM 2992 CB ASP D 263.295 −29.332 11.600 1.00 20.80 D ATOM 2993 CG ASP D 26 2.246 −30.51511.315 1.00 23.26 D ATOM 2994 OD1 ASP D 26 2.364 −31.729 11.789 1.0023.75 D ATOM 2995 OD2 ASP D 26 1.259 −30.212 10.525 1.00 24.99 D ATOM2996 C ASP D 26 5.177 −28.313 12.877 1.00 18.61 D ATOM 2997 O ASP D 264.819 −27.237 13.406 1.00 17.77 D ATOM 2998 N LEU D 27 6.332 −28.49112.248 1.00 16.76 D ATOM 2999 CA LEU D 27 7.291 −27.469 12.091 1.0015.84 D ATOM 3000 CB LEU D 27 8.585 −28.130 11.796 1.00 15.13 D ATOM3001 CG LEU D 27 9.797 −27.199 11.978 1.00 16.33 D ATOM 3002 CD1 LEU D27 9.818 −26.291 13.274 1.00 13.17 D ATOM 3003 CD2 LEU D 27 10.959−28.147 11.769 1.00 13.31 D ATOM 3004 C LEU D 27 6.812 −26.576 10.9441.00 16.06 D ATOM 3005 O LEU D 27 6.507 −27.021 9.914 1.00 15.81 D ATOM3006 N MET D 28 6.678 −25.286 11.174 1.00 16.42 D ATOM 3007 CA MET D 286.161 −24.418 10.170 1.00 15.75 D ATOM 3008 CB MET D 28 4.752 −23.89510.549 1.00 19.93 D ATOM 3009 CG MET D 28 3.791 −24.913 11.165 1.0023.75 D ATOM 3010 SD MET D 28 1.897 −24.566 11.233 1.00 28.97 D ATOM3011 CE MET D 28 1.614 −23.732 9.400 1.00 25.86 D ATOM 3012 C MET D 287.113 −23.263 10.174 1.00 15.06 D ATOM 3013 O MET D 28 7.696 −22.91411.178 1.00 13.55 D ATOM 3014 N GLN D 29 7.242 −22.684 9.006 1.00 15.98D ATOM 3015 CA GLN D 29 8.084 −21.579 8.797 1.00 17.30 D ATOM 3016 CBGLN D 29 9.052 −21.867 7.667 1.00 17.68 D ATOM 3017 CG GLN D 29 10.139−20.782 7.671 1.00 19.83 D ATOM 3018 CD GLN D 29 10.861 −20.601 6.3641.00 20.83 D ATOM 3019 OE1 GLN D 29 11.980 −21.074 6.107 1.00 21.25 DATOM 3020 NE2 GLN D 29 10.223 −19.864 5.534 1.00 21.94 D ATOM 3021 C GLND 29 7.413 −20.282 8.448 1.00 17.75 D ATOM 3022 O GLN D 29 6.899 −20.1817.387 1.00 19.59 D ATOM 3023 N ASN D 30 7.399 −19.251 9.290 1.00 18.30 DATOM 3024 CA ASN D 30 6.829 −17.988 8.824 1.00 17.01 D ATOM 3025 CB ASND 30 6.061 −17.306 9.935 1.00 15.89 D ATOM 3026 CG ASN D 30 4.628−17.813 10.078 1.00 14.36 D ATOM 3027 OD1 ASN D 30 4.107 −17.728 11.0811.00 14.81 D ATOM 3028 ND2 ASN D 30 4.038 −18.303 9.077 1.00 13.62 DATOM 3029 C ASN D 30 7.938 −17.088 8.323 1.00 16.09 D ATOM 3030 O ASN D30 9.123 −17.344 8.420 1.00 16.57 D ATOM 3031 N ILE D 31 7.566 −16.0147.730 1.00 16.06 D ATOM 3032 CA ILE D 31 8.634 −15.175 7.290 1.00 16.21D ATOM 3033 CB ILE D 31 9.034 −15.590 5.892 1.00 16.02 D ATOM 3034 CG2ILE D 31 7.780 −15.568 4.976 1.00 15.37 D ATOM 3035 CG1 ILE D 31 10.090−14.649 5.424 1.00 16.11 D ATOM 3036 CD1 ILE D 31 10.638 −15.207 4.1671.00 18.88 D ATOM 3037 C ILE D 31 8.229 −13.757 7.370 1.00 13.70 D ATOM3038 O ILE D 31 7.129 −13.388 7.080 1.00 12.60 D ATOM 3039 N MET D 329.163 −12.981 7.795 1.00 14.26 D ATOM 3040 CA MET D 32 8.968 −11.5858.045 1.00 15.46 D ATOM 3041 CB MET D 32 8.832 −11.344 9.548 1.00 17.23D ATOM 3042 CG MET D 32 7.462 −11.341 10.167 1.00 20.56 D ATOM 3043 SDMET D 32 6.253 −10.204 9.265 1.00 23.96 D ATOM 3044 CE MET D 32 7.467−8.893 8.974 1.00 22.80 D ATOM 3045 C MET D 32 10.182 −10.878 7.641 1.0014.86 D ATOM 3046 O MET D 32 11.270 −11.131 8.148 1.00 13.91 D ATOM 3047N ASN D 33 10.005 −9.907 6.774 1.00 15.73 D ATOM 3048 CA ASN D 33 11.160−9.114 6.296 1.00 17.19 D ATOM 3049 CB ASN D 33 11.668 −8.141 7.337 1.0017.57 D ATOM 3050 CG ASN D 33 10.563 −7.224 7.866 1.00 18.25 D ATOM 3051OD1 ASN D 33 10.051 −6.361 7.205 1.00 18.03 D ATOM 3052 ND2 ASN D 3310.208 −7.431 9.087 1.00 19.11 D ATOM 3053 C ASN D 33 12.295 −10.0815.965 1.00 18.30 D ATOM 3054 O ASN D 33 13.437 −9.963 6.511 1.00 19.30 DATOM 3055 N ASP D 34 11.935 −11.069 5.121 1.00 17.78 D ATOM 3056 CA ASPD 34 12.838 −12.101 4.619 1.00 17.49 D ATOM 3057 CB ASP D 34 13.892−11.475 3.637 1.00 20.38 D ATOM 3058 CG ASP D 34 13.282 −11.050 2.1981.00 23.62 D ATOM 3059 OD1 ASP D 34 12.038 −10.779 1.983 1.00 26.72 DATOM 3060 OD2 ASP D 34 14.033 −10.929 1.198 1.00 26.71 D ATOM 3061 C ASPD 34 13.506 −12.888 5.678 1.00 16.66 D ATOM 3062 O ASP D 34 14.478−13.551 5.370 1.00 16.47 D ATOM 3063 N MET D 35 13.049 −12.806 6.9221.00 15.98 D ATOM 3064 CA MET D 35 13.697 −13.632 7.930 1.00 16.12 DATOM 3065 CB MET D 35 13.915 −12.838 9.248 1.00 17.65 D ATOM 3066 CG METD 35 14.956 −11.778 9.140 1.00 18.47 D ATOM 3067 SD MET D 35 16.568−12.616 9.066 1.00 23.67 D ATOM 3068 CE MET D 35 16.870 −12.341 7.1121.00 24.72 D ATOM 3069 C MET D 35 12.861 −14.850 8.184 1.00 14.43 D ATOM3070 O MET D 35 11.690 −14.730 8.431 1.00 14.81 D ATOM 3071 N PRO D 3613.409 −16.047 8.014 1.00 14.06 D ATOM 3072 CD PRO D 36 14.674 −16.5017.439 1.00 15.70 D ATOM 3073 CA PRO D 36 12.517 −17.176 8.334 1.00 14.90D ATOM 3074 CB PRO D 36 13.292 −18.412 7.863 1.00 15.07 D ATOM 3075 CGPRO D 36 14.700 −17.981 7.887 1.00 16.46 D ATOM 3076 C PRO D 36 12.295−17.194 9.886 1.00 12.31 D ATOM 3077 O PRO D 36 13.189 −16.903 10.6251.00 10.67 D ATOM 3078 N ILE D 37 11.077 −17.465 10.291 1.00 11.91 DATOM 3079 CA ILE D 37 10.687 −17.566 11.652 1.00 13.97 D ATOM 3080 CBILE D 37 9.611 −16.554 11.935 1.00 14.61 D ATOM 3081 CG2 ILE D 37 9.264−16.521 13.376 1.00 14.67 D ATOM 3082 CG1 ILE D 37 10.071 −15.172 11.5411.00 16.86 D ATOM 3083 CD1 ILE D 37 11.385 −14.818 11.994 1.00 16.59 DATOM 3084 C ILE D 37 10.131 −18.976 11.916 1.00 13.87 D ATOM 3085 O ILED 37 9.016 −19.276 11.533 1.00 13.72 D ATOM 3086 N TYR D 38 10.854−19.865 12.572 1.00 14.15 D ATOM 3087 CA TYR D 38 10.298 −21.185 12.6981.00 15.37 D ATOM 3088 CB TYR D 38 11.376 −22.261 12.647 1.00 14.67 DATOM 3089 CG TYR D 38 12.017 −22.445 11.284 1.00 14.83 D ATOM 3090 CD1TYR D 38 13.003 −21.610 10.853 1.00 15.23 D ATOM 3091 CE1 TYR D 3813.505 −21.714 9.640 1.00 17.05 D ATOM 3092 CD2 TYR D 38 11.554 −23.42810.408 1.00 15.96 D ATOM 3093 CE2 TYR D 38 12.019 −23.568 9.210 1.0015.39 D ATOM 3094 CZ TYR D 38 12.987 −22.743 8.798 1.00 17.92 D ATOM3095 OH TYR D 38 13.549 −22.911 7.578 1.00 20.13 D ATOM 3096 C TYR D 389.467 −21.381 13.919 1.00 16.02 D ATOM 3097 O TYR D 38 9.650 −20.69414.901 1.00 16.56 D ATOM 3098 N MET D 39 8.508 −22.313 13.855 1.00 16.33D ATOM 3099 CA MET D 39 7.682 −22.625 15.027 1.00 17.24 D ATOM 3100 CBMET D 39 6.487 −21.709 15.143 1.00 16.40 D ATOM 3101 CG MET D 39 5.296−22.131 14.376 1.00 16.72 D ATOM 3102 SD MET D 39 4.418 −20.557 14.0381.00 20.61 D ATOM 3103 CE MET D 39 2.950 −20.997 12.993 1.00 22.91 DATOM 3104 C MET D 39 7.184 −24.023 15.040 1.00 15.85 D ATOM 3105 O MET D39 7.157 −24.604 14.035 1.00 16.63 D ATOM 3106 N TYR D 40 6.859 −24.55616.185 1.00 14.80 D ATOM 3107 CA TYR D 40 6.242 −25.857 16.268 1.0015.37 D ATOM 3108 CB TYR D 40 6.938 −26.748 17.313 1.00 15.84 D ATOM3109 CG TYR D 40 7.934 −27.647 16.671 1.00 18.16 D ATOM 3110 CD1 TYR D40 9.308 −27.414 16.766 1.00 18.10 D ATOM 3111 CE1 TYR D 40 10.212−28.251 16.052 1.00 20.09 D ATOM 3112 CD2 TYR D 40 7.497 −28.737 15.8821.00 19.24 D ATOM 3113 CE2 TYR D 40 8.427 −29.590 15.196 1.00 19.90 DATOM 3114 CZ TYR D 40 9.764 −29.319 15.276 1.00 20.26 D ATOM 3115 OH TYRD 40 10.668 −30.032 14.477 1.00 23.35 D ATOM 3116 C TYR D 40 4.727−25.603 16.690 1.00 14.36 D ATOM 3117 O TYR D 40 4.487 −24.863 17.6761.00 13.69 D ATOM 3118 N SER D 41 3.735 −26.085 15.926 1.00 12.57 D ATOM3119 CA SER D 41 2.412 −25.875 16.376 1.00 13.29 D ATOM 3120 CB SER D 411.778 −24.572 15.880 1.00 13.99 D ATOM 3121 OG SER D 41 1.927 −24.37414.557 1.00 16.27 D ATOM 3122 C SER D 41 1.456 −26.996 16.217 1.00 13.90D ATOM 3123 O SER D 41 1.735 −27.929 15.534 1.00 13.93 D ATOM 3124 N VALD 42 0.344 −26.920 16.918 1.00 14.04 D ATOM 3125 CA VAL D 42 −0.674−27.922 16.819 1.00 15.42 D ATOM 3126 CB VAL D 42 −0.842 −28.881 18.0231.00 16.16 D ATOM 3127 CG1 VAL D 42 −1.304 −30.246 17.531 1.00 14.91 DATOM 3128 CG2 VAL D 42 0.345 −28.684 19.042 1.00 14.24 D ATOM 3129 C VALD 42 −1.918 −27.155 17.086 1.00 15.53 D ATOM 3130 O VAL D 42 −1.879−26.182 17.818 1.00 14.82 D ATOM 3131 N CYS D 43 −3.023 −27.761 16.6831.00 15.85 D ATOM 3132 CA CYS D 43 −4.341 −27.172 16.866 1.00 16.96 DATOM 3133 C CYS D 43 −5.450 −28.230 16.646 1.00 16.91 D ATOM 3134 O CYSD 43 −6.345 −27.980 15.931 1.00 17.08 D ATOM 3135 CB CYS D 43 −4.574−26.008 15.843 1.00 17.47 D ATOM 3136 SG CYS D 43 −5.784 −24.716 16.3331.00 18.21 D ATOM 3137 N ASN D 44 −5.365 −29.407 17.221 1.00 16.15 DATOM 3138 CA ASN D 44 −6.410 −30.391 17.140 1.00 15.14 D ATOM 3139 CBASN D 44 −5.796 −31.815 17.270 1.00 15.90 D ATOM 3140 CG ASN D 44 −4.875−32.096 16.207 1.00 15.73 D ATOM 3141 OD1 ASN D 44 −3.998 −32.885 16.3261.00 14.28 D ATOM 3142 ND2 ASN D 44 −5.067 −31.398 15.118 1.00 17.52 DATOM 3143 C ASN D 44 −7.380 −30.157 18.306 1.00 15.21 D ATOM 3144 O ASND 44 −7.484 −31.018 19.207 1.00 14.29 D ATOM 3145 N VAL D 45 −8.049−29.003 18.282 1.00 14.81 D ATOM 3146 CA VAL D 45 −8.961 −28.590 19.3251.00 15.44 D ATOM 3147 CB VAL D 45 −9.142 −27.029 19.476 1.00 16.28 DATOM 3148 CG1 VAL D 45 −7.874 −26.433 19.876 1.00 18.01 D ATOM 3149 CG2VAL D 45 −9.693 −26.362 18.147 1.00 15.85 D ATOM 3150 C VAL D 45 −10.337−29.091 19.168 1.00 16.12 D ATOM 3151 O VAL D 45 −11.154 −28.922 20.0711.00 16.57 D ATOM 3152 N MET D 46 −10.564 −29.806 18.106 1.00 16.47 DATOM 3153 CA MET D 46 −11.875 −30.225 17.735 1.00 16.46 D ATOM 3154 CBMET D 46 −12.088 −29.758 16.259 1.00 19.08 D ATOM 3155 CG MET D 46−13.324 −29.004 15.900 1.00 21.30 D ATOM 3156 SD MET D 46 −13.867−27.607 17.074 1.00 26.09 D ATOM 3157 CE MET D 46 −13.303 −25.962 15.7551.00 24.69 D ATOM 3158 C MET D 46 −11.929 −31.725 17.841 1.00 17.53 DATOM 3159 O MET D 46 −12.845 −32.339 17.330 1.00 16.49 D ATOM 3160 N SERD 47 −10.944 −32.369 18.456 1.00 17.71 D ATOM 3161 CA SER D 47 −11.070−33.853 18.551 1.00 18.11 D ATOM 3162 CB SER D 47 −10.184 −34.490 17.5411.00 18.57 D ATOM 3163 OG SER D 47 −9.644 −33.486 16.639 1.00 20.90 DATOM 3164 C SER D 47 −10.518 −34.076 19.909 1.00 20.01 D ATOM 3165 O SERD 47 −9.593 −33.251 20.327 1.00 21.57 D ATOM 3166 N GLY D 48 −10.992−35.076 20.626 1.00 18.85 D ATOM 3167 CA GLY D 48 −10.497 −35.182 21.9741.00 17.41 D ATOM 3168 C GLY D 48 −9.305 −36.075 22.146 1.00 17.99 DATOM 3169 O GLY D 48 −8.661 −36.431 21.145 1.00 17.72 D ATOM 3170 N ASPD 49 −8.986 −36.422 23.408 1.00 18.20 D ATOM 3171 CA ASP D 49 −7.892−37.355 23.664 1.00 18.08 D ATOM 3172 CB ASP D 49 −8.322 −38.745 23.1651.00 19.81 D ATOM 3173 CG ASP D 49 −9.760 −39.158 23.686 1.00 21.51 DATOM 3174 OD1 ASP D 49 −10.639 −39.552 22.889 1.00 18.09 D ATOM 3175 OD2ASP D 49 −9.950 −39.076 24.959 1.00 24.22 D ATOM 3176 C ASP D 49 −6.649−36.995 22.922 1.00 18.28 D ATOM 3177 O ASP D 49 −6.134 −37.871 22.2891.00 18.47 D ATOM 3178 N GLN D 50 −6.160 −35.758 22.912 1.00 18.14 DATOM 3179 CA GLN D 50 −4.923 −35.503 22.166 1.00 17.18 D ATOM 3180 CBGLN D 50 −4.785 −34.050 21.801 1.00 18.05 D ATOM 3181 CG GLN D 50 −5.805−33.562 20.809 1.00 18.38 D ATOM 3182 CD GLN D 50 −5.821 −34.431 19.5461.00 18.57 D ATOM 3183 OE1 GLN D 50 −4.884 −34.408 18.767 1.00 18.37 DATOM 3184 NE2 GLN D 50 −6.892 −35.193 19.356 1.00 18.84 D ATOM 3185 CGLN D 50 −3.824 −35.872 23.115 1.00 17.28 D ATOM 3186 O GLN D 50 −3.983−35.770 24.293 1.00 16.64 D ATOM 3187 N ASP D 51 −2.732 −36.392 22.5871.00 17.39 D ATOM 3188 CA ASP D 51 −1.573 −36.738 23.377 1.00 16.93 DATOM 3189 CB ASP D 51 −1.656 −38.170 23.899 1.00 17.91 D ATOM 3190 CGASP D 51 −0.582 −38.496 24.980 1.00 18.72 D ATOM 3191 OD1 ASP D 51−0.390 −39.669 25.265 1.00 19.90 D ATOM 3192 OD2 ASP D 51 0.066 −37.60925.572 1.00 18.15 D ATOM 3193 C ASP D 51 −0.394 −36.588 22.396 1.0017.07 D ATOM 3194 O ASP D 51 0.264 −37.549 22.029 1.00 16.71 D ATOM 3195N ASN D 52 −0.135 −35.374 21.942 1.00 15.99 D ATOM 3196 CA ASN D 520.946 −35.173 21.001 1.00 15.18 D ATOM 3197 CB ASN D 52 0.531 −34.18819.930 1.00 17.08 D ATOM 3198 CG ASN D 52 −0.806 −34.484 19.377 1.0018.54 D ATOM 3199 OD1 ASN D 52 −0.925 −35.436 18.598 1.00 19.73 D ATOM3200 ND2 ASN D 52 −1.831 −33.681 19.738 1.00 16.50 D ATOM 3201 C ASN D52 2.281 −34.692 21.632 1.00 14.19 D ATOM 3202 O ASN D 52 2.329 −33.80422.429 1.00 10.84 D ATOM 3203 N TRP D 53 3.348 −35.325 21.165 1.00 13.45D ATOM 3204 CA TRP D 53 4.606 −35.099 21.725 1.00 14.05 D ATOM 3205 CBTRP D 53 5.104 −36.345 22.458 1.00 14.65 D ATOM 3206 CG TRP D 53 4.377−36.737 23.709 1.00 14.96 D ATOM 3207 CD2 TRP D 53 4.833 −36.612 25.0261.00 16.19 D ATOM 3208 CE2 TRP D 53 3.839 −37.143 25.849 1.00 17.40 DATOM 3209 CE3 TRP D 53 5.987 −36.121 25.608 1.00 15.87 D ATOM 3210 CD1TRP D 53 3.207 −37.277 23.762 1.00 14.16 D ATOM 3211 NE1 TRP D 53 2.825−37.521 25.026 1.00 15.87 D ATOM 3212 CZ2 TRP D 53 3.967 −37.209 27.2911.00 19.87 D ATOM 3213 CZ3 TRP D 53 6.130 −36.188 26.990 1.00 17.01 DATOM 3214 CH2 TRP D 53 5.121 −36.731 27.821 1.00 19.17 D ATOM 3215 C TRPD 53 5.667 −34.590 20.841 1.00 14.61 D ATOM 3216 O TRP D 53 5.806−34.980 19.771 1.00 13.50 D ATOM 3217 N LEU D 54 6.451 −33.660 21.3791.00 15.67 D ATOM 3218 CA LEU D 54 7.498 −32.956 20.665 1.00 15.43 DATOM 3219 CB LEU D 54 7.169 −31.456 20.549 1.00 15.58 D ATOM 3220 CG LEUD 54 8.287 −30.667 19.921 1.00 15.12 D ATOM 3221 CD1 LEU D 54 8.559−31.248 18.561 1.00 14.08 D ATOM 3222 CD2 LEU D 54 7.982 −29.174 19.8881.00 13.70 D ATOM 3223 C LEU D 54 8.664 −33.125 21.590 1.00 15.91 D ATOM3224 O LEU D 54 8.601 −32.768 22.767 1.00 15.46 D ATOM 3225 N ARG D 559.691 −33.748 21.048 1.00 16.31 D ATOM 3226 CA ARG D 55 10.885 −33.97421.768 1.00 16.82 D ATOM 3227 CB ARG D 55 11.218 −35.435 21.962 1.0017.34 D ATOM 3228 CG ARG D 55 12.498 −35.548 22.830 1.00 19.18 D ATOM3229 CD ARG D 55 12.870 −36.951 23.350 1.00 19.84 D ATOM 3230 NE ARG D55 13.862 −37.737 22.565 1.00 21.10 D ATOM 3231 CZ ARG D 55 13.999−37.748 21.224 1.00 21.55 D ATOM 3232 NH1 ARG D 55 13.213 −36.954 20.4241.00 24.98 D ATOM 3233 NH2 ARG D 55 14.816 −38.621 20.663 1.00 16.08 DATOM 3234 C ARG D 55 12.037 −33.304 21.077 1.00 16.45 D ATOM 3235 O ARGD 55 12.166 −33.383 19.873 1.00 17.23 D ATOM 3236 N THR D 56 12.828−32.592 21.857 1.00 15.45 D ATOM 3237 CA THR D 56 14.011 −31.959 21.3971.00 13.60 D ATOM 3238 CB THR D 56 14.664 −31.059 22.580 1.00 13.89 DATOM 3239 OG1 THR D 56 15.259 −31.914 23.647 1.00 9.06 D ATOM 3240 CG2THR D 56 13.632 −30.040 23.101 1.00 12.40 D ATOM 3241 C THR D 56 15.017−33.060 21.207 1.00 13.23 D ATOM 3242 O THR D 56 14.830 −34.221 21.5661.00 11.13 D ATOM 3243 N ASN D 57 16.160 −32.660 20.712 1.00 14.15 DATOM 3244 CA ASN D 57 17.222 −33.632 20.608 1.00 16.53 D ATOM 3245 CBASN D 57 18.075 −33.340 19.468 1.00 17.83 D ATOM 3246 CG ASN D 57 17.845−34.356 18.406 1.00 21.60 D ATOM 3247 OD1 ASN D 57 16.764 −34.296 17.6961.00 20.48 D ATOM 3248 ND2 ASN D 57 18.792 −35.368 18.296 1.00 22.87 DATOM 3249 C ASN D 57 18.119 −33.782 21.783 1.00 17.27 D ATOM 3250 O ASND 57 18.178 −32.926 22.629 1.00 17.89 D ATOM 3251 N TRP D 58 18.861−34.863 21.817 1.00 17.73 D ATOM 3252 CA TRP D 58 19.779 −35.215 22.8911.00 18.44 D ATOM 3253 CB TRP D 58 20.732 −36.277 22.378 1.00 19.65 DATOM 3254 CG TRP D 58 21.870 −36.804 23.254 1.00 20.12 D ATOM 3255 CD2TRP D 58 21.768 −37.257 24.574 1.00 19.13 D ATOM 3256 CE2 TRP D 5823.037 −37.805 24.945 1.00 20.24 D ATOM 3257 CE3 TRP D 58 20.728 −37.27325.489 1.00 17.64 D ATOM 3258 CD1 TRP D 58 23.209 −37.083 22.858 1.0022.41 D ATOM 3259 NE1 TRP D 58 23.918 −37.698 23.893 1.00 21.15 D ATOM3260 CZ2 TRP D 58 23.242 −38.340 26.209 1.00 19.82 D ATOM 3261 CZ3 TRP D58 20.913 −37.785 26.657 1.00 16.75 D ATOM 3262 CH2 TRP D 58 22.164−38.326 27.041 1.00 19.77 D ATOM 3263 C TRP D 58 20.541 −33.987 23.2851.00 19.15 D ATOM 3264 O TRP D 58 21.017 −33.252 22.379 1.00 20.09 DATOM 3265 N VAL D 59 20.627 −33.689 24.581 1.00 17.10 D ATOM 3266 CA VALD 59 21.334 −32.477 24.962 1.00 17.02 D ATOM 3267 CB VAL D 59 20.356−31.311 25.458 1.00 15.34 D ATOM 3268 CG1 VAL D 59 21.193 −30.105 25.8281.00 14.94 D ATOM 3269 CG2 VAL D 59 19.340 −30.897 24.437 1.00 12.10 DATOM 3270 C VAL D 59 22.341 −32.847 26.076 1.00 16.27 D ATOM 3271 O VALD 59 21.967 −33.315 27.151 1.00 16.45 D ATOM 3272 N TYR D 60 23.610−32.641 25.780 1.00 14.78 D ATOM 3273 CA TYR D 60 24.660 −32.866 26.7201.00 15.80 D ATOM 3274 CB TYR D 60 26.058 −32.592 26.130 1.00 16.65 DATOM 3275 CG TYR D 60 26.459 −33.568 25.110 1.00 18.65 D ATOM 3276 CD1TYR D 60 26.322 −33.280 23.733 1.00 19.12 D ATOM 3277 CE1 TYR D 6026.568 −34.330 22.789 1.00 20.48 D ATOM 3278 CD2 TYR D 60 26.857 −34.87625.515 1.00 19.52 D ATOM 3279 CE2 TYR D 60 27.113 −35.897 24.637 1.0019.59 D ATOM 3280 CZ TYR D 60 26.993 −35.662 23.278 1.00 20.27 D ATOM3281 OH TYR D 60 27.452 −36.678 22.403 1.00 21.04 D ATOM 3282 C TYR D 6024.528 −31.902 27.884 1.00 14.64 D ATOM 3283 O TYR D 60 24.314 −30.70327.727 1.00 12.28 D ATOM 3284 N ARG D 61 24.674 −32.494 29.048 1.0014.77 D ATOM 3285 CA ARG D 61 24.578 −31.722 30.239 1.00 16.88 D ATOM3286 CB ARG D 61 24.307 −32.624 31.466 1.00 16.82 D ATOM 3287 CG ARG D61 24.533 −31.928 32.905 1.00 15.29 D ATOM 3288 CD ARG D 61 24.049−32.889 34.066 1.00 15.40 D ATOM 3289 NE ARG D 61 25.083 −33.849 34.3511.00 15.86 D ATOM 3290 CZ ARG D 61 26.208 −33.544 35.038 1.00 16.95 DATOM 3291 NH1 ARG D 61 26.400 −32.313 35.542 1.00 16.24 D ATOM 3292 NH2ARG D 61 27.195 −34.426 35.138 1.00 18.08 D ATOM 3293 C ARG D 61 25.826−30.888 30.526 1.00 17.57 D ATOM 3294 O ARG D 61 25.712 −29.745 31.0201.00 17.68 D ATOM 3295 N GLY D 62 26.994 −31.472 30.167 1.00 18.17 DATOM 3296 CA GLY D 62 28.306 −30.891 30.452 1.00 19.04 D ATOM 3297 C GLYD 62 28.538 −30.739 31.967 1.00 19.64 D ATOM 3298 O GLY D 62 28.498−31.685 32.764 1.00 19.02 D ATOM 3299 N GLU D 63 28.716 −29.522 32.3931.00 20.35 D ATOM 3300 CA GLU D 63 28.968 −29.218 33.821 1.00 21.65 DATOM 3301 CB GLU D 63 30.058 −28.070 33.832 1.00 22.59 D ATOM 3302 CGGLU D 63 30.373 −27.398 35.126 1.00 23.69 D ATOM 3303 CD GLU D 63 30.948−28.456 36.070 1.00 27.34 D ATOM 3304 OE1 GLU D 63 31.116 −28.200 37.3941.00 24.00 D ATOM 3305 OE2 GLU D 63 31.218 −29.586 35.370 1.00 30.19 DATOM 3306 C GLU D 63 27.660 −28.736 34.521 1.00 21.40 D ATOM 3307 O GLUD 63 27.742 −28.617 35.721 1.00 22.79 D ATOM 3308 N ALA D 64 26.541−28.408 33.815 1.00 19.66 D ATOM 3309 CA ALA D 64 25.267 −27.955 34.4501.00 17.93 D ATOM 3310 CB ALA D 64 24.147 −27.718 33.375 1.00 14.92 DATOM 3311 C ALA D 64 24.701 −28.833 35.565 1.00 17.29 D ATOM 3312 O ALAD 64 24.844 −30.051 35.545 1.00 17.24 D ATOM 3313 N GLU D 65 24.116−28.162 36.582 1.00 17.50 D ATOM 3314 CA GLU D 65 23.369 −28.856 37.6911.00 18.23 D ATOM 3315 CB GLU D 65 23.857 −28.445 39.116 1.00 20.32 DATOM 3316 CG GLU D 65 25.363 −28.417 39.379 1.00 24.45 D ATOM 3317 CDGLU D 65 25.966 −29.318 39.750 1.00 26.11 D ATOM 3318 OE1 GLU D 6525.514 −30.424 40.743 1.00 26.65 D ATOM 3319 OE2 GLU D 65 26.881 −30.34339.007 1.00 28.20 D ATOM 3320 C GLU D 65 21.825 −28.457 37.600 1.0017.07 D ATOM 3321 O GLU D 65 20.925 −29.263 37.825 1.00 16.29 D ATOM3322 N ARG D 66 21.575 −27.179 37.365 1.00 15.98 D ATOM 3323 CA ARG D 6620.241 −26.667 37.205 1.00 15.62 D ATOM 3324 CB ARG D 66 19.877 −25.63738.241 1.00 15.60 D ATOM 3325 CG ARG D 66 18.454 −25.244 38.275 1.0016.25 D ATOM 3326 CD ARG D 66 17.926 −25.513 39.687 1.00 18.50 D ATOM3327 NE ARG D 66 16.439 −25.348 39.737 1.00 20.44 D ATOM 3328 CZ ARG D66 15.526 −26.247 40.125 1.00 20.77 D ATOM 3329 NH1 ARG D 66 15.894−27.479 40.552 1.00 20.41 D ATOM 3330 NH2 ARG D 66 14.233 −25.895 40.1021.00 20.90 D ATOM 3331 C ARG D 66 20.246 −25.943 35.841 1.00 16.11 DATOM 3332 O ARG D 66 21.181 −25.223 35.501 1.00 16.20 D ATOM 3333 N ASND 67 19.229 −26.161 35.028 1.00 15.68 D ATOM 3334 CA ASN D 67 19.231−25.492 33.762 1.00 16.79 D ATOM 3335 CB ASN D 67 19.298 −26.514 32.5991.00 18.54 D ATOM 3336 CG ASN D 67 18.302 −27.610 32.778 1.00 22.16 DATOM 3337 OD1 ASN D 67 18.292 −28.218 33.888 1.00 27.48 D ATOM 3338 ND2ASN D 67 17.489 −27.941 31.763 1.00 19.29 D ATOM 3339 C ASN D 67 17.936−24.719 33.813 1.00 16.14 D ATOM 3340 O ASN D 67 17.081 −25.053 34.5311.00 15.32 D ATOM 3341 N ASN D 68 17.871 −23.653 33.079 1.00 15.79 DATOM 3342 CA ASN D 68 16.743 −22.841 33.040 1.00 17.53 D ATOM 3343 CBASN D 68 17.248 −21.421 33.329 1.00 19.20 D ATOM 3344 CG ASN D 68 17.696−21.252 34.795 1.00 22.05 D ATOM 3345 OD1 ASN D 68 16.871 −20.873 35.6871.00 23.00 D ATOM 3346 ND2 ASN D 68 18.976 −21.573 35.093 1.00 20.89 DATOM 3347 C ASN D 68 16.133 −22.950 31.584 1.00 16.88 D ATOM 3348 O ASND 68 16.927 −23.068 30.571 1.00 16.43 D ATOM 3349 N PHE D 69 14.786−22.984 31.471 1.00 15.36 D ATOM 3350 CA PHE D 69 14.254 −22.931 30.1101.00 16.24 D ATOM 3351 CB PHE D 69 13.713 −24.207 29.508 1.00 17.54 DATOM 3352 CG PHE D 69 13.461 −25.194 30.440 1.00 20.07 D ATOM 3353 CD1PHE D 69 12.588 −24.926 31.469 1.00 22.38 D ATOM 3354 CD2 PHE D 6914.113 −26.438 30.341 1.00 20.21 D ATOM 3355 CE1 PHE D 69 12.350 −25.92232.448 1.00 24.68 D ATOM 3356 CE2 PHE D 69 13.915 −27.464 31.262 1.0021.71 D ATOM 3357 CZ PHE D 69 13.057 −27.246 32.324 1.00 24.02 D ATOM3358 C PHE D 69 13.253 −21.881 29.873 1.00 15.61 D ATOM 3359 O PHE D 6912.346 −21.713 30.631 1.00 16.02 D ATOM 3360 N GLU D 70 13.508 −21.13428.820 1.00 14.41 D ATOM 3361 CA GLU D 70 12.698 −20.073 28.384 1.0014.48 D ATOM 3362 CB GLU D 70 13.563 −18.880 28.061 1.00 13.90 D ATOM3363 CG GLU D 70 12.780 −17.608 28.136 1.00 15.09 D ATOM 3364 CD GLU D70 13.536 −16.393 27.510 1.00 16.80 D ATOM 3365 OE1 GLU D 70 13.518−15.221 28.089 1.00 16.75 D ATOM 3366 OE2 GLU D 70 14.126 −16.652 26.4361.00 15.11 D ATOM 3367 C GLU D 70 11.899 −20.516 27.134 1.00 14.26 DATOM 3368 O GLU D 70 12.476 −20.857 26.112 1.00 12.31 D ATOM 3369 N LEUD 71 10.567 −20.444 27.294 1.00 15.14 D ATOM 3370 CA LEU D 71 9.511−20.782 26.310 1.00 16.19 D ATOM 3371 CB LEU D 71 8.528 −21.849 26.8311.00 16.92 D ATOM 3372 CG LEU D 71 9.152 −23.156 27.232 1.00 16.27 DATOM 3373 CD1 LEU D 71 8.122 −23.962 27.952 1.00 18.66 D ATOM 3374 CD2LEU D 71 9.628 −23.923 26.133 1.00 15.92 D ATOM 3375 C LEU D 71 8.698−19.515 25.913 1.00 17.85 D ATOM 3376 O LEU D 71 8.204 −18.756 26.7911.00 18.28 D ATOM 3377 N ASN D 72 8.568 −19.310 24.582 1.00 17.64 D ATOM3378 CA ASN D 72 7.818 −18.223 23.982 1.00 16.61 D ATOM 3379 CB ASN D 728.773 −17.373 23.128 1.00 18.61 D ATOM 3380 CG ASN D 72 9.482 −16.23623.995 1.00 21.12 D ATOM 3381 OD1 ASN D 72 10.555 −15.568 23.672 1.0018.69 D ATOM 3382 ND2 ASN D 72 8.845 −16.024 25.151 1.00 24.85 D ATOM3383 C ASN D 72 6.761 −18.918 23.170 1.00 17.10 D ATOM 3384 O ASN D 727.071 −19.733 22.291 1.00 16.98 D ATOM 3385 N PHE D 73 5.491 −18.65223.467 1.00 16.48 D ATOM 3386 CA PHE D 73 4.435 −19.306 22.718 1.0016.23 D ATOM 3387 CB PHE D 73 4.103 −20.603 23.376 1.00 17.40 D ATOM3388 CG PHE D 73 3.731 −20.447 24.816 1.00 18.25 D ATOM 3389 CD1 PHE D73 2.384 −20.339 25.186 1.00 18.03 D ATOM 3390 CD2 PHE D 73 4.733−20.284 25.801 1.00 17.94 D ATOM 3391 CE1 PHE D 73 2.050 −20.066 26.4891.00 18.65 D ATOM 3392 CE2 PHE D 73 4.371 −19.998 27.171 1.00 19.18 DATOM 3393 CZ PHE D 73 3.047 −19.889 27.516 1.00 18.13 D ATOM 3394 C PHED 73 3.155 −18.526 22.646 1.00 16.01 D ATOM 3395 O PHE D 73 3.026−17.529 23.307 1.00 15.01 D ATOM 3396 N THR D 74 2.218 −19.017 21.8451.00 16.10 D ATOM 3397 CA THR D 74 0.953 −18.382 21.799 1.00 18.51 DATOM 3398 CB THR D 74 0.653 −17.624 20.499 1.00 18.64 D ATOM 3399 OG1THR D 74 0.260 −18.528 19.454 1.00 19.30 D ATOM 3400 CG2 THR D 74 1.878−16.874 20.139 1.00 19.47 D ATOM 3401 C THR D 74 −0.066 −19.418 21.9061.00 17.41 D ATOM 3402 O THR D 74 0.229 −20.557 21.620 1.00 18.09 D ATOM3403 N VAL D 75 −1.278 −18.991 22.272 1.00 17.25 D ATOM 3404 CA VAL D 75−2.393 −19.903 22.466 1.00 16.96 D ATOM 3405 CB VAL D 75 −2.479 −20.33523.920 1.00 1626 D ATOM 3406 CG1 VAL D 75 −3.568 −21.243 24.116 1.0013.36 D ATOM 3407 CG2 VAL D 75 −1.201 −21.031 24.293 1.00 16.17 D ATOM3408 C VAL D 75 −3.715 −19.292 21.991 1.00 17.35 D ATOM 3409 O VAL D 75−4.210 −18.287 22.482 1.00 16.92 D ATOM 3410 N ARG D 76 −4.261 −19.92220.997 1.00 17.16 D ATOM 3411 CA ARG D 76 −5.449 −19.402 20.531 1.0017.86 D ATOM 3412 CB ARG D 76 −5.803 −20.006 19.167 1.00 18.87 D ATOM3413 CG ARG D 76 −7.069 −19.460 18.551 1.00 18.28 D ATOM 3414 CD ARG D76 −7.044 −19.606 17.015 1.00 19.29 D ATOM 3415 NE ARG D 76 −8.405−19.484 16.544 1.00 17.58 D ATOM 3416 CZ ARG D 76 −8.857 −20.015 15.4311.00 17.97 D ATOM 3417 NH1 ARG D 76 −8.043 −20.699 14.563 1.00 17.05 DATOM 3418 NH2 ARG D 76 −10.171 −20.014 15.284 1.00 14.83 D ATOM 3419 CARG D 76 −6.512 −19.697 21.528 1.00 18.08 D ATOM 3420 O ARG D 76 −6.599−20.839 22.115 1.00 18.84 D ATOM 3421 N ASP D 77 −7.341 −18.653 21.7151.00 16.95 D ATOM 3422 CA ASP D 77 −8.507 −18.655 22.616 1.00 15.75 DATOM 3423 CB ASP D 77 −9.160 −17.264 22.511 1.00 16.64 D ATOM 3424 CGASP D 77 −10.469 −17.141 23.265 1.00 17.76 D ATOM 3425 OD1 ASP D 77−10.795 −18.045 24.128 1.00 18.11 D ATOM 3426 OD2 ASP D 77 −11.138−16.110 22.944 1.00 16.43 D ATOM 3427 C ASP D 77 −9.455 −19.801 22.2881.00 14.63 D ATOM 3428 O ASP D 77 −9.845 −19.962 21.189 1.00 12.26 DATOM 3429 N CYS D 78 −9.805 −20.614 23.269 1.00 15.43 D ATOM 3430 CA CYSD 78 −10.668 −21.740 22.980 1.00 18.27 D ATOM 3431 C CYS D 78 −12.060−21.378 22.549 1.00 18.14 D ATOM 3432 O CYS D 78 −12.726 −22.218 21.9851.00 19.72 D ATOM 3433 CB CYS D 78 −10.789 −22.663 24.149 1.00 18.95 DATOM 3434 SG CYS D 78 −9.548 −23.969 24.091 1.00 20.60 D ATOM 3435 N ASND 79 −12.471 −20.148 22.829 1.00 17.21 D ATOM 3436 CA ASN D 79 −13.735−19.696 22.443 1.00 16.77 D ATOM 3437 CB ASN D 79 −14.186 −18.625 23.4151.00 16.90 D ATOM 3438 CG ASN D 79 −14.537 −19.162 24.795 1.00 17.05 DATOM 3439 OD1 ASN D 79 −14.511 −18.391 25.702 1.00 17.05 D ATOM 3440 ND2ASN D 79 −14.851 −20.425 24.960 1.00 17.24 D ATOM 3441 C ASN D 79−13.798 −19.149 20.958 1.00 16.53 D ATOM 3442 O ASN D 79 −14.871 −18.78720.404 1.00 15.73 D ATOM 3443 N SER D 80 −12.640 −19.035 20.343 1.0015.74 D ATOM 3444 CA SER D 80 −12.563 −18.493 18.990 1.00 15.25 D ATOM3445 CB SER D 80 −11.191 −17.873 18.749 1.00 15.76 D ATOM 3446 OG SER D80 −10.150 −18.857 18.599 1.00 17.89 D ATOM 3447 C SER D 80 −12.863−19.564 17.898 1.00 15.19 D ATOM 3448 O SER D 80 −12.634 −19.374 16.7641.00 13.48 D ATOM 3449 N PHE D 81 −13.368 −20.702 18.296 1.00 16.93 DATOM 3450 CA PHE D 81 −13.764 −21.698 17.365 1.00 17.91 D ATOM 3451 CBPHE D 81 −13.112 −23.008 17.819 1.00 19.26 D ATOM 3452 CG PHE D 81−11.603 −22.994 17.775 1.00 19.53 D ATOM 3453 CD1 PHE D 81 −10.869−22.792 18.947 1.00 19.84 D ATOM 3454 CD2 PHE D 81 −10.901 −23.16016.548 1.00 18.86 D ATOM 3455 CE1 PHE D 81 −9.432 −22.752 18.914 1.0019.84 D ATOM 3456 CE2 PHE D 81 −9.431 −23.117 16.488 1.00 18.33 D ATOM3457 CZ PHE D 81 −8.708 −22.919 17.635 1.00 18.86 D ATOM 3458 C PHE D 81−15.316 −21.720 17.464 1.00 17.92 D ATOM 3459 O PHE D 81 −15.835 −22.30618.339 1.00 17.34 D ATOM 3460 N PRO D 82 −16.038 −21.084 16.520 1.0020.82 D ATOM 3461 CD PRO D 82 −15.424 −20.904 15.185 1.00 20.79 D ATOM3462 CA PRO D 82 −17.509 −20.949 16.401 1.00 19.73 D ATOM 3463 CB PRO D82 −17.732 −20.676 14.926 1.00 20.80 D ATOM 3464 CG PRO D 82 −16.503−20.071 14.438 1.00 19.96 D ATOM 3465 C PRO D 82 −18.276 −22.183 16.8311.00 20.80 D ATOM 3466 O PRO D 82 −17.897 −23.286 16.363 1.00 21.43 DATOM 3467 N GLY D 83 −19.357 −21.997 17.655 1.00 20.07 D ATOM 3468 CAGLY D 83 −20.116 −23.079 18.215 1.00 18.79 D ATOM 3469 C GLY D 83−19.206 −23.534 19.368 1.00 18.59 D ATOM 3470 O GLY D 83 −18.062 −23.03419.585 1.00 18.31 D ATOM 3471 N GLY D 84 −19.560 −24.466 20.221 1.0017.80 D ATOM 3472 CA GLY D 84 −18.436 −24.676 21.210 1.00 17.68 D ATOM3473 C GLY D 84 −17.171 −25.510 20.879 1.00 17.94 D ATOM 3474 O GLY D 84−17.094 −26.070 19.812 1.00 18.24 D ATOM 3475 N ALA D 85 −16.118 −25.59221.703 1.00 17.35 D ATOM 3476 CA ALA D 85 −15.054 −26.535 21.301 1.0017.01 D ATOM 3477 CB ALA D 85 −13.809 −25.881 20.806 1.00 15.87 D ATOM3478 C ALA D 85 −14.773 −27.299 22.550 1.00 16.95 D ATOM 3479 O ALA D 85−13.705 −27.274 23.019 1.00 17.89 D ATOM 3480 N SER D 86 −15.739 −28.04923.051 1.00 16.46 D ATOM 3481 CA SER D 86 −15.563 −28.774 24.280 1.0016.14 D ATOM 3482 CB SER D 86 −16.689 −29.812 24.451 1.00 14.71 D ATOM3483 OG SER D 86 −16.641 −30.842 23.557 1.00 12.44 D ATOM 3484 C SER D86 −14.235 −29.345 24.690 1.00 15.71 D ATOM 3485 O SER D 86 −13.948−29.211 25.818 1.00 16.17 D ATOM 3486 N SER D 87 −13.423 −29.914 23.8211.00 16.53 D ATOM 3487 CA SER D 87 −12.155 −30.593 24.267 1.00 16.53 DATOM 3488 CB SER D 87 −11.896 −31.888 23.421 1.00 16.81 D ATOM 3489 OGSER D 87 −11.643 −31.489 22.017 1.00 14.92 D ATOM 3490 C SER D 87−10.942 −29.672 24.101 1.00 17.20 D ATOM 3491 O SER D 87 −9.822 −30.00024.462 1.00 17.68 D ATOM 3492 N CYS D 88 −11.151 −28.526 23.540 1.0017.05 D ATOM 3493 CA CYS D 88 −10.082 −27.597 23.304 1.00 16.09 D ATOM3494 C CYS D 88 −9.582 −27.239 24.646 1.00 17.58 D ATOM 3495 O CYS D 88−10.362 −27.205 25.576 1.00 17.80 D ATOM 3496 CB CYS D 88 −10.652−26.411 22.610 1.00 17.01 D ATOM 3497 SG CYS D 88 −9.604 −25.039 22.2901.00 19.02 D ATOM 3498 N LYS D 89 −8.287 −26.933 24.759 1.00 17.62 DATOM 3499 CA LYS D 89 −7.603 −26.647 26.022 1.00 16.33 D ATOM 3500 CBLYS D 89 −6.597 −27.834 26.350 1.00 17.51 D ATOM 3501 CG LYS D 89 −7.273−29.185 26.610 1.00 19.27 D ATOM 3502 CD LYS D 89 −8.190 −29.138 27.9461.00 18.85 D ATOM 3503 CE LYS D 89 −8.611 −30.627 28.363 1.00 20.75 DATOM 3504 NZ LYS D 89 −9.370 −30.769 29.706 1.00 19.02 D ATOM 3505 C LYSD 89 −6.789 −25.423 25.877 1.00 16.45 D ATOM 3506 O LYS D 89 −6.432−25.107 24.799 1.00 15.96 D ATOM 3507 N GLU D 90 −6.435 −24.741 26.9671.00 17.07 D ATOM 3508 CA GLU D 90 −5.496 −23.647 26.806 1.00 17.93 DATOM 3509 CB GLU D 90 −6.188 −22.312 26.967 1.00 16.45 D ATOM 3510 CGGLU D 90 −7.409 −22.217 26.142 1.00 16.16 D ATOM 3511 CD GLU D 90 −8.393−21.045 26.498 1.00 17.60 D ATOM 3512 OE1 GLU D 90 −8.856 −20.931 27.6281.00 17.89 D ATOM 3513 OE2 GLU D 90 −8.746 −20.224 25.627 1.00 17.65 DATOM 3514 C GLU D 90 −4.245 −23.778 27.692 1.00 18.48 D ATOM 3515 O GLUD 90 −3.862 −22.877 28.411 1.00 21.55 D ATOM 3516 N THR D 91 −3.614−24.935 27.682 1.00 18.26 D ATOM 3517 CA THR D 91 −2.357 −25.089 28.4271.00 16.60 D ATOM 3518 CB THR D 91 −2.578 −25.460 29.997 1.00 14.80 DATOM 3519 OG1 THR D 91 −3.294 −26.699 30.125 1.00 10.95 D ATOM 3520 CG2THR D 91 −3.308 −24.369 30.732 1.00 12.00 D ATOM 3521 C THR D 91 −1.683−26.296 27.694 1.00 15.41 D ATOM 3522 O THR D 91 −2.302 −26.905 26.8381.00 14.59 D ATOM 3523 N PHE D 92 −0.421 −26.558 28.023 1.00 15.32 DATOM 3524 CA PHE D 92 0.332 −27.687 27.507 1.00 16.21 D ATOM 3525 CB PHED 92 1.078 −27.348 26.192 1.00 16.80 D ATOM 3526 CG PHE D 92 2.080−26.225 26.297 1.00 17.31 D ATOM 3527 CD1 PHE D 92 3.419 −26.487 26.4651.00 15.49 D ATOM 3528 CD2 PHE D 92 1.669 −24.912 26.084 1.00 18.72 DATOM 3529 CE1 PHE D 92 4.314 −25.530 26.395 1.00 16.65 D ATOM 3530 CE2PHE D 92 2.596 −23.897 26.018 1.00 19.52 D ATOM 3531 CZ PHE D 92 3.944−24.211 26.165 1.00 18.57 D ATOM 3532 C PHE D 92 1.309 −28.083 28.5351.00 15.28 D ATOM 3533 O PHE D 92 1.601 −27.279 29.433 1.00 15.28 D ATOM3534 N ASN D 93 1.857 −29.279 28.413 1.00 14.54 D ATOM 3535 CA ASN D 932.850 −29.753 29.434 1.00 15.33 D ATOM 3536 CB ASN D 93 2.460 −31.08129.928 1.00 14.73 D ATOM 3537 CG ASN D 93 1.130 −31.027 30.584 1.0015.73 D ATOM 3538 OD1 ASN D 93 0.837 −30.179 31.450 1.00 15.93 D ATOM3539 ND2 ASN D 93 0.260 −31.893 30.142 1.00 16.74 D ATOM 3540 C ASN D 934.296 −29.788 29.125 1.00 15.14 D ATOM 3541 O ASN D 93 4.649 −29.96627.986 1.00 16.20 D ATOM 3542 N LEU D 94 5.135 −29.555 30.109 1.00 15.02D ATOM 3543 CA LEU D 94 6.559 −29.651 29.892 1.00 15.21 D ATOM 3544 CBLEU D 94 7.194 −28.392 30.310 1.00 14.73 D ATOM 3545 CG LEU D 94 8.708−28.205 30.268 1.00 16.53 D ATOM 3546 CD1 LEU D 94 9.234 −28.383 28.8581.00 14.89 D ATOM 3547 CD2 LEU D 94 9.058 −26.708 30.809 1.00 16.21 DATOM 3548 C LEU D 94 7.182 −30.860 30.657 1.00 16.17 D ATOM 3549 O LEU D94 6.907 −31.066 31.857 1.00 16.26 D ATOM 3550 N TYR D 95 7.996 −31.66529.942 1.00 15.82 D ATOM 3551 CA TYR D 95 8.707 −32.829 30.471 1.0014.64 D ATOM 3552 CB TYR D 95 8.130 −34.148 29.932 1.00 15.76 D ATOM3553 CG TYR D 95 6.723 −34.529 30.390 1.00 16.54 D ATOM 3554 CD1 TYR D95 5.572 −33.725 30.056 1.00 16.70 D ATOM 3555 CE1 TYR D 95 4.268−34.034 30.572 1.00 16.86 D ATOM 3556 CD2 TYR D 95 6.514 −35.647 31.2211.00 16.07 D ATOM 3557 CE2 TYR D 95 5.218 −35.951 31.723 1.00 16.46 DATOM 3558 CZ TYR D 95 4.135 −35.135 31.389 1.00 16.98 D ATOM 3559 OH TYRD 95 2.938 −35.406 31.914 1.00 19.26 D ATOM 3560 C TYR D 95 10.225−32.848 30.121 1.00 15.26 D ATOM 3561 O TYR D 95 10.791 −32.070 29.3131.00 14.09 D ATOM 3562 N TYR D 96 10.913 −33.787 30.751 1.00 15.14 DATOM 3563 CA TYR D 96 12.315 −33.988 30.457 1.00 13.56 D ATOM 3564 CBTYR D 96 13.205 −32.955 31.144 1.00 16.01 D ATOM 3565 CG TYR D 96 13.509−33.247 32.573 1.00 16.74 D ATOM 3566 CD1 TYR D 96 14.704 −33.880 32.9351.00 18.17 D ATOM 3567 CE1 TYR D 96 14.979 −34.251 34.302 1.00 18.55 DATOM 3568 CD2 TYR D 96 12.575 −32.977 33.562 1.00 16.69 D ATOM 3569 CE2TYR D 96 12.787 −33.331 34.868 1.00 17.48 D ATOM 3570 CZ TYR D 96 13.994−33.962 35.262 1.00 18.37 D ATOM 3571 OH TYR D 96 14.196 −34.286 36.6071.00 17.84 D ATOM 3572 C TYR D 96 12.572 −35.347 30.954 1.00 13.60 DATOM 3573 O TYR D 96 11.739 −35.950 31.570 1.00 11.43 D ATOM 3574 N ALAD 97 13.728 −35.850 30.597 1.00 14.53 D ATOM 3575 CA ALA D 97 14.240−37.162 30.985 1.00 14.44 D ATOM 3576 CB ALA D 97 13.651 −38.323 30.0851.00 13.27 D ATOM 3577 C ALA D 97 15.773 −37.018 30.828 1.00 15.30 DATOM 3578 O ALA D 97 16.304 −36.271 29.926 1.00 16.06 D ATOM 3579 N GLUD 98 16.479 −37.681 31.751 1.00 16.31 D ATOM 3580 CA GLU D 98 17.947−37.731 31.780 1.00 16.24 D ATOM 3581 CB GLU D 98 18.457 −37.594 33.1891.00 16.71 D ATOM 3582 CG GLU D 98 18.471 −36.177 33.670 1.00 19.08 DATOM 3583 CD GLU D 98 19.048 −36.054 35.126 1.00 18.93 D ATOM 3584 OE1GLU D 98 18.284 −36.243 36.075 1.00 17.93 D ATOM 3585 OE2 GLU D 9820.274 −35.836 35.294 1.00 19.32 D ATOM 3586 C GLU D 98 18.421 −39.05731.311 1.00 15.37 D ATOM 3587 O GLU D 98 17.810 −40.024 31.598 1.0014.93 D ATOM 3588 N SER D 99 19.478 −39.114 30.525 1.00 16.72 D ATOM3589 CA SER D 99 20.061 −40.457 30.244 1.00 17.38 D ATOM 3590 CB SER D99 19.288 −41.306 29.182 1.00 16.75 D ATOM 3591 OG SER D 99 19.321−40.720 27.890 1.00 15.75 D ATOM 3592 C SER D 99 21.492 −40.360 29.9151.00 17.91 D ATOM 3593 O SER D 99 22.005 −39.344 29.514 1.00 19.41 DATOM 3594 N ASP D 100 22.180 −41.444 30.127 1.00 19.16 D ATOM 3595 CAASP D 100 23.596 −41.429 29.817 1.00 19.48 D ATOM 3596 CB ASP D 10024.374 −42.313 30.762 1.00 19.63 D ATOM 3597 CG ASP D 100 24.315 −41.80332.236 1.00 21.52 D ATOM 3598 OD1 ASP D 100 24.630 −40.590 32.598 1.0018.39 D ATOM 3599 OD2 ASP D 100 23.918 −42.713 33.067 1.00 23.94 D ATOM3600 C ASP D 100 23.902 −41.790 28.408 1.00 18.32 D ATOM 3601 O ASP D100 25.060 −41.613 28.048 1.00 18.89 D ATOM 3602 N LEU D 101 22.896−42.312 27.677 1.00 17.62 D ATOM 3603 CA LEU D 101 22.980 −42.685 26.2591.00 17.31 D ATOM 3604 CB LEU D 101 22.573 −44.142 25.935 1.00 18.84 DATOM 3605 CG LEU D 101 22.923 −45.377 26.837 1.00 22.54 D ATOM 3606 CD1LEU D 101 22.476 −45.092 28.409 1.00 24.73 D ATOM 3607 CD2 LEU D 10122.061 −46.653 26.357 1.00 23.52 D ATOM 3608 C LEU D 101 21.933 −41.86525.508 1.00 16.75 D ATOM 3609 O LEU D 101 20.892 −41.527 26.032 1.0014.18 D ATOM 3610 N ASP D 102 22.269 −41.604 24.238 1.00 17.50 D ATOM3611 CA ASP D 102 21.417 −41.002 23.255 1.00 19.13 D ATOM 3612 CB ASP D102 22.260 −40.675 22.062 1.00 18.92 D ATOM 3613 CG ASP D 102 21.563−39.738 21.150 1.00 19.98 D ATOM 3614 OD1 ASP D 102 20.327 −39.80120.971 1.00 21.79 D ATOM 3615 OD2 ASP D 102 22.216 −38.864 20.566 1.0020.96 D ATOM 3616 C ASP D 102 20.323 −42.106 22.821 1.00 20.79 D ATOM3617 O ASP D 102 20.648 −43.183 22.204 1.00 21.84 D ATOM 3618 N TYR D103 19.058 −41.870 23.153 1.00 21.04 D ATOM 3619 CA TYR D 103 18.033−42.825 22.768 1.00 20.60 D ATOM 3620 CB TYR D 103 16.664 −42.474 23.4351.00 22.48 D ATOM 3621 CG TYR D 103 16.557 −42.814 24.916 1.00 23.42 DATOM 3622 CD1 TYR D 103 16.933 −44.106 25.410 1.00 23.40 D ATOM 3623 CE1TYR D 103 16.929 −44.408 26.796 1.00 22.01 D ATOM 3624 CD2 TYR D 10316.140 −41.792 25.868 1.00 25.05 D ATOM 3625 CE2 TYR D 103 16.139−42.063 27.268 1.00 23.93 D ATOM 3626 CZ TYR D 103 16.557 −43.404 27.7071.00 24.66 D ATOM 3627 OH TYR D 103 16.627 −43.644 29.156 1.00 27.59 DATOM 3628 C TYR D 103 17.816 −42.795 21.268 1.00 18.98 D ATOM 3629 O TYRD 103 17.120 −43.622 20.726 1.00 17.79 D ATOM 3630 N GLY D 104 18.361−41.831 20.604 1.00 17.98 D ATOM 3631 CA GLY D 104 18.069 −41.774 19.1961.00 18.07 D ATOM 3632 C GLY D 104 16.572 −41.548 18.906 1.00 18.03 DATOM 3633 O GLY D 104 15.978 −40.596 19.370 1.00 18.19 D ATOM 3634 N THRD 105 15.961 −42.466 18.148 1.00 18.73 D ATOM 3635 CA THR D 105 14.541−42.369 17.840 1.00 19.70 D ATOM 3636 CB THR D 105 14.360 −42.928 16.4741.00 19.42 D ATOM 3637 OG1 THR D 105 14.703 −41.840 15.590 1.00 17.63 DATOM 3638 CG2 THR D 105 12.887 −43.426 16.257 1.00 20.26 D ATOM 3639 CTHR D 105 13.559 −42.916 18.868 1.00 19.39 D ATOM 3640 O THR D 10512.389 −42.647 18.781 1.00 18.30 D ATOM 3641 N ASN D 106 14.089 −43.57819.883 1.00 20.32 D ATOM 3642 CA ASN D 106 13.297 −44.136 20.961 1.0022.51 D ATOM 3643 CB ASN D 106 14.103 −44.933 21.931 1.00 24.51 D ATOM3644 CG ASN D 106 14.527 −46.170 21.356 1.00 27.23 D ATOM 3645 OD1 ASN D106 15.458 −46.852 21.929 1.00 29.54 D ATOM 3646 ND2 ASN D 106 13.841−46.564 20.178 1.00 29.52 D ATOM 3647 C ASN D 106 12.666 −43.231 21.9271.00 21.63 D ATOM 3648 O ASN D 106 13.221 −43.036 23.012 1.00 22.55 DATOM 3649 N PHE D 107 11.489 −42.759 21.636 1.00 20.98 D ATOM 3650 CAPHE D 107 10.871 −41.941 22.586 1.00 19.46 D ATOM 3651 CB PHE D 1079.987 −40.960 21.873 1.00 19.20 D ATOM 3652 CG PHE D 107 9.221 −40.12222.831 1.00 17.97 D ATOM 3653 CD1 PHE D 107 9.897 −39.248 23.697 1.0017.02 D ATOM 3654 CD2 PHE D 107 7.841 −40.141 22.824 1.00 16.50 D ATOM3655 CE1 PHE D 107 9.170 −38.405 24.510 1.00 17.42 D ATOM 3656 CE2 PHE D107 7.162 −39.308 23.626 1.00 16.48 D ATOM 3657 CZ PHE D 107 7.811−38.444 24.458 1.00 16.86 D ATOM 3658 C PHE D 107 10.058 −42.827 23.4671.00 17.79 D ATOM 3659 O PHE D 107 9.347 −43.647 22.980 1.00 17.89 DATOM 3660 N GLN D 108 10.149 −42.635 24.765 1.00 17.79 D ATOM 3661 CAGLN D 108 9.323 −43.378 25.755 1.00 17.97 D ATOM 3662 CB GLN D 10810.199 −44.214 26.653 1.00 16.17 D ATOM 3663 CG GLN D 108 11.013 −45.21025.901 1.00 16.60 D ATOM 3664 CD GLN D 108 10.155 −46.331 25.107 1.0017.58 D ATOM 3665 OE1 GLN D 108 10.682 −46.992 24.272 1.00 18.99 D ATOM3666 NE2 GLN D 108 8.874 −46.474 25.372 1.00 17.06 D ATOM 3667 C GLN D108 8.686 −42.334 26.624 1.00 17.83 D ATOM 3668 O GLN D 108 9.404−41.806 27.447 1.00 18.84 D ATOM 3669 N LYS D 109 7.402 −42.026 26.4301.00 18.01 D ATOM 3670 CA LYS D 109 6.728 −41.018 27.206 1.00 18.68 DATOM 3671 CB LYS D 109 5.204 −40.950 26.791 1.00 20.04 D ATOM 3672 CGLYS D 109 4.303 −41.124 28.001 1.00 22.19 D ATOM 3673 CD LYS D 109 2.783−41.200 27.657 1.00 25.55 D ATOM 3674 CE LYS D 109 2.103 −39.828 27.1361.00 24.14 D ATOM 3675 NZ LYS D 109 0.565 −40.135 27.197 1.00 24.06 DATOM 3676 C LYS D 109 6.922 −41.403 28.720 1.00 18.52 D ATOM 3677 O LYSD 109 7.283 −40.553 29.585 1.00 16.85 D ATOM 3678 N ARG D 110 6.779−42.709 28.998 1.00 18.31 D ATOM 3679 CA ARG D 110 6.843 −43.137 30.3691.00 19.11 D ATOM 3680 CB ARG D 110 6.433 −44.587 30.462 1.00 19.77 DATOM 3681 CG ARG D 110 4.849 −44.532 30.652 1.00 23.98 D ATOM 3682 CDARG D 110 3.893 −44.193 29.280 1.00 25.52 D ATOM 3683 NE ARG D 110 2.446−43.971 29.651 1.00 26.82 D ATOM 3684 CZ ARG D 110 2.025 −42.857 30.3511.00 27.51 D ATOM 3685 NH1 ARG D 110 2.985 −41.927 30.712 1.00 25.90 DATOM 3686 NH2 ARG D 110 0.689 −42.632 30.641 1.00 25.29 D ATOM 3687 CARG D 110 8.133 −42.841 31.128 1.00 19.88 D ATOM 3688 O ARG D 110 8.145−42.856 32.385 1.00 20.52 D ATOM 3689 N LEU D 111 9.184 −42.523 30.3571.00 18.67 D ATOM 3690 CA LEU D 111 10.508 −42.236 30.835 1.00 17.43 DATOM 3691 CB LEU D 111 11.574 −42.631 29.833 1.00 16.18 D ATOM 3692 CGLEU D 111 11.620 −44.133 29.762 1.00 16.19 D ATOM 3693 CD1 LEU D 11112.877 −44.441 29.018 1.00 18.14 D ATOM 3694 CD2 LEU D 111 11.663−44.884 31.050 1.00 13.71 D ATOM 3695 C LEU D 111 10.718 −40.808 31.2041.00 17.68 D ATOM 3696 O LEU D 111 11.722 −40.453 31.862 1.00 17.80 DATOM 3697 N PHE D 112 9.792 −39.979 30.747 1.00 17.02 D ATOM 3698 CA PHED 112 9.836 −38.549 31.039 1.00 16.55 D ATOM 3699 CB PHE D 112 9.272−37.756 29.892 1.00 15.63 D ATOM 3700 CG PHE D 112 10.183 −37.620 28.7851.00 15.09 D ATOM 3701 CD1 PHE D 112 10.555 −38.702 28.076 1.00 16.48 DATOM 3702 CD2 PHE D 112 10.680 −36.370 28.454 1.00 14.92 D ATOM 3703 CE1PHE D 112 11.455 −38.566 26.998 1.00 17.44 D ATOM 3704 CE2 PHE D 11211.541 −36.173 27.459 1.00 14.66 D ATOM 3705 CZ PHE D 112 11.949 −37.26426.708 1.00 18.27 D ATOM 3706 C PHE D 112 9.066 −38.125 32.305 1.0016.73 D ATOM 3707 O PHE D 112 7.958 −38.616 32.619 1.00 16.82 D ATOM3708 N THR D 113 9.638 −37.170 33.014 1.00 16.57 D ATOM 3709 CA THR D113 8.987 −36.595 34.214 1.00 16.91 D ATOM 3710 CB THR D 113 10.048−36.377 35.400 1.00 16.91 D ATOM 3711 OG1 THR D 113 10.537 −37.64435.869 1.00 18.22 D ATOM 3712 CG2 THR D 113 9.468 −35.619 36.485 1.0014.61 D ATOM 3713 C THR D 113 8.357 −35.222 33.842 1.00 15.72 D ATOM3714 O THR D 113 8.897 −34.433 33.071 1.00 15.42 D ATOM 3715 N LYS D 1147.218 −34.936 34.405 1.00 15.62 D ATOM 3716 CA LYS D 114 6.571 −33.68734.095 1.00 16.23 D ATOM 3717 CB LYS D 114 5.032 −33.756 34.419 1.0016.53 D ATOM 3718 CG LYS D 114 4.286 −32.365 34.296 1.00 17.20 D ATOM3719 CD LYS D 114 2.707 −32.431 34.308 1.00 17.28 D ATOM 3720 CE LYS D114 2.100 −31.020 34.121 1.00 15.72 D ATOM 3721 NZ LYS D 114 0.682−30.898 34.287 1.00 11.37 D ATOM 3722 C LYS D 114 7.252 −32.595 34.9171.00 16.49 D ATOM 3723 O LYS D 114 7.499 −32.793 36.104 1.00 15.49 DATOM 3724 N ILE D 115 7.573 −31.482 34.267 1.00 17.24 D ATOM 3725 CA ILED 115 8.131 −30.369 34.960 1.00 17.81 D ATOM 3726 CB ILE D 115 9.085−29.566 34.090 1.00 19.19 D ATOM 3727 CG2 ILE D 115 9.431 −28.193 34.7851.00 18.04 D ATOM 3728 CG1 ILE D 115 10.336 −30.425 33.913 1.00 20.74 DATOM 3729 CD1 ILE D 115 11.330 −30.071 32.768 1.00 20.99 D ATOM 3730 CILE D 115 7.071 −29.429 35.520 1.00 18.88 D ATOM 3731 O ILE D 115 7.149−29.035 36.702 1.00 19.12 D ATOM 3732 N ASP D 116 6.075 −29.080 34.6931.00 18.58 D ATOM 3733 CA ASP D 116 5.004 −28.188 35.072 1.00 16.63 DATOM 3734 CB ASP D 116 5.618 −26.813 35.314 1.00 16.92 D ATOM 3735 CGASP D 116 4.622 −25.762 35.919 1.00 17.45 D ATOM 3736 OD1 ASP D 1164.978 −24.575 35.904 1.00 17.71 D ATOM 3737 OD2 ASP D 116 3.546 −26.09536.456 1.00 16.43 D ATOM 3738 C ASP D 116 3.959 −28.086 33.946 1.0017.91 D ATOM 3739 O ASP D 116 4.108 −28.565 32.779 1.00 17.80 D ATOM3740 N THR D 117 2.856 −27.457 34.291 1.00 17.06 D ATOM 3741 CA THR D117 1.883 −27.176 33.278 1.00 15.84 D ATOM 3742 CB THR D 117 0.487−27.143 33.950 1.00 16.17 D ATOM 3743 OG1 THR D 117 0.182 −28.454 34.4731.00 17.40 D ATOM 3744 CG2 THR D 117 −0.623 −26.646 32.971 1.00 12.20 DATOM 3745 C THR D 117 2.280 −25.748 32.787 1.00 15.44 D ATOM 3746 O THRD 117 2.530 −24.906 33.601 1.00 13.77 D ATOM 3747 N ILE D 118 2.338−25.506 31.468 1.00 15.95 D ATOM 3748 CA ILE D 118 2.645 −24.179 30.8751.00 16.02 D ATOM 3749 CB ILE D 118 3.584 −24.303 29.552 1.00 15.86 DATOM 3750 CG2 ILE D 118 3.900 −22.973 28.910 1.00 12.10 D ATOM 3751 CG1ILE D 118 4.884 −25.048 29.907 1.00 15.87 D ATOM 3752 CD1 ILE D 1185.589 −24.704 31.234 1.00 16.68 D ATOM 3753 C ILE D 118 1.274 −23.54430.507 1.00 17.08 D ATOM 3754 O ILE D 118 0.426 −24.171 29.812 1.0016.79 D ATOM 3755 N ALA D 119 1.067 −22.307 30.964 1.00 16.95 D ATOM3756 CA ALA D 119 −0.179 −21.637 30.758 1.00 17.41 D ATOM 3757 CB ALA D119 −0.905 −21.669 32.036 1.00 15.44 D ATOM 3758 C ALA D 119 0.094−20.230 30.288 1.00 18.57 D ATOM 3759 O ALA D 119 1.091 −19.616 30.7141.00 19.42 D ATOM 3760 N PRO D 120 −0.735 −19.688 29.380 1.00 16.85 DATOM 3761 CD PRO D 120 −1.798 −20.320 28.601 1.00 16.90 D ATOM 3762 CAPRO D 120 −0.486 −18.340 28.903 1.00 17.41 D ATOM 3763 CB PRO D 120−1.142 −18.343 27.570 1.00 17.39 D ATOM 3764 CG PRO D 120 −2.364 −19.21027.782 1.00 15.64 D ATOM 3765 C PRO D 120 −1.084 −17.215 29.784 1.0017.94 D ATOM 3766 O PRO D 120 −2.216 −17.262 30.178 1.00 17.99 D ATOM3767 N ASP D 121 −0.303 −16.190 30.034 1.00 17.22 D ATOM 3768 CA ASP D121 −0.765 −15.066 30.783 1.00 18.49 D ATOM 3769 CB ASP D 121 0.380−14.100 31.040 1.00 20.42 D ATOM 3770 CG ASP D 121 1.608 −14.820 31.4281.00 23.31 D ATOM 3771 OD1 ASP D 121 2.282 −15.615 30.549 1.00 27.85 DATOM 3772 OD2 ASP D 121 1.898 −14.641 32.607 1.00 21.86 D ATOM 3773 CASP D 121 −1.753 −14.334 29.899 1.00 17.73 D ATOM 3774 O ASP D 121−2.548 −13.535 30.419 1.00 16.59 D ATOM 3775 N GLU D 122 −1.660 −14.63528.596 1.00 16.93 D ATOM 3776 CA GLU D 122 −2.431 −13.977 27.574 1.0017.36 D ATOM 3777 CB GLU D 122 −1.703 −12.740 27.085 1.00 17.99 D ATOM3778 CG GLU D 122 −1.638 −11.553 28.117 1.00 21.09 D ATOM 3779 CD GLU D122 −1.389 −10.209 27.377 1.00 24.18 D ATOM 3780 OE1 GLU D 122 −0.176−9.976 27.068 1.00 28.65 D ATOM 3781 OE2 GLU D 122 −2.356 −9.400 27.0531.00 24.93 D ATOM 3782 C GLU D 122 −2.773 −14.839 26.378 1.00 17.98 DATOM 3783 O GLU D 122 −1.927 −15.123 25.477 1.00 17.84 D ATOM 3784 N ILED 123 −4.066 −15.157 26.345 1.00 17.50 D ATOM 3785 CA ILE D 123 −4.679−16.004 25.330 1.00 16.88 D ATOM 3786 CB ILE D 123 −5.952 −16.456 25.8871.00 18.94 D ATOM 3787 CG2 ILE D 123 −6.819 −15.160 26.333 1.00 19.73 DATOM 3788 CG1 ILE D 123 −6.733 −17.177 24.888 1.00 19.69 D ATOM 3789 CD1ILE D 123 −8.183 −17.396 25.476 1.00 20.93 D ATOM 3790 C ILE D 123−4.920 −15.123 24.145 1.00 16.31 D ATOM 3791 O ILE D 123 −5.227 −13.96824.305 1.00 15.09 D ATOM 3792 N THR D 124 −4.768 −15.610 22.919 1.0016.46 D ATOM 3793 CA THR D 124 −5.038 −14.656 21.809 1.00 16.71 D ATOM3794 CB THR D 124 −4.156 −14.894 20.688 1.00 15.87 D ATOM 3795 OG1 THR D124 −2.768 −14.465 21.029 1.00 17.18 D ATOM 3796 CG2 THR D 124 −4.680−14.162 19.533 1.00 14.04 D ATOM 3797 C THR D 124 −6.466 −14.749 21.3781.00 17.27 D ATOM 3798 O THR D 124 −6.916 −15.812 21.017 1.00 18.78 DATOM 3799 N VAL D 125 −7.255 −13.694 21.523 1.00 17.85 D ATOM 3800 CAVAL D 125 −8.675 −13.846 21.087 1.00 18.97 D ATOM 3801 CB VAL D 125−9.709 −12.864 21.814 1.00 18.73 D ATOM 3802 CG1 VAL D 125 −9.851−13.253 23.306 1.00 19.13 D ATOM 3803 CG2 VAL D 125 −9.304 −11.43421.597 1.00 16.81 D ATOM 3804 C VAL D 125 −8.933 −13.632 19.592 1.0017.17 D ATOM 3805 O VAL D 125 −8.097 −13.087 18.859 1.00 16.66 D ATOM3806 N SER D 126 −10.133 −13.997 19.210 1.00 16.76 D ATOM 3807 CA SER D126 −10.527 −13.852 17.834 1.00 17.39 D ATOM 3808 CB SER D 126 −12.013−14.154 17.653 1.00 18.04 D ATOM 3809 OG SER D 126 −12.465 −13.71916.387 1.00 17.70 D ATOM 3810 C SER D 126 −10.300 −12.530 17.216 1.0017.18 D ATOM 3811 O SER D 126 −9.815 −12.427 16.058 1.00 16.54 D ATOM3812 N SER D 127 −10.745 −11.484 17.889 1.00 16.97 D ATOM 3813 CA SER D127 −10.453 −10.228 17.272 1.00 17.66 D ATOM 3814 CB SER D 127 −11.251−9.174 17.935 1.00 18.12 D ATOM 3815 OG SER D 127 −10.873 −8.946 19.3141.00 19.82 D ATOM 3816 C SER D 127 −8.956 −9.841 17.275 1.00 17.71 DATOM 3817 O SER D 127 −8.609 −8.877 16.642 1.00 18.67 D ATOM 3818 N ASPD 128 −8.111 −10.584 17.998 1.00 17.39 D ATOM 3819 CA ASP D 128 −6.683−10.298 18.093 1.00 17.49 D ATOM 3820 CB ASP D 128 −6.006 −11.181 19.1661.00 17.29 D ATOM 3821 CG ASP D 128 −6.140 −10.614 20.551 1.00 17.99 DATOM 3822 OD1 ASP D 128 −5.849 −11.350 21.555 1.00 16.33 D ATOM 3823 OD2ASP D 128 −6.555 −9.410 20.584 1.00 19.07 D ATOM 3824 C ASP D 128 −5.980−10.477 16.769 1.00 17.26 D ATOM 3825 O ASP D 128 −5.076 −9.717 16.4001.00 16.55 D ATOM 3826 N PHE D 129 −6.337 −11.511 16.038 1.00 18.26 DATOM 3827 CA PHE D 129 −5.734 −11.657 14.699 1.00 19.61 D ATOM 3828 CBPHE D 129 −6.223 −12.961 14.128 1.00 18.36 D ATOM 3829 CG PHE D 129−5.878 −14.132 15.007 1.00 16.58 D ATOM 3830 CD1 PHE D 129 −6.798−14.681 15.860 1.00 14.71 D ATOM 3831 CD2 PHE D 129 −4.579 −14.65714.968 1.00 16.19 D ATOM 3832 CE1 PHE D 129 −6.437 −15.753 16.650 1.0014.45 D ATOM 3833 CE2 PHE D 129 −4.223 −15.716 15.759 1.00 15.87 D ATOM3834 CZ PHE D 129 −5.120 −16.277 16.586 1.00 14.91 D ATOM 3835 C PHE D129 −6.411 −10.479 14.117 1.00 20.48 D ATOM 3836 O PHE D 129 −6.977−9.726 14.908 1.00 23.62 D ATOM 3837 N GLU D 130 −6.381 −10.193 12.8381.00 18.94 D ATOM 3838 CA GLU D 130 −7.191 −9.002 12.367 1.00 17.38 DATOM 3839 CB GLU D 130 −8.647 −9.143 12.773 1.00 17.26 D ATOM 3840 CGGLU D 130 −9.646 −9.502 11.697 1.00 20.32 D ATOM 3841 CD GLU D 130−11.167 −9.104 12.055 1.00 23.44 D ATOM 3842 OE1 GLU D 130 −11.911−8.869 11.041 1.00 23.75 D ATOM 3843 OE2 GLU D 130 −11.630 −9.031 13.3201.00 24.30 D ATOM 3844 C GLU D 130 −6.562 −7.713 12.931 1.00 16.78 DATOM 3845 O GLU D 130 −5.998 −6.876 12.192 1.00 15.75 D ATOM 3846 N ALAD 131 −6.620 −7.555 14.237 1.00 16.92 D ATOM 3847 CA ALA D 131 −5.906−6.446 14.841 1.00 19.08 D ATOM 3848 CB ALA D 131 −6.317 −6.328 16.2331.00 18.42 D ATOM 3849 C ALA D 131 −4.570 −7.099 14.766 1.00 20.30 DATOM 3850 O ALA D 131 −4.514 −8.363 14.644 1.00 23.18 D ATOM 3851 N ARGD 132 −3.445 −6.424 14.836 1.00 20.31 D ATOM 3852 CA ARG D 132 −2.284−7.364 14.685 1.00 19.52 D ATOM 3853 CB ARG D 132 −1.316 −6.712 13.7101.00 19.93 D ATOM 3854 CG ARG D 132 −1.385 −7.359 12.263 1.00 21.23 DATOM 3855 CD ARG D 132 −2.679 −7.855 11.683 1.00 16.17 D ATOM 3856 NEARG D 132 −2.440 −8.262 10.265 1.00 15.51 D ATOM 3857 CZ ARG D 132−3.114 −9.230 9.604 1.00 13.45 D ATOM 3858 NH1 ARG D 132 −4.058 −9.91910.195 1.00 13.43 D ATOM 3859 NH2 ARG D 132 −2.922 −9.450 8.335 1.0011.77 D ATOM 3860 C ARG D 132 −1.704 −7.572 16.084 1.00 18.61 D ATOM3861 O ARG D 132 −0.567 −7.369 16.331 1.00 17.92 D ATOM 3862 N HIS D 133−2.559 −8.010 16.987 1.00 18.68 D ATOM 3863 CA HIS D 133 −2.214 −8.10718.340 1.00 18.77 D ATOM 3864 CB HIS D 133 −3.239 −7.275 19.188 1.0020.10 D ATOM 3865 CG HIS D 133 −3.185 −5.767 18.975 1.00 21.17 D ATOM3866 CD2 HIS D 133 −2.571 −4.977 18.024 1.00 21.68 D ATOM 3867 ND1 HIS D133 −3.889 −4.885 19.786 1.00 21.87 D ATOM 3868 CE1 HIS D 133 −3.713−3.627 19.351 1.00 20.87 D ATOM 3869 NE2 HIS D 133 −2.913 −3.650 18.2881.00 20.40 D ATOM 3870 C HIS D 133 −2.169 −9.527 18.783 1.00 18.74 DATOM 3871 O HIS D 133 −2.880 −9.906 19.688 1.00 18.52 D ATOM 3872 N VALD 134 −1.397 −10.365 18.134 1.00 19.18 D ATOM 3873 CA VAL D 134 −1.341−11.726 18.664 1.00 19.94 D ATOM 3874 CB VAL D 134 −0.654 −12.602 17.6671.00 20.83 D ATOM 3875 CG1 VAL D 134 −0.577 −14.032 18.205 1.00 20.31 DATOM 3876 CG2 VAL D 134 −1.440 −12.477 16.396 1.00 22.77 D ATOM 3877 CVAL D 134 −0.484 −11.779 19.956 1.00 19.45 D ATOM 3878 O VAL D 134 0.585−11.152 20.017 1.00 20.84 D ATOM 3879 N LYS D 135 −0.850 −12.586 20.9391.00 18.65 D ATOM 3880 CA LYS D 135 −0.094 −12.530 22.214 1.00 15.93 DATOM 3881 CB LYS D 135 −1.087 −12.439 23.394 1.00 16.51 D ATOM 3882 CGLYS D 135 −2.344 −11.633 23.157 1.00 15.27 D ATOM 3883 CD LYS D 135−2.070 −10.209 22.840 1.00 16.85 D ATOM 3884 CE LYS D 135 −3.366 −9.32523.222 1.00 19.41 D ATOM 3885 NZ LYS D 135 −3.198 −7.914 22.807 1.0021.66 D ATOM 3886 C LYS D 135 0.934 −13.619 22.469 1.00 15.29 D ATOM3887 O LYS D 135 0.703 −14.831 22.540 1.00 14.56 D ATOM 3888 N LEU D 1362.124 −13.098 22.553 1.00 15.44 D ATOM 3889 CA LEU D 136 3.348 −13.77522.796 1.00 14.77 D ATOM 3890 CB LEU D 136 4.362 −12.994 22.024 1.0014.78 D ATOM 3891 CG LEU D 136 5.639 −13.838 21.834 1.00 16.18 D ATOM3892 CD1 LEU D 136 6.318 −13.986 23.105 1.00 17.95 D ATOM 3893 CD2 LEU D136 5.375 −15.253 21.325 1.00 15.38 D ATOM 3894 C LEU D 136 3.616−13.800 24.335 1.00 14.99 D ATOM 3895 O LEU D 136 3.797 −12.771 24.9771.00 15.14 D ATOM 3896 N ASN D 137 3.633 −14.983 24.900 1.00 15.59 DATOM 3897 CA ASN D 137 3.851 −15.261 26.322 1.00 16.17 D ATOM 3898 CBASN D 137 2.926 −16.388 26.769 1.00 17.57 D ATOM 3899 CG ASN D 137 1.476−15.949 26.770 1.00 18.81 D ATOM 3900 OD1 ASN D 137 1.090 −15.106 27.5501.00 20.38 D ATOM 3901 ND2 ASN D 137 0.693 −16.516 25.921 1.00 18.69 DATOM 3902 C ASN D 137 5.215 −15.728 26.575 1.00 15.52 D ATOM 3903 O ASND 137 5.769 −16.298 25.712 1.00 15.89 D ATOM 3904 N VAL D 138 5.781−15.502 27.725 1.00 15.15 D ATOM 3905 CA VAL D 138 7.092 −16.008 27.9551.00 14.71 D ATOM 3906 CB VAL D 138 8.172 −14.899 28.136 1.00 13.21 DATOM 3907 CG1 VAL D 138 9.516 −15.520 28.401 1.00 12.37 D ATOM 3908 CG2VAL D 138 8.257 −14.019 26.901 1.00 12.41 D ATOM 3909 C VAL D 138 6.999−16.808 29.206 1.00 16.63 D ATOM 3910 O VAL D 138 6.482 −16.375 30.1721.00 18.50 D ATOM 3911 N GLU D 139 7.455 −18.003 29.254 1.00 16.84 DATOM 3912 CA GLU D 139 7.377 −18.665 30.488 1.00 15.98 D ATOM 3913 CBGLU D 139 6.260 −19.678 30.406 1.00 17.05 D ATOM 3914 CG GLU D 139 4.814−19.146 30.509 1.00 16.08 D ATOM 3915 CD GLU D 139 4.509 −18.487 31.8931.00 16.27 D ATOM 3916 OE1 GLU D 139 5.156 −18.855 32.883 1.00 16.25 DATOM 3917 OE2 GLU D 139 3.613 −17.632 32.002 1.00 14.20 D ATOM 3918 CGLU D 139 8.697 −19.358 30.721 1.00 17.18 D ATOM 3919 O GLU D 139 9.239−20.019 29.813 1.00 17.52 D ATOM 3920 N GLU D 140 9.259 −19.263 31.9221.00 17.31 D ATOM 3921 CA GLU D 140 10.562 −19.960 32.195 1.00 16.57 DATOM 3922 CB GLU D 140 11.688 −19.014 32.521 1.00 18.51 D ATOM 3923 CGGLU D 140 13.011 −19.746 32.639 1.00 20.45 D ATOM 3924 CD GLU D 14014.213 −18.771 32.449 1.00 22.96 D ATOM 3925 OE1 GLU D 140 14.446−17.824 33.278 1.00 25.20 D ATOM 3926 OE2 GLU D 140 14.937 −18.85131.439 1.00 23.12 D ATOM 3927 C GLU D 140 10.424 −20.879 33.321 1.0015.76 D ATOM 3928 O GLU D 140 9.627 −20.610 34.196 1.00 15.39 D ATOM3929 N ARG D 141 11.117 −22.016 33.270 1.00 14.71 D ATOM 3930 CA ARG D141 11.015 −22.967 34.384 1.00 13.96 D ATOM 3931 CB ARG D 141 10.067−24.119 34.145 1.00 11.96 D ATOM 3932 CG ARG D 141 8.627 −23.794 33.8181.00 11.44 D ATOM 3933 CD ARG D 141 7.668 −23.883 34.965 1.00 11.62 DATOM 3934 NE ARG D 141 7.073 −22.619 34.869 1.00 15.89 D ATOM 3935 CZARG D 141 5.926 −22.324 34.279 1.00 18.04 D ATOM 3936 NH1 ARG D 1415.154 −23.253 33.735 1.00 22.44 D ATOM 3937 NH2 ARG D 141 5.597 −21.08334.063 1.00 16.04 D ATOM 3938 C ARG D 141 12.381 −23.477 34.563 1.0014.06 D ATOM 3939 O ARG D 141 13.327 −23.111 33.870 1.00 14.34 D ATOM3940 N SER D 142 12.537 −24.353 35.489 1.00 14.78 D ATOM 3941 CA SER D142 13.877 −24.857 35.619 1.00 16.34 D ATOM 3942 CB SER D 142 14.783−23.877 36.424 1.00 15.76 D ATOM 3943 OG SER D 142 14.511 −24.085 37.7741.00 17.27 D ATOM 3944 C SER D 142 13.869 −26.204 36.269 1.00 15.70 DATOM 3945 O SER D 142 12.947 −26.580 36.973 1.00 15.90 D ATOM 3946 N VALD 143 14.931 −26.938 36.083 1.00 16.29 D ATOM 3947 CA VAL D 143 14.900−28.230 36.728 1.00 18.06 D ATOM 3948 CB VAL D 143 14.054 −29.272 35.8031.00 17.78 D ATOM 3949 CG1 VAL D 143 14.603 −29.407 34.422 1.00 16.75 DATOM 3950 CG2 VAL D 143 13.990 −30.578 36.469 1.00 19.37 D ATOM 3951 CVAL D 143 16.315 −28.685 37.095 1.00 17.29 D ATOM 3952 O VAL D 14317.309 −28.115 36.614 1.00 16.48 D ATOM 3953 N GLY D 144 16.405 −29.66637.986 1.00 18.13 D ATOM 3954 CA GLY D 144 17.735 −30.151 38.373 1.0020.02 D ATOM 3955 C GLY D 144 17.735 −30.669 39.809 1.00 21.41 D ATOM3956 O GLY D 144 16.672 −30.551 40.485 1.00 22.10 D ATOM 3957 N PRO D145 18.890 −31.136 40.337 1.00 21.31 D ATOM 3958 CD PRO D 145 19.228−31.309 41.774 1.00 20.60 D ATOM 3959 CA PRO D 145 20.093 −31.105 39.5201.00 19.69 D ATOM 3960 CB PRO D 145 21.225 −31.240 40.515 1.00 19.27 DATOM 3961 CG PRO D 145 20.590 −31.969 41.659 1.00 19.37 D ATOM 3962 CPRO D 145 20.087 −32.241 38.591 1.00 21.92 D ATOM 3963 O PRO D 14519.556 −33.300 38.868 1.00 22.85 D ATOM 3964 N LEU D 146 20.690 −32.01137.433 1.00 21.75 D ATOM 3965 CA LEU D 146 20.847 −33.048 36.447 1.0020.02 D ATOM 3966 CB LEU D 146 20.993 −32.385 35.058 1.00 20.90 D ATOM3967 CG LEU D 146 19.671 −32.120 34.308 1.00 20.22 D ATOM 3968 CD1 LEU D146 18.645 −31.713 35.281 1.00 21.69 D ATOM 3969 CD2 LEU D 146 19.838−31.002 33.217 1.00 20.64 D ATOM 3970 C LEU D 146 22.140 −33.725 36.8941.00 20.43 D ATOM 3971 O LEU D 146 22.994 −33.167 37.645 1.00 19.74 DATOM 3972 N THR D 147 22.302 −34.940 36.426 1.00 19.52 D ATOM 3973 CATHR D 147 23.511 −35.692 36.704 1.00 17.92 D ATOM 3974 CB THR D 14723.373 −36.568 37.977 1.00 17.00 D ATOM 3975 OG1 THR D 147 22.393−37.583 37.871 1.00 14.64 D ATOM 3976 CG2 THR D 147 22.997 −35.75839.091 1.00 16.40 D ATOM 3977 C THR D 147 24.058 −36.608 35.521 1.0021.08 D ATOM 3978 O THR D 147 25.332 −36.966 35.434 1.00 21.74 D ATOM3979 N ARG D 148 23.156 −37.053 34.613 1.00 20.20 D ATOM 3980 CA ARG D148 23.633 −37.915 33.524 1.00 17.96 D ATOM 3981 CB ARG D 148 22.475−38.653 32.815 1.00 21.01 D ATOM 3982 CG ARG D 148 21.300 −39.094 33.7871.00 22.85 D ATOM 3983 CD ARG D 148 21.602 −40.338 34.679 1.00 22.57 DATOM 3984 NE ARG D 148 22.490 −40.005 35.818 1.00 25.29 D ATOM 3985 CZARG D 148 23.682 −40.644 36.078 1.00 27.89 D ATOM 3986 NH1 ARG D 14824.151 −41.669 35.261 1.00 27.25 D ATOM 3987 NH2 ARG D 148 24.469−40.292 37.150 1.00 28.22 D ATOM 3988 C ARG D 148 24.397 −37.146 32.4741.00 17.52 D ATOM 3989 O ARG D 148 24.563 −35.909 32.546 1.00 15.31 DATOM 3990 N LYS D 149 24.786 −37.898 31.439 1.00 16.63 D ATOM 3991 CALYS D 149 25.635 −37.359 30.402 1.00 16.00 D ATOM 3992 CB LYS D 14926.191 −38.560 29.617 1.00 17.15 D ATOM 3993 CG LYS D 149 27.340 −38.26528.642 1.00 18.94 D ATOM 3994 CD LYS D 149 27.806 −39.517 27.930 1.0020.32 D ATOM 3995 CE LYS D 149 28.821 −39.174 26.866 1.00 22.15 D ATOM3996 NZ LYS D 149 28.349 −39.458 25.376 1.00 26.84 D ATOM 3997 C LYS D149 24.806 −36.398 29.607 1.00 15.57 D ATOM 3998 O LYS D 149 25.312−35.436 29.043 1.00 15.49 D ATOM 3999 N GLY D 150 23.490 −36.624 29.6041.00 15.13 D ATOM 4000 CA GLY D 150 22.618 −35.721 28.830 1.00 14.07 DATOM 4001 C GLY D 150 21.140 −35.813 29.167 1.00 13.01 D ATOM 4002 O GLYD 150 20.715 −36.553 30.077 1.00 11.84 D ATOM 4003 N PHE D 151 20.375−35.094 28.370 1.00 12.47 D ATOM 4004 CA PHE D 151 18.967 −34.987 28.5851.00 13.78 D ATOM 4005 CB PHE D 151 18.751 −34.002 29.801 1.00 14.58 DATOM 4006 CG PHE D 151 19.008 −32.593 29.455 1.00 15.87 D ATOM 4007 CD1PHE D 151 17.980 −31.783 28.914 1.00 15.47 D ATOM 4008 CD2 PHE D 15120.304 −32.065 29.570 1.00 17.20 D ATOM 4009 CE1 PHE D 151 18.244−30.447 28.476 1.00 14.64 D ATOM 4010 CE2 PHE D 151 20.599 −30.74629.163 1.00 17.45 D ATOM 4011 CZ PHE D 151 19.549 −29.923 28.606 1.0016.33 D ATOM 4012 C PHE D 151 18.131 −34.516 27.378 1.00 12.04 D ATOM4013 O PHE D 151 18.633 −33.940 26.438 1.00 11.21 D ATOM 4014 N TYR D152 16.832 −34.693 27.525 1.00 12.73 D ATOM 4015 CA TYR D 152 15.797−34.359 26.571 1.00 13.81 D ATOM 4016 CB TYR D 152 15.066 −35.624 26.0221.00 13.48 D ATOM 4017 CG TYR D 152 15.889 −36.576 25.230 1.00 13.74 DATOM 4018 CD1 TYR D 152 16.418 −37.710 25.795 1.00 13.74 D ATOM 4019 CE1TYR D 152 17.244 −38.545 25.134 1.00 16.59 D ATOM 4020 CD2 TYR D 15216.184 −36.306 23.988 1.00 15.37 D ATOM 4021 CE2 TYR D 152 16.988−37.133 23.278 1.00 18.02 D ATOM 4022 CZ TYR D 152 17.534 −38.257 23.8381.00 18.71 D ATOM 4023 OH TYR D 152 18.377 −39.065 23.042 1.00 22.46 DATOM 4024 C TYR D 152 14.677 −33.516 27.156 1.00 14.20 D ATOM 4025 O TYRD 152 14.276 −33.626 28.274 1.00 15.44 D ATOM 4026 N LEU D 153 14.136−32.660 26.344 1.00 15.00 D ATOM 4027 CA LEU D 153 13.024 −31.856 26.6971.00 14.56 D ATOM 4028 CB LEU D 153 13.338 −30.444 26.462 1.00 13.85 DATOM 4029 CG LEU D 153 13.446 −29.635 27.766 1.00 15.21 D ATOM 4030 CD1LEU D 153 14.321 −30.291 28.847 1.00 13.47 D ATOM 4031 CD2 LEU D 15313.830 −28.168 27.407 1.00 13.96 D ATOM 4032 C LEU D 153 11.917 −32.32625.751 1.00 15.28 D ATOM 4033 O LEU D 153 12.165 −32.684 24.588 1.0015.29 D ATOM 4034 N ALA D 154 10.704 −32.363 26.272 1.00 15.09 D ATOM4035 CA ALA D 154 9.620 −32.783 25.515 1.00 15.28 D ATOM 4036 CB ALA D154 9.389 −34.202 25.783 1.00 15.70 D ATOM 4037 C ALA D 154 8.370−31.950 25.808 1.00 16.51 D ATOM 4038 O ALA D 154 8.198 −31.420 26.9151.00 16.11 D ATOM 4039 N PHE D 155 7.530 −31.816 24.778 1.00 15.97 DATOM 4040 CA PHE D 155 6.288 −31.117 24.964 1.00 16.51 D ATOM 4041 CBPHE D 155 6.282 −29.797 24.205 1.00 17.21 D ATOM 4042 CG PHE D 155 7.503−29.006 24.436 1.00 17.44 D ATOM 4043 CD1 PHE D 155 8.707 −29.386 23.8171.00 17.78 D ATOM 4044 CD2 PHE D 155 7.468 −27.862 25.192 1.00 15.66 DATOM 4045 CE1 PHE D 155 9.884 −28.552 23.966 1.00 17.97 D ATOM 4046 CE2PHE D 155 8.603 −27.051 25.320 1.00 17.24 D ATOM 4047 CZ PHE D 155 9.832−27.387 24.699 1.00 16.03 D ATOM 4048 C PHE D 155 5.007 −31.897 24.6561.00 17.08 D ATOM 4049 O PHE D 155 4.844 −32.510 23.566 1.00 15.90 DATOM 4050 N GLN D 156 4.095 −31.868 25.640 1.00 16.95 D ATOM 4051 CA GLND 156 2.882 −32.562 25.435 1.00 17.15 D ATOM 4052 CB GLN D 156 2.651−33.509 26.570 1.00 18.41 D ATOM 4053 CG GLN D 156 1.479 −34.354 26.3571.00 18.96 D ATOM 4054 CD GLN D 156 0.871 −34.864 27.715 1.00 19.75 DATOM 4055 OE1 GLN D 156 1.136 −34.313 28.786 1.00 18.33 D ATOM 4056 NE2GLN D 156 0.037 −35.932 27.628 1.00 18.57 D ATOM 4057 C GLN D 156 1.663−31.717 25.189 1.00 17.47 D ATOM 4058 O GLN D 156 1.168 −30.993 26.0391.00 17.33 D ATOM 4059 N ASP D 157 1.192 −31.798 23.951 1.00 18.17 DATOM 4060 CA ASP D 157 −0.028 −31.116 23.579 1.00 17.53 D ATOM 4061 CBASP D 157 −0.087 −30.808 22.125 1.00 16.72 D ATOM 4062 CG ASP D 157−1.461 −30.461 21.691 1.00 15.86 D ATOM 4063 OD1 ASP D 157 −1.902−31.159 20.752 1.00 14.70 D ATOM 4064 OD2 ASP D 157 −2.102 −29.51722.271 1.00 16.48 D ATOM 4065 C ASP D 157 −1.219 −31.964 23.924 1.0017.92 D ATOM 4066 O ASP D 157 −1.348 −33.090 23.458 1.00 18.19 D ATOM4067 N ILE D 158 −2.131 −31.344 24.693 1.00 19.34 D ATOM 4068 CA ILE D158 −3.321 −32.008 25.239 1.00 18.15 D ATOM 4069 CB ILE D 158 −3.344−31.741 26.812 1.00 18.57 D ATOM 4070 CG2 ILE D 158 −4.222 −30.63027.276 1.00 16.55 D ATOM 4071 CG1 ILE D 158 −3.498 −33.065 27.422 1.0017.57 D ATOM 4072 CD1 ILE D 158 −2.133 −33.688 27.404 1.00 18.15 D ATOM4073 C ILE D 158 −4.571 −31.631 24.571 1.00 18.22 D ATOM 4074 O ILE D158 −5.604 −31.997 25.054 1.00 18.15 D ATOM 4075 N GLY D 159 −4.470−30.876 23.474 1.00 18.06 D ATOM 4076 CA GLY D 159 −5.671 −30.459 22.7951.00 17.59 D ATOM 4077 C GLY D 159 −5.819 −28.947 22.751 1.00 17.58 DATOM 4078 O GLY D 159 −6.905 −28.409 22.648 1.00 18.06 D ATOM 4079 N ALAD 160 −4.726 −28.221 22.842 1.00 17.50 D ATOM 4080 CA ALA D 160 −4.791−26.781 22.828 1.00 17.35 D ATOM 4081 CB ALA D 160 −3.835 −26.240 23.7761.00 17.01 D ATOM 4082 C ALA D 160 −4.369 −26.416 21.466 1.00 17.73 DATOM 4083 O ALA D 160 −4.013 −27.348 20.687 1.00 19.65 D ATOM 4084 N CYSD 161 −4.533 −25.140 21.099 1.00 16.02 D ATOM 4085 CA CYS D 161 −4.071−24.634 19.824 1.00 13.50 D ATOM 4086 C CYS D 161 −2.861 −23.700 20.1971.00 13.37 D ATOM 4087 O CYS D 161 −3.001 −22.495 20.529 1.00 11.69 DATOM 4088 CB CYS D 161 −5.164 −23.874 19.221 1.00 14.41 D ATOM 4089 SGCYS D 161 −4.749 −23.293 17.573 1.00 16.91 D ATOM 4090 N VAL D 162−1.671 −24.289 20.115 1.00 13.35 D ATOM 4091 CA VAL D 162 −0.442 −23.63320.501 1.00 14.14 D ATOM 4092 CB VAL D 162 0.360 −24.438 21.475 1.0015.06 D ATOM 4093 CG1 VAL D 162 1.347 −23.472 22.171 1.00 15.89 D ATOM4094 CG2 VAL D 162 −0.518 −25.227 22.371 1.00 13.73 D ATOM 4095 C VAL D162 0.527 −23.418 19.448 1.00 14.22 D ATOM 4096 O VAL D 162 0.621−24.202 18.593 1.00 13.78 D ATOM 4097 N ALA D 163 1.322 −22.380 19.5911.00 14.76 D ATOM 4098 CA ALA D 163 2.404 −22.098 18.654 1.00 14.94 DATOM 4099 CB ALA D 163 2.093 −20.879 17.844 1.00 14.64 D ATOM 4100 C ALAD 163 3.709 −21.896 19.469 1.00 16.16 D ATOM 4101 O ALA D 163 3.981−20.838 20.031 1.00 17.24 D ATOM 4102 N LEU D 164 4.569 −22.885 19.5191.00 15.46 D ATOM 4103 CA LEU D 164 5.747 −22.695 20.296 1.00 14.60 DATOM 4104 CB LEU D 164 6.151 −24.020 20.812 1.00 14.41 D ATOM 4105 CGLEU D 164 7.283 −23.973 21.748 1.00 14.58 D ATOM 4106 CD1 LEU D 1647.105 −23.110 22.955 1.00 13.67 D ATOM 4107 CD2 LEU D 164 7.378 −25.37422.135 1.00 16.29 D ATOM 4108 C LEU D 164 6.825 −22.041 19.450 1.0016.15 D ATOM 4109 O LEU D 164 7.460 −22.654 18.574 1.00 16.64 D ATOM4110 N LEU D 165 7.071 −20.774 19.691 1.00 15.96 D ATOM 4111 CA LEU D165 8.016 −20.052 18.882 1.00 15.05 D ATOM 4112 CB LEU D 165 7.490−18.634 18.720 1.00 17.26 D ATOM 4113 CG LEU D 165 5.993 −18.544 18.4791.00 17.12 D ATOM 4114 CD1 LEU D 165 5.776 −17.180 18.075 1.00 17.48 DATOM 4115 CD2 LEU D 165 5.569 −19.338 17.383 1.00 18.30 D ATOM 4116 CLEU D 165 9.445 −19.968 19.371 1.00 14.83 D ATOM 4117 O LEU D 165 10.373−19.426 18.693 1.00 11.84 D ATOM 4118 N SER D 166 9.686 −20.537 20.5301.00 14.57 D ATOM 4119 CA SER D 166 11.046 −20.375 21.005 1.00 15.28 DATOM 4120 CB SER D 166 11.305 −18.907 21.431 1.00 17.01 D ATOM 4121 OGSER D 166 12.641 −18.766 21.853 1.00 18.16 D ATOM 4122 C SER D 16611.282 −21.241 22.197 1.00 15.10 D ATOM 4123 O SER D 166 10.447 −21.27123.098 1.00 13.84 D ATOM 4124 N VAL D 167 12.445 −21.879 22.202 1.0014.46 D ATOM 4125 CA VAL D 167 12.817 −22.744 23.255 1.00 13.80 D ATOM4126 CB VAL D 167 12.703 −24.143 22.830 1.00 13.46 D ATOM 4127 CG1 VAL D167 13.115 −25.068 23.949 1.00 13.37 D ATOM 4128 CG2 VAL D 167 11.297−24.413 22.460 1.00 12.70 D ATOM 4129 C VAL D 167 14.251 −22.432 23.5551.00 15.83 D ATOM 4130 O VAL D 167 15.107 −22.682 22.765 1.00 15.38 DATOM 4131 N ARG D 168 14.529 −21.800 24.687 1.00 16.70 D ATOM 4132 CAARG D 168 15.907 −21.540 25.035 1.00 17.23 D ATOM 4133 CB ARG D 16816.184 −20.073 25.273 1.00 18.88 D ATOM 4134 CG ARG D 168 17.063 −19.56924.226 1.00 19.77 D ATOM 4135 CD ARG D 168 18.139 −18.563 24.640 1.0020.96 D ATOM 4136 NE ARG D 168 17.907 −17.944 25.927 1.00 21.91 D ATOM4137 CZ ARG D 168 18.865 −17.316 26.653 1.00 24.14 D ATOM 4138 NH1 ARG D168 20.186 −17.216 26.248 1.00 20.99 D ATOM 4139 NH2 ARG D 168 18.474−16.691 27.793 1.00 25.15 D ATOM 4140 C ARG D 168 16.158 −22.310 26.3361.00 18.12 D ATOM 4141 O ARG D 168 15.265 −22.281 27.223 1.00 17.72 DATOM 4142 N VAL D 169 17.357 −22.994 26.400 1.00 17.55 D ATOM 4143 CAVAL D 169 17.820 −23.791 27.555 1.00 16.91 D ATOM 4144 CB VAL D 16917.914 −25.236 27.251 1.00 18.23 D ATOM 4145 CG1 VAL D 169 18.393−26.049 28.523 1.00 19.32 D ATOM 4146 CG2 VAL D 169 16.629 −25.71926.854 1.00 18.81 D ATOM 4147 C VAL D 169 19.180 −23.339 27.951 1.0016.90 D ATOM 4148 O VAL D 169 20.053 −23.335 27.155 1.00 15.37 D ATOM4149 N TYR D 170 19.366 −22.918 29.186 1.00 16.74 D ATOM 4150 CA TYR D170 20.696 −22.446 29.553 1.00 17.49 D ATOM 4151 CB TYR D 170 20.833−20.992 29.249 1.00 18.49 D ATOM 4152 CG TYR D 170 19.867 −20.200 30.0891.00 19.33 D ATOM 4153 CD1 TYR D 170 20.314 −19.526 31.255 1.00 19.86 DATOM 4154 CE1 TYR D 170 19.471 −18.675 32.000 1.00 17.87 D ATOM 4155 CD2TYR D 170 18.526 −20.032 29.699 1.00 19.84 D ATOM 4156 CE2 TYR D 17017.670 −19.197 30.456 1.00 18.02 D ATOM 4157 CZ TYR D 170 18.174 −18.50831.594 1.00 17.47 D ATOM 4158 OH TYR D 170 17.397 −17.626 32.239 1.0014.17 D ATOM 4159 C TYR D 170 20.945 −22.627 31.023 1.00 17.65 D ATOM4160 O TYR D 170 20.022 −22.889 31.809 1.00 17.04 D ATOM 4161 N TYR D171 22.206 −22.527 31.381 1.00 17.11 D ATOM 4162 CA TYR D 171 22.524−22.671 32.740 1.00 18.01 D ATOM 4163 CB TYR D 171 23.019 −24.044 33.0481.00 18.49 D ATOM 4164 CG TYR D 171 24.393 −24.280 32.603 1.00 18.53 DATOM 4165 CD1 TYR D 171 25.472 −24.114 33.455 1.00 18.93 D ATOM 4166 CE1TYR D 171 26.742 −24.439 33.048 1.00 19.14 D ATOM 4167 CD2 TYR D 17124.637 −24.759 31.338 1.00 18.89 D ATOM 4168 CE2 TYR D 171 25.874−25.085 30.917 1.00 18.87 D ATOM 4169 CZ TYR D 171 26.945 −24.947 31.7601.00 20.06 D ATOM 4170 OH TYR D 171 28.231 −25.434 31.299 1.00 21.52 DATOM 4171 C TYR D 171 23.482 −21.602 33.180 1.00 18.58 D ATOM 4172 O TYRD 171 24.101 −20.904 32.300 1.00 18.33 D ATOM 4173 N LYS D 172 23.577−21.435 34.528 1.00 18.03 D ATOM 4174 CA LYS D 172 24.408 −20.305 34.9871.00 18.52 D ATOM 4175 CB LYS D 172 23.921 −19.805 36.335 1.00 18.23 DATOM 4176 CG LYS D 172 23.135 −18.520 36.207 1.00 19.29 D ATOM 4177 CDLYS D 172 21.921 −18.682 35.427 1.00 19.71 D ATOM 4178 CE LYS D 17221.022 −17.360 35.417 1.00 22.20 D ATOM 4179 NZ LYS D 172 19.827 −17.38836.471 1.00 24.74 D ATOM 4180 C LYS D 172 25.916 −20.415 34.942 1.0018.29 D ATOM 4181 O LYS D 172 26.527 −21.247 35.578 1.00 17.11 D ATOM4182 N LYS D 173 26.475 −19.498 34.146 1.00 19.34 D ATOM 4183 CA LYS D173 27.938 −19.399 33.869 1.00 21.12 D ATOM 4184 CB LYS D 173 28.452−17.912 33.848 1.00 21.63 D ATOM 4185 CG LYS D 173 27.538 −16.884 33.1371.00 22.64 D ATOM 4186 CD LYS D 173 26.560 −16.208 34.225 1.00 23.72 DATOM 4187 CE LYS D 173 25.051 −15.905 33.704 1.00 23.03 D ATOM 4188 NZLYS D 173 24.321 −17.195 33.418 1.00 23.42 D ATOM 4189 C LYS D 17328.849 −20.235 34.809 1.00 20.67 D ATOM 4190 O LYS D 173 28.983 −21.41234.588 1.00 20.72 D ATOM 4191 N CYS D 174 29.472 −19.603 35.813 1.0020.52 D ATOM 4192 CA CYS D 174 30.368 −20.262 36.790 1.00 20.69 D ATOM4193 CB CYS D 174 29.704 −21.531 37.341 1.00 24.71 D ATOM 4194 SG CYS D174 30.442 −22.141 39.011 1.00 38.34 D ATOM 4195 C CYS D 174 31.883−20.546 36.349 1.00 16.94 D ATOM 4196 O CYS D 174 32.585 −19.637 35.6971.00 13.61 D ATOM 4197 OXT CYS D 174 32.295 −21.691 36.736 1.00 12.96 DATOM 4198 CB GLU B 1 7.612 18.581 18.835 1.00 19.33 B ATOM 4199 CG GLU B1 6.875 18.926 20.079 1.00 21.29 B ATOM 4200 CD GLU B 1 5.396 18.41619.996 1.00 24.09 B ATOM 4201 OE1 GLU B 1 5.202 17.157 19.841 1.00 24.44B ATOM 4202 OE2 GLU B 1 4.433 19.251 20.047 1.00 24.63 B ATOM 4203 C GLUB 1 9.689 20.099 18.466 1.00 18.00 B ATOM 4204 O GLU B 1 10.282 20.73719.304 1.00 18.22 B ATOM 4205 N GLU B 1 9.707 17.977 19.958 1.00 18.81 BATOM 4206 CA GLU B 1 9.153 18.663 18.782 1.00 18.39 B ATOM 4207 N VAL B2 9.522 20.598 17.264 1.00 17.41 B ATOM 4208 CA VAL B 2 10.070 21.89516.917 1.00 16.39 B ATOM 4209 CB VAL B 2 10.926 21.863 15.559 1.00 16.10B ATOM 4210 CG1 VAL B 2 11.341 23.243 15.099 1.00 15.92 B ATOM 4211 CG2VAL B 2 12.182 21.088 15.759 1.00 15.06 B ATOM 4212 C VAL B 2 8.87522.706 16.759 1.00 17.34 B ATOM 4213 O VAL B 2 7.993 22.304 16.063 1.0018.11 B ATOM 4214 N VAL B 3 8.829 23.884 17.351 1.00 17.32 B ATOM 4215CA VAL B 3 7.631 24.704 17.308 1.00 17.02 B ATOM 4216 CB VAL B 3 7.19325.194 18.793 1.00 17.23 B ATOM 4217 CG1 VAL B 3 5.841 25.970 18.7551.00 16.84 B ATOM 4218 CG2 VAL B 3 7.074 23.988 19.760 1.00 16.21 B ATOM4219 C VAL B 3 7.727 25.910 16.491 1.00 17.69 B ATOM 4220 O VAL B 38.484 26.723 16.790 1.00 17.27 B ATOM 4221 N LEU B 4 6.896 26.078 15.4871.00 18.77 B ATOM 4222 CA LEU B 4 6.970 27.277 14.629 1.00 20.01 B ATOM4223 CB LEU B 4 6.905 26.832 13.148 1.00 17.64 B ATOM 4224 CG LEU B 47.620 25.484 12.876 1.00 16.59 B ATOM 4225 CD1 LEU B 4 7.234 24.87411.408 1.00 14.29 B ATOM 4226 CD2 LEU B 4 9.075 25.712 13.008 1.00 13.20B ATOM 4227 C LEU B 4 5.691 27.988 14.918 1.00 21.19 B ATOM 4228 O LEU B4 4.692 27.567 14.356 1.00 25.23 B ATOM 4229 N LEU B 5 5.563 29.04615.642 1.00 19.13 B ATOM 4230 CA LEU B 5 4.191 29.509 15.887 1.00 15.39B ATOM 4231 CB LEU B 5 3.266 29.480 14.681 1.00 15.01 B ATOM 4232 CG LEUB 5 1.947 30.186 15.057 1.00 16.17 B ATOM 4233 CD1 LEU B 5 2.280 31.48015.791 1.00 15.79 B ATOM 4234 CD2 LEU B 5 1.148 30.585 13.864 1.00 14.53B ATOM 4235 C LEU B 5 3.449 28.823 17.044 1.00 14.56 B ATOM 4236 O LEU B5 3.131 27.647 17.030 1.00 13.09 B ATOM 4237 N ASP B 6 3.160 29.67818.050 1.00 14.75 B ATOM 4238 CA ASP B 6 2.532 29.333 19.351 1.00 14.46B ATOM 4239 CB ASP B 6 3.589 28.872 20.276 1.00 17.73 B ATOM 4240 CG ASPB 6 3.046 28.205 21.405 1.00 20.84 B ATOM 4241 OD1 ASP B 6 3.893 27.78722.279 1.00 24.10 B ATOM 4242 OD2 ASP B 6 1.783 28.070 21.446 1.00 23.10B ATOM 4243 C ASP B 6 1.842 30.510 19.971 1.00 14.49 B ATOM 4244 O ASP B6 2.374 31.328 20.641 1.00 14.03 B ATOM 4245 N PHE B 7 0.583 30.53919.754 1.00 15.39 B ATOM 4246 CA PHE B 7 −0.242 31.653 20.101 1.00 15.19B ATOM 4247 CB PHE B 7 −1.660 31.391 19.591 1.00 16.89 B ATOM 4248 CGPHE B 7 −2.673 32.414 20.016 1.00 16.46 B ATOM 4249 CD1 PHE B 7 −2.75033.664 19.371 1.00 16.28 B ATOM 4250 CD2 PHE B 7 −3.521 32.138 21.0711.00 15.35 B ATOM 4251 CE1 PHE B 7 −3.652 34.612 19.787 1.00 16.33 BATOM 4252 CE2 PHE B 7 −4.414 33.065 21.470 1.00 15.35 B ATOM 4253 CZ PHEB 7 −4.483 34.304 20.837 1.00 16.05 B ATOM 4254 C PHE B 7 −0.317 32.02821.535 1.00 15.08 B ATOM 4255 O PHE B 7 −0.280 33.231 21.884 1.00 13.87B ATOM 4256 N ALA B 8 −0.514 30.988 22.319 1.00 15.15 B ATOM 4257 CA ALAB 8 −0.628 31.111 23.736 1.00 16.00 B ATOM 4258 CB ALA B 8 −1.171 29.77824.299 1.00 15.81 B ATOM 4259 C ALA B 8 0.661 31.559 24.472 1.00 16.09 BATOM 4260 O ALA B 8 0.622 31.722 25.668 1.00 15.94 B ATOM 4261 N ALA B 91.786 31.754 23.782 1.00 16.49 B ATOM 4262 CA ALA B 9 3.006 32.16824.452 1.00 17.72 B ATOM 4263 CB ALA B 9 4.124 31.252 24.105 1.00 14.51B ATOM 4264 C ALA B 9 3.367 33.595 24.125 1.00 18.20 B ATOM 4265 O ALA B9 4.239 34.155 24.795 1.00 19.49 B ATOM 4266 N ALA B 10 2.651 34.19923.177 1.00 18.85 B ATOM 4267 CA ALA B 10 2.996 35.544 22.608 1.00 20.20B ATOM 4268 CB ALA B 10 2.617 35.613 21.061 1.00 17.52 B ATOM 4269 C ALAB 10 2.399 36.733 23.345 1.00 21.06 B ATOM 4270 O ALA B 10 1.281 37.30422.951 1.00 20.73 B ATOM 4271 N GLY B 11 3.160 37.087 24.420 1.00 23.08B ATOM 4272 CA GLY B 11 2.844 38.206 25.436 1.00 25.57 B ATOM 4273 C GLYB 11 2.502 39.628 24.886 1.00 26.22 B ATOM 4274 O GLY B 11 3.190 40.67625.111 1.00 27.46 B ATOM 4275 N GLY B 12 1.373 39.649 24.170 1.00 25.67B ATOM 4276 CA GLY B 12 0.827 40.803 23.452 1.00 24.15 B ATOM 4277 C GLYB 12 0.028 40.087 22.273 1.00 23.19 B ATOM 4278 O GLY B 12 0.017 40.55221.047 1.00 22.52 B ATOM 4279 N GLU B 13 −0.541 38.904 22.599 1.00 22.90B ATOM 4280 CA GLU B 13 −1.436 38.168 21.681 1.00 22.48 B ATOM 4281 CBGLU B 13 −2.690 39.123 21.414 1.00 24.88 B ATOM 4282 CG GLU B 13 −2.71240.700 22.103 1.00 25.88 B ATOM 4283 CD GLU B 13 −4.178 41.467 22.2131.00 25.99 B ATOM 4284 OE1 GLU B 13 −5.161 40.604 22.261 1.00 25.78 BATOM 4285 OE2 GLU B 13 −4.308 42.825 22.290 1.00 20.93 B ATOM 4286 C GLUB 13 −0.741 37.633 20.334 1.00 21.79 B ATOM 4287 O GLU B 13 −0.42136.391 20.229 1.00 20.36 B ATOM 4288 N LEU B 14 −0.451 38.619 19.4171.00 21.93 B ATOM 4289 CA LEU B 14 0.234 38.449 18.167 1.00 21.77 B ATOM4290 CB LEU B 14 −0.052 37.055 17.697 1.00 22.73 B ATOM 4291 CG LEU B 141.207 36.164 17.913 1.00 23.69 B ATOM 4292 CD1 LEU B 14 0.699 34.81118.503 1.00 20.15 B ATOM 4293 CD2 LEU B 14 2.093 36.100 16.465 1.0021.19 B ATOM 4294 C LEU B 14 −0.062 39.371 17.013 1.00 21.68 B ATOM 4295O LEU B 14 −1.139 40.089 16.949 1.00 22.37 B ATOM 4296 N GLY B 15 0.81939.191 16.025 1.00 21.01 B ATOM 4297 CA GLY B 15 0.694 39.937 14.8101.00 20.93 B ATOM 4298 C GLY B 15 −0.217 39.142 13.871 1.00 21.44 B ATOM4299 O GLY B 15 0.362 38.443 12.976 1.00 23.16 B ATOM 4300 N TRP B 16−1.569 39.125 14.059 1.00 20.86 B ATOM 4301 CA TRP B 16 −2.424 38.39013.073 1.00 19.41 B ATOM 4302 CB TRP B 16 −3.280 37.285 13.733 1.0019.25 B ATOM 4303 CG TRP B 16 −2.471 36.200 14.230 1.00 18.20 B ATOM4304 CD2 TRP B 16 −2.837 34.871 14.494 1.00 17.00 B ATOM 4305 CE2 TRP B16 −1.711 34.235 15.099 1.00 17.45 B ATOM 4306 CE3 TRP B 16 −3.96634.138 14.294 1.00 15.49 B ATOM 4307 CD1 TRP B 16 −1.192 36.328 14.6481.00 19.78 B ATOM 4308 NE1 TRP B 16 −0.709 35.149 15.176 1.00 19.12 BATOM 4309 CZ2 TRP B 16 −1.712 32.921 15.509 1.00 16.27 B ATOM 4310 CZ3TRP B 16 −3.965 32.785 14.714 1.00 15.94 B ATOM 4311 CH2 TRP B 16 −2.82732.212 15.316 1.00 17.32 B ATOM 4312 C TRP B 16 −3.326 39.293 12.2191.00 19.30 B ATOM 4313 O TRP B 16 −3.593 40.440 12.591 1.00 19.85 B ATOM4314 N LEU B 17 −3.760 38.795 11.060 1.00 18.36 B ATOM 4315 CA LEU B 17−4.653 39.559 10.131 1.00 16.56 B ATOM 4316 CB LEU B 17 −4.221 39.3468.703 1.00 18.10 B ATOM 4317 CG LEU B 17 −5.044 40.121 7.747 1.00 19.82B ATOM 4318 CD1 LEU B 17 −5.201 41.555 8.456 1.00 22.99 B ATOM 4319 CD2LEU B 17 −4.322 40.225 6.367 1.00 18.76 B ATOM 4320 C LEU B 17 −6.08539.123 10.303 1.00 15.21 B ATOM 4321 O LEU B 17 −6.387 37.950 10.5381.00 14.49 B ATOM 4322 N THR B 18 −6.976 40.076 10.185 1.00 14.81 B ATOM4323 CA THR B 18 −8.411 39.812 10.468 1.00 16.08 B ATOM 4324 CB THR B 18−8.840 40.526 11.755 1.00 14.48 B ATOM 4325 OG1 THR B 18 −8.908 39.55312.776 1.00 16.08 B ATOM 4326 CG2 THR B 18 −10.058 41.170 11.664 1.0013.24 B ATOM 4327 C THR B 18 −9.135 40.317 9.355 1.00 17.55 B ATOM 4328O THR B 18 −9.101 41.515 9.187 1.00 17.13 B ATOM 4329 N HIS B 19 −9.81539.443 8.599 1.00 19.55 B ATOM 4330 CA HIS B 19 −10.403 39.997 7.4311.00 21.50 B ATOM 4331 CB HIS B 19 −10.613 38.987 6.330 1.00 22.58 BATOM 4332 CG HIS B 19 −10.873 39.613 4.955 1.00 23.08 B ATOM 4333 CD2HIS B 19 −11.643 39.196 3.902 1.00 21.70 B ATOM 4334 ND1 HIS B 19−10.425 40.880 4.599 1.00 23.45 B ATOM 4335 CE1 HIS B 19 −10.919 41.2303.417 1.00 21.99 B ATOM 4336 NE2 HIS B 19 −11.665 40.229 2.973 1.0023.35 B ATOM 4337 C HIS B 19 −11.610 40.877 7.688 1.00 24.72 B ATOM 4338O HIS B 19 −11.571 41.684 8.714 1.00 26.75 B ATOM 4339 N PRO B 20−12.770 40.695 6.961 1.00 23.56 B ATOM 4340 CD PRO B 20 −13.311 39.3227.145 1.00 20.37 B ATOM 4341 CA PRO B 20 −13.748 41.778 7.404 1.00 20.09B ATOM 4342 CB PRO B 20 −14.763 41.009 8.188 1.00 20.64 B ATOM 4343 CGPRO B 20 −14.814 39.702 7.330 1.00 21.42 B ATOM 4344 C PRO B 20 −13.00642.948 8.233 1.00 22.82 B ATOM 4345 O PRO B 20 −12.596 44.031 7.672 1.0022.68 B ATOM 4346 N TYR B 21 −12.749 42.693 9.542 1.00 23.57 B ATOM 4347CA TYR B 21 −12.066 43.668 10.489 1.00 23.33 B ATOM 4348 CB TYR B 21−10.948 44.539 9.868 1.00 24.13 B ATOM 4349 CG TYR B 21 −10.325 45.39011.058 1.00 25.30 B ATOM 4350 CD1 TYR B 21 −9.547 44.744 12.110 1.0024.18 B ATOM 4351 CE1 TYR B 21 −9.190 45.434 13.301 1.00 25.23 B ATOM4352 CD2 TYR B 21 −10.696 46.778 11.251 1.00 26.09 B ATOM 4353 CE2 TYR B21 −10.315 47.453 12.467 1.00 27.05 B ATOM 4354 CZ TYR B 21 −9.57746.727 13.439 1.00 26.21 B ATOM 4355 OH TYR B 21 −9.302 47.352 14.5991.00 30.88 B ATOM 4356 C TYR B 21 −13.034 44.677 11.069 1.00 24.20 BATOM 4357 O TYR B 21 −13.376 45.669 10.326 1.00 24.27 B ATOM 4358 N GLYB 22 −13.433 44.469 12.339 1.00 25.25 B ATOM 4359 CA GLY B 22 −14.39345.386 12.944 1.00 26.57 B ATOM 4360 C GLY B 22 −15.388 44.534 13.6351.00 26.74 B ATOM 4361 O GLY B 22 −15.522 44.683 14.860 1.00 28.62 BATOM 4362 N LYS B 23 −16.013 43.592 12.887 1.00 25.31 B ATOM 4363 CA LYSB 23 −17.121 42.713 13.439 1.00 22.94 B ATOM 4364 CB LYS B 23 −18.42742.939 12.653 1.00 21.75 B ATOM 4365 CG LYS B 23 −19.098 44.333 12.7181.00 21.55 B ATOM 4366 CD LYS B 23 −18.605 45.346 11.499 1.00 21.23 BATOM 4367 CE LYS B 23 −18.946 46.890 11.762 1.00 17.99 B ATOM 4368 NZLYS B 23 −20.425 47.011 11.972 1.00 19.14 B ATOM 4369 C LYS B 23 −16.76341.185 13.353 1.00 22.33 B ATOM 4370 O LYS B 23 −17.538 40.327 13.8191.00 22.65 B ATOM 4371 N GLY B 24 −15.621 40.868 12.742 1.00 20.12 BATOM 4372 CA GLY B 24 −15.278 39.505 12.683 1.00 17.62 B ATOM 4373 C GLYB 24 −14.649 39.062 13.983 1.00 16.71 B ATOM 4374 O GLY B 24 −15.17039.256 14.996 1.00 15.30 B ATOM 4375 N TRP B 25 −13.552 38.347 13.8471.00 16.97 B ATOM 4376 CA TRP B 25 −12.696 37.820 14.834 1.00 16.53 BATOM 4377 CB TRP B 25 −11.616 37.026 14.093 1.00 16.79 B ATOM 4378 CGTRP B 25 −11.925 35.706 13.500 1.00 15.95 B ATOM 4379 CD2 TRP B 25−12.022 34.469 14.218 1.00 15.70 B ATOM 4380 CE2 TRP B 25 −12.252 33.45713.257 1.00 15.64 B ATOM 4381 CE3 TRP B 25 −11.930 34.120 15.588 1.0014.43 B ATOM 4382 CD1 TRP B 25 −12.107 35.380 12.140 1.00 16.11 B ATOM4383 NE1 TRP B 25 −12.287 34.044 12.017 1.00 15.31 B ATOM 4384 CZ2 TRP B25 −12.391 32.146 13.616 1.00 16.41 B ATOM 4385 CZ3 TRP B 25 −12.05532.847 15.938 1.00 15.11 B ATOM 4386 CH2 TRP B 25 −12.287 31.843 14.9691.00 15.11 B ATOM 4387 C TRP B 25 −11.991 39.001 15.587 1.00 16.75 BATOM 4388 O TRP B 25 −11.402 39.918 14.972 1.00 16.41 B ATOM 4389 N ASPB 26 −12.046 38.938 16.923 1.00 17.33 B ATOM 4390 CA ASP B 26 −11.39339.936 17.834 1.00 16.66 B ATOM 4391 CB ASP B 26 −12.410 40.805 18.6411.00 21.86 B ATOM 4392 CG ASP B 26 −13.349 41.779 17.744 1.00 27.42 BATOM 4393 OD1 ASP B 26 −13.306 42.078 16.448 1.00 28.08 B ATOM 4394 OD2ASP B 26 −14.250 42.380 18.485 1.00 32.32 B ATOM 4395 C ASP B 26 −10.47039.226 18.892 1.00 14.14 B ATOM 4396 O ASP B 26 −10.813 38.240 19.5461.00 10.78 B ATOM 4397 N LEU B 27 −9.301 39.837 19.040 1.00 13.88 B ATOM4398 CA LEU B 27 −8.292 39.460 19.990 1.00 13.89 B ATOM 4399 CB LEU B 27−7.002 40.075 19.525 1.00 14.15 B ATOM 4400 CG LEU B 27 −5.789 39.51420.281 1.00 15.05 B ATOM 4401 CD1 LEU B 27 −5.697 38.022 20.331 1.0014.81 B ATOM 4402 CD2 LEU B 27 −4.648 40.231 19.673 1.00 12.79 B ATOM4403 C LEU B 27 −8.773 40.009 21.354 1.00 14.18 B ATOM 4404 O LEU B 27−9.095 41.098 21.546 1.00 14.28 B ATOM 4405 N MET B 28 −8.898 39.15722.277 1.00 14.56 B ATOM 4406 CA MET B 28 −9.340 39.526 23.487 1.0015.08 B ATOM 4407 CB MET B 28 −10.718 38.921 23.732 1.00 18.06 B ATOM4408 CG MET B 28 −11.688 39.105 22.612 1.00 21.22 B ATOM 4409 SD MET B28 −13.467 38.516 22.863 1.00 24.86 B ATOM 4410 CE MET B 28 −13.97439.828 24.635 1.00 21.11 B ATOM 4411 C MET B 28 −8.362 39.006 24.5681.00 14.66 B ATOM 4412 O MET B 28 −7.758 37.925 24.477 1.00 13.69 B ATOM4413 N GLN B 29 −8.237 39.794 25.636 1.00 15.17 B ATOM 4414 CA GLN B 29−7.400 39.382 26.737 1.00 15.92 B ATOM 4415 CB GLN B 29 −6.415 40.45727.024 1.00 16.68 B ATOM 4416 CG GLN B 29 −5.319 39.848 27.875 1.0018.08 B ATOM 4417 CD GLN B 29 −4.563 40.888 28.712 1.00 18.79 B ATOM4418 OE1 GLN B 29 −3.448 41.224 28.403 1.00 19.28 B ATOM 4419 NE2 GLN B29 −5.193 41.394 29.758 1.00 18.61 B ATOM 4420 C GLN B 29 −8.090 39.06428.011 1.00 14.77 B ATOM 4421 O GLN B 29 −8.585 39.939 28.636 1.00 14.97B ATOM 4422 N ASN B 30 −8.178 37.817 28.385 1.00 14.16 B ATOM 4423 CAASN B 30 −8.686 37.536 29.710 1.00 13.52 B ATOM 4424 CB ASN B 30 −9.42736.221 29.700 1.00 14.16 B ATOM 4425 CG ASN B 30 −10.836 36.393 29.1811.00 14.84 B ATOM 4426 OD1 ASN B 30 −11.467 35.413 28.877 1.00 15.97 BATOM 4427 ND2 ASN B 30 −11.362 37.643 29.128 1.00 12.34 B ATOM 4428 CASN B 30 −7.523 37.493 30.746 1.00 11.42 B ATOM 4429 O ASN B 30 −6.34137.556 30.404 1.00 6.76 B ATOM 4430 N ILE B 31 −7.879 37.407 32.009 1.0012.92 B ATOM 4431 CA ILE B 31 −6.819 37.317 32.956 1.00 16.17 B ATOM4432 CB ILE B 31 −6.358 38.707 33.299 1.00 18.43 B ATOM 4433 CG2 ILE B31 −7.513 39.522 33.865 1.00 22.68 B ATOM 4434 CG1 ILE B 31 −5.21038.634 34.275 1.00 20.76 B ATOM 4435 CD1 ILE B 31 −4.862 40.072 34.7041.00 20.25 B ATOM 4436 C ILE B 31 −7.154 36.475 34.101 1.00 15.67 B ATOM4437 O ILE B 31 −8.201 36.511 34.572 1.00 15.55 B ATOM 4438 N MET B 32−6.240 35.661 34.524 1.00 16.22 B ATOM 4439 CA MET B 32 −6.444 34.70635.589 1.00 16.42 B ATOM 4440 CB MET B 32 −6.603 33.305 35.044 1.0019.18 B ATOM 4441 CG MET B 32 −8.010 32.868 34.704 1.00 21.98 B ATOM4442 SD MET B 32 −9.188 32.807 36.136 1.00 25.56 B ATOM 4443 CE MET B 32−7.793 32.430 37.414 1.00 20.66 B ATOM 4444 C MET B 32 −5.195 34.64136.373 1.00 15.53 B ATOM 4445 O MET B 32 −4.192 34.260 35.842 1.00 14.13B ATOM 4446 N ASN B 33 −5.308 34.914 37.680 1.00 16.51 B ATOM 4447 CAASN B 33 −4.175 34.945 38.622 1.00 16.45 B ATOM 4448 CB ASN B 33 −3.65333.544 38.868 1.00 16.49 B ATOM 4449 CG ASN B 33 −4.672 32.680 39.4941.00 16.71 B ATOM 4450 OD1 ASN B 33 −5.197 32.904 40.642 1.00 18.56 BATOM 4451 ND2 ASN B 33 −5.007 31.692 38.787 1.00 16.19 B ATOM 4452 C ASNB 33 −3.052 35.793 38.020 1.00 17.19 B ATOM 4453 O ASN B 33 −1.89635.386 37.975 1.00 18.47 B ATOM 4454 N ASP B 34 −3.433 36.920 37.4861.00 17.50 B ATOM 4455 CA ASP B 34 −2.510 37.860 36.925 1.00 18.58 BATOM 4456 CB ASP B 34 −1.478 38.394 37.988 1.00 19.45 B ATOM 4457 CG ASPB 34 −2.095 39.454 39.021 1.00 22.25 B ATOM 4458 OD1 ASP B 34 −3.32839.502 39.425 1.00 23.92 B ATOM 4459 OD2 ASP B 34 −1.294 40.270 39.5681.00 25.70 B ATOM 4460 C ASP B 34 −1.847 37.376 35.664 1.00 16.52 B ATOM4461 O ASP B 34 −0.992 38.041 35.062 1.00 17.54 B ATOM 4462 N MET B 35−2.200 36.215 35.220 1.00 15.51 B ATOM 4463 CA MET B 35 −1.651 35.88833.870 1.00 14.80 B ATOM 4464 CB MET B 35 −1.447 34.404 33.772 1.0015.81 B ATOM 4465 CG MET B 35 −0.341 33.964 34.699 1.00 17.60 B ATOM4466 SD MET B 35 1.360 34.661 34.221 1.00 18.40 B ATOM 4467 CE MET B 351.316 36.284 35.435 1.00 18.05 B ATOM 4468 C MET B 35 −2.571 36.34832.673 1.00 13.06 B ATOM 4469 O MET B 35 −3.733 36.057 32.646 1.00 10.06B ATOM 4470 N PRO B 36 −2.048 37.135 31.731 1.00 11.97 B ATOM 4471 CDPRO B 36 −0.768 37.739 31.541 1.00 13.50 B ATOM 4472 CA PRO B 36 −2.91537.491 30.627 1.00 13.77 B ATOM 4473 CB PRO B 36 −2.121 38.541 29.8791.00 13.17 B ATOM 4474 CG PRO B 36 −0.888 38.160 30.088 1.00 14.36 BATOM 4475 C PRO B 36 −3.184 36.169 29.779 1.00 13.15 B ATOM 4476 O PRO B36 −2.315 35.346 29.586 1.00 12.74 B ATOM 4477 N ILE B 37 −4.433 35.93129.430 1.00 13.54 B ATOM 4478 CA ILE B 37 −4.820 34.787 28.614 1.0015.31 B ATOM 4479 CB ILE B 37 −5.857 33.984 29.304 1.00 15.57 B ATOM4480 CG2 ILE B 37 −6.076 32.672 28.638 1.00 14.63 B ATOM 4481 CG1 ILE B37 −5.405 33.640 30.705 1.00 17.71 B ATOM 4482 CD1 ILE B 37 −4.02333.216 30.795 1.00 18.08 B ATOM 4483 C ILE B 37 −5.389 35.318 27.2931.00 14.58 B ATOM 4484 O ILE B 37 −6.484 35.701 27.263 1.00 14.96 B ATOM4485 N TYR B 38 −4.654 35.367 26.205 1.00 15.12 B ATOM 4486 CA TYR B 38−5.283 35.915 25.008 1.00 16.20 B ATOM 4487 CB TYR B 38 −4.261 36.50124.053 1.00 16.22 B ATOM 4488 CG TYR B 38 −3.594 37.757 24.563 1.0015.67 B ATOM 4489 CD1 TYR B 38 −2.583 37.709 25.461 1.00 16.39 B ATOM4490 CE1 TYR B 38 −2.122 38.802 25.950 1.00 15.95 B ATOM 4491 CD2 TYR B38 −4.058 38.983 24.217 1.00 14.70 B ATOM 4492 CE2 TYR B 38 −3.59340.037 24.709 1.00 14.08 B ATOM 4493 CZ TYR B 38 −2.634 39.961 25.5701.00 16.32 B ATOM 4494 OH TYR B 38 −2.156 41.138 26.103 1.00 20.87 BATOM 4495 C TYR B 38 −6.098 34.814 24.250 1.00 16.42 B ATOM 4496 O TYR B38 −5.876 33.588 24.438 1.00 15.71 B ATOM 4497 N MET B 39 −7.011 35.29123.388 1.00 16.19 B ATOM 4498 CA MET B 39 −7.862 34.472 22.585 1.0014.97 B ATOM 4499 CB MET B 39 −8.990 33.929 23.393 1.00 15.17 B ATOM4500 CG MET B 39 −10.195 34.754 23.436 1.00 16.34 B ATOM 4501 SD MET B39 −11.118 34.390 25.002 1.00 18.85 B ATOM 4502 CE MET B 39 −12.53235.626 24.930 1.00 18.74 B ATOM 4503 C MET B 39 −8.433 35.211 21.3771.00 15.27 B ATOM 4504 O MET B 39 −8.525 36.417 21.409 1.00 14.93 B ATOM4505 N TYR B 40 −8.735 34.487 20.278 1.00 14.25 B ATOM 4506 CA TYR B 40−9.373 35.158 19.174 1.00 13.70 B ATOM 4507 CB TYR B 40 −8.620 34.89717.892 1.00 15.06 B ATOM 4508 CG TYR B 40 −7.653 35.936 17.525 1.0015.09 B ATOM 4509 CD1 TYR B 40 −6.272 35.744 17.670 1.00 16.16 B ATOM4510 CE1 TYR B 40 −5.394 36.710 17.302 1.00 14.40 B ATOM 4511 CD2 TYR B40 −8.079 37.113 16.991 1.00 14.86 B ATOM 4512 CE2 TYR B 40 −7.19638.075 16.625 1.00 13.21 B ATOM 4513 CZ TYR B 40 −5.871 37.900 16.7831.00 14.46 B ATOM 4514 OH TYR B 40 −5.043 38.971 16.471 1.00 14.12 BATOM 4515 C TYR B 40 −10.830 34.573 19.194 1.00 12.92 B ATOM 4516 O TYRB 40 −11.057 33.389 19.406 1.00 11.67 B ATOM 4517 N SER B 41 −11.81635.413 19.027 1.00 12.59 B ATOM 4518 CA SER B 41 −13.157 34.894 19.0781.00 13.84 B ATOM 4519 CB SER B 41 −13.711 34.742 20.536 1.00 15.21 BATOM 4520 OG SER B 41 −13.571 35.844 21.337 1.00 16.56 B ATOM 4521 C SERB 41 −14.116 35.670 18.232 1.00 14.15 B ATOM 4522 O SER B 41 −13.74836.778 17.772 1.00 14.28 B ATOM 4523 N VAL B 42 −15.285 35.063 17.9851.00 12.91 B ATOM 4524 CA VAL B 42 −16.299 35.688 17.150 1.00 14.05 BATOM 4525 CB VAL B 42 −16.517 35.202 15.668 1.00 13.30 B ATOM 4526 CG1VAL B 42 −16.772 36.407 14.814 1.00 13.89 B ATOM 4527 CG2 VAL B 42−15.489 34.194 15.214 1.00 10.02 B ATOM 4528 C VAL B 42 −17.545 35.09917.601 1.00 14.51 B ATOM 4529 O VAL B 42 −17.580 33.932 18.033 1.0014.73 B ATOM 4530 N CYS B 43 −18.608 35.819 17.345 1.00 14.37 B ATOM4531 CA CYS B 43 −19.885 35.291 17.774 1.00 18.12 B ATOM 4532 C CYS B 43−21.026 35.978 16.977 1.00 16.79 B ATOM 4533 O CYS B 43 −22.044 36.25717.512 1.00 18.45 B ATOM 4534 CB CYS B 43 −20.096 35.490 19.345 1.0016.58 B ATOM 4535 SG CYS B 43 −21.487 34.552 20.121 1.00 16.93 B ATOM4536 N ASN B 44 −20.866 36.270 15.723 1.00 16.51 B ATOM 4537 CA ASN B 44−22.001 36.822 14.982 1.00 15.71 B ATOM 4538 CB ASN B 44 −21.465 37.49913.723 1.00 15.01 B ATOM 4539 CG ASN B 44 −20.459 38.526 14.075 1.0014.45 B ATOM 4540 OD1 ASN B 44 −19.517 38.810 13.380 1.00 11.21 B ATOM4541 ND2 ASN B 44 −20.703 39.129 15.231 1.00 15.46 B ATOM 4542 C ASN B44 −23.000 35.711 14.620 1.00 14.74 B ATOM 4543 O ASN B 44 −23.16235.445 13.448 1.00 14.71 B ATOM 4544 N VAL B 45 −23.579 35.043 15.6251.00 13.75 B ATOM 4545 CA VAL B 45 −24.539 33.970 15.436 1.00 14.67 BATOM 4546 CB VAL B 45 −24.704 33.011 16.669 1.00 14.25 B ATOM 4547 CG1VAL B 45 −23.486 32.393 16.963 1.00 17.00 B ATOM 4548 CG2 VAL B 45−25.167 33.713 17.891 1.00 15.52 B ATOM 4549 C VAL B 45 −25.916 34.34615.049 1.00 13.23 B ATOM 4550 O VAL B 45 −26.669 33.492 14.723 1.0013.45 B ATOM 4551 N MET B 46 −26.174 35.625 15.009 1.00 14.82 B ATOM4552 CA MET B 46 −27.503 36.183 14.807 1.00 16.63 B ATOM 4553 CB MET B46 −27.800 37.235 15.902 1.00 17.75 B ATOM 4554 CG MET B 46 −29.00237.051 16.744 1.00 19.21 B ATOM 4555 SD MET B 46 −29.425 35.438 17.4941.00 23.11 B ATOM 4556 CE MET B 46 −28.880 35.721 19.629 1.00 22.04 BATOM 4557 C MET B 46 −27.555 36.862 13.472 1.00 17.40 B ATOM 4558 O METB 46 −28.548 37.505 13.133 1.00 17.48 B ATOM 4559 N SER B 47 −26.47236.820 12.711 1.00 18.46 B ATOM 4560 CA SER B 47 −26.612 37.422 11.3521.00 20.09 B ATOM 4561 CB SER B 47 −25.731 38.660 11.269 1.00 20.21 BATOM 4562 OG SER B 47 −25.195 38.890 12.580 1.00 21.46 B ATOM 4563 C SERB 47 −26.206 36.258 10.384 1.00 19.53 B ATOM 4564 O SER B 47 −25.57735.290 10.875 1.00 20.16 B ATOM 4565 N GLY B 48 −26.584 36.296 9.0921.00 19.00 B ATOM 4566 CA GLY B 48 −26.240 35.130 8.299 1.00 18.74 BATOM 4567 C GLY B 48 −25.132 35.455 7.371 1.00 18.48 B ATOM 4568 O GLY B48 −24.690 36.590 7.377 1.00 18.70 B ATOM 4569 N ASP B 49 −24.655 34.4986.600 1.00 18.26 B ATOM 4570 CA ASP B 49 −23.606 34.888 5.680 1.00 19.01B ATOM 4571 CB ASP B 49 −24.103 36.057 4.767 1.00 18.71 B ATOM 4572 CGASP B 49 −25.539 35.756 4.082 1.00 20.20 B ATOM 4573 OD1 ASP B 49−26.355 36.707 3.940 1.00 18.58 B ATOM 4574 OD2 ASP B 49 −25.788 34.5763.684 1.00 19.58 B ATOM 4575 C ASP B 49 −22.333 35.367 6.378 1.00 19.07B ATOM 4576 O ASP B 49 −21.718 36.370 5.976 1.00 19.42 B ATOM 4577 N GLNB 50 −21.905 34.709 7.439 1.00 19.68 B ATOM 4578 CA GLN B 50 −20.67735.216 8.019 1.00 19.50 B ATOM 4579 CB GLN B 50 −20.562 34.762 9.4841.00 19.74 B ATOM 4580 CG GLN B 50 −21.590 35.367 10.404 1.00 17.55 BATOM 4581 CD GLN B 50 −21.569 36.828 10.271 1.00 17.29 B ATOM 4582 OE1GLN B 50 −20.565 37.410 10.500 1.00 13.85 B ATOM 4583 NE2 GLN B 50−22.692 37.430 9.823 1.00 18.47 B ATOM 4584 C GLN B 50 −19.583 34.6167.221 1.00 18.75 B ATOM 4585 O GLN B 50 −19.705 33.505 6.827 1.00 19.54B ATOM 4586 N ASP B 51 −18.521 35.362 7.002 1.00 18.09 B ATOM 4587 CAASP B 51 −17.352 34.877 6.277 1.00 17.00 B ATOM 4588 CB ASP B 51 −17.43135.086 4.713 1.00 16.47 B ATOM 4589 CG ASP B 51 −16.251 34.308 3.8911.00 17.52 B ATOM 4590 OD1 ASP B 51 −15.953 34.766 2.762 1.00 19.94 BATOM 4591 OD2 ASP B 51 −15.611 33.310 4.328 1.00 11.67 B ATOM 4592 C ASPB 51 −16.191 35.686 6.886 1.00 14.22 B ATOM 4593 O ASP B 51 −15.62236.524 6.290 1.00 12.63 B ATOM 4594 N ASN B 52 −15.885 35.376 8.105 1.0014.01 B ATOM 4595 CA ASN B 52 −14.776 35.989 8.779 1.00 13.16 B ATOM4596 CB ASN B 52 −15.184 36.357 10.181 1.00 15.96 B ATOM 4597 CG ASN B52 −16.559 37.056 10.227 1.00 17.25 B ATOM 4598 OD1 ASN B 52 −16.70838.179 9.696 1.00 15.67 B ATOM 4599 ND2 ASN B 52 −17.559 36.377 10.8391.00 14.07 B ATOM 4600 C ASN B 52 −13.505 35.144 8.820 1.00 11.33 B ATOM4601 O ASN B 52 −13.498 33.958 9.163 1.00 6.00 B ATOM 4602 N TRP B 53−12.422 35.858 8.453 1.00 12.31 B ATOM 4603 CA TRP B 53 −11.115 35.3078.383 1.00 13.75 B ATOM 4604 CB TRP B 53 −10.605 35.436 6.984 1.00 15.48B ATOM 4605 CG TRP B 53 −11.375 34.483 5.967 1.00 16.61 B ATOM 4606 CD2TRP B 53 −10.941 33.238 5.407 1.00 17.51 B ATOM 4607 CE2 TRP B 53−11.950 32.821 4.541 1.00 18.24 B ATOM 4608 CE3 TRP B 53 −9.803 32.4395.548 1.00 17.60 B ATOM 4609 CD1 TRP B 53 −12.586 34.720 5.442 1.0015.74 B ATOM 4610 NE1 TRP B 53 −12.939 33.767 4.616 1.00 17.15 B ATOM4611 CZ2 TRP B 53 −11.859 31.568 3.757 1.00 19.10 B ATOM 4612 CZ3 TRP B53 −9.709 31.233 4.808 1.00 17.85 B ATOM 4613 CH2 TRP B 53 −10.72030.808 3.928 1.00 18.71 B ATOM 4614 C TRP B 53 −10.102 35.798 9.305 1.0014.19 B ATOM 4615 O TRP B 53 −10.005 36.976 9.525 1.00 13.72 B ATOM 4616N LEU B 54 −9.321 34.834 9.801 1.00 15.00 B ATOM 4617 CA LEU B 54 −8.23435.066 10.714 1.00 15.33 B ATOM 4618 CB LEU B 54 −8.464 34.455 12.1211.00 15.24 B ATOM 4619 CG LEU B 54 −7.284 34.542 13.117 1.00 14.41 BATOM 4620 CD1 LEU B 54 −6.989 35.953 13.347 1.00 14.23 B ATOM 4621 CD2LEU B 54 −7.536 33.851 14.410 1.00 12.43 B ATOM 4622 C LEU B 54 −7.08434.406 10.121 1.00 14.97 B ATOM 4623 O LEU B 54 −7.127 33.217 9.946 1.0015.04 B ATOM 4624 N ARG B 55 −6.056 35.187 9.788 1.00 15.73 B ATOM 4625CA ARG B 55 −4.795 34.654 9.279 1.00 15.37 B ATOM 4626 CB ARG B 55−4.385 35.337 8.016 1.00 18.12 B ATOM 4627 CG ARG B 55 −3.176 34.5727.368 1.00 20.15 B ATOM 4628 CD ARG B 55 −2.864 34.916 5.942 1.00 18.62B ATOM 4629 NE ARG B 55 −1.799 35.932 5.752 1.00 20.30 B ATOM 4630 CZARG B 55 −1.724 37.078 6.401 1.00 19.77 B ATOM 4631 NH1 ARG B 55 −2.66237.366 7.320 1.00 21.19 B ATOM 4632 NH2 ARG B 55 −0.756 37.933 6.1051.00 18.44 B ATOM 4633 C ARG B 55 −3.635 34.878 10.257 1.00 14.55 B ATOM4634 O ARG B 55 −3.488 35.913 10.841 1.00 12.29 B ATOM 4635 N THR B 56−2.830 33.862 10.421 1.00 14.43 B ATOM 4636 CA THR B 56 −1.681 33.95211.239 1.00 14.33 B ATOM 4637 CB THR B 56 −0.997 32.591 11.473 1.0014.48 B ATOM 4638 OG1 THR B 56 −0.320 32.200 10.263 1.00 12.56 B ATOM4639 CG2 THR B 56 −2.001 31.534 11.999 1.00 11.67 B ATOM 4640 C THR B 56−0.691 34.711 10.379 1.00 16.02 B ATOM 4641 O THR B 56 −0.927 34.9959.208 1.00 15.27 B ATOM 4642 N ASN B 57 0.460 35.004 10.958 1.00 17.53 BATOM 4643 CA ASN B 57 1.529 35.615 10.154 1.00 19.02 B ATOM 4644 CB ASNB 57 2.458 36.356 11.006 1.00 22.56 B ATOM 4645 CG ASN B 57 2.351 37.82210.755 1.00 26.43 B ATOM 4646 OD1 ASN B 57 1.314 38.479 11.082 1.0028.22 B ATOM 4647 ND2 ASN B 57 3.403 38.381 10.090 1.00 28.70 B ATOM4648 C ASN B 57 2.381 34.636 9.392 1.00 18.52 B ATOM 4649 O ASN B 572.365 33.386 9.595 1.00 18.64 B ATOM 4650 N TRP B 58 3.135 35.206 8.4881.00 17.65 B ATOM 4651 CA TRP B 58 4.086 34.437 7.673 1.00 17.38 B ATOM4652 CB TRP B 58 4.990 35.471 6.953 1.00 19.06 B ATOM 4653 CG TRP B 586.139 34.942 6.083 1.00 21.25 B ATOM 4654 CD2 TRP B 58 6.014 34.0635.013 1.00 21.12 B ATOM 4655 CE2 TRP B 58 7.329 33.945 4.382 1.00 22.48B ATOM 4656 CE3 TRP B 58 4.953 33.364 4.506 1.00 19.05 B ATOM 4657 CD1TRP B 58 7.556 35.344 6.089 1.00 24.53 B ATOM 4658 NE1 TRP B 58 8.25134.731 5.049 1.00 24.44 B ATOM 4659 CZ2 TRP B 58 7.526 33.142 3.270 1.0022.22 B ATOM 4660 CZ3 TRP B 58 5.157 32.579 3.423 1.00 19.92 B ATOM 4661CH2 TRP B 58 6.431 32.467 2.802 1.00 21.55 B ATOM 4662 C TRP B 58 4.97433.461 8.573 1.00 17.27 B ATOM 4663 O TRP B 58 5.660 33.857 9.442 1.0016.83 B ATOM 4664 N VAL B 59 4.939 32.179 8.345 1.00 17.46 B ATOM 4665CA VAL B 59 5.734 31.210 9.094 1.00 16.60 B ATOM 4666 CB VAL B 59 4.82930.204 9.754 1.00 16.65 B ATOM 4667 CG1 VAL B 59 5.656 29.275 10.5711.00 14.38 B ATOM 4668 CG2 VAL B 59 3.702 30.914 10.488 1.00 14.75 BATOM 4669 C VAL B 59 6.696 30.403 8.129 1.00 18.16 B ATOM 4670 O VAL B59 6.264 29.712 7.197 1.00 19.98 B ATOM 4671 N TYR B 60 7.989 30.4998.391 1.00 16.76 B ATOM 4672 CA TYR B 60 8.995 29.865 7.665 1.00 14.85 BATOM 4673 CB TYR B 60 10.356 30.272 8.166 1.00 15.39 B ATOM 4674 CG TYRB 60 10.754 31.692 7.811 1.00 17.24 B ATOM 4675 CD1 TYR B 60 10.75532.731 8.768 1.00 18.55 B ATOM 4676 CE1 TYR B 60 11.112 34.039 8.4191.00 20.21 B ATOM 4677 CD2 TYR B 60 11.112 32.022 6.518 1.00 18.32 BATOM 4678 CE2 TYR B 60 11.444 33.279 6.163 1.00 19.59 B ATOM 4679 CZ TYRB 60 11.445 34.275 7.064 1.00 20.63 B ATOM 4680 OH TYR B 60 11.67735.570 6.568 1.00 24.76 B ATOM 4681 C TYR B 60 8.827 28.412 7.843 1.0014.53 B ATOM 4682 O TYR B 60 8.542 27.905 8.912 1.00 12.59 B ATOM 4683 NARG B 61 9.034 27.715 6.754 1.00 15.46 B ATOM 4684 CA ARG B 61 8.87626.296 6.784 1.00 17.85 B ATOM 4685 CB ARG B 61 8.527 25.775 5.363 1.0018.61 B ATOM 4686 CG ARG B 61 8.781 24.240 5.174 1.00 19.13 B ATOM 4687CD ARG B 61 8.344 23.748 3.698 1.00 19.41 B ATOM 4688 NE ARG B 61 9.42223.948 2.686 1.00 16.44 B ATOM 4689 CZ ARG B 61 10.506 23.169 2.633 1.0015.24 B ATOM 4690 NH1 ARG B 61 10.660 22.154 3.462 1.00 12.36 B ATOM4691 NH2 ARG B 61 11.495 23.481 1.838 1.00 17.78 B ATOM 4692 C ARG B 6110.152 25.600 7.314 1.00 18.68 B ATOM 4693 O ARG B 61 10.104 24.5187.983 1.00 19.24 B ATOM 4694 N GLY B 62 11.287 26.242 7.016 1.00 19.55 BATOM 4695 CA GLY B 62 12.587 25.641 7.371 1.00 19.81 B ATOM 4696 C GLY B62 12.747 24.250 6.719 1.00 20.24 B ATOM 4697 O GLY B 62 12.562 24.0585.518 1.00 19.96 B ATOM 4698 N GLU B 63 13.050 23.268 7.516 1.00 20.38 BATOM 4699 CA GLU B 63 13.229 21.908 7.053 1.00 21.08 B ATOM 4700 CB GLUB 63 14.338 21.370 7.949 1.00 21.50 B ATOM 4701 CG GLU B 63 14.68719.900 7.827 1.00 24.81 B ATOM 4702 CD GLU B 63 15.301 19.717 6.429 1.0028.56 B ATOM 4703 OE1 GLU B 63 15.567 18.508 5.970 1.00 30.55 B ATOM4704 OE2 GLU B 63 15.484 20.852 5.783 1.00 30.22 B ATOM 4705 C GLU B 6311.899 21.040 7.172 1.00 21.62 B ATOM 4706 O GLU B 63 11.862 19.8636.838 1.00 22.66 B ATOM 4707 N ALA B 64 10.792 21.566 7.697 1.00 21.48 BATOM 4708 CA ALA B 64 9.566 20.758 7.833 1.00 19.83 B ATOM 4709 CB ALA B64 8.508 21.563 8.664 1.00 18.69 B ATOM 4710 C ALA B 64 8.912 20.2756.512 1.00 18.95 B ATOM 4711 O ALA B 64 8.801 21.039 5.515 1.00 19.15 BATOM 4712 N GLU B 65 8.482 18.995 6.539 1.00 18.69 B ATOM 4713 CA GLU B65 7.736 18.374 5.403 1.00 18.88 B ATOM 4714 CB GLU B 65 8.111 16.8855.082 1.00 18.68 B ATOM 4715 CG GLU B 65 9.572 16.555 4.836 1.00 23.45 BATOM 4716 CD GLU B 65 10.200 17.093 3.497 1.00 25.51 B ATOM 4717 OE1 GLUB 65 9.820 16.545 2.337 1.00 26.33 B ATOM 4718 OE2 GLU B 65 11.03918.104 3.630 1.00 27.68 B ATOM 4719 C GLU B 65 6.283 18.397 5.785 1.0017.56 B ATOM 4720 O GLU B 65 5.441 18.887 5.011 1.00 17.97 B ATOM 4721 NARG B 66 6.021 17.801 6.944 1.00 16.42 B ATOM 4722 CA ARG B 66 4.69217.738 7.499 1.00 17.04 B ATOM 4723 CB ARG B 66 4.324 16.314 7.844 1.0015.87 B ATOM 4724 CG ARG B 66 2.870 16.121 8.110 1.00 18.09 B ATOM 4725CD ARG B 66 2.276 15.034 7.128 1.00 19.99 B ATOM 4726 NE ARG B 66 0.82614.756 7.299 1.00 23.29 B ATOM 4727 CZ ARG B 66 −0.104 14.854 6.337 1.0024.27 B ATOM 4728 NH1 ARG B 66 0.255 15.216 5.108 1.00 24.78 B ATOM 4729NH2 ARG B 66 −1.422 14.591 6.594 1.00 26.23 B ATOM 4730 C ARG B 66 4.64618.607 8.815 1.00 17.98 B ATOM 4731 O ARG B 66 5.605 18.553 9.625 1.0017.40 B ATOM 4732 N ASN B 67 3.601 19.416 9.017 1.00 17.67 B ATOM 4733CA ASN B 67 3.554 20.122 10.275 1.00 19.03 B ATOM 4734 CB ASN B 67 3.59121.604 10.118 1.00 21.52 B ATOM 4735 CG ASN B 67 2.609 22.029 9.077 1.0025.37 B ATOM 4736 OD1 ASN B 67 2.527 21.293 8.015 1.00 30.51 B ATOM 4737ND2 ASN B 67 1.903 23.177 9.258 1.00 20.88 B ATOM 4738 C ASN B 67 2.25819.729 10.893 1.00 19.15 B ATOM 4739 O ASN B 67 1.356 19.456 10.213 1.0018.38 B ATOM 4740 N ASN B 68 2.234 19.636 12.220 1.00 18.54 B ATOM 4741CA ASN B 68 1.090 19.283 12.984 1.00 17.80 B ATOM 4742 CB ASN B 68 1.57818.262 14.045 1.00 19.39 B ATOM 4743 CG ASN B 68 1.992 16.858 13.3841.00 21.86 B ATOM 4744 OD1 ASN B 68 1.161 15.885 13.214 1.00 19.99 BATOM 4745 ND2 ASN B 68 3.265 16.768 12.947 1.00 22.31 B ATOM 4746 C ASNB 68 0.583 20.650 13.618 1.00 18.31 B ATOM 4747 O ASN B 68 1.373 21.61313.916 1.00 16.58 B ATOM 4748 N PHE B 69 −0.731 20.798 13.695 1.00 18.18B ATOM 4749 CA PHE B 69 −1.242 21.928 14.439 1.00 17.82 B ATOM 4750 CBPHE B 69 −1.689 23.119 13.641 1.00 19.88 B ATOM 4751 CG PHE B 69 −2.05022.820 12.318 1.00 21.14 B ATOM 4752 CD1 PHE B 69 −2.999 21.825 12.0641.00 22.59 B ATOM 4753 CD2 PHE B 69 −1.429 23.513 11.309 1.00 19.84 BATOM 4754 CE1 PHE B 69 −3.322 21.515 10.708 1.00 25.59 B ATOM 4755 CE2PHE B 69 −1.698 23.244 10.000 1.00 21.61 B ATOM 4756 CZ PHE B 69 −2.62322.262 9.658 1.00 23.46 B ATOM 4757 C PHE B 69 −2.360 21.578 15.410 1.0018.17 B ATOM 4758 O PHE B 69 −3.344 20.870 15.092 1.00 17.32 B ATOM 4759N GLU B 70 −2.092 22.079 16.641 1.00 18.13 B ATOM 4760 CA GLU B 70−2.901 21.876 17.788 1.00 16.07 B ATOM 4761 CB GLU B 70 −1.993 21.50518.927 1.00 17.62 B ATOM 4762 CG GLU B 70 −2.743 20.687 19.970 1.0017.75 B ATOM 4763 CD GLU B 70 −2.022 20.710 21.327 1.00 16.94 B ATOM4764 OE1 GLU B 70 −1.969 19.707 22.062 1.00 16.49 B ATOM 4765 OE2 GLU B70 −1.516 21.759 21.616 1.00 16.63 B ATOM 4766 C GLU B 70 −3.689 23.11218.020 1.00 15.01 B ATOM 4767 O GLU B 70 −3.129 24.189 18.109 1.00 12.35B ATOM 4768 N LEU B 71 −5.010 22.912 18.041 1.00 15.98 B ATOM 4769 CALEU B 71 −6.052 23.954 18.253 1.00 16.76 B ATOM 4770 CB LEU B 71 −7.02223.998 17.087 1.00 16.88 B ATOM 4771 CG LEU B 71 −6.443 24.472 15.7701.00 17.52 B ATOM 4772 CD1 LEU B 71 −7.444 24.296 14.702 1.00 19.23 BATOM 4773 CD2 LEU B 71 −6.083 25.922 15.820 1.00 15.65 B ATOM 4774 C LEUB 71 −6.851 23.654 19.542 1.00 16.95 B ATOM 4775 O LEU B 71 −7.24822.542 19.764 1.00 17.98 B ATOM 4776 N ASN B 72 −6.990 24.678 20.4021.00 16.90 B ATOM 4777 CA ASN B 72 −7.726 24.676 21.663 1.00 16.38 BATOM 4778 CB ASN B 72 −6.750 24.973 22.819 1.00 17.11 B ATOM 4779 CG ASNB 72 −6.159 23.749 23.387 1.00 17.46 B ATOM 4780 OD1 ASN B 72 −5.13223.742 24.131 1.00 16.01 B ATOM 4781 ND2 ASN B 72 −6.806 22.636 23.0341.00 21.17 B ATOM 4782 C ASN B 72 −8.807 25.789 21.529 1.00 15.99 B ATOM4783 O ASN B 72 −8.500 27.019 21.332 1.00 15.09 B ATOM 4784 N PHE B 73−10.079 25.343 21.635 1.00 15.40 B ATOM 4785 CA PHE B 73 −11.181 26.25821.450 1.00 15.38 B ATOM 4786 CB PHE B 73 −11.526 26.368 19.932 1.0017.03 B ATOM 4787 CG PHE B 73 −11.876 25.033 19.296 1.00 18.18 B ATOM4788 CD1 PHE B 73 −13.193 24.625 19.204 1.00 18.81 B ATOM 4789 CD2 PHE B73 −10.896 24.091 18.962 1.00 17.52 B ATOM 4790 CE1 PHE B 73 −13.49723.313 18.817 1.00 18.20 B ATOM 4791 CE2 PHE B 73 −11.221 22.801 18.5881.00 17.47 B ATOM 4792 CZ PHE B 73 −12.501 22.417 18.517 1.00 17.20 BATOM 4793 C PHE B 73 −12.395 25.838 22.165 1.00 14.62 B ATOM 4794 O PHEB 73 −12.471 24.710 22.645 1.00 13.80 B ATOM 4795 N THR B 74 −13.36626.741 22.189 1.00 13.55 B ATOM 4796 CA THR B 74 −14.603 26.430 22.8321.00 14.60 B ATOM 4797 CB THR B 74 −14.870 27.159 24.170 1.00 13.98 BATOM 4798 OG1 THR B 74 −15.063 28.564 23.937 1.00 11.90 B ATOM 4799 CG2THR B 74 −13.790 26.992 25.017 1.00 13.65 B ATOM 4800 C THR B 74 −15.61326.944 21.884 1.00 13.40 B ATOM 4801 O THR B 74 −15.294 27.818 21.0841.00 12.90 B ATOM 4802 N VAL B 75 −16.832 26.443 22.104 1.00 13.81 BATOM 4803 CA VAL B 75 −17.943 26.721 21.243 1.00 15.93 B ATOM 4804 CBVAL B 75 −18.056 25.607 20.120 1.00 16.07 B ATOM 4805 CG1 VAL B 75−19.101 25.979 19.057 1.00 16.19 B ATOM 4806 CG2 VAL B 75 −16.749 25.46819.471 1.00 15.94 B ATOM 4807 C VAL B 75 −19.262 26.842 21.986 1.0014.37 B ATOM 4808 O VAL B 75 −19.764 25.908 22.577 1.00 13.41 B ATOM4809 N ARG B 76 −19.799 28.039 21.934 1.00 14.06 B ATOM 4810 CA ARG B 76−20.997 28.233 22.605 1.00 15.21 B ATOM 4811 CB ARG B 76 −21.305 29.69222.755 1.00 14.50 B ATOM 4812 CG ARG B 76 −22.594 29.933 23.498 1.0013.14 B ATOM 4813 CD ARG B 76 −22.541 31.245 24.105 1.00 13.87 B ATOM4814 NE ARG B 76 −23.862 31.587 24.506 1.00 16.23 B ATOM 4815 CZ ARG B76 −24.359 32.822 24.703 1.00 17.19 B ATOM 4816 NH1 ARG B 76 −23.60933.955 24.572 1.00 17.54 B ATOM 4817 NH2 ARG B 76 −25.667 32.899 24.9081.00 14.81 B ATOM 4818 C ARG B 76 −22.110 27.544 21.858 1.00 15.93 BATOM 4819 O ARG B 76 −22.258 27.741 20.665 1.00 17.51 B ATOM 4820 N ASPB 77 −22.849 26.714 22.590 1.00 16.16 B ATOM 4821 CA ASP B 77 −24.00025.962 22.152 1.00 16.50 B ATOM 4822 CB ASP B 77 −24.627 25.297 23.3881.00 17.55 B ATOM 4823 CG ASP B 77 −25.975 24.754 23.111 1.00 19.97 BATOM 4824 OD1 ASP B 77 −26.355 24.883 21.899 1.00 24.40 B ATOM 4825 OD2ASP B 77 −26.660 24.251 24.030 1.00 17.39 B ATOM 4826 C ASP B 77 −24.94826.832 21.407 1.00 14.82 B ATOM 4827 O ASP B 77 −25.299 27.821 21.8971.00 14.45 B ATOM 4828 N CYS B 78 −25.356 26.466 20.203 1.00 14.62 BATOM 4829 CA CYS B 78 −26.276 27.368 19.451 1.00 16.17 B ATOM 4830 C CYSB 78 −27.669 27.522 20.014 1.00 15.90 B ATOM 4831 O CYS B 78 −28.35428.483 19.726 1.00 16.87 B ATOM 4832 CB CYS B 78 −26.436 26.962 18.0181.00 14.89 B ATOM 4833 SG CYS B 78 −25.153 27.504 16.883 1.00 15.70 BATOM 4834 N ASN B 79 −28.093 26.556 20.817 1.00 16.65 B ATOM 4835 CA ASNB 79 −29.386 26.696 21.435 1.00 16.39 B ATOM 4836 CB ASN B 79 −29.88425.328 21.789 1.00 16.64 B ATOM 4837 CG ASN B 79 −30.230 24.501 20.5801.00 16.72 B ATOM 4838 OD1 ASN B 79 −30.277 23.238 20.621 1.00 16.35 BATOM 4839 ND2 ASN B 79 −30.487 25.180 19.494 1.00 16.89 B ATOM 4840 CASN B 79 −29.397 27.622 22.693 1.00 16.39 B ATOM 4841 O ASN B 79 −30.36927.793 23.342 1.00 16.12 B ATOM 4842 N SER B 80 −28.239 28.154 23.0601.00 16.95 B ATOM 4843 CA SER B 80 −28.138 29.013 24.199 1.00 16.32 BATOM 4844 CB SER B 80 −26.732 28.934 24.796 1.00 17.02 B ATOM 4845 OGSER B 80 −25.827 29.531 23.911 1.00 18.22 B ATOM 4846 C SER B 80 −28.42930.433 23.735 1.00 15.84 B ATOM 4847 O SER B 80 −28.095 31.324 24.4191.00 15.06 B ATOM 4848 N PHE B 81 −28.963 30.656 22.551 1.00 16.04 BATOM 4849 CA PHE B 81 −29.294 32.014 22.202 1.00 17.04 B ATOM 4850 CBPHE B 81 −28.664 32.391 20.870 1.00 16.65 B ATOM 4851 CG PHE B 81−27.161 32.440 20.901 1.00 17.19 B ATOM 4852 CD1 PHE B 81 −26.412 31.29520.579 1.00 17.94 B ATOM 4853 CD2 PHE B 81 −26.464 33.590 21.342 1.0015.89 B ATOM 4854 CE1 PHE B 81 −25.005 31.282 20.708 1.00 18.01 B ATOM4855 CE2 PHE B 81 −25.078 33.575 21.458 1.00 15.67 B ATOM 4856 CZ PHE B81 −24.314 32.444 21.155 1.00 15.32 B ATOM 4857 C PHE B 81 −30.86232.032 22.218 1.00 18.38 B ATOM 4858 O PHE B 81 −31.462 31.499 21.3071.00 18.60 B ATOM 4859 N PRO B 82 −31.537 32.685 23.239 1.00 18.08 BATOM 4860 CD PRO B 82 −31.017 33.858 23.951 1.00 18.52 B ATOM 4861 CAPRO B 82 −33.014 32.696 23.349 1.00 17.37 B ATOM 4862 CB PRO B 82−33.327 33.728 24.453 1.00 18.46 B ATOM 4863 CG PRO B 82 −32.029 33.97125.128 1.00 18.61 B ATOM 4864 C PRO B 82 −33.786 32.998 22.118 1.0018.85 B ATOM 4865 O PRO B 82 −33.535 34.053 21.440 1.00 16.11 B ATOM4866 N GLY B 83 −34.765 32.078 21.857 1.00 19.90 B ATOM 4867 CA GLY B 83−35.667 32.195 20.695 1.00 22.16 B ATOM 4868 C GLY B 83 −34.778 31.48719.685 1.00 22.85 B ATOM 4869 O GLY B 83 −33.587 31.287 20.089 1.0024.74 B ATOM 4870 N GLY B 84 −35.153 31.085 18.453 1.00 21.78 B ATOM4871 CA GLY B 84 −34.072 30.345 17.732 1.00 19.79 B ATOM 4872 C GLY B 84−32.874 31.159 17.203 1.00 19.52 B ATOM 4873 O GLY B 84 −32.898 32.38117.284 1.00 19.55 B ATOM 4874 N ALA B 85 −31.785 30.558 16.694 1.0019.18 B ATOM 4875 CA ALA B 85 −30.631 31.365 16.108 1.00 17.34 B ATOM4876 CB ALA B 85 −29.401 31.425 17.029 1.00 17.97 B ATOM 4877 C ALA B 85−30.279 30.631 14.872 1.00 16.55 B ATOM 4878 O ALA B 85 −29.171 30.21914.741 1.00 16.67 B ATOM 4879 N SER B 86 −31.278 30.414 14.003 1.0015.82 B ATOM 4880 CA SER B 86 −31.163 29.702 12.706 1.00 12.31 B ATOM4881 CB SER B 86 −32.308 30.119 11.787 1.00 11.37 B ATOM 4882 OG SER B86 −32.335 31.397 11.284 1.00 7.32 B ATOM 4883 C SER B 86 −29.835 29.77611.981 1.00 12.90 B ATOM 4884 O SER B 86 −29.438 28.776 11.507 1.0012.88 B ATOM 4885 N SER B 87 −29.134 30.931 11.901 1.00 14.30 B ATOM4886 CA SER B 87 −27.842 30.991 11.195 1.00 15.27 B ATOM 4887 CB SER B87 −27.647 32.298 10.466 1.00 15.62 B ATOM 4888 OG SER B 87 −27.55033.299 11.409 1.00 17.54 B ATOM 4889 C SER B 87 −26.571 30.646 12.0331.00 14.59 B ATOM 4890 O SER B 87 −25.490 30.499 11.529 1.00 14.90 BATOM 4891 N CYS B 88 −26.780 30.328 13.266 1.00 14.58 B ATOM 4892 CA CYSB 88 −25.708 30.047 14.093 1.00 15.79 B ATOM 4893 C CYS B 88 −25.14228.733 13.693 1.00 15.92 B ATOM 4894 O CYS B 88 −25.865 27.918 13.3251.00 17.64 B ATOM 4895 CB CYS B 88 −26.212 30.017 15.556 1.00 13.94 BATOM 4896 SG CYS B 88 −25.038 29.493 16.816 1.00 13.45 B ATOM 4897 N LYSB 89 −23.845 28.517 13.825 1.00 16.51 B ATOM 4898 CA LYS B 89 −23.20627.244 13.493 1.00 17.72 B ATOM 4899 CB LYS B 89 −22.214 27.448 12.2951.00 17.56 B ATOM 4900 CG LYS B 89 −22.956 28.048 11.093 1.00 20.56 BATOM 4901 CD LYS B 89 −23.853 26.936 10.430 1.00 18.27 B ATOM 4902 CELYS B 89 −24.268 27.379 8.992 1.00 21.22 B ATOM 4903 NZ LYS B 89 −24.99726.311 8.043 1.00 21.37 B ATOM 4904 C LYS B 89 −22.379 26.786 14.6501.00 16.60 B ATOM 4905 O LYS B 89 −21.970 27.586 15.427 1.00 16.83 BATOM 4906 N GLU B 90 −22.048 25.522 14.697 1.00 15.98 B ATOM 4907 CA GLUB 90 −21.140 25.069 15.702 1.00 17.08 B ATOM 4908 CB GLU B 90 −21.84024.133 16.633 1.00 15.98 B ATOM 4909 CG GLU B 90 −23.057 24.782 17.1711.00 17.62 B ATOM 4910 CD GLU B 90 −23.888 23.879 18.120 1.00 19.92 BATOM 4911 OE1 GLU B 90 −24.118 22.668 17.787 1.00 19.73 B ATOM 4912 OE2GLU B 90 −24.337 24.402 19.189 1.00 20.64 B ATOM 4913 C GLU B 90 −19.84424.451 15.135 1.00 17.10 B ATOM 4914 O GLU B 90 −19.359 23.453 15.6771.00 19.22 B ATOM 4915 N THR B 91 −19.301 25.000 14.046 1.00 15.57 BATOM 4916 CA THR B 91 −18.040 24.474 13.552 1.00 14.25 B ATOM 4917 CBTHR B 91 −18.188 23.273 12.460 1.00 12.39 B ATOM 4918 OG1 THR B 91−18.775 23.819 11.293 1.00 12.21 B ATOM 4919 CG2 THR B 91 −18.952 22.06012.984 1.00 7.39 B ATOM 4920 C THR B 91 −17.352 25.663 12.892 1.00 14.09B ATOM 4921 O THR B 91 −17.941 26.764 12.704 1.00 13.26 B ATOM 4922 NPHE B 92 −16.077 25.462 12.578 1.00 14.00 B ATOM 4923 CA PHE B 92−15.336 26.481 11.810 1.00 15.15 B ATOM 4924 CB PHE B 92 −14.591 27.51012.733 1.00 16.53 B ATOM 4925 CG PHE B 92 −13.526 26.881 13.648 1.0016.90 B ATOM 4926 CD1 PHE B 92 −12.217 26.895 13.332 1.00 16.23 B ATOM4927 CD2 PHE B 92 −13.888 26.377 14.859 1.00 18.25 B ATOM 4928 CE1 PHE B92 −11.247 26.432 14.217 1.00 17.76 B ATOM 4929 CE2 PHE B 92 −12.95025.888 15.797 1.00 19.08 B ATOM 4930 CZ PHE B 92 −11.611 25.919 15.4741.00 18.57 B ATOM 4931 C PHE B 92 −14.312 25.766 10.937 1.00 13.55 BATOM 4932 O PHE B 92 −13.924 24.648 11.205 1.00 12.04 B ATOM 4933 N ASNB 93 −13.787 26.489 9.973 1.00 13.21 B ATOM 4934 CA ASN B 93 −12.81025.932 9.045 1.00 13.96 B ATOM 4935 CB ASN B 93 −13.257 26.241 7.6821.00 14.49 B ATOM 4936 CG ASN B 93 −14.538 25.619 7.422 1.00 15.18 BATOM 4937 OD1 ASN B 93 −14.701 24.426 7.747 1.00 16.48 B ATOM 4938 ND2ASN B 93 −15.471 26.351 6.855 1.00 13.61 B ATOM 4939 C ASN B 93 −11.38826.272 9.133 1.00 13.69 B ATOM 4940 O ASN B 93 −11.046 27.383 9.510 1.0013.40 B ATOM 4941 N LEU B 94 −10.565 25.294 8.780 1.00 14.37 B ATOM 4942CA LEU B 94 −9.136 25.455 8.786 1.00 15.67 B ATOM 4943 CB LEU B 94−8.514 24.348 9.602 1.00 14.69 B ATOM 4944 CG LEU B 94 −6.992 24.4339.820 1.00 15.06 B ATOM 4945 CD1 LEU B 94 −6.570 25.804 10.344 1.0012.51 B ATOM 4946 CD2 LEU B 94 −6.574 23.224 10.713 1.00 13.48 B ATOM4947 C LEU B 94 −8.543 25.467 7.382 1.00 16.08 B ATOM 4948 O LEU B 94−8.806 24.555 6.615 1.00 16.41 B ATOM 4949 N TYR B 95 −7.748 26.5007.065 1.00 16.73 B ATOM 4950 CA TYR B 95 −7.039 26.650 5.787 1.00 18.07B ATOM 4951 CB TYR B 95 −7.606 27.767 4.942 1.00 17.89 B ATOM 4952 CGTYR B 95 −9.007 27.502 4.435 1.00 18.90 B ATOM 4953 CD1 TYR B 95 −10.11927.456 5.280 1.00 18.68 B ATOM 4954 CE1 TYR B 95 −11.412 27.222 4.7461.00 18.73 B ATOM 4955 CD2 TYR B 95 −9.245 27.320 3.054 1.00 20.07 BATOM 4956 CE2 TYR B 95 −10.553 27.101 2.515 1.00 18.99 B ATOM 4957 CZTYR B 95 −11.598 27.043 3.356 1.00 18.31 B ATOM 4958 OH TYR B 95 −12.83326.746 2.859 1.00 17.65 B ATOM 4959 C TYR B 95 −5.551 26.971 5.887 1.0017.03 B ATOM 4960 O TYR B 95 −5.042 27.378 6.915 1.00 18.16 B ATOM 4961N TYR B 96 −4.845 26.779 4.791 1.00 16.05 B ATOM 4962 CA TYR B 96 −3.45627.156 4.755 1.00 15.76 B ATOM 4963 CB TYR B 96 −2.585 26.093 5.284 1.0015.67 B ATOM 4964 CG TYR B 96 −2.291 25.091 4.283 1.00 16.34 B ATOM 4965CD1 TYR B 96 −1.113 25.128 3.550 1.00 17.94 B ATOM 4966 CE1 TYR B 96−0.844 24.171 2.536 1.00 19.00 B ATOM 4967 CD2 TYR B 96 −3.191 24.1194.013 1.00 16.93 B ATOM 4968 CE2 TYR B 96 −2.973 23.168 3.020 1.00 18.11B ATOM 4969 CZ TYR B 96 −1.812 23.187 2.294 1.00 18.96 B ATOM 4970 OHTYR B 96 −1.558 22.195 1.393 1.00 20.65 B ATOM 4971 C TYR B 96 −3.13527.482 3.294 1.00 14.11 B ATOM 4972 O TYR B 96 −3.946 27.291 2.459 1.0011.99 B ATOM 4973 N ALA B 97 −2.009 28.107 3.071 1.00 13.70 B ATOM 4974CA ALA B 97 −1.503 28.486 1.781 1.00 14.91 B ATOM 4975 CB ALA B 97−2.051 29.855 1.278 1.00 13.86 B ATOM 4976 C ALA B 97 0.042 28.533 1.9981.00 16.54 B ATOM 4977 O ALA B 97 0.546 28.810 3.148 1.00 15.55 B ATOM4978 N GLU B 98 0.762 28.171 0.916 1.00 16.47 B ATOM 4979 CA GLU B 982.209 28.122 0.885 1.00 16.24 B ATOM 4980 CB GLU B 98 2.689 26.818 0.2591.00 15.85 B ATOM 4981 CG GLU B 98 2.781 25.688 1.217 1.00 15.93 B ATOM4982 CD GLU B 98 3.312 24.448 0.617 1.00 15.89 B ATOM 4983 OE1 GLU B 982.515 23.739 −0.022 1.00 17.23 B ATOM 4984 OE2 GLU B 98 4.525 24.1770.782 1.00 14.77 B ATOM 4985 C GLU B 98 2.671 29.232 0.012 1.00 18.17 BATOM 4986 O GLU B 98 1.991 29.526 −0.931 1.00 18.17 B ATOM 4987 N SER B99 3.733 29.953 0.360 1.00 18.45 B ATOM 4988 CA SER B 99 4.301 30.860−0.655 1.00 18.26 B ATOM 4989 CB SER B 99 3.558 32.182 −0.838 1.00 20.24B ATOM 4990 OG SER B 99 3.593 32.873 0.391 1.00 25.26 B ATOM 4991 C SERB 99 5.800 31.050 −0.401 1.00 17.99 B ATOM 4992 O SER B 99 6.339 30.6400.612 1.00 16.48 B ATOM 4993 N ASP B 100 6.479 31.561 −1.409 1.00 18.22B ATOM 4994 CA ASP B 100 7.881 31.714 −1.298 1.00 19.45 B ATOM 4995 CBASP B 100 8.575 31.391 −2.592 1.00 19.22 B ATOM 4996 CG ASP B 100 8.60829.914 −2.850 1.00 21.25 B ATOM 4997 OD1 ASP B 100 8.845 29.050 −1.8961.00 17.83 B ATOM 4998 OD2 ASP B 100 8.400 29.582 −4.102 1.00 24.79 BATOM 4999 C ASP B 100 8.247 33.076 −0.835 1.00 20.29 B ATOM 5000 O ASP B100 9.386 33.219 −0.369 1.00 21.38 B ATOM 5001 N LEU B 101 7.287 34.005−0.959 1.00 20.64 B ATOM 5002 CA LEU B 101 7.318 35.415 −0.557 1.0020.18 B ATOM 5003 CB LEU B 101 6.880 36.383 −1.662 1.00 20.56 B ATOM5004 CG LEU B 101 7.203 36.279 −3.154 1.00 21.43 B ATOM 5005 CD1 LEU B101 6.609 34.820 −3.597 1.00 24.14 B ATOM 5006 CD2 LEU B 101 6.29237.385 −3.971 1.00 20.67 B ATOM 5007 C LEU B 101 6.210 35.596 0.542 1.0021.16 B ATOM 5008 O LEU B 101 5.194 34.833 0.576 1.00 21.49 B ATOM 5009N ASP B 102 6.456 36.607 1.399 1.00 20.45 B ATOM 5010 CA ASP B 102 5.62337.105 2.440 1.00 20.12 B ATOM 5011 CB ASP B 102 6.453 38.001 3.339 1.0020.39 B ATOM 5012 CG ASP B 102 5.755 38.269 4.626 1.00 21.26 B ATOM 5013OD1 ASP B 102 4.476 38.372 4.607 1.00 19.97 B ATOM 5014 OD2 ASP B 1026.486 38.356 5.666 1.00 22.53 B ATOM 5015 C ASP B 102 4.514 38.030 1.8241.00 20.29 B ATOM 5016 O ASP B 102 4.777 39.140 1.456 1.00 20.40 B ATOM5017 N TYR B 103 3.280 37.596 1.775 1.00 20.58 B ATOM 5018 CA TYR B 1032.248 38.435 1.222 1.00 20.35 B ATOM 5019 CB TYR B 103 0.904 37.7221.195 1.00 21.94 B ATOM 5020 CG TYR B 103 0.830 36.670 0.131 1.00 23.57B ATOM 5021 CD1 TYR B 103 1.122 36.960 −1.239 1.00 24.55 B ATOM 5022 CE1TYR B 103 1.119 35.894 −2.303 1.00 23.64 B ATOM 5023 CD2 TYR B 103 0.49535.356 0.477 1.00 25.26 B ATOM 5024 CE2 TYR B 103 0.464 34.301 −0.5271.00 24.92 B ATOM 5025 CZ TYR B 103 0.804 34.572 −1.911 1.00 25.39 BATOM 5026 OH TYR B 103 0.938 33.437 −2.826 1.00 26.04 B ATOM 5027 C TYRB 103 2.016 39.735 1.956 1.00 19.61 B ATOM 5028 O TYR B 103 1.329 40.6491.440 1.00 19.62 B ATOM 5029 N GLY B 104 2.599 39.889 3.128 1.00 19.20 BATOM 5030 CA GLY B 104 2.266 41.112 3.885 1.00 18.21 B ATOM 5031 C GLY B104 0.739 41.213 4.260 1.00 18.08 B ATOM 5032 O GLY B 104 0.157 40.3464.878 1.00 17.24 B ATOM 5033 N THR B 105 0.086 42.266 3.827 1.00 18.34 BATOM 5034 CA THR B 105 −1.274 42.461 4.130 1.00 18.03 B ATOM 5035 CB THRB 105 −1.417 43.864 4.378 1.00 18.87 B ATOM 5036 OG1 THR B 105 −1.05744.037 5.760 1.00 20.45 B ATOM 5037 CG2 THR B 105 −2.846 44.359 4.0711.00 20.37 B ATOM 5038 C THR B 105 −2.340 41.936 3.198 1.00 18.41 B ATOM5039 O THR B 105 −3.530 41.924 3.494 1.00 17.77 B ATOM 5040 N ASN B 106−1.850 41.411 2.084 1.00 19.83 B ATOM 5041 CA ASN B 106 −2.591 40.7520.989 1.00 20.60 B ATOM 5042 CB ASN B 106 −1.677 40.408 −0.153 1.0022.84 B ATOM 5043 CG ASN B 106 −1.291 41.599 −0.828 1.00 25.27 B ATOM5044 OD1 ASN B 106 −0.415 41.603 −1.755 1.00 29.95 B ATOM 5045 ND2 ASN B106 −1.956 42.716 −0.429 1.00 26.57 B ATOM 5046 C ASN B 106 −3.18639.519 1.308 1.00 19.37 B ATOM 5047 O ASN B 106 −2.591 38.472 1.015 1.0020.06 B ATOM 5048 N PHE B 107 −4.361 39.588 1.860 1.00 18.63 B ATOM 5049CA PHE B 107 −4.939 38.302 2.073 1.00 19.14 B ATOM 5050 CB PHE B 107−5.722 38.268 3.370 1.00 16.66 B ATOM 5051 CG PHE B 107 −6.459 37.0043.569 1.00 15.24 B ATOM 5052 CD1 PHE B 107 −5.789 35.850 3.878 1.0016.36 B ATOM 5053 CD2 PHE B 107 −7.818 36.987 3.495 1.00 14.04 B ATOM5054 CE1 PHE B 107 −6.482 34.699 4.136 1.00 17.20 B ATOM 5055 CE2 PHE B107 −8.498 35.901 3.732 1.00 14.67 B ATOM 5056 CZ PHE B 107 −7.84134.727 4.068 1.00 17.22 B ATOM 5057 C PHE B 107 −5.812 37.931 0.827 1.0017.52 B ATOM 5058 O PHE B 107 −6.674 38.703 0.363 1.00 18.26 B ATOM 5059N GLN B 108 −5.555 36.759 0.303 1.00 17.47 B ATOM 5060 CA GLN B 108−6.404 36.231 −0.752 1.00 19.69 B ATOM 5061 CB GLN B 108 −5.566 35.884−1.980 1.00 18.56 B ATOM 5062 CG GLN B 108 −4.773 37.046 −2.468 1.0018.77 B ATOM 5063 CD GLN B 108 −5.606 38.172 −3.091 1.00 19.09 B ATOM5064 OE1 GLN B 108 −5.160 39.296 −3.150 1.00 19.82 B ATOM 5065 NE2 GLN B108 −6.798 37.878 −3.563 1.00 18.38 B ATOM 5066 C GLN B 108 −7.08234.927 −0.333 1.00 18.56 B ATOM 5067 O GLN B 108 −6.378 33.930 −0.4211.00 19.40 B ATOM 5068 N LYS B 109 −8.362 34.907 0.042 1.00 17.49 B ATOM5069 CA LYS B 109 −8.996 33.667 0.501 1.00 16.85 B ATOM 5070 CB LYS B109 −10.477 34.012 0.856 1.00 19.46 B ATOM 5071 CG LYS B 109 −11.47533.372 −0.072 1.00 21.61 B ATOM 5072 CD LYS B 109 −13.031 33.763 0.1691.00 23.95 B ATOM 5073 CE LYS B 109 −13.721 33.105 1.476 1.00 24.08 BATOM 5074 NZ LYS B 109 −15.170 33.196 1.264 1.00 21.40 B ATOM 5075 C LYSB 109 −8.854 32.571 −0.669 1.00 15.89 B ATOM 5076 O LYS B 109 −8.61731.299 −0.494 1.00 12.35 B ATOM 5077 N ARG B 110 −8.880 33.097 −1.8911.00 14.60 B ATOM 5078 CA ARG B 110 −8.815 32.177 −2.990 1.00 15.89 BATOM 5079 CB ARG B 110 −9.346 32.799 −4.238 1.00 16.83 B ATOM 5080 CGARG B 110 −10.980 32.521 −4.137 1.00 21.24 B ATOM 5081 CD ARG B 110−11.879 33.539 −3.202 1.00 21.02 B ATOM 5082 NE ARG B 110 −13.312 33.170−3.113 1.00 23.25 B ATOM 5083 CZ ARG B 110 −13.784 32.069 −2.476 1.0024.79 B ATOM 5084 NH1 ARG B 110 −12.865 31.223 −1.885 1.00 25.25 B ATOM5085 NH2 ARG B 110 −15.143 31.803 −2.399 1.00 23.68 B ATOM 5086 C ARG B110 −7.557 31.368 −3.194 1.00 17.11 B ATOM 5087 O ARG B 110 −7.59130.318 −3.873 1.00 16.11 B ATOM 5088 N LEU B 111 −6.519 31.758 −2.4451.00 17.17 B ATOM 5089 CA LEU B 111 −5.169 31.137 −2.476 1.00 17.26 BATOM 5090 CB LEU B 111 −4.036 32.167 −2.342 1.00 18.20 B ATOM 5091 CGLEU B 111 −4.060 33.214 −3.474 1.00 19.41 B ATOM 5092 CD1 LEU B 111−2.899 34.138 −3.310 1.00 17.58 B ATOM 5093 CD2 LEU B 111 −3.994 32.545−4.902 1.00 17.72 B ATOM 5094 C LEU B 111 −4.982 30.128 −1.408 1.0018.04 B ATOM 5095 O LEU B 111 −3.982 29.404 −1.374 1.00 17.35 B ATOM5096 N PHE B 112 −5.943 30.109 −0.478 1.00 17.83 B ATOM 5097 CA PHE B112 −5.926 29.104 0.636 1.00 16.42 B ATOM 5098 CB PHE B 112 −6.47029.684 1.927 1.00 17.10 B ATOM 5099 CG PHE B 112 −5.533 30.601 2.5821.00 16.68 B ATOM 5100 CD1 PHE B 112 −5.257 31.854 2.041 1.00 16.52 BATOM 5101 CD2 PHE B 112 −4.898 30.170 3.763 1.00 16.97 B ATOM 5102 CE1PHE B 112 −4.361 32.661 2.678 1.00 16.57 B ATOM 5103 CE2 PHE B 112−4.002 30.918 4.418 1.00 15.70 B ATOM 5104 CZ PHE B 112 −3.725 32.1963.871 1.00 17.79 B ATOM 5105 C PHE B 112 −6.747 27.838 0.338 1.00 17.05B ATOM 5106 O PHE B 112 −7.789 27.846 −0.320 1.00 15.97 B ATOM 5107 NTHR B 113 −6.246 26.745 0.853 1.00 17.20 B ATOM 5108 CA THR B 113 −6.83225.447 0.690 1.00 16.84 B ATOM 5109 CB THR B 113 −5.730 24.379 0.3381.00 17.57 B ATOM 5110 OG1 THR B 113 −5.171 24.614 −0.933 1.00 19.95 BATOM 5111 CG2 THR B 113 −6.232 23.039 0.358 1.00 15.25 B ATOM 5112 C THRB 113 −7.414 25.029 2.038 1.00 17.62 B ATOM 5113 O THR B 113 −6.80525.140 3.131 1.00 18.46 B ATOM 5114 N LYS B 114 −8.571 24.439 1.970 1.0017.70 B ATOM 5115 CA LYS B 114 −9.197 24.006 3.206 1.00 17.47 B ATOM5116 CB LYS B 114 −10.742 23.752 3.006 1.00 16.74 B ATOM 5117 CG LYS B114 −11.429 23.132 4.219 1.00 16.56 B ATOM 5118 CD LYS B 114 −12.95923.310 4.316 1.00 16.18 B ATOM 5119 CE LYS B 114 −13.512 22.429 5.4741.00 15.87 B ATOM 5120 NZ LYS B 114 −15.013 22.221 5.628 1.00 13.84 BATOM 5121 C LYS B 114 −8.474 22.801 3.712 1.00 16.93 B ATOM 5122 O LYS B114 −8.117 21.927 2.911 1.00 17.05 B ATOM 5123 N ILE B 115 −8.176 22.7865.013 1.00 16.93 B ATOM 5124 CA ILE B 115 −7.564 21.598 5.584 1.00 16.66B ATOM 5125 CB ILE B 115 −6.564 21.876 6.713 1.00 16.31 B ATOM 5126 CG2ILE B 115 −6.257 20.522 7.445 1.00 13.14 B ATOM 5127 CG1 ILE B 115−5.379 22.621 6.055 1.00 16.88 B ATOM 5128 CD1 ILE B 115 −4.255 23.1046.829 1.00 15.62 B ATOM 5129 C ILE B 115 −8.665 20.620 6.087 1.00 17.02B ATOM 5130 O ILE B 115 −8.644 19.366 5.714 1.00 16.82 B ATOM 5131 N ASPB 116 −9.622 21.174 6.866 1.00 16.05 B ATOM 5132 CA ASP B 116 −10.65820.382 7.443 1.00 14.70 B ATOM 5133 CB ASP B 116 −10.054 19.448 8.5311.00 13.68 B ATOM 5134 CG ASP B 116 −11.029 18.293 8.978 1.00 12.42 BATOM 5135 OD1 ASP B 116 −10.764 17.458 9.872 1.00 11.35 B ATOM 5136 OD2ASP B 116 −12.081 18.225 8.399 1.00 9.98 B ATOM 5137 C ASP B 116 −11.67321.260 8.092 1.00 16.52 B ATOM 5138 O ASP B 116 −11.486 22.455 8.2331.00 16.01 B ATOM 5139 N THR B 117 −12.796 20.659 8.485 1.00 16.77 BATOM 5140 CA THR B 117 −13.804 21.353 9.261 1.00 15.35 B ATOM 5141 CBTHR B 117 −15.182 20.745 8.943 1.00 17.06 B ATOM 5142 OG1 THR B 117−15.518 21.037 7.562 1.00 19.25 B ATOM 5143 CG2 THR B 117 −16.260 21.2289.920 1.00 13.11 B ATOM 5144 C THR B 117 −13.418 20.987 10.736 1.0016.54 B ATOM 5145 O THR B 117 −13.202 19.763 11.088 1.00 14.72 B ATOM5146 N ILE B 118 −13.293 22.042 11.601 1.00 17.37 B ATOM 5147 CA ILE B118 −13.006 21.852 13.055 1.00 16.98 B ATOM 5148 CB ILE B 118 −12.08522.942 13.548 1.00 17.48 B ATOM 5149 CG2 ILE B 118 −11.748 22.697 15.0501.00 15.79 B ATOM 5150 CG1 ILE B 118 −10.887 23.032 12.582 1.00 17.41 BATOM 5151 CD1 ILE B 118 −10.165 21.768 12.321 1.00 15.94 B ATOM 5152 CILE B 118 −14.368 21.806 13.825 1.00 16.93 B ATOM 5153 O ILE B 118−15.206 22.668 13.674 1.00 17.25 B ATOM 5154 N ALA B 119 −14.554 20.77314.614 1.00 16.02 B ATOM 5155 CA ALA B 119 −15.778 20.566 15.307 1.0015.24 B ATOM 5156 CB ALA B 119 −16.511 19.450 14.673 1.00 12.04 B ATOM5157 C ALA B 119 −15.485 20.212 16.794 1.00 16.10 B ATOM 5158 O ALA B119 −14.612 19.371 17.105 1.00 15.69 B ATOM 5159 N PRO B 120 −16.24520.805 17.737 1.00 16.19 B ATOM 5160 CD PRO B 120 −17.319 21.806 17.5791.00 16.59 B ATOM 5161 CA PRO B 120 −16.016 20.507 19.168 1.00 17.05 BATOM 5162 CB PRO B 120 −16.719 21.646 19.876 1.00 17.65 B ATOM 5163 CGPRO B 120 −17.964 21.829 18.969 1.00 17.14 B ATOM 5164 C PRO B 120−16.648 19.203 19.603 1.00 18.92 B ATOM 5165 O PRO B 120 −17.813 18.94219.301 1.00 19.34 B ATOM 5166 N ASP B 121 −15.920 18.405 20.349 1.0018.94 B ATOM 5167 CA ASP B 121 −16.454 17.189 20.855 1.00 18.21 B ATOM5168 CB ASP B 121 −15.337 16.414 21.476 1.00 20.64 B ATOM 5169 CG ASP B121 −13.999 16.565 20.669 1.00 23.80 B ATOM 5170 OD1 ASP B 121 −13.40617.852 20.492 1.00 25.52 B ATOM 5171 OD2 ASP B 121 −13.607 15.401 20.2501.00 21.30 B ATOM 5172 C ASP B 121 −17.430 17.573 21.957 1.00 18.43 BATOM 5173 O ASP B 121 −18.282 16.788 22.357 1.00 18.55 B ATOM 5174 N GLUB 122 −17.254 18.772 22.499 1.00 18.17 B ATOM 5175 CA GLU B 122 −18.05619.330 23.588 1.00 16.27 B ATOM 5176 CB GLU B 122 −17.347 19.159 24.9191.00 16.98 B ATOM 5177 CG GLU B 122 −17.260 17.720 25.391 1.00 18.67 BATOM 5178 CD GLU B 122 −16.819 17.567 26.832 1.00 19.76 B ATOM 5179 OE1GLU B 122 −15.562 17.684 27.091 1.00 19.83 B ATOM 5180 OE2 GLU B 122−17.747 17.311 27.675 1.00 20.93 B ATOM 5181 C GLU B 122 −18.387 20.79723.398 1.00 15.94 B ATOM 5182 O GLU B 122 −17.581 21.745 23.468 1.0015.41 B ATOM 5183 N ILE B 123 −19.677 20.943 23.223 1.00 16.20 B ATOM5184 CA ILE B 123 −20.284 22.227 23.011 1.00 16.27 B ATOM 5185 CB ILE B123 −21.568 21.950 22.337 1.00 17.11 B ATOM 5186 CG2 ILE B 123 −22.38221.029 23.212 1.00 15.78 B ATOM 5187 CG1 ILE B 123 −22.371 23.189 22.2081.00 18.61 B ATOM 5188 CD1 ILE B 123 −23.754 22.842 21.672 1.00 21.90 BATOM 5189 C ILE B 123 −20.493 22.789 24.431 1.00 15.78 B ATOM 5190 O ILEB 123 −20.795 22.044 25.350 1.00 15.60 B ATOM 5191 N THR B 124 −20.38924.079 24.611 1.00 15.21 B ATOM 5192 CA THR B 124 −20.562 24.535 25.9731.00 16.43 B ATOM 5193 CB THR B 124 −19.636 25.781 26.256 1.00 15.84 BATOM 5194 OG1 THR B 124 −18.249 25.385 26.278 1.00 13.22 B ATOM 5195 CG2THR B 124 −20.067 26.477 27.609 1.00 17.27 B ATOM 5196 C THR B 124−21.998 24.924 26.098 1.00 15.83 B ATOM 5197 O THR B 124 −22.413 25.81225.352 1.00 15.69 B ATOM 5198 N VAL B 125 −22.771 24.285 26.989 1.0015.33 B ATOM 5199 CA VAL B 125 −24.191 24.721 27.122 1.00 16.47 B ATOM5200 CB VAL B 125 −25.183 23.595 27.521 1.00 17.07 B ATOM 5201 CG1 VAL B125 −25.343 22.564 26.354 1.00 16.08 B ATOM 5202 CG2 VAL B 125 −24.76922.966 28.790 1.00 17.79 B ATOM 5203 C VAL B 125 −24.483 25.931 28.0371.00 16.44 B ATOM 5204 O VAL B 125 −23.595 26.402 28.773 1.00 16.07 BATOM 5205 N SER B 126 −25.669 26.480 27.925 1.00 15.05 B ATOM 5206 CASER B 126 −25.974 27.654 28.746 1.00 15.14 B ATOM 5207 CB SER B 126−27.406 28.131 28.517 1.00 14.60 B ATOM 5208 OG SER B 126 −28.068 28.30729.741 1.00 15.76 B ATOM 5209 C SER B 126 −25.767 27.476 30.245 1.0015.82 B ATOM 5210 O SER B 126 −25.308 28.385 30.921 1.00 15.53 B ATOM5211 N SER B 127 −26.067 26.316 30.794 1.00 16.06 B ATOM 5212 CA SER B127 −25.877 26.261 32.182 1.00 17.17 B ATOM 5213 CB SER B 127 −26.72025.195 32.774 1.00 16.50 B ATOM 5214 OG SER B 127 −26.134 23.961 32.4651.00 17.74 B ATOM 5215 C SER B 127 −24.417 26.001 32.530 1.00 18.97 BATOM 5216 O SER B 127 −24.054 26.038 33.728 1.00 20.17 B ATOM 5217 N ASPB 128 −23.608 25.637 31.515 1.00 19.12 B ATOM 5218 CA ASP B 128 −22.16925.428 31.681 1.00 18.68 B ATOM 5219 CB ASP B 128 −21.512 24.958 30.3611.00 18.14 B ATOM 5220 CG ASP B 128 −21.573 23.509 30.175 1.00 17.31 BATOM 5221 OD1 ASP B 128 −21.305 23.105 28.956 1.00 17.10 B ATOM 5222 OD2ASP B 128 −21.896 22.830 31.223 1.00 14.81 B ATOM 5223 C ASP B 128−21.447 26.716 32.153 1.00 18.03 B ATOM 5224 O ASP B 128 −20.466 26.60832.930 1.00 17.44 B ATOM 5225 N PHE B 129 −21.836 27.892 31.646 1.0018.38 B ATOM 5226 CA PHE B 129 −21.200 29.123 32.187 1.00 20.97 B ATOM5227 CB PHE B 129 −21.712 30.304 31.432 1.00 19.70 B ATOM 5228 CG PHE B129 −21.386 30.221 30.022 1.00 19.92 B ATOM 5229 CD1 PHE B 129 −22.26729.580 29.123 1.00 19.64 B ATOM 5230 CD2 PHE B 129 −20.105 30.631 29.5841.00 20.27 B ATOM 5231 CE1 PHE B 129 −21.858 29.320 27.742 1.00 19.36 BATOM 5232 CE2 PHE B 129 −19.667 30.389 28.248 1.00 19.46 B ATOM 5233 CZPHE B 129 −20.542 29.723 27.316 1.00 19.73 B ATOM 5234 C PHE B 129−21.805 29.037 33.576 1.00 20.89 B ATOM 5235 O PHE B 129 −22.275 27.97933.856 1.00 24.07 B ATOM 5236 N GLU B 130 −21.819 30.009 34.455 1.0020.17 B ATOM 5237 CA GLU B 130 −22.545 29.815 35.759 1.00 18.11 B ATOM5238 CB GLU B 130 −24.027 29.554 35.519 1.00 17.97 B ATOM 5239 CG GLU B130 −25.041 30.667 35.618 1.00 18.72 B ATOM 5240 CD GLU B 130 −26.42730.089 35.921 1.00 20.80 B ATOM 5241 OE1 GLU B 130 −27.194 30.956 36.4381.00 21.32 B ATOM 5242 OE2 GLU B 130 −26.753 28.806 35.654 1.00 20.07 BATOM 5243 C GLU B 130 −21.927 28.646 36.513 1.00 17.80 B ATOM 5244 O GLUB 130 −21.408 28.813 37.578 1.00 17.90 B ATOM 5245 N ALA B 131 −22.02027.437 36.021 1.00 16.81 B ATOM 5246 CA ALA B 131 −21.298 26.346 36.6071.00 17.21 B ATOM 5247 CB ALA B 131 −21.688 25.115 35.926 1.00 15.26 BATOM 5248 C ALA B 131 −19.899 26.825 36.077 1.00 18.68 B ATOM 5249 O ALAB 131 −19.794 27.814 35.185 1.00 20.46 B ATOM 5250 N ARG B 132 −18.80026.244 36.490 1.00 18.41 B ATOM 5251 CA ARG B 132 −17.663 26.886 35.8391.00 18.56 B ATOM 5252 CB ARG B 132 −16.627 27.432 36.873 1.00 19.13 BATOM 5253 CG ARG B 132 −16.605 29.079 37.036 1.00 20.34 B ATOM 5254 CDARG B 132 −17.874 29.822 37.020 1.00 16.61 B ATOM 5255 NE ARG B 132−17.717 31.200 37.359 1.00 14.34 B ATOM 5256 CZ ARG B 132 −18.437 32.21736.852 1.00 13.69 B ATOM 5257 NH1 ARG B 132 −19.375 31.975 35.889 1.0011.05 B ATOM 5258 NH2 ARG B 132 −18.290 33.467 37.376 1.00 10.66 B ATOM5259 C ARG B 132 −17.125 25.765 35.016 1.00 19.07 B ATOM 5260 O ARG B132 −15.979 25.346 35.156 1.00 17.92 B ATOM 5261 N HIS B 133 −17.99225.282 34.130 1.00 18.80 B ATOM 5262 CA HIS B 133 −17.644 24.146 33.3511.00 19.87 B ATOM 5263 CB HIS B 133 −18.696 23.073 33.598 1.00 21.82 BATOM 5264 CG HIS B 133 −18.665 22.467 34.977 1.00 23.90 B ATOM 5265 CD2HIS B 133 −18.081 22.871 36.153 1.00 24.98 B ATOM 5266 ND1 HIS B 133−19.289 21.266 35.265 1.00 24.94 B ATOM 5267 CE1 HIS B 133 −19.09320.953 36.556 1.00 25.41 B ATOM 5268 NE2 HIS B 133 −18.363 21.909 37.1221.00 24.84 B ATOM 5269 C HIS B 133 −17.562 24.444 31.864 1.00 21.12 BATOM 5270 O HIS B 133 −18.173 23.755 31.049 1.00 20.74 B ATOM 5271 N VALB 134 −16.832 25.463 31.454 1.00 21.26 B ATOM 5272 CA VAL B 134 −16.80925.755 30.012 1.00 19.73 B ATOM 5273 CB VAL B 134 −16.172 27.078 29.7731.00 20.41 B ATOM 5274 CG1 VAL B 134 −16.186 27.387 28.305 1.00 19.64 BATOM 5275 CG2 VAL B 134 −16.959 28.111 30.535 1.00 18.82 B ATOM 5276 CVAL B 134 −15.963 24.627 29.403 1.00 21.59 B ATOM 5277 O VAL B 134−14.970 24.164 30.028 1.00 22.11 B ATOM 5278 N LYS B 135 −16.342 24.15228.224 1.00 20.69 B ATOM 5279 CA LYS B 135 −15.643 23.033 27.600 1.0018.10 B ATOM 5280 CB LYS B 135 −16.654 22.079 27.001 1.00 18.62 B ATOM5281 CG LYS B 135 −17.918 21.871 27.780 1.00 17.47 B ATOM 5282 CD LYS B135 −17.588 21.210 29.099 1.00 20.44 B ATOM 5283 CE LYS B 135 −18.87420.600 29.715 1.00 20.62 B ATOM 5284 NZ LYS B 135 −18.599 20.214 31.1161.00 23.73 B ATOM 5285 C LYS B 135 −14.667 23.433 26.544 1.00 17.97 BATOM 5286 O LYS B 135 −15.010 24.089 25.508 1.00 18.77 B ATOM 5287 N LEUB 136 −13.422 23.059 26.858 1.00 17.35 B ATOM 5288 CA LEU B 136 −12.20123.317 26.076 1.00 15.80 B ATOM 5289 CB LEU B 136 −11.107 23.694 27.0661.00 15.35 B ATOM 5290 CG LEU B 136 −9.845 24.233 26.446 1.00 14.92 BATOM 5291 CD1 LEU B 136 −9.199 23.060 25.743 1.00 17.73 B ATOM 5292 CD2LEU B 136 −10.104 25.343 25.510 1.00 11.48 B ATOM 5293 C LEU B 136−11.859 22.074 25.221 1.00 15.41 B ATOM 5294 O LEU B 136 −11.508 21.08725.724 1.00 15.64 B ATOM 5295 N ASN B 137 −11.948 22.184 23.927 1.0015.88 B ATOM 5296 CA ASN B 137 −11.723 21.133 23.001 1.00 16.42 B ATOM5297 CB ASN B 137 −12.661 21.297 21.883 1.00 16.31 B ATOM 5298 CG ASN B137 −14.076 21.109 22.321 1.00 17.79 B ATOM 5299 OD1 ASN B 137 −14.53819.946 22.598 1.00 17.36 B ATOM 5300 ND2 ASN B 137 −14.798 22.241 22.4111.00 16.17 B ATOM 5301 C ASN B 137 −10.356 21.204 22.441 1.00 16.76 BATOM 5302 O ASN B 137 −9.830 22.301 22.311 1.00 18.09 B ATOM 5303 N VALB 138 −9.748 20.070 22.119 1.00 16.82 B ATOM 5304 CA VAL B 138 −8.41120.131 21.536 1.00 16.47 B ATOM 5305 CB VAL B 138 −7.350 19.349 22.3781.00 15.77 B ATOM 5306 CG1 VAL B 138 −6.054 19.460 21.672 1.00 15.93 BATOM 5307 CG2 VAL B 138 −7.215 19.909 23.774 1.00 14.29 B ATOM 5308 CVAL B 138 −8.496 19.463 20.167 1.00 17.25 B ATOM 5309 O VAL B 138 −8.93218.373 20.030 1.00 18.38 B ATOM 5310 N GLU B 139 −8.104 20.083 19.1101.00 17.36 B ATOM 5311 CA GLU B 139 −8.183 19.335 17.883 1.00 16.66 BATOM 5312 CB GLU B 139 −9.327 19.873 17.018 1.00 16.47 B ATOM 5313 CGGLU B 139 −10.777 19.462 17.320 1.00 15.21 B ATOM 5314 CD GLU B 139−10.978 18.005 17.296 1.00 14.25 B ATOM 5315 OE1 GLU B 139 −10.20417.302 16.754 1.00 15.84 B ATOM 5316 OE2 GLU B 139 −11.905 17.479 17.8311.00 15.49 B ATOM 5317 C GLU B 139 −6.858 19.504 17.156 1.00 16.69 BATOM 5318 O GLU B 139 −6.329 20.622 16.980 1.00 16.31 B ATOM 5319 N GLUB 140 −6.265 18.393 16.794 1.00 16.98 B ATOM 5320 CA GLU B 140 −5.06718.499 15.978 1.00 17.36 B ATOM 5321 CB GLU B 140 −3.961 17.694 16.5861.00 19.21 B ATOM 5322 CG GLU B 140 −2.604 18.039 15.925 1.00 21.45 BATOM 5323 CD GLU B 140 −1.329 17.695 16.850 1.00 24.11 B ATOM 5324 OE1GLU B 140 −1.083 16.439 17.162 1.00 24.27 B ATOM 5325 OE2 GLU B 140−0.565 18.702 17.248 1.00 24.40 B ATOM 5326 C GLU B 140 −5.258 18.05414.490 1.00 16.73 B ATOM 5327 O GLU B 140 −6.002 17.124 14.180 1.0015.95 B ATOM 5328 N ARG B 141 −4.634 18.773 13.563 1.00 16.19 B ATOM5329 CA ARG B 141 −4.697 18.328 12.157 1.00 16.28 B ATOM 5330 CB ARG B141 −5.593 19.186 11.300 1.00 15.03 B ATOM 5331 CG ARG B 141 −7.09419.307 11.716 1.00 13.64 B ATOM 5332 CD ARG B 141 −7.997 18.224 11.2141.00 13.47 B ATOM 5333 NE ARG B 141 −8.603 17.627 12.393 1.00 14.13 BATOM 5334 CZ ARG B 141 −9.776 17.988 12.877 1.00 15.37 B ATOM 5335 NH1ARG B 141 −10.562 18.914 12.348 1.00 19.59 B ATOM 5336 NH2 ARG B 141−10.149 17.508 13.950 1.00 15.27 B ATOM 5337 C ARG B 141 −3.298 18.45611.624 1.00 16.92 B ATOM 5338 O ARG B 141 −2.420 18.979 12.262 1.0017.24 B ATOM 5339 N SER B 142 −3.063 17.993 10.445 1.00 17.90 B ATOM5340 CA SER B 142 −1.735 18.135 9.951 1.00 19.10 B ATOM 5341 CB SER B142 −0.892 16.941 10.367 1.00 17.92 B ATOM 5342 OG SER B 142 −1.13215.972 9.398 1.00 20.94 B ATOM 5343 C SER B 142 −1.802 18.284 8.434 1.0018.88 B ATOM 5344 O SER B 142 −2.835 17.945 7.807 1.00 20.40 B ATOM 5345N VAL B 143 −0.744 18.808 7.836 1.00 18.94 B ATOM 5346 CA VAL B 143−0.763 18.978 6.414 1.00 20.12 B ATOM 5347 CB VAL B 143 −1.569 20.3496.013 1.00 19.94 B ATOM 5348 CG1 VAL B 143 −0.930 21.571 6.565 1.0020.30 B ATOM 5349 CG2 VAL B 143 −1.670 20.487 4.574 1.00 20.41 B ATOM5350 C VAL B 143 0.612 18.878 5.864 1.00 18.60 B ATOM 5351 O VAL B 1431.553 18.922 6.615 1.00 17.93 B ATOM 5352 N GLY B 144 0.697 18.653 4.5621.00 19.10 B ATOM 5353 CA GLY B 144 1.980 18.510 3.891 1.00 19.68 B ATOM5354 C GLY B 144 1.977 17.485 2.764 1.00 19.29 B ATOM 5355 O GLY B 1440.922 16.866 2.542 1.00 20.60 B ATOM 5356 N PRO B 145 3.136 17.243 2.0731.00 21.01 B ATOM 5357 CD PRO B 145 3.430 16.086 1.163 1.00 18.66 B ATOM5358 CA PRO B 145 4.373 17.959 2.417 1.00 17.49 B ATOM 5359 CB PRO B 1455.478 17.155 1.712 1.00 17.98 B ATOM 5360 CG PRO B 145 4.870 16.4760.630 1.00 17.35 B ATOM 5361 C PRO B 145 4.377 19.341 2.011 1.00 17.21 BATOM 5362 O PRO B 145 3.834 19.657 1.023 1.00 17.81 B ATOM 5363 N LEU B146 4.993 20.187 2.846 1.00 18.84 B ATOM 5364 CA LEU B 146 5.129 21.6162.502 1.00 18.78 B ATOM 5365 CB LEU B 146 5.272 22.454 3.791 1.00 19.59B ATOM 5366 CG LEU B 146 3.933 22.973 4.380 1.00 19.90 B ATOM 5367 CD1LEU B 146 2.956 21.888 4.372 1.00 19.96 B ATOM 5368 CD2 LEU B 146 4.14823.502 5.909 1.00 20.53 B ATOM 5369 C LEU B 146 6.408 21.621 1.687 1.0017.77 B ATOM 5370 O LEU B 146 7.291 20.713 1.816 1.00 17.80 B ATOM 5371N THR B 147 6.524 22.662 0.875 1.00 17.34 B ATOM 5372 CA THR B 147 7.75222.838 0.062 1.00 17.24 B ATOM 5373 CB THR B 147 7.588 22.231 −1.3971.00 15.58 B ATOM 5374 OG1 THR B 147 6.690 23.044 −2.167 1.00 12.89 BATOM 5375 CG2 THR B 147 7.159 20.825 −1.344 1.00 14.21 B ATOM 5376 C THRB 147 8.305 24.258 −0.193 1.00 17.33 B ATOM 5377 O THR B 147 9.44224.377 −0.710 1.00 18.43 B ATOM 5378 N ARG B 148 7.488 25.281 0.001 1.0017.27 B ATOM 5379 CA ARG B 148 7.918 26.664 −0.242 1.00 17.86 B ATOM5380 CB ARO B 148 6.754 27.594 −0.611 1.00 18.33 B ATOM 5381 CG ARG B148 5.554 26.989 −1.296 1.00 19.06 B ATOM 5382 CD ARG B 148 5.801 26.875−2.750 1.00 22.60 B ATOM 5383 NE ARG B 148 6.728 25.771 −3.111 1.0024.69 B ATOM 5384 CZ ARG B 148 7.819 25.948 −3.930 1.00 26.31 B ATOM5385 NH1 ARG B 148 8.099 27.163 −4.494 1.00 21.81 B ATOM 5386 NH2 ARG B148 8.733 24.935 −4.080 1.00 26.44 B ATOM 5387 C ARG B 148 8.616 27.2921.008 1.00 17.51 B ATOM 5388 O ARG B 148 8.639 26.716 2.106 1.00 18.60 BATOM 5389 N LYS B 149 9.207 28.452 0.822 1.00 17.08 B ATOM 5390 CA LYS B149 9.944 29.189 1.878 1.00 17.17 B ATOM 5391 CB LYS B 149 10.339 30.5461.332 1.00 16.42 B ATOM 5392 CG LYS B 149 11.695 30.995 1.744 1.00 17.93B ATOM 5393 CD LYS B 149 11.975 32.460 1.275 1.00 19.98 B ATOM 5394 CELYS B 149 13.057 33.185 2.117 1.00 19.89 B ATOM 5395 NZ LYS B 149 12.64534.592 2.753 1.00 22.50 B ATOM 5396 C LYS B 149 9.081 29.333 3.120 1.0017.33 B ATOM 5397 O LYS B 149 9.510 29.093 4.199 1.00 17.30 B ATOM 5398N GLY B 150 7.813 29.637 2.914 1.00 18.69 B ATOM 5399 CA GLY B 150 6.89329.804 4.021 1.00 18.90 B ATOM 5400 C GLY B 150 5.399 29.428 3.824 1.0018.31 B ATOM 5401 O GLY B 150 4.938 28.890 2.751 1.00 18.68 B ATOM 5402N PHE B 151 4.627 29.760 4.877 1.00 18.11 B ATOM 5403 CA PHE B 151 3.23129.413 4.935 1.00 16.78 B ATOM 5404 CB PHE B 151 3.088 27.904 5.163 1.0017.44 B ATOM 5405 CG PHE B 151 3.382 27.482 6.567 1.00 17.11 B ATOM 5406CD1 PHE B 151 2.379 27.426 7.534 1.00 16.68 B ATOM 5407 CD2 PHE B 1514.665 27.100 6.953 1.00 17.64 B ATOM 5408 CE1 PHE B 151 2.654 27.0008.808 1.00 14.19 B ATOM 5409 CE2 PHE B 151 4.918 26.652 8.295 1.00 13.97B ATOM 5410 CZ PHE B 151 3.933 26.608 9.164 1.00 12.62 B ATOM 5411 C PHEB 151 2.423 30.135 5.945 1.00 15.60 B ATOM 5412 O PHE B 151 2.903 30.5266.914 1.00 15.64 B ATOM 5413 N TYR B 152 1.168 30.282 5.627 1.00 15.57 BATOM 5414 CA TYR B 152 0.163 30.858 6.438 1.00 15.81 B ATOM 5415 CB TYRB 152 −0.565 31.926 5.686 1.00 15.32 B ATOM 5416 CG TYR B 152 0.22433.046 5.302 1.00 16.12 B ATOM 5417 CD1 TYR B 152 0.831 33.092 4.0721.00 15.82 B ATOM 5418 CE1 TYR B 152 1.587 34.221 3.674 1.00 17.14 BATOM 5419 CD2 TYR B 152 0.356 34.137 6.167 1.00 16.49 B ATOM 5420 CE2TYR B 152 1.067 35.247 5.807 1.00 16.67 B ATOM 5421 CZ TYR B 152 1.70635.310 4.563 1.00 17.34 B ATOM 5422 OH TYR B 152 2.492 36.458 4.294 1.0018.36 B ATOM 5423 C TYR B 152 −0.933 29.816 6.876 1.00 15.64 B ATOM 5424O TYR B 152 −1.247 28.826 6.186 1.00 16.19 B ATOM 5425 N LEU B 153−1.544 30.111 8.032 1.00 15.05 B ATOM 5426 CA LEU B 153 −2.660 29.3478.556 1.00 14.67 B ATOM 5427 CB LEU B 153 −2.332 28.764 9.874 1.00 13.90B ATOM 5428 CG LEU B 153 −2.191 27.269 9.922 1.00 13.61 B ATOM 5429 CD1LEU B 153 −1.370 26.740 8.897 1.00 13.27 B ATOM 5430 CD2 LEU B 153−1.719 26.902 11.246 1.00 14.00 B ATOM 5431 C LEU B 153 −3.789 30.3548.671 1.00 14.95 B ATOM 5432 O LEU B 153 −3.583 31.576 8.903 1.00 14.79B ATOM 5433 N ALA B 154 −4.985 29.876 8.398 1.00 14.73 B ATOM 5434 CAALA B 154 −6.083 30.774 8.489 1.00 15.28 B ATOM 5435 CB ALA B 154 −6.28231.529 7.166 1.00 14.40 B ATOM 5436 C ALA B 154 −7.382 30.106 8.953 1.0015.82 B ATOM 5437 O ALA B 154 −7.632 28.972 8.640 1.00 16.05 B ATOM 5438N PHE B 155 −8.215 30.876 9.668 1.00 16.13 B ATOM 5439 CA PHE B 155−9.468 30.391 10.200 1.00 15.47 B ATOM 5440 CB PHE B 155 −9.451 30.38111.698 1.00 15.41 B ATOM 5441 CG PHE B 155 −8.182 29.835 12.296 1.0014.85 B ATOM 5442 CD1 PHE B 155 −6.972 30.589 12.260 1.00 15.26 B ATOM5443 CD2 PHE B 155 −8.177 28.569 12.859 1.00 13.36 B ATOM 5444 CE1 PHE B155 −5.843 30.049 12.760 1.00 15.00 B ATOM 5445 CE2 PHE B 155 −7.02928.012 13.364 1.00 14.50 B ATOM 5446 CZ PHE B 155 −5.861 28.709 13.3261.00 14.69 B ATOM 5447 C PHE B 155 −10.730 31.108 9.742 1.00 16.14 BATOM 5448 O PHE B 155 −10.925 32.340 9.911 1.00 15.30 B ATOM 5449 N GLNB 156 −11.603 30.282 9.133 1.00 15.86 B ATOM 5450 CA GLN B 156 −12.80030.816 8.669 1.00 15.64 B ATOM 5451 CB GLN B 156 −12.990 30.381 7.2921.00 16.47 B ATOM 5452 CG GLN B 156 −14.127 31.041 6.646 1.00 17.66 BATOM 5453 CD GLN B 156 −14.806 30.040 5.674 1.00 19.35 B ATOM 5454 OE1GLN B 156 −14.556 28.805 5.755 1.00 21.53 B ATOM 5455 NE2 GLN B 156−15.673 30.533 4.811 1.00 18.19 B ATOM 5456 C GLN B 156 −14.023 30.5569.561 1.00 15.50 B ATOM 5457 O GLN B 156 −14.419 29.422 9.900 1.00 15.53B ATOM 5458 N ASP B 157 −14.573 31.652 10.033 1.00 14.39 B ATOM 5459 CAASP B 157 −15.705 31.515 10.871 1.00 13.40 B ATOM 5460 CB ASP B 157−15.714 32.526 12.020 1.00 13.18 B ATOM 5461 CG ASP B 157 −17.097 32.74012.546 1.00 12.78 B ATOM 5462 OD1 ASP B 157 −17.648 33.815 12.379 1.0015.04 B ATOM 5463 OD2 ASP B 157 −17.694 31.840 13.061 1.00 9.81 B ATOM5464 C ASP B 157 −16.910 31.702 9.965 1.00 13.07 B ATOM 5465 O ASP B 157−17.033 32.648 9.196 1.00 8.80 B ATOM 5466 N ILE B 158 −17.836 30.78210.209 1.00 15.42 B ATOM 5467 CA ILE B 158 −19.009 30.664 9.400 1.0018.87 B ATOM 5468 CB ILE B 158 −18.976 29.214 8.836 1.00 20.10 B ATOM5469 CG2 ILE B 158 −19.961 28.291 9.293 1.00 19.47 B ATOM 5470 CG1 ILE B158 −19.107 29.401 7.409 1.00 21.36 B ATOM 5471 CD1 ILE B 158 −17.69629.886 6.837 1.00 21.75 B ATOM 5472 C ILE B 158 −20.275 31.074 10.0261.00 19.64 B ATOM 5473 O ILE B 158 −21.341 30.856 9.484 1.00 21.18 BATOM 5474 N GLY B 159 −20.165 31.767 11.163 1.00 19.33 B ATOM 5475 CAGLY B 159 −21.380 32.117 11.915 1.00 17.08 B ATOM 5476 C GLY B 159−21.523 31.333 13.242 1.00 15.47 B ATOM 5477 O GLY B 159 −22.647 31.15313.773 1.00 14.48 B ATOM 5478 N ALA B 160 −20.401 30.815 13.740 1.0014.27 B ATOM 5479 CA ALA B 160 −20.401 30.119 15.020 1.00 14.67 B ATOM5480 CB ALA B 160 −19.522 28.943 14.956 1.00 12.28 B ATOM 5481 C ALA B160 −19.956 31.160 16.173 1.00 14.43 B ATOM 5482 O ALA B 160 −19.75632.392 15.944 1.00 16.31 B ATOM 5483 N CYS B 161 −20.027 30.717 17.4111.00 14.52 B ATOM 5484 CA CYS B 161 −19.581 31.490 18.622 1.00 13.42 BATOM 5485 C CYS B 161 −18.414 30.661 19.150 1.00 12.18 B ATOM 5486 O CYSB 161 −18.548 29.745 19.930 1.00 10.07 B ATOM 5487 CB CYS B 161 −20.63831.534 19.719 1.00 15.19 B ATOM 5488 SG CYS B 161 −20.475 32.886 21.0591.00 18.03 B ATOM 5489 N VAL B 162 −17.243 31.009 18.666 1.00 12.41 BATOM 5490 CA VAL B 162 −16.057 30.307 18.998 1.00 12.71 B ATOM 5491 CBVAL B 162 −15.264 29.877 17.757 1.00 15.52 B ATOM 5492 CG1 VAL B 162−14.353 28.785 18.073 1.00 17.01 B ATOM 5493 CG2 VAL B 162 −16.14029.600 16.546 1.00 16.89 B ATOM 5494 C VAL B 162 −15.099 31.214 19.6691.00 12.25 B ATOM 5495 O VAL B 162 −15.045 32.427 19.391 1.00 9.22 BATOM 5496 N ALA B 163 −14.304 30.533 20.472 1.00 12.60 B ATOM 5497 CAALA B 163 −13.214 31.140 21.120 1.00 14.23 B ATOM 5498 CB ALA B 163−13.464 31.287 22.548 1.00 14.60 B ATOM 5499 C ALA B 163 −11.971 30.31020.873 1.00 14.42 B ATOM 5500 O ALA B 163 −11.774 29.253 21.429 1.0015.48 B ATOM 5501 N LEU B 164 −11.111 30.824 20.040 1.00 14.36 B ATOM5502 CA LEU B 164 −9.885 30.130 19.796 1.00 14.34 B ATOM 5503 CB LEU B164 −9.485 30.418 18.350 1.00 15.10 B ATOM 5504 CG LEU B 164 −8.35329.538 17.966 1.00 15.85 B ATOM 5505 CD1 LEU B 164 −8.630 28.067 18.0921.00 16.13 B ATOM 5506 CD2 LEU B 164 −8.136 29.885 16.547 1.00 17.53 BATOM 5507 C LEU B 164 −8.817 30.606 20.830 1.00 14.80 B ATOM 5508 O LEUB 164 −8.305 31.741 20.825 1.00 12.64 B ATOM 5509 N LEU B 165 −8.48729.688 21.712 1.00 16.26 B ATOM 5510 CA LEU B 165 −7.551 29.984 22.7491.00 17.14 B ATOM 5511 CB LEU B 165 −8.037 29.376 24.044 1.00 19.43 BATOM 5512 CG LEU B 165 −9.530 29.559 24.316 1.00 19.79 B ATOM 5513 CD1LEU B 165 −9.754 29.075 25.719 1.00 20.37 B ATOM 5514 CD2 LEU B 165−9.902 30.972 24.204 1.00 18.03 B ATOM 5515 C LEU B 165 −6.144 29.53822.582 1.00 18.15 B ATOM 5516 O LEU B 165 −5.307 29.840 23.442 1.0017.75 B ATOM 5517 N SER B 166 −5.825 28.855 21.505 1.00 17.73 B ATOM5518 CA SER B 166 −4.474 28.394 21.397 1.00 16.17 B ATOM 5519 CB SER B166 −4.219 27.309 22.426 1.00 14.98 B ATOM 5520 OG SER B 166 −3.02726.736 22.078 1.00 15.42 B ATOM 5521 C SER B 166 −4.304 27.827 20.0111.00 16.84 B ATOM 5522 O SER B 166 −5.247 27.173 19.395 1.00 17.31 BATOM 5523 N VAL B 167 −3.091 28.021 19.525 1.00 16.01 B ATOM 5524 CA VALB 167 −2.796 27.557 18.183 1.00 14.79 B ATOM 5525 CB VAL B 167 −2.92728.686 17.122 1.00 15.41 B ATOM 5526 CG1 VAL B 167 −2.492 28.139 15.8011.00 15.39 B ATOM 5527 CG2 VAL B 167 −4.323 29.203 17.021 1.00 12.61 BATOM 5528 C VAL B 167 −1.351 27.216 18.231 1.00 14.00 B ATOM 5529 O VALB 167 −0.546 28.117 18.252 1.00 11.09 B ATOM 5530 N ARG B 168 −1.07325.918 18.309 1.00 14.19 B ATOM 5531 CA ARG B 168 0.283 25.437 18.2541.00 15.80 B ATOM 5532 CB ARG B 168 0.649 24.444 19.341 1.00 16.65 BATOM 5533 CG ARG B 168 1.576 25.138 20.315 1.00 18.51 B ATOM 5534 CD ARGB 168 2.588 24.256 21.110 1.00 18.84 B ATOM 5535 NE ARG B 168 2.38722.845 20.873 1.00 19.58 B ATOM 5536 CZ ARG B 168 3.349 21.933 20.9241.00 20.14 B ATOM 5537 NH1 ARG B 168 4.593 22.262 21.184 1.00 17.87 BATOM 5538 NH2 ARG B 168 3.035 20.646 20.804 1.00 22.21 B ATOM 5539 C ARGB 168 0.504 24.765 16.897 1.00 16.72 B ATOM 5540 O ARG B 168 −0.44824.080 16.423 1.00 16.12 B ATOM 5541 N VAL B 169 1.718 25.013 16.2991.00 16.99 B ATOM 5542 CA VAL B 169 2.184 24.461 15.045 1.00 16.45 BATOM 5543 CB VAL B 169 2.234 25.477 13.911 1.00 17.41 B ATOM 5544 CG1VAL B 169 2.693 24.749 12.534 1.00 16.86 B ATOM 5545 CG2 VAL B 169 0.87326.148 13.741 1.00 16.77 B ATOM 5546 C VAL B 169 3.556 24.004 15.2371.00 17.13 B ATOM 5547 O VAL B 169 4.390 24.783 15.608 1.00 15.77 B ATOM5548 N TYR B 170 3.821 22.749 14.918 1.00 17.98 B ATOM 5549 CA TYR B 1705.156 22.193 15.137 1.00 18.35 B ATOM 5550 CB TYR B 170 5.250 21.64016.525 1.00 17.90 B ATOM 5551 CG TYR B 170 4.304 20.502 16.832 1.0017.70 B ATOM 5552 CD1 TYR B 170 4.759 19.194 16.837 1.00 17.50 B ATOM5553 CE1 TYR B 170 3.887 18.098 17.112 1.00 17.97 B ATOM 5554 CD2 TYR B170 2.931 20.741 17.103 1.00 17.53 B ATOM 5555 CE2 TYR B 170 2.03219.651 17.352 1.00 17.98 B ATOM 5556 CZ TYR B 170 2.549 18.315 17.3631.00 17.69 B ATOM 5557 OH TYR B 170 1.728 17.256 17.668 1.00 17.02 BATOM 5558 C TYR B 170 5.393 21.063 14.189 1.00 20.07 B ATOM 5559 O TYR B170 4.432 20.661 13.493 1.00 21.18 B ATOM 5560 N TYR B 171 6.657 20.57014.106 1.00 20.52 B ATOM 5561 CA TYR B 171 6.923 19.425 13.229 1.0019.29 B ATOM 5562 CB TYR B 171 7.378 19.841 11.905 1.00 20.20 B ATOM5563 CG TYR B 171 8.734 20.411 11.881 1.00 19.99 B ATOM 5564 CD1 TYR B171 9.838 19.585 11.637 1.00 19.32 B ATOM 5565 CE1 TYR B 171 11.14320.109 11.624 1.00 19.13 B ATOM 5566 CD2 TYR B 171 8.946 21.796 12.0901.00 19.46 B ATOM 5567 CE2 TYR B 171 10.240 22.308 12.044 1.00 19.43 BATOM 5568 CZ TYR B 171 11.341 21.434 11.815 1.00 18.80 B ATOM 5569 OHTYR B 171 12.618 21.865 11.685 1.00 18.79 B ATOM 5570 C TYR B 171 7.87018.507 13.892 1.00 20.15 B ATOM 5571 O TYR B 171 8.436 18.914 14.9351.00 19.24 B ATOM 5572 N LYS B 172 8.006 17.258 13.369 1.00 20.37 B ATOM5573 CA LYS B 172 8.815 16.274 14.110 1.00 20.52 B ATOM 5574 CB LYS B172 8.426 14.837 13.861 1.00 20.27 B ATOM 5575 CG LYS B 172 7.546 14.30815.023 1.00 22.25 B ATOM 5576 CD LYS B 172 6.364 15.276 15.341 1.0022.36 B ATOM 5577 CE LYS B 172 5.366 14.538 16.301 1.00 25.31 B ATOM5578 NZ LYS B 172 4.130 13.686 15.515 1.00 24.77 B ATOM 5579 C LYS B 17210.257 16.425 14.002 1.00 21.56 B ATOM 5580 O LYS B 172 10.806 16.48712.949 1.00 22.58 B ATOM 5581 N LYS B 173 10.861 16.559 15.159 1.0022.45 B ATOM 5582 CA LYS B 173 12.273 16.767 15.371 1.00 21.91 B ATOM5583 CB LYS B 173 12.746 15.958 16.589 1.00 23.05 B ATOM 5584 CG LYS B173 11.858 16.199 17.845 1.00 23.33 B ATOM 5585 CD LYS B 173 10.95814.964 17.974 1.00 23.51 B ATOM 5586 CE LYS B 173 9.492 15.287 18.4831.00 22.79 B ATOM 5587 NZ LYS B 173 8.844 16.223 17.430 1.00 22.82 BATOM 5588 C LYS B 173 13.215 16.543 14.303 1.00 21.24 B ATOM 5589 O LYSB 173 13.193 17.281 13.362 1.00 20.74 B ATOM 5590 N CYS B 174 14.15715.656 14.573 1.00 21.13 B ATOM 5591 CA CYS B 174 15.245 15.298 13.6511.00 23.17 B ATOM 5592 CB CYS B 174 14.860 15.616 12.163 1.00 25.74 BATOM 5593 SG CYS B 174 13.859 14.160 11.367 1.00 35.68 B ATOM 5594 C CYSB 174 16.669 15.784 13.927 1.00 21.06 B ATOM 5595 O CYS B 174 17.43914.813 14.061 1.00 20.42 B ATOM 5596 OXT CYS B 174 16.994 17.056 13.9681.00 21.98 B ATOM 5597 CB GLU E 1 −40.500 −14.824 45.862 1.00 17.54 EATOM 5598 CG GLU E 1 −39.798 −13.752 46.644 1.00 18.18 E ATOM 5599 CDGLU E 1 −38.300 −13.513 46.180 1.00 19.81 E ATOM 5600 OE1 GLU E 1−38.043 −12.903 45.100 1.00 18.92 E ATOM 5601 OE2 GLU E 1 −37.344−13.944 46.882 1.00 19.29 E ATOM 5602 C GLU E 1 −42.565 −15.542 47.2491.00 18.49 E ATOM 5603 O GLU E 1 −43.079 −14.826 48.077 1.00 19.61 EATOM 5604 N GLU E 1 −42.604 −13.559 45.628 1.00 16.63 E ATOM 5605 CA GLUE 1 −42.046 −14.887 45.940 1.00 17.50 E ATOM 5606 N VAL E 2 −42.485−16.868 47.419 1.00 17.50 E ATOM 5607 CA VAL E 2 −42.997 −17.499 48.6101.00 15.10 E ATOM 5608 CB VAL E 2 −43.906 −18.701 48.257 1.00 17.13 EATOM 5609 CG1 VAL E 2 −44.173 −19.546 49.391 1.00 16.22 E ATOM 5610 CG2VAL E 2 −45.175 −18.211 47.626 1.00 17.04 E ATOM 5611 C VAL E 2 −41.754−17.889 49.347 1.00 14.54 E ATOM 5612 O VAL E 2 −40.746 −18.219 48.7841.00 12.59 E ATOM 5613 N VAL E 3 −41.791 −17.727 50.663 1.00 13.91 EATOM 5614 CA VAL E 3 −40.605 −18.009 51.463 1.00 13.41 E ATOM 5615 CBVAL E 3 −40.202 −16.750 52.299 1.00 14.35 E ATOM 5616 CG1 VAL E 3−38.890 −17.047 53.011 1.00 15.74 E ATOM 5617 CG2 VAL E 3 −40.109−15.530 51.406 1.00 13.57 E ATOM 5618 C VAL E 3 −40.748 −19.190 52.3731.00 13.45 E ATOM 5619 O VAL E 3 −41.613 −19.262 53.200 1.00 12.20 EATOM 5620 N LEU E 4 −39.842 −20.104 52.238 1.00 14.58 E ATOM 5621 CA LEUE 4 −39.850 −21.301 53.045 1.00 17.59 E ATOM 5622 CB LEU E 4 −39.672−22.528 52.117 1.00 16.38 E ATOM 5623 CG LEU E 4 −40.414 −22.490 50.7971.00 16.05 E ATOM 5624 CD1 LEU E 4 −40.221 −23.868 50.024 1.00 16.28 EATOM 5625 CD2 LEU E 4 −41.853 −22.204 51.090 1.00 15.40 E ATOM 5626 CLEU E 4 −38.620 −21.142 53.762 1.00 17.49 E ATOM 5627 O LEU E 4 −37.672−21.207 53.125 1.00 21.18 E ATOM 5628 N LEU E 5 −38.494 −21.012 55.0231.00 16.67 E ATOM 5629 CA LEU E 5 −37.097 −20.720 55.451 1.00 16.17 EATOM 5630 CB LEU E 5 −36.085 −21.782 55.078 1.00 14.47 E ATOM 5631 CGLEU E 5 −34.730 −21.530 55.767 1.00 14.74 E ATOM 5632 CD1 LEU E 5−35.041 −21.139 57.195 1.00 17.46 E ATOM 5633 CD2 LEU E 5 −33.892−22.831 55.861 1.00 13.64 E ATOM 5634 C LEU E 5 −36.414 −19.369 55.1391.00 14.29 E ATOM 5635 O LEU E 5 −36.073 −19.062 54.010 1.00 14.40 EATOM 5636 N ASP E 6 −36.192 −18.626 56.229 1.00 14.04 E ATOM 5637 CA ASPE 6 −35.520 −17.319 56.248 1.00 15.78 E ATOM 5638 CB ASP E 6 −36.569−16.239 56.128 1.00 14.96 E ATOM 5639 CG ASP E 6 −35.983 −14.969 55.8511.00 15.94 E ATOM 5640 OD1 ASP E 6 −36.769 −13.997 55.829 1.00 15.54 EATOM 5641 OD2 ASP E 6 −34.733 −14.947 55.617 1.00 16.51 E ATOM 5642 CASP E 6 −34.712 −17.094 57.540 1.00 13.60 E ATOM 5643 O ASP E 6 −35.239−16.630 58.544 1.00 12.68 E ATOM 5644 N PHE E 7 −33.443 −17.407 57.4501.00 13.80 E ATOM 5645 CA PHE E 7 −32.537 −17.344 58.582 1.00 16.27 EATOM 5646 CB PHE E 7 −31.089 −17.747 58.178 1.00 16.28 E ATOM 5647 CGPHE E 7 −30.116 −17.627 59.323 1.00 16.15 E ATOM 5648 CD1 PHE E 7−30.099 −18.560 60.356 1.00 16.21 E ATOM 5649 CD2 PHE E 7 −29.299−16.506 59.409 1.00 16.20 E ATOM 5650 CE1 PHE E 7 −29.249 −18.350 61.4731.00 17.54 E ATOM 5651 CE2 PHE E 7 −28.454 −16.273 60.502 1.00 16.19 EATOM 5652 CZ PHE E 7 −28.422 −17.189 61.528 1.00 17.41 E ATOM 5653 C PHEE 7 −32.514 −15.993 59.381 1.00 14.91 E ATOM 5654 O PHE E 7 −32.831−16.038 60.529 1.00 13.55 E ATOM 5655 N ALA E 8 −32.170 −14.881 58.7321.00 14.66 E ATOM 5656 CA ALA E 8 −32.149 −13.567 59.391 1.00 15.47 EATOM 5657 CB ALA E 8 −31.613 −12.481 58.425 1.00 14.39 E ATOM 5658 C ALAE 8 −33.494 −13.084 60.011 1.00 16.54 E ATOM 5659 O ALA E 8 −33.498−12.020 60.588 1.00 16.72 E ATOM 5660 N ALA E 9 −34.643 −13.812 59.8621.00 16.28 E ATOM 5661 CA ALA E 9 −35.886 −13.363 60.464 1.00 16.12 EATOM 5662 CB ALA E 9 −36.924 −13.354 59.514 1.00 11.82 E ATOM 5663 C ALAE 9 −36.281 −14.104 61.682 1.00 17.75 E ATOM 5664 O ALA E 9 −37.206−13.671 62.367 1.00 19.74 E ATOM 5665 N ALA E 10 −35.593 −15.217 62.0061.00 19.23 E ATOM 5666 CA ALA E 10 −35.894 −16.051 63.239 1.00 20.03 EATOM 5667 CB ALA E 10 −35.552 −17.478 62.942 1.00 16.54 E ATOM 5668 CALA E 10 −35.185 −15.507 64.554 1.00 21.95 E ATOM 5669 O ALA E 10−33.902 −15.785 64.946 1.00 23.19 E ATOM 5670 N GLY E 11 −35.987 −14.66265.233 1.00 23.44 E ATOM 5671 CA GLY E 11 −35.614 −13.986 66.559 1.0023.93 E ATOM 5672 C GLY E 11 −35.226 −14.881 67.817 1.00 23.95 E ATOM5673 O GLY E 11 −35.879 −14.913 68.900 1.00 23.53 E ATOM 5674 N GLY E 12−34.154 −15.672 67.574 1.00 22.90 E ATOM 5675 CA GLY E 12 −33.560−16.587 68.525 1.00 22.04 E ATOM 5676 C GLY E 12 −32.646 −17.465 67.6261.00 21.91 E ATOM 5677 O GLY E 12 −32.429 −18.724 68.021 1.00 20.96 EATOM 5678 N GLU E 13 −32.194 −16.883 66.461 1.00 21.33 E ATOM 5679 CAGLU E 13 −31.283 −17.622 65.514 1.00 23.11 E ATOM 5680 CB GLU E 13−30.039 −18.184 66.300 1.00 24.43 E ATOM 5681 CG GLU E 13 −29.989−18.022 68.018 1.00 28.30 E ATOM 5682 CD GLU E 13 −28.443 −18.128 68.7221.00 30.09 E ATOM 5683 OE1 GLU E 13 −27.472 −17.924 67.876 1.00 32.18 EATOM 5684 OE2 GLU E 13 −28.194 −18.363 70.040 1.00 27.22 E ATOM 5685 CGLU E 13 −32.020 −18.868 64.683 1.00 23.49 E ATOM 5686 O GLU E 13−32.315 −18.717 63.466 1.00 22.95 E ATOM 5687 N LEU E 14 −32.346 −20.01065.395 1.00 22.62 E ATOM 5688 CA LEU E 14 −33.008 −21.138 64.772 1.0023.06 E ATOM 5689 CB LEU E 14 −32.736 −21.159 63.254 1.00 23.18 E ATOM5690 CG LEU E 14 −33.972 −20.635 62.512 1.00 23.29 E ATOM 5691 CD1 LEU E14 −33.518 −19.598 61.376 1.00 20.99 E ATOM 5692 CD2 LEU E 14 −34.839−21.857 61.967 1.00 22.45 E ATOM 5693 C LEU E 14 −32.666 −22.566 65.2581.00 23.87 E ATOM 5694 O LEU E 14 −31.551 −22.891 65.900 1.00 24.06 EATOM 5695 N GLY E 15 −33.585 −23.439 64.828 1.00 21.87 E ATOM 5696 CAGLY E 15 −33.472 −24.817 65.181 1.00 20.86 E ATOM 5697 C GLY E 15−32.546 −25.509 64.117 1.00 21.39 E ATOM 5698 O GLY E 15 −33.145 −26.24663.265 1.00 21.68 E ATOM 5699 N TRP E 16 −31.165 −25.311 64.112 1.0020.01 E ATOM 5700 CA TRP E 16 −30.314 −25.971 63.086 1.00 17.82 E ATOM5701 CB TRP E 16 −29.463 −25.003 62.248 1.00 18.50 E ATOM 5702 CG TRP E16 −30.275 −24.111 61.422 1.00 18.62 E ATOM 5703 CD2 TRP E 16 −29.952−23.451 60.183 1.00 17.92 E ATOM 5704 CE2 TRP E 16 −31.013 −22.57859.870 1.00 17.33 E ATOM 5705 CE3 TRP E 16 −28.899 −23.516 59.296 1.0018.87 E ATOM 5706 CD1 TRP E 16 −31.483 −23.628 61.776 1.00 18.88 E ATOM5707 NE1 TRP E 16 −31.933 −22.704 60.867 1.00 18.19 E ATOM 5708 CZ2 TRPE 16 −31.041 −21.748 58.684 1.00 15.18 E ATOM 5709 CZ3 TRP E 16 −28.950−22.632 58.064 1.00 18.80 E ATOM 5710 CH2 TRP E 16 −30.032 −21.78457.817 1.00 14.99 E ATOM 5711 C TRP E 16 −29.414 −26.981 63.742 1.0017.93 E ATOM 5712 O TRP E 16 −29.262 −26.946 64.907 1.00 18.57 E ATOM5713 N LEU E 17 −28.932 −27.930 62.981 1.00 16.32 E ATOM 5714 CA LEU E17 −28.071 −28.994 63.412 1.00 15.21 E ATOM 5715 CB LEU E 17 −28.536−30.308 62.782 1.00 16.25 E ATOM 5716 CG LEU E 17 −27.665 −31.451 63.2061.00 18.64 E ATOM 5717 CD1 LEU E 17 −27.566 −31.413 64.766 1.00 19.94 EATOM 5718 CD2 LEU E 17 −28.294 −32.796 62.751 1.00 20.55 E ATOM 5719 CLEU E 17 −26.605 −28.623 63.014 1.00 13.68 E ATOM 5720 O LEU E 17−26.330 −27.973 61.982 1.00 12.88 E ATOM 5721 N THR E 18 −25.693 −29.02363.871 1.00 13.55 E ATOM 5722 CA THR E 18 −24.291 −28.681 63.752 1.0014.74 E ATOM 5723 CB THR E 18 −24.018 −27.573 64.744 1.00 14.30 E ATOM5724 OG1 THR E 18 −24.107 −26.349 63.988 1.00 14.02 E ATOM 5725 CG2 THRE 18 −22.791 −27.774 65.450 1.00 13.43 E ATOM 5726 C THR E 18 −23.477−29.885 63.967 1.00 15.28 E ATOM 5727 O THR E 18 −23.401 −30.353 65.0721.00 13.96 E ATOM 5728 N HIS E 19 −22.815 −30.370 62.910 1.00 17.68 EATOM 5729 CA HIS E 19 −22.208 −31.652 63.109 1.00 19.76 E ATOM 5730 CBHIS E 19 −22.121 −32.424 61.850 1.00 20.70 E ATOM 5731 CG HIS E 19−21.826 −33.883 62.077 1.00 20.93 E ATOM 5732 CD2 HIS E 19 −21.168−34.800 61.307 1.00 19.15 E ATOM 5733 ND1 HIS E 19 −22.002 −34.47163.320 1.00 21.74 E ATOM 5734 CE1 HIS E 19 −21.452 −35.678 63.299 1.0020.25 E ATOM 5735 NE2 HIS E 19 −20.939 −35.898 62.090 1.00 19.63 E ATOM5736 C HIS E 19 −20.951 −31.618 63.928 1.00 20.13 E ATOM 5737 O HIS E 19−20.824 −30.701 64.799 1.00 22.46 E ATOM 5738 N PRO E 20 −19.900 −32.29263.541 1.00 18.49 E ATOM 5739 CD PRO E 20 −19.381 −31.767 62.283 1.0016.99 E ATOM 5740 CA PRO E 20 −18.882 −32.141 64.641 1.00 19.63 E ATOM5741 CB PRO E 20 −17.796 −31.279 64.041 1.00 17.90 E ATOM 5742 CG PRO E20 −17.855 −31.716 62.657 1.00 17.15 E ATOM 5743 C PRO E 20 −19.540−31.663 66.032 1.00 18.52 E ATOM 5744 O PRO E 20 −19.851 −32.491 66.9461.00 20.06 E ATOM 5745 N TYR E 21 −19.856 −30.376 66.146 1.00 17.81 EATOM 5746 CA TYR E 21 −20.479 −29.748 67.381 1.00 17.96 E ATOM 5747 CBTYR E 21 −21.661 −30.504 68.048 1.00 17.89 E ATOM 5748 CG TYR E 21−22.219 −29.594 69.152 1.00 18.42 E ATOM 5749 CD1 TYR E 21 −22.912−28.429 68.824 1.00 17.73 E ATOM 5750 CE1 TYR E 21 −23.212 −27.48269.809 1.00 15.75 E ATOM 5751 CD2 TYR E 21 −21.838 −29.767 70.578 1.0018.97 E ATOM 5752 CE2 TYR E 21 −22.120 −28.806 71.524 1.00 15.43 E ATOM5753 CZ TYR E 21 −22.802 −27.688 71.129 1.00 15.38 E ATOM 5754 OH TYR E21 −23.137 −26.703 71.983 1.00 14.78 E ATOM 5755 C TYR E 21 −19.446−29.508 68.463 1.00 15.14 E ATOM 5756 O TYR E 21 −19.024 −30.413 69.1421.00 13.47 E ATOM 5757 N GLY E 22 −19.146 −28.263 68.663 1.00 15.36 EATOM 5758 CA GLY E 22 −18.160 −27.923 69.667 1.00 16.75 E ATOM 5759 CGLY E 22 −17.061 −26.999 69.146 1.00 16.87 E ATOM 5760 O GLY E 22−16.768 −26.026 69.814 1.00 18.12 E ATOM 5761 N LYS E 23 −16.572 −27.29067.938 1.00 16.06 E ATOM 5762 CA LYS E 23 −15.539 −26.581 67.305 1.0014.99 E ATOM 5763 CB LYS E 23 −14.285 −27.454 67.272 1.00 16.08 E ATOM5764 CG LYS E 23 −13.631 −27.744 68.573 1.00 17.84 E ATOM 5765 CD LYS E23 −14.083 −29.042 69.254 1.00 20.21 E ATOM 5766 CE LYS E 23 −13.550−29.339 70.677 1.00 18.57 E ATOM 5767 NZ LYS E 23 −12.133 −29.605 70.7551.00 19.07 E ATOM 5768 C LYS E 23 −15.847 −26.158 65.900 1.00 13.36 EATOM 5769 O LYS E 23 −15.056 −25.486 65.312 1.00 10.77 E ATOM 5770 N GLYE 24 −16.962 −26.625 65.335 1.00 13.52 E ATOM 5771 CA GLY E 24 −17.251−26.320 63.938 1.00 14.07 E ATOM 5772 C GLY E 24 −18.091 −25.056 63.8741.00 14.52 E ATOM 5773 O GLY E 24 −17.796 −24.077 64.557 1.00 12.98 EATOM 5774 N TRP E 25 −19.137 −25.100 63.044 1.00 15.04 E ATOM 5775 CATRP E 25 −20.070 −24.059 62.899 1.00 14.96 E ATOM 5776 CB TRP E 25−21.109 −24.547 61.977 1.00 14.57 E ATOM 5777 CG TRP E 25 −20.779−24.701 60.586 1.00 13.79 E ATOM 5778 CD2 TRP E 25 −20.759 −23.68559.635 1.00 14.35 E ATOM 5779 CE2 TRP E 25 −20.532 −24.302 58.398 1.0013.82 E ATOM 5780 CE3 TRP E 25 −20.900 −22.278 59.703 1.00 15.59 E ATOM5781 CD1 TRP E 25 −20.563 −25.844 59.923 1.00 12.59 E ATOM 5782 NE1 TRPE 25 −20.411 −25.625 58.641 1.00 11.10 E ATOM 5783 CZ2 TRP E 25 −20.454−23.586 57.194 1.00 15.85 E ATOM 5784 CZ3 TRP E 25 −20.815 −21.55758.553 1.00 18.05 E ATOM 5785 CH2 TRP E 25 −20.595 −22.217 57.273 1.0016.95 E ATOM 5786 C TRP E 25 −20.732 −23.723 64.269 1.00 15.40 E ATOM5787 O TRP E 25 −21.207 −24.673 64.929 1.00 14.34 E ATOM 5788 N ASP E 26−20.694 −22.413 64.667 1.00 15.60 E ATOM 5789 CA ASP E 26 −21.345−21.845 65.886 1.00 16.44 E ATOM 5790 CB ASP E 26 −20.404 −21.248 66.9851.00 19.52 E ATOM 5791 CG ASP E 26 −19.460 −22.253 67.711 1.00 24.25 EATOM 5792 OD1 ASP E 26 −19.226 −23.587 67.457 1.00 21.39 E ATOM 5793 OD2ASP E 26 −18.858 −21.525 68.691 1.00 28.89 E ATOM 5794 C ASP E 26−22.294 −20.640 65.562 1.00 15.01 E ATOM 5795 O ASP E 26 −21.956 −19.64864.835 1.00 12.18 E ATOM 5796 N LEU E 27 −23.483 −20.735 66.161 1.0014.51 E ATOM 5797 CA LEU E 27 −24.447 −19.636 66.105 1.00 15.72 E ATOM5798 CB LEU E 27 −25.732 −20.153 66.656 1.00 16.61 E ATOM 5799 CG LEU E27 −26.932 −19.276 66.250 1.00 17.73 E ATOM 5800 CD1 LEU E 27 −27.044−18.900 64.742 1.00 15.98 E ATOM 5801 CD2 LEU E 27 −28.051 −20.06066.847 1.00 16.11 E ATOM 5802 C LEU E 27 −23.886 −18.446 67.020 1.0015.05 E ATOM 5803 O LEU E 27 −23.451 −18.624 68.088 1.00 13.59 E ATOM5804 N MET E 28 −23.903 −17.274 66.489 1.00 15.13 E ATOM 5805 CA MET E28 −23.357 −16.196 67.135 1.00 17.09 E ATOM 5806 CB MET E 28 −21.965−15.846 66.552 1.00 19.52 E ATOM 5807 CG MET E 28 −20.966 −16.978 66.5871.00 22.38 E ATOM 5808 SD MET E 28 −19.171 −16.558 66.266 1.00 26.05 EATOM 5809 CE MET E 28 −18.792 −15.296 67.763 1.00 22.95 E ATOM 5810 CMET E 28 −24.272 −15.007 66.941 1.00 17.06 E ATOM 5811 O MET E 28−24.839 −14.805 65.817 1.00 16.55 E ATOM 5812 N GLN E 29 −24.367 −14.19768.009 1.00 16.75 E ATOM 5813 CA GLN E 29 −25.230 −13.060 67.976 1.0017.76 E ATOM 5814 CB GLN E 29 −26.292 −13.229 69.066 1.00 17.99 E ATOM5815 CG GLN E 29 −27.430 −12.249 68.833 1.00 19.97 E ATOM 5816 CD GLN E29 −28.060 −11.758 70.130 1.00 20.58 E ATOM 5817 OE1 GLN E 29 −29.075−12.290 70.552 1.00 21.59 E ATOM 5818 NE2 GLN E 29 −27.461 −10.74970.756 1.00 19.62 E ATOM 5819 C GLN E 29 −24.560 −11.669 68.133 1.0018.79 E ATOM 5820 O GLN E 29 −24.124 −11.291 69.233 1.00 18.82 E ATOM5821 N ASN E 30 −24.559 −10.880 67.061 1.00 18.71 E ATOM 5822 CA ASN E30 −24.073 −9.545 67.143 1.00 17.17 E ATOM 5823 CB ASN E 30 −23.344−9.130 65.918 1.00 16.68 E ATOM 5824 CG ASN E 30 −22.026 −9.802 65.7891.00 15.39 E ATOM 5825 OD1 ASN E 30 −21.550 −9.981 64.657 1.00 16.10 EATOM 5826 ND2 ASN E 30 −21.427 −10.184 66.891 1.00 11.59 E ATOM 5827 CASN E 30 −25.236 −8.610 67.343 1.00 18.15 E ATOM 5828 O ASN E 30 −26.384−8.916 67.221 1.00 18.49 E ATOM 5829 N ILE E 31 −24.925 −7.397 67.6371.00 18.36 E ATOM 5830 CA ILE E 31 −26.001 −6.532 67.812 1.00 17.29 EATOM 5831 CB ILE E 31 −26.363 −6.585 69.270 1.00 19.25 E ATOM 5832 CG2ILE E 31 −25.198 −6.130 70.057 1.00 19.58 E ATOM 5833 CG1 ILE E 31−27.476 −5.562 69.533 1.00 21.12 E ATOM 5834 CD1 ILE E 31 −28.002 −5.73670.901 1.00 22.51 E ATOM 5835 C ILE E 31 −25.622 −5.140 67.336 1.0016.35 E ATOM 5836 O ILE E 31 −24.620 −4.673 67.607 1.00 14.86 E ATOM5837 N MET E 32 −26.497 −4.534 66.594 1.00 16.48 E ATOM 5838 CA MET E 32−26.358 −3.238 66.026 1.00 17.13 E ATOM 5839 CB MET E 32 −26.364 −3.30664.499 1.00 19.28 E ATOM 5840 CG MET E 32 −25.004 −3.419 63.854 1.0021.71 E ATOM 5841 SD MET E 32 −23.830 −2.155 64.401 1.00 22.92 E ATOM5842 CE MET E 32 −24.954 −0.731 64.372 1.00 16.97 E ATOM 5843 C MET E 32−27.634 −2.527 66.318 1.00 17.04 E ATOM 5844 O MET E 32 −28.738 −3.04765.913 1.00 17.01 E ATOM 5845 N ASN E 33 −27.496 −1.317 66.884 1.0015.90 E ATOM 5846 CA ASN E 33 −28.623 −0.421 67.215 1.00 15.39 E ATOM5847 CB ASN E 33 −29.218 0.236 66.016 1.00 15.11 E ATOM 5848 CG ASN E 33−28.229 1.024 65.257 1.00 16.41 E ATOM 5849 OD1 ASN E 33 −27.722 2.02365.717 1.00 19.30 E ATOM 5850 ND2 ASN E 33 −27.952 0.612 64.060 1.0015.69 E ATOM 5851 C ASN E 33 −29.705 −1.225 67.847 1.00 16.58 E ATOM5852 O ASN E 33 −30.867 −1.120 67.418 1.00 16.52 E ATOM 5853 N ASP E 34−29.312 −2.040 68.816 1.00 15.97 E ATOM 5854 CA ASP E 34 −30.229 −2.86069.497 1.00 17.21 E ATOM 5855 CB ASP E 34 −31.286 −1.973 70.230 1.0017.98 E ATOM 5856 CG ASP E 34 −30.725 −1.315 71.610 1.00 20.73 E ATOM5857 OD1 ASP E 34 −29.505 −0.884 71.756 1.00 20.64 E ATOM 5858 OD2 ASP E34 −31.558 −1.206 72.526 1.00 22.46 E ATOM 5859 C ASP E 34 −30.877−3.973 68.628 1.00 18.02 E ATOM 5860 O ASP E 34 −31.743 −4.745 69.0681.00 18.99 E ATOM 5861 N MET E 35 −30.507 −4.110 67.388 1.00 16.56 EATOM 5862 CA MET E 35 −31.123 −5.256 66.742 1.00 15.52 E ATOM 5863 CBMET E 35 −31.361 −4.912 65.256 1.00 15.76 E ATOM 5864 CG MET E 35−32.481 −3.858 65.058 1.00 15.64 E ATOM 5865 SD MET E 35 −34.138 −4.47065.755 1.00 18.42 E ATOM 5866 CE MET E 35 −34.066 −3.713 67.487 1.0018.66 E ATOM 5867 C MET E 35 −30.184 −6.495 66.886 1.00 15.94 E ATOM5868 O MET E 35 −28.963 −6.362 66.744 1.00 14.48 E ATOM 5869 N PRO E 36−30.707 −7.661 67.305 1.00 14.21 E ATOM 5870 CD PRO E 36 −32.016 −7.94867.882 1.00 14.01 E ATOM 5871 CA PRO E 36 −29.782 −8.819 67.365 1.0014.00 E ATOM 5872 CB PRO E 36 −30.496 −9.825 68.208 1.00 14.34 E ATOM5873 CG PRO E 36 −31.957 −9.378 68.013 1.00 14.93 E ATOM 5874 C PRO E 36−29.569 −9.319 65.857 1.00 15.54 E ATOM 5875 O PRO E 36 −30.496 −9.35065.066 1.00 15.01 E ATOM 5876 N ILE E 37 −28.325 −9.604 65.461 1.0015.54 E ATOM 5877 CA ILE E 37 −27.975 −10.056 64.104 1.00 14.11 E ATOM5878 CB ILE E 37 −26.964 −9.114 63.537 1.00 16.41 E ATOM 5879 CG2 ILE E37 −26.731 −9.324 62.110 1.00 11.52 E ATOM 5880 CG1 ILE E 37 −27.423−7.657 63.790 1.00 19.05 E ATOM 5881 CD1 ILE E 37 −28.756 −7.427 63.3451.00 21.44 E ATOM 5882 C ILE E 37 −27.370 −11.438 64.314 1.00 14.61 EATOM 5883 O ILE E 37 −26.295 −11.566 64.785 1.00 13.92 E ATOM 5884 N TYRE 38 −28.089 −12.510 64.023 1.00 14.65 E ATOM 5885 CA TYR E 38 −27.514−13.820 64.198 1.00 12.84 E ATOM 5886 CB TYR E 38 −28.551 −14.819 64.4451.00 13.47 E ATOM 5887 CG TYR E 38 −29.193 −14.669 65.726 1.00 13.81 EATOM 5888 CD1 TYR E 38 −30.242 −13.747 65.926 1.00 13.74 E ATOM 5889 CE1TYR E 38 −30.747 −13.611 67.171 1.00 14.37 E ATOM 5890 CD2 TYR E 38−28.734 −15.407 66.803 1.00 12.72 E ATOM 5891 CE2 TYR E 38 −29.251−15.274 67.973 1.00 13.34 E ATOM 5892 CZ TYR E 38 −30.236 −14.407 68.1851.00 14.68 E ATOM 5893 OH TYR E 38 −30.746 −14.426 69.445 1.00 18.73 EATOM 5894 C TYR E 38 −26.769 −14.243 62.963 1.00 13.57 E ATOM 5895 O TYRE 38 −27.008 −13.725 61.867 1.00 12.74 E ATOM 5896 N MET E 39 −25.846−15.195 63.152 1.00 14.30 E ATOM 5897 CA MET E 39 −25.018 −15.696 62.0691.00 13.13 E ATOM 5898 CB MET E 39 −23.897 −14.706 61.752 1.00 13.36 EATOM 5899 CG MET E 39 −22.647 −14.802 62.659 1.00 13.27 E ATOM 5900 SDMET E 39 −21.677 −13.379 62.498 1.00 16.34 E ATOM 5901 CE MET E 39−20.266 −13.645 63.797 1.00 17.50 E ATOM 5902 C MET E 39 −24.431 −17.01762.421 1.00 13.77 E ATOM 5903 O MET E 39 −24.268 −17.335 63.569 1.0013.98 E ATOM 5904 N TYR E 40 −24.112 −17.811 61.427 1.00 14.35 E ATOM5905 CA TYR E 40 −23.447 −19.063 61.681 1.00 14.12 E ATOM 5906 CB TYR E40 −24.220 −20.165 60.990 1.00 15.10 E ATOM 5907 CG TYR E 40 −25.184−20.927 61.932 1.00 17.57 E ATOM 5908 CD1 TYR E 40 −26.574 −20.69261.912 1.00 18.28 E ATOM 5909 CE1 TYR E 40 −27.386 −21.272 62.805 1.0018.00 E ATOM 5910 CD2 TYR E 40 −24.707 −21.818 62.908 1.00 17.98 E ATOM5911 CE2 TYR E 40 −25.552 −22.407 63.792 1.00 18.04 E ATOM 5912 CZ TYR E40 −26.867 −22.127 63.736 1.00 18.27 E ATOM 5913 OH TYR E 40 −27.632−22.747 64.669 1.00 19.86 E ATOM 5914 C TYR E 40 −21.954 −18.945 61.1701.00 14.12 E ATOM 5915 O TYR E 40 −21.635 −18.605 60.009 1.00 14.37 EATOM 5916 N SER E 41 −21.008 −19.182 62.027 1.00 15.04 E ATOM 5917 CASER E 41 −19.617 −19.062 61.576 1.00 14.94 E ATOM 5918 CB SER E 41−19.061 −17.678 61.905 1.00 17.47 E ATOM 5919 OG SER E 41 −19.170−17.393 63.258 1.00 17.12 E ATOM 5920 C SER E 41 −18.631 −20.110 62.0511.00 13.51 E ATOM 5921 O SER E 41 −18.896 −20.803 63.007 1.00 12.21 EATOM 5922 N VAL E 42 −17.534 −20.245 61.309 1.00 14.01 E ATOM 5923 CAVAL E 42 −16.479 −21.210 61.626 1.00 14.68 E ATOM 5924 CB VAL E 42−16.298 −22.494 60.687 1.00 15.07 E ATOM 5925 CG1 VAL E 42 −16.034−23.748 61.536 1.00 13.46 E ATOM 5926 CG2 VAL E 42 −17.404 −22.58359.579 1.00 13.20 E ATOM 5927 C VAL E 42 −15.338 −20.506 61.156 1.0014.82 E ATOM 5928 O VAL E 42 −15.487 −19.687 60.269 1.00 14.86 E ATOM5929 N CYS E 43 −14.189 −20.932 61.648 1.00 14.99 E ATOM 5930 CA CYS E43 −12.894 −20.349 61.288 1.00 14.83 E ATOM 5931 C CYS E 43 −11.772−21.274 61.714 1.00 16.17 E ATOM 5932 O CYS E 43 −10.801 −20.726 62.2291.00 18.57 E ATOM 5933 CB CYS E 43 −12.661 −18.964 61.976 1.00 12.22 EATOM 5934 SG CYS E 43 −11.473 −17.828 61.237 1.00 9.84 E ATOM 5935 N ASNE 44 −11.893 −22.609 61.541 1.00 14.86 E ATOM 5936 CA ASN E 44 −10.797−23.518 61.806 1.00 12.39 E ATOM 5937 CB ASN E 44 −11.321 −24.892 62.1951.00 14.16 E ATOM 5938 CG ASN E 44 −12.166 −24.846 63.378 1.00 15.67 EATOM 5939 OD1 ASN E 44 −13.100 −25.573 63.468 1.00 18.08 E ATOM 5940 ND2ASN E 44 −11.864 −23.967 64.322 1.00 17.65 E ATOM 5941 C ASN E 44 −9.792−23.639 60.636 1.00 10.64 E ATOM 5942 O ASN E 44 −9.530 −24.683 60.1171.00 8.56 E ATOM 5943 N VAL E 45 −9.213 −22.511 60.278 1.00 11.44 E ATOM5944 CA VAL E 45 −8.229 −22.324 59.221 1.00 14.14 E ATOM 5945 CB VAL E45 −8.092 −20.889 58.766 1.00 14.24 E ATOM 5946 CG1 VAL E 45 −9.360−20.474 58.209 1.00 15.73 E ATOM 5947 CG2 VAL E 45 −7.643 −19.929 59.9581.00 15.14 E ATOM 5948 C VAL E 45 −6.849 −22.771 59.578 1.00 13.90 EATOM 5949 O VAL E 45 −6.031 −22.904 58.696 1.00 15.60 E ATOM 5950 N METE 46 −6.623 −23.091 60.826 1.00 14.87 E ATOM 5951 CA MET E 46 −5.311−23.442 61.294 1.00 17.11 E ATOM 5952 CB MET E 46 −5.095 −22.675 62.6261.00 18.14 E ATOM 5953 CG MET E 46 −3.816 −21.754 62.749 1.00 20.11 EATOM 5954 SD MET E 46 −3.301 −20.497 61.489 1.00 23.45 E ATOM 5955 CEMET E 46 −3.996 −18.896 62.261 1.00 20.43 E ATOM 5956 C MET E 46 −5.144−24.945 61.488 1.00 16.99 E ATOM 5957 O MET E 46 −4.113 −25.401 61.9861.00 16.29 E ATOM 5958 N SER E 47 −6.182 −25.717 61.178 1.00 17.58 EATOM 5959 CA SER E 47 −6.051 −27.173 61.337 1.00 19.69 E ATOM 5960 CBSER E 47 −6.878 −27.703 62.453 1.00 18.09 E ATOM 5961 OG SER E 47 −7.296−26.542 63.170 1.00 26.32 E ATOM 5962 C SER E 47 −6.549 −27.744 60.0141.00 20.59 E ATOM 5963 O SER E 47 −7.342 −27.120 59.271 1.00 22.35 EATOM 5964 N GLY E 48 −6.109 −28.923 59.670 1.00 20.61 E ATOM 5965 CA GLYE 48 −6.564 −29.375 58.409 1.00 19.90 E ATOM 5966 C GLY E 48 −7.683−30.341 58.520 1.00 19.69 E ATOM 5967 O GLY E 48 −8.174 −30.607 59.6291.00 19.11 E ATOM 5968 N ASP E 49 −8.095 −30.832 57.349 1.00 19.65 EATOM 5969 CA ASP E 49 −9.110 −31.844 57.337 1.00 20.07 E ATOM 5970 CBASP E 49 −8.640 −33.018 58.220 1.00 20.56 E ATOM 5971 CG ASP E 49 −7.290−33.608 57.790 1.00 22.27 E ATOM 5972 OD1 ASP E 49 −6.364 −33.840 58.7191.00 20.74 E ATOM 5973 OD2 ASP E 49 −7.217 −33.852 56.538 1.00 20.58 EATOM 5974 C ASP E 49 −10.457 −31.320 57.942 1.00 19.87 E ATOM 5975 O ASPE 49 −11.171 −32.094 58.567 1.00 19.81 E ATOM 5976 N GLN E 50 −10.830−30.067 57.807 1.00 18.83 E ATOM 5977 CA GLN E 50 −12.097 −29.712 58.4001.00 17.49 E ATOM 5978 CB GLN E 50 −12.257 −28.189 58.416 1.00 17.76 EATOM 5979 CG GLN E 50 −11.228 −27.449 59.312 1.00 14.96 E ATOM 5980 CDGLN E 50 −11.217 −28.037 60.799 1.00 14.65 E ATOM 5981 OE1 GLN E 50−12.187 −27.926 61.487 1.00 11.71 E ATOM 5982 NE2 GLN E 50 −10.107−28.646 61.238 1.00 13.70 E ATOM 5983 C GLN E 50 −13.186 −30.333 57.5531.00 17.28 E ATOM 5984 O GLN E 50 −13.048 −30.398 56.353 1.00 17.32 EATOM 5985 N ASP E 51 −14.238 −30.828 58.217 1.00 15.92 E ATOM 5986 CAASP E 51 −15.448 −31.391 57.602 1.00 13.69 E ATOM 5987 CB ASP E 51−15.380 −32.903 57.463 1.00 13.32 E ATOM 5988 CG ASP E 51 −16.500−33.466 56.555 1.00 14.48 E ATOM 5989 OD1 ASP E 51 −16.748 −34.68756.615 1.00 15.60 E ATOM 5990 OD2 ASP E 51 −17.168 −32.721 55.801 1.0012.38 E ATOM 5991 C ASP E 51 −16.613 −30.985 58.525 1.00 11.84 E ATOM5992 O ASP E 51 −17.261 −31.764 59.171 1.00 9.71 E ATOM 5993 N ASN E 52−16.875 −29.721 58.568 1.00 12.37 E ATOM 5994 CA ASN E 52 −17.958−29.250 59.440 1.00 15.07 E ATOM 5995 CB ASN E 52 −17.491 −27.968 60.1691.00 14.14 E ATOM 5996 CG ASN E 52 −16.213 −28.166 60.761 1.00 13.78 EATOM 5997 OD1 ASN E 52 −16.098 −29.046 61.629 1.00 15.37 E ATOM 5998 ND2ASN E 52 −15.192 −27.419 60.298 1.00 11.95 E ATOM 5999 C ASN E 52−19.278 −28.985 58.722 1.00 13.95 E ATOM 6000 O ASN E 52 −19.312 −28.32357.714 1.00 14.08 E ATOM 6001 N TRP E 53 −20.349 −29.425 59.326 1.0014.78 E ATOM 6002 CA TRP E 53 −21.630 −29.321 58.711 1.00 16.85 E ATOM6003 CB TRP E 53 −22.166 −30.757 58.350 1.00 15.38 E ATOM 6004 CG TRP E53 −21.429 −31.463 57.272 1.00 14.26 E ATOM 6005 CD2 TRP E 53 −21.829−31.594 55.924 1.00 15.05 E ATOM 6006 CE2 TRP E 53 −20.817 −32.30955.278 1.00 15.74 E ATOM 6007 CE3 TRP E 53 −22.947 −31.205 55.201 1.0015.77 E ATOM 6008 CD1 TRP E 53 −20.238 −32.071 57.377 1.00 13.30 E ATOM6009 NE1 TRP E 53 −19.837 −32.571 56.198 1.00 14.03 E ATOM 6010 CZ2 TRPE 53 −20.915 −32.625 53.915 1.00 16.65 E ATOM 6011 CZ3 TRP E 53 −23.028−31.533 53.857 1.00 15.77 E ATOM 6012 CH2 TRP E 53 −22.040 −32.22753.238 1.00 17.16 E ATOM 6013 C TRP E 53 −22.668 −28.582 59.525 1.0016.97 E ATOM 6014 O TRP E 53 −22.757 −28.718 60.775 1.00 17.52 E ATOM6015 N LEU E 54 −23.425 −27.790 58.762 1.00 15.79 E ATOM 6016 CA LEU E54 −24.532 −27.064 59.258 1.00 14.14 E ATOM 6017 CB LEU E 54 −24.342−25.581 59.014 1.00 14.07 E ATOM 6018 CG LEU E 54 −25.539 −24.734 59.4681.00 12.73 E ATOM 6019 CD1 LEU E 54 −25.721 −24.831 60.979 1.00 8.56 EATOM 6020 CD2 LEU E 54 −25.323 −23.339 59.035 1.00 11.88 E ATOM 6021 CLEU E 54 −25.747 −27.549 58.437 1.00 14.50 E ATOM 6022 O LEU E 54−25.755 −27.524 57.172 1.00 12.15 E ATOM 6023 N ARG E 55 −26.771 −28.00459.169 1.00 13.75 E ATOM 6024 CA ARG E 55 −27.985 −28.409 58.542 1.0013.63 E ATOM 6025 CB ARG E 55 −28.313 −29.875 58.751 1.00 16.67 E ATOM6026 CG ARG E 55 −29.633 −30.231 58.023 1.00 18.39 E ATOM 6027 CD ARG E55 −29.835 −31.688 57.901 1.00 19.82 E ATOM 6028 NE ARG E 55 −30.804−32.309 58.818 1.00 19.78 E ATOM 6029 CZ ARG E 55 −30.888 −32.045 60.0741.00 17.91 E ATOM 6030 NH1 ARG E 55 −30.073 −31.162 60.543 1.00 19.61 EATOM 6031 NH2 ARG E 55 −31.735 −32.706 60.813 1.00 15.91 E ATOM 6032 CARG E 55 −29.157 −27.618 58.970 1.00 13.96 E ATOM 6033 O ARG E 55−29.403 −27.433 60.115 1.00 12.33 E ATOM 6034 N THR E 56 −29.917 −27.14657.990 1.00 14.93 E ATOM 6035 CA THR E 56 −31.120 −26.413 58.350 1.0015.15 E ATOM 6036 CB THR E 56 −31.817 −25.778 57.147 1.00 16.31 E ATOM6037 OG1 THR E 56 −32.375 −26.829 56.370 1.00 16.16 E ATOM 6038 CG2 THRE 56 −30.924 −24.988 56.303 1.00 13.90 E ATOM 6039 C THR E 56 −32.101−27.510 58.878 1.00 15.78 E ATOM 6040 O THR E 56 −31.839 −28.750 58.9071.00 15.27 E ATOM 6041 N ASN E 57 −33.268 −27.029 59.252 1.00 16.68 EATOM 6042 CA ASN E 57 −34.271 −27.946 59.679 1.00 16.58 E ATOM 6043 CBASN E 57 −35.163 −27.337 60.751 1.00 19.69 E ATOM 6044 CG ASN E 57−35.055 −28.107 62.075 1.00 23.08 E ATOM 6045 OD1 ASN E 57 −34.077−27.896 62.856 1.00 22.94 E ATOM 6046 ND2 ASN E 57 −36.035 −29.07462.311 1.00 22.21 E ATOM 6047 C ASN E 57 −35.100 −28.328 58.552 1.0014.30 E ATOM 6048 O ASN E 57 −35.004 −27.744 57.516 1.00 12.02 E ATOM6049 N TRP E 58 −35.924 −29.330 58.829 1.00 14.50 E ATOM 6050 CA TRP E58 −36.908 −29.960 57.906 1.00 14.67 E ATOM 6051 CB TRP E 58 −37.772−30.901 58.719 1.00 16.80 E ATOM 6052 CG TRP E 58 −38.855 −31.635 58.0261.00 20.49 E ATOM 6053 CD2 TRP E 58 −38.736 −32.429 56.891 1.00 21.32 EATOM 6054 CE2 TRP E 58 −40.018 −33.041 56.653 1.00 22.89 E ATOM 6055 CE3TRP E 58 −37.692 −32.700 56.034 1.00 21.09 E ATOM 6056 CD1 TRP E 58−40.177 −31.760 58.446 1.00 24.00 E ATOM 6057 NE1 TRP E 58 −40.884−32.609 57.622 1.00 24.86 E ATOM 6058 CZ2 TRP E 58 −40.253 −33.92455.568 1.00 23.20 E ATOM 6059 CZ3 TRP E 58 −37.927 −33.586 54.951 1.0021.85 E ATOM 6060 CH2 TRP E 58 −39.192 −34.181 54.739 1.00 23.10 E ATOM6061 C TRP E 58 −37.742 −28.884 57.224 1.00 14.39 E ATOM 6062 O TRP E 58−38.357 −28.091 57.838 1.00 13.90 E ATOM 6063 N VAL E 59 −37.748 −28.84555.911 1.00 16.03 E ATOM 6064 CA VAL E 59 −38.491 −27.784 55.247 1.0016.25 E ATOM 6065 CB VAL E 59 −37.495 −26.765 54.464 1.00 16.30 E ATOM6066 CG1 VAL E 59 −38.263 −25.743 53.635 1.00 14.52 E ATOM 6067 CG2 VALE 59 −36.534 −26.072 55.464 1.00 11.90 E ATOM 6068 C VAL E 59 −39.419−28.504 54.283 1.00 16.84 E ATOM 6069 O VAL E 59 −38.973 −29.270 53.4581.00 18.24 E ATOM 6070 N TYR E 60 −40.707 −28.182 54.397 1.00 17.02 EATOM 6071 CA TYR E 60 −41.768 −28.723 53.615 1.00 14.98 E ATOM 6072 CBTYR E 60 −43.129 −28.336 54.158 1.00 14.59 E ATOM 6073 CG TYR E 60−43.611 −29.095 55.351 1.00 15.80 E ATOM 6074 CD1 TYR E 60 −43.637−28.499 56.622 1.00 15.68 E ATOM 6075 CE1 TYR E 60 −43.922 −29.24257.751 1.00 15.80 E ATOM 6076 CD2 TYR E 60 −43.897 −30.444 55.277 1.0015.96 E ATOM 6077 CE2 TYR E 60 −44.189 −31.166 56.441 1.00 16.82 E ATOM6078 CZ TYR E 60 −44.195 −30.531 57.660 1.00 15.99 E ATOM 6079 OH TYR E60 −44.528 −31.262 58.779 1.00 18.24 E ATOM 6080 C TYR E 60 −41.651−28.148 52.248 1.00 15.23 E ATOM 6081 O TYR E 60 −41.393 −26.968 52.0991.00 15.08 E ATOM 6082 N ARG E 61 −41.842 −28.984 51.222 1.00 15.41 EATOM 6083 CA ARG E 61 −41.782 −28.483 49.873 1.00 15.24 E ATOM 6084 CBARG E 61 −41.580 −29.651 48.948 1.00 16.41 E ATOM 6085 CG ARG E 61−41.865 −29.377 47.389 1.00 16.00 E ATOM 6086 CD ARG E 61 −41.389−30.574 46.567 1.00 16.59 E ATOM 6087 NE ARG E 61 −42.411 −31.648 46.5891.00 14.77 E ATOM 6088 CZ ARG E 61 −43.534 −31.596 45.859 1.00 12.78 EATOM 6089 NH1 ARG E 61 −43.774 −30.579 45.066 1.00 13.11 E ATOM 6090 NH2ARG E 61 −44.450 −32.495 45.982 1.00 11.46 E ATOM 6091 C ARG E 61−43.053 −27.761 49.433 1.00 15.89 E ATOM 6092 O ARG E 61 −43.083 −26.83248.623 1.00 15.16 E ATOM 6093 N GLY E 62 −44.142 −28.232 49.964 1.0017.47 E ATOM 6094 CA GLY E 62 −45.448 −27.758 49.507 1.00 18.94 E ATOM6095 C GLY E 62 −45.549 −27.969 47.960 1.00 20.23 E ATOM 6096 O GLY E 62−45.263 −29.046 47.402 1.00 20.50 E ATOM 6097 N GLU E 63 −45.857 −26.89947.251 1.00 21.20 E ATOM 6098 CA GLU E 63 −46.056 −26.938 45.804 1.0020.96 E ATOM 6099 CB GLU E 63 −47.237 −25.961 45.542 1.00 20.90 E ATOM6100 CG GLU E 63 −47.547 −25.661 44.165 1.00 22.47 E ATOM 6101 CD GLU E63 −48.359 −26.798 43.581 1.00 26.60 E ATOM 6102 OE1 GLU E 63 −48.673−26.771 42.304 1.00 24.49 E ATOM 6103 OE2 GLU E 63 −48.679 −27.72844.499 1.00 30.49 E ATOM 6104 C GLU E 63 −44.752 −26.552 45.064 1.0021.80 E ATOM 6105 O GLU E 63 −44.712 −26.519 43.875 1.00 23.85 E ATOM6106 N ALA E 64 −43.634 −26.293 45.714 1.00 21.22 E ATOM 6107 CA ALA E64 −42.449 −25.876 44.961 1.00 19.40 E ATOM 6108 CB ALA E 64 −41.409−25.422 45.948 1.00 14.31 E ATOM 6109 C ALA E 64 −41.875 −27.019 44.0661.00 19.72 E ATOM 6110 O ALA E 64 −41.899 −28.200 44.480 1.00 21.85 EATOM 6111 N GLU E 65 −41.361 −26.686 42.860 1.00 19.85 E ATOM 6112 CAGLU E 65 −40.656 −27.656 41.960 1.00 19.09 E ATOM 6113 CB GLU E 65−41.137 −27.553 40.527 1.00 20.89 E ATOM 6114 CG GLU E 65 −42.735−27.667 40.331 1.00 24.27 E ATOM 6115 CD GLU E 65 −43.218 −29.161 40.1231.00 25.72 E ATOM 6116 OE1 GLU E 65 −42.675 −29.849 39.161 1.00 23.25 EATOM 6117 OE2 GLU E 65 −44.099 −29.630 40.961 1.00 28.03 E ATOM 6118 CGLU E 65 −39.165 −27.290 41.972 1.00 17.26 E ATOM 6119 O GLU E 65−38.290 −28.138 42.085 1.00 15.65 E ATOM 6120 N ARG E 66 −38.895 −26.01841.792 1.00 16.68 E ATOM 6121 CA ARG E 66 −37.526 −25.455 41.850 1.0017.26 E ATOM 6122 CB ARG E 66 −37.182 −24.732 40.588 1.00 15.97 E ATOM6123 CG ARG E 66 −35.732 −24.523 40.525 1.00 18.16 E ATOM 6124 CD ARG E66 −35.197 −24.574 39.036 1.00 20.10 E ATOM 6125 NE ARG E 66 −33.736−24.528 38.792 1.00 20.79 E ATOM 6126 CZ ARG E 66 −32.859 −25.553 38.6901.00 20.84 E ATOM 6127 NH1 ARG E 66 −33.232 −26.857 38.818 1.00 21.34 EATOM 6128 NH2 ARG E 66 −31.581 −25.253 38.409 1.00 19.26 E ATOM 6129 CARG E 66 −37.563 −24.420 43.001 1.00 17.96 E ATOM 6130 O ARG E 66−38.556 −23.701 43.157 1.00 18.70 E ATOM 6131 N ASN E 67 −36.532 −24.36243.833 1.00 18.78 E ATOM 6132 CA ASN E 67 −36.530 −23.337 44.901 1.0018.75 E ATOM 6133 CB ASN E 67 −36.535 −23.994 46.286 1.00 19.72 E ATOM6134 CG ASN E 67 −35.572 −25.128 46.336 1.00 22.12 E ATOM 6135 OD1 ASN E67 −35.401 −25.751 45.252 1.00 27.94 E ATOM 6136 ND2 ASN E 67 −34.959−25.472 47.488 1.00 16.83 E ATOM 6137 C ASN E 67 −35.253 −22.584 44.6321.00 19.17 E ATOM 6138 O ASN E 67 −34.345 −23.135 44.053 1.00 19.21 EATOM 6139 N ASN E 68 −35.202 −21.310 44.983 1.00 18.78 E ATOM 6140 CAASN E 68 −34.014 −20.478 44.816 1.00 18.14 E ATOM 6141 CB ASN E 68−34.433 −19.155 44.207 1.00 19.80 E ATOM 6142 CG ASN E 68 −34.941−19.321 42.781 1.00 22.23 E ATOM 6143 OD1 ASN E 68 −34.142 −19.29841.804 1.00 22.35 E ATOM 6144 ND2 ASN E 68 −36.282 −19.553 42.616 1.0022.95 E ATOM 6145 C ASN E 68 −33.467 −20.221 46.237 1.00 18.36 E ATOM6146 O ASN E 68 −34.300 −20.110 47.234 1.00 18.17 E ATOM 6147 N PHE E 69−32.128 −20.227 46.395 1.00 17.31 E ATOM 6148 CA PHE E 69 −31.577−19.848 47.707 1.00 17.41 E ATOM 6149 CB PHE E 69 −31.071 −20.952 48.5831.00 18.43 E ATOM 6150 CG PHE E 69 −30.881 −22.162 47.891 1.00 20.34 EATOM 6151 CD1 PHE E 69 −30.088 −22.173 46.783 1.00 22.64 E ATOM 6152 CD2PHE E 69 −31.406 −23.328 48.366 1.00 19.77 E ATOM 6153 CE1 PHE E 69−29.782 −23.391 46.109 1.00 24.52 E ATOM 6154 CE2 PHE E 69 −31.133−24.503 47.750 1.00 20.70 E ATOM 6155 CZ PHE E 69 −30.312 −24.562 46.6071.00 21.88 E ATOM 6156 C PHE E 69 −30.538 −18.779 47.711 1.00 16.19 EATOM 6157 O PHE E 69 −29.564 −18.786 47.000 1.00 16.60 E ATOM 6158 N GLUE 70 −30.811 −17.804 48.542 1.00 15.29 E ATOM 6159 CA GLU E 70 −29.941−16.652 48.626 1.00 15.38 E ATOM 6160 CB GLU E 70 −30.809 −15.391 48.6121.00 15.60 E ATOM 6161 CG GLU E 70 −30.153 −14.188 48.177 1.00 16.93 EATOM 6162 CD GLU E 70 −30.922 −12.873 48.635 1.00 19.44 E ATOM 6163 OE1GLU E 70 −31.036 −11.898 47.766 1.00 19.19 E ATOM 6164 OE2 GLU E 70−31.384 −12.790 49.854 1.00 17.96 E ATOM 6165 C GLU E 70 −29.125 −16.81649.907 1.00 13.25 E ATOM 6166 O GLU E 70 −29.677 −17.056 50.942 1.0011.55 E ATOM 6167 N LEU E 71 −27.812 −16.804 49.727 1.00 13.10 E ATOM6168 CA LEU E 71 −26.806 −16.855 50.807 1.00 14.19 E ATOM 6169 CB LEU E71 −25.794 −17.950 50.540 1.00 14.82 E ATOM 6170 CG LEU E 71 −26.395−19.292 50.450 1.00 15.47 E ATOM 6171 CD1 LEU E 71 −25.465 −20.22149.900 1.00 16.88 E ATOM 6172 CD2 LEU E 71 −26.809 −19.710 51.824 1.0017.13 E ATOM 6173 C LEU E 71 −26.077 −15.529 50.869 1.00 13.51 E ATOM6174 O LEU E 71 −25.719 −15.019 49.827 1.00 13.35 E ATOM 6175 N ASN E 72−25.904 −14.984 52.070 1.00 13.53 E ATOM 6176 CA ASN E 72 −25.221−13.699 52.413 1.00 13.41 E ATOM 6177 CB ASN E 72 −26.262 −12.747 53.0041.00 13.76 E ATOM 6178 CG ASN E 72 −26.854 −11.816 51.949 1.00 15.72 EATOM 6179 OD1 ASN E 72 −27.948 −11.162 52.030 1.00 14.06 E ATOM 6180 ND2ASN E 72 −26.081 −11.721 50.899 1.00 19.82 E ATOM 6181 C ASN E 72−24.157 −14.199 53.466 1.00 14.48 E ATOM 6182 O ASN E 72 −24.476 −14.82354.494 1.00 14.71 E ATOM 6183 N PHE E 73 −22.884 −13.978 53.155 1.0014.52 E ATOM 6184 CA PHE E 73 −21.795 −14.388 53.965 1.00 14.06 E ATOM6185 CB PHE E 73 −21.488 −15.794 53.599 1.00 15.94 E ATOM 6186 CG PHE E73 −21.114 −15.963 52.098 1.00 17.14 E ATOM 6187 CD1 PHE E 73 −19.800−15.893 51.678 1.00 16.19 E ATOM 6188 CD2 PHE E 73 −22.135 −16.15851.101 1.00 18.13 E ATOM 6189 CE1 PHE E 73 −19.470 −16.002 50.317 1.0018.48 E ATOM 6190 CE2 PHE E 73 −21.795 −16.265 49.718 1.00 19.69 E ATOM6191 CZ PHE E 73 −20.432 −16.182 49.320 1.00 18.38 E ATOM 6192 C PHE E73 −20.565 −13.530 53.719 1.00 13.10 E ATOM 6193 O PHE E 73 −20.555−12.661 52.841 1.00 11.99 E ATOM 6194 N THR E 74 −19.518 −13.810 54.4771.00 12.48 E ATOM 6195 CA THR E 74 −18.253 −13.070 54.291 1.00 14.51 EATOM 6196 CB THR E 74 −17.872 −11.995 55.398 1.00 12.83 E ATOM 6197 OG1THR E 74 −17.494 −12.721 56.591 1.00 13.04 E ATOM 6198 CG2 THR E 74−18.973 −11.147 55.701 1.00 11.29 E ATOM 6199 C THR E 74 −17.258 −14.11154.509 1.00 14.04 E ATOM 6200 O THR E 74 −17.507 −15.090 55.210 1.0015.22 E ATOM 6201 N VAL E 75 −16.093 −13.820 53.962 1.00 15.40 E ATOM6202 CA VAL E 75 −14.959 −14.741 54.055 1.00 16.62 E ATOM 6203 CB VAL E75 −14.848 −15.457 52.750 1.00 15.81 E ATOM 6204 CG1 VAL E 75 −13.743−16.442 52.752 1.00 12.67 E ATOM 6205 CG2 VAL E 75 −16.206 −16.06052.488 1.00 14.62 E ATOM 6206 C VAL E 75 −13.674 −14.030 54.441 1.0015.35 E ATOM 6207 O VAL E 75 −13.290 −13.079 53.774 1.00 14.97 E ATOM6208 N ARG E 76 −13.075 −14.462 55.558 1.00 15.15 E ATOM 6209 CA ARG E76 −11.852 −13.814 55.942 1.00 15.96 E ATOM 6210 CB ARG E 76 −11.464−14.109 57.368 1.00 16.60 E ATOM 6211 CG ARG E 76 −10.273 −13.385 57.7761.00 15.83 E ATOM 6212 CD ARG E 76 −10.324 −13.175 59.274 1.00 18.02 EATOM 6213 NE ARG E 76 −8.934 −12.927 59.682 1.00 18.59 E ATOM 6214 CZARG E 76 −8.403 −13.055 60.893 1.00 18.47 E ATOM 6215 NH1 ARG E 76−9.125 −13.392 61.991 1.00 18.14 E ATOM 6216 NH2 ARG E 76 −7.085 −13.04860.935 1.00 15.37 E ATOM 6217 C ARG E 76 −10.794 −14.308 55.013 1.0015.68 E ATOM 6218 O ARG E 76 −10.772 −15.482 54.720 1.00 15.43 E ATOM6219 N ASP E 77 −9.971 −13.371 54.527 1.00 16.75 E ATOM 6220 CA ASP E 77−8.818 −13.585 53.629 1.00 16.19 E ATOM 6221 CB ASP E 77 −8.206 −12.24053.314 1.00 17.88 E ATOM 6222 CG ASP E 77 −6.775 −12.310 52.629 1.0019.17 E ATOM 6223 OD1 ASP E 77 −6.324 −13.383 52.191 1.00 20.98 E ATOM6224 OD2 ASP E 77 −6.073 −11.265 52.527 1.00 18.67 E ATOM 6225 C ASP E77 −7.850 −14.531 54.325 1.00 17.22 E ATOM 6226 O ASP E 77 −7.530−14.431 55.524 1.00 16.25 E ATOM 6227 N CYS E 78 −7.445 −15.534 53.5751.00 17.78 E ATOM 6228 CA CYS E 78 −6.565 −16.553 54.082 1.00 17.63 EATOM 6229 C CYS E 78 −5.167 −16.083 54.393 1.00 18.33 E ATOM 6230 O CYSE 78 −4.454 −16.736 55.186 1.00 18.96 E ATOM 6231 CB CYS E 78 −6.479−17.735 53.139 1.00 17.54 E ATOM 6232 SG CYS E 78 −7.731 −19.076 53.5341.00 17.45 E ATOM 6233 N ASN E 79 −4.807 −14.939 53.814 1.00 17.70 EATOM 6234 CA ASN E 79 −3.497 −14.372 54.062 1.00 16.39 E ATOM 6235 CBASN E 79 −2.990 −13.636 52.824 1.00 17.34 E ATOM 6236 CG ASN E 79 −2.604−14.575 51.648 1.00 16.94 E ATOM 6237 OD1 ASN E 79 −2.458 −14.126 50.5691.00 18.11 E ATOM 6238 ND2 ASN E 79 −2.457 −15.849 51.871 1.00 19.57 EATOM 6239 C ASN E 79 −3.464 −13.427 55.290 1.00 15.90 E ATOM 6240 O ASNE 79 −2.412 −12.907 55.653 1.00 14.33 E ATOM 6241 N SER E 80 −4.638−13.232 55.894 1.00 16.17 E ATOM 6242 CA SER E 80 −4.816 −12.393 57.0541.00 16.30 E ATOM 6243 CB SER E 80 −6.209 −11.902 57.094 1.00 16.42 EATOM 6244 OG SER E 80 −7.079 −12.953 57.496 1.00 17.09 E ATOM 6245 C SERE 80 −4.522 −13.227 58.328 1.00 16.75 E ATOM 6246 O SER E 80 −4.810−12.789 59.394 1.00 16.99 E ATOM 6247 N PHE E 81 −4.016 −14.448 58.2271.00 16.78 E ATOM 6248 CA PHE E 81 −3.617 −15.132 59.462 1.00 16.00 EATOM 6249 CB PHE E 81 −4.207 −16.533 59.493 1.00 16.43 E ATOM 6250 CGPHE E 81 −5.726 −16.600 59.493 1.00 15.74 E ATOM 6251 CD1 PHE E 81−6.451 −16.671 58.324 1.00 16.05 E ATOM 6252 CD2 PHE E 81 −6.436 −16.48060.673 1.00 14.91 E ATOM 6253 CE1 PHE E 81 −7.855 −16.598 58.343 1.0015.28 E ATOM 6254 CE2 PHE E 81 −7.820 −16.408 60.683 1.00 13.54 E ATOM6255 CZ PHE E 81 −8.522 −16.460 59.526 1.00 13.66 E ATOM 6256 C PHE E 81−2.024 −15.161 59.395 1.00 15.94 E ATOM 6257 O PHE E 81 −1.458 −15.90958.602 1.00 15.49 E ATOM 6258 N PRO E 82 −1.309 −14.349 60.252 1.0017.28 E ATOM 6259 CD PRO E 82 −1.876 −13.871 61.555 1.00 17.72 E ATOM6260 CA PRO E 82 0.181 −14.229 60.316 1.00 16.68 E ATOM 6261 CB PRO E 820.429 −13.529 61.681 1.00 18.21 E ATOM 6262 CG PRO E 82 −0.909 −12.81962.026 1.00 17.84 E ATOM 6263 C PRO E 82 0.968 −15.482 60.256 1.00 14.82E ATOM 6264 O PRO E 82 0.768 −16.383 61.068 1.00 12.06 E ATOM 6265 N GLYE 83 1.933 −15.478 59.378 1.00 15.96 E ATOM 6266 CA GLY E 83 2.726−16.680 59.171 1.00 17.76 E ATOM 6267 C GLY E 83 1.826 −17.401 58.1041.00 18.64 E ATOM 6268 O GLY E 83 0.666 −16.983 57.741 1.00 19.46 E ATOM6269 N GLY E 84 2.240 −18.477 57.497 1.00 19.44 E ATOM 6270 CA GLY E 841.187 −18.903 56.526 1.00 19.59 E ATOM 6271 C GLY E 84 −0.014 −19.61857.123 1.00 19.37 E ATOM 6272 O GLY E 84 −0.063 −19.776 58.307 1.0019.69 E ATOM 6273 N ALA E 85 −1.068 −19.976 56.380 1.00 19.96 E ATOM6274 CA ALA E 85 −2.199 −20.799 56.993 1.00 19.30 E ATOM 6275 CB ALA E85 −3.463 −19.923 57.369 1.00 18.79 E ATOM 6276 C ALA E 85 −2.494−21.775 55.875 1.00 18.29 E ATOM 6277 O ALA E 85 −3.501 −21.699 55.2151.00 19.66 E ATOM 6278 N SER E 86 −1.551 −22.641 55.623 1.00 17.08 EATOM 6279 CA SER E 86 −1.660 −23.605 54.554 1.00 15.47 E ATOM 6280 CBSER E 86 −0.547 −24.661 54.686 1.00 13.48 E ATOM 6281 OG SER E 86 −0.563−25.451 55.823 1.00 7.69 E ATOM 6282 C SER E 86 −2.984 −24.307 54.3121.00 15.71 E ATOM 6283 O SER E 86 −3.321 −24.372 53.225 1.00 16.72 EATOM 6284 N SER E 87 −3.710 −24.833 55.294 1.00 14.82 E ATOM 6285 CA SERE 87 −4.983 −25.535 55.105 1.00 13.49 E ATOM 6286 CB SER E 87 −5.203−26.588 56.230 1.00 12.95 E ATOM 6287 OG SER E 87 −5.582 −25.988 57.5281.00 12.88 E ATOM 6288 C SER E 87 −6.213 −24.616 55.040 1.00 13.31 EATOM 6289 O SER E 87 −7.299 −25.079 54.962 1.00 12.98 E ATOM 6290 N CYSE 88 −6.000 −23.316 55.080 1.00 13.59 E ATOM 6291 CA CYS E 88 −7.066−22.336 55.071 1.00 14.64 E ATOM 6292 C CYS E 88 −7.651 −22.392 53.6691.00 14.44 E ATOM 6293 O CYS E 88 −6.968 −22.687 52.762 1.00 14.06 EATOM 6294 CB CYS E 88 −6.496 −20.944 55.374 1.00 14.18 E ATOM 6295 SGCYS E 88 −7.662 −19.563 55.471 1.00 14.76 E ATOM 6296 N LYS E 89 −8.929−22.119 53.559 1.00 15.70 E ATOM 6297 CA LYS E 89 −9.665 −22.196 52.3231.00 17.40 E ATOM 6298 CB LYS E 89 −10.669 −23.348 52.402 1.00 17.23 EATOM 6299 CG LYS E 89 −9.961 −24.681 52.491 1.00 20.05 E ATOM 6300 CDLYS E 89 −9.193 −25.021 51.083 1.00 20.00 E ATOM 6301 CE LYS E 89 −8.532−26.410 51.119 1.00 23.12 E ATOM 6302 NZ LYS E 89 −7.897 −26.803 49.8301.00 26.04 E ATOM 6303 C LYS E 89 −10.485 −20.939 52.204 1.00 18.57 EATOM 6304 O LYS E 89 −10.697 −20.307 53.225 1.00 19.95 E ATOM 6305 N GLUE 90 −11.001 −20.605 51.004 1.00 17.71 E ATOM 6306 CA GLU E 90 −11.830−19.463 50.861 1.00 16.42 E ATOM 6307 CB GLU E 90 −11.066 −18.290 50.2531.00 16.22 E ATOM 6308 CG GLU E 90 −9.826 −17.865 51.085 1.00 16.01 EATOM 6309 CD GLU E 90 −9.039 −16.687 50.474 1.00 15.59 E ATOM 6310 OE1GLU E 90 −8.772 −16.722 49.283 1.00 17.47 E ATOM 6311 OE2 GLU E 90−8.670 −15.742 51.126 1.00 12.32 E ATOM 6312 C GLU E 90 −13.101 −19.79150.100 1.00 16.80 E ATOM 6313 O GLU E 90 −13.587 −19.010 49.259 1.0017.69 E ATOM 6314 N THR E 91 −13.690 −20.926 50.413 1.00 15.11 E ATOM6315 CA THR E 91 −14.945 −21.295 49.748 1.00 13.04 E ATOM 6316 CB THR E91 −14.763 −22.034 48.314 1.00 12.30 E ATOM 6317 OG1 THR E 91 −14.057−23.242 48.468 1.00 10.81 E ATOM 6318 CG2 THR E 91 −14.084 −21.16647.304 1.00 10.91 E ATOM 6319 C THR E 91 −15.521 −22.273 50.694 1.0013.17 E ATOM 6320 O THR E 91 −14.785 −22.740 51.609 1.00 12.32 E ATOM6321 N PHE E 92 −16.819 −22.552 50.498 1.00 13.58 E ATOM 6322 CA PHE E92 −17.586 −23.547 51.267 1.00 15.03 E ATOM 6323 CB PHE E 92 −18.282−22.969 52.502 1.00 15.29 E ATOM 6324 CG PHE E 92 −19.311 −21.955 52.2001.00 16.38 E ATOM 6325 CD1 PHE E 92 −20.599 −22.282 52.117 1.00 17.33 EATOM 6326 CD2 PHE E 92 −18.972 −20.645 52.065 1.00 16.21 E ATOM 6327 CE1PHE E 92 −21.529 −21.305 51.917 1.00 19.03 E ATOM 6328 CE2 PHE E 92−19.874 −19.678 51.849 1.00 16.57 E ATOM 6329 CZ PHE E 92 −21.143−19.979 51.783 1.00 18.33 E ATOM 6330 C PHE E 92 −18.606 −24.196 50.4341.00 15.15 E ATOM 6331 O PHE E 92 −19.003 −23.654 49.443 1.00 16.22 EATOM 6332 N ASN E 93 −19.107 −25.337 50.888 1.00 15.62 E ATOM 6333 CAASN E 93 −20.085 −26.150 50.098 1.00 15.17 E ATOM 6334 CB ASN E 93−19.608 −27.545 50.031 1.00 13.93 E ATOM 6335 CG ASN E 93 −18.381−27.630 49.246 1.00 13.21 E ATOM 6336 OD1 ASN E 93 −18.272 −27.03248.180 1.00 14.04 E ATOM 6337 ND2 ASN E 93 −17.431 −28.332 49.758 1.0010.33 E ATOM 6338 C ASN E 93 −21.552 −26.220 50.388 1.00 15.92 E ATOM6339 O ASN E 93 −21.951 −26.322 51.494 1.00 16.30 E ATOM 6340 N LEU E 94−22.367 −26.149 49.351 1.00 16.65 E ATOM 6341 CA LEU E 94 −23.745−26.211 49.551 1.00 16.33 E ATOM 6342 CB LEU E 94 −24.385 −25.088 48.7701.00 16.88 E ATOM 6343 CG LEU E 94 −25.939 −24.974 48.781 1.00 17.95 EATOM 6344 CD1 LEU E 94 −26.449 −24.793 50.277 1.00 16.58 E ATOM 6345 CD2LEU E 94 −26.323 −23.776 47.878 1.00 15.22 E ATOM 6346 C LEU E 94−24.270 −27.579 49.089 1.00 16.93 E ATOM 6347 O LEU E 94 −23.914 −28.04048.031 1.00 15.67 E ATOM 6348 N TYR E 95 −25.106 −28.195 49.947 1.0017.18 E ATOM 6349 CA TYR E 95 −25.852 −29.434 49.705 1.00 16.91 E ATOM6350 CB TYR E 95 −25.259 −30.557 50.514 1.00 19.26 E ATOM 6351 CG TYR E95 −23.869 −30.984 50.135 1.00 19.91 E ATOM 6352 CD1 TYR E 95 −22.727−30.109 50.298 1.00 19.04 E ATOM 6353 CE1 TYR E 95 −21.442 −30.57849.963 1.00 18.87 E ATOM 6354 CD2 TYR E 95 −23.661 −32.301 49.641 1.0019.19 E ATOM 6355 CE2 TYR E 95 −22.361 −32.724 49.328 1.00 19.91 E ATOM6356 CZ TYR E 95 −21.314 −31.869 49.501 1.00 19.01 E ATOM 6357 OH TYR E95 −20.164 −32.429 49.241 1.00 22.56 E ATOM 6358 C TYR E 95 −27.342−29.385 50.135 1.00 16.09 E ATOM 6359 O TYR E 95 −27.829 −28.519 50.9351.00 14.36 E ATOM 6360 N TYR E 96 −28.022 −30.430 49.710 1.00 14.99 EATOM 6361 CA TYR E 96 −29.405 −30.586 50.129 1.00 14.75 E ATOM 6362 CBTYR E 96 −30.360 −29.811 49.250 1.00 15.33 E ATOM 6363 CG TYR E 96−30.653 −30.506 47.948 1.00 16.05 E ATOM 6364 CD1 TYR E 96 −31.846−31.182 47.733 1.00 17.53 E ATOM 6365 CE1 TYR E 96 −32.099 −31.89346.508 1.00 17.27 E ATOM 6366 CD2 TYR E 96 −29.705 −30.542 46.947 1.0016.61 E ATOM 6367 CE2 TYR E 96 −29.913 −31.236 45.778 1.00 16.73 E ATOM6368 CZ TYR E 96 −31.108 −31.894 45.562 1.00 17.15 E ATOM 6369 OH TYR E96 −31.258 −32.459 44.366 1.00 16.74 E ATOM 6370 C TYR E 96 −29.716−32.099 50.037 1.00 13.64 E ATOM 6371 O TYR E 96 −28.927 −32.853 49.5721.00 11.59 E ATOM 6372 N ALA E 97 −30.854 −32.485 50.599 1.00 13.95 EATOM 6373 CA ALA E 97 −31.366 −33.828 50.570 1.00 15.10 E ATOM 6374 CBALA E 97 −30.856 −34.760 51.782 1.00 13.81 E ATOM 6375 C ALA E 97−32.851 −33.631 50.603 1.00 14.09 E ATOM 6376 O ALA E 97 −33.353 −32.60651.073 1.00 13.80 E ATOM 6377 N GLU E 98 −33.517 −34.611 49.996 1.0015.05 E ATOM 6378 CA GLU E 98 −35.008 −34.707 49.902 1.00 15.83 E ATOM6379 CB GLU E 98 −35.428 −34.923 48.473 1.00 14.87 E ATOM 6380 CG GLU E98 −35.615 −33.623 47.705 1.00 15.57 E ATOM 6381 CD GLU E 98 −36.085−33.881 46.218 1.00 15.31 E ATOM 6382 OE1 GLU E 98 −35.316 −34.32445.361 1.00 13.39 E ATOM 6383 OE2 GLU E 98 −37.247 −33.646 45.961 1.0016.49 E ATOM 6384 C GLU E 98 −35.493 −35.873 50.753 1.00 14.85 E ATOM6385 O GLU E 98 −34.792 −36.884 50.896 1.00 16.25 E ATOM 6386 N SER E 99−36.591 −35.713 51.448 1.00 14.03 E ATOM 6387 CA SER E 99 −37.144−36.906 52.059 1.00 14.68 E ATOM 6388 CB SER E 99 −36.371 −37.501 53.2441.00 11.64 E ATOM 6389 OG SER E 99 −36.464 −36.657 54.248 1.00 12.92 EATOM 6390 C SER E 99 −38.632 −36.746 52.354 1.00 14.77 E ATOM 6391 O SERE 99 −39.162 −35.679 52.362 1.00 15.41 E ATOM 6392 N ASP E 100 −39.319−37.838 52.564 1.00 15.55 E ATOM 6393 CA ASP E 100 −40.704 −37.74052.846 1.00 16.63 E ATOM 6394 CB ASP E 100 −41.504 −38.899 52.193 1.0017.49 E ATOM 6395 CG ASP E 100 −41.602 −38.795 50.644 1.00 18.85 E ATOM6396 OD1 ASP E 100 −41.892 −37.656 50.151 1.00 17.20 E ATOM 6397 OD2 ASPE 100 −41.345 −39.884 49.949 1.00 19.56 E ATOM 6398 C ASP E 100 −40.938−37.719 54.287 1.00 16.71 E ATOM 6399 O ASP E 100 −42.013 −37.382 54.6881.00 16.40 E ATOM 6400 N LEU E 101 −39.941 −38.146 55.054 1.00 17.37 EATOM 6401 CA LEU E 101 −39.931 −38.213 56.527 1.00 17.39 E ATOM 6402 CBLEU E 101 −39.378 −39.503 57.102 1.00 17.46 E ATOM 6403 CG LEU E 101−39.594 −40.865 56.569 1.00 19.04 E ATOM 6404 CD1 LEU E 101 −39.205−40.840 55.139 1.00 16.93 E ATOM 6405 CD2 LEU E 101 −38.767 −41.87557.403 1.00 17.43 E ATOM 6406 C LEU E 101 −38.919 −37.137 57.069 1.0018.40 E ATOM 6407 O LEU E 101 −37.964 −36.765 56.364 1.00 18.46 E ATOM6408 N ASP E 102 −39.146 −36.703 58.333 1.00 18.50 E ATOM 6409 CA ASP E102 −38.316 −35.754 59.060 1.00 17.72 E ATOM 6410 CB ASP E 102 −39.145−35.128 60.121 1.00 18.22 E ATOM 6411 CG ASP E 102 −38.426 −34.01260.887 1.00 19.07 E ATOM 6412 OD1 ASP E 102 −37.125 −34.029 60.991 1.0017.53 E ATOM 6413 OD2 ASP E 102 −39.221 −33.149 61.384 1.00 17.99 E ATOM6414 C ASP E 102 −37.258 −36.631 59.741 1.00 18.07 E ATOM 6415 O ASP E102 −37.589 −37.424 60.604 1.00 17.74 E ATOM 6416 N TYR E 103 −35.999−36.486 59.359 1.00 17.24 E ATOM 6417 CA TYR E 103 −34.931 −37.27759.923 1.00 15.91 E ATOM 6418 CB TYR E 103 −33.572 −37.037 59.180 1.0018.59 E ATOM 6419 CG TYR E 103 −33.393 −37.736 57.853 1.00 21.01 E ATOM6420 CD1 TYR E 103 −33.710 −39.118 57.706 1.00 22.98 E ATOM 6421 CE1 TYRE 103 −33.583 −39.806 56.432 1.00 23.16 E ATOM 6422 CD2 TYR E 103−32.971 −37.052 56.768 1.00 20.65 E ATOM 6423 CE2 TYR E 103 −32.864−37.686 55.549 1.00 22.35 E ATOM 6424 CZ TYR E 103 −33.150 −39.05655.362 1.00 23.18 E ATOM 6425 OH TYR E 103 −32.970 −39.562 54.073 1.0022.50 E ATOM 6426 C TYR E 103 −34.637 −36.954 61.367 1.00 15.32 E ATOM6427 O TYR E 103 −33.785 −37.655 62.007 1.00 12.42 E ATOM 6428 N GLY E104 −35.278 −35.879 61.862 1.00 14.82 E ATOM 6429 CA GLY E 104 −34.980−35.431 63.208 1.00 15.74 E ATOM 6430 C GLY E 104 −33.455 −35.150 63.3791.00 16.88 E ATOM 6431 O GLY E 104 −32.822 −34.379 62.648 1.00 16.81 EATOM 6432 N THR E 105 −32.806 −35.853 64.303 1.00 18.13 E ATOM 6433 CATHR E 105 −31.396 −35.611 64.490 1.00 18.61 E ATOM 6434 CB THR E 105−31.174 −35.692 65.992 1.00 19.97 E ATOM 6435 OG1 THR E 105 −31.410−34.345 66.507 1.00 20.30 E ATOM 6436 CG2 THR E 105 −29.836 −36.16266.350 1.00 18.82 E ATOM 6437 C THR E 105 −30.328 −36.332 63.641 1.0018.61 E ATOM 6438 O THR E 105 −29.162 −35.971 63.614 1.00 18.06 E ATOM6439 N ASN E 106 −30.788 −37.310 62.879 1.00 19.59 E ATOM 6440 CA ASN E106 −30.006 −38.155 62.005 1.00 19.02 E ATOM 6441 CB ASN E 106 −30.890−39.160 61.321 1.00 21.25 E ATOM 6442 CG ASN E 106 −31.167 −40.33262.139 1.00 23.24 E ATOM 6443 OD1 ASN E 106 −31.919 −41.211 61.698 1.0025.09 E ATOM 6444 ND2 ASN E 106 −30.545 −40.421 63.332 1.00 24.78 E ATOM6445 C ASN E 106 −29.446 −37.396 60.891 1.00 19.65 E ATOM 6446 O ASN E106 −30.075 −37.230 59.900 1.00 19.66 E ATOM 6447 N PHE E 107 −28.252−36.914 60.993 1.00 19.97 E ATOM 6448 CA PHE E 107 −27.720 −36.25559.812 1.00 18.63 E ATOM 6449 CB PHE E 107 −26.951 −35.018 60.228 1.0019.17 E ATOM 6450 CG PHE E 107 −26.181 −34.398 59.083 1.00 17.37 E ATOM6451 CD1 PHE E 107 −26.882 −33.740 58.031 1.00 17.32 E ATOM 6452 CD2 PHEE 107 −24.821 −34.546 59.017 1.00 14.92 E ATOM 6453 CE1 PHE E 107−26.241 −33.266 56.957 1.00 17.07 E ATOM 6454 CE2 PHE E 107 −24.140−34.100 57.976 1.00 14.54 E ATOM 6455 CZ PHE E 107 −24.844 −33.44656.910 1.00 17.52 E ATOM 6456 C PHE E 107 −26.749 −37.297 59.140 1.0019.38 E ATOM 6457 O PHE E 107 −25.982 −38.019 59.804 1.00 18.61 E ATOM6458 N GLN E 108 −26.763 −37.381 57.830 1.00 19.64 E ATOM 6459 CA GLN E108 −25.899 −38.420 57.151 1.00 18.89 E ATOM 6460 CB GLN E 108 −26.747−39.598 56.585 1.00 21.12 E ATOM 6461 CG GLN E 108 −27.830 −40.23357.558 1.00 21.41 E ATOM 6462 CD GLN E 108 −27.154 −41.316 58.272 1.0021.53 E ATOM 6463 OE1 GLN E 108 −27.783 −42.003 59.099 1.00 23.21 E ATOM6464 NE2 GLN E 108 −25.836 −41.506 57.982 1.00 18.21 E ATOM 6465 C GLN E108 −25.374 −37.729 55.966 1.00 18.44 E ATOM 6466 O GLN E 108 −26.048−37.626 54.959 1.00 18.73 E ATOM 6467 N LYS E 109 −24.172 −37.252 56.0341.00 17.82 E ATOM 6468 CA LYS E 109 −23.663 −36.495 54.891 1.00 17.27 EATOM 6469 CB LYS E 109 −22.196 −36.076 55.172 1.00 17.50 E ATOM 6470 CGLYS E 109 −21.225 −36.831 54.295 1.00 19.07 E ATOM 6471 CD LYS E 109−19.754 −36.876 54.774 1.00 19.43 E ATOM 6472 CE LYS E 109 −19.099−35.553 54.600 1.00 21.33 E ATOM 6473 NZ LYS E 109 −17.626 −35.82454.497 1.00 21.30 E ATOM 6474 C LYS E 109 −23.776 −37.224 53.569 1.0015.93 E ATOM 6475 O LYS E 109 −23.958 −36.634 52.527 1.00 16.56 E ATOM6476 N ARG E 110 −23.699 −38.525 53.630 1.00 16.29 E ATOM 6477 CA ARG E110 −23.718 −39.327 52.458 1.00 16.42 E ATOM 6478 CB ARG E 110 −23.203−40.719 52.814 1.00 17.44 E ATOM 6479 CG ARG E 110 −21.743 −40.67052.485 1.00 19.56 E ATOM 6480 CD ARG E 110 −20.868 −40.022 53.663 1.0021.63 E ATOM 6481 NE ARG E 110 −19.425 −39.884 53.254 1.00 22.79 E ATOM6482 CZ ARG E 110 −18.999 −38.938 52.383 1.00 24.03 E ATOM 6483 NH1 ARGE 110 −19.873 −38.022 51.831 1.00 22.73 E ATOM 6484 NH2 ARG E 110−17.713 −38.895 52.028 1.00 24.55 E ATOM 6485 C ARG E 110 −24.985−39.370 51.737 1.00 15.11 E ATOM 6486 O ARG E 110 −24.981 −39.771 50.6411.00 14.00 E ATOM 6487 N LEU E 111 −26.031 −38.867 52.363 1.00 16.11 EATOM 6488 CA LEU E 111 −27.362 −38.779 51.858 1.00 17.20 E ATOM 6489 CBLEU E 111 −28.313 −38.923 53.015 1.00 16.82 E ATOM 6490 CG LEU E 111−28.243 −40.300 53.625 1.00 17.62 E ATOM 6491 CD1 LEU E 111 −29.447−40.341 54.638 1.00 20.07 E ATOM 6492 CD2 LEU E 111 −28.379 −41.49952.584 1.00 16.54 E ATOM 6493 C LEU E 111 −27.586 −37.503 51.110 1.0017.24 E ATOM 6494 O LEU E 111 −28.554 −37.374 50.293 1.00 19.81 E ATOM6495 N PHE E 112 −26.719 −36.536 51.354 1.00 16.22 E ATOM 6496 CA PHE E112 −26.799 −35.207 50.676 1.00 14.57 E ATOM 6497 CB PHE E 112 −26.235−34.093 51.617 1.00 13.54 E ATOM 6498 CG PHE E 112 −27.162 −33.69152.683 1.00 12.97 E ATOM 6499 CD1 PHE E 112 −27.542 −34.616 53.657 1.0014.63 E ATOM 6500 CD2 PHE E 112 −27.687 −32.386 52.674 1.00 13.17 E ATOM6501 CE1 PHE E 112 −28.508 −34.252 54.686 1.00 15.88 E ATOM 6502 CE2 PHEE 112 −28.612 −31.944 53.619 1.00 14.40 E ATOM 6503 CZ PHE E 112 −29.060−32.900 54.672 1.00 17.13 E ATOM 6504 C PHE E 112 −26.123 −35.132 49.3331.00 12.88 E ATOM 6505 O PHE E 112 −25.232 −35.885 49.002 1.00 12.05 EATOM 6506 N THR E 113 −26.585 −34.200 48.541 1.00 13.03 E ATOM 6507 CATHR E 113 −26.069 −34.000 47.227 1.00 14.32 E ATOM 6508 CB THR E 113−27.179 −34.093 46.176 1.00 13.31 E ATOM 6509 OG1 THR E 113 −27.695−35.363 46.236 1.00 10.62 E ATOM 6510 CG2 THR E 113 −26.722 −33.78744.805 1.00 10.98 E ATOM 6511 C THR E 113 −25.532 −32.602 47.196 1.0015.03 E ATOM 6512 O THR E 113 −26.193 −31.654 47.643 1.00 15.83 E ATOM6513 N LYS E 114 −24.357 −32.458 46.588 1.00 15.80 E ATOM 6514 CA LYS E114 −23.749 −31.133 46.519 1.00 15.94 E ATOM 6515 CB LYS E 114 −22.219−31.216 46.207 1.00 15.87 E ATOM 6516 CG LYS E 114 −21.482 −29.89745.896 1.00 15.71 E ATOM 6517 CD LYS E 114 −19.940 −29.891 46.035 1.0015.07 E ATOM 6518 CE LYS E 114 −19.432 −28.458 45.728 1.00 14.75 E ATOM6519 NZ LYS E 114 −17.951 −28.224 45.588 1.00 12.28 E ATOM 6520 C LYS E114 −24.499 −30.361 45.497 1.00 16.48 E ATOM 6521 O LYS E 114 −24.899−30.923 44.484 1.00 16.39 E ATOM 6522 N ILE E 115 −24.725 −29.082 45.7931.00 16.61 E ATOM 6523 CA ILE E 115 −25.367 −28.213 44.850 1.00 16.39 EATOM 6524 CB ILE E 115 −26.386 −27.227 45.462 1.00 14.84 E ATOM 6525 CG2ILE E 115 −26.741 −26.202 44.437 1.00 11.81 E ATOM 6526 CG1 ILE E 115−27.653 −28.035 45.895 1.00 14.66 E ATOM 6527 CD1 ILE E 115 −28.615−27.527 46.817 1.00 9.75 E ATOM 6528 C ILE E 115 −24.307 −27.405 44.0861.00 17.37 E ATOM 6529 O ILE E 115 −24.395 −27.260 42.855 1.00 18.34 EATOM 6530 N ASP E 116 −23.308 −26.926 44.784 1.00 17.29 E ATOM 6531 CAASP E 116 −22.321 −26.076 44.190 1.00 16.48 E ATOM 6532 CB ASP E 116−22.956 −24.771 43.645 1.00 15.51 E ATOM 6533 CG ASP E 116 −21.982−23.940 42.695 1.00 15.30 E ATOM 6534 OD1 ASP E 116 −22.377 −22.87342.087 1.00 14.48 E ATOM 6535 OD2 ASP E 116 −20.844 −24.374 42.530 1.0012.31 E ATOM 6536 C ASP E 116 −21.353 −25.642 45.254 1.00 16.48 E ATOM6537 O ASP E 116 −21.630 −25.701 46.459 1.00 15.57 E ATOM 6538 N THR E117 −20.205 −25.157 44.771 1.00 16.45 E ATOM 6539 CA THR E 117 −19.198−24.570 45.642 1.00 16.37 E ATOM 6540 CB THR E 117 −17.855 −24.69044.989 1.00 15.90 E ATOM 6541 OG1 THR E 117 −17.589 −26.098 44.866 1.0015.41 E ATOM 6542 CG2 THR E 117 −16.804 −23.935 45.775 1.00 12.86 E ATOM6543 C THR E 117 −19.602 −23.074 45.776 1.00 18.17 E ATOM 6544 O THR E117 −19.869 −22.440 44.773 1.00 18.65 E ATOM 6545 N ILE E 118 −19.700−22.540 46.993 1.00 18.37 E ATOM 6546 CA ILE E 118 −19.948 −21.13647.199 1.00 17.75 E ATOM 6547 CB ILE E 118 −20.829 −20.968 48.414 1.0017.69 E ATOM 6548 CG2 ILE E 118 −21.264 −19.529 48.561 1.00 15.50 E ATOM6549 CG1 ILE E 118 −22.019 −21.909 48.313 1.00 17.52 E ATOM 6550 CD1 ILEE 118 −23.006 −21.639 47.101 1.00 16.32 E ATOM 6551 C ILE E 118 −18.611−20.339 47.383 1.00 18.29 E ATOM 6552 O ILE E 118 −17.805 −20.561 48.3071.00 18.52 E ATOM 6553 N ALA E 119 −18.374 −19.384 46.494 1.00 18.76 EATOM 6554 CA ALA E 119 −17.113 −18.573 46.540 1.00 18.15 E ATOM 6555 CBALA E 119 −16.327 −18.864 45.274 1.00 18.06 E ATOM 6556 C ALA E 119−17.424 −17.076 46.611 1.00 17.29 E ATOM 6557 O ALA E 119 −18.222−16.588 45.859 1.00 17.72 E ATOM 6558 N PRO E 120 −16.711 −16.339 47.4471.00 16.44 E ATOM 6559 CD PRO E 120 −15.536 −16.733 48.220 1.00 16.16 EATOM 6560 CA PRO E 120 −16.939 −14.931 47.574 1.00 16.14 E ATOM 6561 CBPRO E 120 −16.229 −14.612 48.854 1.00 16.22 E ATOM 6562 CG PRO E 120−15.044 −15.411 48.702 1.00 15.92 E ATOM 6563 C PRO E 120 −16.404−14.040 46.432 1.00 16.56 E ATOM 6564 O PRO E 120 −15.267 −14.150 45.9741.00 15.51 E ATOM 6565 N ASP E 121 −17.223 −13.114 45.977 1.00 16.58 EATOM 6566 CA ASP E 121 −16.705 −12.190 44.975 1.00 17.95 E ATOM 6567 CBASP E 121 −17.838 −11.352 44.474 1.00 20.01 E ATOM 6568 CG ASP E 121−19.063 −12.183 44.347 1.00 23.40 E ATOM 6569 OD1 ASP E 121 −19.613−12.703 45.500 1.00 24.39 E ATOM 6570 OD2 ASP E 121 −19.441 −12.36543.109 1.00 23.51 E ATOM 6571 C ASP E 121 −15.704 −11.268 45.666 1.0018.36 E ATOM 6572 O ASP E 121 −14.877 −10.644 44.994 1.00 19.20 E ATOM6573 N GLU E 122 −15.845 −11.125 47.004 1.00 16.89 E ATOM 6574 CA GLU E122 −15.024 −10.232 47.786 1.00 15.29 E ATOM 6575 CB GLU E 122 −15.720−8.930 47.947 1.00 15.71 E ATOM 6576 CG GLU E 122 −15.822 −8.082 46.7071.00 18.69 E ATOM 6577 CD GLU E 122 −16.290 −6.625 47.045 1.00 21.92 EATOM 6578 OE1 GLU E 122 −17.491 −6.434 47.423 1.00 20.67 E ATOM 6579 OE2GLU E 122 −15.427 −5.654 46.945 1.00 25.39 E ATOM 6580 C GLU E 122−14.588 −10.765 49.121 1.00 14.92 E ATOM 6581 O GLU E 122 −15.348−10.958 50.082 1.00 14.19 E ATOM 6582 N ILE E 123 −13.318 −11.037 49.1761.00 14.88 E ATOM 6583 CA ILE E 123 −12.735 −11.590 50.375 1.00 16.40 EATOM 6584 CB ILE E 123 −11.484 −12.301 49.944 1.00 18.48 E ATOM 6585 CG2ILE E 123 −10.498 −11.259 49.179 1.00 20.37 E ATOM 6586 CG1 ILE E 123−10.764 −12.819 51.116 1.00 20.55 E ATOM 6587 CD1 ILE E 123 −9.366−13.265 50.561 1.00 26.57 E ATOM 6588 C ILE E 123 −12.440 −10.403 51.3441.00 14.59 E ATOM 6589 O ILE E 123 −12.123 −9.365 50.939 1.00 13.75 EATOM 6590 N THR E 124 −12.586 −10.543 52.625 1.00 14.63 E ATOM 6591 CATHR E 124 −12.379 −9.359 53.479 1.00 16.51 E ATOM 6592 CB THR E 124−13.251 −9.427 54.690 1.00 16.26 E ATOM 6593 OG1 THR E 124 −14.610−9.206 54.296 1.00 16.59 E ATOM 6594 CG2 THR E 124 −12.813 −8.419 55.6671.00 16.04 E ATOM 6595 C THR E 124 −10.963 −9.355 53.928 1.00 15.70 EATOM 6596 O THR E 124 −10.580 −10.325 54.620 1.00 16.38 E ATOM 6597 NVAL E 125 −10.171 −8.361 53.528 1.00 14.98 E ATOM 6598 CA VAL E 125−8.752 −8.436 53.918 1.00 14.90 E ATOM 6599 CB VAL E 125 −7.728 −7.73352.932 1.00 15.04 E ATOM 6600 CG1 VAL E 125 −7.631 −8.524 51.564 1.0014.54 E ATOM 6601 CG2 VAL E 125 −8.081 −6.261 52.723 1.00 14.04 E ATOM6602 C VAL E 125 −8.470 −7.864 55.294 1.00 14.94 E ATOM 6603 O VAL E 125−9.325 −7.158 55.880 1.00 14.74 E ATOM 6604 N SER E 126 −7.300 −8.22155.831 1.00 14.54 E ATOM 6605 CA SER E 126 −6.901 −7.697 57.131 1.0014.49 E ATOM 6606 CB SER E 126 −5.457 −7.978 57.354 1.00 15.66 E ATOM6607 OG SER E 126 −4.853 −6.884 57.999 1.00 18.70 E ATOM 6608 C SER E126 −7.158 −6.171 57.333 1.00 13.59 E ATOM 6609 O SER E 126 −7.667−5.766 58.334 1.00 11.77 E ATOM 6610 N SER E 127 −6.833 −5.333 56.4001.00 14.09 E ATOM 6611 CA SER E 127 −7.085 −3.979 56.723 1.00 15.57 EATOM 6612 CB SER E 127 −6.277 −3.093 55.857 1.00 17.12 E ATOM 6613 OGSER E 127 −6.906 −3.089 54.601 1.00 20.60 E ATOM 6614 C SER E 127 −8.527−3.552 56.641 1.00 16.74 E ATOM 6615 O SER E 127 −8.823 −2.435 57.0911.00 16.95 E ATOM 6616 N ASP E 128 −9.408 −4.415 56.063 1.00 16.20 EATOM 6617 CA ASP E 128 −10.873 −4.216 55.930 1.00 14.45 E ATOM 6618 CBASP E 128 −11.482 −5.347 55.138 1.00 17.24 E ATOM 6619 CG ASP E 128−11.352 −5.150 53.556 1.00 19.18 E ATOM 6620 OD1 ASP E 128 −11.596−6.143 52.812 1.00 20.26 E ATOM 6621 OD2 ASP E 128 −11.019 −4.015 53.0521.00 20.41 E ATOM 6622 C ASP E 128 −11.557 −4.135 57.309 1.00 15.83 EATOM 6623 O ASP E 128 −12.517 −3.377 57.488 1.00 13.37 E ATOM 6624 N PHEE 129 −11.136 −4.943 58.292 1.00 16.40 E ATOM 6625 CA PHE E 129 −11.701−4.792 59.597 1.00 17.76 E ATOM 6626 CB PHE E 129 −11.180 −5.866 60.4721.00 18.43 E ATOM 6627 CG PHE E 129 −11.520 −7.207 59.990 1.00 17.90 EATOM 6628 CD1 PHE E 129 −10.627 −7.933 59.177 1.00 16.58 E ATOM 6629 CD2PHE E 129 −12.791 −7.731 60.228 1.00 17.36 E ATOM 6630 CE1 PHE E 129−11.018 −9.145 58.613 1.00 14.21 E ATOM 6631 CE2 PHE E 129 −13.192−8.994 59.646 1.00 15.67 E ATOM 6632 CZ PHE E 129 −12.309 −9.673 58.8541.00 13.85 E ATOM 6633 C PHE E 129 −11.004 −3.529 59.898 1.00 20.00 EATOM 6634 O PHE E 129 −10.281 −3.052 59.018 1.00 22.54 E ATOM 6635 N GLUE 130 −11.125 −2.900 61.044 1.00 19.43 E ATOM 6636 CA GLU E 130 −10.295−1.618 61.206 1.00 18.56 E ATOM 6637 CB GLU E 130 −8.818 −1.822 60.7891.00 19.67 E ATOM 6638 CG GLU E 130 −7.807 −1.831 61.927 1.00 22.90 EATOM 6639 CD GLU E 130 −6.312 −1.389 61.511 1.00 25.42 E ATOM 6640 OE1GLU E 130 −5.623 −1.004 62.519 1.00 25.22 E ATOM 6641 OE2 GLU E 130−5.827 −1.453 60.250 1.00 25.30 E ATOM 6642 C GLU E 130 −10.914 −0.52260.314 1.00 16.75 E ATOM 6643 O GLU E 130 −11.357 0.466 60.845 1.0015.63 E ATOM 6644 N ALA E 131 −10.913 −0.703 58.982 1.00 15.59 E ATOM6645 CA ALA E 131 −11.633 0.209 58.135 1.00 16.51 E ATOM 6646 CB ALA E131 −11.287 0.018 56.793 1.00 15.31 E ATOM 6647 C ALA E 131 −12.986−0.436 58.445 1.00 17.12 E ATOM 6648 O ALA E 131 −13.070 −1.562 59.0611.00 19.07 E ATOM 6649 N ARG E 132 −14.094 0.161 58.142 1.00 16.64 EATOM 6650 CA ARG E 132 −15.163 −0.703 58.592 1.00 16.72 E ATOM 6651 CBARG E 132 −16.143 0.092 59.429 1.00 18.51 E ATOM 6652 CG ARG E 132−16.226 −0.358 60.934 1.00 20.17 E ATOM 6653 CD ARG E 132 −14.946 −0.37361.698 1.00 17.38 E ATOM 6654 NE ARG E 132 −15.203 −0.532 63.133 1.0013.68 E ATOM 6655 CZ ARG E 132 −14.507 −1.326 63.939 1.00 12.56 E ATOM6656 NH1 ARG E 132 −13.516 −2.098 63.494 1.00 8.35 E ATOM 6657 NH2 ARG E132 −14.678 −1.198 65.253 1.00 13.51 E ATOM 6658 C ARG E 132 −15.802−1.169 57.341 1.00 15.59 E ATOM 6659 O ARG E 132 −16.973 −0.944 57.1521.00 13.78 E ATOM 6660 N HIS E 133 −14.969 −1.755 56.508 1.00 15.20 EATOM 6661 CA HIS E 133 −15.336 −2.233 55.231 1.00 18.08 E ATOM 6662 CBHIS E 133 −14.378 −1.678 54.171 1.00 19.39 E ATOM 6663 CG HIS E 133−14.400 −0.188 54.047 1.00 21.57 E ATOM 6664 CD2 HIS E 133 −14.926 0.79654.842 1.00 22.32 E ATOM 6665 ND1 HIS E 133 −13.798 0.455 52.988 1.0023.50 E ATOM 6666 CE1 HIS E 133 −13.954 1.775 53.136 1.00 23.19 E ATOM6667 NE2 HIS E 133 −14.636 2.012 54.253 1.00 20.89 E ATOM 6668 C HIS E133 −15.344 −3.744 55.124 1.00 18.16 E ATOM 6669 O HIS E 133 −14.589−4.268 54.353 1.00 17.56 E ATOM 6670 N VAL E 134 −16.156 −4.427 55.9281.00 19.28 E ATOM 6671 CA VAL E 134 −16.201 −5.846 55.814 1.00 19.85 EATOM 6672 CB VAL E 134 −16.767 −6.451 57.030 1.00 21.00 E ATOM 6673 CG1VAL E 134 −16.636 −8.013 56.918 1.00 22.46 E ATOM 6674 CG2 VAL E 134−15.921 −6.024 58.189 1.00 18.74 E ATOM 6675 C VAL E 134 −17.022 −6.19554.543 1.00 19.81 E ATOM 6676 O VAL E 134 −18.020 −5.518 54.220 1.0020.32 E ATOM 6677 N LYS E 135 −16.576 −7.214 53.787 1.00 19.28 E ATOM6678 CA LYS E 135 −17.279 −7.550 52.524 1.00 17.66 E ATOM 6679 CB LYS E135 −16.238 −7.903 51.448 1.00 18.76 E ATOM 6680 CG LYS E 135 −15.059−6.976 51.367 1.00 18.77 E ATOM 6681 CD LYS E 135 −15.521 −5.531 51.1741.00 19.68 E ATOM 6682 CE LYS E 135 −14.348 −4.724 50.622 1.00 20.70 EATOM 6683 NZ LYS E 135 −14.684 −3.267 50.708 1.00 22.03 E ATOM 6684 CLYS E 135 −18.338 −8.629 52.649 1.00 16.06 E ATOM 6685 O LYS E 135−18.087 −9.798 53.019 1.00 15.14 E ATOM 6686 N LEU E 136 −19.542 −8.16252.352 1.00 15.57 E ATOM 6687 CA LEU E 136 −20.758 −8.970 52.410 1.0016.54 E ATOM 6688 CB LEU E 136 −21.853 −8.099 53.012 1.00 15.87 E ATOM6689 CG LEU E 136 −23.090 −8.908 53.358 1.00 17.20 E ATOM 6690 CD1 LEU E136 −23.807 −9.239 52.057 1.00 20.95 E ATOM 6691 CD2 LEU E 136 −22.811−10.207 54.060 1.00 16.42 E ATOM 6692 C LEU E 136 −21.115 −9.508 50.9771.00 16.11 E ATOM 6693 O LEU E 136 −21.463 −8.745 50.093 1.00 16.33 EATOM 6694 N ASN E 137 −20.997 −10.810 50.773 1.00 15.86 E ATOM 6695 CAASN E 137 −21.251 −11.398 49.473 1.00 16.10 E ATOM 6696 CB ASN E 137−20.287 −12.499 49.254 1.00 14.53 E ATOM 6697 CG ASN E 137 −18.877−12.020 49.150 1.00 13.48 E ATOM 6698 OD1 ASN E 137 −18.436 −11.40648.169 1.00 9.06 E ATOM 6699 ND2 ASN E 137 −18.148 −12.355 50.151 1.0011.57 E ATOM 6700 C ASN E 137 −22.653 −11.981 49.311 1.00 16.65 E ATOM6701 O ASN E 137 −23.290 −12.515 50.267 1.00 17.37 E ATOM 6702 N VAL E138 −23.235 −11.824 48.133 1.00 16.09 E ATOM 6703 CA VAL E 138 −24.528−12.445 47.990 1.00 16.12 E ATOM 6704 CB VAL E 138 −25.621 −11.45747.586 1.00 16.05 E ATOM 6705 CG1 VAL E 138 −26.960 −12.160 47.618 1.0016.04 E ATOM 6706 CG2 VAL E 138 −25.692 −10.373 48.474 1.00 16.32 E ATOM6707 C VAL E 138 −24.418 −13.548 46.924 1.00 15.29 E ATOM 6708 O VAL E138 −23.984 −13.280 45.799 1.00 14.63 E ATOM 6709 N GLU E 139 −24.772−14.767 47.296 1.00 14.90 E ATOM 6710 CA GLU E 139 −24.780 −15.82346.290 1.00 17.15 E ATOM 6711 CB GLU E 139 −23.698 −16.900 46.557 1.0016.12 E ATOM 6712 CG GLU E 139 −22.204 −16.449 46.245 1.00 15.13 E ATOM6713 CD GLU E 139 −21.966 −16.068 44.833 1.00 14.55 E ATOM 6714 OE1 GLUE 139 −22.753 −16.468 43.958 1.00 16.56 E ATOM 6715 OE2 GLU E 139−20.970 −15.411 44.557 1.00 13.89 E ATOM 6716 C GLU E 139 −26.090−16.488 46.163 1.00 16.86 E ATOM 6717 O GLU E 139 −26.717 −16.868 47.1731.00 19.05 E ATOM 6718 N GLU E 140 −26.592 −16.600 44.960 1.00 16.56 EATOM 6719 CA GLU E 140 −27.865 −17.386 44.820 1.00 16.69 E ATOM 6720 CBGLU E 140 −28.977 −16.536 44.243 1.00 17.39 E ATOM 6721 CG GLU E 140−30.304 −17.307 44.286 1.00 18.53 E ATOM 6722 CD GLU E 140 −31.524−16.399 44.354 1.00 19.91 E ATOM 6723 OE1 GLU E 140 −31.933 −15.84243.278 1.00 17.40 E ATOM 6724 OE2 GLU E 140 −31.985 −16.296 45.539 1.0019.84 E ATOM 6725 C GLU E 140 −27.725 −18.706 43.983 1.00 15.31 E ATOM6726 O GLU E 140 −27.063 −18.757 43.002 1.00 14.18 E ATOM 6727 N ARG E141 −28.302 −19.791 44.422 1.00 15.10 E ATOM 6728 CA ARG E 141 −28.249−20.992 43.645 1.00 15.24 E ATOM 6729 CB ARG E 141 −27.366 −22.05744.258 1.00 14.64 E ATOM 6730 CG ARG E 141 −25.875 −21.724 44.438 1.0013.54 E ATOM 6731 CD ARG E 141 −24.954 −21.901 43.279 1.00 12.12 E ATOM6732 NE ARG E 141 −24.374 −20.578 43.062 1.00 13.29 E ATOM 6733 CZ ARG E141 −23.152 −20.155 43.463 1.00 13.00 E ATOM 6734 NH1 ARG E 141 −22.242−20.851 44.090 1.00 11.44 E ATOM 6735 NH2 ARG E 141 −22.884 −18.91743.369 1.00 13.49 E ATOM 6736 C ARG E 141 −29.653 −21.539 43.577 1.0015.27 E ATOM 6737 O ARG E 141 −30.564 −21.072 44.211 1.00 15.16 E ATOM6738 N SER E 142 −29.826 −22.568 42.798 1.00 16.25 E ATOM 6739 CA SER E142 −31.144 −23.114 42.679 1.00 17.12 E ATOM 6740 CB SER E 142 −31.901−22.334 41.635 1.00 16.28 E ATOM 6741 OG SER E 142 −31.817 −23.13040.551 1.00 16.66 E ATOM 6742 C SER E 142 −31.110 −24.621 42.406 1.0016.25 E ATOM 6743 O SER E 142 −30.151 −25.169 41.961 1.00 16.95 E ATOM6744 N VAL E 143 −32.148 −25.309 42.785 1.00 17.72 E ATOM 6745 CA VAL E143 −32.116 −26.748 42.606 1.00 18.33 E ATOM 6746 CB VAL E 143 −31.273−27.467 43.821 1.00 18.69 E ATOM 6747 CG1 VAL E 143 −32.050 −27.48545.164 1.00 18.76 E ATOM 6748 CG2 VAL E 143 −31.047 −28.839 43.538 1.0019.46 E ATOM 6749 C VAL E 143 −33.529 −27.273 42.431 1.00 17.44 E ATOM6750 O VAL E 143 −34.536 −26.637 42.783 1.00 17.56 E ATOM 6751 N GLY E144 −33.607 −28.425 41.794 1.00 18.15 E ATOM 6752 CA GLY E 144 −34.923−29.007 41.505 1.00 18.55 E ATOM 6753 C GLY E 144 −34.919 −29.899 40.2741.00 18.23 E ATOM 6754 O GLY E 144 −33.858 −30.113 39.688 1.00 18.41 EATOM 6755 N PRO E 145 −36.070 −30.503 39.917 1.00 17.96 E ATOM 6756 CDPRO E 145 −36.395 −31.115 38.598 1.00 18.72 E ATOM 6757 CA PRO E 145−37.297 −30.312 40.699 1.00 18.34 E ATOM 6758 CB PRO E 145 −38.419−30.718 39.713 1.00 17.66 E ATOM 6759 CG PRO E 145 −37.799 −31.75438.841 1.00 17.11 E ATOM 6760 C PRO E 145 −37.362 −31.107 41.994 1.0017.46 E ATOM 6761 O PRO E 145 −36.929 −32.237 42.092 1.00 17.87 E ATOM6762 N LEU E 146 −37.892 −30.488 43.012 1.00 17.07 E ATOM 6763 CA LEU E146 −38.018 −31.205 44.229 1.00 17.15 E ATOM 6764 CB LEU E 146 −38.131−30.181 45.353 1.00 16.92 E ATOM 6765 CG LEU E 146 −36.787 −29.82846.017 1.00 17.41 E ATOM 6766 CD1 LEU E 146 −35.752 −29.684 45.052 1.0016.28 E ATOM 6767 CD2 LEU E 146 −36.892 −28.589 46.855 1.00 16.20 E ATOM6768 C LEU E 146 −39.301 −31.984 44.027 1.00 16.38 E ATOM 6769 O LEU E146 −40.159 −31.589 43.252 1.00 16.87 E ATOM 6770 N THR E 147 −39.440−33.083 44.745 1.00 16.07 E ATOM 6771 CA THR E 147 −40.647 −33.94444.653 1.00 15.53 E ATOM 6772 CB THR E 147 −40.469 −35.098 43.630 1.0014.60 E ATOM 6773 OG1 THR E 147 −39.513 −36.016 44.149 1.00 16.34 E ATOM6774 CG2 THR E 147 −40.047 −34.619 42.322 1.00 11.13 E ATOM 6775 C THR E147 −41.126 −34.587 45.960 1.00 13.99 E ATOM 6776 O THR E 147 −42.252−35.000 46.024 1.00 15.17 E ATOM 6777 N ARG E 148 −40.290 −34.672 46.9951.00 13.67 E ATOM 6778 CA ARG E 148 −40.692 −35.293 48.271 1.00 12.84 EATOM 6779 CB ARG E 148 −39.472 −35.791 49.024 1.00 14.22 E ATOM 6780 CGARG E 148 −38.394 −36.400 48.200 1.00 15.41 E ATOM 6781 CD ARG E 148−38.711 −37.781 47.742 1.00 17.75 E ATOM 6782 NE ARG E 148 −39.645−37.799 46.607 1.00 19.67 E ATOM 6783 CZ ARG E 148 −40.774 −38.55246.551 1.00 21.23 E ATOM 6784 NH1 ARG E 148 −41.159 −39.363 47.541 1.0017.03 E ATOM 6785 NH2 ARG E 148 −41.514 −38.503 45.441 1.00 22.58 E ATOM6786 C ARG E 148 −41.507 −34.343 49.153 1.00 10.99 E ATOM 6787 O ARG E148 −41.798 −33.249 48.778 1.00 7.88 E ATOM 6788 N LYS E 149 −41.872−34.797 50.316 1.00 12.39 E ATOM 6789 CA LYS E 149 −42.693 −33.98151.201 1.00 15.90 E ATOM 6790 CB LYS E 149 −43.165 −34.810 52.367 1.0017.39 E ATOM 6791 CG LYS E 149 −44.362 −34.337 53.172 1.00 18.52 E ATOM6792 CD LYS E 149 −44.741 −35.432 54.249 1.00 20.56 E ATOM 6793 CE LYS E149 −45.699 −34.835 55.268 1.00 21.51 E ATOM 6794 NZ LYS E 149 −45.173−34.855 56.743 1.00 24.22 E ATOM 6795 C LYS E 149 −41.871 −32.836 51.7271.00 16.88 E ATOM 6796 O LYS E 149 −42.283 −31.668 51.822 1.00 17.46 EATOM 6797 N GLY E 150 −40.617 −33.162 51.990 1.00 17.48 E ATOM 6798 CAGLY E 150 −39.695 −32.137 52.461 1.00 17.49 E ATOM 6799 C GLY E 150−38.249 −32.250 52.018 1.00 16.99 E ATOM 6800 O GLY E 150 −37.890−33.157 51.190 1.00 16.65 E ATOM 6801 N PHE E 151 −37.460 −31.331 52.5591.00 15.38 E ATOM 6802 CA PHE E 151 −36.080 −31.202 52.242 1.00 14.94 EATOM 6803 CB PHE E 151 −35.978 −30.503 50.869 1.00 14.76 E ATOM 6804 CGPHE E 151 −36.252 −29.009 50.924 1.00 15.55 E ATOM 6805 CD1 PHE E 151−35.249 −28.094 51.188 1.00 15.30 E ATOM 6806 CD2 PHE E 151 −37.489−28.505 50.626 1.00 16.02 E ATOM 6807 CE1 PHE E 151 −35.543 −26.78951.105 1.00 14.72 E ATOM 6808 CE2 PHE E 151 −37.726 −27.176 50.554 1.0014.01 E ATOM 6809 CZ PHE E 151 −36.788 −26.343 50.777 1.00 13.57 E ATOM6810 C PHE E 151 −35.232 −30.401 53.302 1.00 15.20 E ATOM 6811 O PHE E151 −35.750 −29.547 54.103 1.00 13.46 E ATOM 6812 N TYR E 152 −33.927−30.654 53.199 1.00 14.21 E ATOM 6813 CA TYR E 152 −32.928 −30.07954.033 1.00 14.08 E ATOM 6814 CB TYR E 152 −32.188 −31.163 54.801 1.0015.02 E ATOM 6815 CG TYR E 152 −32.962 −31.879 55.847 1.00 14.78 E ATOM6816 CD1 TYR E 152 −33.545 −33.099 55.548 1.00 13.35 E ATOM 6817 CE1 TYRE 152 −34.320 −33.784 56.470 1.00 16.00 E ATOM 6818 CD2 TYR E 152−33.153 −31.298 57.134 1.00 14.94 E ATOM 6819 CE2 TYR E 152 −33.946−31.934 58.097 1.00 16.09 E ATOM 6820 CZ TYR E 152 −34.558 −33.20357.802 1.00 16.72 E ATOM 6821 OH TYR E 152 −35.331 −33.890 58.770 1.0016.01 E ATOM 6822 C TYR E 152 −31.927 −29.410 53.175 1.00 15.21 E ATOM6823 O TYR E 152 −31.650 −29.851 52.050 1.00 13.99 E ATOM 6824 N LEU E153 −31.361 −28.359 53.741 1.00 14.80 E ATOM 6825 CA LEU E 153 −30.256−27.667 53.146 1.00 15.38 E ATOM 6826 CB LEU E 153 −30.635 −26.25253.033 1.00 15.54 E ATOM 6827 CG LEU E 153 −30.698 −25.694 51.667 1.0016.01 E ATOM 6828 CD1 LEU E 153 −31.519 −26.439 50.739 1.00 15.43 E ATOM6829 CD2 LEU E 153 −31.188 −24.280 51.840 1.00 17.03 E ATOM 6830 C LEU E153 −29.081 −27.865 54.124 1.00 16.34 E ATOM 6831 O LEU E 153 −29.274−27.998 55.381 1.00 17.54 E ATOM 6832 N ALA E 154 −27.867 −27.900 53.6021.00 16.56 E ATOM 6833 CA ALA E 154 −26.700 −28.089 54.474 1.00 15.48 EATOM 6834 CB ALA E 154 −26.459 −29.571 54.734 1.00 14.70 E ATOM 6835 CALA E 154 −25.443 −27.373 53.952 1.00 16.09 E ATOM 6836 O ALA E 154−25.288 −27.075 52.820 1.00 15.33 E ATOM 6837 N PHE E 155 −24.558−27.082 54.861 1.00 16.55 E ATOM 6838 CA PHE E 155 −23.383 −26.37654.531 1.00 16.26 E ATOM 6839 CB PHE E 155 −23.486 −24.933 55.032 1.0016.84 E ATOM 6840 CG PHE E 155 −24.774 −24.203 54.656 1.00 15.32 E ATOM6841 CD1 PHE E 155 −25.897 −24.349 55.408 1.00 15.36 E ATOM 6842 CD2 PHEE 155 −24.802 −23.354 53.604 1.00 13.95 E ATOM 6843 CE1 PHE E 155−26.967 −23.662 55.094 1.00 14.40 E ATOM 6844 CE2 PHE E 155 −25.871−22.666 53.289 1.00 12.91 E ATOM 6845 CZ PHE E 155 −26.924 −22.80353.998 1.00 14.82 E ATOM 6846 C PHE E 155 −22.116 −27.023 55.125 1.0017.92 E ATOM 6847 O PHE E 155 −22.009 −27.260 56.366 1.00 17.38 E ATOM6848 N GLN E 156 −21.146 −27.218 54.251 1.00 16.88 E ATOM 6849 CA GLN E156 −19.991 −27.894 54.605 1.00 15.83 E ATOM 6850 CB GLN E 156 −19.758−28.993 53.627 1.00 17.44 E ATOM 6851 CG GLN E 156 −18.758 −29.97854.121 1.00 18.26 E ATOM 6852 CD GLN E 156 −18.054 −30.675 52.940 1.0018.17 E ATOM 6853 OE1 GLN E 156 −18.218 −30.310 51.785 1.00 19.45 E ATOM6854 NE2 GLN E 156 −17.234 −31.629 53.250 1.00 16.43 E ATOM 6855 C GLN E156 −18.858 −26.949 54.558 1.00 17.03 E ATOM 6856 O GLN E 156 −18.599−26.288 53.469 1.00 15.74 E ATOM 6857 N ASP E 157 −18.237 −26.802 55.7641.00 14.94 E ATOM 6858 CA ASP E 157 −17.142 −25.945 55.882 1.00 14.03 EATOM 6859 CB ASP E 157 −17.090 −25.246 57.250 1.00 13.56 E ATOM 6860 CGASP E 157 −15.722 −24.696 57.568 1.00 11.59 E ATOM 6861 OD1 ASP E 157−15.237 −25.078 58.580 1.00 13.09 E ATOM 6862 OD2 ASP E 157 −15.144−23.972 56.807 1.00 8.80 E ATOM 6863 C ASP E 157 −15.986 −26.792 55.7001.00 14.87 E ATOM 6864 O ASP E 157 −15.890 −27.811 56.344 1.00 14.30 EATOM 6865 N ILE E 158 −15.106 −26.345 54.822 1.00 15.17 E ATOM 6866 CAILE E 158 −13.889 −27.044 54.485 1.00 16.94 E ATOM 6867 CB ILE E 158−13.843 −27.228 52.876 1.00 16.81 E ATOM 6868 CG2 ILE E 158 −12.850−26.361 52.215 1.00 16.58 E ATOM 6869 CG1 ILE E 158 −13.691 −28.67352.583 1.00 16.22 E ATOM 6870 CD1 ILE E 158 −14.878 −29.334 52.981 1.0018.00 E ATOM 6871 C ILE E 158 −12.604 −26.472 55.019 1.00 16.70 E ATOM6872 O ILE E 158 −11.543 −26.842 54.553 1.00 17.08 E ATOM 6873 N GLY E159 −12.692 −25.620 56.039 1.00 16.29 E ATOM 6874 CA GLY E 159 −11.480−25.060 56.561 1.00 15.73 E ATOM 6875 C GLY E 159 −11.297 −23.587 56.2161.00 15.89 E ATOM 6876 O GLY E 159 −10.186 −23.106 56.173 1.00 15.42 EATOM 6877 N ALA E 160 −12.406 −22.896 55.915 1.00 16.10 E ATOM 6878 CAALA E 160 −12.452 −21.493 55.582 1.00 15.12 E ATOM 6879 CB ALA E 160−13.405 −21.226 54.598 1.00 14.72 E ATOM 6880 C ALA E 160 −12.883−20.831 56.823 1.00 14.54 E ATOM 6881 O ALA E 160 −13.103 −21.524 57.8081.00 16.07 E ATOM 6882 N CYS E 161 −12.872 −19.484 56.794 1.00 13.79 EATOM 6883 CA CYS E 161 −13.245 −18.562 57.876 1.00 11.75 E ATOM 6884 CCYS E 161 −14.390 −17.776 57.302 1.00 10.91 E ATOM 6885 O CYS E 161−14.280 −16.664 56.715 1.00 10.17 E ATOM 6886 CB CYS E 161 −12.126−17.582 58.280 1.00 8.68 E ATOM 6887 SG CYS E 161 −12.525 −16.697 59.8061.00 8.53 E ATOM 6888 N VAL E 162 −15.529 −18.394 57.550 1.00 12.28 EATOM 6889 CA VAL E 162 −16.792 −17.846 57.079 1.00 15.17 E ATOM 6890 CBVAL E 162 −17.623 −18.900 56.282 1.00 16.84 E ATOM 6891 CG1 VAL E 162−18.644 −18.183 55.326 1.00 17.21 E ATOM 6892 CG2 VAL E 162 −16.686−19.851 55.574 1.00 17.79 E ATOM 6893 C VAL E 162 −17.726 −17.374 58.1571.00 12.14 E ATOM 6894 O VAL E 162 −17.750 −17.899 59.225 1.00 8.37 EATOM 6895 N ALA E 163 −18.477 −16.392 57.749 1.00 11.78 E ATOM 6896 CAALA E 163 −19.504 −15.901 58.490 1.00 13.52 E ATOM 6897 CB ALA E 163−19.166 −14.637 58.753 1.00 15.31 E ATOM 6898 C ALA E 163 −20.831−15.965 57.610 1.00 14.75 E ATOM 6899 O ALA E 163 −20.983 −15.156 56.6531.00 15.36 E ATOM 6900 N LEU E 164 −21.765 −16.898 57.895 1.00 13.40 EATOM 6901 CA LEU E 164 −22.959 −16.984 57.104 1.00 13.40 E ATOM 6902 CBLEU E 164 −23.319 −18.449 56.939 1.00 14.16 E ATOM 6903 CG LEU E 164−24.573 −18.600 56.049 1.00 15.22 E ATOM 6904 CD1 LEU E 164 −24.492−17.916 54.711 1.00 14.03 E ATOM 6905 CD2 LEU E 164 −24.839 −20.15055.988 1.00 15.62 E ATOM 6906 C LEU E 164 −24.045 −16.190 57.734 1.0013.76 E ATOM 6907 O LEU E 164 −24.615 −16.523 58.752 1.00 13.05 E ATOM6908 N LEU E 165 −24.346 −15.088 57.126 1.00 14.53 E ATOM 6909 CA LEU E165 −25.318 −14.202 57.736 1.00 16.67 E ATOM 6910 CB LEU E 165 −24.882−12.740 57.542 1.00 18.92 E ATOM 6911 CG LEU E 165 −23.420 −12.53957.773 1.00 20.53 E ATOM 6912 CD1 LEU E 165 −23.233 −11.029 57.681 1.0022.40 E ATOM 6913 CD2 LEU E 165 −22.953 −13.071 59.157 1.00 20.79 E ATOM6914 C LEU E 165 −26.779 −14.268 57.323 1.00 16.84 E ATOM 6915 O LEU E165 −27.711 −13.642 57.994 1.00 15.77 E ATOM 6916 N SER E 166 −27.029−14.968 56.215 1.00 15.15 E ATOM 6917 CA SER E 166 −28.444 −15.01955.793 1.00 14.02 E ATOM 6918 CB SER E 166 −28.849 −13.693 55.111 1.0015.14 E ATOM 6919 OG SER E 166 −30.176 −13.770 54.650 1.00 15.62 E ATOM6920 C SER E 166 −28.667 −16.166 54.830 1.00 13.29 E ATOM 6921 O SER E166 −27.843 −16.504 53.997 1.00 11.41 E ATOM 6922 N VAL E 167 −29.823−16.720 54.946 1.00 13.06 E ATOM 6923 CA VAL E 167 −30.168 −17.86954.209 1.00 12.96 E ATOM 6924 CB VAL E 167 −29.941 −19.198 54.999 1.0014.14 E ATOM 6925 CG1 VAL E 167 −30.273 −20.447 54.104 1.00 15.94 E ATOM6926 CG2 VAL E 167 −28.513 −19.300 55.457 1.00 13.60 E ATOM 6927 C VAL E167 −31.600 −17.790 53.931 1.00 12.87 E ATOM 6928 O VAL E 167 −32.404−18.054 54.752 1.00 10.53 E ATOM 6929 N ARG E 168 −31.912 −17.304 52.7501.00 15.13 E ATOM 6930 CA ARG E 168 −33.309 −17.238 52.248 1.00 17.08 EATOM 6931 CB ARG E 168 −33.691 −15.913 51.593 1.00 18.29 E ATOM 6932 CGARG E 168 −34.477 −15.118 52.534 1.00 18.73 E ATOM 6933 CD ARG E 168−35.480 −14.206 51.924 1.00 17.51 E ATOM 6934 NE ARG E 168 −35.244−14.016 50.535 1.00 19.70 E ATOM 6935 CZ ARG E 168 −36.183 −13.53449.679 1.00 22.27 E ATOM 6936 NH1 ARG E 168 −37.464 −13.211 50.057 1.0021.88 E ATOM 6937 NH2 ARG E 168 −35.835 −13.257 48.430 1.00 23.33 E ATOM6938 C ARG E 168 −33.519 −18.322 51.158 1.00 17.23 E ATOM 6939 O ARG E168 −32.607 −18.562 50.321 1.00 16.85 E ATOM 6940 N VAL E 169 −34.706−18.947 51.277 1.00 17.01 E ATOM 6941 CA VAL E 169 −35.168 −20.01950.451 1.00 16.62 E ATOM 6942 CB VAL E 169 −35.212 −21.386 51.120 1.0016.68 E ATOM 6943 CG1 VAL E 169 −35.620 −22.493 49.989 1.00 17.87 E ATOM6944 CG2 VAL E 169 −33.855 −21.708 51.705 1.00 17.09 E ATOM 6945 C VAL E169 −36.551 −19.716 50.100 1.00 15.40 E ATOM 6946 O VAL E 169 −37.404−19.674 50.906 1.00 14.21 E ATOM 6947 N TYR E 170 −36.750 −19.491 48.8311.00 16.12 E ATOM 6948 CA TYR E 170 −38.052 −19.221 48.319 1.00 17.12 EATOM 6949 CB TYR E 170 −38.181 −17.740 48.225 1.00 17.05 E ATOM 6950 CGTYR E 170 −37.260 −17.236 47.188 1.00 18.08 E ATOM 6951 CD1 TYR E 170−37.723 −17.049 45.854 1.00 18.79 E ATOM 6952 CE1 TYR E 170 −36.847−16.516 44.805 1.00 18.94 E ATOM 6953 CD2 TYR E 170 −35.924 −16.91247.514 1.00 18.80 E ATOM 6954 CE2 TYR E 170 −35.017 −16.373 46.539 1.0018.69 E ATOM 6955 CZ TYR E 170 −35.480 −16.162 45.165 1.00 19.13 E ATOM6956 OH TYR E 170 −34.663 −15.576 44.204 1.00 16.63 E ATOM 6957 C TYR E170 −38.286 −19.883 46.910 1.00 16.79 E ATOM 6958 O TYR E 170 −37.371−20.403 46.286 1.00 16.44 E ATOM 6959 N TYR E 171 −39.534 −19.852 46.4601.00 17.66 E ATOM 6960 CA TYR E 171 −39.847 −20.339 45.160 1.00 19.26 EATOM 6961 CB TYR E 171 −40.314 −21.788 45.232 1.00 19.10 E ATOM 6962 CGTYR E 171 −41.643 −21.999 45.758 1.00 19.55 E ATOM 6963 CD1 TYR E 171−42.745 −22.073 44.867 1.00 20.16 E ATOM 6964 CE1 TYR E 171 −44.074−22.258 45.349 1.00 20.50 E ATOM 6965 CD2 TYR E 171 −41.867 −22.11847.152 1.00 18.51 E ATOM 6966 CE2 TYR E 171 −43.175 −22.308 47.625 1.0018.75 E ATOM 6967 CZ TYR E 171 −44.317 −22.385 46.714 1.00 19.47 E ATOM6968 OH TYR E 171 −45.692 −22.688 47.052 1.00 18.56 E ATOM 6969 C TYR E171 −40.825 −19.371 44.466 1.00 19.55 E ATOM 6970 O TYR E 171 −41.454−18.480 45.144 1.00 20.82 E ATOM 6971 N LYS E 172 −40.906 −19.458 43.1321.00 19.23 E ATOM 6972 CA LYS E 172 −41.812 −18.533 42.416 1.00 18.37 EATOM 6973 CB LYS E 172 −41.405 −18.328 41.040 1.00 16.63 E ATOM 6974 CGLYS E 172 −40.651 −17.136 40.922 1.00 16.92 E ATOM 6975 CD LYS E 172−39.289 −17.314 41.460 1.00 17.09 E ATOM 6976 CE LYS E 172 −38.533−16.041 41.271 1.00 20.27 E ATOM 6977 NZ LYS E 172 −37.327 −16.26640.453 1.00 23.79 E ATOM 6978 C LYS E 172 −43.280 −18.798 42.469 1.0018.57 E ATOM 6979 O LYS E 172 −43.823 −19.861 42.126 1.00 17.82 E ATOM6980 N LYS E 173 −43.883 −17.721 42.967 1.00 20.37 E ATOM 6981 CA LYS E173 −45.299 −17.585 43.271 1.00 21.55 E ATOM 6982 CB LYS E 173 −45.744−16.170 43.027 1.00 22.19 E ATOM 6983 CG LYS E 173 −44.778 −15.20843.609 1.00 22.22 E ATOM 6984 CD LYS E 173 −43.889 −14.730 42.367 1.0023.81 E ATOM 6985 CE LYS E 173 −42.448 −14.216 42.674 1.00 21.21 E ATOM6986 NZ LYS E 173 −41.779 −15.463 43.080 1.00 21.67 E ATOM 6987 C LYS E173 −46.141 −18.486 42.518 1.00 21.83 E ATOM 6988 O LYS E 173 −46.498−19.537 42.989 1.00 21.67 E ATOM 6989 N CYS E 174 −46.431 −17.978 41.3331.00 23.48 E ATOM 6990 CA CYS E 174 −47.292 −18.624 40.295 1.00 26.07 EATOM 6991 CB CYS E 174 −46.898 −20.118 40.064 1.00 28.33 E ATOM 6992 SGCYS E 174 −47.547 −21.311 41.242 1.00 37.24 E ATOM 6993 C CYS E 174−48.839 −18.439 40.429 1.00 24.49 E ATOM 6994 O CYS E 174 −49.380−17.418 39.759 1.00 23.93 E ATOM 6995 OXT CYS E 174 −49.404 −19.28841.210 1.00 24.43 E ATOM 6996 CB GLU F 1 −2.728 11.997 57.914 1.00 20.39F ATOM 6997 CG GLU F 1 −3.528 10.624 57.681 1.00 20.38 F ATOM 6998 CDGLU F 1 −5.005 10.820 57.167 1.00 21.53 F ATOM 6999 OE1 GLU F 1 −5.25211.468 56.108 1.00 20.45 F ATOM 7000 OE2 GLU F 1 −5.934 10.324 57.8511.00 20.95 F ATOM 7001 C GLU F 1 −0.640 11.397 59.324 1.00 18.86 F ATOM7002 O GLU F 1 −0.128 10.256 59.410 1.00 18.79 F ATOM 7003 N GLU F 1−0.600 11.207 56.812 1.00 19.68 F ATOM 7004 CA GLU F 1 −1.140 11.96857.995 1.00 19.54 F ATOM 7005 N VAL F 2 −0.774 12.174 60.383 1.00 18.86F ATOM 7006 CA VAL F 2 −0.271 11.690 61.703 1.00 19.81 F ATOM 7007 CBVAL F 2 0.585 12.889 62.400 1.00 19.82 F ATOM 7008 CG1 VAL F 2 0.79512.626 63.926 1.00 19.52 F ATOM 7009 CG2 VAL F 2 1.943 13.026 61.6541.00 19.23 F ATOM 7010 C VAL F 2 −1.507 11.280 62.514 1.00 18.72 F ATOM7011 O VAL F 2 −2.511 12.038 62.483 1.00 19.42 F ATOM 7012 N VAL F 3−1.452 10.157 63.227 1.00 17.02 F ATOM 7013 CA VAL F 3 −2.622 9.72163.945 1.00 16.74 F ATOM 7014 CB VAL F 3 −3.031 8.228 63.577 1.00 16.06F ATOM 7015 CG1 VAL F 3 −4.280 7.826 64.340 1.00 15.77 F ATOM 7016 CG2VAL F 3 −3.210 8.082 62.076 1.00 16.38 F ATOM 7017 C VAL F 3 −2.5239.740 65.427 1.00 16.20 F ATOM 7018 O VAL F 3 −1.719 9.074 65.960 1.0015.73 F ATOM 7019 N LEU F 4 −3.431 10.424 66.093 1.00 15.43 F ATOM 7020CA LEU F 4 −3.446 10.572 67.560 1.00 16.79 F ATOM 7021 CB LEU F 4 −3.54712.101 67.933 1.00 16.42 F ATOM 7022 CG LEU F 4 −2.769 13.085 67.0631.00 16.97 F ATOM 7023 CD1 LEU F 4 −2.972 14.527 67.486 1.00 17.37 FATOM 7024 CD2 LEU F 4 −1.288 12.616 67.125 1.00 16.95 F ATOM 7025 C LEUF 4 −4.750 9.944 67.898 1.00 17.54 F ATOM 7026 O LEU F 4 −5.775 10.51367.580 1.00 19.30 F ATOM 7027 N LEU F 5 −4.844 8.839 68.558 1.00 17.14 FATOM 7028 CA LEU F 5 −6.204 8.343 68.650 1.00 16.97 F ATOM 7029 CB LEU F5 −7.165 9.344 69.279 1.00 17.54 F ATOM 7030 CG LEU F 5 −8.493 8.60369.466 1.00 17.74 F ATOM 7031 CD1 LEU F 5 −8.131 7.328 70.168 1.00 18.18F ATOM 7032 CD2 LEU F 5 −9.331 9.382 70.427 1.00 19.76 F ATOM 7033 C LEUF 5 −6.944 7.769 67.371 1.00 17.10 F ATOM 7034 O LEU F 5 −7.307 8.46366.331 1.00 16.49 F ATOM 7035 N ASP F 6 −7.266 6.497 67.590 1.00 17.53 FATOM 7036 CA ASP F 6 −7.845 5.595 66.584 1.00 17.36 F ATOM 7037 CB ASP F6 −6.759 4.974 65.729 1.00 19.57 F ATOM 7038 CG ASP F 6 −7.277 4.52964.426 1.00 20.55 F ATOM 7039 OD1 ASP F 6 −6.596 3.859 63.692 1.00 22.17F ATOM 7040 OD2 ASP F 6 −8.405 4.864 64.104 1.00 23.58 F ATOM 7041 C ASPF 6 −8.521 4.465 67.275 1.00 16.65 F ATOM 7042 O ASP F 6 −7.930 3.44467.589 1.00 15.42 F ATOM 7043 N PHE F 7 −9.830 4.682 67.411 1.00 16.95 FATOM 7044 CA PHE F 7 −10.667 3.755 68.098 1.00 18.07 F ATOM 7045 CB PHEF 7 −12.118 4.294 68.074 1.00 18.22 F ATOM 7046 CG PHE F 7 −13.069 3.40368.732 1.00 17.78 F ATOM 7047 CD1 PHE F 7 −13.074 3.231 70.114 1.0017.61 F ATOM 7048 CD2 PHE F 7 −13.889 2.666 67.984 1.00 17.91 F ATOM7049 CE1 PHE F 7 −13.965 2.241 70.775 1.00 18.04 F ATOM 7050 CE2 PHE F 7−14.779 1.665 68.607 1.00 19.61 F ATOM 7051 CZ PHE F 7 −14.804 1.46770.001 1.00 18.12 F ATOM 7052 C PHE F 7 −10.604 2.316 67.606 1.00 16.56F ATOM 7053 O PHE F 7 −10.411 1.408 68.334 1.00 16.37 F ATOM 7054 N ALAF 8 −10.800 2.172 66.335 1.00 16.70 F ATOM 7055 CA ALA F 8 −10.879 0.85865.756 1.00 17.11 F ATOM 7056 CB ALA F 8 −11.469 0.918 64.313 1.00 16.64F ATOM 7057 C ALA F 8 −9.611 0.050 65.795 1.00 16.36 F ATOM 7058 O ALA F8 −9.658 −1.141 65.492 1.00 16.80 F ATOM 7059 N ALA F 9 −8.478 0.61566.216 1.00 15.07 F ATOM 7060 CA ALA F 9 −7.297 −0.243 66.297 1.00 14.93F ATOM 7061 CB ALA F 9 −6.154 0.472 65.832 1.00 10.27 F ATOM 7062 C ALAF 9 −7.064 −0.854 67.684 1.00 16.28 F ATOM 7063 O ALA F 9 −6.419 −1.89267.841 1.00 16.88 F ATOM 7064 N ALA F 10 −7.639 −0.239 68.711 1.00 18.01F ATOM 7065 CA ALA F 10 −7.323 −0.561 70.150 1.00 19.18 F ATOM 7066 CBALA F 10 −7.657 0.698 70.992 1.00 16.66 F ATOM 7067 C ALA F 10 −7.901−1.884 70.766 1.00 21.98 F ATOM 7068 O ALA F 10 −9.079 −1.984 71.3371.00 22.74 F ATOM 7069 N GLY F 11 −7.070 −2.937 70.570 1.00 23.93 F ATOM7070 CA GLY F 11 −7.327 −4.364 70.943 1.00 25.28 F ATOM 7071 C GLY F 11−7.831 −4.707 72.372 1.00 26.08 F ATOM 7072 O GLY F 11 −7.342 −5.59973.165 1.00 26.04 F ATOM 7073 N GLY F 12 −8.880 −3.978 72.719 1.00 25.96F ATOM 7074 CA GLY F 12 −9.470 −4.103 74.040 1.00 25.51 F ATOM 7075 CGLY F 12 −10.373 −2.832 74.087 1.00 25.24 F ATOM 7076 O GLY F 12 −10.494−2.250 75.250 1.00 25.74 F ATOM 7077 N GLU F 13 −10.895 −2.361 72.9131.00 23.76 F ATOM 7078 CA GLU F 13 −11.867 −1.238 72.844 1.00 22.92 FATOM 7079 CB GLU F 13 −13.121 −1.566 73.736 1.00 23.20 F ATOM 7080 CGGLU F 13 −13.150 −3.007 74.742 1.00 24.68 F ATOM 7081 CD GLU F 13−14.616 −3.355 75.395 1.00 26.25 F ATOM 7082 OE1 GLU F 13 −15.617 −3.06674.585 1.00 28.23 F ATOM 7083 OE2 GLU F 13 −14.768 −3.935 76.622 1.0022.68 F ATOM 7084 C GLU F 13 −11.247 0.166 73.202 1.00 23.12 F ATOM 7085O GLU F 13 −11.100 1.026 72.244 1.00 22.67 F ATOM 7086 N LEU F 14−10.860 0.355 74.500 1.00 22.47 F ATOM 7087 CA LEU F 14 −10.140 1.51474.964 1.00 22.89 F ATOM 7088 CB LEU F 14 −10.402 2.614 73.980 1.0023.15 F ATOM 7089 CG LEU F 14 −9.076 2.905 73.167 1.00 23.81 F ATOM 7090CD1 LEU F 14 −9.493 3.111 71.611 1.00 22.72 F ATOM 7091 CD2 LEU F 14−8.229 4.247 73.862 1.00 18.84 F ATOM 7092 C LEU F 14 −10.378 2.08676.367 1.00 23.06 F ATOM 7093 O LEU F 14 −11.453 1.821 77.061 1.00 23.98F ATOM 7094 N GLY F 15 −9.502 3.033 76.696 1.00 21.94 F ATOM 7095 CA GLYF 15 −9.730 3.626 78.002 1.00 21.59 F ATOM 7096 C GLY F 15 −10.647 4.85177.834 1.00 21.82 F ATOM 7097 O GLY F 15 −10.098 5.914 77.675 1.00 22.99F ATOM 7098 N TRP F 16 −11.974 4.760 77.832 1.00 21.20 F ATOM 7099 CATRP F 16 −12.814 6.000 77.694 1.00 20.62 F ATOM 7100 CB TRP F 16 −13.6996.024 76.408 1.00 20.02 F ATOM 7101 CG TRP F 16 −12.876 6.041 75.1001.00 19.11 F ATOM 7102 CD2 TRP F 16 −13.222 6.584 73.813 1.00 18.32 FATOM 7103 CE2 TRP F 16 −12.177 6.270 72.950 1.00 18.49 F ATOM 7104 CE3TRP F 16 −14.286 7.277 73.324 1.00 16.95 F ATOM 7105 CD1 TRP F 16−11.631 5.429 74.920 1.00 19.65 F ATOM 7106 NE1 TRP F 16 −11.228 5.57673.666 1.00 18.28 F ATOM 7107 CZ2 TRP F 16 −12.173 6.642 71.560 1.0018.58 F ATOM 7108 CZ3 TRP F 16 −14.288 7.658 71.972 1.00 18.07 F ATOM7109 CH2 TRP F 16 −13.229 7.338 71.091 1.00 18.40 F ATOM 7110 C TRP F 16−13.750 6.238 78.907 1.00 20.08 F ATOM 7111 O TRP F 16 −13.980 5.35479.771 1.00 20.86 F ATOM 7112 N LEU F 17 −14.284 7.423 78.972 1.00 17.51F ATOM 7113 CA LEU F 17 −15.116 7.708 80.102 1.00 16.91 F ATOM 7114 CBLEU F 17 −14.634 9.018 80.774 1.00 17.51 F ATOM 7115 CG LEU F 17 −15.4249.421 81.970 1.00 19.85 F ATOM 7116 CD1 LEU F 17 −15.693 8.134 82.8881.00 22.42 F ATOM 7117 CD2 LEU F 17 −14.699 10.553 82.842 1.00 22.16 FATOM 7118 C LEU F 17 −16.580 7.803 79.665 1.00 15.67 F ATOM 7119 O LEU F17 −16.938 8.370 78.592 1.00 14.78 F ATOM 7120 N THR F 18 −17.429 7.32480.542 1.00 14.69 F ATOM 7121 CA THR F 18 −18.810 7.279 80.264 1.0016.12 F ATOM 7122 CB THR F 18 −19.246 5.832 80.109 1.00 14.46 F ATOM7123 OG1 THR F 18 −19.164 5.529 78.741 1.00 13.32 F ATOM 7124 CG2 THR F18 −20.536 5.598 80.584 1.00 14.57 F ATOM 7125 C THR F 18 −19.533 7.95381.350 1.00 17.16 F ATOM 7126 O THR F 18 −19.548 7.467 82.506 1.00 16.71F ATOM 7127 N HIS F 19 −20.172 9.060 80.999 1.00 18.66 F ATOM 7128 CAHIS F 19 −20.877 9.702 82.021 1.00 22.00 F ATOM 7129 CB HIS F 19 −21.07811.190 81.760 1.00 22.36 F ATOM 7130 CG HIS F 19 −21.421 11.959 83.0261.00 23.66 F ATOM 7131 CD2 HIS F 19 −22.139 13.095 83.222 1.00 22.61 FATOM 7132 ND1 HIS F 19 −20.977 11.565 84.290 1.00 24.95 F ATOM 7133 CE1HIS F 19 −21.398 12.447 85.195 1.00 24.37 F ATOM 7134 NE2 HIS F 19−22.100 13.378 84.567 1.00 23.51 F ATOM 7135 C HIS F 19 −22.125 8.94582.551 1.00 22.68 F ATOM 7136 O HIS F 19 −22.112 7.680 82.513 1.00 24.14F ATOM 7137 N PRO F 20 −23.242 9.599 82.825 1.00 21.34 F ATOM 7138 CDPRO F 20 −23.726 10.082 81.505 1.00 20.46 F ATOM 7139 CA PRO F 20−24.236 8.651 83.405 1.00 23.47 F ATOM 7140 CB PRO F 20 −25.249 8.46782.256 1.00 22.31 F ATOM 7141 CG PRO F 20 −25.218 9.925 81.677 1.0021.85 F ATOM 7142 C PRO F 20 −23.561 7.298 83.895 1.00 24.89 F ATOM 7143O PRO F 20 −23.215 7.125 85.077 1.00 25.33 F ATOM 7144 N TYR F 21−23.259 6.368 82.978 1.00 24.71 F ATOM 7145 CA TYR F 21 −22.568 5.08883.341 1.00 24.45 F ATOM 7146 CB TYR F 21 −21.438 5.168 84.400 1.0024.55 F ATOM 7147 CG TYR F 21 −20.799 3.736 84.529 1.00 24.68 F ATOM7148 CD1 TYR F 21 −19.914 3.217 83.487 1.00 24.10 F ATOM 7149 CE1 TYR F21 −19.507 1.834 83.445 1.00 23.86 F ATOM 7150 CD2 TYR F 21 −21.2382.819 85.560 1.00 26.49 F ATOM 7151 CE2 TYR F 21 −20.832 1.366 85.5591.00 25.94 F ATOM 7152 CZ TYR F 21 −20.000 0.906 84.486 1.00 26.22 FATOM 7153 OH TYR F 21 −19.850 −0.555 84.390 1.00 28.19 F ATOM 7154 C TYRF 21 −23.598 4.148 83.907 1.00 25.68 F ATOM 7155 O TYR F 21 −24.1014.396 85.062 1.00 25.63 F ATOM 7156 N GLY F 22 −23.942 3.120 83.080 1.0025.31 F ATOM 7157 CA GLY F 22 −24.927 2.136 83.507 1.00 25.58 F ATOM7158 C GLY F 22 −26.001 2.009 82.471 1.00 25.87 F ATOM 7159 O GLY F 22−26.439 0.841 82.133 1.00 27.06 F ATOM 7160 N LYS F 23 −26.423 3.16181.951 1.00 24.38 F ATOM 7161 CA LYS F 23 −27.532 3.238 81.023 1.0022.36 F ATOM 7162 CB LYS F 23 −28.799 3.831 81.680 1.00 21.27 F ATOM7163 CG LYS F 23 −29.532 2.942 82.797 1.00 22.18 F ATOM 7164 CD LYS F 23−29.069 3.401 84.282 1.00 21.61 F ATOM 7165 CE LYS F 23 −29.428 2.37885.395 1.00 20.42 F ATOM 7166 NZ LYS F 23 −30.929 2.142 85.730 1.0023.65 F ATOM 7167 C LYS F 23 −27.244 4.081 79.814 1.00 22.42 F ATOM 7168O LYS F 23 −28.089 4.047 78.892 1.00 23.18 F ATOM 7169 N GLY F 24−26.136 4.854 79.788 1.00 20.83 F ATOM 7170 CA GLY F 24 −25.854 5.67778.601 1.00 18.98 F ATOM 7171 C GLY F 24 −25.028 4.828 77.602 1.00 18.79F ATOM 7172 O GLY F 24 −25.414 3.650 77.239 1.00 17.53 F ATOM 7173 N TRPF 25 −23.932 5.455 77.136 1.00 18.17 F ATOM 7174 CA TRP F 25 −22.9914.861 76.230 1.00 18.48 F ATOM 7175 CB TRP F 25 −21.968 5.876 75.9081.00 17.21 F ATOM 7176 CG TRP F 25 −22.399 7.020 75.134 1.00 17.11 FATOM 7177 CD2 TRP F 25 −22.415 7.119 73.693 1.00 17.35 F ATOM 7178 CE2TRP F 25 −22.581 8.483 73.364 1.00 18.05 F ATOM 7179 CE3 TRP F 25−22.303 6.169 72.650 1.00 16.76 F ATOM 7180 CD1 TRP F 25 −22.580 8.31975.582 1.00 17.87 F ATOM 7181 NE1 TRP F 25 −22.661 9.198 74.523 1.0017.86 F ATOM 7182 CZ2 TRP F 25 −22.631 8.905 72.063 1.00 19.01 F ATOM7183 CZ3 TRP F 25 −22.351 6.584 71.386 1.00 16.85 F ATOM 7184 CH2 TRP F25 −22.514 7.910 71.074 1.00 18.20 F ATOM 7185 C TRP F 25 −22.300 3.53976.804 1.00 19.51 F ATOM 7186 O TRP F 25 −21.840 3.532 77.999 1.00 19.97F ATOM 7187 N ASP F 26 −22.325 2.428 75.983 1.00 19.72 F ATOM 7188 CAASP F 26 −21.767 1.036 76.318 1.00 19.12 F ATOM 7189 CB ASP F 26 −22.826−0.071 76.617 1.00 22.63 F ATOM 7190 CG ASP F 26 −23.646 0.134 77.9861.00 27.22 F ATOM 7191 OD1 ASP F 26 −23.657 1.258 78.745 1.00 27.40 FATOM 7192 OD2 ASP F 26 −24.398 −0.916 78.337 1.00 31.20 F ATOM 7193 CASP F 26 −20.886 0.516 75.162 1.00 18.06 F ATOM 7194 O ASP F 26 −21.1900.624 73.980 1.00 16.36 F ATOM 7195 N LEU F 27 −19.745 0.034 75.566 1.0017.18 F ATOM 7196 CA LEU F 27 −18.739 −0.485 74.711 1.00 16.47 F ATOM7197 CB LEU F 27 −17.433 −0.431 75.474 1.00 16.18 F ATOM 7198 CG LEU F27 −16.178 −0.736 74.665 1.00 16.69 F ATOM 7199 CD1 LEU F 27 −16.0110.122 73.446 1.00 15.26 F ATOM 7200 CD2 LEU F 27 −15.060 −0.692 75.6151.00 15.20 F ATOM 7201 C LEU F 27 −19.161 −1.921 74.458 1.00 16.49 FATOM 7202 O LEU F 27 −19.316 −2.674 75.363 1.00 16.40 F ATOM 7203 N METF 28 −19.346 −2.286 73.221 1.00 16.24 F ATOM 7204 CA MET F 28 −19.792−3.613 72.935 1.00 17.30 F ATOM 7205 CB MET F 28 −21.262 −3.636 72.3931.00 19.90 F ATOM 7206 CG MET F 28 −22.075 −2.331 72.522 1.00 23.66 FATOM 7207 SD MET F 28 −24.006 −2.414 72.661 1.00 27.35 F ATOM 7208 CEMET F 28 −24.264 −4.482 72.733 1.00 21.38 F ATOM 7209 C MET F 28 −18.840−4.177 71.856 1.00 16.40 F ATOM 7210 O MET F 28 −18.379 −3.447 70.9711.00 16.32 F ATOM 7211 N GLN F 29 −18.551 −5.447 71.963 1.00 15.08 FATOM 7212 CA GLN F 29 −17.698 −6.110 71.044 1.00 15.65 F ATOM 7213 CBGLN F 29 −16.719 −6.943 71.829 1.00 15.26 F ATOM 7214 CG GLN F 29−15.605 −7.321 71.007 1.00 18.11 F ATOM 7215 CD GLN F 29 −14.874 −8.64171.431 1.00 20.31 F ATOM 7216 OE1 GLN F 29 −13.875 −8.576 72.079 1.0021.94 F ATOM 7217 NE2 GLN F 29 −15.351 −9.825 70.995 1.00 21.20 F ATOM7218 C GLN F 29 −18.387 −7.081 70.069 1.00 15.96 F ATOM 7219 O GLN F 29−18.822 −8.184 70.478 1.00 15.78 F ATOM 7220 N ASN F 30 −18.456 −6.72368.793 1.00 15.49 F ATOM 7221 CA ASN F 30 −19.019 −7.687 67.851 1.0015.99 F ATOM 7222 CB ASN F 30 −19.775 −6.978 66.713 1.00 15.62 F ATOM7223 CG ASN F 30 −21.101 −6.465 67.184 1.00 14.94 F ATOM 7224 OD1 ASN F30 −21.578 −5.542 66.652 1.00 15.76 F ATOM 7225 ND2 ASN F 30 −21.704−7.083 68.185 1.00 14.68 F ATOM 7226 C ASN F 30 −17.863 −8.490 67.3101.00 16.10 F ATOM 7227 O ASN F 30 −16.668 −8.193 67.566 1.00 14.78 FATOM 7228 N ILE F 31 −18.200 −9.548 66.615 1.00 16.26 F ATOM 7229 CA ILEF 31 −17.139 −10.250 66.005 1.00 16.19 F ATOM 7230 CB ILE F 31 −16.744−11.257 66.953 1.00 17.20 F ATOM 7231 CG2 ILE F 31 −17.859 −12.13967.180 1.00 18.41 F ATOM 7232 CG1 ILE F 31 −15.587 −12.007 66.455 1.0017.93 F ATOM 7233 CD1 ILE F 31 −15.281 −13.180 67.345 1.00 17.42 F ATOM7234 C ILE F 31 −17.530 −10.787 64.602 1.00 17.27 F ATOM 7235 O ILE F 31−18.608 −11.332 64.342 1.00 17.19 F ATOM 7236 N MET F 32 −16.617 −10.60963.679 1.00 16.62 F ATOM 7237 CA MET F 32 −16.752 −10.973 62.317 1.0015.80 F ATOM 7238 CB MET F 32 −16.748 −9.747 61.385 1.00 18.12 F ATOM7239 CG MET F 32 −18.155 −9.209 61.079 1.00 21.41 F ATOM 7240 SD MET F32 −19.276 −10.545 60.761 1.00 23.72 F ATOM 7241 CE MET F 32 −17.980−11.479 59.603 1.00 19.76 F ATOM 7242 C MET F 32 −15.544 −11.697 61.9741.00 15.88 F ATOM 7243 O MET F 32 −14.503 −11.099 62.019 1.00 14.27 FATOM 7244 N ASN F 33 −15.708 −12.954 61.500 1.00 16.32 F ATOM 7245 CAASN F 33 −14.584 −13.759 61.045 1.00 16.40 F ATOM 7246 CB ASN F 33−14.065 −13.278 59.720 1.00 17.40 F ATOM 7247 CG ASN F 33 −15.067−13.352 58.672 1.00 17.52 F ATOM 7248 OD1 ASN F 33 −15.472 −14.43958.252 1.00 17.85 F ATOM 7249 ND2 ASN F 33 −15.473 −12.201 58.214 1.0017.46 F ATOM 7250 C ASN F 33 −13.447 −13.699 62.036 1.00 15.93 F ATOM7251 O ASN F 33 −12.309 −13.467 61.689 1.00 16.40 F ATOM 7252 N ASP F 34−13.808 −13.937 63.280 1.00 16.34 F ATOM 7253 CA ASP F 34 −12.909−13.967 64.388 1.00 16.68 F ATOM 7254 CB ASP F 34 −11.912 −15.120 64.1571.00 17.06 F ATOM 7255 CG ASP F 34 −12.536 −16.511 64.486 1.00 20.25 FATOM 7256 OD1 ASP F 34 −13.831 −16.768 64.269 1.00 21.53 F ATOM 7257 OD2ASP F 34 −11.787 −17.485 64.965 1.00 22.23 F ATOM 7258 C ASP F 34−12.243 −12.581 64.634 1.00 16.65 F ATOM 7259 O ASP F 34 −11.312 −12.47065.425 1.00 17.32 F ATOM 7260 N MET F 35 −12.664 −11.524 63.950 1.0016.51 F ATOM 7261 CA MET F 35 −12.067 −10.246 64.245 1.00 15.64 F ATOM7262 CB MET F 35 −11.864 −9.452 62.955 1.00 17.61 F ATOM 7263 CG MET F35 −10.729 −9.931 62.126 1.00 17.09 F ATOM 7264 SD MET F 35 −9.145−9.928 63.022 1.00 21.41 F ATOM 7265 CE MET F 35 −9.110 −11.665 63.7101.00 19.69 F ATOM 7266 C MET F 35 −12.958 −9.451 65.233 1.00 14.08 FATOM 7267 O MET F 35 −14.095 −9.291 65.003 1.00 12.74 F ATOM 7268 N PROF 36 −12.436 −9.057 66.416 1.00 14.60 F ATOM 7269 CD PRO F 36 −11.196−9.422 67.106 1.00 15.37 F ATOM 7270 CA PRO F 36 −13.301 −8.275 67.3281.00 13.87 F ATOM 7271 CB PRO F 36 −12.518 −8.228 68.646 1.00 14.00 FATOM 7272 CG PRO F 36 −11.213 −8.401 68.267 1.00 15.42 F ATOM 7273 C PROF 36 −13.562 −6.890 66.758 1.00 12.90 F ATOM 7274 O PRO F 36 −12.665−6.197 66.395 1.00 12.46 F ATOM 7275 N ILE F 37 −14.798 −6.521 66.6021.00 13.00 F ATOM 7276 CA ILE F 37 −15.108 −5.191 66.099 1.00 14.29 FATOM 7277 CB ILE F 37 −16.137 −5.327 65.062 1.00 15.11 F ATOM 7278 CG2ILE F 37 −16.455 −3.988 64.392 1.00 15.50 F ATOM 7279 CG1 ILE F 37−15.708 −6.417 64.087 1.00 17.19 F ATOM 7280 CD1 ILE F 37 −14.368 −6.23863.639 1.00 17.22 F ATOM 7281 C ILE F 37 −15.695 −4.336 67.329 1.0015.35 F ATOM 7282 O ILE F 37 −16.840 −4.524 67.712 1.00 15.59 F ATOM7283 N TYR F 38 −14.974 −3.438 67.975 1.00 14.97 F ATOM 7284 CA TYR F 38−15.635 −2.802 69.051 1.00 15.15 F ATOM 7285 CB TYR F 38 −14.623 −2.30670.095 1.00 15.34 F ATOM 7286 CG TYR F 38 −13.975 −3.397 70.857 1.0015.22 F ATOM 7287 CD1 TYR F 38 −12.914 −4.057 70.369 1.00 15.04 F ATOM7288 CE1 TYR F 38 −12.429 −5.055 71.078 1.00 14.46 F ATOM 7289 CD2 TYR F38 −14.502 −3.826 72.076 1.00 13.92 F ATOM 7290 CE2 TYR F 38 −13.989−4.836 72.729 1.00 12.69 F ATOM 7291 CZ TYR F 38 −12.959 −5.423 72.2381.00 13.79 F ATOM 7292 OH TYR F 38 −12.349 −6.369 72.977 1.00 16.17 FATOM 7293 C TYR F 38 −16.458 −1.619 68.592 1.00 15.82 F ATOM 7294 O TYRF 38 −16.152 −1.054 67.565 1.00 16.55 F ATOM 7295 N MET F 39 −17.513−1.262 69.354 1.00 15.99 F ATOM 7296 CA MET F 39 −18.264 −0.028 69.1021.00 16.15 F ATOM 7297 CB MET F 39 −19.391 −0.278 68.162 1.00 14.36 FATOM 7298 CG MET F 39 −20.598 −0.756 68.799 1.00 14.60 F ATOM 7299 SDMET F 39 −21.447 −2.038 67.652 1.00 16.18 F ATOM 7300 CE MET F 39−22.997 −2.556 68.622 1.00 11.50 F ATOM 7301 C MET F 39 −18.804 0.62970.399 1.00 15.29 F ATOM 7302 O MET F 39 −18.981 −0.044 71.378 1.0016.10 F ATOM 7303 N TYR F 40 −19.004 1.930 70.398 1.00 15.22 F ATOM 7304CA TYR F 40 −19.701 2.576 71.517 1.00 16.06 F ATOM 7305 CB TYR F 40−18.971 3.880 71.947 1.00 16.47 F ATOM 7306 CG TYR F 40 −17.991 3.68073.074 1.00 17.74 F ATOM 7307 CD1 TYR F 40 −16.658 3.743 72.873 1.0017.70 F ATOM 7308 CE1 TYR F 40 −15.757 3.457 73.872 1.00 19.15 F ATOM7309 CD2 TYR F 40 −18.445 3.330 74.364 1.00 19.42 F ATOM 7310 CE2 TYR F40 −17.551 3.037 75.417 1.00 20.62 F ATOM 7311 CZ TYR F 40 −16.197 3.10375.119 1.00 21.41 F ATOM 7312 OH TYR F 40 −15.259 2.749 76.067 1.0025.97 F ATOM 7313 C TYR F 40 −21.185 2.907 71.075 1.00 15.67 F ATOM 7314O TYR F 40 −21.434 3.597 70.003 1.00 14.18 F ATOM 7315 N SER F 41−22.169 2.437 71.838 1.00 15.42 F ATOM 7316 CA SER F 41 −23.547 2.73171.399 1.00 15.93 F ATOM 7317 CB SER F 41 −24.099 1.571 70.504 1.0016.40 F ATOM 7318 OG SER F 41 −23.882 0.277 71.029 1.00 13.61 F ATOM7319 C SER F 41 −24.519 2.997 72.529 1.00 17.88 F ATOM 7320 O SER F 41−24.264 2.638 73.728 1.00 17.79 F ATOM 7321 N VAL F 42 −25.650 3.60772.154 1.00 17.67 F ATOM 7322 CA VAL F 42 −26.671 3.919 73.146 1.0016.84 F ATOM 7323 CB VAL F 42 −26.893 5.520 73.504 1.00 17.23 F ATOM7324 CG1 VAL F 42 −27.216 5.725 74.948 1.00 15.09 F ATOM 7325 CG2 VAL F42 −25.835 6.408 72.904 1.00 14.70 F ATOM 7326 C VAL F 42 −27.862 3.80672.313 1.00 18.29 F ATOM 7327 O VAL F 42 −27.811 4.181 71.156 1.00 17.36F ATOM 7328 N CYS F 43 −28.980 3.527 72.970 1.00 19.19 F ATOM 7329 CACYS F 43 −30.289 3.517 72.283 1.00 19.70 F ATOM 7330 C CYS F 43 −31.4233.802 73.317 1.00 20.13 F ATOM 7331 O CYS F 43 −32.335 2.999 73.444 1.0019.43 F ATOM 7332 CB CYS F 43 −30.475 2.131 71.674 1.00 21.56 F ATOM7333 SG CYS F 43 −31.671 2.079 70.263 1.00 21.13 F ATOM 7334 N ASN F 44−31.323 4.892 74.075 1.00 19.79 F ATOM 7335 CA ASN F 44 −32.353 5.25975.040 1.00 19.21 F ATOM 7336 CB ASN F 44 −31.727 5.939 76.256 1.0018.46 F ATOM 7337 CG ASN F 44 −30.921 4.992 77.031 1.00 18.16 F ATOM7338 OD1 ASN F 44 −30.092 5.411 77.794 1.00 19.18 F ATOM 7339 ND2 ASN F44 −31.142 3.670 76.826 1.00 16.22 F ATOM 7340 C ASN F 44 −33.341 6.19174.332 1.00 19.99 F ATOM 7341 O ASN F 44 −33.449 7.388 74.687 1.00 21.01F ATOM 7342 N VAL F 45 −34.020 5.654 73.291 1.00 19.37 F ATOM 7343 CAVAL F 45 −34.975 6.424 72.443 1.00 17.16 F ATOM 7344 CB VAL F 45 −35.1155.837 70.982 1.00 17.72 F ATOM 7345 CG1 VAL F 45 −33.883 5.921 70.3521.00 18.04 F ATOM 7346 CG2 VAL F 45 −35.601 4.318 70.929 1.00 16.72 FATOM 7347 C VAL F 45 −36.374 6.487 73.035 1.00 18.31 F ATOM 7348 O VAL F45 −37.167 7.286 72.595 1.00 17.62 F ATOM 7349 N MET F 46 −36.645 5.65474.027 1.00 18.43 F ATOM 7350 CA MET F 46 −37.951 5.568 74.611 1.0018.48 F ATOM 7351 CB MET F 46 −38.195 4.074 74.867 1.00 20.14 F ATOM7352 CG MET F 46 −39.437 3.356 74.388 1.00 20.78 F ATOM 7353 SD MET F 46−40.168 3.552 72.626 1.00 25.07 F ATOM 7354 CE MET F 46 −39.284 1.88471.769 1.00 20.73 F ATOM 7355 C MET F 46 −37.991 6.354 76.032 1.00 20.36F ATOM 7356 O MET F 46 −38.887 6.103 76.884 1.00 20.30 F ATOM 7357 N SERF 47 −37.014 7.230 76.321 1.00 20.61 F ATOM 7358 CA SER F 47 −37.0297.956 77.597 1.00 20.41 F ATOM 7359 CB SER F 47 −36.082 7.308 78.6341.00 21.22 F ATOM 7360 OG SER F 47 −35.616 6.032 78.207 1.00 21.71 FATOM 7361 C SER F 47 −36.585 9.348 77.183 1.00 20.03 F ATOM 7362 O SER F47 −35.855 9.499 76.155 1.00 20.01 F ATOM 7363 N GLY F 48 −37.029 10.36877.917 1.00 19.74 F ATOM 7364 CA GLY F 48 −36.670 11.671 77.422 1.0019.20 F ATOM 7365 C GLY F 48 −35.536 12.244 78.129 1.00 18.38 F ATOM7366 O GLY F 48 −34.999 11.568 78.994 1.00 18.14 F ATOM 7367 N ASP F 49−35.116 13.437 77.702 1.00 18.94 F ATOM 7368 CA ASP F 49 −34.039 14.05878.477 1.00 20.39 F ATOM 7369 CB ASP F 49 −34.513 14.208 79.944 1.0020.22 F ATOM 7370 CG ASP F 49 −35.877 14.932 80.046 1.00 22.03 F ATOM7371 OD1 ASP F 49 −36.746 14.493 80.886 1.00 22.35 F ATOM 7372 OD2 ASP F49 −36.010 15.945 79.299 1.00 19.76 F ATOM 7373 C ASP F 49 −32.78913.203 78.555 1.00 18.83 F ATOM 7374 O ASP F 49 −32.257 12.992 79.6431.00 19.67 F ATOM 7375 N GLN F 50 −32.341 12.651 77.473 1.00 18.22 FATOM 7376 CA GLN F 50 −31.113 11.912 77.603 1.00 17.72 F ATOM 7377 CBGLN F 50 −30.946 10.924 76.434 1.00 17.65 F ATOM 7378 CG GLN F 50−31.944 9.801 76.477 1.00 16.45 F ATOM 7379 CD GLN F 50 −31.923 9.14177.830 1.00 17.91 F ATOM 7380 OE1 GLN F 50 −30.959 8.416 78.211 1.0015.56 F ATOM 7381 NE2 GLN F 50 −32.982 9.437 78.631 1.00 19.35 F ATOM7382 C GLN F 50 −30.060 12.952 77.552 1.00 17.11 F ATOM 7383 O GLN F 50−30.265 14.008 76.932 1.00 16.82 F ATOM 7384 N ASP F 51 −28.927 12.69278.214 1.00 17.64 F ATOM 7385 CA ASP F 51 −27.711 13.628 78.196 1.0017.98 F ATOM 7386 CB ASP F 51 −27.816 14.713 79.303 1.00 19.40 F ATOM7387 CG ASP F 51 −26.734 15.767 79.169 1.00 22.27 F ATOM 7388 OD1 ASP F51 −26.433 16.554 80.218 1.00 22.06 F ATOM 7389 OD2 ASP F 51 −26.17215.821 77.962 1.00 23.40 F ATOM 7390 C ASP F 51 −26.542 12.686 78.5161.00 17.64 F ATOM 7391 O ASP F 51 −25.940 12.783 79.554 1.00 17.33 FATOM 7392 N ASN F 52 −26.275 11.720 77.629 1.00 18.03 F ATOM 7393 CA ASNF 52 −25.214 10.732 77.831 1.00 16.66 F ATOM 7394 CB ASN F 52 −25.6749.460 77.316 1.00 16.91 F ATOM 7395 CG ASN F 52 −26.933 9.099 77.9311.00 16.34 F ATOM 7396 OD1 ASN F 52 −27.000 8.846 79.131 1.00 16.67 FATOM 7397 ND2 ASN F 52 −27.975 9.130 77.153 1.00 14.26 F ATOM 7398 C ASNF 52 −23.948 11.137 77.202 1.00 16.78 F ATOM 7399 O ASN F 52 −23.94711.619 76.076 1.00 16.13 F ATOM 7400 N TRP F 53 −22.863 11.062 77.9751.00 17.70 F ATOM 7401 CA TRP F 53 −21.571 11.490 77.430 1.00 17.73 FATOM 7402 CB TRP F 53 −21.000 12.673 78.225 1.00 18.12 F ATOM 7403 CGTRP F 53 −21.761 13.942 78.057 1.00 17.61 F ATOM 7404 CD2 TRP F 53−21.353 15.101 77.330 1.00 17.68 F ATOM 7405 CE2 TRP F 53 −22.361 16.07377.479 1.00 18.04 F ATOM 7406 CE3 TRP F 53 −20.210 15.416 76.568 1.0018.53 F ATOM 7407 CD1 TRP F 53 −22.974 14.237 78.585 1.00 17.16 F ATOM7408 NE1 TRP F 53 −23.354 15.519 78.210 1.00 17.28 F ATOM 7409 CZ2 TRP F53 −22.271 17.332 76.926 1.00 18.17 F ATOM 7410 CZ3 TRP F 53 −20.10216.664 75.999 1.00 18.75 F ATOM 7411 CH2 TRP F 53 −21.132 17.630 76.1801.00 20.22 F ATOM 7412 C TRP F 53 −20.554 10.419 77.384 1.00 16.97 FATOM 7413 O TRP F 53 −20.457 9.628 78.314 1.00 16.55 F ATOM 7414 N LEU F54 −19.794 10.449 76.281 1.00 16.85 F ATOM 7415 CA LEU F 54 −18.6649.546 76.086 1.00 15.36 F ATOM 7416 CB LEU F 54 −18.822 8.712 74.8291.00 17.24 F ATOM 7417 CG LEU F 54 −17.615 7.845 74.370 1.00 18.00 FATOM 7418 CD1 LEU F 54 −17.312 6.768 75.417 1.00 16.06 F ATOM 7419 CD2LEU F 54 −17.947 7.133 73.024 1.00 16.92 F ATOM 7420 C LEU F 54 −17.53610.480 75.877 1.00 14.02 F ATOM 7421 O LEU F 54 −17.648 11.428 75.1041.00 10.88 F ATOM 7422 N ARG F 55 −16.457 10.195 76.611 1.00 14.52 FATOM 7423 CA ARG F 55 −15.264 10.993 76.482 1.00 16.62 F ATOM 7424 CBARG F 55 −14.911 11.753 77.825 1.00 17.62 F ATOM 7425 CG ARG F 55−13.629 12.620 77.592 1.00 19.50 F ATOM 7426 CD ARG F 55 −13.241 13.65978.640 1.00 20.08 F ATOM 7427 NE ARG F 55 −12.162 13.283 79.578 1.0021.04 F ATOM 7428 CZ ARG F 55 −12.065 12.089 80.162 1.00 21.38 F ATOM7429 NH1 ARG F 55 −12.933 11.115 79.899 1.00 24.29 F ATOM 7430 NH2 ARG F55 −11.189 11.881 81.106 1.00 21.54 F ATOM 7431 C ARG F 55 −14.08910.125 76.109 1.00 17.07 F ATOM 7432 O ARG F 55 −13.866 9.069 76.6721.00 16.85 F ATOM 7433 N THR F 56 −13.307 10.570 75.180 1.00 17.81 FATOM 7434 CA THR F 56 −12.094 9.828 74.878 1.00 17.94 F ATOM 7435 CB THRF 56 −11.345 10.481 73.623 1.00 17.92 F ATOM 7436 OG1 THR F 56 −10.70111.792 73.963 1.00 14.27 F ATOM 7437 CG2 THR F 56 −12.340 10.591 72.4981.00 15.52 F ATOM 7438 C THR F 56 −11.092 10.125 76.002 1.00 20.02 FATOM 7439 O THR F 56 −11.285 11.024 76.899 1.00 20.01 F ATOM 7440 N ASNF 57 −9.948 9.468 75.906 1.00 19.77 F ATOM 7441 CA ASN F 57 −8.952 9.80076.891 1.00 19.46 F ATOM 7442 CB ASN F 57 −8.077 8.669 77.159 1.00 22.49F ATOM 7443 CG ASN F 57 −8.233 8.276 78.586 1.00 26.37 F ATOM 7444 OD1ASN F 57 −9.336 7.764 78.944 1.00 29.26 F ATOM 7445 ND2 ASN F 57 −7.1998.550 79.482 1.00 27.00 F ATOM 7446 C ASN F 57 −8.142 10.920 76.451 1.0018.91 F ATOM 7447 O ASN F 57 −8.290 11.378 75.285 1.00 17.90 F ATOM 7448N TRP F 58 −7.294 11.366 77.388 1.00 18.09 F ATOM 7449 CA TRP F 58−6.340 12.506 77.236 1.00 17.83 F ATOM 7450 CB TRP F 58 −5.432 12.57578.531 1.00 20.23 F ATOM 7451 CG TRP F 58 −4.291 13.579 78.599 1.0022.73 F ATOM 7452 CD2 TRP F 58 −4.412 14.985 78.474 1.00 23.37 F ATOM7453 CE2 TRP F 58 −3.141 15.585 78.847 1.00 24.20 F ATOM 7454 CE3 TRP F58 −5.471 15.814 78.116 1.00 22.39 F ATOM 7455 CD1 TRP F 58 −3.00613.337 79.018 1.00 25.60 F ATOM 7456 NE1 TRP F 58 −2.282 14.572 79.1831.00 26.30 F ATOM 7457 CZ2 TRP F 58 −2.920 16.969 78.833 1.00 23.62 FATOM 7458 CZ3 TRP F 58 −5.262 17.210 78.101 1.00 23.49 F ATOM 7459 CH2TRP F 58 −3.991 17.772 78.456 1.00 24.17 F ATOM 7460 C TRP F 58 −5.46212.331 76.024 1.00 17.18 F ATOM 7461 O TRP F 58 −4.776 11.352 75.9161.00 16.02 F ATOM 7462 N VAL F 59 −5.446 13.304 75.156 1.00 17.28 F ATOM7463 CA VAL F 59 −4.686 13.165 73.961 1.00 17.07 F ATOM 7464 CB VAL F 59−5.634 13.116 72.669 1.00 17.89 F ATOM 7465 CG1 VAL F 59 −4.809 12.99271.428 1.00 16.99 F ATOM 7466 CG2 VAL F 59 −6.650 11.921 72.763 1.0017.27 F ATOM 7467 C VAL F 59 −3.798 14.355 73.815 1.00 17.62 F ATOM 7468O VAL F 59 −4.310 15.489 73.778 1.00 18.42 F ATOM 7469 N TYR F 60 −2.48014.096 73.721 1.00 17.57 F ATOM 7470 CA TYR F 60 −1.438 15.105 73.5631.00 16.69 F ATOM 7471 CB TYR F 60 −0.033 14.475 73.609 1.00 17.15 FATOM 7472 CG TYR F 60 0.413 13.962 74.934 1.00 18.84 F ATOM 7473 CD1 TYRF 60 0.370 12.617 75.253 1.00 20.11 F ATOM 7474 CE1 TYR F 60 0.73012.120 76.563 1.00 21.41 F ATOM 7475 CD2 TYR F 60 0.812 14.830 75.8891.00 19.79 F ATOM 7476 CE2 TYR F 60 1.151 14.425 77.166 1.00 21.31 FATOM 7477 CZ TYR F 60 1.110 13.048 77.524 1.00 22.37 F ATOM 7478 OH TYRF 60 1.396 12.599 78.875 1.00 23.95 F ATOM 7479 C TYR F 60 −1.594 15.77572.232 1.00 16.70 F ATOM 7480 O TYR F 60 −1.828 15.163 71.217 1.00 17.86F ATOM 7481 N ARG F 61 −1.440 17.055 72.210 1.00 16.75 F ATOM 7482 CAARG F 61 −1.527 17.793 70.984 1.00 16.90 F ATOM 7483 CB ARG F 61 −1.67119.290 71.320 1.00 17.05 F ATOM 7484 CG ARG F 61 −1.633 20.231 70.1211.00 18.46 F ATOM 7485 CD ARG F 61 −2.109 21.730 70.517 1.00 21.19 FATOM 7486 NE ARG F 61 −1.017 22.403 71.288 1.00 20.67 F ATOM 7487 CZ ARGF 61 0.115 22.817 70.706 1.00 20.66 F ATOM 7488 NH1 ARG F 61 0.29322.690 69.360 1.00 17.43 F ATOM 7489 NH2 ARG F 61 1.145 23.204 71.4991.00 22.20 F ATOM 7490 C ARG F 61 −0.314 17.622 70.129 1.00 16.98 F ATOM7491 O ARG F 61 −0.445 17.546 68.878 1.00 16.61 F ATOM 7492 N GLY F 620.843 17.562 70.842 1.00 17.87 F ATOM 7493 CA GLY F 62 2.168 17.51970.250 1.00 19.78 F ATOM 7494 C GLY F 62 2.344 18.758 69.366 1.00 21.03F ATOM 7495 O GLY F 62 2.167 19.898 69.849 1.00 21.82 F ATOM 7496 N GLUF 63 2.661 18.594 68.058 1.00 21.36 F ATOM 7497 CA GLU F 63 2.884 19.77567.182 1.00 21.47 F ATOM 7498 CB GLU F 63 4.039 19.394 66.252 1.00 21.39F ATOM 7499 CG GLU F 63 4.270 20.359 65.117 1.00 21.92 F ATOM 7500 CDGLU F 63 4.968 21.643 65.547 1.00 24.82 F ATOM 7501 OE1 GLU F 63 5.05822.632 64.665 1.00 23.24 F ATOM 7502 OE2 GLU F 63 5.397 21.663 66.8051.00 26.86 F ATOM 7503 C GLU F 63 1.612 20.180 66.398 1.00 22.01 F ATOM7504 O GLU F 63 1.694 21.082 65.530 1.00 22.97 F ATOM 7505 N ALA F 640.458 19.563 66.693 1.00 21.93 F ATOM 7506 CA ALA F 64 −0.777 19.84265.908 1.00 21.90 F ATOM 7507 CB ALA F 64 −1.845 18.752 66.263 1.0020.63 F ATOM 7508 C ALA F 64 −1.400 21.201 66.095 1.00 21.51 F ATOM 7509O ALA F 64 −1.445 21.624 67.216 1.00 22.67 F ATOM 7510 N GLU F 65 −1.89121.869 65.049 1.00 21.61 F ATOM 7511 CA GLU F 65 −2.598 23.206 65.1921.00 20.92 F ATOM 7512 CB GLU F 65 −2.243 24.276 64.083 1.00 20.39 FATOM 7513 CG GLU F 65 −0.716 24.636 63.865 1.00 23.79 F ATOM 7514 CD GLUF 65 −0.090 25.495 65.089 1.00 25.42 F ATOM 7515 OE1 GLU F 65 −0.55226.737 65.250 1.00 26.06 F ATOM 7516 OE2 GLU F 65 0.781 24.869 65.8301.00 25.01 F ATOM 7517 C GLU F 65 −4.066 22.834 64.970 1.00 20.61 F ATOM7518 O GLU F 65 −4.912 23.123 65.836 1.00 21.41 F ATOM 7519 N ARG F 66−4.358 22.237 63.796 1.00 20.32 F ATOM 7520 CA ARG F 66 −5.738 21.79663.392 1.00 20.02 F ATOM 7521 CB ARG F 66 −6.135 22.272 61.993 1.0019.21 F ATOM 7522 CG ARG F 66 −7.680 22.212 61.757 1.00 20.29 F ATOM7523 CD ARG F 66 −8.098 23.527 61.039 1.00 21.87 F ATOM 7524 NE ARG F 66−9.549 23.672 60.742 1.00 23.92 F ATOM 7525 CZ ARG F 66 −10.446 24.20661.585 1.00 24.36 F ATOM 7526 NH1 ARG F 66 −10.018 24.628 62.792 1.0025.98 F ATOM 7527 NH2 ARG F 66 −11.718 24.369 61.233 1.00 22.79 F ATOM7528 C ARG F 66 −5.747 20.312 63.300 1.00 20.03 F ATOM 7529 O ARG F 66−4.900 19.774 62.605 1.00 20.79 F ATOM 7530 N ASN F 67 −6.627 19.64264.014 1.00 20.76 F ATOM 7531 CA ASN F 67 −6.711 18.179 63.902 1.0021.01 F ATOM 7532 CB ASN F 67 −6.794 17.561 65.265 1.00 20.04 F ATOM7533 CG ASN F 67 −7.800 18.279 66.145 1.00 20.79 F ATOM 7534 OD1 ASN F67 −8.118 19.460 65.889 1.00 22.65 F ATOM 7535 ND2 ASN F 67 −8.31117.610 67.180 1.00 17.93 F ATOM 7536 C ASN F 67 −7.995 17.866 63.1181.00 21.01 F ATOM 7537 O ASN F 67 −8.892 18.708 63.085 1.00 22.23 F ATOM7538 N ASN F 68 −8.063 16.686 62.460 1.00 21.46 F ATOM 7539 CA ASN F 68−9.242 16.278 61.658 1.00 20.89 F ATOM 7540 CB ASN F 68 −8.777 15.95860.250 1.00 20.26 F ATOM 7541 CG ASN F 68 −8.313 17.199 59.556 1.0020.49 F ATOM 7542 OD1 ASN F 68 −9.147 17.956 58.942 1.00 21.33 F ATOM7543 ND2 ASN F 68 −7.011 17.506 59.690 1.00 18.05 F ATOM 7544 C ASN F 68−9.762 15.093 62.356 1.00 20.02 F ATOM 7545 O ASN F 68 −8.914 14.32362.912 1.00 20.51 F ATOM 7546 N PHE F 69 −11.099 14.972 62.435 1.0020.39 F ATOM 7547 CA PHE F 69 −11.634 13.702 63.024 1.00 20.50 F ATOM7548 CB PHE F 69 −12.089 13.775 64.444 1.00 19.76 F ATOM 7549 CG PHE F69 −12.324 15.085 64.874 1.00 19.51 F ATOM 7550 CD1 PHE F 69 −13.24615.867 64.176 1.00 19.84 F ATOM 7551 CD2 PHE F 69 −11.696 15.561 66.0721.00 17.91 F ATOM 7552 CE1 PHE F 69 −13.561 17.135 64.692 1.00 21.02 FATOM 7553 CE2 PHE F 69 −11.987 16.782 66.580 1.00 17.20 F ATOM 7554 CZPHE F 69 −12.912 17.598 65.930 1.00 18.63 F ATOM 7555 C PHE F 69 −12.73413.076 62.215 1.00 19.34 F ATOM 7556 O PHE F 69 −13.661 13.721 61.7571.00 19.78 F ATOM 7557 N GLU F 70 −12.497 11.793 62.002 1.00 18.40 FATOM 7558 CA GLU F 70 −13.310 10.990 61.176 1.00 16.81 F ATOM 7559 CBGLU F 70 −12.390 10.210 60.232 1.00 18.46 F ATOM 7560 CG GLU F 70−13.045 9.693 59.004 1.00 19.74 F ATOM 7561 CD GLU F 70 −12.271 8.60858.358 1.00 20.63 F ATOM 7562 OE1 GLU F 70 −12.114 8.633 57.084 1.0022.80 F ATOM 7563 OE2 GLU F 70 −11.837 7.724 59.136 1.00 20.41 F ATOM7564 C GLU F 70 −14.041 10.089 62.129 1.00 15.73 F ATOM 7565 O GLU F 70−13.415 9.400 62.986 1.00 11.85 F ATOM 7566 N LEU F 71 −15.371 10.16161.919 1.00 15.25 F ATOM 7567 CA LEU F 71 −16.380 9.434 62.630 1.0016.54 F ATOM 7568 CB LEU F 71 −17.346 10.454 63.234 1.00 17.54 F ATOM7569 CG LEU F 71 −16.801 11.270 64.389 1.00 17.29 F ATOM 7570 CD1 LEU F71 −17.892 12.261 64.735 1.00 19.31 F ATOM 7571 CD2 LEU F 71 −16.38910.395 65.565 1.00 14.19 F ATOM 7572 C LEU F 71 −17.169 8.469 61.7431.00 17.34 F ATOM 7573 O LEU F 71 −17.587 8.884 60.649 1.00 16.94 F ATOM7574 N ASN F 72 −17.352 7.214 62.207 1.00 16.00 F ATOM 7575 CA ASN F 72−18.100 6.132 61.499 1.00 15.09 F ATOM 7576 CB ASN F 72 −17.162 5.02061.064 1.00 14.95 F ATOM 7577 CG ASN F 72 −16.475 5.330 59.758 1.0015.55 F ATOM 7578 OD1 ASN F 72 −15.506 4.671 59.344 1.00 14.82 F ATOM7579 ND2 ASN F 72 −16.994 6.324 59.069 1.00 17.95 F ATOM 7580 C ASN F 72−19.187 5.578 62.492 1.00 16.52 F ATOM 7581 O ASN F 72 −18.943 4.99863.676 1.00 16.09 F ATOM 7582 N PHE F 73 −20.433 5.751 62.062 1.00 14.46F ATOM 7583 CA PHE F 73 −21.496 5.345 62.927 1.00 13.74 F ATOM 7584 CBPHE F 73 −21.819 6.555 63.815 1.00 13.32 F ATOM 7585 CG PHE F 73 −22.1867.811 63.027 1.00 14.30 F ATOM 7586 CD1 PHE F 73 −23.526 8.148 62.7871.00 15.01 F ATOM 7587 CD2 PHE F 73 −21.242 8.565 62.428 1.00 14.39 FATOM 7588 CE1 PHE F 73 −23.865 9.203 61.940 1.00 16.63 F ATOM 7589 CE2PHE F 73 −21.576 9.603 61.598 1.00 17.49 F ATOM 7590 CZ PHE F 73 −22.8959.929 61.341 1.00 17.14 F ATOM 7591 C PHE F 73 −22.795 4.940 62.090 1.0015.69 F ATOM 7592 O PHE F 73 −22.897 5.138 60.864 1.00 13.68 F ATOM 7593N THR F 74 −23.795 4.486 62.799 1.00 15.42 F ATOM 7594 CA THR F 74−24.990 4.219 62.192 1.00 16.86 F ATOM 7595 CB THR F 74 −25.313 2.69762.182 1.00 19.48 F ATOM 7596 OG1 THR F 74 −25.657 2.153 63.497 1.0018.95 F ATOM 7597 CG2 THR F 74 −24.074 1.993 61.785 1.00 23.35 F ATOM7598 C THR F 74 −25.974 4.757 63.110 1.00 18.58 F ATOM 7599 O THR F 74−25.788 4.766 64.362 1.00 18.85 F ATOM 7600 N VAL F 75 −27.120 5.01162.538 1.00 16.99 F ATOM 7601 CA VAL F 75 −28.232 5.477 63.369 1.0016.13 F ATOM 7602 CB VAL F 75 −28.301 7.017 63.125 1.00 15.97 F ATOM7603 CG1 VAL F 75 −29.413 7.672 63.942 1.00 14.56 F ATOM 7604 CG2 VAL F75 −26.995 7.577 63.394 1.00 14.36 F ATOM 7605 C VAL F 75 −29.579 4.68663.080 1.00 14.70 F ATOM 7606 O VAL F 75 −30.040 4.630 61.952 1.00 13.71F ATOM 7607 N ARG F 76 −30.124 4.035 64.084 1.00 14.06 F ATOM 7608 CAARG F 76 −31.343 3.370 63.845 1.00 14.70 F ATOM 7609 CB ARG F 76 −31.7112.487 64.966 1.00 13.28 F ATOM 7610 CG ARG F 76 −32.958 1.821 64.8361.00 10.50 F ATOM 7611 CD ARG F 76 −32.890 0.529 65.546 1.00 9.53 F ATOM7612 NE ARG F 76 −34.251 0.090 65.687 1.00 11.10 F ATOM 7613 CZ ARG F 76−34.732 −0.803 66.589 1.00 13.58 F ATOM 7614 NH1 ARG F 76 −33.918 −1.40567.460 1.00 12.11 F ATOM 7615 NH2 ARG F 76 −36.072 −1.022 66.693 1.0011.13 F ATOM 7616 C ARG F 76 −32.434 4.398 63.593 1.00 16.37 F ATOM 7617O ARG F 76 −32.446 5.461 64.161 1.00 17.13 F ATOM 7618 N ASP F 77−33.308 4.103 62.622 1.00 17.74 F ATOM 7619 CA ASP F 77 −34.412 4.96262.184 1.00 17.52 F ATOM 7620 CB ASP F 77 −35.074 4.321 60.997 1.0020.14 F ATOM 7621 CG ASP F 77 −36.406 4.977 60.634 1.00 22.18 F ATOM7622 OD1 ASP F 77 −36.806 6.040 61.274 1.00 21.73 F ATOM 7623 OD2 ASP F77 −37.041 4.425 59.678 1.00 22.82 F ATOM 7624 C ASP F 77 −35.348 5.02763.336 1.00 18.99 F ATOM 7625 O ASP F 77 −35.673 3.930 63.957 1.00 16.85F ATOM 7626 N CYS F 78 −35.744 6.292 63.669 1.00 19.28 F ATOM 7627 CACYS F 78 −36.680 6.576 64.858 1.00 19.49 F ATOM 7628 C CYS F 78 −38.1026.038 64.713 1.00 20.54 F ATOM 7629 O CYS F 78 −38.841 5.817 65.748 1.0021.74 F ATOM 7630 CB CYS F 78 −36.820 8.101 65.246 1.00 18.84 F ATOM7631 SG CYS F 78 −35.467 8.818 66.334 1.00 16.80 F ATOM 7632 N ASN F 79−38.471 5.803 63.444 1.00 19.80 F ATOM 7633 CA ASN F 79 −39.762 5.21563.144 1.00 17.95 F ATOM 7634 CB ASN F 79 −40.217 5.653 61.726 1.0017.14 F ATOM 7635 CG ASN F 79 −40.618 7.122 61.688 1.00 16.04 F ATOM7636 OD1 ASN F 79 −40.631 7.795 60.678 1.00 13.51 F ATOM 7637 ND2 ASN F79 −40.968 7.615 62.843 1.00 19.12 F ATOM 7638 C ASN F 79 −39.719 3.69263.298 1.00 17.07 F ATOM 7639 O ASN F 79 −40.739 3.119 63.315 1.00 16.31F ATOM 7640 N SER F 80 −38.551 3.096 63.464 1.00 16.20 F ATOM 7641 CASER F 80 −38.468 1.703 63.564 1.00 16.28 F ATOM 7642 CB SER F 80 −37.0651.230 63.232 1.00 16.73 F ATOM 7643 OG SER F 80 −36.062 1.808 64.1191.00 19.07 F ATOM 7644 C SER F 80 −38.808 1.252 64.922 1.00 16.23 F ATOM7645 O SER F 80 −38.445 0.153 65.250 1.00 15.44 F ATOM 7646 N PHE F 81−39.401 2.101 65.768 1.00 16.71 F ATOM 7647 CA PHE F 81 −39.718 1.61467.146 1.00 17.47 F ATOM 7648 CB PHE F 81 −39.046 2.545 68.193 1.0017.52 F ATOM 7649 CG PHE F 81 −37.510 2.527 68.175 1.00 15.80 F ATOM7650 CD1 PHE F 81 −36.790 3.426 67.427 1.00 12.99 F ATOM 7651 CD2 PHE F81 −36.800 1.580 68.920 1.00 14.82 F ATOM 7652 CE1 PHE F 81 −35.4173.363 67.438 1.00 12.15 F ATOM 7653 CE2 PHE F 81 −35.399 1.550 68.9041.00 12.98 F ATOM 7654 CZ PHE F 81 −34.718 2.423 68.176 1.00 10.08 FATOM 7655 C PHE F 81 −41.301 1.615 67.177 1.00 19.38 F ATOM 7656 O PHE F81 −41.903 2.636 67.327 1.00 17.40 F ATOM 7657 N PRO F 82 −41.965 0.42067.059 1.00 20.84 F ATOM 7658 CD PRO F 82 −41.357 −0.816 67.634 1.0021.23 F ATOM 7659 CA PRO F 82 −43.433 0.290 67.005 1.00 20.58 F ATOM7660 CB PRO F 82 −43.733 −1.171 67.406 1.00 22.42 F ATOM 7661 CG PRO F82 −42.352 −1.928 67.245 1.00 21.93 F ATOM 7662 C PRO F 82 −44.127 1.16067.919 1.00 22.52 F ATOM 7663 O PRO F 82 −43.750 1.178 69.113 1.00 22.62F ATOM 7664 N GLY F 83 −45.177 1.828 67.431 1.00 22.64 F ATOM 7665 CAGLY F 83 −45.949 2.760 68.274 1.00 22.27 F ATOM 7666 C GLY F 83 −45.1414.045 68.099 1.00 21.94 F ATOM 7667 O GLY F 83 −44.026 3.941 67.493 1.0022.58 F ATOM 7668 N GLY F 84 −45.557 5.252 68.518 1.00 21.58 F ATOM 7669CA GLY F 84 −44.551 6.336 68.239 1.00 20.94 F ATOM 7670 C GLY F 84−43.291 6.386 69.163 1.00 21.14 F ATOM 7671 O GLY F 84 −43.306 5.67170.195 1.00 20.77 F ATOM 7672 N ALA F 85 −42.188 7.106 68.837 1.00 20.59F ATOM 7673 CA ALA F 85 −41.052 7.198 69.836 1.00 20.44 F ATOM 7674 CBALA F 85 −39.751 6.403 69.414 1.00 18.39 F ATOM 7675 C ALA F 85 −40.7288.672 69.899 1.00 20.58 F ATOM 7676 O ALA F 85 −39.665 9.034 69.531 1.0021.80 F ATOM 7677 N SER F 86 −41.688 9.511 70.310 1.00 19.75 F ATOM 7678CA SER F 86 −41.564 10.983 70.433 1.00 17.42 F ATOM 7679 CB SER F 86−42.684 11.586 71.310 1.00 16.21 F ATOM 7680 OG SER F 86 −42.744 11.01772.616 1.00 14.75 F ATOM 7681 C SER F 86 −40.256 11.567 70.914 1.0017.11 F ATOM 7682 O SER F 86 −39.829 12.629 70.421 1.00 17.13 F ATOM7683 N SER F 87 −39.586 10.946 71.867 1.00 16.91 F ATOM 7684 CA SER F 87−38.301 11.580 72.300 1.00 16.12 F ATOM 7685 CB SER F 87 −38.157 11.43673.842 1.00 15.06 F ATOM 7686 OG SER F 87 −37.918 10.096 74.284 1.0013.73 F ATOM 7687 C SER F 87 −37.048 11.072 71.549 1.00 15.21 F ATOM7688 O SER F 87 −35.999 11.520 71.804 1.00 15.82 F ATOM 7689 N CYS F 88−37.186 10.097 70.667 1.00 15.28 F ATOM 7690 CA CYS F 88 −36.066 9.55469.905 1.00 13.74 F ATOM 7691 C CYS F 88 −35.595 10.623 68.981 1.0014.39 F ATOM 7692 O CYS F 88 −36.346 11.479 68.542 1.00 14.18 F ATOM7693 CB CYS F 88 −36.519 8.343 69.148 1.00 13.08 F ATOM 7694 SG CYS F 88−35.466 7.528 67.910 1.00 13.76 F ATOM 7695 N LYS F 89 −34.302 10.61068.761 1.00 15.83 F ATOM 7696 CA LYS F 89 −33.594 11.591 67.913 1.0017.51 F ATOM 7697 CB LYS F 89 −32.637 12.432 68.825 1.00 18.79 F ATOM7698 CG LYS F 89 −33.406 13.153 70.007 1.00 20.71 F ATOM 7699 CD LYS F89 −34.188 14.326 69.375 1.00 19.47 F ATOM 7700 CE LYS F 89 −34.92615.144 70.373 1.00 20.57 F ATOM 7701 NZ LYS F 89 −35.464 16.526 69.8091.00 21.34 F ATOM 7702 C LYS F 89 −32.721 10.875 66.866 1.00 16.88 FATOM 7703 O LYS F 89 −32.368 9.729 67.027 1.00 16.59 F ATOM 7704 N GLU F90 −32.317 11.571 65.843 1.00 17.11 F ATOM 7705 CA GLU F 90 −31.43310.974 64.847 1.00 19.09 F ATOM 7706 CB GLU F 90 −32.170 10.720 63.5211.00 17.54 F ATOM 7707 CG GLU F 90 −33.348 9.790 63.795 1.00 18.53 FATOM 7708 CD GLU F 90 −34.336 9.609 62.624 1.00 19.25 F ATOM 7709 OE1GLU F 90 −34.583 10.668 61.941 1.00 17.26 F ATOM 7710 OE2 GLU F 90−34.854 8.418 62.437 1.00 18.46 F ATOM 7711 C GLU F 90 −30.147 11.79564.582 1.00 19.97 F ATOM 7712 O GLU F 90 −29.729 11.981 63.421 1.0021.73 F ATOM 7713 N THR F 91 −29.562 12.337 65.640 1.00 20.08 F ATOM7714 CA THR F 91 −28.328 13.075 65.514 1.00 18.48 F ATOM 7715 CB THR F91 −28.544 14.572 65.195 1.00 18.45 F ATOM 7716 OG1 THR F 91 −29.37215.175 66.205 1.00 17.11 F ATOM 7717 CG2 THR F 91 −29.196 14.734 63.8931.00 16.88 F ATOM 7718 C THR F 91 −27.778 12.977 66.916 1.00 19.39 FATOM 7719 O THR F 91 −28.468 12.432 67.845 1.00 18.72 F ATOM 7720 N PHEF 92 −26.522 13.426 67.018 1.00 18.82 F ATOM 7721 CA PHE F 92 −25.74313.472 68.252 1.00 17.54 F ATOM 7722 CB PHE F 92 −25.076 12.106 68.5481.00 18.30 F ATOM 7723 CG PHE F 92 −24.036 11.669 67.534 1.00 18.24 FATOM 7724 CD1 PHE F 92 −22.698 11.996 67.707 1.00 17.06 F ATOM 7725 CD2PHE F 92 −24.434 10.843 66.448 1.00 17.44 F ATOM 7726 CE1 PHE F 92−21.718 11.509 66.831 1.00 19.53 F ATOM 7727 CE2 PHE F 92 −23.482 10.32665.529 1.00 18.36 F ATOM 7728 CZ PHE F 92 −22.105 10.626 65.681 1.0019.37 F ATOM 7729 C PHE F 92 −24.684 14.567 68.155 1.00 17.98 F ATOM7730 O PHE F 92 −24.345 15.064 67.061 1.00 15.98 F ATOM 7731 N ASN F 93−24.111 14.909 69.321 1.00 18.04 F ATOM 7732 CA ASN F 93 −23.161 15.98869.357 1.00 17.17 F ATOM 7733 CB ASN F 93 −23.625 16.935 70.388 1.0019.16 F ATOM 7734 CG ASN F 93 −24.868 17.592 69.949 1.00 20.34 F ATOM7735 OD1 ASN F 93 −24.861 18.108 68.788 1.00 20.41 F ATOM 7736 ND2 ASN F93 −25.953 17.565 70.790 1.00 16.00 F ATOM 7737 C ASN F 93 −21.75215.721 69.594 1.00 17.39 F ATOM 7738 O ASN F 93 −21.413 14.847 70.4051.00 15.99 F ATOM 7739 N LEU F 94 −20.927 16.542 68.908 1.00 17.16 FATOM 7740 CA LEU F 94 −19.477 16.429 69.045 1.00 16.62 F ATOM 7741 CBLEU F 94 −18.820 16.329 67.682 1.00 15.88 F ATOM 7742 CG LEU F 94−17.306 16.222 67.610 1.00 15.26 F ATOM 7743 CD1 LEU F 94 −16.759 15.04968.372 1.00 12.98 F ATOM 7744 CD2 LEU F 94 −16.966 16.188 66.153 1.0014.95 F ATOM 7745 C LEU F 94 −18.848 17.597 69.803 1.00 18.23 F ATOM7746 O LEU F 94 −19.068 18.732 69.457 1.00 17.33 F ATOM 7747 N TYR F 95−18.029 17.277 70.822 1.00 19.17 F ATOM 7748 CA TYR F 95 −17.403 18.32171.655 1.00 19.53 F ATOM 7749 CB TYR F 95 −18.041 18.404 73.037 1.0020.25 F ATOM 7750 CG TYR F 95 −19.466 18.976 73.210 1.00 20.51 F ATOM7751 CD1 TYR F 95 −20.609 18.274 72.806 1.00 18.75 F ATOM 7752 CE1 TYR F95 −21.858 18.839 72.943 1.00 18.77 F ATOM 7753 CD2 TYR F 95 −19.65020.288 73.776 1.00 20.41 F ATOM 7754 CE2 TYR F 95 −20.897 20.829 73.8931.00 20.20 F ATOM 7755 CZ TYR F 95 −21.988 20.112 73.484 1.00 18.71 FATOM 7756 OH TYR F 95 −23.146 20.789 73.646 1.00 19.94 F ATOM 7757 C TYRF 95 −15.931 17.922 71.963 1.00 21.16 F ATOM 7758 O TYR F 95 −15.49716.660 71.993 1.00 20.40 F ATOM 7759 N TYR F 96 −15.178 18.984 72.2571.00 20.41 F ATOM 7760 CA TYR F 96 −13.804 18.781 72.696 1.00 19.39 FATOM 7761 CB TYR F 96 −12.858 19.081 71.534 1.00 19.27 F ATOM 7762 CGTYR F 96 −12.635 20.543 71.298 1.00 17.40 F ATOM 7763 CD1 TYR F 96−11.475 21.179 71.733 1.00 16.51 F ATOM 7764 CE1 TYR F 96 −11.233 22.52271.458 1.00 15.00 F ATOM 7765 CD2 TYR F 96 −13.554 21.291 70.607 1.0016.75 F ATOM 7766 CE2 TYR F 96 −13.314 22.637 70.320 1.00 15.23 F ATOM7767 CZ TYR F 96 −12.161 23.248 70.738 1.00 14.71 F ATOM 7768 OH TYR F96 −11.913 24.566 70.402 1.00 12.37 F ATOM 7769 C TYR F 96 −13.58219.761 73.905 1.00 20.35 F ATOM 7770 O TYR F 96 −14.561 20.424 74.3501.00 18.90 F ATOM 7771 N ALA F 97 −12.333 19.842 74.397 1.00 19.69 FATOM 7772 CA ALA F 97 −11.898 20.745 75.523 1.00 19.37 F ATOM 7773 CBALA F 97 −12.492 20.332 76.945 1.00 16.02 F ATOM 7774 C ALA F 97 −10.39020.544 75.495 1.00 20.97 F ATOM 7775 O ALA F 97 −9.860 19.415 75.1891.00 22.19 F ATOM 7776 N GLU F 98 −9.661 21.653 75.714 1.00 21.67 F ATOM7777 CA GLU F 98 −8.177 21.636 75.697 1.00 19.70 F ATOM 7778 CB GLU F 98−7.662 22.880 74.946 1.00 19.11 F ATOM 7779 CG GLU F 98 −7.529 22.68673.470 1.00 18.15 F ATOM 7780 CD GLU F 98 −7.125 23.890 72.778 1.0017.02 F ATOM 7781 OE1 GLU F 98 −8.032 24.728 72.601 1.00 16.72 F ATOM7782 OE2 GLU F 98 −5.912 23.976 72.411 1.00 16.61 F ATOM 7783 C GLU F 98−7.852 21.768 77.151 1.00 20.71 F ATOM 7784 O GLU F 98 −8.661 22.31577.914 1.00 20.46 F ATOM 7785 N SER F 99 −6.766 21.156 77.588 1.00 21.75F ATOM 7786 CA SER F 99 −6.221 21.501 78.972 1.00 21.94 F ATOM 7787 CBSER F 99 −6.950 20.841 80.143 1.00 22.46 F ATOM 7788 OG SER F 99 −6.78519.415 80.153 1.00 24.05 F ATOM 7789 C SER F 99 −4.758 21.131 79.0351.00 22.13 F ATOM 7790 O SER F 99 −4.312 20.246 78.314 1.00 22.69 F ATOM7791 N ASP F 100 −3.988 21.825 79.830 1.00 21.95 F ATOM 7792 CA ASP F100 −2.561 21.545 79.843 1.00 21.70 F ATOM 7793 CB ASP F 100 −1.76122.743 80.269 1.00 20.70 F ATOM 7794 CG ASP F 100 −1.643 23.838 79.1961.00 21.98 F ATOM 7795 OD1 ASP F 100 −1.208 23.583 78.017 1.00 21.84 FATOM 7796 OD2 ASP F 100 −1.910 25.059 79.536 1.00 23.79 F ATOM 7797 CASP F 100 −2.295 20.422 80.822 1.00 22.54 F ATOM 7798 O ASP F 100 −1.14619.964 80.874 1.00 23.44 F ATOM 7799 N LEU F 101 −3.322 19.996 81.5651.00 21.78 F ATOM 7800 CA LEU F 101 −3.230 18.928 82.531 1.00 21.06 FATOM 7801 CB LEU F 101 −3.627 19.371 83.957 1.00 22.57 F ATOM 7802 CGLEU F 101 −3.225 20.715 84.606 1.00 24.63 F ATOM 7803 CD1 LEU F 101−3.742 21.851 83.601 1.00 24.86 F ATOM 7804 CD2 LEU F 101 −3.937 20.94586.019 1.00 25.84 F ATOM 7805 C LEU F 101 −4.285 17.845 82.159 1.0021.36 F ATOM 7806 O LEU F 101 −5.372 18.093 81.548 1.00 20.77 F ATOM7807 N ASP F 102 −4.016 16.671 82.707 1.00 21.76 F ATOM 7808 CA ASP F102 −4.829 15.520 82.463 1.00 22.41 F ATOM 7809 CB ASP F 102 −3.94314.285 82.681 1.00 24.13 F ATOM 7810 CG ASP F 102 −4.655 12.969 82.2811.00 26.68 F ATOM 7811 OD1 ASP F 102 −5.947 12.969 82.385 1.00 26.81 FATOM 7812 OD2 ASP F 102 −3.897 11.968 81.860 1.00 27.35 F ATOM 7813 CASP F 102 −5.975 15.526 83.412 1.00 21.70 F ATOM 7814 O ASP F 102 −5.76515.201 84.584 1.00 22.52 F ATOM 7815 N TYR F 103 −7.192 15.885 82.9991.00 21.58 F ATOM 7816 CA TYR F 103 −8.250 15.802 84.086 1.00 21.32 FATOM 7817 CB TYR F 103 −9.709 16.172 83.659 1.00 21.33 F ATOM 7818 CGTYR F 103 −9.895 17.609 83.284 1.00 23.03 F ATOM 7819 CD1 TYR F 103−9.444 18.665 84.210 1.00 23.51 F ATOM 7820 CE1 TYR F 103 −9.457 20.04983.828 1.00 23.14 F ATOM 7821 CD2 TYR F 103 −10.415 17.987 81.919 1.0024.52 F ATOM 7822 CE2 TYR F 103 −10.444 19.417 81.479 1.00 24.53 F ATOM7823 CZ TYR F 103 −9.927 20.460 82.486 1.00 25.14 F ATOM 7824 OH TYR F103 −9.833 21.830 82.017 1.00 24.24 F ATOM 7825 C TYR F 103 −8.40214.474 84.744 1.00 20.20 F ATOM 7826 O TYR F 103 −9.134 14.422 85.6571.00 20.37 F ATOM 7827 N GLY F 104 −7.776 13.396 84.303 1.00 20.66 FATOM 7828 CA GLY F 104 −8.074 12.099 84.957 1.00 21.48 F ATOM 7829 C GLYF 104 −9.593 11.759 84.763 1.00 22.31 F ATOM 7830 O GLY F 104 −10.15011.877 83.624 1.00 23.34 F ATOM 7831 N THR F 105 −10.295 11.386 85.8371.00 22.68 F ATOM 7832 CA THR F 105 −11.749 11.075 85.786 1.00 22.14 FATOM 7833 CB THR F 105 −12.008 10.074 86.851 1.00 23.31 F ATOM 7834 OG1THR F 105 −11.624 8.789 86.303 1.00 24.26 F ATOM 7835 CG2 THR F 105−13.517 10.144 87.340 1.00 23.48 F ATOM 7836 C THR F 105 −12.768 12.25885.918 1.00 21.24 F ATOM 7837 O THR F 105 −13.974 12.124 85.979 1.0019.90 F ATOM 7838 N ASN F 106 −12.211 13.434 85.837 1.00 21.10 F ATOM7839 CA ASN F 106 −12.964 14.629 86.016 1.00 23.05 F ATOM 7840 CB ASN F106 −12.126 15.843 86.442 1.00 22.76 F ATOM 7841 CG ASN F 106 −11.80015.841 87.892 1.00 23.72 F ATOM 7842 OD1 ASN F 106 −11.018 16.823 88.4461.00 26.89 F ATOM 7843 ND2 ASN F 106 −12.386 14.834 88.604 1.00 23.43 FATOM 7844 C ASN F 106 −13.655 15.068 84.846 1.00 22.70 F ATOM 7845 O ASNF 106 −13.197 16.063 84.193 1.00 23.91 F ATOM 7846 N PHE F 107 −14.81014.500 84.641 1.00 22.13 F ATOM 7847 CA PHE F 107 −15.448 15.035 83.4961.00 22.36 F ATOM 7848 CB PHE F 107 −16.300 13.932 82.867 1.00 21.74 FATOM 7849 CG PHE F 107 −16.972 14.371 81.640 1.00 20.73 F ATOM 7850 CD1PHE F 107 −16.256 14.882 80.576 1.00 20.44 F ATOM 7851 CD2 PHE F 107−18.324 14.381 81.615 1.00 19.88 F ATOM 7852 CE1 PHE F 107 −16.93315.456 79.449 1.00 21.78 F ATOM 7853 CE2 PHE F 107 −19.032 14.933 80.4951.00 21.12 F ATOM 7854 CZ PHE F 107 −18.332 15.473 79.431 1.00 21.14 FATOM 7855 C PHE F 107 −16.337 16.242 83.844 1.00 21.07 F ATOM 7856 O PHEF 107 −17.204 16.121 84.759 1.00 20.66 F ATOM 7857 N GLN F 108 −16.16817.327 83.060 1.00 20.57 F ATOM 7858 CA GLN F 108 −17.007 18.540 83.2071.00 21.03 F ATOM 7859 CB GLN F 108 −16.208 19.807 83.613 1.00 22.68 FATOM 7860 CG GLN F 108 −15.229 19.563 84.625 1.00 25.02 F ATOM 7861 CDGLN F 108 −15.896 19.503 85.976 1.00 27.43 F ATOM 7862 OE1 GLN F 108−15.128 19.361 87.033 1.00 30.47 F ATOM 7863 NE2 GLN F 108 −17.30519.670 86.011 1.00 26.35 F ATOM 7864 C GLN F 108 −17.597 18.920 81.9161.00 19.49 F ATOM 7865 O GLN F 108 −16.925 19.596 81.117 1.00 19.28 FATOM 7866 N LYS F 109 −18.868 18.559 81.735 1.00 19.62 F ATOM 7867 CALYS F 109 −19.537 18.886 80.485 1.00 18.79 F ATOM 7868 CB LYS F 109−21.022 18.456 80.621 1.00 19.39 F ATOM 7869 CG LYS F 109 −21.937 19.60980.287 1.00 21.43 F ATOM 7870 CD LYS F 109 −23.371 19.345 80.650 1.0024.07 F ATOM 7871 CE LYS F 109 −24.118 18.620 79.439 1.00 27.28 F ATOM7872 NZ LYS F 109 −25.707 18.622 79.557 1.00 26.49 F ATOM 7873 C LYS F109 −19.306 20.398 80.205 1.00 17.99 F ATOM 7874 O LYS F 109 −18.84520.811 79.109 1.00 18.54 F ATOM 7875 N ARG F 110 −19.528 21.216 81.2201.00 18.45 F ATOM 7876 CA ARG F 110 −19.446 22.649 80.952 1.00 18.56 FATOM 7877 CB ARG F 110 −19.953 23.459 82.133 1.00 19.81 F ATOM 7878 CGARG F 110 −21.458 23.667 82.029 1.00 22.73 F ATOM 7879 CD ARG F 110−22.303 22.276 82.312 1.00 25.99 F ATOM 7880 NE ARG F 110 −23.740 22.46481.981 1.00 26.09 F ATOM 7881 CZ ARG F 110 −24.217 22.471 80.737 1.0026.48 F ATOM 7882 NH1 ARG F 110 −23.359 22.279 79.699 1.00 22.86 F ATOM7883 NH2 ARG F 110 −25.566 22.672 80.564 1.00 27.18 F ATOM 7884 C ARG F110 −18.151 23.154 80.488 1.00 17.73 F ATOM 7885 O ARG F 110 −18.09624.256 80.024 1.00 17.45 F ATOM 7886 N LEU F 111 −17.120 22.311 80.5491.00 18.54 F ATOM 7887 CA LEU F 111 −15.734 22.671 80.095 1.00 19.81 FATOM 7888 CB LEU F 111 −14.666 21.912 80.895 1.00 18.84 F ATOM 7889 CGLEU F 111 −14.670 22.440 82.397 1.00 18.97 F ATOM 7890 CD1 LEU F 111−13.473 21.809 83.084 1.00 17.73 F ATOM 7891 CD2 LEU F 111 −14.60024.097 82.561 1.00 18.05 F ATOM 7892 C LEU F 111 −15.485 22.437 78.6431.00 20.38 F ATOM 7893 O LEU F 111 −14.504 22.924 78.078 1.00 21.82 FATOM 7894 N PHE F 112 −16.376 21.611 78.057 1.00 20.35 F ATOM 7895 CAPHE F 112 −16.353 21.279 76.621 1.00 18.43 F ATOM 7896 CB PHE F 112−16.935 19.923 76.437 1.00 18.45 F ATOM 7897 CG PHE F 112 −16.029 18.85976.791 1.00 17.93 F ATOM 7898 CD1 PHE F 112 −15.771 18.586 78.149 1.0018.28 F ATOM 7899 CD2 PHE F 112 −15.417 18.061 75.746 1.00 17.55 F ATOM7900 CE1 PHE F 112 −14.914 17.518 78.499 1.00 18.45 F ATOM 7901 CE2 PHEF 112 −14.564 16.995 76.038 1.00 16.01 F ATOM 7902 CZ PHE F 112 −14.28316.683 77.402 1.00 18.65 F ATOM 7903 C PHE F 112 −17.145 22.232 75.7691.00 18.67 F ATOM 7904 O PHE F 112 −18.187 22.747 76.240 1.00 17.68 FATOM 7905 N THR F 113 −16.640 22.435 74.549 1.00 18.68 F ATOM 7906 CATHR F 113 −17.213 23.261 73.494 1.00 17.39 F ATOM 7907 CB THR F 113−16.179 24.106 72.880 1.00 18.17 F ATOM 7908 OG1 THR F 113 −15.65924.897 73.897 1.00 19.67 F ATOM 7909 CG2 THR F 113 −16.719 25.027 71.7421.00 17.26 F ATOM 7910 C THR F 113 −17.760 22.323 72.384 1.00 18.96 FATOM 7911 O THR F 113 −17.215 21.245 72.007 1.00 19.02 F ATOM 7912 N LYSF 114 −18.901 22.737 71.871 1.00 19.40 F ATOM 7913 CA LYS F 114 −19.52521.974 70.861 1.00 18.20 F ATOM 7914 CB LYS F 114 −21.081 22.327 70.7971.00 18.71 F ATOM 7915 CG LYS F 114 −21.859 21.541 69.715 1.00 18.59 FATOM 7916 CD LYS F 114 −23.333 21.629 69.683 1.00 17.51 F ATOM 7917 CELYS F 114 −23.852 20.980 68.308 1.00 18.89 F ATOM 7918 NZ LYS F 114−25.464 20.928 68.081 1.00 19.46 F ATOM 7919 C LYS F 114 −18.735 22.25769.569 1.00 18.49 F ATOM 7920 O LYS F 114 −18.394 23.374 69.290 1.0018.66 F ATOM 7921 N ILE F 115 −18.352 21.212 68.851 1.00 18.86 F ATOM7922 CA ILE F 115 −17.752 21.360 67.563 1.00 17.76 F ATOM 7923 CB ILE F115 −16.890 20.228 67.233 1.00 16.34 F ATOM 7924 CG2 ILE F 115 −16.57820.337 65.776 1.00 14.37 F ATOM 7925 CG1 ILE F 115 −15.693 20.293 68.1741.00 16.12 F ATOM 7926 CD1 ILE F 115 −14.725 19.228 68.328 1.00 12.42 FATOM 7927 C ILE F 115 −18.878 21.421 66.509 1.00 18.07 F ATOM 7928 O ILEF 115 −18.840 22.323 65.665 1.00 18.75 F ATOM 7929 N ASP F 116 −19.86320.491 66.577 1.00 18.12 F ATOM 7930 CA ASP F 116 −20.960 20.389 65.5881.00 17.75 F ATOM 7931 CB ASP F 116 −20.350 20.039 64.192 1.00 17.80 FATOM 7932 CG ASP F 116 −21.278 20.352 63.027 1.00 18.06 F ATOM 7933 OD1ASP F 116 −20.931 19.980 61.858 1.00 17.33 F ATOM 7934 OD2 ASP F 116−22.337 20.974 63.287 1.00 18.33 F ATOM 7935 C ASP F 116 −21.950 19.28765.954 1.00 16.91 F ATOM 7936 O ASP F 116 −21.635 18.394 66.765 1.0015.63 F ATOM 7937 N THR F 117 −23.138 19.379 65.324 1.00 16.63 F ATOM7938 CA THR F 117 −24.163 18.349 65.392 1.00 16.66 F ATOM 7939 CB THR F117 −25.504 18.920 64.987 1.00 17.21 F ATOM 7940 OG1 THR F 117 −25.88719.832 65.964 1.00 18.24 F ATOM 7941 CG2 THR F 117 −26.599 17.846 65.0111.00 16.97 F ATOM 7942 C THR F 117 −23.730 17.285 64.304 1.00 17.10 FATOM 7943 O THR F 117 −23.411 17.643 63.155 1.00 15.77 F ATOM 7944 N ILEF 118 −23.678 16.008 64.675 1.00 17.28 F ATOM 7945 CA ILE F 118 −23.34514.956 63.719 1.00 18.12 F ATOM 7946 CB ILE F 118 −22.408 13.888 64.3671.00 17.69 F ATOM 7947 CG2 ILE F 118 −22.016 12.707 63.333 1.00 15.57 FATOM 7948 CG1 ILE F 118 −21.205 14.633 64.971 1.00 16.42 F ATOM 7949 CD1ILE F 118 −20.459 15.464 64.046 1.00 13.64 F ATOM 7950 C ILE F 118−24.723 14.281 63.266 1.00 19.40 F ATOM 7951 O ILE F 118 −25.547 13.78064.110 1.00 19.85 F ATOM 7952 N ALA F 119 −24.941 14.289 61.938 1.0018.86 F ATOM 7953 CA ALA F 119 −26.162 13.753 61.366 1.00 18.17 F ATOM7954 CB ALA F 119 −26.960 14.925 60.799 1.00 15.15 F ATOM 7955 C ALA F119 −25.861 12.701 60.281 1.00 17.74 F ATOM 7956 O ALA F 119 −25.02612.897 59.421 1.00 18.40 F ATOM 7957 N PRO F 120 −26.563 11.575 60.3181.00 18.72 F ATOM 7958 CD PRO F 120 −27.731 11.234 61.180 1.00 18.40 FATOM 7959 CA PRO F 120 −26.331 10.527 59.291 1.00 18.72 F ATOM 7960 CBPRO F 120 −27.059 9.289 59.879 1.00 18.18 F ATOM 7961 CG PRO F 120−28.315 9.921 60.428 1.00 18.12 F ATOM 7962 C PRO F 120 −26.954 10.90357.886 1.00 18.31 F ATOM 7963 O PRO F 120 −28.038 11.404 57.796 1.0018.14 F ATOM 7964 N ASP F 121 −26.232 10.647 56.815 1.00 19.05 F ATOM7965 CA ASP F 121 −26.718 10.875 55.489 1.00 19.83 F ATOM 7966 CB ASP F121 −25.569 10.748 54.511 1.00 21.55 F ATOM 7967 CG ASP F 121 −24.31011.330 55.062 1.00 23.79 F ATOM 7968 OD1 ASP F 121 −23.626 10.731 56.0631.00 24.38 F ATOM 7969 OD2 ASP F 121 −24.039 12.436 54.477 1.00 23.34 FATOM 7970 C ASP F 121 −27.676 9.694 55.218 1.00 18.94 F ATOM 7971 O ASPF 121 −28.516 9.777 54.362 1.00 18.08 F ATOM 7972 N GLU F 122 −27.4938.611 55.955 1.00 18.57 F ATOM 7973 CA GLU F 122 −28.314 7.458 55.8061.00 18.47 F ATOM 7974 CB GLU F 122 −27.606 6.439 54.942 1.00 19.00 FATOM 7975 CG GLU F 122 −27.443 6.825 53.547 1.00 21.62 F ATOM 7976 CDGLU F 122 −27.095 5.574 52.634 1.00 24.99 F ATOM 7977 OE1 GLU F 122−25.930 4.973 52.682 1.00 25.45 F ATOM 7978 OE2 GLU F 122 −28.019 5.16251.856 1.00 26.81 F ATOM 7979 C GLU F 122 −28.741 6.757 57.125 1.0018.03 F ATOM 7980 O GLU F 122 −27.969 6.049 57.850 1.00 17.76 F ATOM7981 N ILE F 123 −30.017 6.902 57.386 1.00 17.32 F ATOM 7982 CA ILE F123 −30.549 6.329 58.570 1.00 17.23 F ATOM 7983 CB ILE F 123 −31.8056.981 58.739 1.00 18.05 F ATOM 7984 CG2 ILE F 123 −32.556 6.898 57.3721.00 17.42 F ATOM 7985 CG1 ILE F 123 −32.593 6.313 59.834 1.00 18.47 FATOM 7986 CD1 ILE F 123 −33.986 6.950 59.829 1.00 22.94 F ATOM 7987 CILE F 123 −30.745 4.846 58.227 1.00 16.61 F ATOM 7988 O ILE F 123−30.966 4.567 57.133 1.00 16.45 F ATOM 7989 N THR F 124 −30.711 3.92559.161 1.00 15.83 F ATOM 7990 CA THR F 124 −30.904 2.550 58.835 1.0015.31 F ATOM 7991 CB THR F 124 −30.018 1.644 59.750 1.00 13.78 F ATOM7992 OG1 THR F 124 −28.729 1.667 59.257 1.00 13.94 F ATOM 7993 CG2 THR F124 −30.415 0.326 59.825 1.00 11.84 F ATOM 7994 C THR F 124 −32.3112.301 59.162 1.00 15.76 F ATOM 7995 O THR F 124 −32.688 2.490 60.3601.00 17.16 F ATOM 7996 N VAL F 125 −33.104 1.885 58.193 1.00 16.17 FATOM 7997 CA VAL F 125 −34.527 1.559 58.526 1.00 18.24 F ATOM 7998 CBVAL F 125 −35.571 1.788 57.325 1.00 16.53 F ATOM 7999 CG1 VAL F 125−35.688 3.249 57.056 1.00 16.59 F ATOM 8000 CG2 VAL F 125 −35.174 0.99356.100 1.00 14.89 F ATOM 8001 C VAL F 125 −34.770 0.153 59.032 1.0017.00 F ATOM 8002 O VAL F 125 −33.901 −0.659 59.037 1.00 17.82 F ATOM8003 N SER F 126 −35.957 −0.076 59.532 1.00 17.88 F ATOM 8004 CA SER F126 −36.347 −1.417 59.982 1.00 18.69 F ATOM 8005 CB SER F 126 −37.845−1.364 60.332 1.00 17.96 F ATOM 8006 OG SER F 126 −38.386 −2.662 60.3381.00 20.87 F ATOM 8007 C SER F 126 −36.086 −2.651 58.965 1.00 18.30 FATOM 8008 O SER F 126 −35.642 −3.750 59.317 1.00 18.89 F ATOM 8009 N SERF 127 −36.372 −2.506 57.690 1.00 18.33 F ATOM 8010 CA SER F 127 −36.149−3.674 56.889 1.00 18.60 F ATOM 8011 CB SER F 127 −37.012 −3.648 55.6531.00 17.02 F ATOM 8012 OG SER F 127 −36.576 −2.576 54.874 1.00 18.52 FATOM 8013 C SER F 127 −34.632 −3.754 56.520 1.00 18.68 F ATOM 8014 O SERF 127 −34.225 −4.750 55.944 1.00 20.86 F ATOM 8015 N ASP F 128 −33.822−2.728 56.825 1.00 17.30 F ATOM 8016 CA ASP F 128 −32.366 −2.739 56.5721.00 15.89 F ATOM 8017 CB ASP F 128 −31.714 −1.367 56.907 1.00 17.17 FATOM 8018 CG ASP F 128 −31.868 −0.418 55.824 1.00 18.76 F ATOM 8019 OD1ASP F 128 −31.739 0.845 56.035 1.00 18.67 F ATOM 8020 OD2 ASP F 128−32.132 −0.958 54.684 1.00 21.51 F ATOM 8021 C ASP F 128 −31.649 −3.84157.389 1.00 14.40 F ATOM 8022 O ASP F 128 −30.626 −4.441 56.946 1.0011.88 F ATOM 8023 N PHE F 129 −32.086 −4.061 58.616 1.00 14.15 F ATOM8024 CA PHE F 129 −31.509 −5.182 59.344 1.00 17.47 F ATOM 8025 CB PHE F129 −31.986 −5.163 60.779 1.00 17.76 F ATOM 8026 CG PHE F 129 −31.668−3.883 61.479 1.00 19.38 F ATOM 8027 CD1 PHE F 129 −32.524 −2.775 61.4001.00 18.95 F ATOM 8028 CD2 PHE F 129 −30.419 −3.721 62.065 1.00 20.28 FATOM 8029 CE1 PHE F 129 −32.106 −1.512 61.884 1.00 19.29 F ATOM 8030 CE2PHE F 129 −29.971 −2.457 62.563 1.00 20.74 F ATOM 8031 CZ PHE F 129−30.829 −1.344 62.461 1.00 19.66 F ATOM 8032 C PHE F 129 −32.162 −6.31358.568 1.00 18.25 F ATOM 8033 O PHE F 129 −32.775 −6.036 57.522 1.0020.74 F ATOM 8034 N GLU F 130 −32.103 −7.564 58.932 1.00 16.99 F ATOM8035 CA GLU F 130 −32.908 −8.537 58.044 1.00 17.50 F ATOM 8036 CB GLU F130 −34.406 −8.124 57.890 1.00 17.40 F ATOM 8037 CG GLU F 130 −35.397−8.859 58.772 1.00 19.70 F ATOM 8038 CD GLU F 130 −36.826 −8.685 58.2651.00 22.19 F ATOM 8039 OE1 GLU F 130 −37.534 −9.657 58.624 1.00 25.58 FATOM 8040 OE2 GLU F 130 −37.266 −7.684 57.557 1.00 20.54 F ATOM 8041 CGLU F 130 −32.259 −8.588 56.652 1.00 16.31 F ATOM 8042 O GLU F 130−31.748 −9.636 56.326 1.00 15.71 F ATOM 8043 N ALA F 131 −32.306 −7.48655.889 1.00 15.36 F ATOM 8044 CA ALA F 131 −31.573 −7.379 54.691 1.0016.88 F ATOM 8045 CB ALA F 131 −31.913 −6.190 54.072 1.00 14.70 F ATOM8046 C ALA F 131 −30.284 −7.212 55.358 1.00 18.22 F ATOM 8047 O ALA F131 −30.190 −6.991 56.646 1.00 21.12 F ATOM 8048 N ARG F 132 −29.174−7.239 54.671 1.00 18.79 F ATOM 8049 CA ARG F 132 −27.994 −7.009 55.6231.00 17.03 F ATOM 8050 CB ARG F 132 −27.048 −8.171 55.550 1.00 17.70 FATOM 8051 CG ARG F 132 −27.024 −9.058 56.786 1.00 17.34 F ATOM 8052 CDARG F 132 −28.304 −9.520 57.379 1.00 15.30 F ATOM 8053 NE ARG F 132−28.045 −10.505 58.502 1.00 12.58 F ATOM 8054 CZ ARG F 132 −28.788−10.681 59.633 1.00 10.96 F ATOM 8055 NH1 ARG F 132 −29.846 −9.94759.913 1.00 7.09 F ATOM 8056 NH2 ARG F 132 −28.575 −11.693 60.434 1.008.17 F ATOM 8057 C ARG F 132 −27.376 −5.776 55.142 1.00 16.53 F ATOM8058 O ARG F 132 −26.195 −5.747 54.785 1.00 15.75 F ATOM 8059 N HIS F133 −28.244 −4.769 55.101 1.00 17.21 F ATOM 8060 CA HIS F 133 −27.900−3.499 54.592 1.00 18.39 F ATOM 8061 CB HIS F 133 −28.892 −3.060 53.5361.00 20.15 F ATOM 8062 CG HIS F 133 −28.907 −3.889 52.279 1.00 22.69 FATOM 8063 CD2 HIS F 133 −28.359 −5.107 51.978 1.00 23.95 F ATOM 8064 ND1HIS F 133 −29.548 −3.453 51.123 1.00 23.97 F ATOM 8065 CE1 HIS F 133−29.373 −4.371 50.166 1.00 25.13 F ATOM 8066 NE2 HIS F 133 −28.658−5.385 50.651 1.00 23.81 F ATOM 8067 C HIS F 133 −27.833 −2.467 55.6571.00 17.80 F ATOM 8068 O HIS F 133 −28.509 −1.440 55.538 1.00 18.07 FATOM 8069 N VAL F 134 −27.039 −2.727 56.710 1.00 18.00 F ATOM 8070 CAVAL F 134 −26.926 −1.665 57.705 1.00 19.48 F ATOM 8071 CB VAL F 134−26.349 −2.190 58.931 1.00 19.24 F ATOM 8072 CG1 VAL F 134 −26.444−1.084 60.071 1.00 19.78 F ATOM 8073 CG2 VAL F 134 −27.212 −3.354 59.3121.00 20.08 F ATOM 8074 C VAL F 134 −26.127 −0.396 57.131 1.00 17.18 FATOM 8075 O VAL F 134 −25.172 −0.568 56.426 1.00 16.53 F ATOM 8076 N LYSF 135 −26.576 0.834 57.392 1.00 17.06 F ATOM 8077 CA LYS F 135 −25.9532.052 56.829 1.00 17.62 F ATOM 8078 CB LYS F 135 −26.979 3.128 56.4291.00 17.34 F ATOM 8079 CG LYS F 135 −28.168 2.567 55.672 1.00 18.08 FATOM 8080 CD LYS F 135 −27.748 1.670 54.425 1.00 19.74 F ATOM 8081 CELYS F 135 −28.973 1.624 53.441 1.00 21.68 F ATOM 8082 NZ LYS F 135−28.836 0.505 52.466 1.00 23.72 F ATOM 8083 C LYS F 135 −24.923 2.72057.682 1.00 18.24 F ATOM 8084 O LYS F 135 −25.232 3.291 58.730 1.0018.78 F ATOM 8085 N LEU F 136 −23.695 2.678 57.150 1.00 17.95 F ATOM8086 CA LEU F 136 −22.513 3.177 57.768 1.00 17.68 F ATOM 8087 CB LEU F136 −21.430 2.188 57.488 1.00 17.40 F ATOM 8088 CG LEU F 136 −20.2372.409 58.387 1.00 17.70 F ATOM 8089 CD1 LEU F 136 −19.676 3.566 57.7921.00 20.44 F ATOM 8090 CD2 LEU F 136 −20.504 2.638 59.858 1.00 15.34 FATOM 8091 C LEU F 136 −22.184 4.520 57.256 1.00 18.24 F ATOM 8092 O LEUF 136 −21.797 4.649 56.159 1.00 18.63 F ATOM 8093 N ASN F 137 −22.3135.549 58.060 1.00 18.35 F ATOM 8094 CA ASN F 137 −22.051 6.920 57.6341.00 17.21 F ATOM 8095 CB ASN F 137 −23.000 7.765 58.370 1.00 16.60 FATOM 8096 CG ASN F 137 −24.453 7.473 57.968 1.00 15.91 F ATOM 8097 OD1ASN F 137 −24.920 7.873 56.845 1.00 14.32 F ATOM 8098 ND2 ASN F 137−25.183 6.836 58.860 1.00 11.24 F ATOM 8099 C ASN F 137 −20.635 7.31858.007 1.00 17.68 F ATOM 8100 O ASN F 137 −20.032 6.778 58.968 1.0018.29 F ATOM 8101 N VAL F 138 −20.061 8.207 57.227 1.00 16.72 F ATOM8102 CA VAL F 138 −18.747 8.679 57.553 1.00 15.09 F ATOM 8103 CB VAL F138 −17.699 8.345 56.499 1.00 14.14 F ATOM 8104 CG1 VAL F 138 −16.3768.898 56.926 1.00 13.76 F ATOM 8105 CG2 VAL F 138 −17.579 6.922 56.3261.00 11.12 F ATOM 8106 C VAL F 138 −18.857 10.189 57.694 1.00 16.81 FATOM 8107 O VAL F 138 −19.299 10.876 56.772 1.00 16.76 F ATOM 8108 N GLUF 139 −18.516 10.719 58.871 1.00 17.99 F ATOM 8109 CA GLU F 139 −18.56812.157 59.069 1.00 18.23 F ATOM 8110 CB GLU F 139 −19.673 12.544 60.0161.00 18.48 F ATOM 8111 CG GLU F 139 −21.110 12.523 59.463 1.00 18.05 FATOM 8112 CD GLU F 139 −21.325 13.415 58.210 1.00 18.41 F ATOM 8113 OE1GLU F 139 −20.618 14.460 57.952 1.00 17.12 F ATOM 8114 OE2 GLU F 139−22.232 13.044 57.424 1.00 19.58 F ATOM 8115 C GLU F 139 −17.239 12.63859.604 1.00 20.08 F ATOM 8116 O GLU F 139 −16.667 12.050 60.600 1.0020.67 F ATOM 8117 N GLU F 140 −16.701 13.650 58.903 1.00 20.71 F ATOM8118 CA GLU F 140 −15.460 14.276 59.367 1.00 20.09 F ATOM 8119 CB GLU F140 −14.349 14.245 58.315 1.00 21.57 F ATOM 8120 CG GLU F 140 −12.97414.692 59.013 1.00 22.16 F ATOM 8121 CD GLU F 140 −11.716 14.122 58.3241.00 23.68 F ATOM 8122 OE1 GLU F 140 −11.362 14.754 57.260 1.00 23.94 FATOM 8123 OE2 GLU F 140 −11.137 13.071 58.879 1.00 22.35 F ATOM 8124 CGLU F 140 −15.667 15.723 59.752 1.00 19.99 F ATOM 8125 O GLU F 140−16.518 16.451 59.165 1.00 19.97 F ATOM 8126 N ARG F 141 −14.908 16.15760.743 1.00 19.34 F ATOM 8127 CA ARG F 141 −14.987 17.583 61.156 1.0018.20 F ATOM 8128 CB ARG F 141 −15.926 17.850 62.349 1.00 18.40 F ATOM8129 CG ARG F 141 −17.402 17.364 62.251 1.00 18.91 F ATOM 8130 CD ARG F141 −18.300 18.445 61.718 1.00 19.72 F ATOM 8131 NE ARG F 141 −18.97017.871 60.587 1.00 23.18 F ATOM 8132 CZ ARG F 141 −20.087 17.171 60.6761.00 23.79 F ATOM 8133 NH1 ARG F 141 −20.683 17.009 61.822 1.00 26.82 FATOM 8134 NH2 ARG F 141 −20.499 16.483 59.678 1.00 23.26 F ATOM 8135 CARG F 141 −13.571 17.917 61.589 1.00 17.25 F ATOM 8136 O ARG F 141−12.666 17.031 61.747 1.00 15.49 F ATOM 8137 N SER F 142 −13.395 19.20661.817 1.00 16.54 F ATOM 8138 CA SER F 142 −12.091 19.642 62.232 1.0016.57 F ATOM 8139 CB SER F 142 −11.254 19.984 60.980 1.00 16.75 F ATOM8140 OG SER F 142 −11.510 21.285 60.589 1.00 14.53 F ATOM 8141 C SER F142 −12.186 20.811 63.193 1.00 17.21 F ATOM 8142 O SER F 142 −13.18321.618 63.197 1.00 14.95 F ATOM 8143 N VAL F 143 −11.190 20.855 64.0521.00 17.92 F ATOM 8144 CA VAL F 143 −11.172 21.975 64.972 1.00 19.41 FATOM 8145 CB VAL F 143 −11.956 21.606 66.293 1.00 19.62 F ATOM 8146 CG1VAL F 143 −11.292 20.496 67.055 1.00 19.44 F ATOM 8147 CG2 VAL F 143−12.100 22.812 67.168 1.00 18.93 F ATOM 8148 C VAL F 143 −9.729 22.54265.208 1.00 21.44 F ATOM 8149 O VAL F 143 −8.662 21.854 64.906 1.0021.69 F ATOM 8150 N GLY F 144 −9.660 23.832 65.635 1.00 21.35 F ATOM8151 CA GLY F 144 −8.338 24.501 65.918 1.00 22.07 F ATOM 8152 C GLY F144 −8.396 26.053 65.860 1.00 22.20 F ATOM 8153 O GLY F 144 −9.49226.630 65.459 1.00 21.80 F ATOM 8154 N PRO F 145 −7.280 26.749 66.1511.00 18.78 F ATOM 8155 CD PRO F 145 −6.911 28.027 65.549 1.00 19.69 FATOM 8156 CA PRO F 145 −6.090 25.983 66.493 1.00 21.93 F ATOM 8157 CBPRO F 145 −4.925 26.935 66.203 1.00 19.62 F ATOM 8158 CG PRO F 145−5.544 28.272 66.088 1.00 18.86 F ATOM 8159 C PRO F 145 −6.023 25.43567.892 1.00 22.11 F ATOM 8160 O PRO F 145 −6.545 26.024 68.841 1.0022.14 F ATOM 8161 N LEU F 146 −5.479 24.248 68.048 1.00 20.74 F ATOM8162 CA LEU F 146 −5.351 23.819 69.417 1.00 20.84 F ATOM 8163 CB LEU F146 −5.201 22.312 69.452 1.00 20.19 F ATOM 8164 CG LEU F 146 −6.50321.543 69.593 1.00 20.22 F ATOM 8165 CD1 LEU F 146 −7.681 22.228 68.9121.00 20.95 F ATOM 8166 CD2 LEU F 146 −6.281 20.138 69.026 1.00 19.02 FATOM 8167 C LEU F 146 −4.064 24.499 69.894 1.00 21.36 F ATOM 8168 O LEUF 146 −3.162 24.898 69.089 1.00 20.63 F ATOM 8169 N THR F 147 −3.92824.612 71.220 1.00 21.08 F ATOM 8170 CA THR F 147 −2.663 25.273 71.7221.00 20.61 F ATOM 8171 CB THR F 147 −2.820 26.720 72.016 1.00 19.97 FATOM 8172 OG1 THR F 147 −3.910 26.847 72.933 1.00 17.13 F ATOM 8173 CG2THR F 147 −3.075 27.537 70.770 1.00 17.92 F ATOM 8174 C THR F 147 −2.09824.659 72.990 1.00 22.40 F ATOM 8175 O THR F 147 −0.864 24.792 73.2001.00 24.60 F ATOM 8176 N ARG F 148 −2.944 24.007 73.818 1.00 21.03 FATOM 8177 CA ARG F 148 −2.501 23.386 75.070 1.00 18.24 F ATOM 8178 CBARG F 148 −3.673 23.075 75.991 1.00 18.70 F ATOM 8179 CG ARG F 148−4.852 24.122 75.969 1.00 20.02 F ATOM 8180 CD ARG F 148 −4.482 25.36476.689 1.00 21.40 F ATOM 8181 NE ARG F 148 −3.536 26.237 75.916 1.0023.21 F ATOM 8182 CZ ARG F 148 −2.404 26.750 76.460 1.00 24.44 F ATOM8183 NH1 ARG F 148 −2.089 26.472 77.739 1.00 22.25 F ATOM 8184 NH2 ARG F148 −1.595 27.554 75.750 1.00 24.04 F ATOM 8185 C ARG F 148 −1.73122.130 74.866 1.00 17.86 F ATOM 8186 O ARG F 148 −1.543 21.639 73.7501.00 16.53 F ATOM 8187 N LYS F 149 −1.279 21.599 75.978 1.00 18.10 FATOM 8188 CA LYS F 149 −0.456 20.425 75.972 1.00 19.89 F ATOM 8189 CBLYS F 149 0.012 20.132 77.408 1.00 19.06 F ATOM 8190 CG LYS F 149 1.16619.160 77.579 1.00 19.13 F ATOM 8191 CD LYS F 149 1.461 18.847 79.0821.00 19.48 F ATOM 8192 CE LYS F 149 2.553 17.751 79.201 1.00 20.51 FATOM 8193 NZ LYS F 149 2.377 16.710 80.365 1.00 20.23 F ATOM 8194 C LYSF 149 −1.336 19.231 75.448 1.00 21.71 F ATOM 8195 O LYS F 149 −0.82418.299 74.812 1.00 22.77 F ATOM 8196 N GLY F 150 −2.632 19.264 75.7721.00 22.76 F ATOM 8197 CA GLY F 150 −3.517 18.170 75.376 1.00 22.30 FATOM 8198 C GLY F 150 −4.950 18.571 75.054 1.00 21.92 F ATOM 8199 O GLYF 150 −5.260 19.802 74.997 1.00 21.48 F ATOM 8200 N PHE F 151 −5.78117.524 74.835 1.00 21.12 F ATOM 8201 CA PHE F 151 −7.205 17.644 74.5291.00 19.12 F ATOM 8202 CB PHE F 151 −7.355 18.223 73.160 1.00 19.47 FATOM 8203 CG PHE F 151 −7.021 17.286 72.041 1.00 19.87 F ATOM 8204 CD1PHE F 151 −8.039 16.522 71.423 1.00 20.03 F ATOM 8205 CD2 PHE F 151−5.744 17.168 71.541 1.00 20.02 F ATOM 8206 CE1 PHE F 151 −7.747 15.71970.371 1.00 18.56 F ATOM 8207 CE2 PHE F 151 −5.486 16.336 70.496 1.0019.11 F ATOM 8208 CZ PHE F 151 −6.498 15.615 69.914 1.00 18.60 F ATOM8209 C PHE F 151 −8.008 16.348 74.655 1.00 19.90 F ATOM 8210 O PHE F 151−7.466 15.181 74.612 1.00 19.44 F ATOM 8211 N TYR F 152 −9.309 16.56874.837 1.00 19.06 F ATOM 8212 CA TYR F 152 −10.315 15.504 74.924 1.0018.17 F ATOM 8213 CB TYR F 152 −11.076 15.551 76.229 1.00 19.27 F ATOM8214 CG TYR F 152 −10.257 15.264 77.441 1.00 20.80 F ATOM 8215 CD1 TYR F152 −9.596 16.301 78.144 1.00 20.93 F ATOM 8216 CE1 TYR F 152 −8.77116.022 79.288 1.00 22.33 F ATOM 8217 CD2 TYR F 152 −10.093 13.947 77.8781.00 20.90 F ATOM 8218 CE2 TYR F 152 −9.297 13.642 79.007 1.00 22.21 FATOM 8219 CZ TYR F 152 −8.613 14.702 79.754 1.00 22.99 F ATOM 8220 OHTYR F 152 −7.942 14.406 81.009 1.00 22.87 F ATOM 8221 C TYR F 152−11.398 15.659 73.848 1.00 17.95 F ATOM 8222 O TYR F 152 −11.637 16.72273.309 1.00 18.56 F ATOM 8223 N LEU F 153 −12.070 14.581 73.558 1.0015.59 F ATOM 8224 CA LEU F 153 −13.093 14.652 72.610 1.00 14.44 F ATOM8225 CB LEU F 153 −12.744 13.830 71.389 1.00 15.02 F ATOM 8226 CG LEU F153 −12.628 14.545 70.054 1.00 15.97 F ATOM 8227 CD1 LEU F 153 −11.66315.637 70.051 1.00 16.81 F ATOM 8228 CD2 LEU F 153 −12.199 13.547 69.0651.00 17.36 F ATOM 8229 C LEU F 153 −14.261 14.049 73.322 1.00 13.60 FATOM 8230 O LEU F 153 −14.146 13.111 74.190 1.00 12.89 F ATOM 8231 N ALAF 154 −15.418 14.584 73.027 1.00 12.95 F ATOM 8232 CA ALA F 154 −16.50113.934 73.676 1.00 14.62 F ATOM 8233 CB ALA F 154 −16.793 14.655 75.0551.00 16.24 F ATOM 8234 C ALA F 154 −17.771 13.854 72.806 1.00 14.87 FATOM 8235 O ALA F 154 −17.991 14.619 71.878 1.00 13.87 F ATOM 8236 N PHEF 155 −18.621 12.962 73.215 1.00 14.88 F ATOM 8237 CA PHE F 155 −19.81712.749 72.510 1.00 16.44 F ATOM 8238 CB PHE F 155 −19.767 11.428 71.7081.00 17.75 F ATOM 8239 CG PHE F 155 −18.568 11.253 70.916 1.00 18.05 FATOM 8240 CD1 PHE F 155 −17.393 10.730 71.529 1.00 19.66 F ATOM 8241 CD2PHE F 155 −18.570 11.558 69.589 1.00 16.49 F ATOM 8242 CE1 PHE F 155−16.265 10.525 70.762 1.00 19.11 F ATOM 8243 CE2 PHE F 155 −17.44211.359 68.799 1.00 16.58 F ATOM 8244 CZ PHE F 155 −16.298 10.843 69.3741.00 18.23 F ATOM 8245 C PHE F 155 −21.083 12.712 73.343 1.00 16.10 FATOM 8246 O PHE F 155 −21.303 11.820 74.276 1.00 14.87 F ATOM 8247 N GLNF 156 −21.923 13.642 72.946 1.00 14.96 F ATOM 8248 CA GLN F 156 −23.13413.739 73.600 1.00 15.70 F ATOM 8249 CB GLN F 156 −23.387 15.201 73.8351.00 16.50 F ATOM 8250 CG GLN F 156 −24.481 15.375 74.803 1.00 18.27 FATOM 8251 CD GLN F 156 −25.189 16.716 74.660 1.00 18.95 F ATOM 8252 OE1GLN F 156 −25.047 17.385 73.619 1.00 20.75 F ATOM 8253 NE2 GLN F 156−25.983 17.104 75.692 1.00 16.11 F ATOM 8254 C GLN F 156 −24.367 13.08872.949 1.00 15.52 F ATOM 8255 O GLN F 156 −24.845 13.495 71.850 1.0014.56 F ATOM 8256 N ASP F 157 −24.878 12.078 73.622 1.00 14.30 F ATOM8257 CA ASP F 157 −26.040 11.510 73.141 1.00 15.01 F ATOM 8258 CB ASP F157 −26.150 10.021 73.443 1.00 13.64 F ATOM 8259 CG ASP F 157 −27.5479.478 73.132 1.00 12.51 F ATOM 8260 OD1 ASP F 157 −28.107 8.876 74.0551.00 11.68 F ATOM 8261 OD2 ASP F 157 −28.029 9.666 71.976 1.00 9.63 FATOM 8262 C ASP F 157 −27.275 12.232 73.690 1.00 16.75 F ATOM 8263 O ASPF 157 −27.478 12.330 74.879 1.00 16.06 F ATOM 8264 N ILE F 158 −28.13312.652 72.777 1.00 17.72 F ATOM 8265 CA ILE F 158 −29.354 13.299 73.1251.00 18.64 F ATOM 8266 CB ILE F 158 −29.418 14.513 72.181 1.00 19.36 FATOM 8267 CG2 ILE F 158 −30.429 14.442 71.049 1.00 17.18 F ATOM 8268 CG1ILE F 158 −29.476 15.695 73.088 1.00 19.60 F ATOM 8269 CD1 ILE F 158−28.180 15.987 73.581 1.00 19.72 F ATOM 8270 C ILE F 158 −30.656 12.42973.111 1.00 19.62 F ATOM 8271 O ILE F 158 −31.758 12.962 73.165 1.0018.47 F ATOM 8272 N GLY F 159 −30.510 11.098 73.122 1.00 19.68 F ATOM8273 CA GLY F 159 −31.663 10.216 72.969 1.00 20.40 F ATOM 8274 C GLY F159 −31.843 9.591 71.511 1.00 20.77 F ATOM 8275 O GLY F 159 −32.9789.389 71.016 1.00 21.19 F ATOM 8276 N ALA F 160 −30.728 9.325 70.8231.00 19.60 F ATOM 8277 CA ALA F 160 −30.736 8.745 69.519 1.00 20.03 FATOM 8278 CB ALA F 160 −29.757 9.456 68.566 1.00 17.83 F ATOM 8279 C ALAF 160 −30.287 7.334 69.791 1.00 19.57 F ATOM 8280 O ALA F 160 −29.9187.037 70.949 1.00 21.17 F ATOM 8281 N CYS F 161 −30.422 6.485 68.7781.00 18.38 F ATOM 8282 CA CYS F 161 −30.024 5.089 68.776 1.00 18.34 FATOM 8283 C CYS F 161 −28.866 5.074 67.754 1.00 17.68 F ATOM 8284 O CYSF 161 −29.107 4.840 66.541 1.00 17.74 F ATOM 8285 CB CYS F 161 −31.0784.208 68.156 1.00 17.28 F ATOM 8286 SG CYS F 161 −30.660 2.538 68.4551.00 18.13 F ATOM 8287 N VAL F 162 −27.640 5.289 68.269 1.00 16.61 FATOM 8288 CA VAL F 162 −26.391 5.329 67.516 1.00 15.78 F ATOM 8289 CBVAL F 162 −25.557 6.603 67.853 1.00 16.61 F ATOM 8290 CG1 VAL F 162−24.654 6.992 66.710 1.00 15.97 F ATOM 8291 CG2 VAL F 162 −26.394 7.68468.276 1.00 15.20 F ATOM 8292 C VAL F 162 −25.464 4.204 67.834 1.0015.06 F ATOM 8293 O VAL F 162 −25.512 3.574 68.917 1.00 13.20 F ATOM8294 N ALA F 163 −24.647 3.943 66.843 1.00 15.41 F ATOM 8295 CA ALA F163 −23.578 2.996 67.050 1.00 17.33 F ATOM 8296 CB ALA F 163 −23.8661.713 66.427 1.00 16.50 F ATOM 8297 C ALA F 163 −22.269 3.658 66.4951.00 17.96 F ATOM 8298 O ALA F 163 −22.006 3.753 65.319 1.00 20.30 FATOM 8299 N LEU F 164 −21.426 4.177 67.380 1.00 18.56 F ATOM 8300 CA LEUF 164 −20.219 4.809 66.898 1.00 16.94 F ATOM 8301 CB LEU F 164 −19.8965.882 67.896 1.00 17.95 F ATOM 8302 CG LEU F 164 −18.733 6.589 67.4001.00 17.89 F ATOM 8303 CD1 LEU F 164 −18.995 7.282 66.124 1.00 15.47 FATOM 8304 CD2 LEU F 164 −18.381 7.448 68.493 1.00 20.54 F ATOM 8305 CLEU F 164 −19.161 3.739 66.769 1.00 16.01 F ATOM 8306 O LEU F 164−18.660 3.138 67.768 1.00 13.62 F ATOM 8307 N LEU F 165 −18.864 3.47365.502 1.00 16.80 F ATOM 8308 CA LEU F 165 −17.904 2.361 65.260 1.0017.88 F ATOM 8309 CB LEU F 165 −18.377 1.450 64.143 1.00 19.70 F ATOM8310 CG LEU F 165 −19.865 1.154 64.115 1.00 20.22 F ATOM 8311 CD1 LEU F165 −20.006 0.091 63.073 1.00 22.42 F ATOM 8312 CD2 LEU F 165 −20.3830.571 65.317 1.00 20.24 F ATOM 8313 C LEU F 165 −16.455 2.751 64.9451.00 17.28 F ATOM 8314 O LEU F 165 −15.576 1.899 64.820 1.00 16.77 FATOM 8315 N SER F 166 −16.191 4.047 64.838 1.00 16.42 F ATOM 8316 CA SERF 166 −14.857 4.362 64.615 1.00 14.94 F ATOM 8317 CB SER F 166 −14.4864.023 63.190 1.00 16.92 F ATOM 8318 OG SER F 166 −13.342 4.771 62.7411.00 17.83 F ATOM 8319 C SER F 166 −14.714 5.803 64.881 1.00 13.50 FATOM 8320 O SER F 166 −15.612 6.553 64.597 1.00 10.37 F ATOM 8321 N VALF 167 −13.526 6.136 65.366 1.00 13.03 F ATOM 8322 CA VAL F 167 −13.2257.443 65.680 1.00 14.10 F ATOM 8323 CB VAL F 167 −13.414 7.684 67.1701.00 14.20 F ATOM 8324 CG1 VAL F 167 −12.915 9.039 67.498 1.00 18.13 FATOM 8325 CG2 VAL F 167 −14.806 7.616 67.561 1.00 12.07 F ATOM 8326 CVAL F 167 −11.803 7.635 65.348 1.00 14.46 F ATOM 8327 O VAL F 167−10.934 7.137 66.057 1.00 15.15 F ATOM 8328 N ARG F 168 −11.540 8.29364.247 1.00 15.11 F ATOM 8329 CA ARG F 168 −10.146 8.565 63.932 1.0017.77 F ATOM 8330 CB ARG F 168 −9.778 8.130 62.505 1.00 17.66 F ATOM8331 CG ARG F 168 −8.876 6.956 62.610 1.00 19.47 F ATOM 8332 CD ARG F168 −7.898 6.768 61.396 1.00 21.26 F ATOM 8333 NE ARG F 168 −8.028 7.79260.327 1.00 21.00 F ATOM 8334 CZ ARG F 168 −7.041 8.177 59.477 1.0020.85 F ATOM 8335 NH1 ARG F 168 −5.786 7.667 59.460 1.00 17.36 F ATOM8336 NH2 ARG F 168 −7.327 9.138 58.638 1.00 21.21 F ATOM 8337 C ARG F168 −9.844 10.106 64.134 1.00 16.88 F ATOM 8338 O ARG F 168 −10.71710.949 63.807 1.00 16.38 F ATOM 8339 N VAL F 169 −8.632 10.411 64.6631.00 16.86 F ATOM 8340 CA VAL F 169 −8.172 11.809 64.934 1.00 17.91 FATOM 8341 CB VAL F 169 −8.100 12.158 66.441 1.00 18.20 F ATOM 8342 CG1VAL F 169 −7.660 13.596 66.573 1.00 20.51 F ATOM 8343 CG2 VAL F 169−9.456 12.014 67.146 1.00 16.17 F ATOM 8344 C VAL F 169 −6.736 12.02964.423 1.00 19.08 F ATOM 8345 O VAL F 169 −5.725 11.400 64.899 1.0017.96 F ATOM 8346 N TYR F 170 −6.574 12.943 63.484 1.00 18.49 F ATOM8347 CA TYR F 170 −5.240 13.047 62.988 1.00 18.41 F ATOM 8348 CB TYR F170 −5.114 12.139 61.760 1.00 18.99 F ATOM 8349 CG TYR F 170 −6.04512.616 60.651 1.00 19.19 F ATOM 8350 CD1 TYR F 170 −5.590 13.483 59.6521.00 18.68 F ATOM 8351 CE1 TYR F 170 −6.453 13.874 58.623 1.00 19.39 FATOM 8352 CD2 TYR F 170 −7.416 12.143 60.609 1.00 19.74 F ATOM 8353 CE2TYR F 170 −8.261 12.513 59.616 1.00 19.19 F ATOM 8354 CZ TYR F 170−7.792 13.378 58.609 1.00 19.84 F ATOM 8355 OH TYR F 170 −8.675 13.73157.536 1.00 21.13 F ATOM 8356 C TYR F 170 −5.037 14.423 62.525 1.0019.59 F ATOM 8357 O TYR F 170 −6.007 15.144 62.391 1.00 19.70 F ATOM8358 N TYR F 171 −3.786 14.759 62.203 1.00 19.49 F ATOM 8359 CA TYR F171 −3.493 16.033 61.590 1.00 19.13 F ATOM 8360 CB TYR F 171 −2.93816.974 62.637 1.00 19.53 F ATOM 8361 CG TYR F 171 −1.582 16.675 63.1871.00 19.26 F ATOM 8362 CD1 TYR F 171 −0.480 17.351 62.687 1.00 20.08 FATOM 8363 CE1 TYR F 171 0.836 17.098 63.233 1.00 21.47 F ATOM 8364 CD2TYR F 171 −1.400 15.726 64.243 1.00 19.19 F ATOM 8365 CE2 TYR F 171−0.154 15.446 64.763 1.00 20.64 F ATOM 8366 CZ TYR F 171 0.973 16.11164.275 1.00 22.12 F ATOM 8367 OH TYR F 171 2.244 15.764 64.815 1.0024.13 F ATOM 8368 C TYR F 171 −2.519 15.938 60.386 1.00 20.61 F ATOM8369 O TYR F 171 −1.791 14.978 60.191 1.00 20.69 F ATOM 8370 N LYS F 172−2.462 16.980 59.585 1.00 21.78 F ATOM 8371 CA LYS F 172 −1.608 16.94358.432 1.00 22.09 F ATOM 8372 CB LYS F 172 −1.987 17.963 57.489 1.0021.09 F ATOM 8373 CG LYS F 172 −2.767 17.366 56.466 1.00 22.57 F ATOM8374 CD LYS F 172 −3.985 16.657 57.014 1.00 22.13 F ATOM 8375 CE LYS F172 −4.879 16.193 55.811 1.00 23.79 F ATOM 8376 NZ LYS F 172 −6.16817.147 55.581 1.00 22.42 F ATOM 8377 C LYS F 172 −0.113 17.022 58.6241.00 24.94 F ATOM 8378 O LYS F 172 0.525 18.018 59.227 1.00 25.56 F ATOM8379 N LYS F 173 0.463 15.944 58.076 1.00 24.70 F ATOM 8380 CA LYS F 1731.863 15.699 58.215 1.00 23.81 F ATOM 8381 CB LYS F 173 2.436 15.05956.958 1.00 24.31 F ATOM 8382 CG LYS F 173 1.527 13.942 56.539 1.0024.27 F ATOM 8383 CD LYS F 173 0.602 14.561 55.473 1.00 23.72 F ATOM8384 CE LYS F 173 −0.839 13.906 55.453 1.00 24.62 F ATOM 8385 NZ LYS F173 −1.838 14.334 56.572 1.00 24.16 F ATOM 8386 C LYS F 173 2.727 16.78458.583 1.00 24.88 F ATOM 8387 O LYS F 173 3.145 16.774 59.779 1.00 23.67F ATOM 8388 N CYS F 174 2.782 17.755 57.607 1.00 24.69 F ATOM 8389 CACYS F 174 3.896 18.815 57.497 1.00 25.67 F ATOM 8390 CB CYS F 174 3.79119.978 58.516 1.00 26.56 F ATOM 8391 SG CYS F 174 5.375 21.125 58.1291.00 34.09 F ATOM 8392 C CYS F 174 5.441 18.125 57.645 1.00 24.67 F ATOM8393 O CYS F 174 6.471 18.857 57.943 1.00 24.74 F ATOM 8394 OXT CYS F174 5.617 16.797 57.555 1.00 24.80 F END

1. A method of treating cancer in an individual, comprisingadministering to the individual a therapeutically effective amount ofdoxazosin, wherein the cancer is selected from the group consisting ofskin cancer, lung cancer, pancreatic cancer and melanomas.
 2. A methodof treating cancer in an individual, comprising administering to theindividual a therapeutically effective amount of an agonist of EphAreceptor protein, the agonist inhibiting proliferation of cancer cells,the EphA receptor protein comprising at least one of EphA1, EphA2, orEphA3, the agonist having the general formula:

wherein R¹ is selected from H, C₁₋₆alkyl, C₁₋₆aralkyl, C₁₋₆alkanoyl,aryl, heterocyclyl, C₁₋₆heterocyclylalkyl, C₁₋₆carbocyclylalkyl, andcarbocyclyl, or two occurrences of R¹ together are C₁₋₆alkyl, therebyforming a ring; R², R³, and R⁴ are independently selected from H,C₁₋₆alkyl, C₁₋₆aralkyl, C₁₋₆heterocyclylalkyl, and C₁₋₆carbocyclylalkyl;R⁵ is selected from C₁₋₆alkyl, C₁₋₆alkoxy, halogen, C₁₋₆alkanoyl,C₁₋₆alkoxycarbonyl, C(O)N(R⁶)(R⁷), and SO₂N(R⁶)(R⁷); R⁶ and R⁷ areindependently selected from H and C₁₋₆alkyl; X is selected from CH₂, NH,and O; each Y is independently selected from CH and N; m is an integerfrom 1 to 2; n is an integer from 1 to 3; and p is an integer from 0 to3, wherein the cancer is selected from the group consisting of skincancer, lung cancer, pancreatic cancer, and melanomas.